<SEC-DOCUMENT>0000950123-23-006428.txt : 20230929
<SEC-HEADER>0000950123-23-006428.hdr.sgml : 20230929
<ACCEPTANCE-DATETIME>20230728143701
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-23-006428
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20230728
<PUBLIC-REL-DATE>20230929
DATE AS OF CHANGE:		20230728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Abivax S.A.
		CENTRAL INDEX KEY:			0001956827
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-06511
		FILM NUMBER:		231122346

	BUSINESS ADDRESS:	
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		STATE:			I0
		ZIP:			75009
		BUSINESS PHONE:		01 53 83 09 63

	MAIL ADDRESS:	
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		STATE:			I0
		ZIP:			75009
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on July&nbsp;28,
2023. This amended draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information herein remains strictly confidential. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">F-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>ABIVAX SA </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of
registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>France</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Abivax SA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">7-11</FONT> boulevard Haussmann </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>75009 Paris </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>France
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+33 (0) 1 53 83 08 41 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>C T Corporation System </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1015 15th Street N.W., Suite 1000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20005 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Phone:&nbsp;+1&nbsp;202&nbsp;572&nbsp;3133 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Divakar Gupta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Marc Recht</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ryan
Sansom</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Denny Won</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>55 Hudson
Yards</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10001</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +1 212 479 6000</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alain Decombe</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dechert (Paris) LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>22 rue
Bayard</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>75008 Paris</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +33 1 57 57 80
00</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nathan Ajiashvili</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alison Haggerty</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham
&amp; Watkins LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1271 Avenue of the Americas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10020</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +1
212 906 1200</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Arnaud Duhamel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Guilhem Richard</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gide
Loyrette Nouel A.A.R.P.I.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>15 rue de Laborde</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>75008 Paris</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +33 1 40 75 60 00</B></P></TD></TR>
</TABLE>    <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: As soon as practicable after effectiveness of this registration statement.
</B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, as amended, or the Securities Act, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is filed to
register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Emerging growth company.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new or revised financial account standards&#134; provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial
Accounting Standards Board to its Accounting Standards Codification after April&nbsp;5, 2012. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become
effective in accordance with Section&nbsp;8(a) of the Securities Act or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these
securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>SUBJECT TO COMPLETION,
DATED&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2023 </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>(Including Ordinary Shares in the Form of American Depositary Shares) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g03a03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Ordinary Share </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per American Depositary Share </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">We are offering an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary
shares in a global offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">We are offering
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in the form of American Depositary Shares, or ADSs, in the United States, referred to herein as the U.S. offering. Each ADS represents
the right to receive one ordinary share and the ADSs may be evidenced by American Depositary Receipts, or ADRs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">We are concurrently
offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in Europe (including France) and countries outside of the United States in a private placement exclusively offered to
&#147;qualified investors,&#148; as such term is defined in article 2(e) of Regulation (EU) No.&nbsp;2017/1129 of the European Parliament and Council of June&nbsp;14, 2017, referred to herein as the European private placement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">This is our initial public offering of our ADSs in the United States. We intend to apply to list our ADSs on the Nasdaq Global Market under
the symbol &#147;ABVX.&#148; There is no assurance that such application will be approved, and if our application is not approved, this offering will not be completed. Our ordinary shares are listed on Euronext Paris under the symbol
&#147;ABVX.&#148; The offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros will be determined through negotiations between us and the representatives of the underwriters, and by reference to the
prevailing market prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors, but will not be lower than 85% of the volume-weighted-average price of our ordinary shares on Euronext Paris for fifteen
(15)&nbsp;trading days preceding the day on which the offering price is determined. On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2023, the last reported sale price of our ordinary shares on Euronext Paris was
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, equivalent to a price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, assuming an exchange rate of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
U.S. dollar, the exchange rate on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2023 as reported by the European Central Bank. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">The closings of the U.S. offering and the European private placement, which are together referred to as the global offering, will occur
simultaneously. The total number of ordinary shares (including in the form of ADSs) in the U.S. offering and European private placement is subject to reallocation between these offerings, as permitted under applicable laws and regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to
comply with certain reduced public company reporting requirements. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in the ordinary shares and ADSs involves a high degree
of risk. See &#147;<A HREF="#toc609070_5">Risk Factors</A>&#148; beginning on page 16 of this prospectus. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman"><B>Under the authority
granted by our shareholders to conduct the global offering, the ADSs and ordinary shares that we are offering may only be purchased initially by (i)&nbsp;French or foreign individuals, legal entities, including companies, trusts or investment funds
or other investment vehicles of any kind, investing, as a main activity, or having invested more than &#128;1&nbsp;million during the 24 months preceding the considered capital increase (a)&nbsp;in the pharmaceutical sector; and/or (b)&nbsp;in a
growth stock listed on a regulated market or a multilateral negotiation system (type Euronext Growth) considered as &#147;community small and <FONT STYLE="white-space:nowrap">medium-sized</FONT> companies&#148; in the meaning of annex I to the
Regulation (CE) No.&nbsp;651/2014 of the European Commission of June&nbsp;17, 2014; (ii)&nbsp;one or more of our strategic partners, located in France or abroad, who has (have) entered into or will enter into one or more partnership agreements
(development, <FONT STYLE="white-space:nowrap">co-development,</FONT> distribution, manufacturing agreements, etc.) or commercial agreements with us (or a subsidiary) and/or companies they control, that control them or are controlled by the same
person(s), directly or indirectly, within the meaning of Article L. <FONT STYLE="white-space:nowrap">233-3</FONT> of the French Commercial Code; and/or (iii) any French or foreign investment services provider, or any foreign institution having an
equivalent status, likely to guarantee the realization of an issue intended to be placed with the persons referred to in (i) and/or (ii) above and, in this context, to subscribe the securities issued. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any U.S. state or other securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER&nbsp;ORDINARY</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Underwriting commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We refer you to &#147;Underwriters&#148; beginning on page 235 of this prospectus for additional information
regarding underwriting compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable within 30&nbsp;days
from the date of this prospectus, to purchase up to an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs and/or ordinary shares (representing up to 15% of the initial size
of the global offering) in the global offering to be sold to the several underwriters at the applicable offering price. If the underwriters exercise this option in full, the total underwriting commissions payable by us will be
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) and the total proceeds to us, before expenses, will be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;), based on the exchange rate on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2023. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">The underwriters expect to deliver the ADSs to purchasers in the U.S. offering on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 through the book-entry facilities of The Depository Trust Company. The underwriters expect to deliver the ordinary shares to purchasers in the European private placement
on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 through the book-entry facilities of Euroclear France. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top"><B>Morgan Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Leerink Partners</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top"><FONT STYLE="font-size:11pt"><B>LifeSci Capital</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-size:11pt"><B>Bryan,&nbsp;Garnier&nbsp;&amp;&nbsp;Co</B></FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2023. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_4">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_6">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_9">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_10">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_11">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_12">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_13">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_14">MANAGEMENT </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_15">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_16">PRINCIPAL SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_17">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_18">LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_19">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_20">ORDINARY SHARES AND ADSs ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_21">MATERIAL UNITED STATES FEDERAL INCOME AND FRENCH TAX
CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_22">UNDERWRITERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_23">EXPENSES RELATING TO THE GLOBAL OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_24">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_25">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_25a">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_26">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc609070_27">INDEX TO THE FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>For investors outside the United States: Neither we nor any of the underwriters have done anything that would permit the global offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the ordinary shares and ADSs and the distribution of this prospectus outside the United States. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated in France, and under the rules of the U.S. Securities and Exchange Commission (the &#147;SEC&#148;), we are currently
eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities
are registered under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout this prospectus,
references to ADSs mean ADSs or ordinary shares represented by ADSs, as the case may be. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_1"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including
our general expectations and market position, market opportunity and market size estimates, is based on information from independent industry analysts, third-party sources and management estimates. Management estimates are derived from publicly
available information released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made by us based on such data and our knowledge of such industry and market, which we
believe to be reasonable. In addition, while we believe the market opportunity information included in this prospectus is reliable and is based on reasonable assumptions, such data involves risks and uncertainties and is subject to change based on
various factors, including those discussed under the heading &#147;Risk Factors.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_2"></A>PRESENTATION OF FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes our audited financial statements as of and for the years ended December&nbsp;31, 2022 and 2021 prepared in accordance
with International Financial Reporting Standards (&#147;IFRS&#148;), as issued by the International Accounting Standards Board (&#147;IASB&#148;). None of our financial statements were prepared in accordance with U.S. generally accepted accounting
principles (&#147;U.S. GAAP&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements are presented in euros and, unless otherwise stated, all monetary amounts
are in euros. All references in this prospectus to &#147;$&#148;, &#147;U.S. dollars&#148; and &#147;dollars&#148; mean U.S. dollars, and all references to &#147;&#128;&#148;, &#147;EUR&#148; and &#147;euros&#148; mean European Monetary Union euros,
unless otherwise noted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Union uses a flexible exchange rate system to determine the value of the euro against the
U.S.&nbsp;dollar. The following table sets forth the rate of exchange for the euro at the end of the five most recent fiscal periods ended December 31, the average rates for the period, and the range of high and low rates for the period. The data
for the six months ended June&nbsp;30, 2023 is also included. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this table, the rate of exchange means the closing
daily rate used by the U.S. Department of Treasury. The table sets forth the number of euros required under that formula to buy one U.S. dollar. The average rate means the average of the exchange rates on the last day of each month during the
period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Close</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Six Months Ended June 30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year Ended December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year Ended December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year Ended December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year Ended December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year Ended December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_3"></A>TRADEMARKS AND SERVICE MARKS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Abivax&#148; and the Abivax logo and other trademarks or service marks of Abivax SA appearing in this prospectus are the property of
Abivax SA. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus are listed without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and
<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their right thereto. All
other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. We do not intend to use or display other companies&#146; trademarks and trade names to imply any relationship with, or
endorsement or sponsorship of us by, any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_4"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information you should consider
before investing in our ordinary shares (including ordinary shares in the form of ADSs). You should read the entire prospectus carefully, including &#147;Risk Factors&#148; &#147;Cautionary Note Regarding Forward-Looking Statements&#148;
&#147;Business&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes appearing elsewhere in this prospectus before making an investment
decision. Unless otherwise indicated or the context otherwise requires, &#147;Abivax,&#148; &#147;the company,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Abivax SA and its consolidated subsidiary,
taken as a whole. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body&#146;s natural regulatory mechanisms to
modulate the immune response in patients with chronic inflammatory diseases. We are currently evaluating our lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative
colitis (&#147;UC&#148;). We are also in the planning stages of initiating a Phase 2a clinical trial of obefazimod in patients with Crohn&#146;s disease (&#147;CD&#148;), as well as evaluating other potential inflammatory indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational
agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial populations and represent large commercial opportunities, pending regulatory approvals and successful
commercialization. Our initial focus is on inflammatory bowel diseases (&#147;IBD&#148;), chronic conditions involving inflammation of the gastrointestinal (&#147;GI&#148;) tract, of which the two most common forms are UC and CD. As of 2022, an
aggregate of approximately 2.9&nbsp;million patients across the United States, EU4 (France, Germany, Italy and Spain), the United Kingdom and Japan suffered from IBD, with 1.5&nbsp;million of these patients in the United States alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the primary goals of IBD therapy is to achieve durable&nbsp;clinical remission while simultaneously taking into consideration a
patient&#146;s quality of life and concerns regarding potential side effects. Despite a number of different therapies approved for UC and CD, the vast majority of these therapies require chronic administration via injections or intravenous
infusions, and may come with serious and concerning warnings, including, but not limited to, risks of serious infections leading to hospitalizations or death and increased risks of various malignancies. A vast majority of IBD patients do not achieve
clinical remission with existing therapies, and a significant number of patients will lose response over time, especially those patients on TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapy where anti-drug antibodies are very
common. Further, despite the increased number of biosimilars, such as TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapies, becoming available for the treatment of IBD, biosimilars unfortunately do not alleviate any of the
potential side&nbsp;effect concerns that often cause patients to delay, or avoid altogether, stepping up to more advanced therapies. In addition, although a small number of oral therapies have more recently been approved for the treatment of IBD,
these therapies also come with concerning potential side effects, which can discourage patients from initiating treatment with advanced therapies. Therefore, there continues to be significant unmet need for novel oral therapies with durable
efficacy, improved safety profiles and minimal preinitiation requirements for patients with moderately to severely active IBD. Moreover, we believe the IBD market has significant growth potential driven by growing diagnosis of these diseases and
increased penetration of oral treatments with improved benefit/risk profiles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is
differentiated from competing approaches for the treatment of IBD via its unique mechanism of action. Obefazimod is designed to specifically induce the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT
STYLE="white-space:nowrap">miR-124,</FONT> which plays a critical role in the regulation of the immune response. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In the context of inflammation, <FONT STYLE="white-space:nowrap">miR-124</FONT> modulates the immune response, controlling progression of inflammation and restoring homeostasis of the immune
system, without causing broader immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which target only a single cytokine or pathway, <FONT STYLE="white-space:nowrap">miR-124</FONT>
modulates the expression of several key cytokines and pathways resulting in regulation of the inflammatory process. Modulating multiple inflammatory pathways simultaneously may result in more durable efficacy over the long-term, which is critical in
lifelong conditions such as IBD, potentially differentiating obefazimod from currently available IBD treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our Phase 2 clinical
trials for the treatment of moderately to severely active UC, consistent with the pharmacological effects observed in our preclinical studies, obefazimod demonstrated an onset of symptom relief by day 8 of dosing, with meaningful reductions in
rectal bleeding and stool frequency scores. In our induction Phase 2b clinical trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant reduction in Modified Mayo Score, a measure of disease activity, as
well as secondary endpoints of clinical remission, endoscopic improvement, clinical response, and reduction of fecal calprotectin, as compared to placebo. In addition, we observed high rates of sustained and newly achieved clinical remission in the
subsequent open-label maintenance extension trial of up to two years of treatment, of which approximately 45% of patients were previously exposed to biologics or Janus kinase (&#147;JAK&#148;) inhibitors. The majority of patients previously exposed
to advanced therapy prior to enrollment were highly refractory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, we reported the results from the final analysis of our
Phase 2b open-label maintenance trial, including 217 patients of which 164 patients (76%) completed the second year of once-daily oral treatment with 50 mg obefazimod. At the conclusion of the second year of treatment, 114 of the 217 patients
enrolled (53%) achieved clinical remission and 158 patients (73%) achieved clinical response. Among the 98 <FONT STYLE="white-space:nowrap">bio-refractory</FONT> patients, 66 patients (67%) had a clinical response, 38 patients (39%) were in clinical
remission, 46 patients (47%) had an endoscopy improvement and 20 patients (20%) had an endoscopy remission at week 96. Among the 124 patients that achieved clinical response at the end of the 8 week induction period of the double-blind study, 74
patients (60%) achieved clinical remission, 95 patients (77%) had clinical response, 79 patients (64%) achieved endoscopic improvement and 52 patients (42%) achieved endoscopic remission at week 96. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obefazimod&#146;s tolerability profile indicates potentially important clinical differentiation. As of November&nbsp;30, 2022 (the last safety
data <FONT STYLE="white-space:nowrap">cut-off</FONT> date), 1,074 patients and volunteers had been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one year or more with no change in the observed tolerability
profile underscored by 76% of patients that remained on therapy throughout the <FONT STYLE="white-space:nowrap">two-year</FONT> open-label maintenance trial period. No new adverse safety signals were observed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated our pivotal Phase 3 clinical trials of obefazimod for the treatment of moderately to severely active UC in October 2022, which
consist of two induction trials <FONT STYLE="white-space:nowrap">(ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2)</FONT> and one ABTECT maintenance trial. <FONT STYLE="white-space:nowrap">Top-line</FONT> data from the <FONT
STYLE="white-space:nowrap">ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2</FONT> induction trials is expected to be announced by the first quarter of 2025, and <FONT STYLE="white-space:nowrap">top-line</FONT> data from the ABTECT
maintenance trial is expected to be announced by the first quarter of 2026. We intend to file an Investigational New Drug Application (&#147;IND&#148;) in the fourth quarter of 2023 and plan to initiate a Phase 2 clinical trial in patients with CD
in the first quarter of 2024 with the objective to demonstrate clinical response and tolerability profile consistent with that already observed in our clinical trials for moderately to severely active UC. Based on the results from this Phase 2
clinical trial, we intend to proceed directly to a Phase 3 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is comprised of industry leaders in the fields of
biology, data analytics, and drug development, as well as scientific experts in chronic inflammatory diseases, including IBD. We are led by Marc de Garidel, our Chief Executive Officer, who has more than 40 years of experience in the pharmaceutical
and biotechnology sector. Collectively, our team has decades of experience and a proven track record of advancing compounds into and through clinical development and commercialization, including at the following organizations: Amgen, Arena
Pharmaceuticals, AstraZeneca, BioNTech, Boehringer Ingelheim, Eli Lilly, Genentech/Roche, Guerbet, Ipsen Pharmaceuticals, J&amp;J, Pfizer, Sanofi, Sanofi-Pasteur and Shire/Takeda. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead drug candidate, obefazimod, is in clinical development for the treatment of moderately to severely active UC. We are continuing to
develop obefazimod for the treatment of CD and we are evaluating additional potential inflammatory indications to pursue, subject to the availability of necessary resources and funding. In parallel, we are in the process of generating <FONT
STYLE="white-space:nowrap">follow-on</FONT> compounds based on the <FONT STYLE="white-space:nowrap">miR-124</FONT> platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart
below sets forth details relating to the current stages of development of our lead drug candidate: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g29f00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IBD Overview and Limitations of Existing Treatments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IBD, such as UC and CD, is a chronic life-long immune-mediated inflammatory condition of the GI tract with many contributing factors, including
genetic, environmental and immunologic. UC and CD are the two most common forms of IBD and are characterized by dysregulation of lymphocytes contributing to inflammation. Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of
the GI tract that begin most commonly during adolescence and young adulthood. UC involves the innermost lining of the large intestine, and symptoms include abdominal pain and diarrhea, frequently with blood and mucus. CD can affect the entire
thickness of the bowel wall and all parts of the GI tract from mouth to anus. CD symptoms include abdominal pain, diarrhea and other more systemic symptoms, such as weight loss, nutritional deficiencies and fever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IBD, as of 2022, affected approximately 1.5&nbsp;million patients in the United States alone. As of 2022, the prevalence of UC and CD in the
United States were estimated at approximately 0.9&nbsp;million and 0.6&nbsp;million patients, respectively. The prevalence of IBD in the EU4 and the United Kingdom is estimated at 1.2&nbsp;million with approximately 0.7&nbsp;million patients with UC
and 0.5&nbsp;million patients with CD. As of 2022, an aggregate of approximately 2.9&nbsp;million patients across the United States, EU4, the United Kingdom and Japan suffered from IBD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2022, pharmaceutical sales in IBD were $16.3&nbsp;billion in the United States and $7.4&nbsp;billion in the rest of the world, totaling
$23.7&nbsp;billion worldwide. Pharmaceutical sales in IBD are estimated to be $17.5&nbsp;billion and $26.8&nbsp;billion in the United States and worldwide, respectively, in 2028. Worldwide sales in the UC market were $7.4&nbsp;billion in 2022 and
are estimated to be $10.2&nbsp;billion in 2028, while in the CD market worldwide sales reached $16.3&nbsp;billion in 2022 and are estimated to be $16.6&nbsp;billion in 2028. We believe the IBD market has significant growth potential driven by
growing diagnosis of these diseases and increased penetration of oral treatments with improved benefit/risk profiles. We believe the potential for oral agents to gain significant market share is supported by physician and patient preference for the
convenience of oral administration over injectable agents, increasing demand for therapies with long-term efficacy profiles, and the opportunity for potent and well-tolerated oral agents to expand the overall segment of the moderately to severely
active UC population undergoing treatment. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the widespread use of conventional therapies to treat mild to moderately active
IBD, due to the progressive and lifelong nature of both UC and CD, for many patients the severity of their disease progresses in activity and are considered moderately to severely active. This requires patients and their physicians to consider using
more targeted therapies typically termed &#147;advanced therapies.&#148; The majority of advanced therapies require chronic parenteral administration including
<FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors (e.g., infliximab, adalimumab and golimumab), Interleukin <FONT STYLE="white-space:nowrap">(&#147;IL&#148;)-12/23</FONT> inhibitor (ustekinumab),
anti-integrin antibodies (vedolizumab), or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors (mirikizumab). There are also two classes of oral treatments including JAK inhibitors (e.g., tofacitinib, filgotinib and upadacitinib) and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sphingosine-1-phosphate</FONT></FONT> (&#147;S1P&#148;) receptor agonists (ozanimod). Although these therapies have demonstrated efficacy in UC and/or CD, the majority of IBD patients do
not achieve clinical remission, and a significant number of patients lose response over time, especially those treated with TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapies where anti-drug antibodies are common. Due to
mechanisms of action that are poorly understood, with each line of advanced therapy that is exhausted, patients become less likely to respond to the next advanced therapy utilized in the sequence of care. Moreover, each of the advanced therapy
classes are associated with notable side effect and safety tradeoffs that must be considered before initiating treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following strengths will allow us to advance our proprietary drug candidates through clinical trials, while building upon our
advanced position in the development of therapeutics for IBD and other chronic inflammatory diseases: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our focus on indications of high unmet need and substantial commercial potential, with an initial focus on
IBD. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We focus on indications where existing treatments have left patients with significant unmet needs, and where we
believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial populations and represent large commercial opportunities, pending regulatory
approvals and successful commercialization. Our initial focus is on IBD, chronic conditions involving inflammation of the GI tract, of which the two most common forms are UC and CD. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe the IBD market has significant growth potential driven by growing diagnosis of these diseases and increased penetration of oral
treatments with improved benefit/risk profiles. We believe the need for differentiated treatment options is high, in particular for patients with moderate and severe forms of IBD, for whom available therapies often have limited efficacy and
durability while carrying significant safety and tolerability challenges. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>We believe we are market leaders in leveraging <FONT STYLE="white-space:nowrap">micro-RNA</FONT> biology to
target inflammation. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for
the treatment of IBD via its unique mechanism of action. Obefazimod is designed to specifically induce the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> which plays a
critical role in the regulation of the immune response. In the context of inflammation, <FONT STYLE="white-space:nowrap">miR-124</FONT> modulates the immune response, controlling progression of inflammation and restoring homeostasis of the immune
system, without causing broader immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which target only a single cytokine or pathway, <FONT STYLE="white-space:nowrap">miR-124</FONT>
modulates the expression of several key cytokines and pathways resulting in regulation of the inflammatory process. Modulating multiple inflammatory pathways simultaneously may result in more durable efficacy over the long-term, which is critical in
lifelong conditions such as IBD, potentially differentiating obefazimod from currently available IBD treatments. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Robust data generated from our Phase 2 clinical trials of obefazimod for the treatment of moderately to
severely active UC. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In our Phase 2 clinical trials for the treatment of moderately to severely active UC, consistent
with the pharmacological effects observed in our preclinical studies, obefazimod demonstrated an onset of symptom relief by day 8 of dosing, with meaningful reductions in rectal bleeding and stool frequency scores. In our induction Phase 2b clinical
trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant reduction in Modified Mayo Score, a measure of disease activity, as well as secondary endpoints of clinical remission, endoscopic improvement,
clinical response, and reduction of fecal calprotectin, as compared to placebo. In addition, we observed high rates of sustained and newly achieved clinical remission in the subsequent open-label maintenance extension trial of up to two years of
treatment, of which approximately 45% of patients were previously exposed to biologics or JAK inhibitors. The majority of patients previously exposed to advanced therapy prior to enrollment were highly refractory. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our lead drug candidate, obefazimod, has been well-tolerated in our clinical trials to date.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Obefazimod&#146;s tolerability profile indicates potentially important clinical differentiation. Many existing
therapies for IBD have been limited by safety and tolerability concerns, including increased risks of serious infections or various malignancies, sometimes requiring warning labels. By contrast, as of November&nbsp;30, 2022 (the last safety data <FONT
STYLE="white-space:nowrap">cut-off</FONT> date), the tolerability profile of obefazimod is supported by more than 1,074 patients and volunteers that had been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one
year or more with no change in the observed tolerability profile. In addition, to date, the entire obefazimod safety database presents no death or malignancies and no reported clinically significant changes in laboratory parameters, such as liver
function, hemoglobin levels and white blood cell counts. The most common treatment emergent adverse event (&#147;TEAE&#148;) reported has been mild to moderate headache, which has been transient and manageable with or without <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> medications. Furthermore, at present, no increased rate of opportunistic infections or malignancies compared with placebo have been observed across all
clinical trials. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Compelling and differentiating clinical characteristics position obefazimod as a potential early-line therapy
for moderately to severely active UC. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Therapies currently available to patients with UC in the first-line setting
are limited to older, broad immunosuppressive agents with safety, tolerability, and efficacy challenges. Advanced therapies, which include biologic agents such as TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors, <FONT
STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors, carry significant safety and tolerability challenges and their administration, as injectable agents, is not convenient to patients.
Newer oral molecules, such as JAK inhibitors and S1P receptor agonists, while addressing convenient route of administration for patients, also present safety and tolerability challenges. Comparatively, obefazimod is being developed as a once-daily,
oral medication which, combined with its observed tolerability to date, would represent a meaningfully differentiated clinical profile from existing therapies. We believe this may position obefazimod as an early-line, or first-line after failure of
conventional therapies, treatment choice for both prescribers and patients, if approved. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our experienced team is comprised of global industry leaders in the development of therapeutics for chronic
inflammatory diseases. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe that the breadth of experience and accomplishments of our management team, board
of directors and scientific advisory board, combined with our broad network of established relationships with leaders in the industry and medical community, provide us with fresh insights into drug development and commercialization, and have allowed
us to bring together top researchers to build interdisciplinary research and development teams. We are led by Marc de Garidel, our Chief Executive Officer, who has more than 40 years of experience in the pharmaceutical and biotechnology sector and
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
successfully led the sales of CinCor Pharma to AstraZeneca in 2023 and Corvidia Therapeutics to Novo Nordisk in 2020. Collectively, our team has decades of experience and a proven track record of
advancing compounds into and through clinical development and commercialization, including at the following organizations: Amgen, Arena Pharmaceuticals, AstraZeneca, BioNTech, Boehringer Ingelheim, Eli Lilly, Genentech/Roche, Guerbet, Ipsen
Pharmaceuticals, J&amp;J, Pfizer, Sanofi, Sanofi-Pasteur and Shire/Takeda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary goal is to develop and commercialize obefazimod for the treatment of inflammatory diseases, starting with moderately to severely
active UC. We have already generated compelling data in moderately to severely active UC from our Phase 2a and 2b clinical trials, which we believe provides us with potential readthrough into broader set of inflammatory diseases. We focus on
indications with high unmet needs with substantial commercial potential. To achieve our goal, we are pursuing the following key elements of our strategy: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance obefazimod through pivotal clinical trials and establish obefazimod as a new treatment for moderately
to severely active UC. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe that the strength of the data we have generated in our Phase 2 clinical trials,
specifically its potential to demonstrate rapid onset of action, durable efficacy and tolerability, uniquely position obefazimod as a potential leader in moderately to severely active UC. We believe our data, if supported by the results of our Phase
3 clinical trials, well-positions obefazimod as a potential early-line, or first-line after failure of conventional therapies, treatment choice for UC, if approved. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand the IBD opportunity for obefazimod to include patients with CD. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">CD shares many of the underlying pathophysiological processes and clinical manifestations of UC. Based on the positive clinical data generated
in our UC trials, preclinical studies in dextran sulfate sodium model which provide support for pursuing further development in CD, and underlying biological and mechanistic rationale, we plan to initiate a Phase 2a clinical trial in patients with
CD to potentially demonstrate outcomes consistent with those observed in our Phase 2 clinical trials for moderately to severely active UC. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Optimize value of <FONT STYLE="white-space:nowrap">miR-124</FONT> modulation platform to expand our pipeline
of novel therapeutics for the treatment of IBD and other inflammatory indications. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Since obefazimod&#146;s
upregulation of <FONT STYLE="white-space:nowrap">miR-124</FONT> exerts anti-inflammatory effects via modulating translation of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines and chemokines, we believe obefazimod may have a role
in other indications which may benefit from therapeutic intervention by such an approach. Our strategy is to conduct <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies with obefazimod to show
that <FONT STYLE="white-space:nowrap">miR-124</FONT> upregulation demonstrates disease-modifying effects in other inflammatory conditions where there is unmet medical need. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Opportunistically evaluate strategic partnerships to maximize the value of obefazimod and our therapeutic
pipeline. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We currently hold and intend to retain worldwide development and commercialization rights for obefazimod.
For certain geographies, we may opportunistically enter into strategic partnerships to accelerate development activities in order to realize the commercial potential of obefazimod as well as other assets in our pipeline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is comprised of
industry leaders in the fields of biology, data analytics, and drug development, as well as scientific experts in chronic inflammatory diseases including IBD, with 34 full-time employees as of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
June&nbsp;30, 2023. Collectively, our team has decades of experience and a proven track record of advancing compounds into and through clinical development and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marc de Garidel, our Chief Executive Officer, has more than 40 years of experience in the pharmaceutical and biotechnology sector, including
12 years of experience as Chief Executive Officer of pharmaceutical and biotechnology companies. Between July 2021 and April 2023, he served as Chief Executive Officer of CinCor Pharma and led its successful sale for up to $1.8&nbsp;billion, subject
to the achievement of certain milestones, to AstraZeneca in February 2023. From April 2018 until August 2020, he was Chief Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for $2.1&nbsp;billion in total consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team also consists of other top industry veterans such as Didier Blondel, our Chief Financial Officer and Board Secretary, who
was previously Chief Financial Officer at Sanofi Pasteur MSD; Sheldon Sloan, MD, M Bioethics, our Chief Medical Officer, who has over 30 years of experience in academia and the biopharmaceutical industry, with an extensive track record in the field
of gastroenterology and IBD; Michael Ferguson, MBA, our Chief Commercial Officer, who has over 22 years of experience in the biopharmaceutical industry, including 13 years in leading commercial positions at Shire/Takeda, followed by Arena
Pharmaceuticals; and Pierre Courteille, Pharmacist, MBA, our Chief Business Officer, who has more than 25 years of experience in marketing, sales and business development within the pharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is led by our Chairman and Chief Executive Officer, Marc de Garidel. Additional board members include: Corinna zur
Bonsen-Thomas, <FONT STYLE="white-space:nowrap">Co-founder</FONT> and Chief Executive Officer of RetInSight and former General Counsel at Baxter International; Carol Brosgart, MD, Clinical Professor of Medicine, Epidemiology and Biostatistics at the
University of California, San Francisco; Kinam Hong MD, MBA, CFA, Partner at the Crossover Fund of Sofinnova; Troy Ignelzi, CFO of Karuna Therapeutics; June Lee, MD, Venture Partner at 5AM Ventures; Antonino Ligresti MD, representing Sant&eacute;
Holdings SRL, and former President of G&eacute;n&eacute;rale de Sant&eacute;; and Philippe Pouletty, MD, our founder and Managing Partner at Truffle Capital, representing Truffle Capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An
investment in our securities involves a high degree of risk. Any of the factors set forth under &#147;Risk Factors&#148; may limit our ability to successfully execute our business strategy. You should carefully consider all of the information set
forth in this prospectus and, in particular, should evaluate the specific factors set forth under &#147;Risk Factors&#148; in deciding whether to invest in our ordinary shares or ADSs. Among these important risks are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a clinical-stage company with a limited operating history and no approved products and no historical
product revenues, which makes it difficult to assess our future prospects and financial results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred considerable losses historically, which we anticipate will continue and may increase in the
future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we consummate the offering, we will require substantial additional funding, which may not be available on
acceptable terms or at all, and failure to obtain this necessary capital may force us to delay, limit or terminate our product development efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our financial statements contain a footnote describing management&#146;s assumption regarding our ability to
continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have significant debt commitments, which require us to meet certain operating covenants, and if we fail to
comply with those covenants the bondholders would be able to accelerate our repayment obligations. Additionally, the conversion of some or all of our bonds into ordinary shares would dilute the ownership interests of existing shareholders.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drug candidates under development must undergo costly, rigorous and highly regulated preclinical studies and
clinical trials, whose time of completion, number and outcomes are uncertain. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are heavily dependent on the success of our drug candidates, in particular obefazimod, and we cannot be
certain that obefazimod or any of our other current or future drug candidates will receive regulatory approval, and, without regulatory approval, we will not be able to market our drug candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical failure can occur at any stage of clinical development. The results of earlier clinical trials as well
as data from any interim analysis of ongoing trials are not necessarily predictive of future results and any drug candidate we advance through clinical trials may not have favorable results in later clinical trials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future may depend on our most advanced clinical development program, obefazimod, since our other drug
candidates are in a less advanced stage of development. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth,
which could disrupt our operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on a small number of third-party suppliers, and in certain cases a single-source supplier, and we may be
in a position of dependence with respect to our subcontractors. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future success depends on our ability to retain our key executives and to attract, retain and motivate
qualified personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There are material weaknesses in our internal controls over financial reporting and if we are unable to maintain
effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected, which could adversely affect our business, investor confidence and the market price of our securities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to exclusively commercialize our drug candidates may decrease if we are unable to protect our
intellectual property rights or if these rights are insufficient for our purposes. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate and Other Information </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as a <I>soci&eacute;t&eacute; anonyme</I> (limited liability company) on December&nbsp;4, 2013 and registered at the
Paris Trade and Company Register on December&nbsp;27, 2013 for a period of 99 years until December&nbsp;22, 2112, subject to extension or early dissolution, under the number 799&nbsp;363&nbsp;718. Our principal executive offices are located at <FONT
STYLE="white-space:nowrap">7-11</FONT> boulevard Haussmann 75009 Paris, France, and our telephone number is +33&nbsp;(0)&nbsp;1&nbsp;53&nbsp;83&nbsp;08&nbsp;41. We have one wholly owned subsidiary, Abivax LLC, a Delaware limited liability company,
formed on March 20, 2023. Our agent for service of process in the United States is CT Corporation System, 1015 15th Street N.W., Suite 1000, Washington, D.C. 20005. We also maintain a website at www.abivax.com. The reference to our website is an
inactive textual reference only, and the information contained in, or that can be accessed through, our website is not a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to make our reports and other information filed with or furnished to the SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange
Act available, free of charge, through our website, as soon as reasonably practicable after those reports and other information are electronically filed with or furnished to the SEC. Information on our website or any other website is not
incorporated by reference into this prospectus and does not constitute a part of this prospectus. The SEC maintains an internet site at http://www.sec.gov that contains reports and other information regarding issuers that file electronically with
the SEC. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;).
As an emerging growth company, we may take advantage of certain reduced disclosure and other requirements that are otherwise generally applicable to public companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (the
&#147;Sarbanes-Oxley Act&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to present only two years of audited financial statements in addition to any required interim
financial statements and correspondingly reduced disclosure in management&#146;s discussion and analysis of financial condition and results of operations in the registration statement for the global offering of which this prospectus forms a part;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that we no longer qualify as a foreign private issuer: (i)&nbsp;reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements; and (ii)&nbsp;exemptions from the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation, including golden
parachute compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions for up to five years or until such earlier time that
we no longer qualify as an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of: (i)&nbsp;the last day of the fiscal year in which our annual gross revenues exceed $1.235&nbsp;billion; (ii)&nbsp;the
first day of the year following the first year in which, as of the last business day of our most recently completed second fiscal quarter, the market value of our common equity held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$700&nbsp;million; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the previous three years; and (iv)&nbsp;the last day of the fiscal year
ending after the fifth anniversary of our initial public offering of our ADSs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to take advantage of some but not all of
these exemptions. For example, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended (&#147;the Securities
Act&#148;), for complying with new or revised accounting standards. Given that we currently report and expect to continue to report under IFRS, as issued by the IASB, we have irrevocably elected not to avail ourselves of this extended transition
period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB. Since IFRS make no distinction between public and private companies for purposes of
compliance with new or revised accounting standards, the requirements for our compliance as a private company and as a public company are the same. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the
information contained herein may be different than the information you receive from other public companies in which you hold equity securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of being a Foreign Private Issuer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also considered a &#147;foreign private issuer&#148; under U.S. securities laws. In our capacity as a foreign private issuer, we are
exempt from certain rules under the Exchange Act, which impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&nbsp;14 of the Exchange Act. In addition, our officers, directors and principal
shareholders are exempt from the reporting and short-swing profit recovery provisions of Section&nbsp;16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our securities. Moreover, we are not
required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation FD, which
restricts the selective disclosure of material information. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until such time as we are no longer a foreign
private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S.&nbsp;residents and any of the following three circumstances applies: (i)&nbsp;the majority of our
executive officers or directors are U.S. citizens or residents; (ii)&nbsp;more than 50% of our assets are located in the United States; or (iii)&nbsp;our business is administered principally in the United States. For additional information relating
to our principal shareholders, see &#147;Principal Shareholders.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have taken advantage of certain reduced reporting and
other requirements in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity securities. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE GLOBAL OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Global&nbsp;offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares offered by us, consisting of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the form of ADSs offered in the U.S. offering and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares offered in the European private placement. The closing of the U.S. offering and the European private placement
will occur simultaneously. The total number of ordinary shares (including in the form of the ADSs) in the U.S. offering and the European private placement is subject to reallocation between these offerings, as permitted under the applicable laws and
regulations. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">U.S. offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs, each representing one ordinary share. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">European private placement </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering&nbsp;price </P></TD>
<TD>The offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros will be determined through negotiations between us and the representatives of the underwriters, and by reference to the prevailing market
prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors, but will not be lower than 85% of the volume-weighted-average price of our ordinary shares on Euronext Paris for the fifteen
(15)&nbsp;trading days preceding the day the offering price is determined. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Purchaser Restrictions </P></TD>
<TD>Under the authority granted by our shareholders to conduct the global offering, the ADSs and ordinary shares that we are offering may only be purchased initially by (i)&nbsp;French or foreign individuals, legal entities, including companies,
trusts or investment funds or other investment vehicles of any kind, investing, as a main activity, or having invested more than &#128;1&nbsp;million during the 24 months preceding the considered capital increase (a)&nbsp;in the pharmaceutical
sector; and/or (b)&nbsp;in a growth stock listed on a regulated market or a multilateral negotiation system (type Euronext Growth) considered as &#147;community small and <FONT STYLE="white-space:nowrap">medium-sized</FONT> companies&#148; in the
meaning of annex I to the Regulation (CE) No.&nbsp;651/2014 of the European Commission of June&nbsp;17, 2014; (ii)&nbsp;one or more of our strategic partners, located in France or abroad, who has (have) entered into or will enter into one or more
partnership agreements (development, <FONT STYLE="white-space:nowrap">co-development,</FONT> distribution, manufacturing agreements, etc.) or commercial agreements with us (or a subsidiary) and/or companies we control, that control us or are
controlled by the same person(s), directly or indirectly, within the meaning of Article L. <FONT STYLE="white-space:nowrap">233-3</FONT> of the French Commercial Code; and/or (iii) any French or foreign investment services provider, or any foreign
institution having an equivalent status, likely to guarantee the realization of an issue intended to be placed with the persons referred to in (i) and/or (ii)&nbsp;above and, in this context, to subscribe the securities issued.
</TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares (including ordinary shares in the form of ADSs) to be outstanding immediately after the
global offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional ADSs and/or ordinary shares in the global offering </P></TD>
<TD>We have agreed to issue, at the option of the underwriters, within 30&nbsp;days after the date of this prospectus, up to an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional
ordinary shares (representing up to 15% of the initial size of the global offering). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">American Depositary Shares (or ADSs) </P></TD>
<TD>Each ADS represents one ordinary share, par value &#128;0.01 per share. Purchasers of ADSs in the U.S. offering will have the rights of an ADS holder as provided in the deposit agreement among us, the depositary and all holders and beneficial
owners of ADSs issued thereunder. To better understand the terms of the ADSs, purchasers of ADSs should carefully read the section in this prospectus titled &#145;&#145;Description of American Depositary Shares.&#146;&#146; We also encourage
purchasers of ADSs to read the deposit agreement, which is filed as an exhibit to the registration statement of which this prospectus forms a part. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Depositary </P></TD>
<TD>Citibank, N.A. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that we will receive net proceeds from the global offering of approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), based on an assumed
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS, or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, the closing price of our ordinary shares on Euronext Paris on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, after deducting the estimated underwriting commissions and estimated offering expenses payable by us. We intend to use the net proceeds from the global offering,
together with our existing resources as follows: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million) to fund the development of obefazimod for UC;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million) to fund the development of obefazimod for CD; and
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder, if any, for working capital and for other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may also use a portion of the remaining net proceeds and our existing cash and cash equivalents to in-license, acquire, or invest in complementary businesses, technologies, products or assets. However, we have no
current commitments or obligations to do so. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Use of Proceeds&#148; for more information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dividend policy </P></TD>
<TD>We do not expect to pay any dividends on the ordinary shares or ADSs in the foreseeable future. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in the ordinary shares or ADSs. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol for our ADSs </P></TD>
<TD>&#147;ABVX&#148; </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Euronext Paris trading symbol for our ordinary shares </P></TD>
<TD>&#147;ABVX&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares (including ordinary shares in the form of ADSs) that will be outstanding
after the global offering is based on 42,547,568 ordinary shares outstanding as of June&nbsp;30, 2023 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">308,984 ordinary shares issuable upon the exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2023
at a weighted-average exercise price of &#128;7.57 per ordinary share (or $8.24) based on the exchange rate in effect as of June&nbsp;30, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">422,909 ordinary shares issuable upon the exercise of founder&#146;s share warrants (BCE) outstanding as of
June&nbsp;30, 2023 at a weighted-average exercise price of &#128;9.77 per ordinary share (or $10.64) based on the exchange rate in effect as of June&nbsp;30, 2023; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">769,834 ordinary shares issuable upon the conversion of convertible bonds (OCEANE) outstanding as of
June&nbsp;30, 2023 at a weighted-average conversion price of &#128;32.47 per ordinary share (or $35.36) based on the exchange rate in effect as of June&nbsp;30, 2023; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,413,543 ordinary shares reserved for future issuance under our share-based compensation plans and other
delegations of authority from our shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References to outstanding ordinary shares included in this prospectus
include 11,487 treasury shares issued by us as of June 30, 2023. Except as otherwise noted, the information in this prospectus assumes no exercise by the underwriters of their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADS and/or ordinary shares in the global offering and no exercise of share subscription warrants or vesting of free
shares or other equity awards subsequent to June&nbsp;30, 2023. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our historical financial data. We derived the summary statement of income (loss) for the years ended,
December&nbsp;31, 2022 and 2021 from our audited financial statements included elsewhere in this prospectus. Our audited financial statements have been prepared in accordance with International Financial Reporting Standards (&#147;IFRS&#148;), as
issued by the International Accounting Standards Board (&#147;IASB&#148;) and endorsed by the European Union (the &#147;EU&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
summary interim condensed consolidated statements of income (loss) for the six months ended June&nbsp;30, 2023 and 2022 and summary interim condensed consolidated financial position data as of June&nbsp;30, 2023 have been derived from our unaudited
interim condensed consolidated financial statements included elsewhere in this prospectus, prepared in accordance with IAS 34, Interim Financial Reporting, the standard of IFRS applicable to interim financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary financial data for the periods as of the dates indicated are qualified by reference to and should be read in conjunction
with our audited financial statements and related notes and our unaudited interim condensed consolidated financial statements and related notes included elsewhere in this prospectus, as well as the sections entitled &#147;Presentation of Financial
Information&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical results for any prior period do not necessarily indicate our expected results for any future period, and our interim results
are not necessarily indicative of the results that may be expected for a full fiscal year. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Statement of Income (Loss) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six&nbsp;Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,961</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,284</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and Development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(53,361</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(69,419</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(28,317</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(64,836</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(26,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,052</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,849</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of outstanding shares used for computing basic/diluted loss per
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,455,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,092,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,759,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic / diluted loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2.75</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3.18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1.26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Condensed Consolidated Statement of Financial Position Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As adjusted to give effect to the issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares (including ordinary shares in the form of ADSs) in the global offering at the assumed initial offering price of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), which is the last reported closing price of our ordinary shares on Euronext Paris on June&nbsp;30, 2023, after
deducting the estimated underwriting commissions and estimated offering expenses payable by us. The as adjusted information presented above is illustrative only and will depend on the actual initial public offering price and other terms of the
global offering determined at pricing, including the amount by which actual offering expenses are higher or lower than estimated. Each &#128;1.00 ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed offering price
of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), which is the last reported sale price of our ordinary shares on Euronext Paris on June&nbsp;30, 2023 would
increase or decrease as adjusted cash and cash equivalents, premiums related to share capital, total shareholders&#146; equity and total capitalization by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming that the number of ordinary shares (which may be in the form of ADSs) offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the
estimated underwriting commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (including ordinary shares in the form of ADSs) we are offering. An increase or decrease in the number
of ordinary shares (which may be in the form of ADSs) offered by us by 1,000,000 ordinary shares (which may be in the form of ADSs) would increase or decrease as adjusted cash and cash equivalents, premiums related to share capital, total
shareholders&#146; equity and total capitalization by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming that the assumed offering price remains the same, and after
deducting the estimated underwriting commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>An investment in our ordinary shares (including ordinary shares in the form of ADSs) involves a high degree of risk. You should carefully
consider the risks and uncertainties described below, together with all of the information contained in this prospectus, including our financial statements and the related notes, before making an investment decision regarding the ordinary shares
(including ordinary shares in the form of ADSs). If any of the following risks are realized, our business, financial condition, results of operations or prospects could be materially and adversely affected. In that event, the market price of our
securities could decline, and you could lose part or all of your investment. The risks discussed below also include forward-looking statements, and our actual results may differ substantially from those discussed in these forward-looking statements.
See &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Financial Position and Need for Additional Capital
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage company with a limited operating history and no approved products and no historical product revenues, which makes it
difficult to assess our future prospects and financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company with a limited
operating history upon which you can evaluate our business and prospects. We were incorporated as a <I>soci</I><I>&eacute;</I><I>t</I><I>&eacute;</I><I> anonyme</I> (limited liability company) on December&nbsp;4, 2013 and, to date, we have focused
primarily on organizing and staffing our company, business planning, raising capital, identifying, acquiring <FONT STYLE="white-space:nowrap">and&nbsp;in-licensing&nbsp;our</FONT> drug candidates, establishing our intellectual property portfolio,
conducting research, preclinical studies and clinical trials, establishing arrangements with third parties for the manufacture of our drug candidates and related raw materials, and providing general and administrative support for these
operations.&nbsp;Investment in product development in the healthcare industry, including of biopharmaceutical products, is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential drug
candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval or become commercially viable. As a result, our ability to reduce our losses and reach consistent profitability from product sales is
unproven, and we may never sustain profitability. We have no products approved for commercial sale and have not generated any revenue from product sales to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue from product sales and achieve and maintain profitability depends on our ability, alone or with any future
collaborators, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our lead drug candidate, obefazimod. Our prospects, including our ability to finance our operations and generate revenue from
product sales, therefore will depend substantially on the development and commercialization of obefazimod, as other programs in our preclinical portfolio are still in earlier stages of development. Since our inception in 2013, the majority of our
operating income has been derived from our reliance on research collaborations unrelated to obefazimod, and we do not anticipate generating revenue from product sales for the next several years, if ever. Our ability to generate revenue from product
sales depends heavily on our or any future collaborators&#146; success in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely and successful completion of clinical development of obefazimod, our lead drug candidate;
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining regulatory and marketing approval for obefazimod and any future drug candidates for
which we successfully complete clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching and commercializing any drug candidates for which we obtain regulatory and marketing approval by
establishing a sales force, marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining coverage and adequate reimbursement from government and third-party payors for our current or any
future drug candidates, if approved, both in the United States and internationally, and reaching acceptable agreements with foreign government and third-party payors on pricing terms; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing, validating and maintaining a commercially viable, sustainable, scalable, reproducible and
transferable manufacturing process for obefazimod or any future drug candidates that are compliant with current good manufacturing practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide an
adequate amount and quality of drugs and services to support our planned clinical development, as well as the market demand for obefazimod and any future drug candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining market acceptance, if and when approved, of obefazimod or any future drug candidates as a viable
treatment option by physicians, patients, third-party payors and others in the medical community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementing additional internal systems and infrastructure, as needed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter, and
performing our obligations pursuant to such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade
secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">avoiding and defending against third-party interference or infringement claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attracting, hiring and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred considerable losses historically, which we anticipate will continue and may increase in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred net losses. For the years ended December&nbsp;31, 2022 and 2021, we incurred net losses of
&#128;60.7&nbsp;million and &#128;42.5&nbsp;million, respectively. As of June 30, 2023, we had an accumulated deficit of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have devoted most of our financial resources to research and development, including our clinical and preclinical development activities.
Even if we obtain regulatory approval to market a drug candidate, our future revenues will depend upon the size of any markets in which our drug candidates have received approval and our ability to achieve sufficient market acceptance, reimbursement
from third-party payors and adequate market share for our drug candidates in those markets. There can be no assurance that we will ever earn any revenues or revenues sufficient to offset past, current and future losses or achieve profitability,
which would impair our ability to sustain our operations. Moreover, even if we achieve profitability, such profitability may not be sustainable. Any inability to generate sustained profits could have a material adverse effect on our business,
prospects, financial condition, cash flows and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and operating
losses for the foreseeable future. We do not anticipate achieving profitability in the future unless we obtain the regulatory approvals necessary to commercialize obefazimod and any additional drug candidates that we may pursue in the future. We
anticipate that our expenses will increase substantially if, and as, we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely and successfully complete clinical development of obefazimod, our clinical-stage drug candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek and maintain regulatory and marketing approvals for obefazimod and any future drug candidates for which we
successfully complete clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the preclinical and clinical development of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the scope of our current clinical trials for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">begin new clinical trials for our drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, scale and validate our commercial manufacturing capabilities for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we may obtain
marketing approval for which we have not entered into a collaboration with a third-party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to discover, identify and validate additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other drug candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty or other payments under <FONT STYLE="white-space:nowrap">in-license</FONT> or
collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect, enforce and expand our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract new and retain existing skilled personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create additional infrastructure to support our operations as a U.S. public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, following the issuance of royalty certificates in September 2022 and other royalties that may become payable under our royalty
agreements, the payment of royalties in the event of commercialization of obefazimod will result in a decrease in cash flows generated by sales of the product, which could have an unfavorable impact on our financial position, particularly at the
beginning of the commercialization phase. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net losses we incur may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> such that a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future performance. In any particular period or periods, our operating
results could be below the expectations of securities analysts or investors, which could cause the price of the ordinary shares (which may be in the form of ADSs) to decline. An increase in operational losses would have a material adverse effect on
our business, financial position, income, growth and outlook. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we consummate the offering, we will require substantial additional funding,
which may not be available on acceptable terms or at all, and failure to obtain this necessary capital may force us to delay, limit or terminate our product development efforts or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. We are currently advancing obefazimod through clinical development
and conducting preclinical studies with respect to other programs. Developing drug candidates is expensive, lengthy and risky, and we expect our research and development expenses to increase substantially in connection with our ongoing activities,
particularly as we seek to advance obefazimod toward commercialization. If our clinical trials are successful and we obtain regulatory approval for drug candidates that we develop, we will incur commercialization expenses before these drug
candidates are marketed and sold. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, our cash and cash equivalents were
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. We expect that the net proceeds from the global offering and our existing cash and cash equivalents (after taking into account deduction of current
financial liabilities) will be sufficient to fund our current operations for at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months. However, our operating plans may change as a result of a variety of factors, and we may need
to seek additional funds sooner than planned. In any event, we will require additional capital to pursue preclinical and clinical activities, obtain regulatory approval for and commercialize our drug candidates. More specifically, we will require
additional funding to further advance our Phase 3 clinical trials in UC. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate sufficient product or royalty revenue
to finance our cash requirements, which we may never do, we may seek additional financing in the form of public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and
collaborations, strategic alliances and licensing arrangements or a combination of these sources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount and timing of our funding needs will depend on factors that are largely outside
of our control, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher costs and slower-than-expected progress on our research and development programs and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to preparing, filing, enforcing and maintaining our patents and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of the research required and time needed to sign licensing agreements with industrial partners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to respond to technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher costs and longer-than-expected lead times obtaining regulatory authorizations, including time for
preparing application dossiers for the relevant authorities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new opportunities for developing new products or acquiring technologies, products or companies.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and, if approved, commercialize our drug candidates. In addition, we cannot guarantee that future financing will be available in
sufficient amounts or on terms acceptable to us, if at all. Under French law, our share capital may be increased only with shareholders&#146; approval at an extraordinary general shareholders&#146; meeting on the basis of a report from the board of
directors. In addition, the French Commercial Code imposes certain limitations on our ability to price certain offerings of our share capital without preferential subscription rights (<I>droit pr&eacute;f&eacute;rentiel de souscription</I>), which
limitation may prevent us from successfully completing any such offering. See &#147;Description of Share Capital&#151;Rights, Preferences and Restrictions Attaching to Ordinary Shares (Articles 7, 11, 30, 31 and 32 of the <FONT
STYLE="white-space:nowrap">By-Laws).&#148;</FONT> To the extent that we raise additional capital, the terms of any financing may adversely affect the holdings or the rights of our shareholders and the issuance of additional securities, whether
equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary shares (which may be in the form of ADSs) to decline. The sale of additional equity or convertible securities will dilute our shareholders
ownership interest. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our
ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. To the extent that we raise additional funds through arrangements with research and
development partners or otherwise, we may be required to relinquish some of our technologies, drug candidates or revenue streams, license our technologies or drug candidates on unfavorable terms, or otherwise agree to terms unfavorable for us. If we
are unable to obtain adequate financing, we may be required to delay, reduce or eliminate the number or scope of our projects and drug candidates (including our preclinical studies and clinical trial programs). In order to obtain financing, we may
be required to relinquish rights to some of our technologies or drug candidates or otherwise agree to terms unfavorable to us. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue
one or more of our research or development programs or the commercialization of any drug candidate or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could impair our prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our financial statements contain a footnote describing management&#146;s assumption regarding our ability to continue as a going concern, which could
prevent us from obtaining new financing on reasonable terms or at all. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our independent registered public accounting firm
included an emphasis of matter in its report that our financial statements, included elsewhere in this prospectus, have been prepared assuming that we will continue as a going concern. We have incurred net losses of &#128;60.7 million and
&#128;42.5&nbsp;million for the years ended December&nbsp;31, 2022 and 2021, respectively. As of June&nbsp;30, 2023, we had an accumulated deficit of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million.
Recurring losses may cast significant doubt or raise substantial doubt about our ability to continue as a going concern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There cannot be any assurance that we will be successful in obtaining necessary
financing in the future to continue as a going concern or achieve profitability. We expect that we will need to raise additional capital following the completion of this equity offering in order to complete the necessary trials to achieve commercial
viability of some or all of our drug candidates. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to our products. The sale of
additional equity may dilute existing shareholders and newly issued shares may contain senior rights and preferences compared to currently outstanding ordinary shares. Issued debt securities may contain covenants and limit our ability to pay
dividends or make other distributions to our shareholders. If we are unable to obtain such additional financing, future operations (such as our clinical development programs) would need to be scaled back or discontinued. These factors may raise
substantial doubt about our ability to continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There are material weaknesses in our internal controls over financial reporting
and if we are unable to maintain effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected, which could adversely affect our business, investor confidence and the market
price of our securities. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting for external purposes in accordance with international financial reporting standards. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and
fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; providing reasonable assurance that receipts and expenditures of our assets are made in
accordance with management authorization; and providing reasonable assurance that unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements would be prevented or detected on a timely
basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must maintain effective internal controls over financial reporting in order to accurately and timely report our results of operations and
financial condition. In addition, as a public company listed in the United States, the Sarbanes-Oxley Act will require, among other things, that we assess the effectiveness of our internal controls over financial reporting at the end of each fiscal
year, starting with the end of the first full fiscal year after the completion of the U.S. offering. However, our independent registered public accounting firms will not be required to attest to the effectiveness of our internal controls over
financial reporting for so long as we are an &#147;emerging growth company,&#148; which may be up to five fiscal years following the date of this U.S. offering. An independent assessment of the effectiveness of our internal controls could detect
problems that our management&#146;s assessment might not. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has not completed an assessment of the effectiveness of our
internal controls over financial reporting, and our independent registered public accounting firms have not conducted an audit of our internal controls over financial reporting. In conjunction with preparing our financial statements as of and for
the years ended December&nbsp;31, 2022 and 2021, material weaknesses in our internal controls over financial reporting were identified. These material weaknesses related to a lack of risk assessment, as well as formal, documented and implemented
processes, controls and review procedures, specifically due to a lack of a sufficient number of professionals with an appropriate level of internal control knowledge, training and experience. These material weaknesses could result in material
inaccuracies in our financial statements and impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a remediation plan to address these material weaknesses and strengthen our controls in these areas. In this regard, we have
started to reorganize our finance and accounting function by hiring additional experienced employees to provide more review and oversight over our financial processes. While we are working to remediate the material weaknesses as quickly and
efficiently as possible, we cannot at this time provide the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected timeline in connection with implementing our remediation plan. As of December 31, 2022, we had not yet completed remediation of these material weaknesses. These remediation measures may
be time-consuming and costly and might place significant demands on our financial and operational resources. There is no assurance that the actions we may take in the future will be sufficient to remediate the control deficiencies that led to these
material weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that will have to be met for our management to assess our internal controls over financial reporting
pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act are complex and require significant documentation, testing and possible remediation. These stringent standards require that our audit committee be advised and regularly updated on
management&#146;s review of internal controls over financial reporting. We have begun the process of designing, implementing, and testing the internal controls over financial reporting required to comply with this obligation. This process is
time-consuming, costly, and complicated. Our management may not be able to effectively and timely implement controls and procedures that adequately respond to the increased regulatory compliance and reporting requirements that will be applicable to
us as a public company listed in the United States. If we fail to staff our accounting and finance function adequately or maintain internal controls over financial reporting adequate to meet the demands that will be placed upon us as a public
company listed in the United States, our business and reputation may be harmed and the price of our ordinary shares and ADSs may decline. In addition, undetected material weaknesses in our internal controls over financial reporting could lead to
restatements of financial statements and require us to incur the expense of remediation. Any of these developments could result in investor perceptions of us being adversely affected, which could cause a decline in the market price of our
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our growth
will place significant additional pressure on our system of internal control over financial reporting. Any failure to maintain an effective system of internal control over financial reporting could limit our ability to report our financial results
accurately and timely or to detect and prevent fraud. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant impairment of our goodwill could materially impact our financial position and
results of our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry a goodwill balance, which is allocated to obefazimod and ABX196 cash generating units, on our
balance sheet as a result of past business acquisitions, including with respect to obefazimod and ABX196. We are required to review our goodwill for impairment on an annual basis or more frequently if events or changes in circumstances indicate
evidence of impairment. For the year ended December 31, 2022, we recorded a goodwill impairment loss of &#128;13.6 million. The goodwill impairment loss was related to an impairment test conducted with respect to the ABX196 cash-generating unit as a
result of significant external changes in the hepatocellular carcinoma treatment landscape, which are expected to require a new, lengthy, heavy and risky internal development process (use of a combination of compounds). As such, due to the lack of
progress made in the negotiation of a development partnership, we made the decision to freeze the development program for ABX196 in the treatment of hepatocellular cancer, which led to full impairment of ABX196 goodwill. In July 2023, we have
decided to completely stop our ABX196 program, which will be reflected in our next financial statements. There can be no assurance that, based on the results of our annual goodwill impairment tests, we will not be required to identify further
goodwill impairment losses, which could have a material adverse effect on our results of operations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have significant debt commitments,
which require us to meet certain operating covenants, and if we fail to comply with those covenants the bondholders would be able to accelerate our repayment obligations. Additionally, the conversion of some or all of our bonds into ordinary shares
would dilute the ownership interests of existing shareholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12, 2020, we entered into a bonds issue agreement
with Kreos Capital entities (&#147;KC&#148;), pursuant to which we issued bonds in a total principal amount of &#128;15&nbsp;million, comprised of (i)&nbsp;a &#128;10&nbsp;million tranche (the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;Second Tranche A Notes&#148;) and a &#128;5&nbsp;million tranche (the &#147;Second Tranche B Notes&#148;), with an option to issue an additional &#128;5&nbsp;million tranche (the
&#147;Second Tranche C Notes&#148; and collectively with the Second Tranche A Notes and the Second Tranche B Notes, the &#147;Second KC Notes&#148;). The Second Tranche A Notes were issued in October 2020, and the Second Tranche B Notes were issued
in November 2020. The Second KC Notes rank pari passu with the First KC Notes. The bond documentation includes certain restrictive covenants and prepayment provisions, as well as exit fees. If we breach our obligations, it could result in default
and trigger an early repayment of the bond. There is no guarantee that we would have the necessary resources to fund an advance repayment of the bond. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;30, 2021, we issued &#128;25&nbsp;million 6% convertible senior unsecured and unsubordinated bonds due July&nbsp;30, 2026
corresponding to 654,621 convertible bonds (the &#147;OCEANE bonds&#148;). The OCEANE bonds are exchangeable, at the option of the bondholders, for new or existing shares and bear interest at a rate of 6% per annum, payable semi-annually on
January&nbsp;30 and July&nbsp;30 of each year, beginning January&nbsp;30, 2022. The nominal value of each OCEANE bond was set at &#128;38.19, representing a conversion/exchange premium of 25% over the reference share price and corresponding to the
placing price of the newly-issued shares in the concurrent accelerated bookbuilding process announced on July&nbsp;22, 2021. The issue price of each OCEANE bond was &#128;38.19, representing 100% of the principal amount. The exchange ratio was
adjusted on January 30, 2023 in accordance with the terms and conditions of the OCEANE bonds by a decrease of the conversion price to &#128;32.47 per share. The number of underlying shares has increased from 654,621 to 769,834 shares. The exchange
ratio will further be adjusted if the adjusted conversion ratio is higher than the updated conversion ratio on July&nbsp;30, 2023 and January&nbsp;30, 2024. The exchange ratio may be adjusted in the event of certain financial transactions being
undertaken by us as set out in the terms and conditions of the OCEANE bonds. Prior to maturity, bondholders have the right to receive new and/or existing shares by way of <FONT STYLE="white-space:nowrap">set-off</FONT> against amounts owed under the
OCEANE bonds. Exercising this right results in the cancellation of the OCEANE bonds for which it is exercised. We may suspend this right for a period of up to three months in the event of a share capital increase or other financial transaction as
set out in the terms and conditions of the OCEANE bonds. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2020, we obtained a
<FONT STYLE="white-space:nowrap">non-dilutive</FONT> financing in the form of a State-guaranteed loan of &#128;5.0&nbsp;million. The loan was structured with an initial maturity of 12 months at 0.25% and a five-year extension option. In March 2021,
we exercised the five-year extension option with a <FONT STYLE="white-space:nowrap">one-year</FONT> deferral of principal repayment, with the following conditions: (i)&nbsp;a revised interest rate of 0.58% <I>per annum,</I> excluding insurance and
State-guaranteed premium; and (ii)&nbsp;a State-guaranteed premium of &#128;0.1&nbsp;million to be paid by installments over the contract period starting in June 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loan includes certain customary covenants and prepayment provisions. The negative covenants include an undertaking not to dispose of all
or part of our assets for more than 50% of the gross value of our fixed assets. If we breach our obligations under the contract, it could result in default and thus trigger an early repayment of the loan. There is no guarantee that we would have the
necessary resources to cope with an advance repayment demand of the loan. We can also not guarantee that we will have sufficient cash to make the scheduled payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also no guarantee that we will have sufficient cash to pay the bonds issued to KC at maturity, which could have a negative impact on
our business as security interests have been granted on our principal tangible and intangible assets: in particular, on our goodwill, intellectual property rights relating to our main drug candidates, as well as a pledge of our bank accounts and
claims. There is also no guarantee that we will have sufficient cash to make the scheduled payments on the OCEANE bonds or the State-guaranteed loan, which could have a material adverse effect on our business, financial position and results of
operations. Any failure to make scheduled payments or trigger for early repayment of the loan could have a material adverse effect on our business, financial position, income, growth and outlook. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on grants and subsidies, which may not continue to be available and we may be forced to repay
conditional advances prematurely if we fail to comply with our contractual obligations under certain innovation grant agreements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received various grants and conditional advances from Bpifrance under various development programs, in a total amount of
&#128;20.1&nbsp;million as of December 31, 2022. In the event that we do not comply with the contractual conditions stipulated in the aid agreements we have entered into, we may have to repay the sums advanced early. Such premature repayment could
deprive us of the necessary financial resources for our research and development projects and we cannot guarantee that we will find necessary additional financial resources, the timeline for or the possibility of replacing these financial resources
with others. We cannot guarantee that we will have the necessary resources to cope with an early repayment. A material repayment would result in a material adverse effect on our business, operations, financial position, income, growth, and outlook.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the amount and date of payment of current and future grants and subsidies depend on many factors that are not in our
control, including possible <FONT STYLE="white-space:nowrap">non-distribution</FONT> decisions or the freezing of funds, as well as the achievement of key milestones previously agreed on with Bpifrance. Delays or failure in obtaining or replacing
these grants and subsidies in the future could have a material adverse effect on our business, financial position, income, growth and outlook. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current equity agreements and convertible debt instruments may dilute our equity resulting in dilution to our shareholders, including purchasers of our
ordinary shares (including in the form of ADSs) in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our incorporation, we have issued and granted founder
warrants (&#147;BCEs&#148;) and stock subscription warrants (&#147;BSA<B>s</B>&#148;) and granted free bonus shares (&#147;AGAs&#148;) to persons linked to us and financing entities. We have also issued convertible bonds. See &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#151;Liquidity and Capital Resources.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The theoretical
exercise of all the founder warrants and stock subscription warrant instruments giving access to our capital issued and outstanding as of June&nbsp;30, 2023, excluding securities held by financing entities, would allow for the subscription of
731,893 potential new ordinary shares, resulting in a hypothetical dilution equal to 1.7% based on our existing share capital as of June&nbsp;30, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the financing through the issue of OCEANE bonds confers entitlement to subscribe for 769,834 shares, given the adjustment of the
conversion parity on January 30, 2023 in accordance with the terms and conditions of the OCEANE bonds. The hypothetical exercise in full of all these rights would also result in dilution. The full dilution resulting from the potential exercise of
all financial instruments entitling their holders to our capital, which would result in the issue of 1,501,727 shares, corresponds to a potential dilution of 3.5% based on our fully diluted share capital as of June 30, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our general meeting of June 5, 2023 delegated authority to the board of directors (the &#147;Board&#148;) to carry out one or
more capital increases and/or issues of securities giving access to our capital subject to the following limitations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a total maximum nominal amount of the capital increases set at &#128;500,000 (or the equivalent value of that
amount in the event of an issue in another currency) with a total maximum nominal amount of the debt securities that may be issued set at &#128;150,000,000 (or the equivalent value of that amount in the event of an issue in another currency); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares that may be issued or allotted in the context of equity incentive plans (BSAs, stock options and/or
AGA) may not exceed 10% of the share capital on a fully diluted basis recorded as of June 5, 2023. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to maintain certain tax benefits applicable to French biopharmaceutical companies may
adversely affect our operations and finances. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a French biopharmaceutical company, we have benefited from certain tax
advantages, including, for example, the Research and Development Tax Credit (<I>cr</I><I>&eacute;</I><I>dit imp</I><I>&ocirc;</I><I>t recherche</I>) (&#147;Research Tax Credit&#148;), which is a French tax credit aimed at stimulating research and
development. The Research Tax Credit can be offset against French corporate income tax due and the portion in excess, if any, may be refunded. The Research Tax Credit is calculated based on our claimed amount of eligible research and development
expenditures in France and represents &#128;4,476,000 for 2022. The French tax authorities, with the assistance of the Higher Education and Research Ministry, may audit each research and development program in respect of which a Research Tax Credit
benefit has been claimed and assess whether such program qualifies in its view for the Research Tax Credit benefit. The French tax authorities may challenge our eligibility for, or our calculation of, certain tax reductions or deductions in respect
of our research and development activities and, should the French tax authorities be successful, our credits may be reduced, which would have a negative impact on our results of operations and future cash flows. Furthermore, the French Parliament
may decide to eliminate, or to reduce the scope or the rate of, the Research Tax Credit benefit, either of which it could decide to do at any time. If we fail to receive future Research Tax Credit amounts, our business, prospects, financial
condition, cash flows or results of operations could be adversely affected. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to carry forward existing tax losses.
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, our tax losses carried forward amounted to
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. In 2014, we acquired the companies Splicos, Wittycell and Zophis by means of a universal transfer of assets and liabilities. The tax losses carried forward of the three
companies combined (Splicos, Wittycell and Zophis) amounted to &#128;26,021,000 on the date of the mergers and transfer of remaining assets. The transfer to us of these losses was subject to a post-merger approval by the French tax authorities,
which approved the transfer of a total amount of &#128;22,531,000. As a result of the transfer of these tax losses to us, our tax losses carried forward amounted to &#128;308,829,000 as at the end of 2022. To the extent we have continued conducting
the business that led to these losses for a minimum period of three years, without making significant changes during this period, the transfer of such tax losses should be definitive. In France, the maximum amount of carried forward tax losses that
can be written off against the tax profits of a given financial year is limited to &#128;1&nbsp;million plus 50% of the amount of taxable profits for the financial year exceeding &#128;1&nbsp;million. The outstanding tax losses remain valid and can
be carried forward to be written off against tax profits of subsequent financial years subject to the same limit, for an unlimited period of time (subject to any &#147;significant change of activity&#148; at our level). It cannot be ruled out that
regulatory or legislative changes in corporate taxation may suppress or limit all or part of the ability to use carried forward tax losses, or limit how long they can be used, to offset future profits. Changes in corporate taxation regarding the use
of carried forward tax losses to offset future tax profits, could have a material adverse effect on our financial position and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Product Development, Regulatory Approval and Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug candidates under development must undergo costly, rigorous and highly regulated preclinical studies and clinical trials, whose time of completion,
number and outcomes are uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of a drug candidate is a long and expensive process with an uncertain outcome,
progressing in several phases, where the objective is to demonstrate the therapeutic benefit provided by the drug candidate for one or more indications. Any failure during the various preclinical and clinical phases for a given indication could
delay development, production and commercialization of the therapeutic product concerned or even lead to discontinuing its development. Identifying potential drug candidates and conducting preclinical testing and clinical trials is a time-consuming,
expensive and uncertain process that takes years to complete, and we may never generate the data or required results required to obtain regulatory approval and achieve commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During clinical trials, we may encounter difficulties determining and recruiting patients
with the appropriate profile. This profile could also vary depending on the different phases of these clinical trials. Patients might then not be recruited according to a timetable compatible with our financial resources which may result in a harm
to our operation results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each phase of clinical development, we must ask for authorization from the relevant authorities of various
countries, according to our development plan, to conduct clinical trials and then present the results of the clinical trials to these authorities. The authorities may refuse to provide the authorizations necessary for clinical trials or have
additional requirements (for example, relating to study protocols, patient characteristics, treatment durations, post-treatment <FONT STYLE="white-space:nowrap">follow-up,</FONT> certain differences in interpreting results between local regulatory
agencies), and in some cases may require additional studies. Any refusal or decision by health authorities to require additional trials or examinations would be likely to result in the discontinuation or delay of the development of the products
concerned. An absence of or delay in therapeutic response could also result in the delay or even discontinuation of the development of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that the development of our drug candidates will ultimately be successful, and especially within time frames compatible
with our financial resources or market needs. Any failure or delay in the development of these products would have a material adverse effect on our business, income, financial position and outlook. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing drug candidates for inflammatory diseases. To our knowledge, currently, there are no similar immunological treatments with a
mechanism of action based on the upregulation on a single microRNA miR-124, with marketing authorization granted by competent regulatory authorities. As a result, the outlook is uncertain for the development and profitability of obefazimod in the
area of inflammatory diseases, its efficacy and acceptance by patients, doctors and paying agencies. Animal testing does not necessarily predict the results that will be obtained in humans. Positive results for obefazimod during Phase 1 or Phase 2b
or 3 clinical trials or those for all the products in the portfolio during their research or preclinical phases might not be confirmed by subsequent phases. Such outcomes could have a material adverse impact on our business, income, financial
position and growth. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily dependent on the success of our drug candidates, in particular obefazimod, and we cannot be certain that
obefazimod or any of our other current or future drug candidates will receive regulatory approval, and, without regulatory approval, we will not be able to market our drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no drug candidates approved for sale, and we cannot guarantee that we will ever have marketable drug candidates. Our ability
to generate revenue related to sales, if any, will in the near future depend entirely on the successful development and regulatory approval of obefazimod. In Europe and the United States, as well as in many other countries, access to the drug market
is controlled and marketing must be authorized by a regulatory authority. Most of the time, this registration application is filed with a national health authority, except in the case of the European Union, where a centralized procedure for
reviewing marketing authorization application (&#147;MAA&#148;) managed by the European Medicines Agency (&#147;EMA&#148;) exists for specific kind of medicinal products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing and distribution of our drug candidates are, and
will remain, subject to comprehensive and extensive regulation by the EMA in the European Union, the Food and Drug Administration (&#147;FDA&#148;) in the United States, the Pharmaceuticals and Medical Devices Agency (&#147;PMDA&#148;) in Japan and
regulatory authorities in other countries, with regulations differing from country to country. Subject to limited exceptions, we are not permitted to market our drug candidates in the European Union, the United States or Japan until we receive
approval of an MAA from the European Commission or (a) Member State(s) authority(ies) or a new drug application (&#147;NDA&#148;) from the FDA or the PMDA. We have not submitted any marketing applications for any of our drug candidates. Regulators
of each jurisdiction have their own procedures for approval of drug candidates. Failure to obtain regulatory approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for our drug candidates in any jurisdiction will prevent us from commercializing and marketing our drug candidates in such jurisdictions, and marketing authorizations may be granted for narrow
indications which may significantly reduce the market of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining marketing authorization, by
country or by geographical area in the case of the European Union, presupposes compliance with the mandatory standards imposed by the regulatory authorities and submission to the authorities of a great deal of information about the new product
regarding its toxicity, dosage, quality, efficacy and safety all over its life cycle. The authorization process is long and expensive, and the result of this process remains uncertain. We are therefore careful to continuously comply with good
practices in order not to jeopardize our chances of ultimately obtaining, directly or via our business partners, marketing authorization for the products we are developing. Obtaining marketing authorization in a given country or geographical area
does not automatically ensure or immediately lead to obtaining marketing authorization in other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain marketing
authorization for one of our products, we may have to perform preclinical animal studies and complete human clinical trials in order to demonstrate the safety and efficacy of the product. In the event patients are exposed to unforeseen and serious
risks, we or the regulatory authorities may choose to suspend or terminate these clinical trials. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAAs, NDAs and similar
authorizations must include extensive preclinical and clinical data and supporting information to establish the drug candidate&#146;s safety and effectiveness for each desired indication. NDAs, MAAs and similar authorizations must also include
significant information regarding the chemistry, manufacturing and controls for the drug. Obtaining approval of a MAA or a NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The EMA, Member States
national authorities, FDA and PMDA review processes can take years to complete and approval is never guaranteed. If we submit an NDA to the FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any
submissions will be accepted for filing and review by the FDA. Regulators of other jurisdictions, such as the EMA and the PMDA, have their own procedures for the scientific evaluation or approval of drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a drug is approved, the FDA, the EMA or the PMDA, as the case may be, may limit the indications for which the drug may be marketed,
require extensive warnings on the drug labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside the European Union, the United States and Japan also have
requirements for approval of drug candidates with which we must comply prior to marketing in those countries. Obtaining regulatory approval for marketing of a drug candidate in one country does not ensure that we will be able to obtain regulatory
approval in any other country. In addition, delays in approvals or rejections of marketing applications in the European Union, the United States or other countries may be based upon many factors, including regulatory requests for additional
analyses, reports, data, preclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes in regulatory policy during the period of drug development and the emergence of new information
regarding our drug candidates or other drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval for any drug candidate, we will be subject to
ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we
receive approval of any of our drug candidates, such regulatory approval may be withdrawn, or such approvals may be contingent on ongoing obligations and continued regulatory review, which may result in significant additional expense. As a general
matter, any regulatory approvals that we may receive for our drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our drug
candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as ongoing compliance with current Good
Manufacturing Practice (&#147;GMP&#148;) and Good Clinical Practice requirements (&#147;GCPs&#148;) for any clinical trials that we may continue to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conduct. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for
compliance with GMP regulations and standards. In addition, any regulatory approvals we may receive will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the drug candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our drug candidates, even if approved, may include limitations related to use restrictions for specified age groups, warnings,
precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#147;REMS&#148;) as a condition of approval of our drugs
candidates, which could include requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may need to maintain or obtain a Good Manufacturing Practice (&#147;GMP&#148;) certificate in order to produce the immunotherapies
that we are developing (for clinical trial purposes or during the commercialization phase). We cannot guarantee that we will obtain or be able to maintain this certificate, nor that certain additional constraints related to this certificate will not
be imposed on us in the future. Any failure to follow and document adherence to such GMP regulations or other regulatory requirements may lead to significant delays in the availability of products for commercial sale or clinical trials, may result
in the termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable regulations could also result in the FDA or other applicable regulatory
authorities taking various actions, including: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">levying fines and other civil penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposing consent decrees or injunctions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us to suspend or put on hold one or more of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspending or withdrawing regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delaying or refusing to approve pending applications or supplements to approved applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us or our third-party manufacturers to suspend manufacturing activities or product sales, imports or
exports; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requiring us to communicate with physicians and other customers about concerns related to actual or potential
safety, efficacy, and other issues involving our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandating product recalls or seizing products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposing operating restrictions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking criminal prosecutions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA generally requires two adequate and well-controlled clinical trials to support approval. In addition, we must scale up manufacturing
and complete other standard preclinical studies and clinical trials. We cannot predict whether our future trials will be successful or whether regulators will agree with our conclusions regarding the preclinical studies and clinical trials we have
conducted to date and will conduct in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to obtain authorization for our drug candidates in one or more jurisdictions,
particularly in respect of our lead drug candidate, obefazimod, would have a material adverse effect on our business, outlook, financial position, results and development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, or, if approval
is received, require our drug candidates to be withdrawn from the market, require them to include safety warnings or otherwise limit their sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials, or
even discontinuation and could result in a more restrictive label or the delay or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
denial of regulatory approval by the European Commission, FDA, PDMA or other comparable authorities in other jurisdictions. If severe side effects were to occur, or if one of our drug candidates
is shown to have other unexpected characteristics, we may need to either restrict the use of such product to a smaller population or abandon development of such drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one or more of our drug candidates received marketing approval, and we or others later identify undesirable side effects caused by such
drugs or negative interactions with other products or treatments (including, for example, as a result of interactions with other products once on the market), a number of potentially significant negative consequences could result, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approvals of such product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the product&#146;s label; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to
patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">physicians, healthcare payors, patients or the medical community in general may not recommend/use our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of the product may decrease significantly; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the particular drug candidate, if approved, and could
have a material adverse effect on our business, prospects, financial condition, cash flows or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical failure can occur at
any stage of clinical development. The results of earlier clinical trials as well as data from any interim analysis of ongoing trials are not necessarily predictive of future results and any drug candidate we advance through clinical trials may not
have favorable results in later clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its
outcome is inherently uncertain. Clinical failure can occur at any stage of our clinical development. Success in preclinical studies and early clinical trials, as well as data from any interim analysis of ongoing trials do not ensure that subsequent
clinical trials will generate the same or similar results. A number of companies in the pharmaceuticals industry, including those with greater resources and experience than us, have suffered significant setbacks in Phase 3 clinical trials, even
after seeing promising results in earlier clinical trials, and we could face similar setbacks. In some instances, there can be significant variation in safety or efficacy results between different clinical trials of the same drug candidate due to
numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout
among clinical trial participants. Moreover, data obtained from preclinical and clinical activities is subject to varying interpretations, which may delay, limit or prevent regulatory approval. Any such delays or failures could negatively impact our
business, financial condition, results of operation and prospects. The positive results generated in preclinical and clinical trials for obefazimod does not ensure that current or future trials will continue to demonstrate similar safety and/or
efficacy results. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite
having progressed through preclinical studies and earlier clinical trials. In addition to the safety and efficacy traits of any drug candidate, clinical trial failures may result from a multitude of factors including flaws in trial design, dose
selection, placebo effect and patient enrollment criteria. Based upon negative or inconclusive results, we or our collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. Further, data
obtained from trials and studies are susceptible to varying interpretation, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot guarantee the commercial success of the drug candidates that we develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or one or more of our commercial partners succeeds in obtaining marketing authorization, allowing us or them to market the therapeutic
products developed by us, it may nevertheless take time to gain the support of the medical community, health care providers and third-party payers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The level of market acceptance for each of our products will depend on several factors, notably on the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prescribers&#146; perception of the product&#146;s therapeutic benefit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">healthcare policies established in each of the countries in which we are considering marketing our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">possible occurrence of adverse reactions once marketing authorization has been obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ease of use of the product, especially relating to its mode of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of treatment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reimbursement policies of governments and other third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effective implementation of a scientific publication strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">development of one or more competing products for the same indication; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the use of the product together with medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the products we are developing are intended to provide a therapeutic response to a need that is presently unmet, poor market
penetration resulting from one or more of the factors described above would have a negative impact on their commercialization and on our ability to generate profits, which could have a material adverse effect on our business, outlook, financial
position, income and growth. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future may depend on our most advanced clinical development program, obefazimod, since our other drug
candidates are in a less advanced stage of development. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obefazimod is our most advanced drug candidate. Obefazimod has
required, and may continue to require, significant investments of our time and financial resources, as well as the special attention of highly qualified staff. Consequently, if we were unable to obtain conclusive results in ongoing maintenance
trials, Phase 3 of obefazimod in UC or Phase 2 of obefazimod in CD, it could have a material adverse effect on our business, outlook, financial position, results and development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience setbacks that could delay or prevent regulatory approval of our drug candidates or our ability to commercialize any
products, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others
for drug candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product-related side effects experienced by subjects in our clinical trials or by individuals using drugs or
therapeutics comparable to our drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in submitting investigational new drug applications in the United States or comparable foreign
applications or delays or failure in obtaining the necessary approvals from regulators or institutional review boards (&#147;IRBs&#148;) or ethics committees to commence a clinical trial, or a suspension or termination of a clinical trial once
commenced; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the FDA or comparable foreign authorities do not accept the earlier preclinical and clinical trial work, then
we may need to conduct additional preclinical studies or clinical trials beyond that which we currently have planned and significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive
right to commercialize our drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our drug candidates and may harm our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in contracting with clinical sites or enrolling subjects in clinical trials, including due to any health
pandemic and/or other macroeconomic factors; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or interruptions in the supply of materials necessary for the conduct of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators or IRBs or ethics committees may not authorize us or our investigators to commence a clinical trial or
conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable regulatory authorities may disagree with our clinical trial design, including with
respect to dosing levels administered in our planned clinical trials, which may delay or prevent us from initiating our clinical trials with our originally intended trial design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching, or failure to reach, agreement on acceptable terms with prospective trial sites,
investigators and prospective contract research organizations (&#147;CROs&#148;) which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subjects required for clinical trials of any drug candidates may be larger than we anticipate or
subjects may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our CROs for preclinical studies or clinical trials may fail to comply with regulatory requirements or meet their
contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or take actions that could cause clinical sites or clinical investigators to drop out of the trial, which may require that we add new
clinical trial sites or investigators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater than anticipated clinical trial costs, including as a result of delays or interruptions that could
increase the overall costs to finish our clinical trials as our fixed costs are not substantially reduced during delays; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may elect to, or regulators, IRBs or Data Safety Monitoring Boards (&#147;DSMBs&#148;) may require that we or
our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not have the financial resources available to begin and complete the planned trials, or the cost of
clinical trials of any drug candidates may be greater than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug
candidates may be insufficient or inadequate to initiate or complete a given clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable foreign regulatory authorities may require us to submit additional data such as long
term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial, including because the FDA has not reviewed our preclinical or clinical data, to date, having been developed outside the United States;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to compete with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">poor efficacy of our drug candidates during clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable FDA or other regulatory agency inspection and review of clinical trial sites or manufacturing
facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable product labeling associated with any product approvals and any requirements for a Risk Evaluation and
Mitigation Strategy (&#147;REMS&#148;) that may be required by the FDA or comparable requirements in other jurisdictions to ensure the benefits of an individual product outweigh its risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable acceptance of our clinical trial data by the patient or medical communities or third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional
regulatory oversight around clinical testing generally or with respect to our technology in particular; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">varying interpretations of data by the FDA and similar foreign regulatory agencies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission
process, potential threats to our intellectual property rights and our manufacturing, marketing, distribution and sales efforts or that of any future collaborator. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical
development activities could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is a significant factor in the timing
of clinical trials, and the timing of our clinical trials will depend, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or
continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#146;s conclusion as required by applicable regulatory authorities. The
eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient
enrollment in clinical trials may be affected by other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">size and nature of the targeted patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severity of the disease or condition under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability and efficacy of approved therapies for the disease or condition under investigation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient eligibility criteria for the trial in question as defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of the drug candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug candidate being
studied in relation to other available therapies, including any products that may be approved for, or any drug candidates under investigation for, the indications we are investigating; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued enrollment of prospective patients by clinical trial sites; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of such trials before completion.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, other pharmaceutical companies targeting these same diseases are
recruiting clinical trial patients from these patient populations, which may make it more difficult to fully enroll any clinical trials. We also rely on, and will continue to rely on, CROs and clinical trial sites to ensure proper and timely conduct
of our clinical trials and preclinical studies. Though we have entered into agreements governing their services, we will have limited influence over their actual performance. Our inability to enroll a sufficient number of patients for our clinical
trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our drug candidates and jeopardize our ability to
obtain regulatory approval for the sale of our drug candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical
trials. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are developing certain of our drug candidates in combination with other therapies, and safety or supply issues with combination use
products may delay or prevent development and approval of our therapeutic candidates. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing certain of our drug
candidates in combination with one or more approved or investigational therapies. Even if any drug candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue
to be subject to the risks that the FDA, European Commission, PDMA or similar foreign regulatory authorities could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could
arise with any of those existing therapies. If the therapies we use in combination with our drug candidates are replaced as the standard of care for the indications we choose for any of our drug candidates, the EMA, FDA, PDMA or similar foreign
regulatory authorities outside may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also may evaluate our drug candidates in combination with one or more therapies that have not yet been approved for marketing by the FDA,
European Commission, PDMA or similar foreign regulatory authorities. We will not be able to market and sell any drug candidate we develop in combination with an unapproved therapy if that unapproved therapy does not ultimately obtain marketing
approval. In addition, unapproved therapies face the same risks described with respect to our drug candidates currently in development, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA, European
Commission, or PDMA, or similar foreign regulatory authorities or PDMA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA, European Commission or similar foreign
regulatory authorities do not approve these other therapies or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the therapies we choose to evaluate in combination with our drug candidates, we may be
unable to obtain approval of or market any such drug candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may conduct clinical trials for our drug candidates outside of the U.S., and the
FDA may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have in the past conducted clinical trials or a portion of our clinical trials for our drug candidates outside the U.S. The acceptance of
study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical
trials are intended to serve as the sole basis for marketing approval in the U.S., for example, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S.
medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA
considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing
approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have
similar requirements for clinical data gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no
assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the relevant jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it
may result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future drug candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, &#147;topline&#148; and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to time may
change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose interim, topline, or preliminary data from our clinical trials and preclinical studies, which is
based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions,
estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline, or preliminary results that we report may
differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and
verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are
available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interim data from clinical trials that we may complete are further subject to the risk that one or more of the clinical
outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, topline, or preliminary data and final data could significantly harm our business prospects. Further,
disclosure of such data by us or by our competitors could result in volatility in the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others,
including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the
approvability or commercialization of the particular drug candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically
extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with
respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug candidate or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including
regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our drug candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health
concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified products from being developed, review, approved or commercialized in a timely manner or at all, which could negatively impact
our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a
variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#146;s or foreign regulatory authorities&#146; ability to hire and retain key personnel and accept the payment of user fees, and
other events that may otherwise affect the FDA&#146;s or foreign regulatory authorities&#146; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In
addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA
following its relocation to Amsterdam and resulting staff changes, may also slow the time necessary for new drugs or modifications to approved drugs and to be reviewed and/or approved by necessary government agencies, which would adversely affect
our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the global COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities
at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its
employees and those of the firms it regulates, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays.&nbsp;Regulatory authorities outside the United States have adopted similar policy measures in
response to COVID-19. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly
impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and
restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval that the FDA grants is limited to those
specific diseases and indications for which a product is deemed to be safe and effective by FDA. While physicians in the United States may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#146;s
labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote any products will be narrowly limited to those indications that are specifically approved by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied
large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or
permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion any drug candidates, if approved, we could become subject to significant liability, which would materially
adversely affect our business and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to find industrial partners to pursue the clinical and commercial development of
obefazimod. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We aim to enter into licensing and distribution partnerships with pharmaceutical companies in order to fund the
completion of the clinical development and marketing preparation of our lead drug candidate, obefazimod. Consequently, we should find partners with sufficient capacity to perform Phase 1, 2 and/or 3 clinical trials on a national or international
scale and mass-produce, distribute and market immunotherapies, anti-inflammatory treatments such as obefazimod. If we were to enter into such partnerships, the commercialization of our products would depend, in part, on the clinical, industrial,
marketing and commercial development efforts of our business partners and the ability of these partners to produce and sell obefazimod. Any failure on the part of our partners could have a material adverse effect on our growth and outlook. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that we may not be able to enter into partnerships under economically reasonable conditions or at all. This could have a
material adverse effect on our business, outlook, financial position, results and development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to conduct, or contract others to
conduct, animal testing in the future, which could harm our research and development activities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain laws and regulations
relating to drug development require us to test our drug candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other
organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these
groups are successful, our research and development activities may be interrupted or delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Operations and Strategic
Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to manage our anticipated development and expansion, including the potential commercialization of our drug
candidates in Europe and the United States we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited
financial resources and the limited experience of our management team in managing a company with such expected growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The
expansion of our operations may lead to significant costs and may divert the attention of our management and business development resources away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
activities and devote a substantial amount of time to managing internal or external growth. Our inability to manage growth or unexpected difficulties encountered during expansion could have a material adverse effect on our business, income,
financial position, growth and outlook. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our international operations subject us to various risks, and our failure to manage these risks could
adversely affect our results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant operational risks as a result of doing business internationally,
such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in foreign currency exchange rates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing payor reimbursement regimes, governmental payors or
<FONT STYLE="white-space:nowrap">patient&nbsp;self-pay&nbsp;systems</FONT> and price controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential changes to the accounting standards, which may influence our financial situation and results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">becoming subject to the different, complex and changing laws, regulations and court systems of multiple
jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection of, or significant difficulties in enforcing, intellectual property rights in certain
countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in attracting and retaining qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions imposed by local labor practices and laws on our business and operations, including unilateral
cancellation or modification of contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rapid changes in global government, economic and political policies and conditions, political or civil unrest or
instability, terrorism or epidemics and other similar outbreaks or events, and potential failure in confidence of our suppliers or customers due to such changes or events; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tariffs, trade protection measures, import or export licensing requirements, trade embargoes and other trade
barriers. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market opportunities for our drug candidates may be limited to patients who are ineligible for or have failed prior
treatments and may be small or different from our estimates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current IBD treatment approach is influenced by multiple factors,
including disease severity, previous response to treatment, side effects and <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> The current standard of care for treatment of patients with mild IBD involves the use of conventional
anti-inflammatory therapies. Conventional anti-inflammatory therapies include: aminosalicylates (e.g., <FONT STYLE="white-space:nowrap">5-ASA),</FONT> immunosuppressants or immunomodulators (e.g.,
<FONT STYLE="white-space:nowrap">6-mercaptopurine</FONT> <FONT STYLE="white-space:nowrap">(&#147;6-MP&#148;),</FONT> methotrexate (&#147;MTX&#148;)) and corticosteroids that are usually prescribed for
<FONT STYLE="white-space:nowrap">short-term</FONT> treatment to manage <FONT STYLE="white-space:nowrap">flare-ups.</FONT> Despite these conventional therapies, patients suffering from mild IBD may evolve towards moderate and severe forms of IBD
requiring the use of advanced therapies. However, available therapies often only have moderate efficacy that changes or may wane over time, as patients have the potential to stop responding or do not respond at all to these treatments and thus
require new therapeutic management options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we hope to position obefazimod as a first line therapy after failure of conventional
treatments, there is no guarantee that even if approved, it would be approved for first line therapy. This could limit our potential market opportunity. In addition, we may have to conduct additional clinical trials prior to gaining approval for
first line therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The estimates of market opportunity and forecasts of market growth included in this prospectus may prove to be inaccurate, and
even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market opportunity estimates and growth forecasts included in this prospectus are subject to significant uncertainty and are based on
assumptions and estimates which may not prove to be accurate. The estimates and forecasts included in this prospectus relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet
the size estimates and growth forecasts included in this prospectus, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many
risks and uncertainties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of our drug candidates could be adversely impacted by the reluctance of physicians, healthcare payors, patients or
the medical community in general to adopt them and by the availability of competing drugs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval
for one or more of our drug candidates, physicians and healthcare payors, patients or the medical community in general may be reluctant to try a new drug due to the high degree of risk associated with the application of new drugs in the field of
human medicine, especially if the new drug differs from the currently prevailing medication for a given complaint. We will need to expend significant sums of money to market our products to increase the public&#146;s awareness within numerous limits
set by the regulations concerning the promotion of drugs. If our products do not achieve an adequate level of acceptance, we may not generate enough revenues to become profitable or the profitability may occur much later. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competing drug candidates in the chronic inflammatory disease field are being manufactured
and marketed by other companies, including, but not limited to, AbbVie, Pfizer, Eli Lilly, Takeda and Johnson&nbsp;&amp; Johnson. To compete with other drugs, particularly any that sell at lower prices, our drug candidates will have to provide
medically significant advantages or be more cost-effective. Even if we can overcome physician reluctance and compete with products that are currently on the market, our competitors may succeed in developing new, safer, more accurate or more
cost-effective treatments or therapeutic indications that could render our drug candidates obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global economic conditions could materially adversely impact demand for our drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations and performance depend significantly on economic conditions. Global financial conditions continue to be subject to volatility
arising from international geopolitical developments, such as the war in Ukraine and global economic phenomena, as well as general financial market turbulence, natural phenomena and any public health outbreak. Uncertainty about global economic
conditions could result in: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party suppliers being unable to produce components for our drug candidates in the same quantity or on the
same timeline or being unable to deliver such parts and components as quickly as before or subject to price fluctuations, which could have a material adverse effect on our production or the cost of such production; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">once our drug candidates are available for sale, customers postponing purchases of our drug candidates in
response to tighter credit, unemployment, negative financial news and/or declines in income or asset values and other macroeconomic factors, which could have a material adverse effect on demand for our drug candidates, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">either of which could, accordingly, have a material adverse effect on our business, results of operations or financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Access to public financing and credit can be negatively affected by the effect of these events on European, U.S. and global credit markets.
The health of the global financing and credit markets may affect our ability to obtain equity or debt financing in the future and the terms at which financing or credit is available to us. These instances of volatility and market turmoil could
adversely affect our operations and the trading price of our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes to trade policy, tariffs, and import/export regulations may
have a material adverse effect on our business, financial condition, and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in laws and policies
governing foreign trade could adversely affect our business. As a result of recent and future policy changes, there may be greater restrictions and economic disincentives on international trade. Such changes have the potential to adversely impact
the global and local economies, our industry and global demand for our drug candidates and, as a result, could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fluctuations in currency exchange rates may significantly impact our results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is located, and our operations are conducted, in Europe. As a result, we are exposed to an exchange rate risk between the U.S.
dollar and the Euro. The exchange rates between these currencies in recent years have fluctuated significantly and may continue to do so in the future. An appreciation of the Euro against the U.S.&nbsp;dollar could increase the relative cost of our
drug candidates outside of Europe, which could have a negative effect on sales. Conversely, to the extent that we are required to pay for goods or services in U.S.&nbsp;dollars, the depreciation of the Euro against the U.S.&nbsp;dollar would
increase the cost of such goods and services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not hedge our currency exposure and, therefore, we incur currency transaction risk
whenever we enter into either a purchase or sale transaction using a currency other than the Euro. Given the volatility of exchange rates, we might not be able to effectively manage our currency transaction risks, and volatility in currency exchange
rates might have a material adverse effect on our business, financial condition or results of operations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on a small number of
third-party suppliers and manufacturers, and in certain cases a single-source supplier, and we may be in a position of dependence with respect to these third parties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities and have no current plans to develop our own clinical or commercial-scale manufacturing
capabilities. We currently rely, and expect to continue to rely, on a small number of third-party suppliers, and in certain cases a single-source supplier, for the supply of various raw materials and chemical products and clinical batches needed for
our preclinical studies and clinical trials. In the case of certain manufactured and clinical supplies, we rely on single-source suppliers. The supply of specific raw materials and products required for conducting clinical trials and manufacturing
our products cannot be guaranteed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent on third parties for the supply of various materials, including chemical or
biological products that are necessary to produce drug candidates for our clinical trials and, ultimately, commercial supply for any of our drug candidates that may receive approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The facilities used by our third-party manufacturers must be approved for the manufacture of our drug candidates by the FDA, or any comparable
foreign regulatory authority, pursuant to inspections that will be conducted after we submit an NDA to the FDA, MAA to the EMA, or submit a comparable marketing application to a comparable regulatory authority. We do not control the manufacturing
process of, and are completely dependent on, third-party manufacturers for compliance with GMP requirements for manufacture of our drug candidates. If these third-party manufacturers cannot successfully manufacture material that conforms to our
specifications and the strict regulatory requirements of any applicable regulatory authority, they will not be able to secure and/or maintain regulatory approval for the use of their manufacturing facilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and
qualified personnel. If any regulatory authority does not approve these facilities for the manufacture our drug candidates, or if such authorities withdraw any such approval in the future, we may be required to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our drug candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could
result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls, operating restrictions and criminal prosecutions, any of which could
significantly and adversely affect our financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our or a third party&#146;s failure to execute on our manufacturing
requirements on commercially reasonable terms and in compliance with GMP or other regulatory requirements could adversely affect our business in a number of ways, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate or complete clinical trials of our drug candidates in a timely manner;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving regulatory approvals, for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease development or to recall batches of our drug candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize any drug candidate, an inability to meet commercial demands.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we do not have any long-term commitments or supply agreements with any
third-party manufacturers. We may be unable to establish any long-term supply agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of failing to timely obtain sufficient quantities of our drug
candidates or such quantities at an acceptable cost. Any performance failure on the part of our existing or future manufacturers or suppliers could delay clinical development or marketing approval, and any related remedial measures may be costly or
time consuming to implement. We do not currently have second source for all required raw materials used in the manufacture of our drug candidates. If our existing or future third-party manufacturers cannot perform as agreed, we may be required to
replace such manufacturers and we may be unable to replace them on a timely basis or at all, which would have a material adverse impact on our financial position. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual
duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent on third parties to conduct our clinical trials and preclinical studies. Specifically, we rely on, and will continue to rely
on, medical institutions, clinical investigators, CROs and consultants to conduct preclinical studies and clinical trials, in each case in accordance with trial protocols and regulatory requirements. These CROs, investigators and other third parties
play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. Though we expect to carefully manage our relationships with such CROs, investigators and other third parties, there can be no assurance
that we will not encounter challenges or delays in the future, or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. Further, while we have and will have agreements governing
the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal,
regulatory and scientific standards and requirements, and our reliance on our CROs and other third parties does not relieve us of our regulatory responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we and our CROs are required to comply with stringent standards governing the conduct of preclinical studies and clinical trials,
including Good Laboratory Practice (&#147;GLP&#148;) and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities, for our drug candidates in clinical development. Regulatory
authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GLP, GCP or other requirements, the data generated in our
clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications, if ever. Furthermore, our clinical trials must be
conducted with materials manufactured in accordance with GMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no guarantee that any of our CROs, investigators or other third parties will devote adequate time and resources to such trials or
studies or perform as contractually required. If any of these third parties fails to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise perform in a substandard manner, our clinical trials may be
extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other
activities that could harm our competitive position. In addition, principal investigators for our clinical trials may be asked to serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in
connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the
integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or
rejection could prevent us from commercializing our drug candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our CROs have the right to terminate their agreements with us in the event
of an uncured material breach and under other specified circumstances. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or
at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management&#146;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a
result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we work to carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance
that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties
on commercially reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management&#146;s time and focus. In addition, there is a natural transition period when
a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we work to carefully manage our relationships with our CROs, investigators and other third
parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain our key executives and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on our management, scientific and medical personnel whose services are critical to our success. Our success depends
greatly on the involvement and expertise of our senior executives and qualified scientific staff. While Dr.&nbsp;Philippe Pouletty, MD, our founder and Chairman of our Board since our inception in 2013, resigned from his Chairman position in August
2022, he continues to support our development as a member of our Board as the representative for Truffle Capital. We do not maintain key person insurance. The temporary or permanent unavailability of our management and scientific staff, as well as
Dr.&nbsp;Pouletty, could lead to: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of <FONT STYLE="white-space:nowrap">know-how</FONT> and weakening of certain activities, especially in the
case of transfer to the competition; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deficiencies in terms of technical skills that could slow down activity and ultimately impair our ability to
reach our objectives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining additional qualified management and scientific, clinical, manufacturing
and sales and marketing personnel will also be critical to our success, particularly as we expand in order to acquire additional skills, such as manufacturing, quality assurance and regulatory and medical affairs. The loss of the services of our
senior management team or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive
officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of
and commercialize drug candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and
biotechnology companies for similar personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also experience intense competition for the hiring of scientific and clinical personnel
from other companies, universities and research institutions. We may not be able to attract or retain qualified management and scientific personnel in the future due to intense competition for a limited number of qualified personnel. Many of those
that compete with us for qualified personnel have greater financial and other resources, different </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
risk profiles and a longer history in the industry than we do. Our competitors may also provide more diverse opportunities and better chances for career advancement. An inability to attract and
retain high quality personnel will have a material adverse effect on our business, prospects, financial condition, cash flow or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and
development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we
are unable to continue to attract and retain high quality personnel, the marketing and production of our drugs could be delayed or prevented, which could, in turn, have a material adverse effect on our business, prospects, financial condition, cash
flows or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to
the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activity that
violates (i)&nbsp;the laws and regulations of the European Economic Area (&#147;EEA&#148;) countries, the European Commission, FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate
information to such authorities, (ii)&nbsp;manufacturing standards, (iii)&nbsp;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in Europe, the United States and elsewhere and (iv)&nbsp;laws that
require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud,
misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or
clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and
the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply
with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in
defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs,
such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational
harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited infrastructure in market access, sales, marketing and distribution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lack infrastructure and resources in the fields of sales, marketing and distribution. We need to develop our own marketing and sales
capacity, either alone or with partners once marketing authorizations have been obtained. As part of setting up our sales and marketing infrastructure, we will need to incur additional expenses, mobilize management resources, implement new skills
and take the time necessary to set up the appropriate organization and structure to support the products in accordance with current legislation and, more generally, optimize commercialization efforts. We compete with many companies that currently
have extensive, experienced and well-funded market access, marketing and sales operations to recruit, hire, train and retain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing and sales personnel, and will have to compete with those companies to recruit, hire, train and retain any of our own market access, marketing and sales personnel. If we are unable to
expand our sales and marketing team, we may be unable to compete successfully against these more established companies. Alternatively, if we choose to collaborate, either globally or on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">territory-by-territory</FONT></FONT> basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales
force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at
all, we may not be able to successfully commercialize any of our drug candidates that receive regulatory approval or any such commercialization may experience delays or limitations. Factors that may inhibit our efforts to build a sales, marketing
and distribution organization: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians, educate physicians about patients for whom our
drug candidates may be appropriate treatment options and attain adequate numbers of physicians to prescribe any drugs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and
other acceptance by payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the
patient population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There are numerous competitors in the market for therapeutic treatments of inflammatory diseases. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change as researchers
learn more about diseases and develop new technologies and treatments. Many pharmaceutical companies, biotech companies, institutions, universities and other research organizations are actively engaged in the research, discovery, development and
commercialization of therapeutic responses for the treatment of the diseases targeted by us. Significant competitive factors in our industry include: (i)&nbsp;product efficacy and safety; (ii)&nbsp;quality and breadth of an organization&#146;s
technology; (iii)&nbsp;skill of an organization&#146;s employees and its ability to recruit and retain key employees; (iv)&nbsp;timing and scope of regulatory approvals; (v)&nbsp;government reimbursement rates for, and the average selling price of,
pharmaceutical products; (vi)&nbsp;the availability of raw materials and qualified manufacturing capacity; (vii)&nbsp;manufacturing costs; (viii)&nbsp;intellectual property and patent rights and their protection; and (ix)&nbsp;sales and marketing
capabilities. Given the intense competition in our industry, we cannot assure you that any of the products that we successfully develop will be clinically superior or scientifically preferable to products developed or introduced by our competitors.
In addition, significant delays in the development of our drug candidates could allow our competitors to succeed in obtaining European Commission, FDA, PMDA or other regulatory approvals for their drug candidates more rapidly than us, which could
place us at a significant competitive disadvantage or deny us marketing exclusivity rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors in the chronic inflammatory
disease field are primarily large pharmaceuticals companies including, but not limited to AbbVie, Pfizer, Eli Lilly, Takeda and Johnson&nbsp;&amp; Johnson. Several lines of research are being developed to improve the treatment of IBD. Many companies
are working to develop new, more effective and better tolerated treatments with more practical formulations, especially small molecules administered orally, better accepted than monoclonal antibodies that require administration by injection. See
&#147;Business&#151;Competition.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our competitors may be more effective at using their technologies to develop
commercial products. Many of the organizations competing with us have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals
and marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or <FONT STYLE="white-space:nowrap">early-stage</FONT>
companies may also prove to be significant competitors, particularly through partnership arrangements with large and established companies. These companies also compete with us in recruiting and retaining qualified scientific and management
personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development potential in the markets in which we operate is such that the arrival of new competition is probable. New market entrants,
increased competition in specific areas, or in general, would have a material adverse effect on our business, income, financial position and outlook for growth. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on, and will continue to depend on, collaboration and strategic alliances with third partners. To the extent we are able to enter into
collaborative arrangements or strategic alliances, we will be exposed to risks related to those collaborations and alliances. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An
important element of our strategy for developing, manufacturing and commercializing our drug candidates is entering into partnerships and strategic alliances with other pharmaceutical companies or other industry participants. The collaboration
agreements that we have established, and any collaboration arrangements that we may enter into in the future, may not be successful, which would have a negative impact on our business, results of operations, financial condition and growth prospects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any partnerships or alliance we have or may have in the future may be terminated for reasons beyond our control or we may not be able to
negotiate future alliances on acceptable terms, if at all. These arrangements may result in us receiving less revenue than if we sold our products directly, may place the development, sales and marketing of our products outside of our control, may
require us to relinquish important rights or may otherwise be on unfavorable terms. Collaborative arrangements or strategic alliances will also subject us to a number of risks, including the risk that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to control the amount and timing of resources that our strategic partner/collaborators may
devote to the drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic partner/collaborators may experience financial difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure to successfully collaborate with third parties may delay, prevent or otherwise impair the development
or commercialization of our drug candidates or revenue expectations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">products being developed by partners/collaborators may never reach commercial stage resulting in reduced or even
no milestone or royalty payments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business combinations or significant changes in a collaborator&#146;s business strategy may also adversely affect
a collaborator&#146;s willingness or ability to complete their obligations under any arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator could independently move forward with a competing product developed either independently or in
collaboration with others, including our competitors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborative arrangements are often terminated or allowed to expire, which would delay the development and may
increase the cost of developing drug candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our partnerships and licensing agreements relating to the technologies belonging
to us may not be successful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The various drug candidates developed by us arise from proprietary or licensed technologies with
leading academic partners, including Scripps Research Institute, University of Chicago, Brigham Young University, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Montpellier Institute of Molecular Genetics at the <I>Centre National de la Recherche Scientifique</I> (&#147;CNRS&#148;) and the <I>Institut Curie</I>. If the clinical trials conducted by us
were to reveal safety and/or therapeutic efficacy problems or if the use of one of the platforms were to violate an intellectual property right held by a third party, this could threaten the use and operation of some of our technology platforms and
require additional research and development efforts and additional time and expense to address these difficulties, with success not being guaranteed. The development of a portion of our product portfolio would be affected, which would have a
material adverse effect on our business, outlook, growth, financial position and income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The reimbursement of drugs and treatments is beyond our
control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After achieving regulatory authorization and once marketing authorization is granted, the process of setting the sales
price of drugs and their reimbursement rates begins. The conditions for setting the sales price and reimbursement rate for drugs are beyond the control of pharmaceutical companies. They are decided by competent public committees and bodies and by
social security or private insurance companies. In this context, we or our partners could be asked to perform additional studies on our products. These studies could generate additional costs for us or our partners and lead to delays in marketing
the drug, which could have an impact on our financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the reimbursement of
newly-approved drugs. The level of reimbursement will impact market acceptance and sale of our drug candidates. Reimbursement by a third-party is dependent on a number of factors, including, without limitation, the third-party payor&#146;s
determination that use of a product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The possibility that we could receive royalties from our industrial partner or partners on the sale of some of our products and our ability to
make sufficient profits on the marketing of our treatments or those for which we have entered into distribution contracts will depend on these reimbursement conditions. If delays in the price negotiation procedure result in a significant delay in
marketing, if our product does not obtain an appropriate level of reimbursement, or if the accepted price level and reimbursement rate of the treatments we market are changed, our profitability will be reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also unable to guarantee that we will succeed in maintaining, over time, the price level of our products or those for which licenses
have been granted, or the accepted reimbursement rate. Under these conditions, there could be a material adverse effect on our business, financial position and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The pricing, insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and
reimbursement for our drug candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful sales of our drug candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors
including governmental healthcare programs, such as Medicare and Medicaid in the United States, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any drug
candidates for which we obtain regulatory approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy for coverage and reimbursement exists, and
coverage and reimbursement for drug products can differ significantly from payor to payor. Therefore, one payor&#146;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug
product. Third-party payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage
determination process is often a <FONT STYLE="white-space:nowrap">time-consuming</FONT> and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Moreover, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is
attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement may impact the demand for, and/or the price of, any product for which we obtain marketing approval. Assuming we obtain coverage
for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients who are prescribed
medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products
unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we or our collaborators may develop companion diagnostic tests for use with our drug candidates. We or our collaborators will be
required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our drug candidates, once approved. Similar challenges to obtaining coverage and reimbursement, applicable to
pharmaceutical or biological products, will apply to companion diagnostics. Our inability to promptly obtain coverage and adequate reimbursement from both third-party payors for the drug candidates and companion diagnostic tests that we or our
collaborators develop and for which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only
after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies. EU member states may approve a specific
price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and
control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <FONT
STYLE="white-space:nowrap">low-priced</FONT> markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations may not allow favorable reimbursement and pricing
arrangements, and prices are usually revised periodically, such that any given price may decrease upon various occurrences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally,
the containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus of this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in
implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive
policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Price controls may be imposed in markets in which we operate, which may negatively affect our future
profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some countries, particularly EU member states, Japan, Australia and Canada, the pricing of prescription drugs is
subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and
other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after
reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce prices. In some
countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our drug candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval.
Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our drug candidates is unavailable or limited
in scope or amount, or if pricing is set at unsatisfactory levels, there could be a material adverse effect on our business, financial condition or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has been highly disruptive to our business, industry and in general. An outbreak of other
communicable diseases around the world may cause further disruption. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any public health outbreak may cause any of the following:
</P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in recruiting patients for our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in launching clinical trial sites, including difficulties in recruiting investigators and
clinical site staff; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of health care resources from the conduct of clinical trials, of hospital staff supporting the conduct
of clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the risks listed above, and as part of our clinical trials in countries in pandemic
zones, we may also experience the following adverse effects: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential delays in the conduct of our research and preclinical studies, preventing research and preclinical
studies from being conducted as planned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining authorizations from the administrative and regulatory authorities required to launch the
planned preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the receipt of supplies and equipment necessary for the completion of our research activities and our
preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays affecting the activity of contractors who provide research services to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the competent regulatory authorities to accept data from clinical trials conducted in the geographical
areas affected by the pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interruption of global maritime trade could affect the transportation of research materials for preclinical
studies and clinical trials, such as experimental drugs and comparator drugs used in our clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the necessary interactions with local authorities, ethics committees or other important and third-party
<FONT STYLE="white-space:nowrap">co-contracting</FONT> bodies due to limitations in human resources or forced leave of state employees. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one or more of the above risks were to materialize, the planned and ongoing clinical trials and, therefore, the publication of the data and
results of these studies and all subsequent steps leading to the commercialization of drug candidates being studied, could be significantly delayed. Such a situation could have a material adverse effect on our business, income, financial position
and growth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The extent to which the outbreak of communicable diseases around the world may impact
our activity and clinical trials will depend on future developments, which cannot be predicted with certainty, such as the emergence of diseases that may be resistant to the vaccines or treatments currently available, access to vaccines and
treatments for the various populations worldwide, the final geographical spread of the disease, its duration, travel restrictions and social distancing measures in the European Union, the United States and other countries, business closures or
disruptions, and the effectiveness of measures taken in those countries to contain and treat the disease. There can be no assurance that the outbreak of communicable diseases around the world will not result in an adverse effect on financial
markets, our stock price and our ability to obtain finance. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The war between Ukraine and Russia may affect our business, industry and the
markets in which we operate. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the
global economy and the rate of inflation, particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the financial markets, something that is still ongoing at the reporting date and
has pushed down stock market prices around the world. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given these developments, we have decided not to include Ukraine, Russia and
Belarus in our global Phase&nbsp;3 program for obefazimod in UC. However, the global scale of this conflict cannot be predicted at this stage. We, therefore, cannot rule out an adverse impact of this conflict on our business, including in terms of
access to raw materials, logistics, the performance of clinical trials and in relation to any future financing we may seek. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase
2b maintenance trial of obefazimod in moderately to severely active UC is our only clinical trial currently in progress in Ukraine. We have, however, terminated a few trial sites since the Russia/Ukraine war began. The 12-month assessment was
carried out in all the Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance
trial have been transitioned to the long-term safety and efficacy trial that is still on-going. None of these sites are located in the Crimea Region of Ukraine, the so-called Donetsk People&#146;s Republic, or the so-called Luhansk People&#146;s
Republic. We are also evaluating the possibility to include a few Ukrainian sites in the western part of Ukraine in the ABTECT Phase 3 clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability
to exclusively commercialize our drug candidates may decrease if we are unable to protect our intellectual property rights or if these rights are insufficient for our purposes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our ability and the ability of our partners to obtain, maintain and ensure, against third parties,
the protection of our patents, trademarks and related applications and other intellectual property rights or similar rights (such as trade secrets, business secrets and <FONT STYLE="white-space:nowrap">know-how)</FONT> or those we are authorized to
use in the course of our business in Europe, the United States, Asia and other key countries. We dedicate substantial financial and human resources to this and intend to continue our policy of protection through new patent applications as soon as we
deem it appropriate.<B><I></I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology is currently protected by patents and patent applications that we have filed or for
which we have an exclusive license. However, we or our partners might not be able to maintain the protection of our intellectual property rights and we could, thereby, lose our technological and competitive advantage in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Firstly, our intellectual property rights and those of our partners offer protection for a period that may vary from one territory to another.
The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we have obtained or are seeking patent protection for our drug candidates, the patent term is 20 years
from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent application. In the United States, the term of a patent may be lengthened by a patent term adjustment, which provides for term extension in the case of administrative delays at the United
States Patent and Trademark Office (&#147;USPTO&#148;) in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent with an earlier expiration date. Furthermore, in the United States, the term of a patent
covering an FDA approved drug may be eligible for a patent term extension under the Hatch-Waxman Amendments as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond
the expiration of the patent but cannot extend the term of a patent beyond a total of 14 years from the date of product approval. Only one patent covering a single FDA-approved product among those eligible for an extension may be extended. In the
future, if any of our drug candidates receives FDA approval, we expect to apply for a patent term extension, if available, to extend the term of the patent covering such approved drug product. In France and the rest of Europe generally, the term of
a patent is 20 years from the date the patent application is filed, with the understanding that this period may be extended up to another five years if a supplementary protection certificate is filed and an additional six months if a pediatric
investigation plan is applied. We expect to seek patent term extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such
an extension should be granted, and even if granted, the length of such an extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Secondly, we and our partners could encounter
difficulties in the filing or examination of some of our patent, trademark or other intellectual property rights applications currently being examined/registered. During the patent application process, we may receive Office Actions from the USPTO or
from comparable agencies in foreign jurisdictions rejecting the claims of the patent application. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. At the time a patent
application is filed, there may be other patents that could constitute opposable prior art that may have not yet been published. Despite prior art searches and monitoring, we cannot be certain that we are the first to conceive of an invention and
file a patent application relating thereto; in particular, it should be noted that in most countries, the publication of patent applications takes place 18 months after the earliest priority date of patent filing, or in some cases not at all, and
that discoveries are sometimes only the subject of publication or patent application months or even years later. Likewise, when filing one of our trademarks in a country where it is not covered, we could find that the trademark in question is not
available in that country. A new trademark would then need to be sought for the country in question or an agreement negotiated with the prior holder of the trademark. We may not be able to prevent a disclosure of information to third parties that
could have an impact on our future intellectual property rights. Therefore, it is in no way certain that our current and future applications for patents, trademarks and other intellectual property rights will result in registrations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thirdly, the simple granting or registration of a patent, trademark or other intellectual property right does not guarantee validity or
enforceability. Our competitors may at any time contest the validity or enforceability of our or our partners&#146; patents, trademarks or applications relating thereto before a court or in the context of other specific procedures which, depending
on the outcome of such disputes, could reduce their scope, result in their invalidation or allow them to be circumvented by competitors. In addition, developments, changes or divergences in the interpretation of the legal framework governing
intellectual property in Europe, the United States or other countries could allow competitors to use our or our partners&#146; inventions or intellectual property rights to develop or market our products or technologies without financial
compensation. Moreover, there are still certain countries that do not protect intellectual property rights in the same way as in Europe and the United States, and the effective procedures and rules necessary to ensure the defense of our rights may
not exist in these countries. There is therefore no certainty that our existing and future patents, trademarks and other intellectual property rights will not be disputed, invalidated or circumvented, or that they will provide effective protection
against competition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, our rights to our owned or licensed patents, trademarks and related applications and other
intellectual property rights may not confer the protection expected against competition. We therefore cannot guarantee with certainty that: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will be able to develop novel inventions for which a patent could be filed or issued; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applications for patents and other property rights currently under review will actually result in the granting of
patents, trademarks or other registered intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patents or other intellectual property rights granted to us or our partners will not be contested, invalidated or
circumvented; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection conferred by our or our partners&#146; patents, trademarks and intellectual property
rights is and will remain sufficient to protect us against competition. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Were these eventualities to occur, they
could have a material adverse effect on our business and growth. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, third parties (or even our employees) could use or
attempt to use elements of our technologies protected by an intellectual property right, which would create a detrimental situation for us. We may therefore be compelled to bring legal or administrative proceedings against these third parties in
order to enforce our intellectual property rights (patents, trademarks, designs and models or domain names) in court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim
that a party illegally infringed or misappropriated our intellectual property is difficult, expensive and time-consuming, and the outcome is unpredictable. Any litigation or dispute, regardless of the outcome, could lead to substantial costs, affect
our reputation, negatively influence our income and financial position, and possibly not lead to the desired protection or sanction. Some competitors with more substantial resources than us may be able to bear the costs of litigation more easily.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third parties or otherwise
experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to pursue the development of some of our drug-based candidates depends on the maintenance in force of the licensing agreements
entered into with various institutes. We have licenses granted by the CNRS, the University of Montpellier and/or the <I>Institut Curie</I> for certain patents or patent <FONT STYLE="white-space:nowrap">co-ownership</FONT> rights resulting from
cooperation with the CNRS, the University of Montpellier and the <I>Institut Curie</I>, which allowed obefazimod to be developed and a chemical library of more than 2,200 small molecules to be generated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These license contracts provide the possibility for the licensor to end an agreed exclusivity or terminate the contracts in certain events,
including the event of <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees, a dispute over the validity of the patents licensed or a violation by us of our obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time be party to license or collaboration agreements with third parties to advance our research or allow commercialization
of current or future drug candidates. Such agreements may impose numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other
obligations on us and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our licensors might
conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any termination of these licenses, or if the underlying licensed rights fail to provide the intended exclusivity, could
result in the loss of significant rights and could harm our ability to commercialize our current or future drug candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products
identical to ours and we may be required to cease our development and commercialization of certain of our current or future drug candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial
conditions, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may also arise between us and our licensors regarding intellectual property
subject to a license agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate
intellectual property rights of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our current or future drug candidates, and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of any patented technology; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and&nbsp;know-how&nbsp;resulting from the joint creation or use of intellectual
property by our future licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we may license
intellectual property or technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The adverse resolution of any contract interpretation disagreement that may
arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a
material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed or may license prevent or impair our ability to maintain future licensing
arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected current or future drug candidates, which could have a material adverse effect on our business, financial conditions, results of operations and
prospects. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be sued for infringing or misappropriating the intellectual property rights of third parties, and if we are, such litigation
could be costly and time consuming and could prevent or delay us from developing or commercializing our drug candidates. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
commercial success will also depend on our ability to develop products and technologies that do not infringe the patents or other rights of third parties. It is important for the success of our business that we are able to use our products and
conduct research and development efforts leading to commercialization of our products without infringing patents or other third-party rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to carry out, as we have done to date, the preliminary studies that we consider necessary in view of the above risks, before
investing in the development of our various products and technologies. With the help of intellectual property consulting and law firms, we monitor our competitors&#146; activity (particularly with respect to patent filings). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We therefore cannot guarantee with certainty that: </P>   <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are no prior patents or other intellectual property rights of third parties covering certain of our
products, methods, technologies, results or activities and that, consequently, third parties might bring an action for infringement or violation of their rights against us with a view to obtaining damages and interest and/or the cessation of our
activities in the manufacture and/or commercialization of products, methods and the like thus disputed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are no trademark rights or other prior rights of third parties that could be the basis of an infringement
or liability action against us; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our domain names are not subject, on the part of third parties who have prior rights (for example trademark
rights), to a Uniform Domain-Name Dispute-Resolution Policy (&#147;UDRP&#148;) or similar policy, or an infringement action. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of intellectual property litigation, we may have to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stop developing, making, selling, offering for sale, or using the product or products that depended on the
disputed intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain a license from the holder of the intellectual property rights, however, such a license may be unobtainable
or only be obtainable under unfavorable economic conditions for us; or </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revise the design of some of our products/technologies or, in the case of trademark applications, rename our
products to avoid infringing the intellectual property rights of third parties, which may prove impossible or time-consuming and expensive, and could impact our marketing efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation can also result in an order to pay damages (including treble damages) and being subject to injunctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our drugs for an adequate amount of time, and we may seek to rely, but may not be
able to rely, on other forms of protection, such as regulatory exclusivity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the amount of time required for the development,
testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For example, the certain patents protecting obefazimod&#146;s composition of matter
expire in 2030 and the certain patents protecting obefazimod methods of use expire in 2035 which pose a risk to its successful commercialization. We expect to seek extensions of patent terms in the United States and, if available, in other countries
where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the
approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may
not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may also seek to rely on other forms of protection, such as
regulatory exclusivity, but there can be no assurance that such other forms of protection will be available or sufficient. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will not seek to
protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on our drug candidates in all countries and jurisdictions throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States, assuming that rights are obtained in the United States. Competitors may use our technologies in
jurisdictions where we do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the
United States. These products may compete with our drugs and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular
jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the federal and state laws
in the United States. Many companies have encountered significant problems in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of
patents and other intellectual property protection, especially those relating to biopharmaceuticals or biotechnologies. This could make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other
intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties,
including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain
countries, and we will not have the benefit of patent protection in such countries. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our patent rights in
foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of
not being issued and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law
and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of our intellectual property. In addition, monitoring the unauthorized use of our
products and technology and the infringement of our intellectual property rights is challenging. We cannot guarantee with certainty that we will be able to prevent, take legal action against, and obtain compensation for infringement,
misappropriation or unauthorized use of our products and technologies, particularly in foreign countries where our rights are less well protected because of the territorial scope of intellectual property rights. Accordingly, our efforts to enforce
our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in Europe, a new unitary patent system took effect June 1, 2023, which significantly impacts European patents, including those
granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court, or
the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and
remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who
are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, geo-political
actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications and the maintenance, enforcement or defense of our issued patents. For example,
the United States and foreign government actions related to Russia&#146;s invasion of Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued
patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on
our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, we
would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business,
financial condition, results of operations and prospects may be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected by us or our partners that develop
trademarks for our future products, then we may not be able to build name or brand recognition in our markets of interest, and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registered or unregistered trademarks and trade names and the registered or unregistered trademarks and trade names that our partners will
develop may be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other marks. We and our partners may not be able to protect our rights to these trademarks and trade names, which we need to build name
and brand recognition among potential partners or customers in our markets of interest. We expect to rely on our partners to protect the trade names and trademarks that they will develop, and they may not adequately protect such tradenames and
trademarks, and we may have little or no recourse in respect thereof. At times, competitors may adopt trademarks and trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. During
the trademark registration process, we may receive Office Actions from the USPTO or from comparable agencies in foreign jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond to those
objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the
cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademark applications or registrations, and our trademark applications or registrations may not survive such proceedings. In addition, there
could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. Over the long term, if we are unable to establish name and
brand recognition based on our trademarks, then we may not be able to compete effectively and our business may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid
to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governmental patent
agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in which
<FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets and <FONT STYLE="white-space:nowrap">know-how,</FONT> our business and competitive
position could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patent protection for our drug candidates, we also rely on trade secrets,
including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to establish and maintain our competitive position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also important for us to protect against the unauthorized use and disclosure of our confidential information, <FONT
STYLE="white-space:nowrap">know-how</FONT> and trade secrets. Unpatented and/or unpatentable technologies, processes, methods, <FONT STYLE="white-space:nowrap">know-how</FONT> and data are considered trade secrets that we seek to protect, in part,
by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants, advisors, university and/or institutional researchers and
other third parties. We also have entered or seek to enter into confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the context of collaboration, partnership or research contracts, or other types of cooperation between us and researchers from academic
institutions, and with other public or private entities, subcontractors, or any <FONT STYLE="white-space:nowrap">co-contracting</FONT> third parties, various information and/or products may be entrusted to them in order to conduct
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain tests and clinical trials. In such cases, we require that confidentiality agreements be signed. Furthermore, as a general rule, we take care that the collaboration or research contracts
that we are party to give us access to full ownership or <FONT STYLE="white-space:nowrap">co-ownership</FONT> of results and/or inventions resulting from the collaboration, or to an exclusive license based on these results and/or inventions
resulting from the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite these efforts, counterparties may breach our agreements and disclose our proprietary
information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Our trade secrets may also be obtained by third parties by other means, such as breaches of our physical or computer security systems.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or
unwilling to protect trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that
technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor, our competitive position would be harmed and our business may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the agreements put in place to protect our technology and trade secrets and/or the <FONT
STYLE="white-space:nowrap">know-how</FONT> being used will provide the protection sought or will not be violated, that we will have appropriate solutions for such violations, or that our trade secrets will not be disclosed to or independently
developed by our competitors. In the context of contracts that we enter into with third parties, we sometimes take the precaution of providing that they are not authorized to use third-party services or that they may only do so with our prior
approval. However, it cannot be ruled out that some of these <FONT STYLE="white-space:nowrap">co-contractors</FONT> may nevertheless use third parties. In this event, we have no control over the conditions under which third parties with which we do
not contract protect their confidential information, irrespective of whether we provide in our agreements with our <FONT STYLE="white-space:nowrap">co-contractors</FONT> that they undertake to pass on confidentiality obligations to their own <FONT
STYLE="white-space:nowrap">co-contractors.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such contracts therefore expose us to the risk of having the third parties
concerned (i)&nbsp;claim the benefit of intellectual property rights on our inventions or other intellectual property rights, (ii)&nbsp;fail to ensure the confidentiality of unpatented innovations or improvements of our confidential information and <FONT
STYLE="white-space:nowrap">know-how,</FONT> (iii)&nbsp;disclose our trade secrets to our competitors or independently develop these trade secrets and/or (iv)&nbsp;violate such agreements, without our having an appropriate solution for such
violations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, our rights to our confidential information, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT>
may not confer the expected protection against competition and we cannot guarantee with certainty that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our knowledge and trade secrets will not be obtained, stolen, circumvented, transmitted, or used without our
authorization; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors have not already developed similar technologies or products, or ones similar in nature or purpose
to ours; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no <FONT STYLE="white-space:nowrap">co-contracting</FONT> party will claim the benefit of all or part of the
intellectual property rights relating to inventions, knowledge or results that we hold in our own right or in <FONT STYLE="white-space:nowrap">co-ownership,</FONT> or for which we would be entitled to a license; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our employees will not claim rights or payment of additional compensation or fair price for inventions in the
creation of which they participated. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of one or more of these risks could have a material adverse effect
on our business, outlook, financial position, income and growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to cyber risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent upon the availability, capacity, reliability and security of our information technology infrastructure to conduct daily
operations. We depend on various information technology systems to process and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
record financial data, research data and confidential information, process clinical data, manage financial resources and communicate with employees and third parties. In particular, we store
information about drug candidates, which is critical to our research and development, on our computer systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties on which we
rely have in the past been affected by cyberattacks and may in the future fail, or are perceived to have failed, to maintain sufficient cyber-security safeguards, which could compromise data they hold on our behalf. If our suppliers or other third
parties we collaborate with suffer from cyberattacks or cybersecurity breaches, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and
similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain industry-standard backups and procedures, however we are at risk of financial loss, reputational damage and general disruption
from a failure of our information technology infrastructure or an attack for the purposes of espionage, extortion, terrorism or to cause embarrassment. Any failure of, or attack against, our information technology infrastructure may be difficult to
prevent or detect, and our internal policies to mitigate these risks may be inadequate or ineffective. We may not be able to recover any losses that may arise from such a failure or attack, which could have a material adverse effect on our business,
outlook, financial position, income and growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not address all potential threats to our competitive advantage.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights
have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Competitors may be able to formulate compositions that are similar to ours but that are not covered by our
intellectual property rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Competitors may independently develop similar or alternative compositions or otherwise circumvent any of our
applications or registrations without infringing our intellectual property rights. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or any of our collaboration partners might not have been the first to conceive and reduce to practice the
inventions covered by the patents or patent applications that we own, license or will own or license. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or any of our collaboration partners might not have been the first to file patent applications covering
certain of the patents or patent applications that we or they own or have licensed, or will own or will have licensed. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is possible that any pending patent applications that we have filed, or will file, will not lead to issued
patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Issued patents that we own may not provide us with any competitive advantage, or may be held invalid or
unenforceable, as a result of legal challenges by our competitors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our competitors might conduct research and development activities in countries where we do not have patent
rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ownership of our patents or patent applications may be challenged by third parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may infringe on the patents of third parties or pending or future applications of third parties, if issued,
and the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Legal and Compliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to a restrictive and changing regulatory framework. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the major issues for a growing company like ours is to successfully develop, alone or with the help of partners, products incorporating
our technologies in an increasingly restrictive regulatory environment. The pharmaceutical industry faces constant changes in its legal and regulatory environment and increased oversight by the competent authorities, such as the National Agency for
Medicines and Health Products Safety (&#147;ANSM&#148;) in France, the EMA in the European Union, the FDA in the United States or the PMDA in Japan, and other regulatory authorities in the rest of the world. At the same time, the public is demanding
more guarantees regarding drug safety and efficacy. This may at any time lead to a more restrictive regulatory environment for our drug candidates which may have a material adverse effect on business, financial position, income, growth and outlook.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health authorities oversee research and development, preclinical studies, clinical trials, the regulation of pharmaceutical companies,
and drug manufacturing and commercialization. This increasing stringency of the legislative and regulatory framework is common worldwide; however, requirements may vary from country to country. In particular, health authorities, especially the ANSM,
EMA, FDA and PMDA, have imposed increasingly burdensome requirements in terms of the volume of data required to demonstrate the efficacy and safety of a product. These increased requirements may have thus reduced the number of products authorized in
comparison to the number of applications filed. Products on the market are also subject to regular reassessment of the risk/benefit ratio after their authorization. The delayed discovery of problems not identified at the research stage can lead to
marketing restrictions, suspension or withdrawal of the product, and to an increased risk of litigation. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, the
authorization process is long and expensive; it can take many years and the result is not predictable. Insofar as new legal or regulatory provisions would result in an increase in the cost of obtaining and maintaining product marketing
authorizations or limit the targeted indications for a product that a product targets or the economic value of a new product to its inventor, the growth prospects for the pharmaceutical industry, and us, could be reduced. If we experience delays
completing, or if we terminate, any of our clinical trials, or if we are required to conduct additional clinical trials, the commercial prospects for our drug candidates may be harmed and our ability to generate product revenue will be delayed. The
occurrence of one or more of these risks could have a material adverse effect on our business, outlook, financial position, income and growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
are subject to healthcare laws and regulations which may require substantial compliance efforts and could expose us to criminal sanctions, civil and administrative penalties, contractual damages, reputational harm and diminished profits and future
earnings, among other penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, including physicians, and others will play a primary role in the
recommendation and prescription of our products, if approved. Our arrangements with such persons and third-party payors and our general business operations will expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our drugs, if we obtain marketing approval. Restrictions under applicable U.S. federal, state and foreign
healthcare laws and regulations include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly
and willfully soliciting, offering, receiving or providing remuneration, including any kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the
purchase or lease, order or recommendation of, any item, good, facility or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False
Claims Act (&#147;FCA&#148;), which impose criminal and civil penalties, including those from civil whistleblower or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment that are false or fraudulent or making a false
statement to avoid, decrease, or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with their alleged
<FONT STYLE="white-space:nowrap">off-label</FONT> promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to
customers with the expectation that the customers would bill federal health care programs for the product. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the FCA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), which created
additional federal criminal statutes that impose criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or
covering up a material fact or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or
specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#147;HITECH&#148;)
and its implementing regulations, which impose certain requirements on covered entities and their business associates, as well as their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security
and transmission of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities
and activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the
Affordable Care Act (&#147;ACA&#148;), that require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with
specific exceptions, to track and annually report to Concerned Member States (&#147;CMS&#148;) payments and other transfers of value provided to physicians, certain other healthcare providers (such as physicians assistants and nurse practitioners),
and teaching hospitals, and require certain manufacturers and group purchasing organizations to report annually certain ownership and investment interests held by physicians or their immediate family members; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state or foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to items or services reimbursed by any third-party payor, including commercial insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements, state laws that require
biopharmaceutical companies to comply with the biopharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and state laws governing the privacy and security of health
information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect as HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It
cannot be excluded that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our
operations were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment,
possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could substantially disrupt
our operations. If the physicians or other providers or entities with whom we expect to do business are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. We may
incur significant costs achieving and maintaining compliance with applicable federal and state privacy, security, and fraud laws. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur
significant legal expenses and divert our management&#146;s attention from the operation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and future health reform measures
could adversely affect our business operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions there have been, and we expect
there will continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system to contain costs, improve quality, and expand access to care. For example, in March 2010, President Obama signed the ACA into law,
which substantially changed the way healthcare is financed by both governmental and private insurers and continues to significantly impact the United States pharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been judicial, congressional, and executive branch challenges to certain aspects of the ACA. For example, on June&nbsp;17, 2021,
the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress. Moreover, there have been a number of health reform
initiatives by the Biden administration that have impacted the ACA. For example, on August&nbsp;16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#147;IRA&#148;), into law, which among other things, extends enhanced subsidies
for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#147;donut hole&#148; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost through a newly-established manufacturer discount program. It is unclear how other healthcare reform measures, if any, will impact our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, on
August&nbsp;2, 2011, the Budget Control Act of 2011 was signed into law which among other things, led to aggregate reductions in Medicare payments to providers. These reductions went into effect on April&nbsp;1, 2013, and, due to subsequent
legislative amendments, will remain in effect until 2032, with the exception of a temporary suspension from May&nbsp;1, 2020, through March&nbsp;31, 2022, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, unless additional
Congressional action is taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, there have been several recent U.S. presidential executive orders, congressional inquiries
and proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under
Medicare, and reform government program reimbursement methodologies for drugs. For example, on March 11, 2023, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100%
of a drug&#146;s average manufacturer price, beginning January 1, 2024. In addition, the IRA, among other things, (1)&nbsp;directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2)&nbsp;imposes
rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will
continue to issue and update guidance as these programs are implemented. These provisions took effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to litigation. It is
currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#146;s October 2022 executive order, on February 14, 2023, HHS released a
report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility and improve quality of care. It is unclear whether the models will be utilized in
any health reform measures in the future. We&nbsp;expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products
and services, which could result in reduced demand for our drug candidates or additional pricing pressures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, legislatures have increasingly passed legislation and implemented
regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing. If healthcare policies or reforms intended to curb healthcare costs are adopted, or if we experience negative publicity with respect to the pricing of our
products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in
additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of
cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drug candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail
to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to other laws and regulations governing our international operations, including regulations administered by the governments of
the United States, and authorities in the European Union and in Japan, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as
the trade control laws. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977, as
amended (&#147;FCPA&#148;), which prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the
purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business, and other state and national anti-bribery and anti-money laundering laws in the countries in which we
conduct activities, including the French <FONT STYLE="white-space:nowrap">anti-corruption</FONT> laws: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">433-1-1</FONT></FONT> of the French
Criminal Code (bribery of domestic public officials); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">433-1-2</FONT></FONT> of the French
Criminal Code (influence peddling involving domestic public officials); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article <FONT STYLE="white-space:nowrap">434-9</FONT> of the French Criminal Code (bribery of domestic judicial
staff); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">434-9-1</FONT></FONT> of the French
Criminal Code (influence peddling involving domestic judicial staff); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles <FONT STYLE="white-space:nowrap">435-1</FONT> and <FONT STYLE="white-space:nowrap">435-3</FONT> of the
French Criminal Code (bribery of foreign or international public officials); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles <FONT STYLE="white-space:nowrap">435-7</FONT> and <FONT STYLE="white-space:nowrap">435-9</FONT> of the
French Criminal Code (bribery of foreign or international judicial staff); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles <FONT STYLE="white-space:nowrap">435-2,</FONT> <FONT STYLE="white-space:nowrap">435-4,</FONT> <FONT
STYLE="white-space:nowrap">435-8</FONT> and <FONT STYLE="white-space:nowrap">435-10</FONT> of the French Criminal Code (active and passive influence peddling involving foreign or international public officials and foreign or international judicial
staff); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Articles <FONT STYLE="white-space:nowrap">445-1</FONT> and <FONT STYLE="white-space:nowrap">445-2</FONT> of the
French Criminal Code (bribery of private individuals); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">French Law No.&nbsp;2016-1691 of December&nbsp;9, 2016 on Transparency, the Fight Against Corruption and the
Modernization of the Economy (Sapin 2 Law), which provides for numerous new obligations for large companies such as the obligation to draw up and adopt a code of conduct defining and illustrating the different types of behavior to be proscribed as
being likely to characterize acts of corruption or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
influence peddling, to set up an internal warning system designed to enable the collections of reports from employees relating to the existence of conduct or situations contrary to the
company&#146;s code of conduct, to set up accounting control procedures, whether internal or external, designed to ensure that the books, registers and accounts are not used to conceal acts of corruption or influence peddling, to set up a
disciplinary system for sanctioning company employees in the event of a breach of the company&#146;s code of conduct or a system for monitoring and evaluating the measures implemented. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company
to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.
Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and debarment from government contracts. The scope and enforcement of these laws is
uncertain and subject to rapid change. Further, enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers. This has resulted in an increase in the number of investigations, prosecutions,
convictions and settlements in the healthcare industry. Responding to investigations can be both resource and time consuming and can divert management&#146;s attention from the business. Any such investigation or settlement could increase our costs
or otherwise have a material adverse effect on our business, outlook, financial position, income and growth. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA and other
anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of
value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory
approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of
our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no complete assurance that we will be effective in ensuring our compliance with all applicable anti-corruption laws, including the
FCPA, the French anti-corruption laws or other legal requirements, including trade control laws. If we are not in compliance with the FCPA, the French anti-corruption laws and other anti-corruption laws or trade control laws, we may be subject to
criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of
any potential violations of the FCPA, the French anti-corruption laws, other anti-corruption laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and
financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changes in our products and drug candidates or changes in applicable export or import laws and
regulations may create delays in the introduction or provision of our products and drug candidates in other jurisdictions, prevent others from using our products and drug candidates or, in some cases, prevent the export or import of our products and
drug candidates to certain countries, governments or persons altogether. Any limitation on our ability to export or provide our products and drug candidates could adversely affect our business, financial condition and results of operations. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our drug
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk that we may be sued on product liability claims is inherent in the development and commercialization of our
drug candidates. Side effects of, or manufacturing defects in, drugs that we develop could result in the deterioration of a patient&#146;s condition, injury or even death. For example, our liability could be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sought after by patients participating in the clinical trials in the context of the development of the therapeutic products tested and unexpected side effects resulting from the administration of
these drugs. In addition, we could face liability due to undetected side-effects caused by the interaction of our drugs with other drugs following release of the drug candidate to the market. Once a product is approved for sale and commercialized,
the likelihood of product liability lawsuits increases. Criminal or civil proceedings might be filed against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing our drugs. These actions
could include claims resulting from actions by our partners, licensees and subcontractors, over which we have little or no control. These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In
addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities, may be forced to limit or forgo further commercialization of the affected products and may suffer damage to our reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could be exposed to the risk of liability claims during the clinical development of our products, in particular product liability claims,
related to the manufacture of therapeutic products and trials in humans and animals. We could be held liable by patients participating in clinical trials as part of the development of the therapeutic products tested for unexpected side effects
resulting from the administration of these products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also be held liable during the commercialization phase of our products.
Criminal complaints or lawsuits could be filed or brought against us by patients, regulatory agencies, pharmaceutical companies and any other third parties using or marketing our products. These actions may include claims arising from acts of our
partners, licensees or subcontractors, over which we have little or no control. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain product liability insurance coverage for our clinical trials at levels which we believe are appropriate for our clinical trials.
Nevertheless, we cannot guarantee that the insurance policy taken out or the contractually limited indemnification, if applicable, granted by our subcontractors will be sufficient to cover the claims that could be brought against us or losses we may
suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our liability, or that of our partners, licensees and subcontractors, was thereby activated, if we or our partners, licensees
and subcontractors were unable to obtain and maintain appropriate insurance coverage at an acceptable cost or protect ourselves in any way against liability claims, this would seriously affect the commercialization of our products and, more
generally, have a material adverse effect on our business, income, financial position and outlook for growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to stringent and
evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations
or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure,
dispose of, transmit, and share (collectively, processing) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans,
transactions, and financial information (collectively, sensitive data). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our data processing activities may subject us to numerous data
privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach
notification laws, personal data privacy laws, consumer protection laws (e.g., </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, the California Consumer Privacy Act of 2018 (&#147;CCPA&#148;) requires
businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by
certain data breaches to recover significant statutory damages. In addition, the California Privacy Rights Act of 2020 (&#147;CPRA&#148;), which becomes operative January&nbsp;1, 2023, will expand the CCPA&#146;s requirements, including applying to
personal information of business representatives and employees and establishing a new regulatory agency to implement and enforce the law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other states, such as Virginia, Colorado, Utah, and Connecticut have also passed comprehensive privacy laws, and similar laws are being
considered in several other states, as well as at the federal and local levels. These developments may further complicate compliance efforts and may increase legal risk and compliance costs for us and the third parties upon whom we rely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security. For
example, the European Union&#146;s Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, as amended (&#147;EU GDPR&#148;), the United
Kingdom&#146;s GDPR (&#147;UK GDPR&#148;), Brazil&#146;s General Data Protection Law (Lei Geral de Prote&ccedil;&atilde;o de Dados Pessoais, or &#147;LGPD&#148;) (Law No.&nbsp;13,709/2018), and China&#146;s Personal Information Protection Law
(&#147;PIPL&#148;) impose strict requirements for processing personal data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we seek to obtain marketing authorization from
the European Union for our drug candidates. Moreover, a significant portion of the personal data that we may use is managed by third parties (primarily clinical sites and CROs in clinical trials). The collection and use of personal health data in
the European Union is governed by the provisions of the EU GDPR. Under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to &#128;20&nbsp;million or 4% of annual global revenue,
whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to
data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the EEA and the
United Kingdom (&#147;UK&#148;) have significantly restricted the transfer of personal data to countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and
cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the Trans-Atlantic Data Privacy Framework or the EEA
and UK&#146;s standard contractual clauses, being specified that these mechanisms of standard contractual clauses are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal
data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face
significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to
regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.
Some European regulators have prevented companies from transferring personal data out of Europe for allegedly violating the EU GDPR&#146;s cross-border data transfer limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups and may become
subject to such obligations in the future. We may also be bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may publish privacy policies, marketing materials, and other statements, such as
compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our
practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obligations related to
data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict
among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that
process personal data on our behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy
and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely
fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines,
penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. Any of these events could
have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or
commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience
adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other
adverse consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we and the third parties upon which we rely may process sensitive data,
and, as a result, we and the third parties upon which we rely face a variety of evolving threats, including but not limited to ransomware attacks, which could cause security incidents. Cyber-attacks, malicious internet-based activity, online and
offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and
continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#147;hackers,&#148; threat actors, &#147;hacktivists,&#148; organized criminal threat actors, personnel (such as through
theft or misuse), sophisticated nation states, and nation-state-supported actors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some actors now engage and are expected to continue to
engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which
we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering
attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions),
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs,
server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to
significant interruptions in our operations, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such
payments due to, for example, applicable laws or regulations prohibiting such payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Remote work has become more common and has
increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations.
Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or
integrated entities&#146; systems and technologies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our reliance on third-party service providers could introduce new
cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We may rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a
variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, employee email, and other functions. We may also rely on third-party service providers to provide other products, services, parts, or otherwise
to operate our business. Our ability to monitor these third parties&#146; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers
experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award
may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#146; infrastructure in our supply chain or
our third-party partners&#146; supply chains have not been compromised. One of our CROs has experienced a data breach that involved personal data being compromised, affecting all the CRO&#146;s customers, including fully pseudonymized and encoded
electronic case report forms relating to 14 of our trials. While our Data Protection Committee concluded in October 2021 that there is no critical risk to the privacy of data subjects, we have conducted additional corrective and preventive measures
to ensure any such data breach incident can be prevented in the future (including root cause analysis audits and risk analysis). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or
access to our sensitive data or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our
services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may expend significant resources or modify our business activities to try to protect against security incidents.
Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures
will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a
security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are
costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we (or a third party
upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive
data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and
other similar harms. Security incidents and attendant consequences may cause customers to stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our
contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate
liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Offering, Ownership of Our ADSs and Our Status as a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Company with Foreign Private
Issuer Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There has been no market for our ADSs prior to the U.S. offering and an active and liquid market for our securities may fail to
develop, which could harm the market price of our ADSs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although our ordinary shares have been traded on Euronext Paris since <FONT
STYLE="white-space:nowrap">mid-2015,</FONT> there has been no public market on a U.S. national securities exchange for our ADSs in the United&nbsp;States. Although we anticipate that our ADSs will be approved for listing on the Nasdaq Global Market,
an active trading market for our ADSs may never develop or be sustained following the offering. The offering price of our ADSs was determined through negotiations between us and the underwriters based on a number of factors. This offering price may
not be indicative of the market price of our ADSs after the offering. In the absence of an active trading market for our ADSs, investors may not be able to sell their ADSs at or above the offering price or at the time that they would like to sell.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, our business will be harmed,
and the price of our securities could decline as a result. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sometimes estimate for planning purposes the timing of the
accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies, clinical trials, the submission of
regulatory filings, or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt
of marketing approval, or a commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which may cause the timing of achievement of the
milestones to vary considerably from our estimates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities, including
the extent of scheduling conflicts with participating clinicians and collaborators, and our ability to identify and enroll patients who meet clinical trial eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our receipt of approvals by the European Commission, FDA and other regulatory agencies and the timing thereof;
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other actions, decisions or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of compounds and raw materials used in the
manufacture of our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts of our collaborators with respect to the commercialization of our products; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and
marketing activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve announced milestones in the timeframes we expect, the commercialization of
our drug candidates may be delayed, our business and results of operations may be harmed, and the trading price of the ADSs may decline as a result. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be a &#147;passive foreign investment company&#148; for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax
consequences to U.S. investors. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if, for any taxable year, at least 75% of our gross income is passive income
(&#147;income test&#148;), or at least 50% of the value of our assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce passive income or are held for the production of passive
income, including cash, we would be characterized as a passive foreign investment company (&#147;PFIC&#148;) for U.S. federal income tax purposes. For purposes of these tests, passive income includes, among other things, dividends, interest, and
gains from the sale or exchange of investment property and rents or royalties other than rents or royalties which are received from unrelated parties in connection with the active conduct of a trade or business. Cash and cash equivalents are
generally treated as passive assets. Goodwill is treated as an active asset to the extent associated with business activities that produce active income. For purposes of the PFIC rules, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation
that owns, directly or indirectly, at least 25% by value of the equity interests of another corporation or partnership is treated as if it held its proportionate share of the assets of the other corporation or partnership, and received directly its
proportionate share of the income of the other corporation or partnership. Equity interests of less than 25% by value in any other corporation or partnership are treated as passive assets, regardless of the nature of the other corporation or
partnership&#146;s business. If we are a PFIC for any taxable year in which a U.S. Holder (as defined in &#147;Material United States Federal Income and French Tax Considerations&#151;Material U.S. Federal Income Tax Considerations for U.S.
Holders&#148;) holds an ADS, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder including increased tax liability on disposition gains and certain &#147;excess distributions&#148; and additional reporting
requirements. See &#147;Material United States Federal Income and French Tax Considerations&#151;Material U.S. Federal Income Tax Considerations for U.S. Holders&#151;Passive Foreign Investment Company Rules.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our analysis of our financial statements, activities and relevant market and shareholder data, we do not believe that we were a PFIC
for the taxable year ended December 31, 2022. Whether we are a PFIC for any taxable year will depend on the composition of our income and the composition, nature and value of our assets from time to time (including the value of our goodwill, which
may be determined by reference to the value of our ADSs, which could fluctuate considerably). We currently do not generate product revenues and therefore we may be a PFIC for any taxable year in which we do not generate sufficient amounts of
non-passive income to offset our passive financing income. As a result, there can be no assurance that we will not be treated as a PFIC for the current or any future taxable year and our U.S. counsel expresses no opinion with respect to our PFIC
status for any prior, current or future taxable year. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the Internal Revenue Service, or the IRS, will agree with our conclusion and that the IRS would not
successfully challenge our position. Each U.S. holder is strongly urged to consult its tax advisor regarding these issues and any available elections to mitigate such tax consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If a United States person is treated as owning at least 10% of the value or voting power of our ADSs, such holder may be subject to adverse U.S. federal
income tax consequences. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a United States person is treated as owning (directly, indirectly, or constructively) at least 10%
of the aggregate value or voting power of our ADSs, such person may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled foreign corporation&#148; in our group (if any), which may subject such person to adverse
U.S. federal income tax consequences. Our group currently includes one U.S. subsidiary corporation and, therefore, under current law our current non-U.S. subsidiary and any future newly formed or acquired non-U.S. subsidiaries that are treated as
corporations for U.S. federal income tax purposes will be treated as controlled foreign corporations, regardless of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether we are treated as a controlled foreign corporation. A United States shareholder of a controlled foreign corporation generally is required to report annually and include in its U.S.
taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global intangible <FONT STYLE="white-space:nowrap">low-taxed</FONT> income,&#148; and investments in U.S. property by controlled foreign corporations, regardless of whether we
make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be available to a United States
shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject a United States shareholder to significant monetary penalties and may prevent the statute of limitations with respect to such shareholder&#146;s
U.S. federal income tax return for the year for which reporting was due from starting. We cannot provide any assurances that we will assist investors in determining whether we are treated as a controlled foreign corporation or whether any holder of
our ADSs is treated as a United States shareholder with respect to any such controlled foreign corporation or furnish to any United States shareholders information that may be necessary to comply with the aforementioned reporting and tax paying
obligations. The United States Internal Revenue Service provided limited guidance on situations in which investors may rely on publicly available information to comply with their reporting and tax paying obligations with respect to
foreign-controlled CFCs. Each U.S. holder of our ADSs should consult its advisors regarding the potential application of these rules to an investment in our ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from the global offering and may use them in ways with which you do not agree and in ways that
may not increase the value of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds
that we receive from the global offering. We may spend or invest these proceeds in a way with which our shareholders and ADS holders disagree. The failure by our management to apply these funds effectively could harm our business and financial
condition. Pending their use, we may invest the net proceeds from the global offering in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase ADSs in the offering, you will experience substantial and immediate dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase ADSs in the offering, you will experience substantial and immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS in net tangible book value as of June&nbsp;30, 2023, after giving effect to the U.S. offering at an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS. This dilution is due in large part to the fact that our earlier investors paid substantially less than the offering price when they purchased their ordinary shares.
You will experience additional dilution upon exercise of any outstanding warrants to purchase ordinary shares or if we otherwise issue additional ordinary shares or ADSs below the offering price. For a further description of the dilution that you
will experience immediately after the offering, see the section of this prospectus titled &#147;Dilution.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future, or the possibility of
future sales, of a substantial number sales of our ordinary shares or ADSs by existing shareholders could depress the market price of the ordinary shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future sales of a substantial number of our ADSs, or the perception that such sales will occur, could cause a decline in the market price of
our ADSs. Based upon the number of shares outstanding as of June&nbsp;30, 2023, after giving effect to the closing of the offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding
(including ordinary shares in the form of ADSs), assuming the underwriters do not exercise their option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs. ADSs issued and sold in the U.S. offering
may be resold in the public market immediately without restriction, unless purchased by our affiliates. A significant portion of these ADSs will be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in &#147;Ordinary
Shares and ADSs Eligible for Future Sale&#148; and &#147;Underwriters.&#148; If, after the end of such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, these shareholders or ADS holders sell substantial amounts of ADSs in the public
market, or the market perceives that such sales may occur, the market price of our ADSs and our ability to raise capital through an issuance of equity securities in the future could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The rights of shareholders in companies subject to French corporate law differ in material respects from the rights of shareholders of corporations
incorporated in the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a French company with limited liability. Our corporate affairs are governed by our <FONT
STYLE="white-space:nowrap">by-laws</FONT> and by the laws governing companies incorporated in France. The rights of shareholders and the responsibilities of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
members of our Board are in many ways different from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. For example, in the performance of its
duties, our Board is required by French law to consider the interests of our company, its shareholders, its employees and other stakeholders, rather than solely our shareholders and/or creditors. It is possible that some of these parties will have
interests that are different from, or in addition to, your interests as a shareholder or holder of ADSs. See the sections of this prospectus titled &#147;Management&#151;Board Practices&#151;Corporate Governance Practices&#148; and &#147;Description
of Share Capital.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. investors may have difficulty enforcing civil liabilities against our company and directors and senior management
and the experts named in this prospectus. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain members of our Board and senior management and certain experts named in this
prospectus are <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to
serve process on such persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States. Additionally, it may be difficult to assert
U.S. securities law claims in actions originally instituted outside of the United States. Courts outside the United States may refuse to hear a U.S. securities law claim because <FONT STYLE="white-space:nowrap">non-U.S.</FONT> courts may not be the
most appropriate forums in which to bring such a claim. Even if a court outside the United States agrees to hear a claim, it may determine that the law of the jurisdiction in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> court resides,
and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still
be governed by the law of the jurisdiction in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> court resides. In particular, there is some doubt as to whether French courts would recognize and enforce certain civil liabilities under U.S.
securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in France. An award for
monetary damages under the U.S. securities laws would be considered punitive if it does not seek to compensate the claimant for loss or damage suffered but is intended to punish the defendant. French law provides that a shareholder, or a group of
shareholders, may initiate a legal action to seek indemnification from the directors of a corporation in the corporation&#146;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the
corporation and any legal fees relating to such action may be borne by the relevant shareholder or the group of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
enforceability of any judgment in France will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and France do not currently have a treaty providing for recognition and enforcement of
judgments, other than arbitration awards, in civil and commercial matters. See &#147;Enforcement of Civil Liabilities.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may face
difficulties protecting your interests, and your ability to protect your rights through the U.S.&nbsp;federal courts may be limited because we are incorporated under the laws of France, all of our assets are in the European Union and a majority of
our directors and executive officers reside outside the United&nbsp;States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are constituted under the laws of France. A
majority of our officers, and directors, reside outside the United&nbsp;States. In addition, a substantial portion of their assets and our assets are located outside of the United&nbsp;States. As a result, you may have difficulty serving legal
process within the United&nbsp;States upon us or any of these persons. You may also have difficulty enforcing, both in and outside of the United&nbsp;States, judgments you may obtain in U.S.&nbsp;courts against us or these persons in any action,
including actions based upon the civil liability provisions of U.S.&nbsp;Federal or state securities laws. Furthermore, there is substantial doubt as to the enforceability in France against us or against any of our directors, officers and the expert
named in this prospectus who are not residents of the United&nbsp;States, in original actions or in actions for enforcement of judgments of U.S.&nbsp;courts, of liabilities based solely upon the civil liability provisions of the U.S.&nbsp;federal
securities laws. In addition, shareholders in French corporations may not have standing to initiate a shareholder derivative action in U.S.&nbsp;federal courts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, our public shareholders may have more difficulty in protecting their interests
through actions against us, our management, our directors or our major shareholders than would shareholders of a corporation incorporated in a jurisdiction in the United&nbsp;States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The dual listing of our ordinary shares and the ADSs may adversely affect the liquidity and value of the ADSs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this global offering and after the ADSs begin trading on the Nasdaq Global Market, our ordinary shares will continue to be listed on
Euronext Paris. Trading of the ADSs or ordinary shares in these markets will take place in different currencies (U.S. dollars on Nasdaq and euros on Euronext Paris), and at different times (resulting from different time zones, different trading days
and different public holidays in the United States and France). The trading prices of our ordinary shares on these two markets may differ due to these and other factors. Any decrease in the price of our ordinary shares on Euronext Paris could cause
a decrease in the trading price of the ADSs on Nasdaq. Investors could seek to sell or buy our ordinary shares to take advantage of any price differences between the markets through a practice referred to as arbitrage. Any arbitrage activity could
create unexpected volatility in both our share prices on one exchange, and the ordinary shares available for trading on the other exchange. In addition, holders of ADSs will not be immediately able to surrender their ADSs and withdraw the underlying
ordinary shares for trading on the other market without effecting necessary procedures with the depositary. This could result in time delays and additional cost for holders of ADSs. We cannot predict the effect of this dual listing on the value of
our ordinary shares and the ADSs. However, the dual listing of our ordinary shares and the ADSs may reduce the liquidity of these securities in one or both markets and may adversely affect the development of an active trading market for the ADSs in
the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap">by-laws</FONT> and French corporate law contain provisions that may delay or discourage a
takeover attempt. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions contained in our <FONT STYLE="white-space:nowrap">by-laws</FONT> and French corporate law could make
it more difficult for a third party to acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of our <FONT STYLE="white-space:nowrap">by-laws</FONT> impose various procedural and other requirements, which could
make it more difficult for shareholders to effect certain corporate actions. These provisions include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, the owner of 90% of the share capital or voting rights of a public company listed on a
regulated market in a Member State of the European Union or in a state party to the EEA Agreement, including from the main French stock exchange, has the right to force out minority shareholders following a tender offer made to all shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a <FONT STYLE="white-space:nowrap">non-resident</FONT> of France as well as any French entity
controlled by <FONT STYLE="white-space:nowrap">non-residents</FONT> of France may have to file a declaration for statistical purposes with the Bank of France (<I>Banque de France</I>) within 20 working days following the date of certain direct
foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &#128;15&nbsp;million that lead to the acquisition of at least 10% of our share capital or voting rights
or cross such 10% threshold. See &#147;Limitations Affecting Shareholders of a French Company&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, certain foreign investments in companies incorporated under French laws are subject to the
prior authorization from the French Minister of the Economy, where all or part of the target&#146;s business and activity relate to a strategic sector, such as energy, transportation, public health, telecommunications, research and development in
biotechnologies, activities relating to public health, etc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger (i.e.,&nbsp;in a French law context, a share for share exchange following which our company would be
dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of our Board as well as a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger of our company into a company incorporated outside of the European Union would require 100% of our
shareholders to approve it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a cash merger is treated as a share purchase and would require the consent of each
participating shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have granted and may grant in the future our Board broad authorizations to increase our share
capital or to issue additional ordinary shares or other securities, such as warrants, to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our shares;
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have preferential subscription rights on a <I>pro rata</I> basis on the issuance by us of any
additional securities for cash or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts, which rights may only be waived by the extraordinary general meeting by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote of our
shareholders or on an individual basis by each shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Board has the right to appoint directors to fill a vacancy created by the resignation or death of a director,
subject to the approval by the shareholders of such appointment at the next shareholders&#146; meeting, which prevents shareholders from having the sole right to fill vacancies on our Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Board can be convened by our chairman, including upon request from our Chief Executive Officer (<I>directeur
general</I>), if the positions of Chief Executive Officer and Chairman of the Board are not held by the same person, or, when no board meeting has been held for more than two consecutive months, from directors representing at least <FONT
STYLE="white-space:nowrap">one-third</FONT> of the total number of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Board meetings can only be regularly held if at least half of the directors attend either physically or by
way of videoconference or teleconference enabling the directors&#146; identification and ensuring their effective participation in the Board&#146;s decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shares are registered or bearer, if the legislation so permits, according to the shareholder&#146;s choice;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of at least a majority of the votes held by shareholders present, represented by a proxy, or voting by
mail at the relevant ordinary shareholders&#146; general meeting is required to remove directors with or without cause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice is required for nominations to the Board or for proposing matters to be acted upon at a
shareholders&#146; meeting, except that a vote to remove and replace a director can be proposed at any shareholders&#146; meeting without notice; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <FONT STYLE="white-space:nowrap">by-laws</FONT> can be changed in accordance with applicable French laws and
regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the crossing of certain thresholds must be disclosed and can impose certain obligations (including filing a
mandatory public tender offer). See &#147;Description of Share Capital&#151;Disclosure Requirements for Holdings Exceeding Certain Thresholds&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares shall comply with applicable insider trading rules and regulations and, in particular, with
the EU Market Abuse Directive and Regulation dated April&nbsp;16, 2014; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to French law, the sections of our <FONT STYLE="white-space:nowrap">by-laws</FONT> relating to the
number of directors and election and removal of a director from office, may only be modified by a resolution adopted by <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes of our shareholders present, represented by a proxy or voting by
mail at the meeting. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing and potential investors in our ordinary shares or ADSs may have to request the prior
authorization from the French Ministry of Economy prior to acquiring a significant ownership position in our ordinary shares or ADSs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, direct and indirect acquisition of control of all or part of a branch of activity, and investments of more than 25% by
foreign individuals or entities (except, in the last case, EU/EEA investors) in a French company deemed to be a strategic industry is subject to prior authorization of the French Ministry of Economy pursuant to Articles L. <FONT
STYLE="white-space:nowrap">151-1</FONT> et seq. and R. <FONT STYLE="white-space:nowrap">151-1</FONT> et seq. of the French Monetary and Financial code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an investment requiring the prior authorization of the French Minister of Economy is
completed without such authorization having been granted, the French Minister of Economy might direct the relevant investor to (i)&nbsp;submit a request for authorization, (ii)&nbsp;have the previous situation restored at its own expense or
(iii)&nbsp;amend the investment. The relevant investor might also be found criminally liable and might be sanctioned with a fine which cannot exceed the greater of: (i)&nbsp;twice the amount of the relevant investment, (ii) 10% of the annual
turnover before tax of the target company and (iii) &#128;5&nbsp;million (for an entity) or &#128;1&nbsp;million (for an individual). The French Minister of Economy may also adopt precautionary measures it deems necessary to protect strategic
sovereign assets , including the suspension of voting rights or the prohibition or limitation of the distribution of dividends and remuneration attached to shares whose ownership by the investor should have been subject to prior authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the context of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Decree (<I>d&eacute;cret</I>) No.&nbsp;2020-892 dated
July&nbsp;22, 2020, as amended by the Decree (<I>d&eacute;cret</I>) No.&nbsp;2020-1729 dated December&nbsp;28, 2020, on December&nbsp;22, 2021 by the Decree (d&eacute;cret) n&deg; 2021-1758 and lastly on December&nbsp;23, 2022 by the Decree
(<I>d&#233;cret</I>) n&deg; 2022-1622, has implemented a 10% threshold of the voting rights for the non-EU/EEA investments made (i)&nbsp;in an entity incorporated under the laws of France and (ii)&nbsp;whose shares are admitted to trading on a
regulated market, in addition to the 25% above-mentioned threshold. Set to expire on December 31, 2023, this 10% threshold could become permanent. The transactions falling within the scope of the Decree (<I>d&eacute;cret</I>) <FONT
STYLE="white-space:nowrap">No.&nbsp;2020-892,</FONT> as amended, benefit from a &#147;fast-track procedure&#148; pursuant to which the investor is exempt from the authorization request provided for in Article R.
<FONT STYLE="white-space:nowrap">151-5</FONT> of the Monetary and Financial Code, provided that the investment project has been the subject of prior notification to the French Minister of Economy and that the transaction is carried out within six
months following the notification. Unless the French Minister of Economy objects, the authorization is granted at the end of a period of ten working days following notification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with such measures could result in significant consequences in the concerned investment. Such measures could also delay or
discourage a takeover or more broadly a foreign investment attempt, and we cannot predict whether these measures will result in a lower or more volatile market price of our ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more details on the French foreign investment control regime see &#147;Limitations Affecting Shareholders of a French Company.&#148; </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may not be able to exercise your right to vote the ordinary shares underlying your ADSs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the provisions
of the deposit agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give
instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (i)&nbsp;the notice of the meeting or solicitation of consent or proxy sent
by us and (ii)&nbsp;a statement as to the manner in which instructions may be given by the holders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchasers of ADSs may instruct
the depositary of their ADSs to vote the ordinary shares underlying their ADSs. Otherwise, purchasers of ADSs will not be able to exercise voting rights unless they withdraw the ordinary shares underlying the ADSs they hold. However, a holder of
ADSs may not know about the meeting far enough in advance to withdraw those ordinary shares. If we ask for a holder of ADSs&#146; instructions, the depositary, upon timely notice from us, will notify him or her of the upcoming vote and arrange to
deliver our voting materials to him or her. We cannot guarantee to any holder of ADSs that he or she will receive the voting materials in time to ensure that he or she can instruct the depositary to vote his or her ordinary shares or to withdraw his
or her ordinary shares so that he or she can vote them. If the depositary does not receive timely voting instructions from a holder of ADSs, it may give a proxy to a person designated by us to vote the ordinary shares underlying his or her ADSs. In
addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that a holder of ADSs may not be able to exercise his or her right to vote,
and there may be nothing he or she can do if the ordinary shares underlying his or her ADSs are not voted as he or she requested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchasers of ADSs are not holders of our ordinary shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of ADSs will not be treated as one of our shareholders and will not have direct shareholder rights. French law governs our shareholder
rights. The depositary will be the holder of the ordinary shares underlying ADSs held by purchasers of ADSs. Purchasers of ADSs will have ADS holder rights. The deposit agreement among us, the depositary and purchasers of ADSs, as ADS holders, and
all other persons directly and indirectly holding ADSs, sets out ADS holder rights, as well as the rights and obligations of the depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A double voting right is attached to each registered ordinary share (except treasury shares) that is held in the name of the same shareholder
for at least two years. However, the ordinary shares underlying our ADSs will not be entitled to double voting rights as the depositary will hold the ordinary shares underlying our ADSs in bearer form. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The right as a holder of ADSs to participate in any future preferential subscription rights or to elect to receive dividends in shares may be limited,
which may cause dilution to the holdings of purchasers of ADSs in the ADS offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to French law, if we issue
additional securities for cash, current shareholders will have preferential subscription rights for these securities on a <I>pro rata</I> basis unless they waive those rights at an extraordinary meeting of our shareholders by a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority vote or individually by each shareholder. However, ADS holders will not be entitled to exercise or sell such rights unless we register the rights and the securities to which the rights relate
under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit agreement provides that the depositary will not make rights available to purchasers of ADSs unless the distribution to ADS holders of
both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. Further, if we offer holders of our ordinary shares the option to receive dividends in either cash or
shares, under the deposit agreement the depositary may require satisfactory assurances from us that extending the offer to holders of ADSs does not require registration of any securities under the Securities Act before making the option available to
holders of ADSs. We are under no obligation to file&nbsp;a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish
an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings or to elect to receive dividends in shares and may experience dilution in their holdings. In addition, if the
depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you will receive no value for these rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchasers of ADSs may be subject to limitations on the withdrawal of the underlying ordinary shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its
transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#146; meeting or we are paying a dividend on our ordinary shares. In addition, a holder of ADSs may not be able to
cancel his or her ADSs and withdraw the underlying ordinary shares when he or she owes money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply
to ADSs or to the withdrawal of ordinary shares or other deposited securities. See the section of this prospectus titled &#147;Description of American Depositary Shares.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable
outcomes to the plaintiffs in any such action. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement governing the ADSs representing our ordinary shares provides
that, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under
the U.S. federal securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or the depositary opposed a jury trial demand based on the waiver, the court would
determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual
<FONT STYLE="white-space:nowrap">pre-dispute</FONT> jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual <FONT
STYLE="white-space:nowrap">pre-dispute</FONT> jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual <FONT STYLE="white-space:nowrap">pre-dispute</FONT> jury trial waiver provision,
courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal
counsel regarding the jury waiver provision before entering into the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you or any other holders or beneficial owners
of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury
trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and the depositary. If a lawsuit is brought against either or both of us and the depositary under the deposit agreement, it may be heard
only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have, including results that could be less favorable to the
plaintiffs in any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could
proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with
U.S. federal securities laws and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer, we are exempt from a number of
rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company. This may limit the information available to holders of ADSs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer, as defined in the SEC&#146;s rules and regulations and, consequently, we are not subject to all of the
disclosure requirements applicable to public companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the
solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section&nbsp;14 of the Exchange Act. In addition, our officers and directors are exempt from the
reporting and &#147;short-swing&#148; profit recovery provisions of Section&nbsp;16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we currently make annual and semi-annual filings
with respect to our listing on Euronext Paris and expect to file financial reports on an annual and semi-annual basis, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public
companies and will not be required to file quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> or current reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> under the Exchange Act. Accordingly, there will be
less publicly available information concerning our company than there would be if we were not a foreign private issuer. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private
issuer, we are permitted, and we expect, to follow certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq&#146;s corporate governance standards. These practices may afford less protection to
shareholders than they would enjoy if we complied fully with the corporate governance standards of the Nasdaq Global Market. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
foreign private issuer listed on the Nasdaq Global Market, we will be subject to Nasdaq&#146;s corporate governance standards. However, Nasdaq rules provide that foreign private issuers are permitted to follow home country corporate governance
practices in lieu of Nasdaq&#146;s corporate governance standards as long as notification is provided to Nasdaq of the intention to take advantage of such exemptions. We intend to rely on exemptions for foreign private issuers and follow French
corporate governance practices in lieu of Nasdaq&#146;s corporate governance standards, to the extent possible. Certain corporate governance practices in France, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is our home country, may differ significantly from Nasdaq corporate governance standards. For example, as a French company, neither the corporate laws of France nor our <FONT
STYLE="white-space:nowrap">by-laws</FONT> require a majority of our directors to be independent and we can include <FONT STYLE="white-space:nowrap">non-independent</FONT> directors as members of our remuneration committee, and our independent
directors are not required to hold regularly scheduled meetings at which only independent directors are present. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also exempt
from provisions set forth in Nasdaq rules which require an issuer to provide in its <FONT STYLE="white-space:nowrap">by-laws</FONT> for a generally applicable quorum, and that such quorum may not be less than
<FONT STYLE="white-space:nowrap">one-third</FONT> of the outstanding voting stock. Consistent with French law, our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that a quorum requires the presence of shareholders having at least
(i)&nbsp;20% of the shares entitled to vote in the case of an ordinary shareholders&#146; general meeting or at an extraordinary shareholders&#146; general meeting where shareholders are voting on a capital increase by capitalization of reserves,
profits or share premium, or (ii)&nbsp;25% of the shares entitled to vote in the case of any other extraordinary shareholders&#146; general meeting. If a quorum is not present, the meeting is adjourned. There is no quorum requirement when an
ordinary general meeting is reconvened, but the reconvened meeting may consider only questions which were on the agenda of the adjourned meeting. When an extraordinary general meeting is reconvened, the quorum required is 20% of the shares entitled
to vote, except where the reconvened meeting is considering capital increases through capitalization of reserves, profits or share premium. For these matters, no quorum is required at the reconvened meeting. If a quorum is not present at a
reconvened meeting requiring a quorum, then the meeting may be adjourned for a maximum of two months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are
required to comply with <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> of the Exchange Act, relating to audit committee composition and responsibilities. Under French law, the audit committee may only have an advisory role and appointment
of our statutory auditors, in particular, must be decided by the shareholders at our annual meeting. Therefore, our shareholders may be afforded less protection than they otherwise would have under Nasdaq&#146;s corporate governance standards
applicable to U.S. domestic issuers. For an overview of our corporate governance practices, see &#147;Management&#151;Board Practices&#151;Corporate Governance Practices.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; under the JOBS Act and will be able to avail ourselves of reduced disclosure requirements applicable to
emerging growth companies, which could make our ADSs less attractive to investors. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth
company,&#148; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148;, including not
being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002 (&#147;Sarbanes-Oxley Act&#148;), and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved. In addition, Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided
in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. We will not take advantage of the extended transition period provided under Section&nbsp;7(a)(2)(B) of the Securities Act for complying with
new or revised accounting standards. Since IFRS makes no distinction between public and private companies for purposes of compliance with new or revised accounting standards, the requirements for our compliance as a private company and as a public
company are the same. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find our ADSs less attractive because we may rely on these exemptions. If
some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging
growth company. We will remain an emerging growth company until the earliest of (1)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of $1.235&nbsp;billion or more; (2)&nbsp;the last day of our fiscal year following
the fifth anniversary of the date of the completion of the offering; (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; and (4)&nbsp;the date on which we are deemed to be a
large accelerated filer under the rules of the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may lose our foreign private issuer status in the future, which could result in significant
additional cost and expense. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we currently qualify as a foreign private issuer, the determination of foreign private
issuer status is made annually on the last business day of an issuer&#146;s most recently completed second fiscal quarter and, accordingly, the next determination will be made with respect to us on June&nbsp;30, 2024. In the future, we could lose
our foreign private issuer status if we fail to meet the requirements necessary to maintain our foreign private issuer status as of the relevant determination date. We will remain a foreign private issuer until such time that more than 50% of our
outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the majority of our executive officers or directors are U.S. citizens or residents; (ii)&nbsp;more than 50% of our assets are
located in the United States; or (iii)&nbsp;our business is administered principally in the United States. For additional information relating to our principal shareholders, see &#147;Principal Shareholders.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we incur
as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than
the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance with U.S.&nbsp;GAAP, rather than IFRS, and modify certain of our policies to comply with corporate
governance practices associated with U.S. domestic issuers. Such conversion of our financial statements to U.S.&nbsp;GAAP would involve significant time and cost. In addition, we may lose our ability to rely upon exemptions from certain corporate
governance requirements on U.S. stock exchanges that are available to foreign private issuers such as the ones described herein and exemptions from procedural requirements related to the solicitation of proxies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in
obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions <FONT STYLE="white-space:nowrap">and&nbsp;in-licenses.</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The growth of our business may depend in part on our ability to <FONT STYLE="white-space:nowrap">acquire,&nbsp;in-license&nbsp;or</FONT> use
third-party proprietary rights. For example, our drug candidates may require specific formulations to work effectively and efficiently, we may develop drug candidates containing our compounds
<FONT STYLE="white-space:nowrap">and&nbsp;pre-existing&nbsp;pharmaceutical</FONT> compounds, or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our drug candidates, any
of which could require us to obtain rights to use intellectual property held by third parties. In addition, with respect to any patents we <FONT STYLE="white-space:nowrap">may&nbsp;co-own&nbsp;with</FONT> third parties, we may require licenses to <FONT
STYLE="white-space:nowrap">such&nbsp;co-owner&#146;s&nbsp;interest</FONT> to such patents. We may be unable to acquire <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;any</FONT> compositions, methods of use, processes or other third-party
intellectual property rights from third parties that we identify as necessary or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to
happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on those intellectual property rights, which may
entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may <FONT STYLE="white-space:nowrap">be&nbsp;non-exclusive,&nbsp;which</FONT>
means that our competitors may also receive access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written
agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Even if we hold such an option, we may
be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our
ability to pursue our program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party intellectual property rights is a competitive
area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to
commercialize our drug candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to
be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property surrounding the
additional drug candidates that we may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon
development of certain programs and our business financial condition, results of operations and prospects could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our
equity securities may be volatile, and purchasers of our ADSs could incur substantial losses. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price for our ADSs
may be volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. In particular, our
stock price in Paris has fluctuated from a <FONT STYLE="white-space:nowrap">52-week</FONT> high of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to a low of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. As a result of this
volatility, investors may not be able to sell their ADSs at or above the price originally paid for the security. The market price for our ADSs and ordinary shares may be influenced by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in our financial condition and operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in our growth rate relative to our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition from existing products or new products that may emerge; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures,
collaborations, or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to
the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuance of new or updated research or reports by securities analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key management or scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lawsuits threatened or filed against us, disputes or other developments related to proprietary rights, including
patents, litigation matters, and our ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to coverage policies or reimbursement levels by commercial third-party payors and government payors and
any announcements relating to coverage policies or reimbursement levels; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional debt or equity financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our ordinary shares or ADSs by us, our insiders or our other shareholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and market conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate substantially, regardless of our
actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of the trading market for our ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable
research about our business, the price of our ADSs and their trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our ADSs depends
in part on the research and reports that securities or industry analysts publish about us or our business. If no or few securities or industry analysts cover our company, the trading price for our ADSs would be negatively impacted. If one or more of
the analysts who covers us downgrades our equity securities or publishes incorrect or unfavorable research about our business, the price of our ADSs would likely decline. If one or more of these analysts ceases coverage of our company or fails to
publish reports on us regularly, or downgrades our securities, demand for our ADSs could decrease, which could cause the price of our ADSs or their trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The requirements of being a U.S. public company may strain our resources and divert management&#146;s attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to comply with various corporate governance and financial reporting requirements under the Sarbanes-Oxley Act, the Exchange
Act, and the rules and regulations adopted by the SEC and the Public Company Accounting Oversight Board. Further, compliance with various regulatory reporting requires significant commitments of time from our management and our directors, which
reduces the time available for the performance of their other responsibilities. Our failure to track and comply with the various rules may materially adversely affect our reputation, ability to obtain the necessary certifications to financial
statements, lead to additional regulatory enforcement actions, and could adversely affect the value of our ordinary shares or ADSs. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After the
completion of the offering, we may be at an increased risk of securities class action litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, securities class
action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant share
price volatility in recent years. If we were to be sued, it could result in substantial costs, which could be insufficiently covered by insurance, and a diversion of management&#146;s attention and resources, which could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently intend to pay dividends on our securities and, consequently, your ability to achieve a return on your investment will depend on
appreciation in the price of the ordinary shares and our ADSs. In addition, French law may limit the amount of dividends we are able to distribute. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our ordinary shares and do not currently intend to do so for the foreseeable future. We
currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your ADSs for the foreseeable future and the success of an investment in ADSs will depend upon any future
appreciation in its value. Consequently, investors may need to sell all or part of their holdings of ADSs after price appreciation, which may never occur, as the only way to realize any future gains on their investment. There is no guarantee that
the ADSs will appreciate in value or even maintain the price at which our shareholders have purchased them. Investors seeking cash dividends should not purchase our ADSs. Furthermore, certain of our debt instruments restrict the payment of dividends
or require consent to pay dividends. See &#147;Dividend Policy.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, under French law, the determination of whether we
have been sufficiently profitable to pay dividends is made on the basis of our statutory financial statements prepared and presented in accordance with accounting standards applicable in France. In addition, payment of dividends may subject us to
additional taxes under French law. Therefore, we may be more restricted in our ability to declare dividends than companies not based in France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, exchange rate fluctuations may affect the amount of euros that we are able to distribute, and the amount in U.S. dollars that our
shareholders receive upon the payment of cash dividends or other distributions we declare and pay in euros, if any. These factors could harm the value of our ADSs, and, in turn, the U.S. dollar proceeds that holders receive from the sale of our
ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_6"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are
contained principally in the sections titled &#147;Prospectus Summary&#148; &#147;Risk Factors&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business&#148; but are also
contained elsewhere in this prospectus. In some cases, you can identify forward-looking statements by the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;future,&#148; &#147;goals,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;ongoing,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;seek,&#148; &#147;should,&#148; &#147;strategy,&#148; &#147;will&#148; and &#147;would&#148; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and
unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we
believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future,
about which we cannot be certain. Forward-looking statements include but are not limited to statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prospects of attaining, maintaining and expanding marketing authorization for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential attributes and clinical advantages of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our preclinical and clinical trials (and those conducted by third
parties) and other research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the availability of data from our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to advance drug candidates through clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory meetings and filings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approvals for any of our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and develop new drug candidates from our preclinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop sales and marketing capabilities and transition into a commercial-stage company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of increased competition as well as innovations by new and existing competitors in our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into strategic relationships or partnerships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain, maintain, protect and enforce our intellectual property rights and propriety technologies
and to operate our business without infringing the intellectual property rights and proprietary technology of third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the use of proceeds from the global offering and our existing cash and cash
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenues, capital requirements and the need for additional financing,
including the period of time over which we expect the net proceeds of the global offering together with cash and cash equivalents will be sufficient to fund our operations and capital requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the &#147;Risk Factors&#148; section of this prospectus for a discussion of important factors that may cause our actual
results to differ materially from those expressed or implied by our forward-looking </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements. The Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act, do not protect any forward-looking statements that we make in connection with the
global offering. The forward-looking statements and opinions contained in this prospectus are based upon information available to us as of the date of this prospectus and, while we believe such information forms a reasonable basis for such
statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. In addition, statements
that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate.
Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or
warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We undertake no
obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required <FONT STYLE="white-space:nowrap">by-law.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus also contains certain data and information that we obtained from various government and private publications. Statistical data
in these publications also include projections based on a number of assumptions. Our industry may not grow at the rate projected by market data or at all. Failure of this market to grow at the projected rate may have a material and adverse effect on
our business and the market price of our ordinary shares (including ordinary shares in the form of ADSs). Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from
the projections based on these assumptions. You should not place undue reliance on this data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we
believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable
basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements
are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds from the global offering of approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming an offering price of &#128;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), which is the last reported sale price of our ordinary
shares on Euronext Paris on June&nbsp;30, 2023, after deducting the estimated underwriting commissions and estimated offering expenses payable by us, and assuming no exercise of the underwriters&#146; option to purchase additional ordinary shares
(which may be in the form of ADSs). If the underwriters exercise in full their option to purchase additional ordinary shares (which may be in the form of ADSs) in the global offering, we estimate that we will receive net proceeds from the offering
of approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming an offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) per ordinary share in the offering, which is the last reported sale price of our ordinary shares on Euronext Paris on June&nbsp;30, 2023, after deducting the estimated underwriting commissions and
estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00 ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase (decrease) in the
assumed offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), the last reported sale price of our ordinary shares on Euronext Paris on June&nbsp;30,
2023, would increase or decrease our net proceeds from the offering by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming the number of ordinary shares offered by us
(which may be in the form of ADSs), as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting commissions and estimated offering expenses payable by us. We may also increase or decrease the
number of ordinary shares (which may be in the form of ADSs) we are offering. An increase or decrease of 1,000,000 ordinary shares offered by us (which may be in the form of ADSs) would increase or decrease the net proceeds to us from the sale of
the ordinary shares (which may be in the form of ADSs) we are offering by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming that the assumed offering price remains
the same and after deducting the estimated underwriting commissions and estimated offering expenses payable by us. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use
the net proceeds from the global offering, together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million) to fund the development of obefazimod for UC;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million) to fund the development of obefazimod for CD; and
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder, if any, for working capital and for other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also use a portion of the remaining net proceeds and our existing cash and cash equivalents to in-license, acquire, or invest in
complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our
planned use of the net proceeds of this offering, and our current cash and cash equivalents, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements at least through
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently
expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This expected use of net proceeds from the global offering represents our intentions based upon our current plans and business
conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status
of and results from clinical trials, as well as any collaborations that we may enter into with third parties for our drug candidates, and any unforeseen cash needs. As a result, our management retains broad discretion over the allocation of the net
proceeds from the global offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from the global offering, we intend to invest the net proceeds in
a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our ordinary shares. We do not have any present plan to pay any cash dividends on our
equity securities in the foreseeable future after the global offering. We currently intend to retain all of our available funds and any future earnings to operate and expand our business. For as long as any amount is outstanding under the First
Kreos Agreement and the Second Kreos Agreement, we are not permitted to declare or make any dividend without consent from KC. In the event a dividend is made or declared, the terms and conditions of the OCEANE bonds provide for an adjustment of the
conversion ratio. We do not anticipate paying cash dividends on our equity securities in the foreseeable future and intend to retain all available funds and any future earnings for use in the operation and expansion of our business, given our state
of development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the requirements of French law and our <FONT STYLE="white-space:nowrap">by-laws,</FONT> dividends may only be
distributed from our distributable profits, plus any amount held in our available reserves, which are those reserves other than the legal and statutory reserves and the revaluation surplus. See &#147;Description of Share Capital&#148; for further
details on the limitations on our ability to declare and pay dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay any dividends, we will pay our ADS holders to the same
extent as holders of our ordinary shares, subject to the terms of the deposit agreement, including deduction in respect of the fees and expenses payable thereunder. See &#147;Description of American Depositary Shares&#148; for further information.
Cash dividends on our ordinary shares, if any, will be paid in euros and converted into U.S. dollars with respect to ADSs, as provided in the deposit agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth our cash and cash equivalents and total capitalization as of June&nbsp;30, 2023 on an actual and as adjusted basis
to reflect the issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares (which may be in the form of ADSs) in the global offering, consisting of (i)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs in the U.S. offering at an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, and (ii)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in the European private placement assuming an offering price of &#128;&nbsp;per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), which is the last reported sale price of our ordinary shares on Euronext Paris June&nbsp;30, 2023, after deducting the estimated underwriting commissions and estimated offering expenses
payable by us. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our as adjusted capitalization following the global offering will depend on the actual initial public offering price
and other terms of the global offering determined at pricing, including the amount by which actual offering expenses are higher or lower than estimated. The table should be read in conjunction with the information contained in &#147;Use of
Proceeds,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; as well as our financial statements and the related notes included elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term debt and current portion of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt (other than current portion)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity attributable to shareholders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares &#128;0.01&nbsp;par value: 42,547,568 shares outstanding actual; shares
outstanding as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premiums related to share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our as adjusted capitalization following the global offering will depend on the actual initial public offering
price and other terms of the global offering determined at pricing, including the amount by which actual offering expenses are higher or lower than estimated. Each &#128;1.00 ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease
in the assumed offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), which is the last reported sale price of our ordinary shares on Euronext Paris on
June&nbsp;30, 2023 would increase or decrease as adjusted cash and cash equivalents, premiums related to share capital, total shareholders&#146; equity and total capitalization by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming that the number of ordinary shares (which may be in the form of ADSs) offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the
estimated underwriting commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares (which may be in the form of ADSs) we are offering. An increase or decrease in the number of ordinary
shares (which may be in the form of ADSs) offered by us by 1,000,000 ordinary shares (which may be in the form of ADSs) would increase or decrease as adjusted cash and cash equivalents, premiums related to share capital, total shareholders&#146;
equity and total capitalization by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming that the assumed offering price remains the same, and after deducting the
estimated underwriting commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ordinary shares
(including ordinary shares in the form of ADSs) that will be outstanding after the global offering is based on 42,547,568 ordinary shares outstanding as of June 30, 2023 and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">308,984 ordinary shares issuable upon the exercise of share warrants (BSA) outstanding as of June 30, 2023 at a
weighted-average exercise price of &#128;7.57 per ordinary share (or $8.24) based on the exchange rate in effect as of June 30, 2023; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">422,909 ordinary shares issuable upon the exercise of founder&#146;s share warrants (BCE) outstanding as of
June&nbsp;30, 2023 at a weighted-average exercise price of &#128;9.77 per ordinary share (or $10.64) based on the exchange rate in effect as of June&nbsp;30, 2023; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">769,834 ordinary shares issuable upon the conversion of convertible bonds (OCEANE) outstanding as of
June&nbsp;30, 2023 at a weighted-average conversion price of &#128;32.47 per ordinary share (or $35.36) based on the exchange rate in effect as of June&nbsp;30, 2023; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,413,543 ordinary shares reserved for future issuance under our share-based compensation plans and other
delegations of authority from our shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References to outstanding ordinary shares included in this prospectus
include 11,487 treasury shares issued by us as of June 30, 2023. Except as otherwise noted, the information in this prospectus assumes no exercise by the underwriters of their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADS and/or ordinary shares in the global offering and no exercise of share subscription warrants or vesting of free shares or other equity
awards subsequent to June&nbsp;30, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_10"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our ordinary shares or ADSs in the global offering, your ownership interest will be diluted to the extent of the difference
between the public offering price per ordinary share or ADS paid by purchasers in the global offering and the as adjusted net tangible book value per ordinary share or ADS, as applicable, after completion of the global offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of June&nbsp;30, 2023 was &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million based on the exchange rate of &#128;1.00&nbsp;= $1.09 as of June&nbsp;30, 2023), or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), based on the exchange rate in effect as of June&nbsp;30, 2023. Net tangible book value per ordinary share is determined by dividing (i)&nbsp;our total assets less our intangible assets and
our total liabilities by (ii)&nbsp;the number of ordinary shares outstanding as of June&nbsp;30, 2023 or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the receipt of the estimated net proceeds from our sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares (which may be in the form of ADSs) in the global offering, at an assumed offering price of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), the last reported sale price of our ordinary shares on Euronext Paris
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, and after deducting the estimated underwriting commissions and estimated offering expenses payable by us, our as adjusted net tangible book value
as of June&nbsp;30, 2023 would have been &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS). This represents an immediate increase in net tangible book value of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS) to existing shareholders and an immediate dilution in net tangible book value of &#128;&nbsp;per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS) to new investors.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per ordinary share and per ADS basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Ordinary</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per ordinary share<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per ordinary share or ADS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per ordinary share or ADS attributable to new investors
participating in the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per ordinary share or ADS after the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in as adjusted net tangible book value per ordinary share or ADS to new investors
participating in the global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and will depend on the actual offering
price and other terms of the offering determined at pricing. Each &#128;1.00 ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the assumed offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), the last reported sale price of our ordinary shares on Euronext Paris on June&nbsp;30, 2023, would increase or decrease our as adjusted net tangible book value by
approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), and the dilution to new investors participating in the offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), assuming that the number of ordinary shares offered by us (which may be in the form of ADSs), as set forth on the cover page of this prospectus, remains the same, and after deducting the
estimated underwriting commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. An increase of 1,000,000 ordinary shares offered by us would increase the as adjusted
net tangible book value by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), and the dilution to new investors participating in the offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), assuming that the assumed offering price remains the same, and after deducting the estimated underwriting commissions and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
estimated offering expenses payable by us. Similarly, a decrease of 1,000,000 ordinary shares (which may be in the form of ADSs) offered by us would decrease the as adjusted net tangible book
value by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), and the dilution to new investors participating in the offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), assuming that the assumed offering price remains the same, and after deducting the estimated underwriting commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares and/or ADSs in full, the as adjusted net tangible book value per ordinary share after the offering would be
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), the increase in the as adjusted net tangible book value to existing shareholders would be
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS), and the dilution to new investors participating in the offering would be
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth, as of June&nbsp;30, 2023, the number of ordinary shares purchased from us, the total consideration paid to us
and the average price per ordinary share paid by existing shareholders and to be paid by new investors participating in the global offering, based on an assumed offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary
share, which was the closing price of our ordinary shares on Euronext Paris on June&nbsp;30, 2023, after deducting the estimated underwriting commissions and estimated offering expenses payable by us. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;Shares</B><br><B>(Which&nbsp;May&nbsp;Be&nbsp;In</B><br><B>The&nbsp;Form&nbsp;Of&nbsp;ADSs)</B><br><B>Purchased From</B><br><B>Us</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Price</B><br><B>Per&nbsp;Ordinary</B><br><B>Share </B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price Per<BR>ADS</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each &#128;1.00 ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) increase or decrease in the
assumed offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS), the last reported sale price of our ordinary shares on Euronext Paris on
June&nbsp;30, 2023, would increase or decrease the total consideration paid by new investors participating in the offering by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million
($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million), assuming that the number of ordinary shares offered by us (which may be in the form of ADSs), as set forth on the cover page of the prospectus, remains the same and before deducting
underwriting commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. An increase or decrease in 1,000,000 ordinary shares offered by us would increase or decrease the
total consideration paid by new investors participating in the global offering by &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), assuming that the assumed offering price
remains the same and before deducting underwriting commissions and estimated offering expenses payable by us. The as adjusted information discussed above is illustrative only and will be adjusted based on the actual offering price, the actual number
of ordinary shares offered by us (which may be in the form of ADSs) and other terms of the offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table
above assumes no exercise of the underwriters&#146; option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs and/or ordinary shares in the global offering and no exercise of
share subscription warrants or vesting of free shares or other equity awards subsequent to June&nbsp;30, 2023. If the underwriters exercise their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs and/or ordinary shares (which may be in the form of ADSs) in full, the number of ordinary shares held by the existing shareholders after
the global offering would be reduced to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of ordinary shares (including ordinary
shares represented by ADSs) outstanding after the global offering, and the number of shares held by new investors participating in the global offering (including ordinary shares represented by ADSs) would increase to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of ordinary shares outstanding after the global offering (including ordinary
shares represented by ADSs). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing tables and calculations above (other than historical net tangible book
value calculations) are based on 42,547,568 ordinary shares outstanding as of June&nbsp;30, 2023 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">308,984 ordinary shares issuable upon the exercise of share warrants (BSA) outstanding as of June&nbsp;30, 2023
at a weighted-average exercise price of &#128;7.57 per ordinary share (or $8.24) based on the exchange rate in effect as of June&nbsp;30, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">422,909 ordinary shares issuable upon the exercise of founder&#146;s share warrants (BCE) outstanding as of
June&nbsp;30, 2023 at a weighted-average exercise price of &#128;9.77 per ordinary share (or $10.64) based on the exchange rate in effect as of June&nbsp;30, 2023; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">769,834 ordinary shares issuable upon the conversion of convertible bonds (OCEANE) outstanding as of
June&nbsp;30, 2023 at a weighted-average conversion price of &#128;32.47 per ordinary share (or $35.36) based on the exchange rate in effect as of June&nbsp;30, 2023; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,413,543 ordinary shares reserved for future issuance under our share-based compensation plans and other
delegations of authority from our shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References to outstanding ordinary shares included in this prospectus
include 11,487 treasury shares issued by us as of June 30, 2023. Except as otherwise noted, the information in this prospectus assumes no exercise by the underwriters of their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADS and/or ordinary shares in the global offering and no exercise of share subscription warrants or vesting of free shares or other equity
awards subsequent to June&nbsp;30, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_11"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a <I>soci&eacute;t&eacute; anonyme</I>, organized under the laws of France. The majority of our directors and officers are residents of
countries other than the United States, and the majority of our assets are located outside of the United States. We have appointed an agent for service of process in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, U.S. investors may find it difficult and may be unable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to obtain jurisdiction over us or our officers and directors in U.S. courts in actions predicated on the civil
liability provisions of the U.S. federal securities laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce, either inside or outside of the United States, judgments obtained in U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> courts in actions predicated upon the civil liability provisions of the U.S. federal securities laws against us or our officers and directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to bring an original action in a French court to enforce liabilities based upon the U.S. federal securities laws
against us or our officers or directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce against us or our directors our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> courts, including
French courts, judgments of U.S. courts predicated upon the civil liability provisions of the U.S. federal securities laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, actions in the United States under U.S. federal securities laws could be affected under certain circumstances by French Law <FONT
STYLE="white-space:nowrap">No.&nbsp;68-678</FONT> of July&nbsp;26, 1968, as amended by French Law <FONT STYLE="white-space:nowrap">No.&nbsp;80-538</FONT> of July&nbsp;16, 1980 and French Ordinance
<FONT STYLE="white-space:nowrap">No.&nbsp;2000-916</FONT> of September&nbsp;19, 2000 (relating to the communication of documents and information of an economic, commercial, industrial, financial or technical nature to foreign authorities or
persons), which may preclude or restrict the obtaining of evidence in France or from French persons in connection with those actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, a final judgment for the payment of money rendered by any federal or state court in the United&nbsp;States based on civil
liability, whether or not predicated solely upon the U.S. federal securities laws, would be recognized and enforced in France provided that a French judge considers that this judgment meets the French legal requirements concerning the recognition
and the enforcement of foreign judgments and is capable of being immediately enforced in the United States. A French court is therefore likely to grant the enforcement of a foreign judgment without a review of the merits of the underlying claim,
only if: (i)&nbsp;that judgment does not contravene international public order and public policy of France, both pertaining to the merits and to the standards of due process; and (ii) the dispute is clearly connected to the territory of the court
which rendered the judgement, and French courts did not have exclusive jurisdiction on the matter. The French court would also require that the U.S. judgment is not tainted with fraud and is not incompatible with a judgment rendered by a French
court in the same matter, or with an earlier judgment rendered by a foreign court which has become effective in France in the same matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, French law guarantees full compensation for the harm suffered but is limited to the actual damages, so that the victim does not
suffer or benefit from the situation. Such system excludes damages such as, but not limited to, punitive and exemplary damages. Therefore, there is some uncertainty as to whether a foreign judgement awarding punitive and exemplary damages well above
actual damages would be granted enforcement in France. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the enforcement, by U.S. investors, of any judgments obtained in
U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities law against us or members of our Board, officers or certain experts named herein who are residents of France or countries other than the United States
would be subject to the above conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, there may be doubt as to whether a French court would impose civil liability on us,
the members of our Board, our officers or certain experts named herein in an original action predicated solely upon the U.S.&nbsp;federal securities laws brought in a court of competent jurisdiction in France against us or such members, officers or
experts, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_12"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements
and the related notes thereto included elsewhere in this prospectus. In addition to historical information, the following discussion and analysis contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results
and the timing of events could differ materially from those anticipated in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in
the sections titled &#147;Risk Factors&#148; and &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body&#146;s natural regulatory mechanisms to
modulate the immune response in patients with chronic inflammatory diseases. We are currently evaluating our lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative
colitis (&#147;UC&#148;). We are also in the planning stages of initiating a Phase 2a clinical trial of obefazimod in patients with Crohn&#146;s disease (&#147;CD&#148;), as well as evaluating other potential inflammatory indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational
agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial populations and represent large commercial opportunities, pending regulatory approvals and successful
commercialization. Our initial focus is on inflammatory bowel diseases (&#147;IBD&#148;), chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD. As of 2022, an aggregate of
approximately 2.9&nbsp;million patients across the United States, EU4 (France, Germany, Italy and Spain), the United Kingdom and Japan suffered from IBD, with 1.5 million of these patients in the United States alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the treatment of IBD via its unique mechanism
of action. Obefazimod is designed to specifically induce the expression of a single micro-RNA, miR-124, which plays a critical role in the regulation of the immune response. In the context of inflammation, miR-124 modulates the immune response,
controlling progression of inflammation and restoring homeostasis of the immune system, without causing broader immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which target
only a single cytokine or pathway, miR-124 modulates the expression of several key cytokines and pathways resulting in regulation of the inflammatory process. Modulating multiple inflammatory pathways simultaneously may result in more durable
efficacy over the long-term, which is critical in lifelong conditions such as IBD, potentially differentiating obefazimod from currently available IBD treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is comprised of industry leaders in the fields of biology, data analytics, and drug development, as well as scientific experts in
chronic inflammatory diseases, including IBD. We are led by Marc de Garidel, our Chief Executive Officer, who has more than 40 years of experience in the pharmaceutical and biotechnology sector. Collectively, our team has decades of experience and a
proven track record of advancing compounds into and through clinical development and commercialization, including at the following organizations: Amgen, Arena Pharmaceuticals, AstraZeneca, BioNTech, Boehringer Ingelheim, Eli Lilly, Genentech/Roche,
Guerbet, Ipsen Pharmaceuticals, J&amp;J, Pfizer, Sanofi, Sanofi-Pasteur and Shire/Takeda. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as a
<I>soci&eacute;t&eacute; anonyme </I>on December 4, 2013 and, in 2014, we acquired Splicos, Wittycell and Zophis by means of a universal transfer of assets and liabilities (<I>transmission universelle de patrimoine </I>(&#147;TUP&#148;)). We have
been listed on Euronext Paris since June&nbsp;26, 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 1, 2022, we acquired 100% of the share capital of Prosynergia S.&agrave;.r.L
(&#147;Prosynergia&#148;), a Luxembourg-based biotechnology company, with the aim of strengthening our research and development portfolio, for an amount of &#128;3.25&nbsp;million. On December 12, 2022, we completed the merger with Prosynergia
through a TUP and all of Prosynergia&#146;s assets and liabilities were transferred to us. Following the merger, Prosynergia was dissolved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception<I> </I>in 2013, we have devoted substantially all of our efforts to organizing and staffing our company, business
planning, raising capital, establishing our intellectual property portfolio, acquiring or discovering drug candidates, research and development activities for obefazimod and other compounds, establishing arrangements with third parties for the
manufacture of our drug candidates and component materials, and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product sales or otherwise. We
do not expect to generate significant revenue from product sales or royalties unless and until our drug candidates are approved for marketing and successfully commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses since inception, and we expect to continue to incur significant expenses and operating losses
for the foreseeable future. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of obefazimod and any future drug candidates. For the years
ended December 31, 2022 and 2021, we reported net losses of &#128;60.7&nbsp;million and &#128;42.5&nbsp;million, respectively. As of December&nbsp;31, 2022, we carried forward accumulated tax losses of &#128;308.8&nbsp;million. We expect to continue
to incur net operating losses for at least the next several years, and we do not anticipate achieving profitability in the future unless we obtain regulatory approvals necessary to commercialize obefazimod and any additional drug that we may pursue
in the future. We expect our research and development expenses, general and administrative expenses, and capital expenditures will increase substantially in connection with our ongoing activities, particularly if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to advance our existing drug candidates through clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely and successfully complete clinical development of obefazimod, our clinical-stage drug candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek and maintain regulatory and marketing approvals for obefazimod and any future drug candidates for which we
successfully complete clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the preclinical and clinical development of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the scope of our current clinical trials for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">begin new clinical trials for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, scale and validate our commercial manufacturing capabilities for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we may obtain
regulatory and marketing approval for which we have not entered into a collaboration with a third-party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to discover, identify and validate additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other drug candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty or other payments under <FONT STYLE="white-space:nowrap">in-license</FONT> or
collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect, enforce and expand our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacture, or have manufactured, <FONT STYLE="white-space:nowrap">non-clinical,</FONT> clinical and potentially
commercial supplies of obefazimod and any future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract new and retain existing clinical, scientific, operational, financial and management personnel; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting, and other costs associated with operating as a U.S. public company following
the completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net losses may fluctuate significantly from period to period, depending on the
timing of expenditures related to our research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not generate revenue from product sales unless and
until we successfully complete clinical development and obtain regulatory approval for a drug candidate. In particular, following the issuance of royalty certificates in September 2022 and other royalties that may become payable under our royalty
agreements, the payment of royalties in the event of commercialization of obefazimod will result in a decrease in cash flows generated by sales of the product, which could have an unfavorable impact on our financial position, particularly at the
beginning of the commercialization phase. In addition, if we obtain regulatory approval for a drug candidate and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our
commercialization capability to support product sales, marketing, manufacturing and distribution activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we will need
substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through equity offerings,
debt financings or other capital sources, which could include collaborations, strategic alliances, or additional licensing arrangements. We may be unable to raise additional funds or enter into such arrangements when needed, on favorable terms, or
at all. Our failure to raise capital or enter into such agreements as, and when, needed, could have a material adverse effect on our business, results of operations, and financial condition, including requiring us to have to delay, reduce or
eliminate product development or future commercialization efforts. The amount and timing of our future funding requirements will depend on many factors, including the successful advancement of obefazimod or any future drug candidates. Our ability to
raise additional funds may also be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, such as those resulting from the
ongoing war in Ukraine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with development of treatment of chronic inflammatory
diseases, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become
profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our operations and growth to date primarily through private and public offerings of our equity securities
(&#128;336.8&nbsp;million in gross proceeds to date, of which &#128;57.7&nbsp;million of gross proceeds were from the initial public offering of our ordinary shares on Euronext Paris in June 2015, and &#128;46.2&nbsp;million and
&#128;130.0&nbsp;million of gross proceeds were from offerings of our ordinary shares on Euronext Paris in September 2022 and February 2023, respectively), bank borrowings and structured loans (&#128;65.0&nbsp;million to date), royalty certificates
and reimbursements of Research Tax Credits (<I>Cr&eacute;dit d&#146;Imp&ocirc;t Recherche</I> (&#147;CIR&#148;)) (in an aggregate amount of &#128;26.6&nbsp;million) and subsidies received from Bpifrance (including &#128;13.5&nbsp;million of
subsidies and &#128;6.6&nbsp;million of conditional advances to date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, we had cash and cash equivalents of
&#128;27.0&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash and cash equivalents, the net proceeds of the February 2023 capital increase amounting to &#128;123.3 million and the
reimbursement of the 2022 Research Tax Credit in 2023, and under the assumption that R&amp;D needs are being substantially increased in 2023, as we continue to make progress on our lead drug candidate obefazimod, which has started enrollment of
patients in its UC Phase 3 clinical trials in October 2022, will enable us to fund our operating expenses and capital expenditure requirements through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital as we seek regulatory approval of our drug candidates. We intend to assess and plan for any such funding requirements and aim to regularly update the market on our financing need
projections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond that date, our ability to fund operations will depend upon our ability to raise additional capital from existing
and/or new specialized investors and/or debt from lenders. In particular, we may consider carrying out one or more capital increases, entering into loan agreements or issuing bonds and entering into regional licensing agreements for obefazimod,
specifically targeting third-party partners in Asia. Our operating plans may change as a result of a variety of factors, and we may need to seek additional funds sooner than planned. In any event, we will require additional capital to pursue
preclinical and clinical activities, obtain regulatory approval for and commercialize our drug candidates. If sufficient funds on acceptable terms are not available when needed, or at all, we could be required to significantly reduce our operating
expenses and delay, reduce the scope of, or eliminate one or more of our development programs. See the subsection titled &#147;&#151;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation of Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audited financial statements as of, and for the years ended, December 31, 2022 and 2021 were prepared in accordance with International
Financial Reporting Standards (&#147;IFRS&#148;), as issued by the International Accounting Standards Board (&#147;IASB&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Factors
Affecting Our Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following factors have affected, and we expect will continue to affect, our results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business. Since our inception, most of our resources have been allocated to research and
development and it accounts for the majority of our operating expenses. For the year ended December 31, 2022, research and development expenses accounted for 87%, excluding goodwill impairment loss, of our total operating expenses, as compared to
90% for the year ended December 31, 2021. Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of
later-stage clinical trials. Accordingly, we expect that our research and development expenses will increase in the foreseeable future as we seek to advance the development of our drug candidates. The successful development of our drug candidates
remains highly uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At this time, we cannot accurately determine or estimate the nature, timing and costs of the research and
development activities that will be necessary to complete the remainder of the development of obefazimod, and we may never succeed in obtaining regulatory approval for obefazimod or any future drug candidates we may develop. The duration, costs and
timing of clinical trials and the development of our drug candidates will depend on numerous risks and uncertainties associated with clinical development, including risks and uncertainties related to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, outcome and expenses of our clinical trials and other research and development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll suitable patients and successful patient enrollment in, and the initiation
and completion of, clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the establishment of commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expense of filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual
property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changing government regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching commercial sales of our drug candidates, if and when approved, whether alone or in collaboration with
others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of the drug candidates following regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to market, commercialize and achieve market acceptance for obefazimod or any other drug candidate
that we may develop in the future; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant competition and rapidly changing technologies within the biopharmaceutical industry.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of any of our drug candidates could
significantly change the costs and timing associated with the development of that drug candidate. The actual probability of success for our drug candidates will be affected by a variety of factors, including the safety and efficacy of our drug
candidates, investment in our clinical programs, manufacturing capability and competition with other products and drug candidates. As a result of these variables, we are unable to determine the duration and completion costs of our research and
development projects or when and to what extent we may generate revenue from the commercialization and sale of our drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Regulatory
Approval and Market Acceptance of our Drug Candidates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never succeed in achieving regulatory approval for any of our drug
candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some drug candidates or focus on others. A change in the outcome of any of these factors with respect to the
development of drug candidates that we are developing could result in a significant change in the costs and timing associated with the development of such drug candidates. For example, if the EMA or the FDA or other regulatory authority were to
require us to conduct <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in
enrollment in any clinical trials, we could be required to spend significant additional financial resources and time on the completion of clinical development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity and Debt Financing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At this stage,
we have not generated any revenue from sales of products or otherwise, and we do not expect to do so unless and until we successfully complete development of, obtain marketing approval for, and successfully commercialize, one or more of our drug
candidates. Until such time that we can generate substantial revenue from sales of products, if ever, we expect to finance our operating activities through a combination of equity offerings, debt financings and government or other third-party
funding. However, we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or
terminate our development programs or commercialization efforts or grant to others the rights to develop or market drug candidates that we would otherwise prefer to develop and market ourselves. Failure to receive additional funding could cause us
to cease operations, in part or in full. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acquisition of Prosynergia </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 1, 2022, we acquired 100% of the share capital of Prosynergia with the aim of strengthening our research and development portfolio,
for an amount of &#128;3.25&nbsp;million. On December 12, 2022, we completed the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger with Prosynergia through a TUP and all of Prosynergia&#146;s assets and liabilities were transferred to us. Following the merger, Prosynergia was dissolved. Accordingly, as Prosynergia was
dissolved in December 2022, we did not prepare consolidated financial statements as of December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Impact of the Ukraine/Russia
Hostilities on our Business </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global
economy and the rate of inflation, particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the financial markets, something that is still ongoing at the reporting date and has
pushed down stock market prices the world over. The global scale of this conflict cannot be predicted at this stage. We, therefore, cannot rule out an adverse impact of this conflict on our business, including in terms of access to raw materials,
logistics, the performance of clinical trials and in relation to any future financing we may seek. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2b maintenance trial of
obefazimod in moderately to severely active UC is our only clinical trial currently in progress in Ukraine. We have, however, terminated a few trial sites since the Russia/Ukraine war began. The <FONT STYLE="white-space:nowrap">12-month</FONT>
assessment was carried out in all the Ukrainian patients before the war broke out and these patients are therefore included in the <FONT STYLE="white-space:nowrap">one-year</FONT> maintenance results that were reported on April&nbsp;6, 2022.
Ukrainian patients who completed the <FONT STYLE="white-space:nowrap">two-year</FONT> Phase 2b maintenance trial have been transitioned to the long-term safety and efficacy trial that is still <FONT STYLE="white-space:nowrap">on-going.</FONT> None
of these sites are located in the Crimea Region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, or the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic. We are also
evaluating the possibility to include a few Ukrainian sites in the western part of Ukraine in the ABTECT Phase 3 clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Together with our contract research organization, we are making considerable efforts to ensure the
<FONT STYLE="white-space:nowrap">follow-up</FONT> of patients who are unable to come to the study centers. Monitoring takes place through a remote monitoring system that was established and used successfully during the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion sets forth certain components of our results of operations, as well as factors that impact those items. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Operating Income </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
not generated any revenue from product sales or from other sources, and we do not expect to generate any revenue from the sale of products or otherwise, even if approved, in the near future. Our ability to generate revenue in the future, if ever,
will depend almost entirely on our ability to successfully develop, obtain regulatory approval for, and then commercialize our drug candidates or conclude a partnering business development agreement within our product portfolio. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Operating Income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other operating
income comprises subsidies in the form of <FONT STYLE="white-space:nowrap">non-refundable</FONT> subsidies from Bpifrance, and research tax credits (CIR), each as described below. Subsidies that are upfront payments are presented as deferred income
and recognized as other income for the amount of the expenses incurred as part of the research program to which the subsidy relates. Subsidies that are received either as compensation for expenses or losses already incurred, or for our immediate
financial support without associated future costs, are recognized as other income when there we have reasonable assurance that the subsidies will be received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsidies are <FONT STYLE="white-space:nowrap">non-repayable</FONT> grants received by us. They are recognized in the financial statements in
the period in which the related expenses are incurred when there is reasonable assurance that the subsidies will be received and that we will comply with their conditions. We have received various subsidies and other assistance from Bpifrance since
our creation. The funds are intended to finance our operations or specific projects. See &#147;&#151;Liquidity and Capital Resources&#151;Sources of Liquidity&#151;Bpifrance &#150; Conditional Advances and Subsidies.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The French tax authorities grant a research tax credit to companies to encourage
technical and scientific research by French companies. Companies demonstrating that they have incurred research expenses that meet the required criteria, including research expenses located in France or certain other European countries, receive a
tax credit that can be used against the payment of the corporate tax due for the fiscal year in which the expenses were incurred and during the next three fiscal years. Companies may receive cash reimbursement for any excess portion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply for the CIR for research expenses incurred in each fiscal year and recognize the amounts claimed in the same fiscal year. As we meet
the EU definition of a small and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprise (&#147;SME&#148;), we are eligible for payment in cash of our CIR in the year following the request for reimbursement, which corresponds to the period
after which we incurred the eligible costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have concluded that the CIR meet the definition of a government grant as defined in IAS
20, Accounting for Government Grants and Disclosure of Government Assistance, and, as a result, they have been classified as &#147;Other income&#148; within operating income in our statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received the CIR for 2021 in October 2022, and we expect to request the CIR for 2022 in 2023, in each case under the community tax rules
for SMEs and in compliance with the current regulations. The CIRs we are granted may be subject to audit by the French tax authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total
Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating expenses consist of research and development expenses and general and administrative expenses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses consist primarily of the following items: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel expenses, including salaries, benefits, and share-based compensation expenses, for employees engaged in
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">sub-contracting,</FONT> collaboration and consultant expenses that primarily
include the cost of third-party contractors such as CROs who conduct our <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials, and research related to our proprietary platforms, as well as investigative sites and
consultants that conduct our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with contract manufacturing organizations (&#147;CMOs&#148;), including
manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to regulatory affairs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocated expenses for facility costs, including rent, utilities and maintenance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to the implementation of our quality assurance system. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We allocate these costs by drug candidate and by therapeutic indication. Costs that are not directly attributable to a specific therapeutic
indication are included under the category of transversal activities, which include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical developments, such as clinical trials relating to the compound and not indication related (e.g<I>.</I>,
Phase 1 trials); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical activities, such as studies relating to the compound and not indication related (e.g., toxicological
studies); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">research activities, which relate to the mechanism of action of the compound; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory activities, which relate to interactions with regulatory authorities for the compound;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pharmacovigilance activities, which relate to studies for the safety and tolerability of the compound; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">chemistry, manufacturing and control activities, which relate to the manufacturing of drug substance and drug
product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses may vary significantly in the future based on factors, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of <FONT STYLE="white-space:nowrap">non-clinical</FONT> and Investigational New Drug
Application (&#147;IND&#148;)-enabling studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of manufacturing our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the phase of development of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety profile of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we establish additional collaboration or license agreements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we choose to partner any of our drug candidates and the terms of such partnership. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of any of our drug candidates could significantly change the
costs and timing associated with the development of that drug candidate. We may never succeed in obtaining regulatory approval for any of our drug candidates. We may obtain unexpected results from our
<FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and future clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses primarily comprise personnel-related expenses, including salaries, benefits and share-based compensation
expenses, for personnel other than employees engaged in research and development activities. General and administrative expenses also include fees for professional services, mainly related to audit and legal services, consulting costs,
communications and travel costs, allocated expenses for facility costs, including rent, utilities and maintenance, directors&#146; attendance fees, and insurance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a strict containment policy in respect of our administrative expenses. We expect that our general and administrative expenses will
continue to increase for the foreseeable future as we continue to grow </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our support functions for the expected increase in our research and development activities and the potential commercialization of our drug candidates. We also anticipate increased expenses
associated with being a public company in the United States, including costs related to audit, legal, regulatory, and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with U.S. exchange listing and
SEC requirements, director and officer insurance premiums, and investor relations costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Income/(Loss) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial income/(loss) includes the amortized cost of the conditional advances, convertible notes,
<FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds, royalty certificates, fair value adjustments on financial instruments, and other financial income and expenses such as the unwinding effect of CRO advances. We expect to incur additional
financial expenses related to financing agreements or similar transactions that we may enter into to finance our further development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of
Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Years Ended December 31, 2022 and 2021 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our results of operations for the years ended December 31, 2022 and 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(In thousands of euros)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2021</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2022</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>%&nbsp;Change</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Other operating income</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I> 11,961</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&#128;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I> 4,583</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(62</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,961</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(62</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Research and development expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(47,781</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(48,295</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>General and administrative expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(5,580</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(7,492</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>34</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Goodwill impairment loss</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(13,632</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(53,361</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(69,419</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(64,836</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Financial expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(3,561</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(7,022</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(97</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Financial income</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>2,509</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>11,118</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>343</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,052</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>489</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Income Tax</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Operating Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our total operating income was &#128;4.6&nbsp;million, as compared to &#128;12.0&nbsp;million for the
year ended December 31, 2021, a decrease of &#128;7.4&nbsp;million, or 62%, as detailed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Operating Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our other operating income for the years ended December 31, 2022 and 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CIR (Research Tax Credits)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>-Income recognized from BPI to finance <FONT STYLE="white-space:nowrap">COVID-19</FONT> project
</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>7,722</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>29</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(100</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,962</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(62</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our other operating income was &#128;4.6&nbsp;million, as
compared to &#128;12.0&nbsp;million for the year ended December 31, 2021, a decrease of &#128;7.4&nbsp;million, or 62%. This decrease was primarily due to a 100% decrease in subsidies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research Tax Credits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year
ended December 31, 2022, we recognized research tax credits for our research and development projects of &#128;4.5&nbsp;million, as compared to &#128;4.2&nbsp;million for the year ended December 31, 2021, an increase of &#128;0.3&nbsp;million, or
6%. This increase was primarily due to a slight increase in research and development expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subsidies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our subsidy income was &#128;29,000, as compared to &#128;7.7&nbsp;million for the year ended
December&nbsp;31 2021. This decrease was primarily due to there being no new subsidy entitlement in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31,
2021, we recorded a &#128;7.7&nbsp;million subsidies income, mainly composed by subsidies received from Bpifrance for the obefazimod <FONT STYLE="white-space:nowrap">COVID-19</FONT> Program. This subsidy was initially recorded as a conditional
advance in 2020 and as subsidy in 2021, following the waiver received from Bpifrance in April 2021 after the termination of trial in March 2021. As a result, we terminated our related financing agreement with Bpifrance in March 2021, recording in
2021 an income of &#128;4.5&nbsp;million, corresponding to the carrying amount of the advance at this date, as a result of Bpifrance&#146;s agreement to waive the conditions of the advance. In addition, for the year ended December 31, 2021, we
recorded income of &#128;3.3&nbsp;million reflecting additional payments received from Bpifrance to reimburse additional expenses incurred until the termination date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
year ended December 31, 2022, our total operating expenses were &#128;69.4&nbsp;million, as compared to &#128;53.4&nbsp;million for the year ended December 31, 2021, an increase of &#128;16.1&nbsp;million, or 30%. This increase was primarily due to
an increase in goodwill impairment loss and in general and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Goodwill Impairment Loss </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, we recorded a goodwill impairment loss of &#128;13.6&nbsp;million, as compared to no goodwill impairment
loss for the year ended December 31, 2021. The goodwill impairment loss was primarily related to an impairment test conducted with respect to the ABX196 cash-generating unit as a result of significant external changes in the hepatocellular carcinoma
treatment landscape, which are expected to require a new, lengthy, heavy and risky internal development process (use of a combination of compounds). As such, while we considered the option of entering into a licensing partnership to fund the
completion of the clinical development of ABX196, we made the decision to freeze the development program for ABX196 in the treatment of hepatocellular cancer, which led to full impairment of ABX196 goodwill. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our research and development expenses by drug candidate and therapeutic indication for the years ended December
31, 2022 and 2021. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Obefazimod</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45,024</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Ulcerative Colitis</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>20,684</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>38,555</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>86</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Crohn&#146;s Disease</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>136</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(100</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Rheumatoid Arthritis</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>2,422</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>848</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(65</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Covid-19</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,171</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(768</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(166</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Obefazimod Others Indication</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>433</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>68</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(84</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Transversal activities</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>19,132</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>6,321</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(67</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)%&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ABX196</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,198</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>693</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ABX711</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>287</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B><I></I></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B><I>&#151;</I></B><B>&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B><I></I></B><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Others</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,604</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,291</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our research and development expenses were
&#128;48.3&nbsp;million, as compared to &#128;47.8&nbsp;million for the year ended December 31, 2021, an increase of &#128;0.5&nbsp;million, or 1%. This increase was primarily due to the &#128;17.9&nbsp;million, or 86%, increase in obefazimod for UC
expenses, as we completed our Phase 2b clinical trial in early 2022 and initiated our Phase 3 clinical trial in the first half of 2022, with the first patient in the United States enrolled in October 2022, as well as an increase of
&#128;0.3&nbsp;million related to commencing development of our novel drug candidate ABX711. This increase was offset by a decrease of &#128;12.8&nbsp;million in transversal activities following the completion of our existing studies and no new
studies on these projects began in 2022, a decrease of &#128;1.9&nbsp;million in <FONT STYLE="white-space:nowrap">COVID-19</FONT> research expenses and a decrease of &#128;1.6&nbsp;million in expenses related to our rheumatoid arthritis clinical
trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our general and administrative expenses were &#128;7.5&nbsp;million, as compared to
&#128;5.6&nbsp;million for the year ended December 31, 2021, an increase of &#128;1.9&nbsp;million, or 34%. This increase was primarily due to an increase in other general and administrative expenses, as well as increases in consulting, and
professional fees. The &#128;2.2&nbsp;million, or 181%, increase in other general and administrative expenses in 2022 was primarily due to increased expenses related to financial and legal consulting fees. These increases were partially offset by a
decrease in personnel costs, mainly due to a reversal of share-based compensation expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Income (Loss) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our net operating loss was &#128;64.8&nbsp;million, as compared to a net operating loss of
&#128;41.4&nbsp;million for the year ended December 31, 2021, an increase of &#128;23.4&nbsp;million, or 57%. This increase was primarily due to an increase in goodwill impairment charges, a decrease in other operating income, as well as an increase
in general and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Income (Loss) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our net financial income was &#128;4.1&nbsp;million, as compared to a net financial loss of
&#128;1.1&nbsp;million for the year ended December 31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, our net financial income was mainly a result of a
&#128;9.4&nbsp;million decrease in the fair value of derivatives (mainly due to the decrease in our share price over the period) and a &#128;1.4&nbsp;million decrease in other liabilities at fair value through profit or loss (mainly in Prosynergia <FONT
STYLE="white-space:nowrap">earn-out</FONT> liability), which was partially offset by an increase in interest expenses of &#128;3.7&nbsp;million in relation to the Kreos bonds and &#128;2.6&nbsp;million in relation to our OCEANE bonds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, our net financial loss was mainly a result of interest expenses of &#128;2.3&nbsp;million in relation to
the Kreos bonds and &#128;1.1&nbsp;million in relation to our OCEANE bonds, partially offset by a &#128;2.4&nbsp;million decrease in the fair value of derivatives. The decrease in the fair value of derivatives is mainly due to the decrease in our
share price over the period. See &#147;&#151;Liquidity and Capital Resources.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of the years ended December 31, 2022 and 2021, our income tax charge was zero. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended
December 31, 2022, our net loss for the period was &#128;60.7&nbsp;million, as compared to &#128;42.5&nbsp;million for the year ended December 31, 2021, an increase of &#128;18.3&nbsp;million, or 43%. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of
Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred substantial operating losses since inception and expect to continue to incur significant operating
losses for the foreseeable future and may never become profitable. For the year ended December 31, 2022, we had a net loss of &#128;60.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have financed our operations through the issuance of ordinary shares with gross aggregate proceeds of &#128;336.8 million,
of which &#128;130 million of gross proceeds were from offerings of our ordinary shares on Euronext Paris in February 2023, bank borrowings and structured loans for &#128;65.0 million to date, reimbursements of Research Tax Credits (CIR) in an
aggregate amount of &#128;26.6 million, and subsidies received from Bpifrance (including &#128;13.5 million of subsidies and &#128;6.6 million of conditional advances to date). As a result of the level of available cash and cash equivalent of
&#128;27.0 million as of December 31, 2022, the February 2023 capital increase amounting to &#128;123.3 million in net proceeds and the reimbursement of the 2022 Research Tax Credit in 2023, and under the assumption that R&amp;D needs are being
substantially increased in 2023, as we continue to make progress on our lead drug candidate obefazimod, which has started enrollment of patients in our UC Phase 3 clinical trials in October 2022, we expect we will be able to fund our forecasted
operating cash flow requirements throughout the second quarter of 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect we will be able to extend our financing horizon beyond
the second quarter of 2024 through additional dilutive and non-dilutive financing, which could include a combination of capital increase, venture loans and convertible bonds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the above and the actions we have taken, management has concluded that the substantial doubt about our ability to continue as a going
concern has been alleviated beyond 12 months from issuance of the accompanying financial statements, and the accompanying financial statements have been prepared on a going concern basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capital Increases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have
been financed primarily by capital increases from our founders and investors, net proceeds from the initial public offering of our ordinary shares on the regulated market of Euronext Paris in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
France in 2015, and additional <FONT STYLE="white-space:nowrap">follow-on</FONT> capital increases. We have not yet commercialized any of our drug candidates, which are in various phases of
clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through
the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our main capital increases since inception. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(In thousands of euros)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;proceeds&nbsp;amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Public Offering (Euronext) - June&nbsp;23, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">57,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares - July 11, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares - October 29, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares - July 27, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">60,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares - September 7, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">46,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares - March&nbsp;1, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2015, we received gross proceeds of &#128;57.7&nbsp;million from the issuance of
2,707,089 new ordinary shares at a subscription price of &#128;21.30 per share. The proceeds were primarily used for financing older research and development programs (pivotal study in Asia for ABX203 in chronic hepatitis B treatment and the Phase 2
trial for obefazimod in HIV/AIDS treatment), which have since been terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;11, 2019, we received gross proceeds of
&#128;12.0&nbsp;million from the issuance of 1,500,000 new ordinary shares at a subscription price of &#128;8.00 per share. The proceeds were primarily used for the clinical development of obefazimod (including a phase 2b study), phase 2a studies of
RA disease and the ABX196 treatment of hepatocellular cancer in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 29, 2020, we received gross proceeds of
&#128;28.0&nbsp;million from the issuance of 1,620,370 new ordinary shares at a subscription price of &#128;17.28 per share. The proceeds were primarily used to finance the progress of obefazimod clinical trials in chronic inflammatory diseases and
for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 30, 2021, we received gross proceeds of &#128;60.0&nbsp;million from the issuance of 1,964,031
ordinary shares at a subscription price of &#128;30.55 per share. The proceeds were primarily used to finance the progress of obefazimod clinical trials in chronic inflammatory diseases, for general corporate purposes, payments in respect of, and
redemption of, certain existing indebtedness, and advancement of ABX196 for the treatment of hepatocellular carcinoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 2,
2022, we received gross proceeds of &#128;46.2&nbsp;million from the issuance of 5,530,000 ordinary shares at a subscription price of &#128;8.36 per share, and the issuance of royalty certificates of &#128;2.9&nbsp;million, for a total financing of
&#128;49.2&nbsp;million. See &#147;Business&#151;Key Collaborations and Partners&#151;Financing Arrangements&#151;Royalty Certificates.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2023, we received gross proceeds of &#128;130.0&nbsp;million from the issuance of 20,000,000 ordinary shares at a
subscription price of &#128;6.50 per share. The proceeds were primarily used to finance the progress of obefazimod clinical trials in chronic inflammatory diseases and for general corporate purposes (research and development expenses and loans
maturities payments). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Line </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into an equity line agreement with Kepler Cheuvreux in September 2017. In accordance with the terms of this agreement, Kepler
Cheuvreux, acting as financial intermediary and guarantor, committed to subscribe for 970,000 ordinary shares, at its option in line with a schedule lasting no longer than 24 months, at an issuance price based on an average market price weighted
according to the volumes traded over the two trading days preceding each issue, less a maximum discount of 7.0%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We renewed this financing line and entered into an agreement on September 30, 2019, with
Kepler Cheuvreux, who committed to subscribe for 730,000 ordinary shares (corresponding to the number of shares unsubscribed as of September 30, 2019, and granted under the previous agreement) under the same terms and conditions for a period of 24
months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 24, 2021, we extended the agreement for an additional <FONT STYLE="white-space:nowrap">12-month</FONT> period in
respect of the unsubscribed shares at that date. This agreement was terminated on September 30, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research Tax Credits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From our inception to December&nbsp;31, 2022, we have benefited from refunds of CIRs in a total amount of &#128;26.6&nbsp;million. In August
2021, we received CIRs of &#128;2.6&nbsp;million in respect of the year ended December 31, 2020. In October 2022, we received CIRs of &#128;4.2&nbsp;million in respect of the year ended December 31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance&#151;Conditional Advances and Subsidies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received several conditional advances and subsidies from Bpifrance since our inception. Funds received from Bpifrance in the form of
conditional advances are recognized as financial liabilities, as we have a contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. Each award of an advance is made to help fund a specific
development milestone. Subsidies are <FONT STYLE="white-space:nowrap">non-repayable</FONT> grants, which are recognized in the financial statements when there exists reasonable assurance that we will comply with the conditions attached to the
subsidies and the subsidies will be received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the monies granted by and received from Bpifrance as of
December&nbsp;31, 2022. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Contract&nbsp;status</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;awarded</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;collected</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Conditional advances</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,387</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Carena</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Ongoing</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>3,830</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>2,187</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">RNP-VIR</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Ongoing</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>6,298</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>4,032</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Ebola</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Stopped</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>390</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>390</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">COVID-19</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Stopped</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>15,869</I></TD>
<TD NOWRAP VALIGN="bottom"><I><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Subsidies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 7,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,524</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Carena</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Ongoing</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,397</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,187</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">RNP-VIR</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Ongoing</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>2,112</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,123</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Ebola</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Stopped</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">COVID-19</FONT></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>Stopped</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>3,967</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>11,214</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33,863</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,133</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the termination of the study in March 2021, the conditional advance of &#128;6.3&nbsp;million paid in
2020 was reclassified as a subsidy. See &#147;&#151;Bpifrance &#150; <FONT STYLE="white-space:nowrap">COVID-19.&#148;</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance CARENA Contract </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the
development of therapeutic and diagnostic solutions targeting alternative splicing and RNA interference in the fields of virology <FONT STYLE="white-space:nowrap">(HIV-AIDS,</FONT> <FONT STYLE="white-space:nowrap">HTLV-1)</FONT> and metabolism
(obesity), SPLICOS, which we acquired in October 2014, entered into a Master Support Agreement and a conditional advance contract on December 2013 for the &#147;CARENA&#148; Strategic Industrial Innovation Project (&#147;CARENA project&#148;), with
Bpifrance. Under this contract, we are eligible to receive up to &#128;3.8&nbsp;million in conditional advances to develop a therapeutic HIV treatment program with obefazimod. As of December 31, 2022, we had received &#128;2.2&nbsp;million of
conditional advances, of which &#128;1.2&nbsp;million was received in December 2013, &#128;1.0&nbsp;million in September 2014 and &#128;29,000 in June 2016. The repayment of these funds is spread from the date on which the repayments are called by
Bpifrance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> Contract </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the CARENA project, focused on the clinical development of a drug molecule and demonstrating the validity of an innovative
therapeutic approach targeting viral RNPs, we entered into a Master Support Agreement with Bpifrance, as well as a beneficiary agreement dated March 21, 2017, with conditional advances for the
<FONT STYLE="white-space:nowrap">&#147;RNP-VIR&#148;</FONT> structuring research and development project for competitiveness. Under the <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> contract, we are eligible to receive up to &#128;6.3&nbsp;million
in conditional advances to develop methods for the discovery of new molecules for the treatment of viral infectious diseases through the development of the &#147;Modulation of RNA biogenesis&#148; platform. As of December&nbsp;31, 2022, we had
received &#128;4.0&nbsp;million of conditional advances, of which &#128;1.8&nbsp;million was received in September 2017, &#128;0.3&nbsp;million in August 2018 and &#128;1.9&nbsp;million in November 2019. The repayment of these funds is spread from
the date on which the repayments are called by Bpifrance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance Ebola </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <I>Bpifrance </I>and Occitane Region joint support agreement was entered into on June&nbsp;2, 2017 and provides for conditional advances
for a total amount of &#128;0.4&nbsp;million (&#128;0.1&nbsp;million from the Languedoc Roussillon Midi Pyr&eacute;n&eacute;es Region and &#128;0.3&nbsp;million from <I>Bpifrance</I>) for the Ebola program. All funds under this contract were
received. In September 2019, we terminated this program due to the imminent licensing of a competing vaccine for this indication, as well as changes in the macroeconomic climate for public funding. The reimbursement of the conditional advance is
spread over the period from September 2019 to June 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Bpifrance&#151;COVID-19</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2020, we entered into agreements with Bpifrance setting out the conditions for aid to contribute to the financing of the
development of ABX464 as a potential therapeutic option for the treatment of <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients at risk of developing a severe form of the disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This financing covered the conduct of a <FONT STYLE="white-space:nowrap">&#147;miR-AGE&#148;</FONT> international clinical trial as well as
all additional clinical, preclinical, regulatory and industrial work to enable registration and accelerated access to ABX464 in the <FONT STYLE="white-space:nowrap">COVID-19</FONT> indication. The
<FONT STYLE="white-space:nowrap">&#147;miR-AGE&#148;</FONT> clinical trial was conducted under our sole responsibility, in collaboration with the University Hospital of Nice, which was tasked with the financial and administrative coordination of the
study, with the rest of the work being borne by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum amount of aid available under the framework agreement was
&#128;36.0&nbsp;million, of which &#128;19.8&nbsp;million was allocated directly to us (reflecting &#128;15.9&nbsp;million in conditional advances and &#128;4.0&nbsp;million in grants). Bpifrance&#146;s participation was paid according to the
achievement of certain phases and milestones during the development program for the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Program, broken down as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grants for a maximum total amount of &#128;20.1&nbsp;million, including &#128;4.0&nbsp;million for us (or a grant
rate of 16% of planned expenditure) and &#128;16.2&nbsp;million for the University Hospital of Nice (or a grant rate of 100% of planned expenditure); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditional advances for a maximum total amount of &#128;15.9&nbsp;million for us (or a rate of 64% of total
planned expenditure). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2020, we had received a grant of &#128;1.6&nbsp;million and net proceeds from
the conditional advance of &#128;6.3&nbsp;million. In view of the results of the study and the recommendations of the Data and Safety Monitoring Board, we terminated the study on March 5, 2021. As Bpifrance had recorded the project as unsuccessful,
we recognized an income of &#128;4.5&nbsp;million (discounted amount) as a result of Bpifrance&#146;s agreement to waive the conditions of the advance as of June 30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, we had also received an additional payment covering expenses incurred until the termination date amounting to
&#128;3.3&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Indebtedness </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>First KC Agreement and Second KC Agreement </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 24, 2018, we entered into a &#128;20&nbsp;million venture loan agreement with certain Kreos Capital entities (&#147;KC&#148;) (the
&#147;First KC Agreement&#148;). The financing consists of two tranches of structured debt financing: (i)&nbsp;a total principal amount of &#128;10&nbsp;million, comprised of (x) &#128;8&nbsp;million in
<FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds issued in July 2018 and (y) &#128;2&nbsp;million in convertible bonds issued in August 2018 (the &#147;First Tranche A Notes&#148;) and (ii)&nbsp;a total principal amount of
&#128;10&nbsp;million, comprised of (x) &#128;8&nbsp;million in <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds and (y) &#128;2&nbsp;million in convertible bonds, each issued in May 2019 (the &#147;First Tranche B Notes&#148;, together
with the First Tranche A Notes, the &#147;First KC Notes&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 12, 2020, we entered into a bonds issue agreement with KC
(the &#147;Second KC Agreement&#148;), pursuant to which we issued bonds in a total principal amount of &#128;15&nbsp;million, comprised of (i)&nbsp;a &#128;10&nbsp;million tranche (the &#147;Second Tranche A Notes&#148;) and a &#128;5&nbsp;million
tranche (the &#147;Second Tranche B Notes&#148;), with an option to issue an additional &#128;5&nbsp;million tranche (the &#147;Second Tranche C Notes&#148; and collectively with the Second Tranche A Notes and the Second Tranche B Notes, the
&#147;Second KC Notes&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Second Tranche A Notes were issued in October 2020, and the Second Tranche B Notes were issued in
November 2020. The Second KC Notes rank pari passu with the First KC Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information regarding these agreements, see
&#147;Business&#151;Key Collaborations and Partners&#151; Financing Arrangements&#151;First KC Agreement&#148; and &#147;Business&#151;Key Collaborations and Partners&#151;Financing Arrangements&#151;Second KC Agreement.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>OCEANE Bonds </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 30, 2021, we issued
&#128;25&nbsp;million 6% convertible senior unsecured and unsubordinated bonds due July 30, 2026 corresponding to 654,621 convertible bonds (the &#147;OCEANE bonds&#148;). The OCEANE bonds are exchangeable, at the option of the bondholders, for new
or existing shares and bear interest at a rate of 6% per annum, payable semi-annually on January 30 and July 30 of each year, beginning January 30, 2022. See &#147;Business&#151;Key Collaborations and Partners&#151;Financing Arrangements&#151;OCEANE
Bonds.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>State-Guaranteed Loan (Pr&ecirc;t Garantis par l&#146;Etat (&#147;PGE&#148;)) </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2020, we obtained a <FONT STYLE="white-space:nowrap">non-dilutive</FONT> financing in the form of a state-guaranteed loan of
&#128;5.0&nbsp;million. The loan was structured with an initial maturity of 12 months at 0.25% and a five-year extension option. In March 2021, we exercised the five-year extension option with a <FONT STYLE="white-space:nowrap">one-year</FONT>
deferral of principal repayment, with the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a revised interest rate of 0.58% per annum, excluding insurance and state-guaranteed premium; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a state-guaranteed premium of &#128;0.1&nbsp;million to be paid by installments over the contract period starting
in June 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalty Certificates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the completion of the capital increase from issuance of ordinary shares on September 2, 2022, we issued royalty certificates with a
subscription price amounting to &#128;2.9&nbsp;million. The royalty certificates entitle their holders to royalties equal to 2% of the future net sales of obefazimod (worldwide and for all indications) as from the commercialization of such product.
The amount of royalties that may be paid under the royalty certificates is capped at &#128;172&nbsp;million in the aggregate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in Cash Flows </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash inflows and outflows for the years ended December 31, 2022 and 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows from (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows from (used in) investing activities </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(93</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows from (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(207</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at the beginning of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,302</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at the end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 60,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 26,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(56</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December 31, 2022, cash used in operating activities was &#128;53.9&nbsp;million, as compared to &#128;45.0&nbsp;million
for the year ended December 31, 2021, an increase of &#128;8.9&nbsp;million, or 20%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, cash used in
operating activities mainly reflected our net loss of &#128;60.7&nbsp;million and was primarily used for our research and development efforts (&#128;48.3 million) as a result of progression of our portfolio development (partially offset by the
elimination of the amortization of intangibles and depreciation of property and equipment on the ABX196 cash generating unit), enhanced by an increase in derivatives and liabilities fair value of &#128;10.8&nbsp;million, a decrease in trade payables
of &#128;2.4&nbsp;million and offset by an increase in interest expenses of &#128;7.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021,
cash used in operating activities mainly reflected our net loss of &#128;42.5&nbsp;million and was primarily used for our research and development efforts (&#128;47.8 million) as a result of progression of our portfolio development and net <FONT
STYLE="white-space:nowrap">non-cash</FONT> expense of &#128;1.9&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cash used in investing activities for the year ended December&nbsp;31, 2022, was mainly composed of (i)&nbsp;CRO contracts advances for
clinical trials which have to be recovered at the end of the trials, amounting to &#128;12.2&nbsp;million, and by (ii)&nbsp;the completion of the acquisition of Prosynergia in 2022 and the remaining payment of the acquisition price of
&#128;2.9&nbsp;million, partially offset by (iii)&nbsp;the <FONT STYLE="white-space:nowrap">non-recurring</FONT> &#128;3.3&nbsp;million advance repayment from University Hospital of Nice as part of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Program clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, cash used in investing
activities was &#128;6.2&nbsp;million, and was mainly composed by the &#128;4.0&nbsp;million advance payment to the University Hospital of Nice as part of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Program clinical trial, as well as our
entry in 2021 of a &#128;1.4&nbsp;million loan agreement to fund the acquisition of Prosynergia and an advance payment made in respect of the acquisition of &#128;0.3&nbsp;million. The loan was made to allow early repayment by Prosynergia of its
existing indebtedness. For accounting purposes, this loan is considered as a prepayment for the acquisition of Prosynergia&#146;s assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing
Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, cash from financing activities was &#128;32.2&nbsp;million, which consisted primarily
of &#128;46.2&nbsp;million of net proceeds from a capital increase (including transaction costs of &#128;3.3 million), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
net proceeds from the issuance of the royalty certificates in an amount of &#128;2.9&nbsp;million, partially offset by &#128;13.4&nbsp;million of repayments under the First KC Notes and the
Second KC Notes and interest paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, cash from financing activities was &#128;82.7&nbsp;million,
which consisted primarily of &#128;60.0&nbsp;million of net proceeds from a capital increase (including transaction costs of &#128;4.2 million), &#128;8.1&nbsp;million of net proceeds from the exercise of share warrants under the equity line
agreement, &#128;1.5&nbsp;million of net proceeds from the exercise of other share warrants, and net proceeds from the issuance of the OCEANE bonds in an amount of &#128;24.9&nbsp;million, partially offset by &#128;7.4&nbsp;million of repayments
under the First KC Notes and the Second KC Notes and interest paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Cash Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contractual Obligations and Loans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth aggregate information about material contractual obligations as of December&nbsp;31, 2022 and December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commitment amounts in the table below are associated with contracts that are enforceable and legally binding and that specify all
significant terms, including, fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. <FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet obligations are
classified at less than one year maturity in the table below in the absence of a fixed schedule in contracts. Future events could cause actual payments to differ from these estimates. All amounts except the retirement benefits in the table below are
presented gross and are undiscounted. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(In thousands of euros)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial debt obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">47,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>59,915</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">39,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>220</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>693</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,495</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>194,731</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37,540</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,563</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>86,103</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>208,473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,697</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>249,170</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we regularly use the services of subcontractors and enters
into research and partnership arrangements with various CROs and with public- sector partners or subcontractors, who conduct clinical trials and studies in relation to the drug candidates. <FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet
obligations in the table above are commitments related to these research and partnership agreements. They are classified at less than one year maturity in the absence of a fixed schedule in contracts, in case of multiple-year contracts, such as CRO
contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, our contractual obligations and loans were &#128;249.2&nbsp;million, comprising financial debt
obligations of &#128;52.4&nbsp;million (in turn, comprising &#128;13.1&nbsp;million in respect of First KC Notes and the Second KC Notes, &#128;25.0&nbsp;million in respect of the OCEANE bonds, &#128;5.0&nbsp;million in respect of the PGE,
&#128;6.4&nbsp;million in respect of conditional advances from Bpifrance and &#128;2.9&nbsp;million in respect of royalty certificates), and <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet obligations of &#128;194.7&nbsp;million in respect
of purchase obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, our contractual obligations and loans were &#128;86.1&nbsp;million, comprising
financial debt obligations of &#128;59.9&nbsp;million (in turn, comprising &#128;23.4&nbsp;million in respect of the First KC Notes and the Second KC Notes, &#128;25.0&nbsp;million in respect of the OCEANE bonds, &#128;5.0&nbsp;million in respect of
the PGE and &#128;6.5&nbsp;million in respect of conditional advances from Bpifrance), and <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet obligations of &#128;25.5&nbsp;million in respect of purchase obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating Capital and Capital Expenditures Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred substantial operating losses since inception and expect to continue to incur significant operating losses for the foreseeable
future and may never become profitable. For the year ended December 31, 2022, we had a net loss of &#128;60.7 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception,
we have financed our operations through the issuance of ordinary shares with gross aggregate proceeds of &#128;336.8 million, of which &#128;130 million of gross proceeds were from offerings of our ordinary shares on Euronext Paris in February 2023,
bank borrowings and structured loans for &#128;65.0 million to date, reimbursements of Research Tax Credits (CIR) in an aggregate amount of &#128;26.6 million, and subsidies received from Bpifrance (including &#128;13.5 million of subsidies and
&#128;6.6 million of conditional advances to date). As a result of the level of available cash and cash equivalent of &#128;27.0 million as of December 31, 2022, the February 2023 capital increase amounting to &#128;123.3 million in net proceeds and
the reimbursement of the 2022 Research Tax Credit in 2023, and under the assumption that R&amp;D needs are being substantially increased in 2023, as we continue to make progress on our lead drug candidate obefazimod, which has started enrollment of
patients in our UC Phase 3 clinical trials in October 2022, we expect we will be able to fund our forecasted operating cash flow requirements throughout the second quarter of 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect we will be able to extend our financing horizon beyond the second quarter of 2024 through additional dilutive and non-dilutive
financing, which could include a combination of capital increase, venture loans and convertible bonds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the above and the actions
we have taken, management has concluded that the substantial doubt about our ability to continue as a going concern has been alleviated beyond 12 months from issuance of the accompanying financial statements, and the accompanying financial
statements have been prepared on a going concern basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our present and future funding requirements will depend on many factors,
including, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size, progress, timing, and completion of our preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of potential new drug candidates we identify and decide to develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against
claims or infringements raised by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the time and costs involved in obtaining regulatory approval for our drug candidates and any delays we may
encounter as a result of evolving regulatory requirements or adverse results with respect to any of these drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selling and marketing activities undertaken in connection with the anticipated commercialization of obefazimod
and any other current or future drug candidates and costs involved in the creation of an effective sales and marketing organization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of revenue, if any, we may derive either directly or in the form of milestones or royalty payments
from our existing or future partnership or collaboration agreements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity, duration and impact of the Russia/Ukraine war, which may continue to adversely impact our business
and clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#151;Risks Related to our Financial Position and Need for Additional
Capital&#148; for additional risks associated with our substantial capital requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company&#146;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#146;s principal
executive and principal financial officers, or persons performing similar functions, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effected by a company&#146;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements in accordance with IFRS. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or
interim financial statements will not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must maintain effective internal controls over
financial reporting in order to accurately and timely report our results of operations and financial condition. In addition, as a public company listed in the United States, the Sarbanes-Oxley Act will require, among other things, that we assess the
effectiveness of our internal controls over financial reporting at the end of each fiscal year, starting with the end of the first full fiscal year after the completion of the U.S. offering. However, our independent registered public accounting
firms will not be required to attest to the effectiveness of our internal controls over financial reporting for so long as we are an &#147;emerging growth company,&#148; which may be up to five fiscal years following the date of this U.S. offering.
An independent assessment of the effectiveness of our internal controls could detect problems that our management&#146;s assessment might not. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has not completed an assessment of the effectiveness of our internal controls over financial reporting, and our independent
registered public accounting firms have not conducted an audit of our internal controls over financial reporting. In conjunction with preparing our financial statements as of and for the years ended December 31, 2022 and 2021 for this offering,
material weaknesses in our internal controls over financial reporting were identified. The material weaknesses related to a lack of risk assessment as well as formal, documented and implemented processes, controls and review procedures, specifically
due to a lack of a sufficient number of professionals with an appropriate level of internal control knowledge, training and experience. These material weaknesses did not result in a material misstatement to our financial statements included herein,
however these material weaknesses could result in material inaccuracies in our financial statements and impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a remediation plan to address these material weaknesses and strengthen our controls in these areas. In this regard, we have
started to reorganize our finance and accounting function by hiring experienced employees to provide more review and oversight over our financial process and also increasing our headcount in this area. While we are working to remediate the material
weaknesses as quickly and efficiently possible, we cannot at this time provide the expected timeline in connection with implementing our remediation plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, we had not yet completed remediation of these material weaknesses. These remediation measures may be
time-consuming and costly and might place significant demands on our financial and operational resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, neither our
management nor an independent registered public accounting firm has performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes- Oxley Act. Had we or our independent registered public
accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#151;Risks Related to our Financial Position and Need for Additional Capital&#151;There are material weaknesses in our
internal controls over financial reporting and if we are unable to maintain effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected, which could adversely affect our
business, investor confidence and the market price of our securities.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recent Pronouncements Issued by the IASB </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of accounting policies and estimates along with a description of the recently-issued accounting pronouncements that may
potentially impact our financial position and results of operations is disclosed in Note 4 and 2 respectively to our financial statements as of and for the year ended December 31, 2022, appearing elsewhere in this prospectus. We did not have to
change our accounting policies or make retrospective adjustments as a result of adopting these standards, which include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendment to IFRS 16
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Leases&#151;COVID-19-Related</FONT></FONT> Rent Concessions beyond 30&nbsp;June, 2021 whose application is for annual reporting periods beginning on or after April&nbsp;1, 2021;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IFRS 3 Business Combinations&#151;Reference to the Conceptual Framework, whose application is for
annual reporting periods beginning on or after January&nbsp;1, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 16&#151;Property, Plant and Equipment&#151;Proceeds before Intended Use, whose application is
for annual reporting periods beginning on or after January&nbsp;1, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets&#151;Onerous Contracts&#151;Cost of
Fulfilling a Contract, whose application is for annual reporting periods beginning on or after January&nbsp;1, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Improvements to IFRS Standards 2018-2020&#151;Amendments to IFRS 1 First-time Adoption of International
Financial Reporting Standards, IFRS 9 Financial Instruments, IFRS 16 Leases, and IAS 41 Agriculture, whose application is for annual reporting periods beginning on or after January 1, 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not elect for early application of the new standards, amendments and interpretations, which were issued but not mandatory as of January
1, 2022. We assessed the impacts resulting from the application of these recently issued accounting pronouncements and concluded that impacts are not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no standards that are issued and not yet effective that are expected to have a material impact on our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of quantitative and qualitative disclosures about market risk is disclosed in Note 27 to our financial statements as of and for
the year ended December 31, 2022 appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal financial instruments we hold are cash and cash
equivalents. The purpose of holding these instruments is to finance our ongoing business activities. It is not our policy to invest in financial instruments for speculative purposes. We do not use derivative financial instruments for hedging
purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal risks to which we are exposed are liquidity risk, interest rate risk, foreign currency exchange risk and credit
risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidity Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Liquidity risk
management aims to ensure that we dispose of sufficient liquidity and financial resources to be able to meet our present and future obligations. We prepare short-term cash forecasts and annual operating cash flow forecasts as part of our budget
procedures. Prudent liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate credit facilities and being able to unwind market positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have required substantial amounts of cash since inception. Developing pharmaceutical drug candidates, including conducting
clinical trials, is expensive, lengthy, and risky, and we expect our research and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development expenses to increase substantially in connection with our ongoing activities. Accordingly, we will continue to require substantial additional capital to continue our clinical
development activities and potentially engage in commercialization activities. See &#147;&#151;Operating Capital and Capital Expenditures Requirements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to meet any additional financing needs, we may seek to obtain one or more dilutive or
<FONT STYLE="white-space:nowrap">non-dilutive</FONT> financings depending on market conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Rate Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in connection with our medium- and long-term borrowings that are subject to variable interest rates. We have not
adopted any other recurring mechanism of hedging to protect against interest rate fluctuations. We may consider in the future using a suitable policy to hedge interest rate risks in a more significant manner, if needed. Due to a significant increase
in market interest rates over the year ended December&nbsp;31, 2022, we have performed a reassessment of our exposure to interest rate risk. As of December&nbsp;31, 2022, all of our financial liabilities accounted for at amortized cost bear fixed
interest rates, except for the First KC Notes, which bear interest based on <FONT STYLE="white-space:nowrap">3-month</FONT> Euribor plus an 8% margin. Due to the <FONT STYLE="white-space:nowrap">3-month</FONT> Euribor being capped at 1% (in
accordance with contractual terms), the First Tranche A Notes being repaid in full in December 2022 and the First Tranche B Notes maturing November 2023, we have limited exposure. We believe a hypothetical 100 basis point change in interest rates
during any of the periods presented would not have had a material effect on our financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign
Currency Exchange Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to a risk of exchange rate fluctuations on commercial transactions performed in currencies
different from our functional currency in which we record the transactions. We have not adopted any other recurring mechanism of hedging to protect against currency fluctuations. From time to time, we may nevertheless subscribe for currency term
accounts in order to cover a commitment in currency. We may consider in the future using a suitable policy to hedge exchange risks in a more significant manner, if needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the operating expenses we incurred in foreign currencies in the years ended December 31, 2022 and 2021. </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Foreign&nbsp;currency</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euros</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Foreign&nbsp;currency</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euros</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Currency </B><I>(thousands)</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Australian dollar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Israeli shekel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Japanese yen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hungarian forints</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pound sterling</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swedish krona</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swiss franc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States dollar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,049</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, the total amount of operating expenses we incurred in foreign
currencies was &#128;2.2&nbsp;million, or 3.1% of our total operating expenses of &#128;69.4&nbsp;million in that year. For the year ended December 31, 2021, the total amount of operating expenses we incurred in foreign currencies was
&#128;3.0&nbsp;million, or 5.7% of our total operating expenses of &#128;53.4&nbsp;million in that year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Credit Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The credit risk related to our cash and cash equivalents is not significant in light of the quality of our
<FONT STYLE="white-space:nowrap">co-contracting</FONT> financial institutions. As of December&nbsp;31, 2022, substantially all our cash and cash equivalents were maintained with one financial institution in France. While our deposit accounts are
insured up to the legal limit, the balances we maintain may, at times, exceed this insured limit. As of December&nbsp;31, 2022 we maintained &#128;26.8&nbsp;million in bank deposit accounts that are in excess of the legally insured limit in one
legally insured financial institution. We have not experienced any losses in such accounts and we do not believe that we are exposed to any significant credit risk related to these instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The credit risk related to our other receivables and related account is minimal. In particular, the credit risk related to advances made to
CROs is deemed insignificant due to their credit ratings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Exemptions and Foreign Private Issuer Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the U.S. Jumpstart Our Business Startups Act of 2012 (&#147;JOBS Act&#148;).
An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting pursuant to the Sarbanes-Oxley Act of 2002; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with any requirement that may be adopted by the PCAOB regarding mandatory audit firm
rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that we no longer qualify as a foreign private issuer, reduced disclosure about our company&#146;s
executive compensation arrangements and exemptions from the requirements to obtain a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation or a shareholder approval of any golden parachute arrangements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging
growth company. We would cease to be an emerging growth company if we have more than $1.235&nbsp;billion in annual revenue, have more than $700&nbsp;million in market value of our ordinary shares held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> or issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. We may choose to take advantage of some but not all of these
reduced burdens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period
for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. Given that we currently
report and expect to continue to report under IFRS, as issued by the IASB, we are not able to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which
adoption of such standards is required by the IASB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have taken advantage of reduced reporting requirements in this prospectus.
Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon consummation of the offering, we will report under the Exchange Act as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company with
foreign private issuer status. As a result, in accordance with Nasdaq Listing Rule 5615(a)(3), we may choose to comply with home country governance requirements and certain exemptions thereunder rather than complying with certain of the corporate
governance requirements of Nasdaq. Even after we no longer qualify as an emerging </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public
companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of
a security registered under the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading
activities and liability for insiders who profit from trades made in a short period of time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> containing unaudited financial and other specified information, or current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> upon the occurrence of specified significant events; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulation FD, which regulates selective disclosures of material information by issuers. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_13"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biotechnology company focused on developing therapeutics that harness the body&#146;s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. We are currently evaluating our lead drug candidate,
obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis (&#147;UC&#148;). We are also in the planning stages of initiating a Phase 2a clinical trial of obefazimod in patients with
Crohn&#146;s disease (&#147;CD&#148;), as well as evaluating other potential inflammatory indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on indications where
existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial
populations and represent large commercial opportunities, pending regulatory approvals and successful commercialization. Our initial focus is on inflammatory bowel diseases (&#147;IBD&#148;), chronic conditions involving inflammation of the
gastrointestinal (&#147;GI&#148;) tract, of which the two most common forms are UC and CD. As of 2022, an aggregate of approximately 2.9&nbsp;million patients across the United States, EU4 (France, Germany, Italy and Spain), the United Kingdom and
Japan suffered from IBD, with 1.5&nbsp;million of these patients in the United States alone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the primary goals of IBD therapy is
to achieve durable&nbsp;clinical remission while simultaneously taking into consideration a patient&#146;s quality of life and concerns regarding potential side effects. Despite a number of different therapies approved for UC and CD, the vast
majority of these therapies require chronic administration via injections or intravenous infusions, and may come with serious and concerning warnings, including, but not limited to, risks of serious infections leading to hospitalizations or death
and increased risks of various malignancies. A vast majority of IBD patients do not achieve clinical remission with existing therapies, and a significant number of patients will lose response over time, especially those patients on TNF-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapy where anti-drug antibodies are very common. Further, despite the increased number of biosimilars, such as TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapies, becoming
available for the treatment of IBD, biosimilars unfortunately do not alleviate any of the potential side&nbsp;effect concerns that often cause patients to delay, or avoid altogether, stepping up to more advanced therapies. In addition, although a
small number of oral therapies have more recently been approved for the treatment of IBD, these therapies also come with concerning potential side effects, which can discourage patients from initiating treatment with advanced therapies. Therefore,
there continues to be significant unmet need for novel oral therapies with durable efficacy, improved safety profiles and minimal preinitiation requirements for patients with moderately to severely active IBD. Moreover, we believe the IBD market has
significant growth potential driven by growing diagnosis of these diseases and increased penetration of oral treatments with improved benefit/risk profiles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the treatment of IBD via its unique mechanism
of action. Obefazimod is designed to specifically induce the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> which plays a critical role in the regulation of the immune
response. In the context of inflammation, <FONT STYLE="white-space:nowrap">miR-124</FONT> modulates the immune response, controlling progression of inflammation and restoring homeostasis of the immune system, without causing broader
immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which target only a single cytokine or pathway, <FONT STYLE="white-space:nowrap">miR-124</FONT> modulates the expression of
several key cytokines and pathways resulting in regulation of the inflammatory process. Modulating multiple inflammatory pathways simultaneously may result in more durable efficacy over the long-term, which is critical in lifelong conditions such as
IBD, potentially differentiating obefazimod from currently available IBD treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our Phase 2 clinical trials for the treatment of
moderately to severely active UC, consistent with the pharmacological effects observed in our preclinical studies, obefazimod demonstrated an onset of symptom relief by day 8 of dosing, with meaningful reductions in rectal bleeding and stool
frequency scores. In our induction </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Phase 2b clinical trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant reduction in Modified Mayo Score, a measure of disease activity, as well
as secondary endpoints of clinical remission, endoscopic improvement, clinical response, and reduction of fecal calprotectin, as compared to placebo. In addition, we observed high rates of sustained and newly achieved clinical remission in the
subsequent open-label maintenance extension trial of up to two years of treatment, of which approximately 45% of patients were previously exposed to biologics or Janus kinase (&#147;JAK&#148;) inhibitors. The majority of patients previously exposed
to advanced therapy prior to enrollment were highly refractory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, we reported the results from the final analysis of our
Phase 2b open-label maintenance trial, including 217 patients of which 164 patients (76%) completed the second year of once-daily oral treatment with 50 mg obefazimod. At the conclusion of the second year of treatment, 114 of the 217 patients
enrolled (53%) achieved clinical remission and 158 patients (73%) achieved clinical response. Among the 98 <FONT STYLE="white-space:nowrap">bio-refractory</FONT> patients, 66&nbsp;patients (67%) had a clinical response, 38 patients (39%) were in
clinical remission, 46&nbsp;patients (47%) had an endoscopy improvement and 20&nbsp;patients (20%) had an endoscopy remission at week&nbsp;96. Among the 124&nbsp;patients that achieved clinical response at the end of the 8 week induction period of
the double-blind study, 74 patients (60%) achieved clinical remission, 95 patients (77%) had clinical response, 79 patients (64%) achieved endoscopic improvement and 52 patients (42%) achieved endoscopic remission at week 96. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obefazimod&#146;s tolerability profile indicates potentially important clinical differentiation. As of November&nbsp;30, 2022 (the last safety
data <FONT STYLE="white-space:nowrap">cut-off</FONT> date), 1,074 patients and volunteers had been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one year or more with no change in the observed tolerability
profile underscored by 76% of patients that remained on therapy throughout the <FONT STYLE="white-space:nowrap">two-year</FONT> open-label maintenance trial period. No new adverse safety signals were observed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated our pivotal Phase 3 clinical trials of obefazimod for the treatment of moderately to severely active UC in October 2022, which
consist of two induction trials <FONT STYLE="white-space:nowrap">(ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2)</FONT> and one ABTECT maintenance trial. <FONT STYLE="white-space:nowrap">Top-line</FONT> data from the <FONT
STYLE="white-space:nowrap">ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2</FONT> induction trials is expected to be announced by the first quarter of 2025, and <FONT STYLE="white-space:nowrap">top-line</FONT> data from the ABTECT
maintenance trial is expected to be announced by the first quarter of 2026. We intend to file an Investigational New Drug Application (&#147;IND&#148;) in the fourth quarter of 2023 and plan to initiate a Phase 2 clinical trial in patients with CD
in the first quarter of 2024 with the objective to demonstrate clinical response and tolerability profile consistent with that already observed in our clinical trials for moderately to severely active UC. Based on the results from this Phase 2
clinical trial, we intend to proceed directly to a Phase 3 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is comprised of industry leaders in the fields of
biology, data analytics, and drug development, as well as scientific experts in chronic inflammatory diseases, including IBD. We are led by Marc de Garidel, our Chief Executive Officer, who has more than 40 years of experience in the pharmaceutical
and biotechnology sector. Collectively, our team has decades of experience and a proven track record of advancing compounds into and through clinical development and commercialization, including at the following organizations: Amgen, Arena
Pharmaceuticals, AstraZeneca, BioNTech, Boehringer Ingelheim, Eli Lilly, Genentech/Roche, Guerbet, Ipsen Pharmaceuticals, J&amp;J, Pfizer, Sanofi, Sanofi-Pasteur and Shire/Takeda. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Pipeline </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead drug
candidate, obefazimod, is in clinical development for the treatment of moderately to severely active UC. We are continuing to develop obefazimod for the treatment of CD and we are evaluating additional potential inflammatory indications to pursue,
subject to the availability of necessary resources and funding. In parallel, we are in the process of generating <FONT STYLE="white-space:nowrap">follow-on</FONT> compounds based on the <FONT STYLE="white-space:nowrap">miR-124</FONT> platform. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart below sets forth details relating to the current stages of development of our
lead drug candidate: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g29f00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IBD Overview and Limitations of Existing Treatments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IBD, such as UC and CD, is a chronic life-long immune-mediated inflammatory condition of the GI tract with many contributing factors, including
genetic, environmental and immunologic. UC and CD are the two most common forms of IBD and are characterized by dysregulation of lymphocytes contributing to inflammation. Both UC and CD are chronic, relapsing, remitting, inflammatory conditions of
the GI tract that begin most commonly during adolescence and young adulthood. UC involves the innermost lining of the large intestine, and symptoms include abdominal pain and diarrhea, frequently with blood and mucus. CD can affect the entire
thickness of the bowel wall and all parts of the GI tract from mouth to anus. CD symptoms include abdominal pain, diarrhea and other more systemic symptoms, such as weight loss, nutritional deficiencies and fever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IBD, as of 2022, affected approximately 1.5&nbsp;million patients in the United States alone. As of 2022, the prevalence of UC and CD in the
United States were estimated at approximately 0.9&nbsp;million and 0.6&nbsp;million patients, respectively. The prevalence of IBD in the EU4 and the United Kingdom is estimated at 1.2&nbsp;million with approximately 0.7&nbsp;million patients with UC
and 0.5&nbsp;million patients with CD. As of 2022, an aggregate of approximately 2.9&nbsp;million patients across the United States, EU4, the United Kingdom and Japan suffered from IBD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the primary goals of IBD therapy is to achieve durable&nbsp;clinical remission while simultaneously taking into consideration a
patient&#146;s quality of life and concerns regarding potential side effects. Despite a number of different therapies approved for UC and CD, the vast majority of these therapies require chronic administration via injections or intravenous
infusions, and may come with serious and concerning warnings, including, but not limited to, risks of serious infections leading to hospitalizations or death and increased risks of various malignancies. A vast majority of IBD patients do not achieve
clinical remission with existing therapies, and a significant number of patients will lose response over time, especially those patients on TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapy where anti-drug antibodies are very
common. Further, despite the increased number of biosimilars, such as TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapies, becoming available for the treatment of IBD, biosimilars unfortunately do not alleviate any of the
potential side&nbsp;effect concerns that often cause patients to delay, or avoid altogether, stepping up to more advanced therapies. In addition, although a small number of oral therapies have more recently been approved for the treatment of IBD,
these therapies also come with concerning potential side effects, which can also discourage patients from initiating treatment with advanced therapies. Therefore, there continues to be significant unmet need for novel oral therapies with durable
efficacy, improved safety profiles and minimal preinitiation requirements for patients with moderately to severely active IBD. Moreover, we believe the IBD market has significant growth potential driven by growing diagnosis of these diseases and
increased penetration of oral treatments with improved benefit/risk profiles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2022, pharmaceutical sales in IBD were
$16.3&nbsp;billion in the United States and $7.4&nbsp;billion in the rest of the world, totaling $23.7&nbsp;billion worldwide. Pharmaceutical sales in IBD are estimated to be $17.5&nbsp;billion and </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$26.8&nbsp;billion in the United States and worldwide, respectively, in 2028. Worldwide sales in the UC market were $7.4&nbsp;billion in 2022 and are estimated to be $10.2&nbsp;billion in 2028,
while in the CD market worldwide sales reached $16.3&nbsp;billion in 2022 and are estimated to be $16.6&nbsp;billion in 2028. We believe the IBD market has significant growth potential driven by growing diagnosis of these diseases and increased
penetration of oral treatments with improved benefit/risk profiles. We believe the potential for oral agents to gain significant market share is supported by physician and patient preference for the convenience of oral administration over injectable
agents, increasing demand for therapies with long-term efficacy profiles, and the opportunity for potent and well-tolerated oral agents to expand the overall segment of the moderately to severely active UC population undergoing treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical treatment of IBD is typically divided into two types of therapy: induction and maintenance. Induction therapy is used to reduce
inflammation quickly (in three months or less) and maintenance therapy is used to sustain that reduction. Patients with IBD are classified by the activity of their disease as either mild to moderately active or moderately to severely active based on
the level of symptoms experienced, inflammatory biomarkers and severity of disease on endoscopy. The current standard of care for the treatment of patients with&nbsp;moderately to severely active&nbsp;IBD is to reduce inflammation with
anti-inflammatory agents. Patients with mild to moderately active IBD are treated with <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;conventional therapies&#148; which are anti-inflammatory treatments that include: aminosalicylates (e.g., <FONT
STYLE="white-space:nowrap">5-ASAs),</FONT> immunosuppressants or immunomodulators (e.g., <FONT STYLE="white-space:nowrap">6-mercaptopurine,</FONT> methotrexate and azathioprine) and corticosteroids. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the widespread use of conventional therapies to treat mild to moderately active IBD, due to the progressive and lifelong nature of
both UC and CD, for many patients the severity of their disease progresses in activity and are considered moderately to severely active. This requires patients and their physicians to consider using more targeted therapies typically termed
&#147;advanced therapies.&#148; The majority of advanced therapies require chronic parenteral administration including <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors (e.g., infliximab,
adalimumab and golimumab), Interleukin <FONT STYLE="white-space:nowrap">(&#147;IL&#148;)-12/23</FONT> inhibitor (ustekinumab), anti-integrin antibodies (vedolizumab), or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors (mirikizumab). There
are also two classes of oral treatments including JAK inhibitors (e.g., tofacitinib, filgotinib and upadacitinib) and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sphingosine-1-phosphate</FONT></FONT> (&#147;S1P&#148;) receptor
agonists (ozanimod). Although these therapies have demonstrated efficacy in UC and/or CD, the majority of IBD patients do not achieve clinical remission, and a significant number of patients lose response over time, especially those treated with
TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor therapies where anti-drug antibodies are common. Due to mechanisms of action that are poorly understood, with each line of advanced therapy that is exhausted, patients become less likely
to respond to the next advanced therapy utilized in the sequence of care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the advanced therapy classes are associated with
notable side effect and safety tradeoffs that must be considered before initiating treatment. For instance: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U><FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors</U>:
Boxed warnings for increased risk of serious infections leading to hospitalizations or death and various forms of malignancies are noted in the United States prescribing information with similar warnings in the European Medicines Agency
(&#147;EMA&#148;) summary of product characteristics (&#147;SmPCs&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U><FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors</U>: Warnings in label for serious infections,
tuberculosis, malignancies and posterior reversible encephalopathy syndrome (PRES). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Anti-integrin antibodies</U>: Warnings in label for potential risk of Progressive Multifocal
Leukoencephalopathy (&#147;PML&#148;), gut specificity of vedolizumab may be connected with exacerbating or causing extraintestinal manifestations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U><FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors</U>: Warnings in the EU for severe infections and
risk of hepatic enzyme elevations (mirikizumab not approved in the United States). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>JAK inhibitors</U>: Boxed warnings for increased risk of serious infections leading to hospitalization or
death, higher rates of <FONT STYLE="white-space:nowrap">all-cause</FONT> mortality, malignancies, cardiovascular death, myocardial infarction, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
stroke and thrombosis appear in the United States prescribing information with similar warnings in the EU. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>S1P receptor agonists: Warnings in label for infections, bradyarrhythmia and atrioventricular conduction
delays, liver injury and macular edema. These warnings result in multiple preinitiation requirements prior to initiating therapy. Risk of PML also exists. </U></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients and physicians must take into consideration the lifelong burden of chronic parenteral administration for injectable agents and the
potential safety warnings for all therapies when deciding which treatment, if any, to initiate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts the current
IBD treatment landscape: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g27m26.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Not approved in CD </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates market share of existing therapies in the UC market in the United States for 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g27m05.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For patients who do not or no longer respond to treatment, or experience complications,
surgical treatment may be necessary. Approximately 50% to 80% of CD patients and 10% to 30% of UC patients require surgery over their lifetime. In light of the above, we believe that there is significant unmet medical need in the UC treatment
paradigm due to imperfect existing therapies with unfavorable clinical characteristics and limited efficacy that frequently wanes over time. A general patient preference for oral agents over injectables suggests a potential untapped market
opportunity available for efficacious, well-tolerated oral therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following strengths will allow us to advance our proprietary drug candidates through clinical trials, while building upon our
advanced position in the development of therapeutics for IBD and other chronic inflammatory diseases: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our focus on indications of high unmet need and substantial commercial potential, with an initial focus on
IBD.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We focus on indications where existing treatments have left patients with significant unmet needs, and where we
believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies. The indications we target have substantial populations and represent large commercial opportunities, pending regulatory
approvals and successful commercialization. Our initial focus is on IBD, chronic conditions involving inflammation of the GI tract, of which the two most common forms are UC and CD. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe the IBD market has significant growth potential driven by growing diagnosis of these diseases and increased penetration of oral
treatments with improved benefit/risk profiles. We believe the need for differentiated treatment options is high, in particular for patients with moderate and severe forms of IBD, for whom available therapies often have limited efficacy and
durability while carrying significant safety and tolerability challenges. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>We believe we are market leaders in leveraging <FONT STYLE="white-space:nowrap">micro-RNA</FONT> biology to
target inflammation.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for
the treatment of IBD via its unique mechanism of action. Obefazimod is designed to specifically induce the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> which plays a
critical role in the regulation of the immune response. In the context of inflammation, <FONT STYLE="white-space:nowrap">miR-124</FONT> modulates the immune response, controlling progression of inflammation and restoring homeostasis of the immune
system, without causing broader immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which target only a single cytokine or pathway, <FONT STYLE="white-space:nowrap">miR-124</FONT>
modulates the expression of several key cytokines and pathways resulting in regulation of the inflammatory process. Modulating multiple inflammatory pathways simultaneously may result in more durable efficacy over the long-term, which is critical in
lifelong conditions such as IBD, potentially differentiating obefazimod from currently available IBD treatments. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Robust data generated from our Phase 2 clinical trials of obefazimod for the treatment of moderately to
severely active UC. </B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In our Phase 2 clinical trials for the treatment of moderately to severely active UC,
consistent with the pharmacological effects observed in our preclinical studies, obefazimod demonstrated an onset of symptom relief by day 8 of dosing, with meaningful reductions in rectal bleeding and stool frequency scores. In our induction Phase
2b clinical trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant reduction in Modified Mayo Score, a measure of disease activity, as well as secondary endpoints of clinical remission, endoscopic
improvement, clinical response, and reduction of fecal calprotectin, as compared to placebo. In addition, we observed high rates of sustained and newly achieved clinical remission in the subsequent open-label maintenance extension trial of up to two
years of treatment, of which approximately 45% of patients were previously </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
exposed to biologics or JAK inhibitors. The majority of patients previously exposed to advanced therapy prior to enrollment were highly refractory. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our lead drug candidate, obefazimod, has been well-tolerated in our clinical trials to date. </B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Obefazimod&#146;s tolerability profile indicates potentially important clinical differentiation. Many existing therapies
for IBD have been limited by safety and tolerability concerns, including increased risks of serious infections or various malignancies, sometimes requiring warning labels. By contrast, as of November&nbsp;30, 2022 (the last safety data <FONT
STYLE="white-space:nowrap">cut-off</FONT> date), the tolerability profile of obefazimod is supported by more than 1,074 patients and volunteers that had been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one
year or more with no change in the observed tolerability profile. In addition, to date, the entire obefazimod safety database presents no death or malignancies and no reported clinically significant changes in laboratory parameters, such as liver
function, hemoglobin levels and white blood cell counts. The most common treatment emergent adverse event (&#147;TEAE&#148;) reported has been mild to moderate headache, which has been transient and manageable with or without <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> medications. Furthermore, at present, no increased rate of opportunistic infections or malignancies compared with placebo have been observed across all
clinical trials. We conduct an annual analysis of clinical safety data from our ongoing clinical trials using an annual <FONT STYLE="white-space:nowrap">cut-off</FONT> date of November&nbsp;30 with the intention to provide additional safety data in
January of the following year. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Compelling and differentiating clinical characteristics position obefazimod as a potential early-line therapy
for moderately to severely active UC.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Therapies currently available to patients with UC in the first-line setting
are limited to older, broad immunosuppressive agents with safety, tolerability, and efficacy challenges. Advanced therapies, which include biologic agents such as TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors, <FONT
STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors, carry significant safety and tolerability challenges and their administration, as injectable agents, is not convenient to patients.
Newer oral molecules, such as JAK inhibitors and S1P receptor agonists, while addressing convenient route of administration for patients, also present safety and tolerability challenges. Comparatively, obefazimod is being developed as a once-daily,
oral medication which, combined with its observed tolerability to date, would represent a meaningfully differentiated clinical profile from existing therapies. We believe this may position obefazimod as an early-line, or first-line after failure of
conventional therapies, treatment choice for both prescribers and patients, if approved. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our experienced team is comprised of global industry leaders in the development of therapeutics for chronic
inflammatory diseases.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe that the breadth of experience and accomplishments of our management team, board
of directors and scientific advisory board, combined with our broad network of established relationships with leaders in the industry and medical community, provide us with fresh insights into drug development and commercialization, and have allowed
us to bring together top researchers to build interdisciplinary research and development teams. We are led by Marc de Garidel, our Chief Executive Officer, who has more than 40 years of experience in the pharmaceutical and biotechnology sector and
successfully led the sales of CinCor Pharma to AstraZeneca in 2023 and Corvidia Therapeutics to Novo Nordisk in 2020. Collectively, our team has decades of experience and a proven track record of advancing compounds into and through clinical
development and commercialization, including at the following organizations: Amgen, Arena Pharmaceuticals, AstraZeneca, BioNTech, Boehringer Ingelheim, Eli Lilly, Genentech/Roche, Guerbet, Ipsen Pharmaceuticals, J&amp;J, Pfizer, Sanofi,
Sanofi-Pasteur and Shire/Takeda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary goal is to develop and commercialize obefazimod for the treatment of inflammatory diseases, starting with moderately to severely
active UC. We have already generated compelling data in moderately to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
severely active UC from our Phase 2a and 2b clinical trials, which we believe provides us with potential readthrough into broader set of inflammatory diseases. We focus on indications with high
unmet needs with substantial commercial potential. To achieve our goal, we are pursuing the following key elements of our strategy: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance obefazimod through pivotal clinical trials and establish obefazimod as a new treatment for moderately
to severely active UC.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Currently available first-line advanced therapies have limited efficacy and durability, carry
significant safety and tolerability challenges, and most of them are injectable biologics. We believe the potential for oral agents to gain significant market share is supported by physician and patient preference for the convenience of oral
administration over injectable agents, increasing demand for therapies with long-term efficacy profiles, and the opportunity for potent and well-tolerated oral agents to expand the overall segment of the moderately to severely active UC population
undergoing treatment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe that the strength of the data we have generated in our Phase 2 clinical trials, specifically its
potential to demonstrate rapid onset of action, durable efficacy and tolerability, uniquely position obefazimod as a potential leader in moderately to severely active UC. We believe our data, if supported by the results of our Phase 3 clinical
trials, well-positions obefazimod as a potential early-line, or first-line after failure of conventional therapies, treatment choice for UC, if approved. In addition, we believe that obefazimod&#146;s clinical profile observed <FONT
STYLE="white-space:nowrap">to-date</FONT> lends itself to potential combinations with existing or new therapies which we may explore. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand the IBD opportunity for obefazimod to include patients with CD.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">CD causes long-lasting inflammation and ulcers in the digestive tract, with fibrosis and stricturing, playing a key role in disease
progression. It differs from UC in that it affects the entire thickness of the bowel wall and all parts of the digestive tract from mouth to anus. However, CD shares many of the underlying pathophysiological processes and clinical manifestations of
UC, and, as a result, the current treatment paradigm of CD is similar to UC, as described further below. Based on the positive clinical data generated in our UC trials, preclinical studies in dextran sulfate sodium model which provide support for
pursuing further development in CD, and underlying biological and mechanistic rationale, we plan to initiate a Phase 2a clinical trial in patients with CD to potentially demonstrate outcomes consistent with those observed in our Phase 2 clinical
trials for moderately to severely active UC. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Optimize value of <FONT STYLE="white-space:nowrap">miR-124</FONT> modulation platform to expand our pipeline
of novel therapeutics for the treatment of IBD and other inflammatory indications.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We are currently prioritizing
development of IBD treatments including for moderately to severely active UC and CD, but are evaluating other additional indications that have similar immunologic characteristics. Since obefazimod&#146;s upregulation of <FONT
STYLE="white-space:nowrap">miR-124</FONT> exerts anti-inflammatory effects via modulating translation of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines and chemokines, we believe obefazimod may have a role in other indications
which may benefit from therapeutic intervention by such an approach. Our strategy is to conduct <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies with obefazimod to show that <FONT
STYLE="white-space:nowrap">miR-124</FONT> upregulation demonstrates disease-modifying effects in other inflammatory conditions where there is unmet medical need, similar to our Phase 2a clinical trial in patients with rheumatoid arthritis
(&#147;RA&#148;), where we saw encouraging <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data supporting obefazimod&#146;s potential role in addressing inflammatory conditions beyond IBD, to fully
explore its potential. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Opportunistically evaluate strategic partnerships to maximize the value of obefazimod and our therapeutic
pipeline.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We have discovered and are developing obefazimod as an innovative medicinal product and we currently hold
its worldwide rights. We intend to retain worldwide development and commercialization rights for obefazimod. For certain geographies, we may opportunistically enter into strategic partnerships to accelerate development activities in order to realize
the commercial potential of obefazimod as well as other assets in our pipeline. In connection with any potential strategic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
partnership, we plan to pursue and receive upfront funding, milestone payments and future royalties for these agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is comprised of
industry leaders in the fields of biology, data analytics, and drug development, as well as scientific experts in chronic inflammatory diseases including IBD, with 34 full-time employees as of June&nbsp;30, 2023. Collectively, our team has decades
of experience and a proven track record of advancing compounds into and through clinical development and commercialization. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Marc de Garidel, our Chief Executive Officer, has more than 40 years of experience in the pharmaceutical and
biotechnology sector, including 12 years of experience as Chief Executive Officer of pharmaceutical and biotechnology companies. Between July 2021 and April 2023, he served as Chief Executive Officer of CinCor Pharma and led its successful sale for
up to $1.8&nbsp;billion, subject to the achievement of certain milestones, to AstraZeneca in February 2023. From April 2018 until August 2020, he was Chief Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for
$2.1&nbsp;billion in total consideration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Didier Blondel, our Chief Financial Officer and Board Secretary, was previously Chief Financial Officer at Sanofi
Pasteur MSD, a Lyon-based joint venture between Sanofi and Merck. Over the past 20 years, he has held a wide variety of senior finance positions at Sanofi in both Commercial Operations and Research and Development, including as Global Research and
Development Chief Financial Officer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sheldon Sloan, MD, M Bioethics, our Chief Medical Officer, has over 30 years of experience in academia and the
biopharmaceutical industry, with an extensive track record in the field of gastroenterology and IBD. Prior to joining us, Dr.&nbsp;Sloan worked for Arena Pharmaceuticals and, after its acquisition, for Pfizer, where he was Program Lead for
Etrasimod. Before joining Arena Pharmaceuticals, he held different leadership positions at Johnson and Johnson in Medical Affairs, Research and Development, and Science Policy, including Global Medical Affairs Leader for IBD, leading the global
launch strategy and execution for CD and UC for Stelara. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Michael Ferguson, MBA, our Chief Commercial Officer, has over 22 years of experience in the biopharmaceutical
industry, with an extensive track record in the field of gastroenterology and IBD. He has spent the last 16 years of his career in large pharmaceutical and biotech companies, including 13&nbsp;years in leading commercial positions at Shire/Takeda,
followed by Arena Pharmaceuticals, where he served as Vice President Global Commercial Marketing and Planning and specifically as Global Commercial Lead for Etrasimod across all GI Indications. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pierre Courteille, Pharmacist, MBA, our Chief Business Officer, has more than 25 years of experience in
marketing, sales and business development within the pharmaceutical industry. He has extensive commercial launch and marketing experience from prior roles as Senior Vice President of Sales and Marketing for Guerbet and Chief Executive Officer of
MEDEX, a medical device company owned by Guerbet, and Marketing Manager at Sanofi Pasteur Japan&#146;s joint-venture with Daiichi Sankyo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our management team also consists of other top industry veterans such as Paul Gineste, PharmD, our VP of Clinical
Operations and formerly International Clinical Trials Manager at Boehringer Ingelheim; Didier Scherrer, Ph.D., our VP of Research and Development and formerly CEO&nbsp;&amp; Scientific Director at Splicos; J&eacute;r&ocirc;me Denis, Ph.D., our VP of
Process Development&nbsp;&amp; Manufacturing and formerly Executive Head of Development&nbsp;&amp; Associate Director of Vaccine Development at Imaxio; and Mary Mantock, MSc, our VP of Regulatory Affairs and formerly Executive Director, RA, Global
Development for immune-oncology at Astellas. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is led by our Chairman and Chief Executive Officer,
Marc de Garidel. Additional board members include: Corinna zur Bonsen-Thomas, Co-founder and Chief Executive Officer of RetInSight and former General Counsel at Baxter International; Carol Brosgart, MD, Clinical Professor of Medicine,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Epidemiology and Biostatistics at the University of California, San Francisco; Kinam Hong MD, MBA, CFA, Partner at the Crossover Fund of Sofinnova; Troy Ignelzi, CFO of Karuna Therapeutics; June
Lee, MD, Venture Partner at 5AM Ventures; Antonino Ligresti MD, representing Sant&#233; Holdings SRL, and former President of G&#233;n&#233;rale de Sant&#233;; and Philippe Pouletty, MD, our founder and Managing Partner at Truffle Capital,
representing Truffle Capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead drug candidate, obefazimod, is in clinical development for the treatment of moderately to severely active UC. We are continuing to
develop obefazimod for the treatment of CD and we are evaluating additional potential inflammatory indications to pursue, subject to the availability of necessary resources and funding. In parallel, we are in the process of generating <FONT
STYLE="white-space:nowrap">follow-on</FONT> compounds based on the <FONT STYLE="white-space:nowrap">miR-124</FONT> platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart
below sets forth details relating to the current stages of development of our lead drug candidate: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g29f00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Lead Drug Candidate for the Treatment of Inflammatory Diseases: Obefazimod </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obefazimod is an oral small molecule drug candidate in clinical development for the treatment of moderately to severely active UC. We believe
that obefazimod is the only small molecule drug candidate in clinical development with a mechanism of action that is designed to specifically induce the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT
STYLE="white-space:nowrap">miR-124,</FONT> which plays a critical role in the regulation of the immune response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our induction Phase
2b clinical trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant reduction in Modified Mayo Score, a measure of disease activity, as well as secondary endpoints of clinical remission, endoscopic
improvement, clinical response and the reduction of fecal calprotectin, as compared to placebo. We have observed an onset of symptom relief by day 8 of dosing, with meaningful reductions in rectal bleeding and stool frequency scores, consistent with
the pharmacological effects observed in our preclinical studies, and high rates of sustained and newly achieved clinical remission in the subsequent open-label maintenance extension trial of up to two years of treatment, of which approximately 45%
of patients were previously exposed to biologics or JAK inhibitors. In April 2023, we reported the results from the final analysis of our Phase 2b open-label maintenance trial, including 217 patients of which 164 patients (76%) completed the second
year of once-daily oral treatment with 50 mg obefazimod. At the conclusion of the second year of treatment, 114 of the 217 patients enrolled (53%) achieved clinical remission and 158 patients (73%) achieved clinical response. Among the 98 <FONT
STYLE="white-space:nowrap">bio-refractory</FONT> patients, 66 patients (67%) had a clinical response, 38 patients (39%) were in clinical remission, 46 patients (47%) had an endoscopy improvement and 20 patients (20%) had an endoscopy remission at
week 96. Among the 124 patients that achieved clinical response at the end of the 8 week induction period of the double-blind study, 74 patients (60%) achieved clinical remission, 95 patients (77%) had clinical response, 79 patients (64%) achieved
endoscopic improvement and 52 patients (42%) achieved endoscopic remission at week 96. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, obefazimod&#146;s tolerability profile indicates potentially important
clinical differentiation. As of November&nbsp;30, 2022 (the last safety data <FONT STYLE="white-space:nowrap">cut-off</FONT> date), 1,074 patients and volunteers had been treated with obefazimod, of which 209 patients were treated with 50 mg
obefazimod for one year or more with no change in the observed tolerability profile underscored by 76% of patients that remained on therapy throughout the <FONT STYLE="white-space:nowrap">two-year</FONT> open-label maintenance trial period. No new
adverse safety signals were observed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated our pivotal Phase 3 clinical trials of obefazimod for the treatment of moderately to
severely active UC in consultation with international regulators, including the U.S. Food and Drug Administration (the &#147;FDA&#148;), the EMA, the Pharmaceuticals and Medical Devices Agency (&#147;PMDA&#148;) and the China Center for Drug
Evaluation (&#147;CDE&#148;). These pivotal Phase 3 clinical trials consist of two induction trials <FONT STYLE="white-space:nowrap">(ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2)</FONT> and one ABTECT maintenance trial in doses of
25 mg and 50 mg across 36 countries in North America, Latin America, Europe and Asia Pacific, involving 1,200 moderately to severely active UC patients in over 600 sites. Each of the trials will be randomized, double-blind and placebo-controlled,
using independent and central review of video-taped endoscopies with the primary endpoint of clinical remission according to the Modified Mayo Score assessed at week 8 (induction) and at week 44 (maintenance), as recommended by the FDA. Enrollment
of the first patient under this program occurred on October&nbsp;11, 2022. <FONT STYLE="white-space:nowrap">Top-line</FONT> data from the <FONT STYLE="white-space:nowrap">ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2</FONT> induction
trials is expected to be announced by the first quarter of 2025, and <FONT STYLE="white-space:nowrap">top-line</FONT> data from the ABTECT maintenance trial is expected to be announced by the first quarter of 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, the obefazimod safety database is supported by more than 1,000 subjects treated with obefazimod across different indications,
including UC patients, some of whom are in their fifth year of continuous daily dosing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Obefazimod&#146;s Mechanism of Action
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the treatment of IBD via its
unique mechanism of action. Obefazimod is designed to specifically induce the expression of a single <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> which plays a critical role in the regulation of
the immune response. In the context of inflammation, <FONT STYLE="white-space:nowrap">miR-124</FONT> modulates the immune response, controlling progression of inflammation and restoring homeostasis of the immune system, without causing broader
immunosuppression. Once expressed, <FONT STYLE="white-space:nowrap">micro-RNA</FONT> will bind to their specific mRNA targets and moderately reduce their translation into proteins. By binding to the cap binding complex, a complex playing a role in
cellular RNA biogenesis, obefazimod is designed to specifically enhance the selective splicing of a single long <FONT STYLE="white-space:nowrap">non-coding</FONT> RNA to generate the anti-inflammatory
<FONT STYLE="white-space:nowrap">micro-RNA,</FONT> <FONT STYLE="white-space:nowrap">miR-124,</FONT> in immune cells. Importantly, obefazimod does not impact the splicing of cellular messenger RNA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">miR-124,</FONT> a known anti-inflammatory <FONT STYLE="white-space:nowrap">micro-RNA,</FONT> by targeting key
inflammatory mRNA players such as STAT3 and MCP1, regulates inflammation by downregulating the translation of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines and chemokines, such as
TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, <FONT STYLE="white-space:nowrap">IL-6,</FONT> <FONT STYLE="white-space:nowrap">MCP-1</FONT> and <FONT STYLE="white-space:nowrap">IL-17,</FONT> as well as Th17+ cells, to control overactive immune
stimulation seen in chronic inflammatory diseases. This downregulation thereby regulates the inflammatory process and suggests broad potential as a novel anti-inflammatory therapeutic agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Laboratory analysis of the Phase 2b clinical trial at week 8 showed a highly statistically significant upregulation of <FONT
STYLE="white-space:nowrap">miR-124</FONT> in rectal tissue in all patients treated with obefazimod, compared to baseline. The median increases were <FONT STYLE="white-space:nowrap">13-fold</FONT> for the 25 mg group,
<FONT STYLE="white-space:nowrap">25-fold</FONT> for the 50 mg group and <FONT STYLE="white-space:nowrap">25-fold</FONT> for the 100 mg group, while no upregulation was observed in the placebo group <FONT STYLE="white-space:nowrap">(1.02-fold</FONT>
increase), indicative of the positive pharmacological effect of obefazimod. Downstream effects of <FONT STYLE="white-space:nowrap">miR-124</FONT> upregulation have been demonstrated by the reduction in <FONT STYLE="white-space:nowrap">IL-17</FONT>
and <FONT STYLE="white-space:nowrap">Il-23</FONT> levels in the blood and rectal biopsies of patients treated with obefazimod. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which target only a single cytokine or pathway, <FONT STYLE="white-space:nowrap">miR-124</FONT> modulates the expression of several key cytokines and
pathways resulting in regulation of the inflammatory process. Modulating multiple inflammatory pathways </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
simultaneously may result in more durable efficacy over the long-term, which is critical in lifelong conditions such as IBD, potentially differentiating obefazimod from currently available IBD
treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart provides a schematic representation of obefazimod&#146;s mechanism of action: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00y99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Obefazimod in UC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>UC Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UC, one of the most
common forms of IBD, is a chronic inflammatory disease of the large intestine or colon, that affects the lining of the colon and causes small sores or ulcers. UC is the result of several factors that are not yet well understood. Abnormal immune
response, genetics, microbiome and environmental factors all contribute to UC. UC can occur at any age, though most people are diagnosed aged 20 to 30, and men and women are equally likely to be affected. UC can affect people of any racial or ethnic
group. UC symptoms can vary, depending on the severity of inflammation and where it occurs. Signs and symptoms may include diarrhea, rectal bleeding, abdominal pain and cramping, weight loss, fatigue and fever, substantially impacting the quality of
life of patients with this debilitating disease. There were an estimated 4.1&nbsp;million prevalent cases of UC globally in 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing
Therapies and Their Limitations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current UC treatment approach is influenced by multiple factors, including disease severity,
previous response to treatment, side effects and <FONT STYLE="white-space:nowrap">co-morbidities.</FONT> Both existing conventional therapies as well as advanced therapies, including approved products and drug candidates in development, face
significant room for improvement in efficacy, safety and tolerability, and convenience from dosing and route of administration standpoints as discussed below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conventional Therapies for UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aminosalicylates <FONT STYLE="white-space:nowrap">(5-ASAs)</FONT> are used as a first-line therapy in mildly to moderately active UC.
Corticosteroids are used primarily during induction therapy and are effective for reducing symptoms, but do not address mucosal healing which limit their ability to modify and improve the underlying cause of disease. In addition, there are safety
considerations with extended corticosteroid use, including lowered quality of life, bone loss, weight gain and cardiovascular complications. As a result, corticosteroids are used primarily as a bridge to manage symptoms until immunomodulators or
biologic agents become effective and enable mucosal healing. Oral immunosuppressants (e.g. azathioprine, <FONT STYLE="white-space:nowrap">6-mercatopurine</FONT> and methotrexate) have not been effective as induction agents and are generally used for
steroid-sparing or as an adjunctive therapy for reducing immunogenicity against biologic agents. Oral immunosuppressants are also associated with known toxicities such as drops in white blood cell counts and increased risk for infection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the above insufficiencies of these conventional therapies, patients suffering from
mild UC may evolve towards moderate and severe forms requiring the use of advanced therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advanced Therapies for UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advanced therapies for UC include biological agents as well as emerging oral molecules. Biological agents such as TNF-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors (including infliximab, adalimumab and golimumab), <FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors (such as ustekinumab) or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors,
which specifically block certain inflammatory factors involved in UC. Biological agents also include <FONT STYLE="white-space:nowrap">gut-specific</FONT> anti-integrin antibodies (such as vedolizumab and natalizumab). New oral molecules acting on
certain pathways of the inflammation include JAK inhibitors (including tofacitinib and upadacitinib) &#150; or, on the trafficking of inflammatory cells such as S1P receptor agonists (e.g., ozanimod). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, these therapies often only have moderate efficacy that may wane over time, as patients stop responding or do not respond at all to
these treatments and thus require new therapeutic management options. For patients who do not or no longer respond to treatment, or experience complications, surgical treatment may be necessary. Approximately 10% to 30% of UC patients require
surgery over their lifetime. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors and JAK inhibitors and
newer biological agents, including anti-integrin antibodies, <FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors and <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors, have generally improved the care of moderate to severely active
IBD (JAK inhibitors specifically in UC), these are all anti-inflammatory agents with safety and tolerability concerns. These include increased risks for cancers, infections and blood clots due to their systemic impact and resulting effects on the
immune system outside of the GI tract. In addition, prolonged treatment with biological therapies can lead to anti-drug antibody development by patients&#146; immune systems which may lead to gradual waning of therapeutic efficacy and patients
needing to switch to other biological agents. Furthermore, biological agents require injections or intravenous infusions, resulting in patient inconvenience and burden, which often negatively impacts patient compliance. Injections can also lead to
injection-related events such as sciatica, neuralgia, neuropathic pain and peripheral neuropathy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2021, the FDA published
strict warnings about increased risk of serious heart-related events, cancer, blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions (including UC). In January 2023, the EMA stated recommendations to minimize the
risk of serious side effects with JAK inhibitors used to treat several chronic inflammatory disorders, noting that these side effects include cardiovascular conditions, blood clots, cancer and serious infections which were adopted by the European
Commission in March 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently, there have been efforts to develop drug candidates targeting novel mechanisms, such as S1P receptor
agonists and TL1A inhibitors. S1P agonists, while offering convenient oral dosing, have not achieved meaningful commercial adoption. Ozanimod and other S1P agonists work by blocking capacity of lymphocytes to egress from lymph nodes, thereby
reducing the number of lymphocytes in peripheral blood, which can lead to increased susceptibility to infections. Furthermore, Ozanimod, in its UC Study 1 which assessed efficacy during the induction period, achieved 18% clinical remission in all
patients at week 10, with only 10% of patients with prior exposure to TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors showing clinical remission. TL1A inhibitors have garnered interest from those seeking newer targets and agents with
differentiated clinical profile. While Merck-Prometheus and <FONT STYLE="white-space:nowrap">Pfizer-Roivant</FONT> have generated promising early Phase 2 data in both biologics-experienced and
<FONT STYLE="white-space:nowrap">biologics-na&iuml;ve</FONT> patients, neither have initiated Phase 3 clinical trials and do not have long-term safety and efficacy data beyond 56 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In summary, we believe that there is significant unmet medical need in the UC treatment paradigm due to imperfect existing therapies with
unfavorable clinical characteristics and limited efficacy that frequently wanes over time. </P>  <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obefazimod is being developed as a once-daily, oral medication which, combined with its
observed tolerability to date, would represent a meaningfully differentiated clinical profile from existing therapies. We believe this may position obefazimod as an early-line, or first-line after failure of conventional therapies, treatment choice
for both prescribers and patients, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Market Opportunity: UC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated market opportunity for UC was approximately $7.4&nbsp;billion in worldwide sales in 2022 and is expected to reach
$10.2&nbsp;billion in worldwide sales in 2028. In 2022, there were 4.1&nbsp;million prevalent cases of UC worldwide. In the United States, EU4, the United Kingdom and Japan, there were 2.0&nbsp;million prevalent cases of UC, of which
1.3&nbsp;million of these cases in G7 countries were treated with <FONT STYLE="white-space:nowrap">5-ASAs</FONT> or advanced therapies. The UC market has significant growth potential driven by increasing incidence of the disease as well as the
development of innovative oral therapeutics. We believe the potential for oral agents to gain significant market share is supported by physician and patient preference for the convenience of oral administration over injectable agents, increasing
demand for therapies with long-term efficacy profiles and the opportunity for potent and well-tolerated oral agents to expand the overall segment of the moderately to severely active UC population undergoing treatment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Trial Results of Obefazimod in Moderately to Severely Active UC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&nbsp;30, 2022 (the last safety data <FONT STYLE="white-space:nowrap">cut-off</FONT> date), 1,074 patients and volunteers had
been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one year or more with no change in the observed tolerability profile. At present, no increased rate of opportunistic infections or malignancies compared with
placebo have been observed across all clinical trials. We are conducting Phase 3 clinical trials in moderately to severely active UC in the United States, Europe, Asia Pacific and Latin America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2a Clinical Trial with Obefazimod for the Treatment of Moderately to Severely Active UC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The induction Phase 2a clinical trial was a randomized trial of an eight-week placebo-controlled, double-blind induction phase followed by an
open-label long term extension trial. It was completed in September 2018. This <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial enrolled 32 adult patients who had been diagnosed with moderately
to severely active UC for at least 12 weeks and who failed or were intolerant to conventional treatments (50%) or biologics (50%). Patients who completed the induction phase were eligible to continue in the open-label extension trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the induction phase, patients were randomized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">two-to-one</FONT></FONT> to
a once-daily orally-administered 50 mg dose of obefazimod or placebo for eight weeks. In the long-term extension, all patients received a once-daily orally-administered 50 mg dose of obefazimod. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This double-blind, placebo-controlled trial, follows a standard study design in this indication for which a dose response as well as placebo
effect can be frequently observed. The 50 mg daily dose was selected on the basis of the safety data accumulated for this dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trial
design of our Phase 2a clinical trial for obefazimod in patients with moderately to severely active UC is depicted below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g56a56.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Primary Endpoints of Induction Phase 2a Clinical Trial with Obefazimod for the Treatment
of UC </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary endpoint in the induction Phase 2a clinical trial was safety, assessed as the rate of TEAEs. The primary endpoint in
the induction phase, evaluation of safety and tolerability of obefazimod, was met. The most frequently reported adverse events reported in the 25 mg group were GI disorders, experienced by 19% of subjects in the obefazimod group and 16% of subjects
in the placebo group and headaches (21% for 25 mg and 8% for placebo), which occurred early and were transient (lasting only a few days), mainly mild or moderate (grade 1 or 2) and manageable with or without <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> medications. No serious adverse events related to treatment were observed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table provides an overall summary of TEAEs by treatment group: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g59g59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">AE = adverse event; TEAE = treatment-emergent adverse event </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Secondary Endpoints of Induction Phase 2a Clinical Trial with Obefazimod for the Treatment of UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table depicts secondary efficacy endpoints of our Phase 2a clinical trial with obefazimod in moderately to severely active UC at
week 8: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g60a60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">ITT = <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Intent-to-treat;</FONT></FONT> PP = Per Protocol
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The secondary endpoints in the induction Phase 2a clinical trial included the proportion of patients achieving clinical remission at week
8 as compared to placebo, change from baseline to week 8 in total Modified Mayo Score (which is based on stool frequency, rectal bleeding, physician global assessment and endoscopic subscore), rate of endoscopic improvement, clinical response rate,
as well as <FONT STYLE="white-space:nowrap">miR-124</FONT> expression in the rectal tissue of the patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Additional <FONT STYLE="white-space:nowrap">Follow-Up</FONT> Data from Long Term
Extension Portion of Phase 2a Clinical Trial with Obefazimod for the Treatment of Moderately to Severely Active UC </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the long-term
extension, the primary objective was long term safety of obefazimod. Additional efficacy endpoints included clinical and endoscopic rates of response and remission. Overall, 32 patients were enrolled in the induction phase, 23 patients were
randomized to obefazimod, and nine patients were randomized to placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the 29 patients who completed the induction phase (20 patients
for obefazimod and nine patients for placebo), 22 patients continued their treatment into the long-term extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2019, we
announced the <FONT STYLE="white-space:nowrap">12-month</FONT> data from this Phase 2a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial. This open-label maintenance trial was conducted in 22
patients, of which 19 completed the first year of treatment. At 12&nbsp;months, an endoscopy was performed in 16 of the 19 patients to evaluate the rate of clinical remission, and 12 of the 16 evaluable patients (75%) were observed to achieve
clinical remission. Obefazimod was also observed to maintain overexpression of <FONT STYLE="white-space:nowrap">miR-124</FONT> throughout the 12 months of the trial. At month&nbsp;12, mean change in Mayo Score was observed at -2.6 points compared to
the maintenance baseline. Median fecal calprotectin decreased from 153.1&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g/g (baseline) to 27.9&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g/g and
31.6&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g/g at week&nbsp;52 and month&nbsp;24, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table depicts
secondary efficacy endpoints of our Phase&nbsp;2a clinical trial with obefazimod in moderately to severely active UC at 24 and 48 months: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00a15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2b Clinical Trial with Obefazimod for the Treatment of UC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Induction Phase 2b Clinical Trial with Obefazimod for the Treatment of UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The induction Phase 2b clinical trial for the treatment of moderately to severely active UC, was conducted in 252 patients enrolled at 130
trial sites across 15 European countries, Canada and the United States. It was completed in April 2021. The trial was a randomized, double-blind and placebo-controlled <FONT STYLE="white-space:nowrap">16-week</FONT> induction trial involving four
treatment groups (receiving an oral once-daily 25 mg, 50 mg or 100 mg dose of obefazimod or placebo). Endoscopies were read centrally and blinded, by independent reviewers. Electronic patient diaries were used to enhance the reliability of the
collection of stool frequency, rectal bleedings, and other patient reported outcomes- all efficacy endpoints were set according to FDA guidance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts the design of our Phase 2b clinical trial with obefazimod in
moderately to severely active UC: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00m62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between August&nbsp;13, 2019 and April&nbsp;16, 2021, 252 patients were randomly allocated to obefazimod
100 mg (n=64), obefazimod 50 mg (n=63), obefazimod 25 mg (n=61), or placebo (n=64). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Baseline characteristics were well-balanced among the
treatment groups, indicating a moderately to severely active UC population. At screening, 49% of patients had an inadequate response, loss of response, or intolerance to TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors, vedolizumab,
other biologics and/or JAK inhibitors treatments, while the other patients were refractory to conventional treatments only. Enrolled patients suffered from longstanding UC with an overall mean disease duration of 8.05 years and 71% of the patients
had a severe disease profile (baseline Modified Mayo Score of 7 to 9 points). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table depicts the baseline characteristics of
our Phase 2b clinical trial: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g00m61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Primary Endpoints of Induction Phase 2b Clinical Trial with Obefazimod for the Treatment of UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Modified Mayo Score</U>: In the full analysis set (&#147;FAS&#148;), corresponding to an ITT analysis, the primary endpoint was met at week
8 (statistically significant reduction of Modified Mayo Score) with <FONT STYLE="white-space:nowrap">-2.9</FONT> (95% CI <FONT STYLE="white-space:nowrap">-3.4</FONT> to <FONT STYLE="white-space:nowrap">-2.5)</FONT> for the obefazimod 100 mg group, <FONT
STYLE="white-space:nowrap">-3.2</FONT> <FONT STYLE="white-space:nowrap">(-3.7</FONT> to <FONT STYLE="white-space:nowrap">-2.7)</FONT> for the obefazimod 50 mg group, <FONT STYLE="white-space:nowrap">-3.1</FONT>
<FONT STYLE="white-space:nowrap">(-3.6</FONT> to <FONT STYLE="white-space:nowrap">-2.6)</FONT> for the obefazimod 25 mg group, and <FONT STYLE="white-space:nowrap">-1.9</FONT> <FONT STYLE="white-space:nowrap">(-2.4</FONT> to <FONT
STYLE="white-space:nowrap">-1.5)</FONT> for placebo group. The magnitude of the difference in Modified Mayo Score from baseline was significantly greater in all three obefazimod groups compared with placebo (p=0.0039 for obefazimod 100 mg vs
placebo, p=0.0003 for obefazimod 50 mg vs placebo, and p=0.0010 for obefazimod 25 mg vs placebo). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Clinical Response, Clinical Remission and Endoscopic Improvement</U>: Furthermore,
rates of clinical response and clinical remission at week 8 in the FAS were higher in the three obefazimod dosage groups than with placebo. The subgroup of patients who were refractory to one or more second line therapies showed results that were
consistent with the overall analysis for clinical response and clinical remission at week 8. Rates of endoscopic improvement at week 8 were also higher in the obefazimod dosage groups than in the placebo group in the FAS. Change in fecal
calprotectin from baseline in the FAS was greater in all obefazimod groups than with placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables depict clinical
outcomes at week 8 of double-blind treatment: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g64a10.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g64b20.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Modified Mayo Score (MMS) is the sum of assessment
scores <FONT STYLE="white-space:nowrap">(0-3)</FONT> of mucosal appearance at endoscopy, stool frequency and rectal bleeding. Clinical remission is defined as patient rate of MMS stool frequency subscore of &#8804;1; Clinical response is defined as
patient rate of decrease from baseline in MMS &#8805;2 points and &#8805;30&nbsp;percent from baseline, plus a decrease in rectal bleeding subscore &#8805;1 or an absolute rectal bleeding subscore &#8804;1; Endoscopic improvement is defined as
patient rate of endoscopic subscore &#8804;1 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">P value is based on nonparametric ANCOVA using the ranked data. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Maintenance Phase 2b Clinical Trial with Obefazimod for the Treatment of UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the 222 patients who completed the <FONT STYLE="white-space:nowrap">16-week</FONT> Phase 2b induction trial, 217 patients (98%) enrolled in
the subsequent open-label maintenance trial to evaluate the induction Phase 2b clinical trial long-term safety and efficacy profile of obefazimod for up to two years, irrespective of treatments or treatment outcome during the induction phase. Of
those patients who received a 50 mg once-daily oral dosing with obefazimod, 178 patients (82%) had a clinical response relative to induction baseline, of which 119 patients (55%) were in clinical remission, 133 patients (61%) had an endoscopic
improvement, and 72 patients (33%) had an endoscopic remission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, at week 48, 38 patients were in sustained clinical remission and 107 patients
showed sustained clinical response. A total of 71 patients exhibited de novo clinical response and 81 patients exhibited de novo clinical remission. Among the 98 bio-refractory patients, 66 patients (67%) had a clinical response, 38 patients (39%)
were in clinical remission, 46 patients (47%) had an endoscopy improvement and 20 patients (20%) had an endoscopy remission at week 96. These results demonstrate the long-term clinical response of obefazimod in patients who were refractory to
conventional treatments, as well as patients who were previously exposed to biologics and/or JAK inhibitors treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
chart depicts clinical results of our long-term extension Phase 2b clinical trial at weeks 48 and 96: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g67a67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Sustained clinical remission/response or endoscopic remission/improvement means a clinical remission or clinical response
or endoscopic remission or endoscopic improvement in the subpopulation of patients <U>with clinical remission or clinical response or endoscopic remission or endoscopic improvement at maintenance trial entry (i.e., at week 8 of induction trial).
</U></I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>De novo clinical remission/response or endoscopic remission/improvement means a clinical remission or clinical response or endoscopic remission
or endoscopic improvement in the subpopulation of patients <U>without</U> clinical remission or clinical response or endoscopic remission or endoscopic improvement at maintenance trial entry (i.e. at week 8 of induction trial). </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>* For week 48, with respect to six subjects, endoscopic data were missing at week 8 of the induction trial and were not included in this analysis. </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>* For week 96, drop outs were considered as treatment failures in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> analysis (30 patients dropped out during the first year; six patients did not qualify for the second year of treatment due to <FONT
STYLE="white-space:nowrap">non-response</FONT> after the first year and 17 patients dropped out during the second year). </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At week 96,
of the patients who continued treatment with 50 mg once-daily oral obefazimod, 33 patients (67%) remained in clinical remission. Of the 168 patients who were not in clinical remission at the end of the induction phase, 81 patients (48%) exhibited de
novo clinical remission. Furthermore, the clinical remission rate for patients who did not show at least a clinical response at the end of the <FONT STYLE="white-space:nowrap">8-week</FONT> induction phase was 43% (40 patients). Of the patients
included in the maintenance trial, 164 patients (75%) completed two years of once-daily oral dosing with 50 mg obefazimod. 30 patients dropped out during the first year of treatment. Six patients did not qualify for the second year due to <FONT
STYLE="white-space:nowrap">non-response</FONT> after the first year of treatment, and 17 patients dropped out during the second year. These patients were all considered as treatment failures in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the induction and the maintenance treatments of the Phase 2b
clinical trial, the safety and tolerability profile observed was consistent with previous findings and no new adverse safety signals were observed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&nbsp;30, 2022 (the last safety data <FONT STYLE="white-space:nowrap">cut-off</FONT> date), 1,074 patients and volunteers had
been treated with obefazimod, of which 209 patients were treated with 50 mg obefazimod for one year or more with no change in the observed tolerability profile. At present, no increased rate of opportunistic infections or malignancies compared with
placebo have been observed across all clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 3 Clinical Trials and Regulatory Pathway in UC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are working with IQVIA, a global premier contract research organization, to conduct the Phase 3 clinical trials with obefazimod in
moderately to severely active UC, following consultations with regulatory agencies, including FDA, EMA, CDE and PMDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These pivotal Phase
3 clinical trials consist of two induction trials <FONT STYLE="white-space:nowrap">(ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2)</FONT> and the subsequent ABTECT maintenance trial investigating obefazimod at doses of 25 mg and 50
mg across 36&nbsp;countries in North America, Latin America, Europe and Asia Pacific, involving 1,200 moderately to severely active UC patients in over 600 sites. Each of the trials will be randomized, double-blind and placebo-controlled, using
independent and central review of the video-taped endoscopies with the primary endpoint of clinical remission according to the Modified Mayo Score assessed at week 8 (induction) and at week 44 (maintenance), as recommended by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Modified Mayo Score evaluates UC stage, based on three parameters: stool frequency, rectal bleeding, and endoscopic evaluation. Each
parameter of the score ranges from zero (normal or inactive disease) to three (severe activity). The patient rates stool frequency score (&#147;SFS&#148;) and rectal bleeding score (&#147;RBS&#148;) daily. The endoscopy subscore is evaluated by a
central reader (who is blinded to any clinical information about the patient) from an endoscopy that is performed at the trial site. The inclusion criteria based on FDA guidance for moderately to severely active UC is active disease defined by a
Modified Mayo Score &#8805; 5 with (RBS) &#8805; 1 and endoscopy subscore of 2 or 3 (confirmed by central reader). The primary endpoint for induction and maintenance is clinical remission defined as SFS of 0 or 1 and no greater than baseline and RBS
= 0 and endoscopy subscore of 0 or 1. At week 8, secondary endpoints include endoscopic improvement, clinical response symptomatic remission and histologic-endoscopic mucosal improvement (&#147;HEMI&#148;). At week 44, secondary endpoints include
endoscopic improvement, symptomatic remission, corticosteroid-free clinical remission, sustained clinical remission, HEMI and endoscopic remission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts the design of our Phase 3 clinical trial with obefazimod in moderately to severely active UC: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g01b19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enrollment of the first patient under this program in the United States occurred on October&nbsp;11, 2022. <FONT
STYLE="white-space:nowrap">Top-line</FONT> data from the <FONT STYLE="white-space:nowrap">ABTECT-1</FONT> and <FONT STYLE="white-space:nowrap">ABTECT-2</FONT> induction trials is expected to be announced by the first quarter of 2025, and <FONT
STYLE="white-space:nowrap">top-line</FONT> data from the ABTECT maintenance trial is expected to be announced by the first quarter of 2026. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts our recently completed and expected upcoming milestones for
our Phase 3 clinical trials of obefazimod for moderately to severely active UC: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g39i77.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional Clinical Trials Completed with
Obefazimod </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, four Phase 1 clinical trials have recently been completed to assess the tolerability and safety profile of
obefazimod: (i)&nbsp;a Phase 1 heart rhythm (QT interval) trial, for which we enrolled 120 healthy volunteers; (ii)&nbsp;a Phase 1 clinical trial of drug-drug interactions, for the purposes of providing further information on any possible
interactions of obefazimod with other drugs, for which we enrolled 60 healthy volunteers; (iii)&nbsp;a Phase 1 absorption, distribution, metabolism and excretion trial for the purposes of generating additional data to further evaluate the safety
profile of obefazimod, for which we enrolled 12 healthy volunteers; and (iv)&nbsp;a Phase 1 clinical trial conducted in Japanese subjects to further evaluate pharmacokinetics and tolerability of obefazimod in this population, for which we enrolled
48 healthy volunteers. The results of these Phase 1 clinical trials provide supportive data for our further clinical development and New Drug Application (&#147;NDA&#148;) submission. Furthermore, additional Phase 1 clinical trials to support NDA
submission are planned. While we have decided not to pursue additional clinical work in RA at this point, we have completed a Phase 2a clinical trial in patients with RA, where we saw encouraging <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data supporting obefazimod&#146;s potential role in addressing inflammatory conditions beyond IBD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Obefazimod in CD </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CD Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CD is a chronic inflammatory condition that can affect the GI tract from mouth to anus but typically affects the colon and last section of the
ileum (terminal ileum). Although considered in the same category of IBD as UC, the inflammation occurs across the bowel wall which leads to different complications including stricture and fistula formation. CD affects about 3.2 per 1,000 people in
Europe, North America&nbsp;and the United Kingdom. Collectively, we estimate there are approximately 1.1&nbsp;million CD patients in G7 countries. Of these patients, approximately 0.5&nbsp;million patients (or approximately 56%) are estimated to be
diagnosed with moderately to severely active CD, with approximately 0.6&nbsp;million patients (or approximately 44%) diagnosed with mildly to moderately active CD.&nbsp;While this disease is diagnosed at any age, onset is more common among
adolescents and young adults.&nbsp;Patients typically present with abdominal pain, diarrhea, fatigue and weight loss.&nbsp;In cases of bowel obstruction, patients will also experience bloating and vomiting.&nbsp;The likelihood of having surgery
mostly due to bowel obstruction within the lifetime of a CD patient is approximately 80%.&nbsp;Besides bowel complications, patients can experience extra-intestinal manifestations (&#147;EIMs&#148;), which impact the skin, eye and joints
primarily.&nbsp;The prevalence rate of EIMs is approximately 24% in all IBD patients, 27% in UC patients, but as high as 35% in CD patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing Therapies and Their Limitations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to existing UC treatments, patients may receive oral immunosuppressants, such as azathioprine and methotrexate as well as short courses
of corticosteroids.&nbsp;In cases of moderately to severely active CD, the options for advanced therapy include very commonly prescribed TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors, anti-integrin antibodies, <FONT
STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors, <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors and JAK inhibitors.&nbsp;Therapies such as <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>
inhibitors, <FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors or <FONT STYLE="white-space:nowrap">IL-23</FONT> inhibitors are injectable agents, representing a significant commercial disadvantage due to patients&#146; and prescribers&#146;
preference for the convenience of oral therapies.&nbsp;JAK inhibitors are often accompanied by safety warnings due to increased risk of adverse events such as infection, cancer or blood clots. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Induction remission rates for these existing therapies vary from 8% to 16% and maintenance remission rates often decrease over time. There
remains unmet needs for more effective and durable therapy, including those with more convenient delivery methods (as there are no approved oral therapies for first-line use), durable efficacy, treatment of biologic failures, improved mucosal
healing, improved treatment for fistulizing CD and improved corticosteroid free remission. We believe obefazimod&#146;s differentiated clinical profile, including dosing as a once-daily, oral therapy as well as its demonstrated tolerability and
durability to date, position it favorably as an early-line treatment option for patients and prescribers, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Market Opportunity: CD
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated market opportunity for CD was approximately $16.3&nbsp;billion in worldwide sales in 2022 and is expected to reach
$16.6&nbsp;billion in worldwide sales in 2028. In 2022, approximately $11.4&nbsp;billion of sales came from the United States and all moderately to severely active CD sales came exclusively from injectable products. Similar to the UC market, we
believe oral agents represent a significant commercial opportunity, particularly if such therapeutics can provide long-term safety and efficacy profiles comparable to injectable agents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proposed Obefazimod CD Development Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the pathophysiological and clinical similarities of CD and UC, we plan to initiate a Phase 2a clinical trial in patients with CD to
potentially demonstrate outcomes consistent with those observed in our Phase 2 clinical trials for moderately to severely active UC. We believe the preclinical and Phase 1 data generated in our UC clinical trials are sufficient for completion of
these equivalent trials in CD. We intend to file an IND in the fourth quarter of 2023 and plan to initiate a Phase 2 clinical trial in patients with CD in the first quarter of 2024 with the objective to demonstrate clinical response and tolerability
profile consistent with that already observed in our clinical trials for moderately to severely active UC. Based on the results from this Phase 2 clinical trial, we intend to proceed directly to a Phase 3 clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Combination Therapy for the Treatment of IBD with Obefazimod as the Cornerstone </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the development of various advanced targeted therapies for IBD over the past 20 years, a single agent with transformational efficacy
remains elusive. Although cross-trial efficacy comparisons must be interpreted with caution, induction of clinical remission rates have currently reached a placebo-adjusted therapeutic ceiling up to 30%. Improved efficacy of combination therapy with
thiopurines and TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors has been well described (SONIC and <FONT STYLE="white-space:nowrap">UC-SUCCESS)</FONT> but did not breach the aforementioned efficacy ceiling. Emerging data utilizing dual
advanced targeted therapy affecting complementary mechanisms of action indicate a potential path to higher efficacy rates. The first trial utilizing this strategy (VEGA) randomized patients to three parallel treatment groups: (1) dual combination
therapy with guselkumab <FONT STYLE="white-space:nowrap">(IL-23</FONT> inhibitor) plus golimumab (TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor); (2) guselkumab alone; or (3)&nbsp;golimumab alone. At the end of the <FONT
STYLE="white-space:nowrap">12-week</FONT> induction period, a greater proportion of patients randomized to dual combination therapy achieved clinical remission (approximately 47%) compared to either monotherapy treatment arms (guselkumab at
approximately 25%; golimumab at approximately 24%). Importantly, adverse events, serious adverse events and infection rates were comparable among treatment groups. </P>  <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe synergistic improvements that may be achieved with advanced combination
therapy should be balanced with patient adherence to multiple biologic injections and safety considerations associated with immune suppression. Several of obefazimod&#146;s attributes make it a potentially attractive candidate to pair with other
advanced treatments. First, the oral route of administration is preferred by a majority of patients, potentially resulting in higher levels of medication adherence. Further, obefazimod&#146;s proposed mechanism of action harnesses the body&#146;s
natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The unique mechanism of action of obefazimod potentially lends itself as complementary to be combined with other oral agents with the
potential of improving the induction and remission efficacy over monotherapy. We believe the current clinical results we have observed with obefazimod including a lack of signals for malignancy, opportunistic, or serious infection risk up to 96
weeks of treatment support development as an agent to be used in potential combination therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Follow-On</FONT>
Compounds Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the mechanistic concept of obefazimod, a research and development program is currently ongoing to generate
new potential drug candidates to strengthen our intellectual property portfolio on the <FONT STYLE="white-space:nowrap">miR-124</FONT> platform. The first <FONT STYLE="white-space:nowrap">follow-on</FONT> drug candidate is expected to be selected
and enter preclinical development in 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obefazimod </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead compound,
obefazimod, is manufactured using commercially available, widely used raw materials and common chemical engineering and synthetic processes. Obefazimod is formulated as an oral solid capsule. We have successfully
<FONT STYLE="white-space:nowrap">scaled-up</FONT> active pharmaceutical ingredients and drug product processes, and we have a large supply of active pharmaceutical ingredients and capsules available for clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We outsource all manufacturing operations and rely on European third-party contract manufacturing organizations (&#147;CMOs&#148;) to supply
clinical trials and finalize the development of obefazimod. These operations are designed to be in compliance with the standards imposed by Good Manufacturing Practice (&#147;GMP&#148;). We believe our outsourcing strategy and internal organization
allow us to focus our resources on the development of different drug candidates and the management of third parties, without investing in expensive manufacturing facilities and equipment. All third parties are assessed under our quality system and
agreements are in place to compel compliance and we maintain agreements with manufacturers which include confidentiality and intellectual property provisions to protect proprietary rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of further optimizing and scaling up our supply chain for obefazimod to ensure capacity for our expected commercial
supply, if the FDA or foreign regulatory authority approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our incorporation in 2013, the majority of our resources have been allocated to research and development activities. We are conducting
development activities to expand the commercial potential of our drug candidates, in particular obefazimod. In the years ended December&nbsp;31, 2021 and 2022, we incurred &#128;47.8&nbsp;million and &#128;48.3&nbsp;million, respectively, of
research and development expenses, or 89.5% and 69.6% respectively, of our total operating expenses. Our research and development expenses consist primarily of the following items: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel expenses, including salaries, benefits, and share-based compensation expenses, for employees engaged in
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">sub-contracting,</FONT> collaboration and consultant expenses that primarily
include the cost of third-party contractors such as CROs who conduct our preclinical studies and clinical trials, and research related to our proprietary platforms, as well as investigative sites and consultants that conduct our preclinical studies
and clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with CMOs, including manufacturing
<FONT STYLE="white-space:nowrap">scale-up</FONT> expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to regulatory affairs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to the implementation of our quality assurance system. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, our total operating expenses were &#128;69.4&nbsp;million, as compared to &#128;53.4&nbsp;million
for the year ended December&nbsp;31, 2021, an increase of &#128;16.1&nbsp;million, or 30%. This increase was primarily due to an increase in goodwill impairment loss and in general and administrative expenses while research and development expenses
remained at a consistent level. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compete with companies that have drugs on the market or are developing drug candidates for chronic inflammatory disease. The biotechnology
and pharmaceutical industries are highly competitive and subject to significant and rapid technological change, as researchers learn more about chronic inflammatory diseases and develop new technologies and treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant competitive factors in our industry include: (i)&nbsp;product efficacy and safety; (ii)&nbsp;quality and breadth of an
organization&#146;s technology; (iii)&nbsp;skill of an organization&#146;s employees and its ability to recruit and retain key employees; (iv)&nbsp;timing and scope of regulatory approvals; (v)&nbsp;government reimbursement rates for, and the
average selling price of, pharmaceutical products; (vi)&nbsp;the availability of raw materials and qualified manufacturing capacity; (vii)&nbsp;manufacturing costs; intellectual property and patent rights and their protection; and (viii)&nbsp;sales
and marketing capabilities. Given the intense competition in our industry, we cannot assure you that even if we are able to successfully develop any products, that they will have a higher benefit-risk profile or better cost effectiveness compared to
products developed or introduced by our competitors. Our competitors in the chronic inflammatory disease field are primarily large pharmaceuticals companies including, but not limited to, AbbVie, Pfizer, Eli Lilly, Takeda and Johnson&nbsp;&amp;
Johnson. Several lines of research are being developed to improve the treatment of IBD. Many companies are working to develop new, more effective and better tolerated treatments with more practical formulations, especially small molecules
administered orally, better accepted than monoclonal antibodies that require administration by injection or intravenous infusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
molecules in development have various mechanisms of action and are primarily: (i)&nbsp;TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors; <FONT STYLE="white-space:nowrap">(ii)&nbsp;IL-12/23</FONT> inhibitors; (iii)&nbsp;anti-integrin
anti-bodies; <FONT STYLE="white-space:nowrap">(iv)&nbsp;IL-23</FONT> inhibitors; (v)&nbsp;JAK inhibitors; (vi)&nbsp;S1P receptor agonists; or (vii)&nbsp;TL1A inhibitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> treatment class, Remicade<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
(Janssen) was first approved by the FDA in 1998. In 2012, the European Commission approved AbbVie&#146;s Humira<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> for the treatment of pediatric patients aged six to 17 years with severe active
CD who have an inadequate response, are intolerant or have contraindications to conventional therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IL-12/23</FONT> inhibitors entered the UC market in 2019 as ustekinumab (Johnson&nbsp;&amp; Johnson&#146;s
Stelara<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>). In 2021, AbbVie filed an authorization application with FDA and EMA for Risankizumab
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Anti-IL-23&#151;Skyrizi</FONT></FONT><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) for the treatment of moderately to severely active CD and a Phase 3 clinical trial in
patients with UC is underway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Etrolizumab, a selective
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-alpha-4/beta-7</FONT></FONT> monoclonal antibody developed by Roche/Genentech, recently failed in Phase 3 for CD after failing in Phase 3 in UC in 2020. The anti-integrin class
is currently represented by vedolizumab/Entyvio<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and natalizumab/Tysabri<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. We are also aware of Morphic Therapeutic&#146;s <FONT
STYLE="white-space:nowrap">MORF-057</FONT> and Protagonist Therapeutics/Johnson&nbsp;&amp; Johnson&#146;s <FONT STYLE="white-space:nowrap">PN-943</FONT> currently in development. The anti-integrin drugs work
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by preventing the leukocytes to move from the blood vessels to sites of inflammation. They block the action of integrin on the surface of circulating immune cells and endothelial cell adhesion
molecules, thereby inhibiting the interactions between leukocytes and intestinal blood vessels. Natalizumab and vedolizumab block <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><FONT STYLE="white-space:nowrap">4-integrin</FONT> and <FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><FONT STYLE="white-space:nowrap">4&szlig;7-integrin</FONT> respectively. These drugs are injectable (Humanized mAb). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, Eli Lilly reported that mirikizumab <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Anti-IL-23)</FONT></FONT>
generated data in a Phase 3 maintenance trial in patients with UC that led to the submission of an authorization request to regulatory agencies. Phase 3 clinical trials in CD are also underway with mirikizumab. All these drugs are injectable
(Humanized mAb). <FONT STYLE="white-space:nowrap">IL-23</FONT> is a regulator of <FONT STYLE="white-space:nowrap">T-helper</FONT> <FONT STYLE="white-space:nowrap">(Th)-17</FONT> cell. <FONT STYLE="white-space:nowrap">IL-23</FONT> prevents regulatory
<FONT STYLE="white-space:nowrap">T-cell</FONT> response in the intestine, and therefore increases inflammation in the gut. Anti-interleukins targeting the <FONT STYLE="white-space:nowrap">IL-23</FONT> have been shown to be effective for induction
and maintenance of remission in patients with moderate-severe UC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JAK correspond to four intracellular tyrosine kinases: JAK1, JAK2,
JAK3 and tyrosine kinase 2. Inhibition of the <FONT STYLE="white-space:nowrap">JAK-STAT</FONT> signal channel makes it possible to block the production of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines, including <FONT
STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, to block other pathways of inflammation and to regulate innate and adaptive immunity. Thus, several cytokines and several inflammation pathways are blocked
simultaneously, unlike <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitors, which only have a single target. In September 2021, FDA published a black box warning, requiring pharmaceutical companies
to provide a warning for increased risk of serious cardiac events, cancer, blood clots and death linked to JAK inhibitor treatments used for the treatment of certain IBD, including UC. Consequently, these treatments are only accessible to patients
who do not respond to any other available treatment and who have certain well-defined conditions. In the JAK inhibitor class, to our knowledge the following products are authorized or in advanced development: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pfizer&#146;s tofacitinib (Xeljanz<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) is a <FONT
STYLE="white-space:nowrap">non-selective</FONT> JAK inhibitor. It obtained marketing approval in UC in June 2018. In September 2021, the FDA concluded that there was a high risk of serious side effects following a randomized clinical trial conducted
to assess the safety of tofacitinib. Consequently, the molecule will be used as a third line treatment in patients who meet specific criteria. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gilead and Galapagos&#146; filgotinib (Jyseleca<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) is a
selective JAK1 inhibitor. Since November 2021, filgotinib has been approved for the treatment of UC in the European Union (the &#147;EU&#148;). Authorization requests have also been submitted to the UK Medicines and Healthcare products Regulatory
Agency (&#147;MHRA&#148;) and the Japanese PMDA for the treatment of moderately to severely active UC. A Phase 3 clinical trial in patients with CD is also underway. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AbbVie&#146;s upadacitinib (Rinvoq<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), which is also a
selective JAK1 inhibitor, was approved by the FDA in March 2022 for the treatment of moderately to severely active UC. EMA authorization for the treatment of moderately to severely active UC was granted in July 2022. A Phase 3 clinical trial in
patients with CD is currently underway. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">S1P receptor agonists allow sequestration of activated lymphocytes in lymph
nodes and thus reduce their circulation in the GI tract. Ozanimod (Zeposia<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) is a S1P receptor modulator that is selective for the S1P1 and S1P5 receptors. It was approved by the FDA and EMA
for the treatment of moderately to severely active UC in 2021. Phase 3 clinical trials are currently being conducted to assess the efficacy of ozanimod in CD. <FONT STYLE="white-space:nowrap">Top-line</FONT> results of a Phase 3 induction trial of
ARENA Pharmaceuticals&#146; Etrasimod for the treatment of UC were announced in March 2022 and the primary endpoint, as well as the key secondary endpoints were reached; a Phase 2/3 clinical trial is currently being conducted in CD. In addition, in
June 2023, Ventyx Biosciences announced completion of enrollment of its Phase 2 clinical trial of VTX002 in UC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also aware of
other types of treatments currently under various stages of development, such as NImmune Biopharma&#146;s omilancor (a Lanthionine Synthetase <FONT STYLE="white-space:nowrap">C-Like</FONT> 2 activator) as well as tyrosine kinase 2 inhibitors from
Bristol Myers Squibb&#146;s Sotyktu (deucravacitinib &#150; approved in the EU) and Ventyx Biosciences&#146; VTX 958. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, TL1A inhibitors have garnered interest from those seeking newer targets and
agents with differentiated clinical profile. While PRA023 (Merck-Prometheus) and <FONT STYLE="white-space:nowrap">RVT-3101</FONT> <FONT STYLE="white-space:nowrap">(Pfizer-Roivant)</FONT> have generated promising early Phase 2 data in both
biologics-experienced and <FONT STYLE="white-space:nowrap">biologics-na&iuml;ve</FONT> patients, neither have initiated Phase 3 clinical trials and do not have long-term safety and efficacy data beyond 56 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may also succeed in obtaining European Commission, FDA or other regulatory approvals for their drug candidates more rapidly
than us, which could place us at a significant competitive disadvantage. Market acceptance of our drug candidates will depend on a number of factors, including: (i)&nbsp;potential advantages over existing or alternative therapies or tests;
(ii)&nbsp;the actual or perceived safety of similar classes of products; (iii)&nbsp;the effectiveness of our sales, marketing, and distribution capabilities; and (iv)&nbsp;the scope of any approval provided by the FDA or foreign regulatory
authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we will face intense and increasing competition as new drugs and therapies enter the market and advanced
technologies become available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies operating in the pharmaceutical industry are subject to increased scrutiny by the competent authorities and must deal with an
ever-changing and increasingly restrictive legal and regulatory environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of drugs involves several stages: research
and development, preclinical tests, clinical trials, authorization, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of these stages are subject
to specific requirements that impose substantial and onerous constraints, compliance with which is ensured by various national, regional (in the EU, the EMA) or federal (in the United States, the FDA) authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with these regulations may be subject to fines, to the suspension or withdrawal of the authorizations and certifications
required to perform pharmaceutical activities, to the seizure or withdrawal of products from the market, or to partial or total suspension of their manufacturing. Regulatory authorities may also withdraw marketing authorizations (&#147;MAs&#148;)
previously granted or reject MA applications (&#147;MAAs&#148;) and initiate legal proceedings, and their outcome remains uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the regulatory constraints may differ from a country to another, development of therapeutic products for human use must comply with
requirements shared by all developed countries. The steps to be completed before obtaining an MA in the EU and in the United States are generally as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct of preclinical laboratory tests and studies in animals, in accordance with Good Laboratory Practice
(&#147;GLP&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct of clinical trials in humans to demonstrate the safety and efficacy of the product for each considered
indication, in accordance with Good Clinical Practice (&#147;GCP&#148;), if necessary after authorization by a competent authority and an ethics committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission of an MAA to the competent authority, in order to market the product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inspection by the competent authority of the manufacturing facilities in which the product and/or its ingredients
are manufactured to assess compliance with Good Manufacturing Practices (&#147;GMP&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inspection by the competent authority of establishments distributing medicinal products in order to assess their
compliance with Good Distribution Practice (&#147;GDP&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if needed, commitment by the applicant to comply with <FONT STYLE="white-space:nowrap">post-MA</FONT>
requirements. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to these regulatory constraints, the development and approval process of a drug candidate for
commercialization, which varies according to its nature, complexity and novelty, usually extends over several years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EU Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within all EU Member
States, preclinical studies include laboratory evaluation of the composition, purity and stability of the active pharmaceutical ingredient and the formulated product, as well as studies to evaluate the tolerance (toxicological studies), activity and
behavior of the product candidate in vitro and in animals (in vivo). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conduct of preclinical studies is subject to legal and
regulatory provisions. <FONT STYLE="white-space:nowrap">Non-clinical</FONT> studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. <FONT STYLE="white-space:nowrap">Non-clinical</FONT>
(pharmaco-toxicological) studies must be conducted in compliance with GLP, as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products &#150; e.g., radio-pharmaceutical precursors for radio-labelling
purposes). In particular, <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of
rules and criteria for a quality system for the organizational process and the conditions for <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies. These GLP standards reflect the Organization for Economic
<FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies are a prerequisite for the
initiation of clinical trials in humans: all the results of these trials are submitted to the regulatory authorities at the same time as the application to initiate clinical trials. However, while preclinical tests must be performed prior to
conducting clinical trials in humans, certain long-term preclinical tests, such as tests on reproductive toxicity and carcinogenicity, may continue after the submission of an application to initiate clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trials in Humans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The various
phases of clinical trials in the EU are subject to significant regulatory controls. They must be conducted in accordance with EU and national regulations, the standards adopted by the International Conference on Harmonization (&#147;ICH&#148;) and
GCP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directive no. 2001/20/EC on the conduct of clinical trials sought to harmonize the regulatory framework for clinical trials in the
EU, setting out common rules for the monitoring and authorization of clinical trials in the EU. To reduce disparities between the transpositions by the Member States, Regulation 536/2014 on clinical trials on medicinal products for human use and
repealing Directive 2001/20/EC, was adopted on April&nbsp;16, 2014. This regulation aims to further harmonize and streamline the clinical trial authorization process, simplify adverse event reporting procedures, improve the supervision of clinical
trials, and increase the transparency of clinical trials. This regulation became applicable on January&nbsp;31, 2022. However, it provides for a three-year transition period (i.e., clinical trials for which an application was submitted in accordance
with Directive no. 2001/20/EC before January&nbsp;31, 2022, will continue to be subject to the Directive provisions for a period of three years). Furthermore, sponsors having submitted a clinical trial under the Directive until January&nbsp;31, 2023
may remain governed by the Directive until January&nbsp;31, 2025. By that date, all ongoing trials will become fully subject to the provisions of the Regulation 536/2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the clinical trials regulation, the sponsor may submit its application for a clinical trial authorization to one or several Member
States, in which case the evaluation of Part I of the dossier (scientific part) is carried out according to a coordinated procedure. In this framework, the sponsor must submit a single application for authorization via the portal associated with the
EU database (&#147;CTIS&#148;), comprising a common scientific part evaluated jointly by all the EU Member States in which the trial will be carried out (with one of the Member States concerned acting as rapporteur Member State) and a national part
covering the ethical aspects of the trial, evaluated independently by each Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conclusion of the rapporteur Member State
with regard to Part I of the assessment report is deemed to be the conclusion of all Member States concerned. However, the Member States concerned may disagree with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this conclusion for a number of limited reasons, for example when they consider that participation in the clinical trial would lead to a subject receiving a treatment inferior to that of normal
clinical practice on their territory. The Member State concerned may then refuse the clinical trial on its territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
&#147;single&#148; decision covering the conclusions of the Part I and Part II evaluations is issued by each of the Member States concerned and is notified to the sponsor on the dedicated European portal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sponsor of a clinical trial conducted in the EU notifies through the EudraVigilance database without delay and at the latest within the
deadlines set by the clinical trials regulation, of all relevant information on suspected serious and unexpected adverse reactions to the investigational medicinal product. If the competent bodies concerned consider that the adverse effects outweigh
the benefits for the participants, they may require the immediate suspension or early termination of the trial at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
the sponsor must submit through CTIS once a year, for the duration of the clinical trial, an Annual Safety Report (ASR) for each investigational drug used in the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, the EU framework applicable to clinical trials has also been significantly strengthened with Regulation (EU) 2016/679 of the European
Parliament and of the Council of April&nbsp;27, 2016, on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation,
&#147;GDPR&#148;), which entered into force on May&nbsp;25, 2018. This regulation has significantly increased EU citizens&#146; rights by giving them more control over their personal data. Thus, depending on the type of personal data processing
carried out during clinical trials and the nature of such trials, it might be necessary to carry out formalities by the local Data Protection Authority, in addition to seeking formal informed consent which must be obtained from each clinical trial
subject. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Responsibility of the Sponsor and Insurance Obligation of the Sponsor </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, the sponsor shall indemnify the subject of the trial in case of damage arising as a consequence of the research, unless he proves
that the damage does not result from his fault or the fault of any other person intervening in the trial. In the EU, Member States generally require a sponsor to have an insurance covering its civil liability and the liability of any person
intervening in the research. In addition, any breach to the provisions concerning clinical trials may lead to significant administrative, criminal and/or reputational penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within the EU,
marketing of medicinal products is governed by EU regulations (including but not limited to Directive 2001/83/EC and Regulation 726/2004/EU). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2023, the European Commission issued proposals for a revision of the current legal framework. Although the proposal is
subject to adoption by EU institutions, which become effective upon adoption, this new framework, which in particular aims at granting timely access to patients for safe, effective and affordable medicines and at enhancing supply of medicines, may
significantly amend general principles described above, notably timelines and market exclusivity periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, medicinal product
candidates can only be commercialized after obtaining an MA. To obtain regulatory approval of a product candidate under EU regulatory systems, we must submit an MAA. The process for doing this depends, among other things, on the nature of the
medicinal product. There are two types of MAs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Centralized MAs&#148; are granted by the European Commission through the centralized procedure based on the
opinion of the Committee for Medicinal Products for Human Use (&#147;CHMP&#148;) of the EMA. The MA issued under this procedure is valid in all EU Member States. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The centralized procedure is compulsory for some types of medicinal products such as biotechnology products,
designated orphan medicinal products, products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes or autoimmune and viral diseases, advanced therapy medicinal products (such as gene
therapy, somatic cell therapy and tissue engineered products). The centralized procedure is optional for products containing a new active substance that has not yet been authorized in the EU or for products which present a significant therapeutic,
scientific or technical innovation or are of interest for the public health in the EU. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;National MAs&#148; are issued at a national level by the competent authorities of the concerned Member
States. They are valid only on their territory. National MAs can be issued for products that do not fall within the mandatory scope of the centralized procedure. Medicinal products which have not received a national MA in any of the Member States,
may be authorized through the decentralized procedure. This procedure enables the simultaneous issuance of national MAs in several EU countries. Under the decentralized procedure, an identical dossier is submitted to the competent authorities of
each of the Member States in which an MA is sought. One of these Member States is designated by the applicant to act as the Reference Member State (&#147;RMS&#148;). The competent authority of the RMS drafts an assessment report and prepares an
SmPC, a package leaflet and a draft labelling, which are sent to the other Member States involved in the procedure, known as the Concerned Member States (&#147;CMS&#148;), for approval. If the CMS do not raise any objections based on a potential
serious risk to public health, regarding the assessment, the SmPC, the labelling or the packaging proposed by the RMS, a national MA is granted for the product in all Member States involved in the procedure (i.e., in the RMS and the CMS). Where a
product has already been authorized for marketing in an EU Member State, this national MA can be recognized in another member state through the mutual recognition procedure. In this procedure, the Member State which issued the initial MA, known as
the RMS, must prepare an assessment report on the medicinal product or update any existing report. This report is sent to the CMS, together with the approved SmPC and the labelling and package leaflet. Unless an objection based on a potential
serious risk to public health is raised, the CMS issue(s) a national MA for the product, the terms of which are identical to the MA granted by the RMS. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the procedure used, the EMA or the national competent authority(ies) must, before granting a MA, make an assessment of the
benefit/risk ratio of the product based on scientific criteria of quality, safety of use and efficacy. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops. In exceptional
cases, the CHMP might perform an accelerated review of an MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a
number of expedited development and review programs, such as the Priority Medicines (&#147;PRIME&#148;) scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. In March 2016, the EMA launched an initiative, the
PRIME scheme, a voluntary scheme aimed at enhancing the EMA&#146;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to
optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is not guaranteed. Many
benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and
accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#146;s committee level. An
initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, in the EU, a conditional MA may be granted by the European Commission for a period of one year and is renewable annually. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A conditional MA is granted in the absence of sufficient clinical data to obtain an
ordinary MA if the following requirements are met: (i)&nbsp;the medicinal product is intended to treat, prevent or diagnose a fatal or seriously debilitating disease, (ii)&nbsp;it fulfils to an unmet medical need, (iii)&nbsp;its benefit/risk ratio
is, on the basis of the available data, positive, (iv)&nbsp;it is likely that the applicant will be able to provide the required comprehensive <FONT STYLE="white-space:nowrap">post-MA</FONT> clinical data and (v)&nbsp;in terms of public health, the
benefits of the product&#146;s immediate availability to patients outweigh the risks inherent to the lack of sufficient clinical data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The granting of a conditional MA is accompanied by specific obligations, in particular relating to the completion of clinical trials, the
performance of new studies and the collection of pharmacovigilance data in order to confirm the benefit/risk ratio of the product. Once the pending studies are provided, it can become a &#147;standard&#148; MA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAs may also be granted under exceptional circumstances to medicinal products for which a complete evaluation file cannot be provided when the
product&#146;s indication is too rarely encountered and reasonably prevents the provision of comprehensive evidence, when the current state of scientific knowledge prevents the provision of such data or when the collection of the necessary data
would be unethical. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a
MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#147;under exceptional circumstances&#148; is granted definitively, the risk-benefit balance of the medicinal
product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, despite the granting
of a MA, both the MA holder and the competent authorities may decide to withdraw (voluntarily or compulsorily) a product from the market or a MA, when it appears that the product presents more risks than benefits for the patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Data and Marketing Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
EU, new products authorized for marketing (<I>i.e.</I>, reference products) generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period prevents generic and
biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the
reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial MA of the reference
product in the EU. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the MA holder obtains an authorization for
one or more new therapeutic indications, which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will
be considered by the EU&#146;s regulatory authorities to be a new chemical or biological entity, and products may not qualify for data exclusivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric Development </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, MAAs
for new medicinal products must include the results of studies conducted in the pediatric population, in compliance with a Pediatric Investigation Plan (&#147;PIP&#148;) agreed with the EMA&#146;s Pediatric Committee (&#147;PDCO&#148;). The PIP sets
out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until
there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is
likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for
pediatric </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patients. Once the MA is obtained in all the EU member states and study results are included in the product information, even when negative, the product is eligible for six months&#146;
supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a <FONT STYLE="white-space:nowrap">two-year</FONT> extension of the orphan market exclusivity is granted.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Manufacturing and Distribution-related Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To ensure patients&#146; safety, the manufacturing, distribution and import of active pharmaceutical ingredients and finished products into the
EU are also subject to extensive requirements and both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the Member
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicines (including their active substances) must be manufactured in accordance with GMP requirements. These regulations govern
manufacturing processes and procedures, and notably provide for requirements relating to the implementation of quality systems to control and ensure the quality of materials and products. Manufacturing activities must be performed only within
companies holding valid licenses from the competent regulatory authorities of the Member States which is issued following an inspection of the concerned facilities. In addition, routine inspections are conducted on a regularly basis to ensure that
compliance is maintained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributors must also comply with very strict requirements, including good distribution practices
(&#147;GDP&#148;). These regulations provide for strict requirements including the implementation of an effective quality system and adequate procedures to ensure the quality of the products all over the distribution chain and efficiently respond to
claims, recalls, and risks of falsification, or the use of appropriate facilities, equipment and personnel. Similarly to manufacturing, distribution activities are subject to a prior approval from the competent regulatory authorities of the Member
States which is issued following an inspection of the concerned facilities which aims at ensuring that the establishment complies with the applicable regulations. Routine inspections are also conducted on a regularly basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, the import of active pharmaceutical ingredients and medicines into the EU must also be authorized in advance, in order to ensure that
the products are manufactured and distributed in accordance with standards at least equivalent to those existing for the EU market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with the above requirements may be sanctioned by the suspension or withdrawal of the manufacturing/distribution/import
authorization, civil, criminal or administrative penalties, or the withdrawal of the concerned active ingredients and finished products from the market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Pharmacovigilance
Requirements</U></I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MA holder must establish and maintain a pharmacovigilance system and designate a Qualified Person Responsible for
Pharmacovigilance (&#147;QPPV&#148;) who is responsible for the establishment and maintenance of that system, and oversees the safety profiles of medicinal products and any emerging safety concerns. The main obligations of the QPPV include prompt
reporting of suspected serious adverse reactions and submission of periodic pharmacovigilance update reports (&#147;PSURs&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new
MAA must include a risk management plan (&#147;RMP&#148;) describing the risk management system that the company will put in place and setting out measures to prevent or minimize the risks associated with the medicinal product. The regulatory
authorities may also issue an MA subject to the fulfillment of specific obligations. These risk reduction measures or post-authorization obligations may consist, in particular, of reinforced safety monitoring, more frequent submission of PSURs, the
conduct of additional clinical trials or the performance of post- authorization safety studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Advertising Requirements</U></I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, the advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions
with physicians, misleading and comparative advertising and unfair commercial practices. The general principles applicable to the advertising of medicines, which is broadly defined as any form of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">door-to-door</FONT></FONT> information, canvassing activity or inducement designed to promote the prescription, supply, sale or consumption of medicinal products, are established by EU directives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any advertising or promotion of a medicinal product must comply with its approved SmPC. Consequently, any promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. Indeed, the advertising must encourage the rational use of medicines by presenting them objectively without exaggeration and thus, must not be misleading. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is also prohibited in the EU. Although general requirements for advertising and promotion of medicinal products are
established under EU directives, the details are governed by regulations in each Member State and can differ from one country to another. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the Member States, advertising-related regulatory requirements may be sanctioned notably by fines, suspension or withdrawal of
regulatory authorizations, medicinal products recalls, medicinal products seizures, operating restrictions and even criminal and/or civil prosecution and significant fines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the European Economic Area (&#147;EEA&#148;) which consists of the 27 EU member states
plus Norway, Liechtenstein and Iceland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Coverage and Reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, pricing and reimbursement systems widely vary from one country to another and remain exclusively the responsibility of the Member
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thus, Member States may restrict the range of medicines for which their national health insurance system provides reimbursement
and to control the price of medicines for human use, provided that time limits for review of a reimbursement application provided in Directive 89/105/EEC of 21&nbsp;December 1988 must be complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some Member States use a system of positive and negative lists, whereby medicines can only be marketed after a reimbursement price has been
agreed. Others may require additional studies comparing the cost-effectiveness of a medicinal product to existing therapies in order to obtain approval for reimbursement or pricing. Finally, Member States can agree to a set price or, instead, allow
companies to set their own prices while having their profits monitored and controlled (e.g., control of the quantity of prescriptions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the last few years, many EU Member States have increased the amount of rebates applied to medicinal products, and these efforts may
continue as Member States exercise greater control over their healthcare spending due to often large debts. The downward pressure on healthcare costs in general, including medicinal products subject to mandatory prescription, has become
considerable. Changing political, economic and regulatory conditions can complicate price negotiations. This price negotiation can continue after reimbursement has been achieved and is generally subject to periodic reviews. Finally, reference prices
used by various EU Member States and parallel trade (i.e., arbitrage by distributors between low and high price Member States) may also lead to further price reductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#147;HTA&#148;) amending Directive 2011/24/EU, was
adopted. While the Regulation entered into force in January 2022 it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once the Regulation becomes applicable, it will
have a phased implementation depending on the concerned products. This regulation intends to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at the
EU level for joint </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical assessments in these areas. The regulation will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas,
including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health
technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing <FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g.,
economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Healthcare Laws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Relationships between the pharmaceutical industry and healthcare professionals are subject to national restrictions and regulations in order to
avoid any incentive to prescribe drugs that is not justified by the patient&#146;s state of health and profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in France,
relations between companies producing and/or marketing health products or providing services associated with these products, regardless of their nationality and/or the location of their registered office, and healthcare professionals practicing in
France are governed by the &#147;anti-gift&#148; and &#147;transparency&#148; laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose is to ensure that healthcare
professionals, in their choice of a medicinal product, equipment or service, are guided solely by medical information and considerations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By way of principle, under the French anti-gift law, persons providing health services, manufacturing or marketing healthcare products are
prohibited from promising or offering advantages, in cash or in kind, either directly or indirectly, to healthcare professionals practicing in France, students intending to enter such professions or associations of these individuals, including
learned societies and national professional councils. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The list of benefits that do that do not qualify as &#147;advantages&#148; under
the anti-kickback regulation is very limited and includes, for example, benefits that relate to the exercise of the beneficiary&#146;s profession and of negligible value, which may not exceed the amounts provided for by a Ministerial Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By way of exception, above-mentioned health stakeholders may provide advantages to the healthcare professionals/associations mentioned above,
subject to the conclusion of a written agreement and to a prior declaration to or approval from the authority to which the concerned beneficiary belongs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This exception is however limited to specific situations mainly including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The remuneration, compensation and expenses for research activities, research promotion, scientific evaluation,
consultancy, provision of services or commercial promotion, provided that the remuneration is proportionate to the service provided and that the compensation or expenses do not exceed the costs actually incurred by the persons concerned;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Donations and gifts, in cash or in kind, exclusively intended to finance research activities, the promotion of
research or scientific evaluation; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hospitality offered during events of an exclusively professional or scientific nature, or during events promoting
healthcare products or services, provided that this hospitality is of a reasonable level, strictly limited to the main purpose of the event and to healthcare professionals (excluding students); </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When failing to comply with these regulations, in addition to a significant risk to their reputation, the companies and professionals
concerned may be subject to significant criminal penalties and, in the case of the latter, disciplinary penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The French transparency provision, for its part, provides citizens with access to
certain information on a website so that they can more objectively assess the relationships between health actors (i.e., a broad list including healthcare professionals, associations of healthcare professionals, students, associations of users of
the health system, health establishments, academic institutions, foundations, learned societies and societies or advisory bodies involved in the health product or health services sector, etc.) and companies producing or marketing health products or
providing services associated with these products. Under the terms of this regulation, the companies concerned must disclose the main information relating to their relationships with healthcare professionals, such as compensation or benefits paid,
and agreements entered into. Companies that knowingly fails to disclose such information may be subject to criminal penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>UK Regulation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the end of the Brexit transition period on January&nbsp;1, 2021, Great Britain (&#147;GB&#148;) (England, Scotland and
Wales) has not been directly subject to EU laws. However, under the terms of the Ireland/Northern Ireland Protocol, EU laws have generally applied to Northern Ireland. On February&nbsp;27, 2023, the UK government and the European Commission reached
a political agreement on the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Windsor Framework&#148; which is intended to revise the Ireland/Northern Ireland Protocol in order to address some of the perceived shortcomings in its operation.
The agreement was adopted at the Withdrawal Agreement Joint Committee on March&nbsp;24, 2023. If the changes are adopted in the form proposed, medicinal products to be placed on the market in the UK will be authorized solely in accordance with UK
laws. Northern Ireland would be reintegrated back into a <FONT STYLE="white-space:nowrap">UK-only</FONT> regulatory environment under the authority of the MHRA with respect to all medicinal products. The implementation of the Windsor Framework would
occur in various stages, with new arrangements relating to the supply of medicines into Northern Ireland anticipated to take effect in 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU laws that have been transposed into United Kingdom (&#147;UK&#148;) law through secondary legislation remain applicable in Great
Britain. However, new EU legislation that was either adopted or entered into application after Brexit such as the EU CTR is not applicable in Great Britain. The UK regulatory framework in relation to clinical trials is derived from previously
existing EU legislation (as implemented into UK law, through secondary legislation). On January&nbsp;17, 2022, the UK MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials. The consultation closed on
March&nbsp;14, 2022, and aims to streamline clinical trial approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality and promote patient and public involvement in clinical trials. The outcome of the
consultation is being closely watched and will determine whether the UK chooses to align with the (EU) CTR or diverge from it. Under the terms of the Ireland/Northern Ireland Protocol, provisions of the EU CTR which relate to the manufacture and
import of investigational medicinal products and auxiliary medicinal products currently apply in Northern Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1,
2021, the MHRA has been the sole regulatory of medicines and medical devices in GB and for medicinal products that are not authorized through the centralized procedure in Northern Ireland. The MHRA has introduced changes to national licensing
procedures, including procedures to prioritize access to new medicines that will benefit patients, including a <FONT STYLE="white-space:nowrap">150-day</FONT> assessment and a rolling review procedure. All existing EU MAs for centrally authorized
products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January&nbsp;1, 2021, unless the MA holder <FONT STYLE="white-space:nowrap">opted-out.</FONT> In order to use the centralized procedure to
obtain an MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, since Brexit, companies established in the UK can no longer use the EU centralized procedure for authorization of medicinal products intended to
be marketed in the UK. In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the UK and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international
cooperation procedures to obtain an MA to commercialize products in the UK. Until December&nbsp;31, 2023, the MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure) MA when reviewing an
application for authorization of a medicinal product to be supplied in GB. Depending on the nature and intended therapeutic purpose of the medicinal product, the MHRA may, alternatively, use its own </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decentralized or mutual recognition procedures which enable the MHRA to have regard to MAs approved in EU Member States, Iceland, Liechtenstein, Norway) when granting an MA in the UK or GB. From
the first quarter of 2024, a new international recognition framework should be in place with an aim to extend the countries whose assessments the MHRA will take into account. The UK government will need to adopt new legislation to introduce this
route. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no <FONT STYLE="white-space:nowrap">pre-MA</FONT> orphan designation procedure. Applications for orphan designation are
made at the same time as an application for MA and the MHRA will review applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the market (i.e., the
prevalence of the condition in GB, rather than the EU, must not be more than five in 10,000). Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in GB. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Government Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, (&#147;FDCA&#148;) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state,
and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval,
may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold on a clinical trial, issuance of warning letters, product
recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completion of preclinical laboratory studies, animal studies and formulation studies in compliance with the
FDA&#146;s GLP regulations, and other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of an IND which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval by the Institutional Review Board (&#147;IRB&#148;) or ethics committee, at each clinical site before
each trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Performance of adequate and well-controlled human clinical trials, in accordance with GCP requirements to
establish the safety and effectiveness of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of an NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is
produced to assess compliance with current good manufacturing practice (&#147;cGMP&#148;) requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity, and of
potential inspection of selected clinical investigation sites to assess compliance with GCPs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Studies and INDs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical
studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical studies may
continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical
trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve
the administration of the investigational drug to human patients under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their
informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness
criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the IRB(s) competent for the institution(s) participating in the clinical trial must
review and approve the plan for any clinical trial before it commences. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their
www.clinicaltrials.gov website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the IND is active, progress reports detailing the results of the clinical trials and nonclinical
studies performed since the last progress report, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse
events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a
serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research
patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been
associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its
charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of FDA approval, human clinical trials are generally conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 1:</I> The drug candidate is initially introduced into healthy human subjects and tested for safety,
dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 2:</I> The drug candidate is administered to a limited patient population with a specified disease or
condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the drug candidate for specific targeted diseases and to determine dosage tolerance and appropriate dosage. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3:</I> The drug candidate is administered to an expanded patient population to further evaluate dosage,
to provide substantial evidence of efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the drug candidate and
provide an adequate basis for product labeling. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after
initial marketing approval. These trials are used to, among other things, gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical
trials as a condition of approval of an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and
must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with GMPs. The manufacturing process must be capable of
consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected
and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful
completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things,
are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act
guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date
the NDA is submitted to FDA because the FDA has approximately two months to make a &#147;filing&#148; decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the
Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric
subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or
all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy (&#147;REMS&#148;) plan to ensure that the benefits of the
drug outweigh its risks. The REMS plan could include Medication Guides (FDA approved patient labeling to be provided to patients when the drug is dispensed), physician communication plans, assessment plans, or Elements to Assure Safe Use, such as
restricted distribution methods, patient registries, or other risk minimization tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of all NDAs
within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this
event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT
STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets
standards designed to assure the product&#146;s continued safety, quality and purity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug
to an Advisory Committee. An Advisory Committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under
what conditions. The FDA is not bound by the recommendations of an Advisory Committee, but it considers such recommendations carefully when making decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect the facility or facilities where
the commercial product would be manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to verify the clinical data submitted in the NDA, and to assure compliance with GCP requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After evaluating the NDA and all related information, including the Advisory Committee recommendation, if any, and inspection reports
regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing
information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form, and describes the specific deficiencies in the NDA
identified by the FDA and may require additional clinical data, such as an additional clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the
sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications,
warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#146;s safety after approval, require testing and surveillance programs to
monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product.
The FDA may at any time prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After initial approval, some types of changes to the approved product, such as adding new indications,
manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval
Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the
FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, the submission of advertising and promotion, and reporting of adverse experiences with the product. After approval,
most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any marketed products, as well as new
application fees for certain supplemental applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may impose a number of post-approval requirements as a condition of
approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and
often require prior FDA approval before being implemented. FDA regulations also require manufacturers to investigate and correct of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any
third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with
regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or
with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety
risks; or imposition of distribution or other restrictions under a REMS program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other potential consequences include, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of
product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted
only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of unapproved uses
<FONT STYLE="white-space:nowrap">(&#147;off-label&#148;</FONT> uses), and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. Physicians may prescribe
legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA
does, however, restrict manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity
provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity within the United States to the first
applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of
the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (&#147;ANDA&#148;), or an NDA submitted under Section&nbsp;505(b)(2) (&#147;505(b)(2) NDA&#148;) submitted by another company
for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to
all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA
by the innovator NDA holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an
existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or
strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for
drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to
conduct, or obtain a right of reference to, all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of marketing exclusivity available in the United
States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a
written request does not require the sponsor to undertake the described clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Coverage and Reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our drug candidates, if approved, will depend, in part, on the extent to which such products will be covered by third-party payors,
such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors determine which medications they will cover and establish reimbursement levels. In addition, these third-party payors are
increasingly limiting coverage or reducing reimbursements for medical products and services. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement
for products can differ significantly from payor to payor. In addition, the U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for
substitution of generic products. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their
prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. As a result, adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our drug candidates or a decision by a third-party
payor to not cover our drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition. Additionally, we or our collaborators may
develop companion diagnostic tests for use with our drug candidates. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our drug
candidates, once approved. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Healthcare Laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also be
subject to other healthcare regulation and enforcement by the U.S. federal government and the states in which we will conduct our business once our drug candidates are approved. Failure to comply with these laws, where applicable, can result in the
imposition of significant administrative, civil, and criminal penalties. The laws that may affect our ability to operate in the United States include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal healthcare programs&#146; Anti-Kickback Statute, which prohibits, among other things, persons from
knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which
payment may be made under federal healthcare programs such as the Medicare and Medicaid programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal false claims act laws, including the civil False Claims Act, which prohibit, among other things,
individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal health care fraud statutes, which created additional federal criminal statutes that impose criminal
and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering up a material fact or making false statements relating
to healthcare matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics, and medical
supplies to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, information </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as
physicians assistants and nurse practitioners), and teaching hospitals, as well as and ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), which created
additional federal criminal statutes that impose criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or
covering up a material fact or making false statements relating to healthcare matters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#147;HITECH&#148;),
which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may
apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Further, certain states enacted laws that require: pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government; drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing
expenditures; the reporting of information related to drug pricing; the registration of pharmaceutical sales representatives. Certain states have also enacted legislation to govern the privacy and security of health information, many of which differ
from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Healthcare Reform </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The enactment
of the Affordable Care Act (&#147;ACA&#148;) has substantially changed healthcare financing and delivery by both governmental and private insurers, and significantly impacted the pharmaceutical industry. The ACA, among other things, established an
annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered
outpatient drugs under the Medicaid Drug Rebate Program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate program to utilization of
prescriptions of individuals enrolled in Medicaid managed care organizations, and provided incentives to programs that increase the federal government&#146;s comparative effectiveness research. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and congressional challenges to certain aspects of the ACA. Most recently, on June&nbsp;17,
2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress. In addition, there have been a number of health reform
initiatives by the Biden administration that have impacted the ACA. For example, on August&nbsp;16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#147;IRA&#148;), into law, which among other things, extends enhanced subsidies
for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#147;donut hole&#148; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost through a newly established manufacturer discount program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted. For example, on August&nbsp;2, 2011, the Budget Control
Act of 2011 was signed into law which among other things, led to aggregate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reductions in Medicare payments to providers. These reductions went into effect on April&nbsp;1, 2013, and, due to subsequent legislative amendments, will remain in effect until 2032, except for
a temporary suspension from May&nbsp;1, 2020, through March&nbsp;31, 2022, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products.
For example, there have been several congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform
government program reimbursement methodologies for drug products. For example, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a
drug&#146;s average manufacturer price, beginning January 1, 2024. In addition, the IRA, among other things, (1)&nbsp;directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2)&nbsp;imposes rebates
under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions took effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to
litigation. Further, the Biden administration released an additional executive order on October&nbsp;14, 2022, directing HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation (&#147;CMMI&#148;) can be further
leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. In response, on February 14, 2023, HHS released a report outlining three new models for testing by the CMMI which will be evaluated on their ability to
lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. At the state level, legislatures are increasingly passing legislation and
implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that additional U.S.
federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our drug candidates or
additional pricing pressures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend upon our ability to obtain and maintain patents and other intellectual property for our drug candidates in the United
States and internationally, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter,</FONT></FONT> pharmaceutical composition, synthesis process, method of manufacture and method of treatment, as well as
patent and other intellectual property and proprietary protection for our novel discoveries and other important technology inventions and <FONT STYLE="white-space:nowrap">know-how.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is also to file new patents to extend obefazimod&#146;s intellectual property protection and to generate new intellectual
property through the protection of potential <FONT STYLE="white-space:nowrap">follow-on</FONT> compounds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patents, we rely
upon unpatented trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> and continuing technological innovation to develop and maintain our competitive position. We protect our proprietary information, in part, using confidentiality
agreements with our commercial partners, collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our commercial partners and
selected consultants. Despite these measures, any of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated, or such intellectual property and proprietary rights may not be
sufficient to permit us to take advantage of current market trends or otherwise to provide competitive advantages. In addition, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies
for any such breach. For more information, please see &#147;Risk factors&#151;Risks Relating to Intellectual Property.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of
individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we are seeking patent protection for our drug candidates, the patent term is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, the term of a patent may be lengthened by a patent
term adjustment, which provides for term extension in the case of administrative delays at the United States Patent and Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent with an
earlier expiration date. Furthermore, in the United States, the term of a patent covering an FDA approved drug may be eligible for patent term extension (&#147;PTE&#148;) under the Hatch-Waxman Amendments as compensation for the loss of patent term
during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent but cannot extend the term of a patent beyond a total of 14 years from the date of product approval. Only one patent
covering a single FDA-approved product among those eligible for an extension may be extended. In the future, if any of our drug candidates receives FDA approval, we expect to apply for a PTE, if available, to extend the term of a patent covering
such approved drug product. We also expect to seek PTEs in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such an extension
should be granted, and even if granted, the length of such an extension. See &#147;Risk Factors&#151;Risks Related to our Intellectual Property &#151; Our ability to commercialize our drug candidates may decrease if we are unable to protect our
intellectual property rights or if these rights are insufficient for our purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All the patents and patent applications covering obefazimod are <FONT STYLE="white-space:nowrap">co-owned</FONT> with the French National
Centre for Scientific Research (the &#147;CNRS&#148;), the University of Montpellier, and the Institut Curie, except U.S. patent 10,464,903 and U.S. patent 10,745,357, as described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Obefazimod </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, the
principal patent rights related to obefazimod, include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent 10,017,498, which is directed to the composition of matter of obefazimod generically and specifically
and to a pharmaceutical composition comprising it. This patent is also granted in Europe and several other countries (Australia, Brazil, Canada, China, Hong Kong, Cuba, India, Japan, South Korea, Mexico, Russia, South Africa) and has an expiry date
of 2030, not including patent term adjustment or any potential PTE. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent 10,975,063, which is directed specifically to obefazimod (composition of matter), free base and salts
of obefazimod, a pharmaceutical composition comprising it, a process for preparing it and a method for treating HIV infection. This patent has an expiry date of 2030, not including patent term adjustment or any potential PTE. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent 10,435,370, which is directed to methods of treating inflammatory diseases including UC and CD by
obefazimod generically and specifically. This patent is also granted in Europe and several other countries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. continuation patent 11,649,211 is directed to the method of treating inflammatory diseases including UC and
CD by obefazimod specifically. Divisional U.S. patents protect methods of treating additional inflammatory diseases (U.S. patent 10,981,874 and U.S. patent 11,649,210). These patents have an expiry date of 2035, not including patent term adjustment
or any potential PTE. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent 10,464,903 and U.S. patent 10,745,357, which are directed to a synthesis process for manufacturing
obefazimod and derivatives thereof, a polymorphic form of the free base of obefazimod and crystalline forms of various salts of obefazimod. These patents have an expiry date of 2037, not including patent term adjustment or any potential PTE. A
corresponding European patent has also been granted. These patents are solely owned by us. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Further indications are also protected by other patents: U.S. patent 9,827,237, which is directed to the method
of treating Human Leukemia virus infection. This patent is also granted in Europe and several other countries and has an expiry date of 2034. U.S. patent 9,145,367, which is directed to the method of treating AIDS by obefazimod generically and
specifically. This patent is also granted in Europe and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
several other countries and has an expiry date of 2030. U.S. patent 9,108,919, which is directed to the method of treating cancer by obefazimod generically and specifically. This patent is also
granted in Europe and several other countries and has an expiry date of 2030. Another patent application directed to a method of treating cancer has been filed worldwide in 2019. U.S. patent 10,806,729 which is directed to the method of treating HIV
resistant patients by obefazimod generically and specifically. This patent is also granted in Europe and other countries and has an expiry date of 2036. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent applications 17/416,856 and 17/416,679, which are respectively directed to the method of treating
other inflammatory diseases and cancer by obefazimod generically and specifically or its N-glucuronide metabolite have been filed in 2019, as well as counterpart applications in other countries. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent application 17/913,063, which is directed to the method of treating Coronaviridae infection by
obefazimod generically and specifically or its N-glucuronide metabolite has been filed in 2021, as well as counterpart applications in other countries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent application 17/796,834, which is directed to the amorphous solid dispersion (ASD) of obefazimod, its
method of preparation, pharmaceutical composition and method of treating inflammatory disease, cancer and viral diseases therewith has been filed in 2021, as well as counterpart applications in other countries. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. patent application 17/793,133, which is directed to co-crystals and salts of obefazimod, pharmaceutical
composition and method of treating inflammatory disease, cancer and viral diseases therewith has been filed in 2021, as well as counterpart applications in other countries. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PCT international patent application PCT/EP2022/057628, which is directed to a synthesis process for
manufacturing obefazimod and derivatives thereof and was filed in 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Two PCT international patent applications were filed under PCT/EP2023/050641 and PCT/EP2023/051424 in 2023
directed to combinations products with obefazimod respectively with etrasimod and Rinvoq. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks and Domain Names
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own a number of trademarks and domain names, including our logo and the URL for our website, as well as a number of websites
including the name &#147;abivax&#148; or &#147;obefazimod.&#148; &#147;Abivax&#148; is a registered trademark of our company in Canada, China, Cuba, the EU, France, India, South Africa and the United Kingdom. We also hold pending applications for
the &#147;Abivax&#148; trademark in Australia, Brazil, Canada, Cuba, India, Japan, Mexico, South Africa, South Korea and the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key
Collaborations and Partners </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>First KC Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;24, 2018,
we entered into a &#128;20&nbsp;million venture loan agreement with certain Kreos Capital entities (&#147;KC&#148;) (the &#147;First KC Agreement&#148;). The financing consists of two tranches of structured debt financing: (i)&nbsp;a total principal
amount of &#128;10&nbsp;million, comprised of (x) &#128;8&nbsp;million in <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds issued in July 2018 and (y) &#128;2&nbsp;million in convertible bonds issued in August 2018 (the &#147;First
Tranche A Notes&#148;) and (ii)&nbsp;a total principal amount of &#128;10&nbsp;million, comprised of (x) &#128;8&nbsp;million in <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds and (y) &#128;2&nbsp;million in convertible bonds, each
issued in May 2019 (the &#147;First Tranche B Notes&#148;, together with the First Tranche A Notes, the &#147;First KC Notes&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest on the First KC Notes, as set out in a (i)&nbsp;convertible bonds issue agreement and (ii)&nbsp;a bonds issue agreement, each between
us and KC and dated July&nbsp;24, 2018 (the &#147;Convertible Bonds Issue Agreement&#148; and the &#147;Bonds Issue Agreement&#148;, respectively), accrues annually at a rate of 8% plus <FONT STYLE="white-space:nowrap">3-month</FONT> Euro Interbank
Offer Rate (&#147;Euribor&#148;) (subject to a minimum interest rate of 8% and a maximum interest rate of 9%) in 54 monthly installments. Principal of the <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds is repaid in 42 monthly
installments, commencing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thirteenth interest payment date. An additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;end-of-loan&#148;</FONT></FONT> payment amounting to 9% of the initial
principal of the <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds is due on the final repayment date (including any prepayment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on July&nbsp;24, 2018, concurrent with First KC Agreement, we entered into a warrant issue agreement with KC (the &#147;Warrant
Issue Agreement&#148;), pursuant to which we issued 185,723 share warrants (&#147;BSAs&#148;) (the &#147;KC Warrants&#148;), of which 110,957 were issued in respect of the First Tranche A Notes and 74,766 were issued in respect of the First Tranche
B Notes. The exercise price of the BSAs issued in respect of the First Tranche A Notes is &#128;7.21 per BSA, and the exercise price of the BSAs issued in respect of the First Tranche B Notes is &#128;10.70 per BSA pursuant to the amending agreement
with KC on January&nbsp;31, 2019. The KC Warrants are transferable only to certain financial institutions and cannot be listed on a stock exchange. The KC Warrants expire on the occurrence of the earlier of: (i)&nbsp;the tenth anniversary of the
issue date; or (ii)&nbsp;the sale of our entire issued share capital. We entered into a put option agreement with KC in connection with the Warrant Issue Agreement pursuant to which, KC may sell option warrants to us upon each exercise of all or
part of the KC Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2020, the &#128;4&nbsp;million convertible bonds (in respect of both the First Tranche A Notes and
the First Tranche B Notes) were converted into 464,309 shares. The final repayment date for the <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds portion of the First Tranche A Notes was December&nbsp;1, 2022. The final repayment date
for the <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds portion of the First Tranche B Notes is November&nbsp;1, 2023. In May 2023, Kreos Capital V UK Ltd. exercised its share warrants on a cashless basis, resulting in a repurchase by
us of 43,070 tranche A share warrants and 43,070 tranche B share warrants and the corresponding issuance of 67,887 and 31,696 ordinary shares, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The First KC Agreement includes certain restrictive covenants (subject to customary exceptions) which include, inter alia, restrictions on the
incurrence of indebtedness, cross-default, the distribution of dividends and the grant of security interests. As security for the First KC Notes, KC benefits from the grant of first-ranking collateral on our principal tangible and intangible assets,
including pledges over our business as a going concern and intellectual property rights in our principal drug candidates, as well as a pledge over our bank accounts and receivables. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Second KC Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12,
2020, we entered into a bonds issue agreement with KC (the &#147;Second KC Agreement&#148;), pursuant to which we issued bonds in a total principal amount of &#128;15&nbsp;million, comprised of (i)&nbsp;a &#128;10&nbsp;million tranche (the
&#147;Second Tranche A Notes&#148;) and a &#128;5&nbsp;million tranche (the &#147;Second Tranche B Notes&#148;), with an option to issue an additional &#128;5&nbsp;million tranche (the &#147;Second Tranche C Notes&#148; and collectively with the
Second Tranche A Notes and the Second Tranche B Notes, the &#147;Second KC Notes&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Second Tranche A Notes were issued in
October 2020, and the Second Tranche B Notes were issued in November 2020. The Second KC Notes rank pari passu with the First KC Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest on the Second KC Notes accrues annually for the first 12 months from their respective issue dates at a rate of 8% plus <FONT
STYLE="white-space:nowrap">3-month</FONT> Euribor (subject to a minimum interest rate of 8% and a maximum interest rate of 9%), after which the annual interest rate is increased to a fixed rate of 9.75% for the remainder of the term. Interest is
paid in 48 monthly installments. Principal is repaid in 36 monthly installments, commencing on the thirteenth interest payment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
security for the Second KC Agreement, KC benefits from the grant of first-ranking collateral on our principal tangible and intangible assets, including pledges over our business as a going concern and intellectual property rights in our principal
drug candidates, as well as a pledge over our bank accounts and receivables. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>OCEANE Bonds </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;30, 2021, we issued &#128;25&nbsp;million 6% convertible senior unsecured and unsubordinated bonds due July&nbsp;30, 2026
corresponding to 654,621 convertible bonds (the &#147;OCEANE bonds&#148;). The OCEANE bonds are exchangeable, at the option of the bondholders, for new or existing shares and bear interest at a rate of 6% per annum, payable semi-annually on
January&nbsp;30 and July&nbsp;30 of each year, beginning January&nbsp;30, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominal value of each OCEANE bond was set at &#128;38.19, representing a
conversion/exchange premium of 25% over the reference share price and corresponding to the placing price of the newly-issued shares in the concurrent accelerated bookbuilding process announced on July&nbsp;22, 2021. The issue price of each OCEANE
bond was &#128;38.19, representing 100% of the principal amount. The exchange ratio has been adjusted as of January&nbsp;30, 2023 by a decrease of the conversion price to &#128;32.47 per share. The number of underlying shares has thus been increased
from 654,621 to 769,834 shares. The exchange ratio will be further adjusted if the adjusted conversion ratio is higher than the updated conversion ratio on July&nbsp;30, 2023, and January&nbsp;30, 2024. The exchange ratio may also be adjusted in the
event of certain financial transactions being undertaken by the Company as set out in the terms and conditions of the OCEANE bonds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior
to maturity, bondholders have the right to receive new and/or existing shares by way of <FONT STYLE="white-space:nowrap">set-off</FONT> against amounts owed under the Convertible Bonds. Exercising this right results in the cancellation of the
Convertible Bonds for which it is exercised. We may suspend this right for a period of up to three months in the event of a share capital increase or other financial transaction as set out in the terms and conditions of the OCEANE bonds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The OCEANE bonds may be redeemed early by repurchase, tender or exchange at our option, or at the option of the bondholders in the event of a
change of control of the Company, a delisting of our shares or if our free float falls below 25%. Unless converted, exchanged, previously redeemed or bought back and cancelled, the OCEANE bonds will be redeemed and cancelled at their principal value
on July&nbsp;30, 2026, and no longer be outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalty Certificates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;31, 2022, we issued &#128;2.9&nbsp;million in royalty certificates (the &#147;Royalty Certificates&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions of the Royalty Certificates provide holders with the right to royalties equal to 2% of the future net sales of
obefazimod (worldwide and for all indications) following its commercialization. The amount of royalties that may be paid under the Royalty Certificates is capped at &#128;172&nbsp;million (the &#147;Royalty Cap&#148;). The Royalty Certificates do
not provide for any dividend rights, coupon payments or any other additional financial rights other than the right to royalties. In particular, the Royalty Certificates do not grant any financial rights in respect of any other products that may be
developed by us beyond obefazimod. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Royalty Certificates have a term of 15 years and do not provide for an accelerated repayment in
case of a change of control. We may at any time repay the Royalty Certificates in full by paying an amount equal to the Royalty Cap minus any royalties paid prior to such reimbursement. The Royalty Certificates are subject to a <FONT
STYLE="white-space:nowrap">one-year</FONT> <FONT STYLE="white-space:nowrap">lock-up,</FONT> after which they will become freely transferable by each holder thereof in whole, but not in part. The Royalty Certificates are not listed nor assigned an
ISIN. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prosynergia S.&agrave;.r.L. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;1, 2022, we entered into a share purchase agreement pursuant to which we acquired 100% of the capital and voting rights of Prosynergia S.&agrave;.r.L, a Luxembourg biotech company, registered in the Luxembourg Trade and Companies Register
under no. B257479, with registered offices located at 241 route de Longwy &#150; 1941 Luxembourg City, Luxembourg for consideration of &#128;3.25&nbsp;million (the &#147;Prosynergia Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 1, 2021, we granted a loan to Prosynergia, for &#128;1,400,000. On December 12, 2022, we completed a merger with Prosynergia
through a <I>Transmission Universelle du Patrimoine</I> (&#147;TUP&#148;) and all of Prosynergia&#146;s assets and liabilities were transferred to us. Following the merger, Prosynergia was dissolved. See Note 4.15 to our audited financial statements
as of and for the years ended December 31, 2021 and 2022 included elsewhere in this prospectus for further detail. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration, Research and Development Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>IQVIA Master Services Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;17, 2018, we entered into a master services agreement with IQVIA Ltd (&#147;IQVIA&#148;) for the provision of clinical trial services, research and other services for individual clinical trials on human beings (the &#147;IQVIA Master
Services Agreement&#148;), as amended on September&nbsp;9, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the IQVIA Master Services Agreement and underlying Work
Order, IQVIA agreed to perform certain services on our behalf as we request, subject to IQVIA&#146;s acceptance of the services and related budget in the applicable Work Order, including, but not limited to, strategic planning, expert consultation,
clinical trial services, statistical programming and analysis, data processing, data management, regulatory, project management, pharmacovigilance, central laboratory services, clinical pharmacology services, electrocardiogram services and device
services. In consideration therefore, we agreed to pay IQVIA an agreed set of fees based on our requests, as set forth in the applicable Work Order. We have the right to terminate the IQVIA Master Services Agreement or requested work without cause
and at any time upon 45 days&#146; written notice. We and IQVIA each have the right to terminate the IQVIA Master Services Agreement in the event of a breach by the other party, if such breach has not been substantially cured within the <FONT
STYLE="white-space:nowrap">30-day</FONT> period. We have the right to terminate the IQVIA Master Services Agreement and/or any Work Order with immediate effect by written notice and without any liability whatsoever in case IQVIA becomes debarred.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the IQVIA Master Services Agreement and a study specific Work Order executed with IQVIA, IQVIA is responsible for
coordinating our Phase 3 clinical trial for obefazimod in moderately to severely active UC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022,
&#128;12.2&nbsp;million in undiscounted advance payments to IQVIA had been paid in connection with the IQVIA agreement. Such amounts are to be recovered at the end of the relevant studies (i.e., between April 2025 and July 2026). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Evotec Drug Discovery Services Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;1, 2017, we entered into a drug discovery services agreement with Evotec International GmbH (&#147;Evotec&#148;), pursuant to
which Evotec provides drug discovery services to us, in order to have optimized leads obtained for various viral indications for further developments within the context of a global collaborative program and to any further development programs under
which we would require the assistance of Evotec in the provision of services (the &#147;Evotec Drug Discovery Services Agreement&#148;). Under the Evotec Drug Discovery Services Agreement, Evotec must provide its services in accordance with common
industry standard of current established practices by suitably qualified staff, using equipment in an agreed premises, under allocated timelines agreed between the parties and in compliance with all relevant legislation. Evotec may not subcontract
its obligations to us other than to an affiliate without our express prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for services provided, we
are required to pay Evotec an agreed set of fees as agreed in the relevant project description relating to such services. As of June&nbsp;30, 2023, we have paid &#128;7,612,000 to Evotec, and no amounts were received as of such date. We own, and
Evotec assigns to us to the extent permissible under applicable law, all intellectual property rights conceived, discovered, invented or made by Evotec in connection with the provision of drug discovery services. No milestone payments or royalties
are payable pursuant to the Evotec Drug Discovery Services Agreement. No drug candidate has currently been discovered pursuant to this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right to terminate Evotec Drug Discovery Services Agreement or any project without cause at any time upon 60 days&#146; written
notice. We and Evotec each have the right to terminate any ongoing project upon 20 days&#146; written notice for a breach by the other party, if such breach has not been remedied within the <FONT STYLE="white-space:nowrap">20-day</FONT> period. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delpharm Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;24, 2016, we entered into a manufacturing agreement with Delpharm Lille S.A.S. (&#147;Delpharm&#148;), pursuant to which
Delpharm produces batches of capsules containing obefazimod required to carry out clinical trials (the &#147;Delpharm Agreement&#148;). The Delpharm Agreement renews automatically for successive periods of one year until either party notifies the
other of its intention not to renew the agreement. The agreement is still in effect on the date hereof. Either party may terminate the agreement upon serious breach or a serious <FONT STYLE="white-space:nowrap">non-execution</FONT> of the agreement
by the other party. Abivax may also terminate the Delpharm Agreement at any time, subject to certain reimbursement obligations to Delpharm. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Seqens
Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2016, we entered into a clinical batch development and production agreement with &#147;Produits Chimiques
Auxiliaires et de Synth&egrave;se&#148; (&#147;Seqens&#148;), under which Seqens provides services relating to the development and production of active ingredients, including obefazimod (the &#147;Seqens Agreement&#148;). The Seqens Agreement was
amended on March&nbsp;2, 2021, in connection with our UC Phase 3 clinical trials. In accordance with the Seqens Agreement, in consideration for services provided, we are required to pay Seqens an agreed set of fees as agreed in the relevant Work
Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Seqens Agreement remains in full force and effect until the earlier of (i)&nbsp;the execution of an agreement for the
commercial manufacturing by Seqens of obefazimod under Phase IV, such agreement to be negotiated between Seqens and us in good faith, (ii)&nbsp;the failure to reach such a Phase IV agreement or (iii)&nbsp;the failure to obtain all marketing approval
by the FDA and other relevant regulators in Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Seqens Agreement, either party may terminate the agreement in the
event of the other party&#146;s failure to perform one or more of its obligations. This termination shall only become effective one month after the issuance by the complaining party of a registered letter with acknowledgement of receipt setting out
the reasons for the complaint, unless within this period the defaulting party has fulfilled its obligations or has provided proof of an impediment due to force majeure. The termination may take effect without delay by simple written notification in
case of fraud or intentional fault by the party in default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Seqens Agreement, we have the right to postpone or terminate
any pending work at any time upon 30 days prior written notice, subject to payment to Seqens of the sums due in proportion to the actual progress of the work on the day of receipt by Seqens of its notification, as well as any costs incurred prior to
such receipt by Seqens that would be <FONT STYLE="white-space:nowrap">non-revocable</FONT> and not subject to reallocation within a reasonable time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>State-Guaranteed Loan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;11, 2020, we obtained <FONT STYLE="white-space:nowrap">non-dilutive</FONT> financing from Soci&eacute;t&eacute; G&eacute;n&eacute;rale in the form of a &#128;5&nbsp;million State-guaranteed loan (the &#147;State-guaranteed loan&#148;). The
State-guaranteed loan had an initial duration of 12&nbsp;months (subject to a five-year extension option) and accrues interest at a rate of 0.25% with repayment of principal falling due in June 2021. The State-guaranteed loan was immediately made
available to us in June 2020. In March 2021, we entered into an amendment to the State-guaranteed loan, which extended the repayment date of the State- guaranteed loan by five years until June 2026 with a
<FONT STYLE="white-space:nowrap">one-year</FONT> deferral of principal repayment, with the following conditions: (i)&nbsp;a revised interest rate of 0.58% per annum, excluding insurance and State-guaranteed premium; and (ii)&nbsp;a State-guaranteed
premium of &#128;0.1&nbsp;million to be paid by instalments over the contract period starting in June 2021. The State-guaranteed loan includes certain customary covenants and prepayment provisions, as well as a negative covenant restricting the
disposal of assets representing more than 50% of the gross value of our fixed assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Royalties Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2008, we entered into an agreement with (i)&nbsp;the CNRS, (ii)&nbsp;the University of Montpellier, and (iii)&nbsp;the
Institut Curie, which sets out financial conditions under which we can use any intellectual property </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights and research results derived from certain research collaboration programs we had with the CNRS, the University of Montpellier, and the Institut Curie and which have now been terminated
(the &#147;Royalties Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Royalties Agreement, the CNRS and the Institut Curie are entitled to receive
milestone payments, as well as royalty payments on global net sales of products using the intellectual property rights and research results jointly developed with them (including obefazimod) (each, a &#147;Qualifying Product&#148;). The amounts of
the milestone payments for each Qualifying Product are limited and not material compared to the amount of the expected royalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case
we commercialize directly a Qualifying Product (either (i)&nbsp;implementing the jointly developed patents and the jointly developed <FONT STYLE="white-space:nowrap">know-how</FONT> or (ii)&nbsp;only implementing the jointly developed <FONT
STYLE="white-space:nowrap">know-how),</FONT> royalties due under the Royalties Agreement are in the low single-digit percentages subject to an annual minimum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we commercialize a Qualifying Product by way of a license granted to a third-party, we may elect (i)&nbsp;to pay royalties
calculated in the same manner as if we were commercializing the Qualifying Product directly, or (ii) to pay royalties (high single-digit to low double-digit percentages) calculated based on the revenues we receive under the license granted to the
third-party. We must notify the CNRS regarding which royalty amount we elect to pay at the same time that the third-party grants the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Royalties Agreement does not include any cap on the total payments which may be due by us under such Royalties
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Royalties Agreement survives until the expiration of the underlying intellectual property rights (without any termination
rights to either party). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sublease approximately 765 m&sup2; of office space and three parking spaces at <FONT STYLE="white-space:nowrap">7-11</FONT> boulevard
Haussmann, 75009 Paris, France, for our headquarters and other administrative functions. The sublease agreement has been entered into for a period of three years expiring on June&nbsp;21, 2025. Unless terminated by either party, it will be
automatically renewed for additional successive periods of one year. The sublease of these facilities may, subject to certain restrictions provided by law, be terminated by us or by the lessor from June&nbsp;30, 2024, subject to nine months&#146;
prior written notice. Furthermore, the sublease will automatically terminate in the event of the early termination of the head lease (which expires on June&nbsp;30, 2027). We believe that our facilities are sufficient to meet our current needs and
that suitable additional space will be available in the future on commercially reasonable terms, if required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we had 34 full-time employees, consisting of 18 employees within the research and development department,
six employees within the commercial, marketing and market access department, and 10&nbsp;employees within the general administrative department. Our employees based in France are subject to the national collective bargaining agreement for the
pharmaceutical industry (the <I>convention collective nationale de l&#146;industrie pharmaceutique</I>). We believe that we maintain good relations with our employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, 25 full-time employees were based in France and nine full-time employees were based in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT> we may be a party to legal, administrative or arbitration proceedings arising in the ordinary course of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we are not a party to any material legal,
administrative or arbitration proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, financial condition, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management
resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_14"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing, Management and Supervisory Bodies and Executive management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the name, age and position of each of our executive officers and directors as of June&nbsp;30, 2023. The business address of our executive officers and directors is our principal executive offices located at <FONT
STYLE="white-space:nowrap">7-11</FONT> boulevard Haussmann, 75009 Paris, France. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="50%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>POSITION(S)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and Director, Chairman of the Board</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Didier Blondel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer and Board Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheldon Sloan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Ferguson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Commercial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pierre Courteille</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Business Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors*</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director, Chair of the Appointments and Compensation Committee</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Ignelzi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director, Chair of the Audit Committee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol L. Brosgart</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinna zur Bonsen-Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Independent Director, Member of the Audit Committee and the Appointments and Compensation Committee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kinam Hong (Sofinnova Partners)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director, Member of the Audit Committee and the Appointments and Compensation Committee</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antonino Ligresti (Sant&eacute; Holdings
SRL)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Pouletty (Truffle Capital)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director, Member of the Appointments and Compensation Committee</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Independence criteria assessed in accordance with the definition provided in the Middlenext Code of
Corporate Governance </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Dr. Ligresti will resign from our Board in September 2023 in application of age limit rules, at which time a
successor will be appointed. </I></P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Marc de Garidel</B> has been our Chief Executive Officer and Chairman of the Board since May 5, 2023 and has more than 40 years of
experience in the pharmaceutical and biotechnology sector, including 12 years of experience as Chief Executive Officer of pharmaceutical and biotechnology companies. Between July 2021 and April 2023, he served as Chief Executive Officer of CinCor
Pharma and led its successful sale for up to $1.8 billion, subject to the achievement of certain milestones, to AstraZeneca in February 2023. Between September 2020 and May 2021, Mr.&nbsp;de Garidel served as Chief Executive Officer of AZTherapies.
From April 2018 until August 2020, he was Chief Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for $2.1 billion in total consideration. Mr. de Garidel was the Chief Executive Officer of Ipsen between November 2010 and
July 2016, overseeing the development of its U.S. presence. Prior to that, he worked for Amgen and Eli Lilly in jobs of increasing responsibilities and in various markets, including the United States and Europe. Mr. de Garidel has served as chairman
of the board of directors of Ipsen since 2010 and has been a member of the board of directors of Claris Bio since 2020. He holds a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, a Master&#146;s degree in International
Management from Thunderbird Global School Management and an executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MBA from Harvard Business School. We believe that Mr. de Garidel is qualified to serve on our Board because of his experience as an executive and member of the boards of companies in the life
sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Didier Blondel</B> has been our Chief Financial Officer and Board Secretary since January 2017. From January 2012
to December 2016, he was Chief Financial Officer at Sanofi Pasteur MSD, a Lyon-based joint-venture between Sanofi and Merck and a European leader in human vaccines. Prior to that, over a <FONT STYLE="white-space:nowrap">20-year</FONT> period,
Mr.&nbsp;Blondel held a wide range of senior finance positions at Sanofi, in Commercial Operations and then research and development, where he became global research and development Chief Financial Officer. He started his career as an auditor at
PricewaterhouseCoopers, after graduating with a Master&#146;s degree in Business and Administration from the Commercial Institute of Nancy, a leading French business school. Mr.&nbsp;Blondel also holds a Master&#146;s degree in Finance and
Accounting from Nancy II University, as well as a Graduate Diploma in Finance and Accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Sheldon Sloan</B> has been our Chief
Medical Officer since March 2023. He has over 30 years of experience in academia and the biopharmaceutical industry, with an extensive track record in the field of gastroenterology and IBD. From March 2022 to January 2023, Dr. Sloan was Program Lead
for etrasimod UC at Pfizer. From November 2019 to March 2022, Dr. Sloan worked for Arena Pharmaceuticals. Between September 1997 and October 2019, Dr. Sloan held different leadership positions at Johnson and Johnson in Medical Affairs, Research and
Development, and Science Policy, including Global Medical Affairs Leader for IBD, leading the global launch strategy and execution for CD and UC for Stelara. He holds a Doctor of Medicine from Rush Medical College, Chicago and a Master of Bioethics
from the University of Pennsylvania. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Michael Ferguson</B> has been our Chief Commercial Officer since April 2023. He has over 22 years
of experience in the biopharmaceutical industry, with an extensive track record in the field of Gastroenterology (GI) and IBD. From August 2019 through May 2022, Mr. Ferguson served as Vice President Global Commercial Marketing and Planning and
specifically as Global Commercial Lead for etrasimod across all GI Indications at Arena Pharmaceuticals. From March 2007 to August 2019, he held various leading commercial leadership positions at Shire/Takeda. Mr. Ferguson holds both a B.S. and an
MBA in Finance from the Pennsylvania State University as well as a post graduate degree in Pharmaceutical Marketing from St. Joseph&#146;s University, Philadelphia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Pierre Courteille</B> has been our Chief Business Officer since May 2023. Prior to this appointment, he served as our Chief Commercial
Officer and Vice President Business Development. Mr. Courteille has over 25 years of experience in marketing, sales and business development within the pharmaceutical industry (13 years based in Japan). Prior to joining us in April 2015, he was
Senior VP sales and marketing for Guerbet as well as Chief Executive Officer of MEDEX (medical devices company owned by Guerbet) from 2012. From 2009, Mr.&nbsp;Courteille served as VP Sales for Asia, Latin America and EMEA and met the ambitious
objective of optimizing commercial performance across these three regions. As President of Guerbet Japan and VP for Guerbet Asia, Mr.&nbsp;Courteille has successfully managed the roll-out of its Japanese subsidiary and led the development of other
branches in Asia. Mr. Courteille holds a pharmacy degree and MBA (with Honors) from The University of Chicago Booth School of Business. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors
</B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>June Lee</B> has been one of our independent directors since July 2023. Dr. Lee has served as a venture partner at 5AM Venture
Management, LLC since July 2022. Dr. Lee was most recently Founder and Chief Executive Officer of Esker Therapeutics until September 2021. Dr. Lee previously served as the Executive Vice President and Chief Development Officer of MyoKardia, Inc.
from January 2019 to June 2020, and was the Chief Operating Officer from February 2017 until January 2019, and the Chief Development Officer from October 2017 to January 2019. From April 2011 until February 2017, Dr. Lee served on the faculty of the
University of California, San Francisco, or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations
for enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was a disease area lead, early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as well as management of staff, budget, and
resource allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a Medical Director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities
for licensed product of the company. She currently serves on Johns Hopkins University Center for Therapeutic Translation&#146;s Advisory Board, serves on the board of directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is
a member of the Scientific Advisory Board for Foresite Labs, and previously served as a member of the board of directors of CinCor Pharma, Inc. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of
California, Davis. We believe that Dr.&nbsp;Lee is qualified to serve on our Board because of her experience as an investor and member of the boards of companies in the life sciences industry. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Troy Ignelzi</B> has been one of our independent directors since July 2023. Mr. Ignelzi has served as the Chief Financial Officer of Karuna
Therapeutics, Inc. since March 2019. Prior to that, Mr. Ignelzi was the Chief Financial Officer of scPharmaceuticals Inc. from March 2016 to February 2019, and provided consulting services to scPharmaceuticals Inc. in February and March 2016. Mr.
Ignelzi previously served as Chief Financial Officer and as a member of the executive leadership teams at Juventas Therapeutics Inc., a privately held biotechnology company, from October 2014 to February 2016. From October 2013 to October 2014, Mr.
Ignelzi served as Senior Vice President&#151;Operations and Business Development of Pharmalex GmbH. Prior to Pharmalex, Mr. Ignelzi was Vice President&#151;Business Development at Esperion Therapeutics, Inc., a public pharmaceutical company, from
January 2009 to September 2013. Mr. Ignelzi served as Vice President, Business Development &amp; Strategic Planning at Insys Therapeutics, Inc., a specialty pharmaceutical company, from February 2007 to February 2009. Previously, Mr. Ignelzi had
served as a specialty senior sales representative at Eli Lilly from February 2002 to August 2005. Mr. Ignelzi currently serves as a member of the board of directors of Vedanta Biosciences, Inc. and previously served as a member of the board of
directors of CinCor Pharma, Inc. Mr. Ignelzi has a B.S. in accounting from Ferris State University. We believe that Mr. Ignelzi is qualified to serve on our Board because of his experience as an executive and member of the boards of companies in the
life sciences industry. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Carol L. Brosgart</B> has been one of our independent directors since January 2018. She has held several
executive management positions, notably those of Chief Medical Officer at Alios (now J&amp;J), from February 2011 to August 2011, and Senior Vice President and Medical Director at the Children&#146;s Hospital and Research Center in Oakland,
California from December 2009 to January 2011. She held several executive management positions at Gilead Sciences (Vice President Clinical Research, Vice President Medical Affairs, Vice President Public Health and Strategy) between 1998 and 2009.
She has served as a member of the board of directors of Galmed Pharmaceuticals, a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases, since 2017, and Enochian Biosciences, a biotechnology company
committed to developing advanced allogenic cell and gene therapies, since 2020. Dr. Brosgart also serves as a director on the board of Mirum Pharmaceuticals, a clinical stage drug development biopharmaceutical company for rare liver diseases, since
2021. Dr.&nbsp;Brosgart is the chair of the scientific advisory board at Hepion Pharmaceuticals, formerly ContraVir, a biotech company operating in the area of NASH, HBV, HCV and HDV in the field of HBV cures. She is also a consultant at Dynavax and
several biotech companies working in the fields of liver diseases and infectious diseases. In addition, Dr.&nbsp;Brosgart currently sits on the board of the Hepatitis B Foundation, the Management Committee of the National Viral Hepatitis Roundtable,
the Executive Committee of the Forum for Collaborative Research and the Management Committee of the HBV Cure Forum. She is also a clinical professor of medicine, biostatistics and epidemiology in the Global Health Sciences Department of the
University of California, San Francisco. Dr.&nbsp;Brosgart holds a degree in Community Medicine from UC Berkeley and earned a Doctor of Medicine from UC San Francisco. We believe that Dr.&nbsp;Brosgart is qualified to serve on our Board because of
her extensive experience as an executive and as a member of the boards of companies in the life sciences industry and her medical background. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Corinn</B><B>a</B><B> </B><B>zu</B><B>r</B><B> </B><B>Bonsen-Thoma</B><B>s</B><B> </B>served as our Chair between August 2022 and May 2023
and has been one of our independent directors since June 2017. Since April 2020, Ms. zur Bonsen-Thomas has held the position of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Managing Director and Chief Executive Officer of RetInSight GmbH, a company which she co-founded in April&nbsp;2020 and specializes in ophthalmic imaging. Ms. zur Bonsen-Thomas was General
Counsel for Smart Reporting GmbH from February 2017 to December 2022. From 1999 to 2015, she served as a member of the Supervisory Board of Baxter AG, an Austrian company. She has more than thirty years of international professional experience in
the pharmaceutical, biopharmaceutical, medical and biotechnology industries. Ms. zur Bonsen-Thomas received her First Law State Examination from Ludwig Maximilian Universitaet and her Second Law State Examination from the Bavarian Ministry of
Justice. We believe that Ms. zur Bonsen-Thomas is qualified to serve on our Board because of her extensive professional experience in the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Kinam Hong </B>has served as the permanent representative of Sofinnova Partners on our Board since September 2019. He has served as the
partner responsible for Sofinnova&#146;s strategy of crossover and growth investment in late development stage companies at Sofinnova Partners since January 2017. He has served as the permanent representative of Sofinnova Partners on the board of
directors of CytoImmune Therapeutics, Inc. since July 2021 and as an observer then board member of Limflow SA since April 2018. Prior to Sofinnova Partners, Dr. Hong spent ten years as an investor and research analyst covering the biotechnology
sector. Dr. Hong co-led the Exane Equinox Fund, a global healthcare fund investing in public biotech companies. He also worked at Citigroup investment research where he focused on small- and midcap biotechnology companies. Before his investment
career, Dr. Hong worked in new product development at Sanofi, a multinational pharmaceutical company, where he held positions in business development and strategic/new product marketing. Dr. Hong is a doctor and scientist who holds a Bachelor of
Science degrees in molecular biology/biochemistry and a Doctor of Medicine from the University of Florida. He also holds a Chartered Financial Analyst and a Master of Business Administration from INSEAD, France. We believe that Dr. Hong is qualified
to serve on our Board because of his extensive experience as an investor and as a member of the boards of companies in the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Antonino Ligresti</B><B> </B>has served as the permanent representative of Sant&#233; Holdings SRL on our Board since September 14, 2015.
Dr. Ligresti has served as the reference shareholder of G&#233;n&#233;rale de Sant&#233; and a Group Director since June 2003. Dr. Ligresti has served as a member of the Executive Committee of the European Institute of Oncology and has chaired the
General Health Foundation and was Chairman of the Medical Committee. Dr. Ligresti is also currently the permanent representative of Sant&#233; Holding SRL on the board of directors of CARMAT SA, a French company engaged in the development and
production of an orthotopic and biocompatible artificial heart. Dr. Ligresti holds a Doctor of Medicine from the University of Catania in Italy. We believe that Dr. Ligresti is qualified to serve on our Board because of his experience as an
executive of several healthcare organizations and as an investor and member of the boards of companies in the life sciences industry. Dr. Ligresti will resign from our Board in September 2023 in application of age limit rules, at which time a
successor will be appointed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Philippe</B><B> </B><B>Pouletty,</B><B> </B><B>MD </B>has served as a director since December 2013 and is
our co-founder, as well as founder or co-founder of Carbios, Carmat, Vexim, Symetis, Affluent Medical, SpikImm and more than a dozen other biotechnology and medical technology companies of Truffle Capital, several being listed or were acquired. He
was the Chairman of France Biotech from 2001 to 2006 and from 2007 to 2009, the French association of biotech companies and Vice-Chairman of Europabio from 2002 to 2006, the European federation of biotechnologies. Dr. Pouletty is a member of the
board of directors or the chairman of several biotechnology and medical device companies in Europe. Dr. Pouletty, acting as permanent representative of Truffle Capital, has served as director of Pharnext SA, from April 2016 to October 2021, Carmat
SA, from April 2021 to July 2021, and Deinove SA, from 2009 to 2021. Dr. Pouletty holds a Doctor of Medicine from Universit&#233; Paris VI and was a Post-doctoral fellow at Stanford University and is a permanent member of the hall of fame of
inventors of Stanford University. We believe that Dr. Pouletty is qualified to serve on our Board because of his extensive experience as co-founder and member of the boards of companies in the life sciences industry, his medical background and his
experience as an executive of several biotechnology organizations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Family relationships </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our executive officers or directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to French law and our <FONT STYLE="white-space:nowrap">by-laws,</FONT> our Board must be comprised of between three and 18 members,
without prejudice to the derogation established by law in the event of a merger. As of the date of this prospectus, our Board is comprised of eight directors. The number of directors of each gender may not be less than 40% under French law. In case
a board of directors comprises up to eight members, the difference between the number of directors of each gender may not exceed two. Any appointment made in violation of this limit that is not remedied within six months of this appointment will be
null and void and payment of directors&#146; compensation will be suspended. Within these limits, the number of directors is determined by our shareholders. Our directors are appointed for four-year renewable terms, in accordance with our <FONT
STYLE="white-space:nowrap">by-laws</FONT> and the chairperson is appointed for the duration of his term as director. In accordance with French law, our <FONT STYLE="white-space:nowrap">by-laws</FONT> also provide that our directors may be removed
with or without cause by the holders of at least a majority of the voting rights of the shareholders present, represented by a proxy or voting by mail at the relevant ordinary shareholders&#146; meeting, and that any vacancy on our Board be filled
by a vote of a majority of our directors then in office provided that there has been no shareholders meeting since such death or resignation. Directors chosen or appointed to fill a vacancy shall be elected by the Board for the remaining duration of
the current term of the replaced director. The appointment must then be ratified at the next shareholders&#146; meeting. In the event that the Board would be composed of less than three directors as a result of a vacancy, the remaining directors
shall immediately convene a shareholders&#146; meeting to elect one or several new directors so there are at least three directors serving on the Board, in accordance with French law. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CURRENT&nbsp;POSITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>YEAR&nbsp;OF&nbsp;INITIAL</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>APPOINTMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TERM&nbsp;EXPIRATION</B><br><B>YEAR<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Chairman</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2023&nbsp;(as&nbsp;Director), 2023&nbsp;(as&nbsp;Chairman)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinna zur Bonsen-Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Ignelzi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sant&eacute; Holdings SRL<BR>(permanent representative to the Board: Antonino Ligresti)<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Truffle Capital<BR>(permanent representative to the Board: Philippe Pouletty)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol L. Brosgart</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Partners (permanent representative to the Board: Kinam Hong)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The mandates expire at the annual shareholders&#146; meeting approving the financial statements closed on
December&nbsp;31 of the previous year. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(2)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Dr. Ligresti will resign from our Board in September 2023 in application of age limit rules, at which time a
successor will be appointed. </I></P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, under the listing requirements and rules of Nasdaq, we are not required to have independent directors on our
Board, except to the extent that our audit committee is required to be consistent with independence requirements, subject to certain <FONT STYLE="white-space:nowrap">phase-in</FONT> schedules. In determining whether a director is an independent
director, our Board considers the relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with the Board and all other facts and circumstances that our Board deems relevant in determining the director&#146;s
independence, including the number of ordinary shares beneficially owned by the director and his or her affiliated entities, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have four independent directors (as defined by the Middlenext Code of
Corporate Governance), including June Lee, Troy Ignelzi, Corinna zur Bonsen-Thomas and Carol L. Brosgart. The Middlenext Code sets out the five following criteria justifying the independence of directors, characterized by the absence of any
significant financial, contractual or family relationship likely to affect their independence of judgment: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they must not be a salaried employee or corporate officer of us or our group and must not have held such a
position within the last five years; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they must not be in a significant business relationship with us or our group (e.g., client, supplier, competitor,
provider, creditor, banker, etc.) within the last two years; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they must not be a reference shareholder or hold a significant number of voting rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they must not have close relationships or family ties with any of our corporate officer or reference shareholder;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they must not have been our auditor within the last six years. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-voting</FONT> Board Members </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our <FONT STYLE="white-space:nowrap">by-laws,</FONT> the General Meeting or the Board may appoint
<FONT STYLE="white-space:nowrap">non-voting</FONT> board members. To date, no <FONT STYLE="white-space:nowrap">non-voting</FONT> directors have been appointed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of Interest Among the Management and Supervisory Bodies and Executive Management </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Chairperson and Chief Executive Officer, our Chief Financial Officer and Board Secretary and our directors are direct or indirect
shareholders or holders of securities giving access to our share capital. See &#147;Compensation and Benefits&#151;Compensation of Chief Executive Officer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are agreements between related parties, as described in &#147;Certain Relationships and Related Person Transactions.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Practices </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Governance Practices
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a French <I>soci&eacute;t&eacute; anonyme </I>(limited liability company) listed on the regulated market of Euronext Paris,
we are subject to various corporate governance requirements under French law. In particular, we refer to the Code of Corporate Governance for small and <FONT STYLE="white-space:nowrap">medium-sized</FONT> firms as published in September 2021 by
Middlenext, as amended from time to time. In addition, as a foreign private issuer listed on the Nasdaq Global Market, we will be subject to Nasdaq&#146;s corporate governance listing standards. Nasdaq&#146;s listing standards provide that foreign
private issuers are permitted to follow home country governance practices in lieu of Nasdaq rules, with certain exceptions. We intend to rely on certain exemptions for foreign private issuers and follow French corporate governance practices in lieu
of Nasdaq corporate governance rules, which would require that (i)&nbsp;a majority of our Board consists of independent directors and (ii)&nbsp;the audit committee be composed of entirely independent directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are required to comply with Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> of the Exchange Act, relating
to audit committee composition and responsibilities. Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> provides that the audit committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as control
over the performance of their duties, management of complaints made and selection of consultants. However, if the laws of the foreign private issuer&#146;s home country require that any such matter be approved by the Board or the shareholders, the
audit committee&#146;s responsibilities or powers with respect to such matter may instead be advisory. Under French law, the audit committee may only have an advisory role and appointment of our statutory auditors, in particular, must be decided by
our shareholders at our annual meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Nasdaq rules require that a listed company specify that the quorum for any
meeting of the holders of common stock (or ordinary shares) be at least 33<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB><SUB STYLE="font-size:75%; vertical-align:bottom"></SUB>&nbsp;%
of the outstanding shares of the company&#146;s common voting stock. Consistent with French Law, our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that, for ordinary shareholders&#146; meetings to be quorate,
<FONT STYLE="white-space:nowrap">one-fifth</FONT> of the holders of shares entitled to voting rights must be present in person or vote by mail or by proxy or by authorized intermediary or by any means of telecommunication permitting their
identification. An extraordinary shareholders&#146; meeting is quorate if <FONT STYLE="white-space:nowrap">one-fourth</FONT> of the holders of shares entitled to voting rights are present or vote by mail or by proxy or by authorized intermediary or
by any means of telecommunication. As an exception, an extraordinary shareholders&#146; meeting deciding upon a share capital increase by capitalization of reserves, profits or share premium as the same quorum requirement as an ordinary
shareholders&#146; meeting. If the requirements for a quorum are not satisfied, the meeting is adjourned. When an adjourned ordinary shareholders&#146; meeting is resumed, there is no quorum requirement. When an adjourned extraordinary
shareholders&#146; meeting is resumed, there is a quorum of <FONT STYLE="white-space:nowrap">one-fifth</FONT> of the holders of shares entitled to voting rights. If a quorum is not present, the reconvened extraordinary shareholders&#146; meeting may
be adjourned for a maximum of two months. No deliberation by the shareholders may take place without a quorum. For special meetings of holders of a certain class of shares, the quorum requirement is <FONT STYLE="white-space:nowrap">one-third</FONT>
of the certain class of shares entitled to voting rights for the meeting convened on the first call, notice and <FONT STYLE="white-space:nowrap">one-fifth</FONT> of the holders of shares entitled to voting rights, should the meeting be reconvened.
See &#147;Description of Share Capital&#151;Shareholders&#146; Meetings and Voting Rights (Article 22 of the <FONT STYLE="white-space:nowrap">By-Laws)&#151;Quorum.&#148;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board consists of eight members and the composition of our Board is described further below in this section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules of procedure of our Board set the principles guiding the composition of the Board. The most recent version of this document was
adopted by our Board in April 2021. We have established an audit committee, appointment and compensation committee and scientific committee, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has established two permanent, specialized committees to assist the Board in its work: the audit committee and the appointments and
compensation committee, as well as one ad hoc committee, the scientific committee. Subject to available exemptions the composition and functioning of all of our committees will comply with applicable requirements of the French Commercial Code, the
Exchange Act, the Nasdaq Global Market and SEC rules and regulations.<B><I> </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with French law, committees of our
Board only have an advisory role and can only make recommendations to our Board. As a result, decisions will be made by our Board taking into account <FONT STYLE="white-space:nowrap">non-binding</FONT> recommendations of the relevant Board
committee. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mission and
Responsibilities </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee monitors issues relating to the elaboration and control of accounting and financial
information as provided for by French law and by our <FONT STYLE="white-space:nowrap">by-laws</FONT> and by the rules of procedure of the Board. It then formulates recommendations to the Board in its task of permanent control of our management. It
also issues recommendations in relation to the proposed statutory auditors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is responsible for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the preparation and development of accounting and financial information and, where appropriate,
formulating recommendations in this respect to ensure its accuracy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the efficiency of the internal control and risk management systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensuring proper legal oversight of the preparation of the annual financial statements and financial statements by
the statutory auditors; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting and ensuring the independence of the statutory auditors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is also responsible for approving: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by the statutory auditors (including the
permitted level of fees); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all budgets for statutory audits and other engagements provided by the statutory auditors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee further controls the services provided by the auditors in relation to what is permitted by law or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is responsible for formulating recommendations regarding the statutory auditors proposed for nomination by the General
Meeting of Shareholders and/or during the renewal of their term. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within this context, the audit committee may examine our annual
financial statements in the form that they are presented to the Board, hear the opinions of the statutory auditors and the finance director and receive communications in relation to their analysis work and their conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee may use external experts at our expense, after approval of the chairperson of the Board or the audit committee or of the
Chief Executive Officer, and render any expert reports to the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee may hear any director and carry out any internal
or external audit on any subject it considers relevant to its mission. The chairperson of the audit committee shall inform the Board in advance. In particular, the audit committee has the power to interview the persons involved in the preparation of
the accounts or in their control (administrative and financial director and the main managers of the financial department). </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Composition and
Compensation </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee and chairperson of the audit committee are appointed by the Board from members of the Board,
excluding executive directors, with finance or accounting skills and at least one member must be independent in accordance with the provisions of the Middlenext Code. Members of the audit committee are appointed for a fixed period of time, which may
not exceed the duration of their terms of office as director and may be revoked by the Board at any time and without reason. Appointments are renewable without limitation. The audit committee is composed of at least two members and members receive
no compensation other than attendance fees. Their duties on the audit committee may be taken into account in determining the allocation of such attendance fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current members of the audit committee are Troy Ignelzi, Corinna zur Bonsen-Thomas and Kinam Hong (representing Sofinnova Partners). The
current chairperson of the audit committee is Mr. Ignelzi. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The committee may invite any person, internal or external to us, to take
part in its meetings and its work. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has determined that each of the members of our audit committee is independent within the
meaning of the applicable listing rules and the independence requirements contemplated by Rule <FONT STYLE="white-space:nowrap">10A-3.</FONT> Committee members must be competent in financial or accounting matters and at least one member must be
independent in accordance with the provisions of the Middlenext Code. Our Board has further determined that Mr. Ignelzi is an &#147;audit committee financial expert&#148; as defined by SEC rules and regulations and that Mr. Ignelzi qualifies as
financially sophisticated under the applicable exchange listing rules. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditions of Functioning </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee meets when the chairperson of the audit committee, at least two members of the audit committee, the chairperson of the
Board or the Chief Executive Officer deems useful and at least twice per year, particularly before publication of the financial statements. The committee may be convened by any means 24&nbsp;hours before the meeting by the chairperson of the audit
committee or of the Board or any individual to whom </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
one of them shall have delegated the necessary authority. The committee meets at the registered office or in any other place specified in the notice of the meeting. It may also meet by video
conference or by any means of telecommunication as specified in the internal regulation of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To deliberate validly, at least
half of the members of the committee must be present. At meetings, one member of the audit committee may be represented by another audit committee member and the audit committee&#146;s recommendations are adopted by simple majority. Upon completion
of each meeting, if the members deem it necessary, meeting minutes may be prepared. The chairperson of the audit committee regularly reports to the Board on the committee&#146;s work and immediately report any difficulty encountered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointments and Compensation Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mission and
Responsibilities </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee makes recommendations to the Board in relation to the nomination of,
and compensation for, executive directors and the operational and functional management, and with regard to appointments and compensation policy and internal profit sharing. In particular, the appointments and compensation committee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provides recommendations and proposals to the Board concerning the appointment, in particular in the research of
a balanced representation of men and women on the Board, compensation, retirement and provident scheme, supplementary pension benefits, benefits in kind, various financial rights of our managers and executive officers, the allocation of founder
warrants, bonus shares, share subscription warrants, share subscription or share purchase options, for the benefit of our employees, managers or consultants and, where applicable, its subsidiaries, in accordance with legal provisions;
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defines the methods for determining the variable portion of the compensation of corporate officers and monitors
its application; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proposes a general policy for awarding founder warrants, free or performance shares, and options to subscribe or
purchase shares, and determines the frequency thereof, depending on the categories of beneficiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">examines the system of for the allocation of directors&#146; fees among the members of the Board, particularly
according to their participation in our committees; and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expresses its opinion to senior management about the compensation of the principal senior executives.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee is also involved in discussing each independent director&#146;s
qualifications upon his or her nomination and during the exercise of his or her term of office, as applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Composition and Compensation </I></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee is composed of at least two members. The chairperson of the compensation committee and the
committee&#146;s members are appointed by the Board from members of the Board. Members are appointed for a fixed period of time, which may not exceed, as applicable, the duration of their term of office as director and may be revoked by the Board at
any time and without reason. Their appointments shall be renewable without limitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of the Board, if not a member of
the appointments and compensation committee, may be invited to participate in the appointments and compensation committee&#146;s meetings. The appointments and compensation committee shall invite him/her to present its proposals. He/she shall not
have the right to vote and shall not be present during the deliberations relating to his/her own situation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current members of the appointments and compensation committee are June Lee,
Philippe Pouletty (representing Truffle Capital), Corinna zur Bonsen-Thomas and Kinam Hong (representing Sofinnova Partners). The current chairperson of the compensation committee is Dr. Lee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee may invite any person, internal or external to us, to take part in its meetings and its work. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Appointments and compensation committee members shall receive no compensation other than attendance fees. Their duties on the compensation
committee may be taken into consideration in determining the allocation of such attendance fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditions of Functioning </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee meets when the chairperson of the appointments and compensation committee, at least two members of
the appointments and compensation committee, the chairperson of the Board or the Chief Executive Officer deems useful and at least once a year. The appointments and compensation committee may be convened by any means, 24 hours before the meeting, by
the chairperson of the appointments and compensation committee or of the Board, or any individual to whom one of them shall have delegated the authority necessary for the convocation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The committee meets at the registered office or in any other place specified in the notice of the meeting. It may also meet by video
conference or by any means of telecommunication, as specified in the internal regulation of the Board. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To deliberate validly, at
least half of the members of the committee must be present. A member of the appointments and compensation committee may be represented by another appointments and compensation committee member and the appointments and compensation committee&#146;s
recommendations are adopted by simple majority. Upon completion of each meeting, if the members deem it necessary, meeting minutes may be prepared. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The appointments and compensation committee chairperson reports regularly to the Board on the appointments and compensation committee&#146;s
work and shall immediately report any difficulty encountered. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mission and Responsibilities </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
scientific committee was created by a decision by the Board on September&nbsp;27, 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The role of the scientific committee is to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">examine specific scientific questions submitted to it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make recommendations for determining the general guidelines to be adopted in the scientific field; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make recommendations for defining our priorities in the field of research and development and the means for
achieving such objectives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The committee meets at least once a year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It works in collaboration with the Chief Executive Officer, who may request its opinion on subjects related to its mission. At the request of
the Board, the chairperson of the scientific committee reports on the committee&#146;s work to the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Composition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scientific committee is composed of at least four members appointed by the Board upon proposal of the Chief Executive Officer. The members
of the scientific committee do not have to be members of the Board. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current members of the scientific committee are Prof. Ian
McGowan, MD, PhD, (Chairman); Prof. Christian Br&eacute;chot; Prof. Christoph Huber; Prof. J&uuml;rgen Rockstroh; Prof. Christian Trepo; Prof. Lawrence R. Stanberry; Prof. Luc Teyton; and Claude Bertrand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition of the scientific committee is currently under review in light of our needs for the continued development of our clinical
programs. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we intend to adopt a Code of Business Conduct and Ethics policy in connection with the offering. Under this policy, our employees
and members of our Board have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related-party transactions, our Board will take into
account the relevant available facts and circumstances including, but not limited to: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits and perceived benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the opportunity costs of alternative transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the materiality and character of the related party&#146;s interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the actual or apparent conflict of interest of the related party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">and the terms available to or from, as the case may be, unrelated third parties or to or from employees
generally. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related-party
transaction, our Board must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as our Board determines in the good faith exercise of its
discretion. All of the transactions referred to above were entered into prior to the adoption of the written related-party transaction policy but all were approved by our Board to the extent required by, and in compliance with, French law. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation and Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of Chief Executive Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets out the compensation awarded to our Chief Executive Officer in the applicable period: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Marc de Garidel&#151;Chief Executive Officer and Chairman from May 5, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Fixed compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Variable annual compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:6.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:6.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Variable multi-year compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Exceptional variable compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Remuneration allocated due to mandate as director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Benefits in kind</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>N/A</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>N/A</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Hartmut Ehrlich&#151;Chief Executive Officer until May 5, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Fixed compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>303,685</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>321,906</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Variable annual
compensation<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>144,250</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>193,144</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Variable multi-year compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Exceptional variable compensation</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>43,384</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Remuneration allocated due to mandate as director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Benefits in kind</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>8,880</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>8,880</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>500,199</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>523,930</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Variable compensation paid for the financial year corresponds to the amount due for the previous year.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate compensation paid and benefits in-kind granted by us to our current executive officers and directors,
including share-based compensation, for the year ended December 31, 2022 and 2021 were &#128;1.0 million and &#128;0.9 million, respectively. For both years, we did not allocate any amounts to be set aside or accrued to provide pension, retirement
or similar benefits to our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets out the compensation awarded to our directors in the applicable period: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>YEAR&nbsp;ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinna zur Bonsen-Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joy Amundson<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Jacques Bertrand<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sant&eacute; Holdings SRL<BR>(permanent representative to the Board: Antonino Ligresti)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Truffle Capital<BR>(permanent representative to the Board: Christian Pierret)<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol L. Brosgart</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Partners (permanent representative to the Board: Kinam Hong)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June Lee<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Ignelzi<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Pouletty<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,350</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>80,065</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of July 2023, Ms. Amundson resigned from our Board, and Dr. Lee was appointed to our Board.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of July 2023, Mr. Bertrand resigned from our Board, and Mr. Ignelzi was appointed to our Board.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On May 5, 2023, Dr. Pouletty resigned from his personal office as director and became Truffle Capital&#146;s
representative to the Board in replacement of Mr. Pierret. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the general meeting of shareholders held on June&nbsp;9,
2022, our shareholders approved a package of attendance fees and the compensation policy applicable to the chairperson of the Board and the Chief Executive Officer. For the fiscal year ended June&nbsp;30, 2023, none of the amounts set aside or
accrued to provide pension, retirement or similar benefits to our employees was attributable to our executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth the AGAs allocated to the chairperson and chief executive officer: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>CHAIRPERSON&nbsp;&amp; CEO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Allocation date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Type&nbsp;of&nbsp;AGAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;AGAs</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>allocated</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Subscription&nbsp;price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Acquisition period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">July-11-2023</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Free&nbsp;Shares&nbsp;2023-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,382,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Minimum&nbsp;of&nbsp;1&nbsp;year&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(*)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,382,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acquisition Periods shall be as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 212,738 Free Shares 2023-1: the Acquisition Period shall end on the first (1st) anniversary of the allocation
date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 638,214 Free Shares 2023-1: the Free Shares 2023-1 shall progressively be definitively acquired on a monthly
basis over a period of three (3) years starting after the first (1st) anniversary of the allocation date (i.e. 17,728 Free Shares 2023-1 per month except for the last month of the three-year period where 17,734 Free Shares 2023-1 shall be acquired).
The duration of the Acquisition Period of these Free Shares 2023-1 shall be calculated accordingly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 212,738 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i)&nbsp;the first
(1st) anniversary of the allocation date, and (ii)&nbsp;the date on which a specific performance condition is fulfilled (condition&nbsp;1); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 106,369 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i)&nbsp;the first
(1st) anniversary of the allocation date, and (ii)&nbsp;the date on which a specific performance condition is fulfilled (condition&nbsp;2); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 106,369 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i)&nbsp;the first
(1st) anniversary of the allocation date, and (ii)&nbsp;the date on which a specific performance condition is fulfilled (condition&nbsp;3); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For 106,368 Free Shares 2023-1: the Acquisition Period shall end on the first (1st)&nbsp;anniversary of the
allocation date subject to the completion, prior to such date, of a specific performance condition (condition&nbsp;4). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>History of
Awards of Share Warrants (BSAs), Founder&#146;s Share Warrants (BCEs) and Free Shares (AGAs) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The history of the award of BSAs,
BCEs and AGAs is set forth in the Section &#147;Description of Share Capital.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions or Allocations to Pay Pensions, Retirement or
Other Benefits for Directors and Management </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended December&nbsp;31, 2022, none of the amounts set aside or
accrued to provide pension, retirement or similar benefits to our employees was attributable to our administrative, supervisory or management bodies. We have not set aside any provisions to pay pensions, retirement and other benefits for corporate
directors. The directors&#146; compensation does not include any profit-sharing plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Functioning of Governing and Management Bodies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Company Management </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a French
limited liability company with a board of directors (<I>soci&eacute;t&eacute; anonyme &agrave; conseil d&#146;administration</I>). Since May 5, 2023, our Board has been chaired by our Chief Executive Officer, Mr. de Garidel, who represents us <I><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT></I> third parties in his capacity as Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All members of the Board may serve for a maximum of four years, expiring at the end of the shareholders&#146; meeting called to approve the
financial statements from the previous year and held during the year in which the term expires. Members of the Board may be <FONT STYLE="white-space:nowrap">re-elected.</FONT> They may be dismissed at any time by a decision of the ordinary general
meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended December&nbsp;31, 2022, the Board met 18 times. The average attendance rate of the
Directors was approximately 98%. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreements with our Directors and Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of our agreements with certain of our directors and executive officers, see &#147;Certain Relationships and Related Person
Transactions.&#148; Except for the arrangements described in such section, there are no arrangements or understandings between us and any of our other executive officers or directors that provide for benefits upon termination of their employment,
other than as required by applicable law. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, provisions of <FONT STYLE="white-space:nowrap">by-laws</FONT> that limit the liability of directors are prohibited. However,
French law allows <I>soci&eacute;t&eacute;s anonyme </I>to contract for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, provided that they acted in good
faith and within their capacities as directors or officers of Abivax SA. Criminal liability cannot be indemnified under French law, whether directly by us or through liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain liability insurance for our directors and officers, including insurance against liability under the Securities Act and we intend
to enter into agreements with our directors and executive officers to provide contractual indemnification. With certain exceptions and subject to limitations on indemnification under French law, these agreements will provide for indemnification for
damages and expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding arising out of his or her actions in that capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These agreements may discourage shareholders from bringing a lawsuit against our directors and executive officers for breach of their
fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and executive officers, even though such an action, if successful, might otherwise benefit us and our shareholders.
Furthermore, a shareholder&#146;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these insurance agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers or
partnerships, be insured and/or indemnified against certain liabilities in their capacity as members of our Board. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any
underwriting agreement we enter into in connection with the sale of ordinary shares (including in the form of ADSs) being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and
persons who control us within the meaning of the Securities Act against certain liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we had 34 full-time employees, consisting of 18 within the research and development department and 16 within the
general administrative department. Our employees based in France are subject to the national collective bargaining agreement for the pharmaceutical industry (the <I>convention collective nationale de l&#146;industrie pharmaceutique</I>). We believe
that we maintain good relations with our employees. As of June&nbsp;30, 2023, 25 full-time employees were based in France and nine full-time employees were based in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on skilled, experienced and innovative employees to conduct the operations of our company. We are committed to building an
outstanding, committed team and we focus on a culture that values a focus on scientific innovation, inclusion, collaboration and equity. We focus on recruiting, retaining and developing employees from a diverse range of backgrounds to conduct our
research, development, clinical, commercial, marketing and market access activities. We recognize that recruiting, motivating and retaining talented employees is vital to our success. The principal purposes of our equity and cash incentive plans are
to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their
abilities and achieve our objectives. We aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing, expanding and retaining our workforce to
support our current pipeline and future business goals. Employees are encouraged to attend scientific, clinical and technological meetings and conferences and have access to broad resources they need to be successful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_15"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2021, we have engaged in the following transactions with our directors, executive officers and holders of more than
5% of our outstanding voting securities and their affiliates, which we refer to as to our related parties. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intra-Group Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;1, 2022, we acquired 100% of the share capital of Prosynergia S.&agrave;.r.L, a Luxembourg biotech company pursuant to the terms
of a share purchase agreement entered into on November&nbsp;15, 2021 (the &#147;Prosynergia SPA&#148;). On December&nbsp;1, 2021, we granted a loan to Prosynergia, for &#128;1,400,000. On December 12, 2022, we completed a merger with Prosynergia
through a <I>Transmission Universelle du Patrimoine</I> (&#147;TUP&#148;) and all of Prosynergia&#146;s assets and liabilities were transferred to us. Following the merger, Prosynergia was dissolved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrangements with our Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Securities </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
issued (i) 1,964,031 ordinary shares in a private placement on July&nbsp;27, 2021; (ii)&nbsp;5,530,000 ordinary shares in a private placement on September&nbsp;7, 2022; and (iii)&nbsp;20,000,000 ordinary shares in a private placement on February 23,
2023. The following table summarizes the ordinary shares acquired in connection with these offerings by our executive officers, directors and holders of more than 5% of our outstanding voting securities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Entities&nbsp;affiliated<BR>with<BR>Truffle&nbsp;Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Sofinnova</B><br><B>Crossover</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TCG<BR>Crossover</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Entities<BR>affiliated</B><br><B>With<BR>Venrock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deep<BR>Track<BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Invus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private placement in 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Number of ordinary shares purchased (#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Purchase price per share (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private placement in 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Number of ordinary shares purchased (#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,688,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,126,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Purchase price per share (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private placement in 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Number of ordinary shares purchased (#)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,535,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Purchase price per share (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 197,000 ordinary shares subscribed by FCPI BioMedTech, which is controlled by Truffle Capital
(&#147;Truffle Capital&#148; and together the &#147;Truffle Entities&#148;), itself controlled at 39.66% (of the share capital) respectively by Dr.&nbsp;Philippe Pouletty, a member of our Board, and Mr.&nbsp;Bernard-Louis Roques. The principal
business address of the Truffle Entities is 5 rue de la Baume, 75008, Paris, France. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,039,900 ordinary shares subscribed by Venrock Healthcare Capital Partners EG, L.P.
(&#147;VHCP EG&#148;), (ii) 384,623 ordinary shares subscribed by Venrock Healthcare Capital, Partners III, L.P. (&#147;VHCP III&#148;), and (iii) 38,477 ordinary shares subscribed by VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT>
Holdings III, LLC </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(&#147;VHCP <FONT STYLE="white-space:nowrap">Co-Investment&#148;).</FONT> VHCP EG, VHCP III and VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> are controlled by Venrock
(&#147;Venrock&#148; and together the &#147;Venrock Entities&#148;). Venrock Entities are controlled by Dr.&nbsp;Bong Koh and Nimish Shah. The principal business address of the Venrock Entities is 7, Bryant Park, 23rd Floor, <FONT
STYLE="white-space:nowrap">New-York,</FONT> NY 10018, United States. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 817,420 ordinary shares subscribed by VHCP EG, (ii) 302,335 ordinary shares subscribed by VHCP
III, and (iii) 30,245 ordinary shares subscribed by VHCP Co-Investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further issued 374 ordinary shares on
November&nbsp;9, 2020 to the benefit of Mr.&nbsp;Didier Blondel, our Chief Financial Officer and Board Secretary. Following his exercise of 374 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1,</FONT></FONT> he holds 374
ordinary shares at an issue price per share equal to &#128;6.39. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further issued royalty certificates on September 7, 2022 to each of
FCPI BioMedTech, Deep Track Biotechnology Master Fund, Ltd., Sofinnova Crossover I SLP, TCG Crossover Fund I, L.P., Invus Public Equities, L.P., and VHCP III. The terms and conditions of these royalty certificates are further detailed in an exhibit
to this registration statement for the global offering of which this prospectus forms a part. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director and Executive Officer Compensation
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are parties to employment agreements and other compensation arrangements, including equity compensation arrangements, with
our directors and executive officers in the ordinary course of business. See &#147;Compensation and Benefits&#151;Compensation of Chief Executive Officer&#148; for information regarding compensation of the Directors and Executive Officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with each of our executive officers, except for our Chief Executive Officer, who is a corporate
officer (mandataire social) with whom we have entered into a management contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Chief Executive Officer has been appointed for a
term lasting until the end of the Board meeting following the general meeting of shareholders held to approve the financial statements for the year ending December 31, 2026. He has also been appointed as Chairman of the Board for a term lasting
until the end of the Board meeting following the general meeting of shareholders held to approve the financial statements for the year ending December 31, 2024. In case of termination of the Chief Executive Officer as a result of
(i)&nbsp;non-renewal, (ii) revocation except for gross negligence or willful misconduct and/or (iii) resignation justified by invalidity or health issues or Mr. de Garidel&#146;s definitive retirement (a &#147;Qualifying Departure&#148;), Mr. de
Garidel shall be entitled to a severance payment equal to 12 months of the higher of either (i) the monthly average fixed remuneration and variable remuneration received by Mr. de Garidel during the 12-month period preceding the effective date of
the Qualifying Departure, or (ii) the monthly average fixed remuneration received by Mr. de Garidel during the 12-month period preceding the effective date of the Qualifying Departure plus 1/12th of the variable remuneration for the financial year
immediately preceding the date of the Qualifying Departure, irrespective of the date of payment of that variable remuneration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
February 2023, we entered into an offer letter with Dr. Sloan. Dr. Sloan may terminate his employment with us without good reason (as defined in his offer letter), and we may terminate his employment with us without cause (as defined in his offer
letter) upon four months of notice. If Dr. Sloan&#146;s employment is terminated by us without cause or Dr. Sloan resigns with good reason (as defined in his offer letter), then he will be entitled to receive severance pay in an amount equal to (i)
six months of his then-current base compensation, (ii) prorated portion of the variable compensation and (iii) any premiums for healthcare plans provided by us (including any eligible COBRA coverage) for the earlier of a period of six months from
the date of termination and the date on which Dr. Sloan becomes eligible to receive such benefits with a new employer. The offer letter also includes a non-competition provision lasting during and for six months following his employment with us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, we entered into an offer letter with Mr. Ferguson. Mr. Ferguson may terminate his employment with us without good reason
(as defined in his offer letter), and we may terminate his employment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with us without cause (as defined in his offer letter) upon four months of notice. If Mr. Ferguson&#146;s employment is terminated by us without cause or Mr. Ferguson resigns with good reason (as
defined in his offer letter), then he will be entitled to receive severance pay in an amount equal to (i) six months of his then-current base compensation, (ii) prorated portion of the variable compensation and (iii) any premiums for healthcare
plans provided by us (including any eligible COBRA coverage) for the earlier of a period of six months from the date of termination and the date on which Mr. Ferguson becomes eligible to receive such benefits with a new employer. The offer letter
also includes a non-competition provision lasting during and for six months following his employment with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our executive
officers has agreed to maintain the confidentiality of any confidential information, both during and after the employment/management agreement expires or is earlier terminated. In addition, they are subject to loyalty and confidentiality obligations
and certain of them are bound by a non-solicitation covenant that prohibits such executive officer from soliciting our customers, or soliciting or hiring our executive employees and those of our employees working in the same team as our executive
officer, during his or her employment/office and for one year after the termination of his or her employment/office. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Warrants (bons de
souscription d&#146;actions) </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2021, we have not granted any share warrants or founder&#146;s warrants to
employees, consultants or directors. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Assignment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 7, 2021, we entered into an intellectual property assignment agreement with Hartmut Ehrlich, who served as our Chief Executive Officer
until May 5, 2023. The purpose of this agreement is to transfer to us all the intellectual property rights held by Dr. Hartmut Ehrlich on certain patents of which he is a <FONT STYLE="white-space:nowrap">co-inventor.</FONT> No compensation has been
paid in respect of this transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Free Shares (attributions gratuites d&#146;actions) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2022, Dr. Hartmut Ehrlich received long-term remuneration in the form of a grant of free shares. As of June
30, 2023, all of these free shares have become null and void, as the performance conditions applicable to such free shares have not been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further entered into a transition protocol with Dr. Hartmut Ehrlich, our previous Chief Executive Officer, according to which he was
granted by a Board decision on July 11, 2023 100,000 free shares that are subject to the achievement of specific performance conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, pursuant to a Board decision on July 11, 2023, we have allocated a total number of 1,382,796 free shares to Mr. Marc de Garidel, as
our current Chief Executive Officer, to which performance conditions and presence conditions apply. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transition Protocol </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of Dr. Hartmut Ehrlich&#146;s upcoming retirement and in order to ensure a smooth transition with our new Chief Executive Officer and
protect our interests, the Board approved, during its meeting on April 18, 2023, the entering into a transition protocol with Dr. Hartmut Ehrlich which provides that Dr. Hartmut Ehrlich will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be entitled to the payment of a departure indemnity equal to &#128;1,209,825; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agree to be bound by a non-compete undertaking for a duration of twelve months following the termination of his
role as Chief Executive Officer (not compensated); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">remain our employee on a part-time basis until December 31, 2023 in a capacity as advisor to the new Chief
Executive Officer against payment of a total compensation of &#128;100,000; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be eligible to receive up to 100,000 free shares depending on the achievement of specific performance conditions.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into this transition protocol on April 18, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The payment of Dr. Hartmut Ehrlich&#146;s departure indemnity will be subject to shareholders&#146; approval pursuant to Article L. 22-10-34
of the French Commercial Code. The entering into the transition protocol is subject to the procedure applicable to related-party agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend
to enter into indemnification agreements with our Board members and the members of our executive management. See the section of this prospectus titled &#147;Management&#151;Limitations on Liability and Indemnification.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
comply with French law regarding approval of transactions with related parties. In particular, in accordance with article <FONT STYLE="white-space:nowrap">L.225-38</FONT> and seq. of the French Commercial Code, transactions with our general
managers, directors, shareholders holding more than 10% of the voting rights of the company and any company controlling a shareholder holding more than 10% of our voting rights, other than transactions in the ordinary course of business and at
arm&#146;s length, are (i)&nbsp;subject to a prior approval by the Board, (ii)&nbsp;reported to the statutory auditors who must then prepare a report on such transaction, and (iii)&nbsp;ratified by the our shareholders at the annual general meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have adopted a related-party transaction policy that sets forth our procedures for the identification, review,
consideration and approval or ratification of related-party transactions. For purposes of our policy only, a related-party transaction is defined as (1)&nbsp;any individual or series of financial transactions, arrangements or relationships
(including any indebtedness or guarantee of indebtedness), in which we and any related parties are, were or will be participants, or otherwise have a direct or indirect interest, or (2)&nbsp;any agreement or similar transaction under French law
which falls within the scope of Article L. <FONT STYLE="white-space:nowrap">225-38</FONT> of the French Commercial Code. For purposes of this policy, a related party is any person who is or at any time since the beginning of the our last fiscal year
was, a director, director nominee, executive officer, beneficial owner of more than 10% of any class of our voting securities or any immediate family member(s) of the foregoing persons, or any firm, corporation or other entity in which any of the
foregoing persons is employed or is a partner or principal or in a similar position or in which such person has more than a 10% beneficial ownership interest. Under the policy, related-party transactions must be reported to us by the relevant
related parties. If a transaction has been identified as a related-party transaction, management must present information regarding the related-party transaction to our Board for review, consideration and approval or ratification. Regarding certain
transactions, our Board may appoint an independent expert whenever the signing of a related person transaction is likely to have a material impact on our balance sheet or results. In this case, this expert review will be mentioned in the special
report of the statutory auditors and disclosed to the public subject, as the case may be, to any information likely to adversely affect trade secret. Our Board may also seek the opinion of the audit committee and/or of the independent statutory
auditors if there is any doubt about the qualification of a related person transaction subject to his evaluation. When submitted to our Board&#146;s review, the persons who have a direct or indirect interest in the transaction shall not participate
in its review. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_16"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes set forth information with respect to the beneficial ownership of our ordinary shares as of
June 30, 2023 for: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each beneficial owner, known by us, of more than 5% of our outstanding ordinary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors and executive officers individually; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To our knowledge, as of June 30, 2023, approximately 20,223,539 ordinary shares, or 47.53% of our outstanding ordinary shares, were held of
record by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; residents of the United States. To our knowledge, as of June 30, 2023, approximately 10,026,568 ordinary shares, or 23.57% of our outstanding ordinary shares, were held in bearer form and,
accordingly, it is not possible for us to ascertain if such ordinary shares are held by persons located in the United States. See &#147;Description of Share Capital&#151;Form, Holding and Transfer of Shares (Articles&nbsp;10 and 11 of the <FONT
STYLE="white-space:nowrap">By-Laws).&#148;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC. These rules
generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include ordinary shares that can be acquired within 60 days of June&nbsp;30, 2023. The
percentage ownership information shown in the table prior to the global offering is based upon 42,536,081 ordinary shares outstanding as of June 30, 2023 (excluding 11,487 treasury shares issued by us). The percentage ownership information shown in
the table after the global offering is based upon ordinary shares outstanding (excluding 11,487 treasury shares issued by us), assuming the sale of ordinary shares (which may be in the form of ADSs) by us in the global offering and no exercise of
the underwriters&#146; option to purchase additional ADSs and/or ordinary shares. The percentage ownership information shown in the table after the global offering if the underwriters&#146; option to purchase additional ADSs and/or ordinary shares
is exercised in full is based upon ordinary shares outstanding (excluding 11,487 treasury shares issued by us), assuming the sale of ordinary shares (which may be in the form of ADSs) by us in the global offering and the exercise in full of the
underwriters&#146; option to purchase additional ADSs and/or ordinary shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, the table below does
not reflect any ordinary shares that may be purchased in the global offering, all of the shares reflected in the table are ordinary shares and all persons listed below have sole voting and investment power with respect to the shares beneficially
owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In computing the number of ordinary shares beneficially owned by a person and the percentage ownership of that person, we deemed outstanding
ordinary shares subject to options and warrants held by that person that are immediately exercisable or exercisable within 60 days of June&nbsp;30, 2023. We did not deem these shares outstanding, however, for the purpose of computing the percentage
ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in the table below is based on information known to us or ascertained by us
from public filings made by the shareholders (which may be in the form of ADSs). Except as otherwise indicated in the table below, addresses of the directors, executive officers and named beneficial owners are in care of Abivax SA, <FONT
STYLE="white-space:nowrap">7-11&nbsp;boulevard</FONT> Haussmann, 75009 Paris, France. Our major shareholders do not have any special voting rights. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2"><B>NAME OF BENEFICIAL OWNER</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ORDINARY</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>SHARES</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>BENEFICIALLY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OWNED&nbsp;BEFORE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OFFERING</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PERCENTAGE OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ORDINARY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>SHARES&nbsp;BENEFICIALLY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OWNED</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PERCENTAGE OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>VOTING POWER+</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>BEFORE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OFFERING</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>AFTER</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OFFERING</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>BEFORE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OFFERING</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>AFTER</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OFFERING</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Truffle Capital(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,869,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCG Crossover(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,338,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,191,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Crossover(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,064,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Capital(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,126,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Venrock(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,613,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Didier Blondel(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pierre Courteille(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheldon Sloan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Ferguson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Troy Ignelzi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol L. Brosgart(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinna zur Bonsen-Thomas(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kinam Hong (representing Sofinnova Partners)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Antonino Ligresti (representing Sant&#233; Holdings SRL)(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.97</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Pouletty (representing Truffle Capital)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and officers as a group (12&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A double voting right is attached to each registered ordinary share (except treasury share) that is held in the
name of the same shareholder for at least two years. For additional information, see &#147;Description of Share Capital&#151;Attendance and Voting at Shareholders&#146; Meetings.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 2,213,333 ordinary shares held by FCPR Truffle Capital II (&#147;Truffle Capital II&#148;),
(ii) 1,357,639 ordinary shares held by FCPI UFF Innovation 7 (&#147;UFF Innovation&nbsp;7&#148;), (iii) 119,000 ordinary shares held by FCPI UFF Innovation 15 (&#147;UFF Innovation 15&#148;), (iv) 171,600 ordinary shares held by FCPI Fortune 4
(&#147;FCPI Fortune 4&#148;), (v) 91,973 ordinary shares held by FCPI Fortune 3&nbsp;(&#147;FCPI Fortune 3&#148;) (vi) 157,100 ordinary shares held by FCPI UFF Innovation 12 (&#147;UFF Innovation 12&#148;), (vii) 193,900 ordinary shares held by FCPI
UFF Innovation 8 (&#147;UFF Innovation 8&#148;), (viii) 103,400 ordinary shares held by FCPI UFF Innovation 14 (&#147;UFF Innovation 14&#148;), (ix) 84,983 ordinary shares held by FCPI Truffle Fortune 5 (&#147;FCPI Fortune 5&#148;), (x) 54,120
ordinary shares held by FCPI UFF Innovation 16 (&#147;UFF Innovation 16&#148;), (xi) 28,263 ordinary shares held by FCPI Truffle Fortune 6 (&#147;FCPI Fortune 6&#148;), (xii) 23,493 ordinary shares held by FCPI UFF Innovation 17 (&#147;UFF
Innovation 17&#148;), (xiii) 16,394 ordinary shares held by FCPI Truffle Innocroissance 2015 (&#147;Truffle Innocroissance 2015&#148;), (xiv) 36,400 ordinary shares held by Truffle Developpement (&#147;Truffle Developpement&#148;), (xv) 21,252
ordinary shares held by FCPI Truffle </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Innocroissance 2018 (&#147;Truffle Innocroissance 2018&#148;) and (xvi) 197,000 ordinary shares held by FCPI BioMedTech (&#147;BioMedTech&#148;). Truffle Capital II, UFF Innovation 7, UFF
Innovation 15, FCPI Fortune 4, FCPI Fortune 3, UFF Innovation 12, UFF Innovation 8, UFF Innovation 14, FCPI Fortune 5, UFF Innovation 16, FCPI Fortune 6, UFF Innovation 17, Truffle Innocroissance 2015, Truffle Developpement, Truffle Innocroissance
2018 and BioMedTech are controlled by Truffle Capital (&#147;Truffle Capital&#148; and together the &#147;Truffle Entities&#148;), itself controlled at 39.66% (of the share capital) respectively by Dr.&nbsp;Philippe&nbsp;Pouletty and
Mr.&nbsp;Bernard-Louis Roques. The principal business address of the Truffle Entities is 5 rue de la Baume, 75008, Paris, France. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 4,338,000 ordinary shares held by TCG Crossover Management, LLC. (&#147;TCG Crossover&#148;) acting
on behalf of funds it manages. TCG Crossover is controlled by TCG Crossover GP I, LLC (&#147;TCG Crossover GP&#148; and together the &#147;TCG Crossover Entities&#148;), itself controlled at the highest level by its managing partners. TCG Crossover
declares that it acts independently of the persons who control it, in accordance with the conditions set out in Articles L. 233-9 II of the French Commercial Code and 223-12 and 223-12-1 of the General Regulation of the AMF. The principal business
address of the TCG Crossover Entities is c/o Corporation Trust Center 1209 Orange St., DE 19801, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 4,191,422 ordinary shares held by Invus Public Equities, L.P. (&#147;Invus&#148;). The latter is
controlled by Mr.&nbsp;Pascal Minne. The registered address of the Invus is Clarendon House, 2 Church Street, Hamilton HM11, &#206;les des Bermudes. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 4,064,739 ordinary shares held by Sofinnova Crossover I SLP (&#147;Sofinnova Crossover&#148;).
Sofinnova Crossover is controlled by Sofinnova Partners (&#147;Sofinnova Partners&#148; and together the &#147;Sofinnova Entities&#148;). The principal business address of the Sofinnova Entities is 7-11 boulevard Haussmann, 75009 Paris, France.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,126,000 ordinary shares held by Deep Track Biotechnology Master Fund, Ltd. (&#147;Deep Track
Fund&#148;) acting on behalf of funds it manages. Deep Track Fund is controlled by Deep Track Capital GP, LLC. The latter is controlled by Mr.&nbsp;David Kroin who is also its managing member. The principal business address of the Deep Track
Entities is 200 Greenwich Avenue 3rd Floor, Greenwich, CT 06830, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,857,320 ordinary shares held by Venrock Healthcare Capital Partners EG, L.P. (&#147;VHCP
EG&#148;), (ii) 686,958 ordinary shares held by Venrock Healthcare Capital, Partners III, L.P. (&#147;VHCP III&#148;), and (iii) 68,722 ordinary shares held by VHCP Co-Investment Holdings III, LLC (&#147;VHCP Co-Investment&#148;). VHCP EG, VHCP III
and VHCP Co-Investment are controlled by Venrock (&#147;Venrock&#148; and together the &#147;Venrock Entities&#148;). Venrock Entities are controlled by Dr.&nbsp;Bong Koh and Nimish Shah. The principal business address of the Venrock Entities is 7,
Bryant Park, 23rd Floor, New-York, NY 10018, United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes up to 67,000 ordinary shares issuable upon the exercise of options and warrants that are immediately
exercisable or exercisable within 60 days of June 30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes up to 67,373 ordinary shares issuable upon the exercise of options and warrants that are immediately
exercisable or exercisable within 60 days of June 30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes up to 16,400 ordinary shares issuable upon the exercise of options and warrants that are immediately
exercisable or exercisable within 60 days of June 30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes up to 16,400 ordinary shares issuable upon the exercise of options and warrants that are immediately
exercisable or exercisable within 60 days of June 30, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes up to 96,924 ordinary shares issuable upon the exercise of options and warrants that are immediately
exercisable or exercisable within 60 days of June 30, 2023. Dr. Ligresti will resign from our Board in September 2023 in application of age limit rules, at which time a successor will be appointed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_17"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as a
<I>soci&eacute;t&eacute; anonyme</I> (limited liability company), on December&nbsp;4, 2013 and registered at the Paris Trade and Company Register on December&nbsp;27, 2013 for a period of 99 years until December&nbsp;22, 2112, subject to extension
or early dissolution, under the number 799&nbsp;363&nbsp;718. Our corporate purpose in France and abroad includes the research, development and marketing of therapeutic and prophylactic vaccines and small therapeutic molecules that primarily have
applications in the anti-infective field, as set forth in Article 4 of our by-laws. We may participate, by any means, directly or indirectly in any operations that may be related to our purpose through the creation of new companies, contribution,
subscription or purchase of company securities or rights, merger or otherwise, creation, acquisition, leasing, management lease of any businesses or establishments. Our principal executive offices are located at
<FONT STYLE="white-space:nowrap">7-11&nbsp;boulevard</FONT> Haussmann, 75009&nbsp;Paris, France, and our telephone number is +33&nbsp;(0)&nbsp;1&nbsp;53&nbsp;83&nbsp;08&nbsp;41. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our <FONT STYLE="white-space:nowrap">by-laws</FONT> and share capital does not purport to be complete and is
qualified in its entirety by reference to our <FONT STYLE="white-space:nowrap">by-laws</FONT> as of the date of this prospectus. Copies of our <FONT STYLE="white-space:nowrap">by-laws</FONT> may be obtained from the Trade and Company Registry
(<I>Greffe du Registre du Commerce et des Soci&eacute;t&eacute;s</I>) of Paris, France or our corporate headquarters and are filed as an exhibit to this registration statement for the global offering of which this prospectus forms a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Capital History </I></B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, our share capital amounts to &#128;223,131.85 and is divided into 22,313,185 ordinary shares of &#128;0.01<B>
</B>par value each after taking into account: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAR&nbsp;VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT&nbsp;OF&nbsp;PAID</B><br><B>UP CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,313,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">223,131.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,313,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.01</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">223,131.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares are fully subscribed and paid. As of the date of this prospectus, we have not issued
securities that do not represent our share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the changes in our share capital over the last three fiscal
years. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<br>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br>shares<br>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<br>number of<br>shares after<br>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<br>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<br>capital after<br>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<br>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">07/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,019.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,203,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,032.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">11/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,032.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,219,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,196.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">16/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,196.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,222,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">17/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,222,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">22/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,224,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,240.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<br>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br>shares<br>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<br>number of<br>shares after<br>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<br>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<br>capital after<br>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<br>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">11/02/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,240.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,225,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,256.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">17/03/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-7</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,256.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,228,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,282.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">29/07/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-7</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,282.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,230,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,308.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">30/10/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Conversion of convertible bonds</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,308.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,995,356.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,695,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,951.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,951.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,983,789.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,620,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,315,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,155.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">09/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,155.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,386.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,315,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,159.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">30/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,159.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,316,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,166.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/12/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,166.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,623.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,318,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,183.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">08/12/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,183.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,320,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,202.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">04/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,202.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,321,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,212.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,212.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,322,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,220.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,220.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,324,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,240.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,240.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,325,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,253.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">07/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,253.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,327,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,273.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">08/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,273.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,343,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">11/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,343,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">12/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,344,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,447.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">22/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,447.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,346,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,462.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">28/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,462.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,347,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,472.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">28/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,472.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523,343.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,394,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,942.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">01/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,942.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,397,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,972.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,972.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,002.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">09/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,000.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,404,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,042.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">22/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,032.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,406,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,062.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,062.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,408,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,085.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<br>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br>shares<br>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<br>number of<br>shares after<br>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<br>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<br>capital after<br>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<br>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,085.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,810.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,411,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,113.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">03/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,113.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,895.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,411,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,117.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">25/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,117.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,531,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,317.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">26/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,317.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,249,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,581,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,817.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">31/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,817.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">519,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,601,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,601,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">03/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,623,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,237.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">15/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,237.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,626,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,262.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">24/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,262.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,646,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,462.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">25/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,462.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,651,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,512.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">29/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,512.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,661,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,612.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">30/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,612.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,671,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,712.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">01/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,712.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,673,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,732.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">02/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,732.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">539,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,693,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,932.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">05/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,932.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">944,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,728,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,282.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">22/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issuance of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,282.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,981,506.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.692.268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,922.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">06/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,922.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,731.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,693,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,933.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">09/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,933.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,327.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,696,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,963.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">09/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,963.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,696,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,967.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">10/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,967.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,292.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,706,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,067.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">20/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,067.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,282.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,709,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,097.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">18/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,097.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,710,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,107.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">20/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,107.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,245.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,713,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,137.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">20/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,137.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,005.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,717,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,171.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">25/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,171.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,718,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,181.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<br>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br>shares<br>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<br>number of<br>shares after<br>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<br>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<br>capital after<br>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<br>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">25/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,181.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,719,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,191.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">30/11/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,191.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,740,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,401.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">21/12/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,401.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,048.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,764,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,640.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">08/03/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,640.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,444.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,764,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167.643,85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">30/05/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167.643,85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,783,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,831.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">07/09/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,831.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,175,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,530,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,313,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,131.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">20/01/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap">BCE-2014-4</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,131.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,331,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">27/02/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,331,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">10/05/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,347,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,479.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">24/05/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of BSA-2018-KREOS-A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,479.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488,786.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,415,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,158.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">24/05/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of BSA-2018-KREOS-b</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,158.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,830.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,447,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">19/06/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap">BCE-2014-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,547,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Meetings and Voting Rights (Articles 12, 22, 23, 24, 25 and 26 of the <FONT
STYLE="white-space:nowrap">By-Laws)</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the French Commercial Code (<I>Code de Commerce</I>), there are three types of shareholders&#146; meetings: ordinary,
extraordinary and special. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinary shareholders&#146; meetings are required to elect, replace or remove directors, appoint independent
statutory auditors, approve the annual financial statements, approve share repurchase programs, declare dividends or authorizing dividends to be paid in shares and approve regulated agreements. In addition, pursuant to AMF recommendation, French
listed companies may be required to conduct a consultation of the Ordinary Shareholders Meeting prior to the disposal of the majority of their assets, under certain conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Extraordinary shareholders&#146; meetings are required for approval of matters such as amendments to our
<FONT STYLE="white-space:nowrap">by-laws,</FONT> including amendments required in connection with extraordinary corporate actions (i.e., changing our name, corporate purpose or registered office, increasing or decreasing our share capital and
creating a new class of equity securities (ordinary or preferred shares)). Shareholders&#146; rights may be modified as allowed by French law. Only the extraordinary shareholders&#146; meeting is authorized to amend any and all provisions of our <FONT
STYLE="white-space:nowrap">by-laws.</FONT> It may not, however, increase shareholder commitments without the prior approval of each shareholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of holders of a certain category of shares or of securities giving access to our share capital are required for any
modification of the rights relating to such categories of shares. The resolutions of the shareholders&#146; meeting modifying these rights are effective only after they have been approved by the relevant special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special Voting Rights of Warrant Holders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, the holders of warrants of the same class (<I>i.e.,</I> warrants that were issued at the same time and with the same rights),
including founder&#146;s share warrants, are entitled to vote as a separate class at a general meeting of that class of warrant holders under certain circumstances, principally in connection with any proposed modification of the terms and conditions
of the class of warrants or any proposed issuance of preferred shares or any modification of the rights of any outstanding class or series of preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders&#146; Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board convenes an annual ordinary shareholders&#146; meeting for the approval of the annual financial statements. This meeting is held
within six months of the end of each fiscal year. This period may be extended by an order of the President of the French Commercial Court (<I>Tribunal de Commerce</I>) at the request of the Board. The Board may also convene an ordinary or
extraordinary shareholders&#146; meeting upon proper notice at any time during the year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Board fails to convene a
shareholders&#146; meeting at the shareholders&#146; request, our statutory auditors may call the meeting. In the event of bankruptcy, the liquidator or court-appointed agent may also call a shareholders&#146; meeting. In addition, any of the
following may request the President of the French Commercial Court to appoint an agent to convene the shareholders&#146; meeting: one or several shareholders holding at least 5% of our share capital, any interested party in cases of urgency, the
workers council in cases of urgency or duly qualified associations of shareholders who have held their shares in registered form for at least two years and who together hold a minimum number of the voting rights of our share capital. Shareholders
holding a majority of the share capital or voting may also convene a shareholders&#146; meeting after the filing of a public offer or sale of a controlling interest in our share capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders&#146; meetings shall be chaired by the chairperson of the Board or, in his or her absence, by a Deputy chairperson or by a
director elected for this purpose. Failing that, the meeting itself shall elect a chairperson. Vote counting shall be performed by the two members of the meeting who are present and accept such duties, who represent, either on their own behalf or as
proxies, the greatest number of votes. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice of Shareholders&#146; Meeting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to French law requirements in relation to notice of shareholders&#146; meetings and announce shareholders&#146; meetings at
least 35 days in advance by means of a preliminary notice published in the <I>Bulletin des annonces l&eacute;gales obligatoires</I> (BALO), as well as on our website at least 21&nbsp;days prior to the meeting. At least 15 days prior to the date set
for a shareholders&#146; meeting, or ten days if it is a second call, we must publish a final notice in accordance with French law requirements. In addition to the particulars relative to us, the final notice indicates, notably, the meeting&#146;s
agenda and the draft resolutions that will be presented. The requests for recording of issues or draft resolutions on the agenda must be addressed to the company under the conditions provided for in the current legislation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, shareholders can only take action at shareholders&#146; meetings on matters listed on the agenda for the meeting. As an exception
to this rule, shareholders may take action, among other things, with respect to the dismissal of directors, even if these actions have not been included on the agenda. The Board must submit properly proposed resolutions to a vote of the
shareholders. When a shareholder submits a blank proxy form without naming a representative, his vote is deemed to be in favor of the resolutions (or amendments) proposed or recommended by the Board and against all others. As of the date of the
publication of the final notice of a meeting but no later than four business days before the shareholders&#146; meeting, any shareholder may submit written questions to the Board relating to the agenda for the meeting. The Board must respond to
these questions during the meeting. A common answer can be given to several questions if they have the same content or bear on the same topic. The answer to a written question is deemed to have been given insofar as it is published on our website in
a section devoted to questions and answers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agenda and Conduct of Annual Shareholders&#146; Meetings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agenda of the shareholders&#146; meeting shall appear in the notice to convene the meeting and is set by the author of the notice. The
shareholders&#146; meeting may only deliberate on the items on the agenda except for the removal of directors and the appointment of their successors which may be put to vote by any shareholder during any shareholders&#146; meeting. Pursuant to
French law and our current share capital, one or more shareholders representing 5% of our share capital may request the inclusion of items or proposed resolutions on the agenda. Such request must be received at the latest on the 25th day preceding
the date of the shareholders&#146; meeting, and in any event no later than the 20th day following the date of the convening notice to the shareholders&#146; meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Attendance and Voting at Shareholders&#146; Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of one share implies, <I>ipso jure</I>, adherence to our <FONT STYLE="white-space:nowrap">by-laws</FONT> and the decision of the
shareholders&#146; meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting rights attached to equity or dividend shares are proportional to the percentage of the share
capital they represent. Each share entitles the holder to one vote. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, a double voting right compared to that conferred to
other shares with regard to the percentage of share capital they represent is allocated to all fully <FONT STYLE="white-space:nowrap">paid-up</FONT> ordinary shares with proof of being held in registered form by the same owner for at least two
(2)&nbsp;years. Under French law, treasury shares or ordinary shares held by entities controlled by us are not entitled to voting rights and do not count for quorum purposes. Purchasers of ADSs or ordinary shares in this global offering, in the open
market following the completion of this global offering or in subsequent offerings will be unlikely to meet the requirements to have double voting rights attach to any ordinary shares held by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to participate in any general meeting, shareholders are required to have their shares registered under the conditions and time limits
provided for the applicable laws before such general meeting in their name or in the name of an intermediary registered on their behalf, either in the registered shares shareholder account or in the bearer shares shareholder account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proxies and Votes by Mail or Videoconference </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, all shareholders who have properly registered and fully paid their shares or duly presented a certificate from their accredited
intermediary may participate in shareholders&#146; meetings. Shareholders may participate in shareholders&#146; meetings either in person, by proxy or by mail or, if provided for by the <FONT STYLE="white-space:nowrap">by-laws,</FONT> by
videoconference or by any means of telecommunications in accordance with applicable regulations, if the Board provides for such possibility when convening the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proxies are sent to any shareholder upon request. In order to be counted, such proxies must be received at our registered office, or at any
other address indicated on the notice convening the meeting, prior to the date of the meeting. A shareholder may grant proxies to his or her spouse, civil partner, to another shareholder or to any other person (individual or legal) of his/her/its
choice. A shareholder that is a corporation may grant proxies to a legal representative. A shareholder who is a <FONT STYLE="white-space:nowrap">non-resident</FONT> of France may be represented at a shareholders&#146; meeting by an intermediary
registered under the conditions set forth by French law. Alternatively, the shareholder may send a blank proxy to us without nominating a representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to votes by mail, we will send shareholders a voting form. The completed form must be returned to us at least three days prior to
the date of the shareholders&#146; meeting. The final date for returning votes by mail is disclosed in the notice of meeting published in accordance with French law requirements. Under our <FONT STYLE="white-space:nowrap">by-laws,</FONT>
shareholders&#146; meetings by means of telecommunications permitting their identification are possible if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Board so determines in the preliminary or final notice of the meeting. Shareholders voting by proxy, mail, authorized intermediary or, if provided for in the preliminary or final notice of
the meeting by any means of telecommunications permitting them to be identified, will be considered to be present at the meeting for the computation of the quorum and the majority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder who has voted by correspondence will no longer be able to participate directly in the meeting or to be represented. In the case
of returning the proxy form and the voting by correspondence form, the proxy form is taken into account, subject to the votes cast in the voting by correspondence form. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quorum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For an ordinary
shareholders&#146; meeting to be quorate, <FONT STYLE="white-space:nowrap">one-fifth</FONT> of the holders of shares entitled to voting rights must be present in person or vote by mail or by proxy or by authorized intermediary or by any means of
telecommunication permitting their identification. An extraordinary shareholders&#146; meeting is quorate if <FONT STYLE="white-space:nowrap">one-fourth</FONT> of the holders of shares entitled to voting rights are present or vote by mail or by
proxy or by authorized intermediary or by any means of telecommunication. As an exception, an extraordinary shareholders&#146; meeting deciding upon a share capital increase by capitalization of reserves, profits or share premium has the same quorum
requirement as an ordinary shareholders&#146; meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the requirements for a quorum are not satisfied, the meeting is adjourned. When
an adjourned ordinary shareholders&#146; meeting is resumed, there is no quorum requirement. Extraordinary shareholders&#146; meetings require a quorum of <FONT STYLE="white-space:nowrap">one-fifth</FONT> of the holders of shares entitled to voting
rights. If a quorum is not present, the reconvened meeting may be adjourned for a maximum of two months. No deliberation by the shareholders may take place without a quorum. For special meetings of holders of a certain class of shares, the quorum
requirement is <FONT STYLE="white-space:nowrap">one-third</FONT> of the certain class of shares entitled to voting rights for the meeting convened on the first call. Should the special meeting be reconvened, the quorum requirement is <FONT
STYLE="white-space:nowrap">one-fifth</FONT> of the certain class of shares entitled to voting rights for the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Majority </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A simple majority of shareholders may pass a resolution at either an ordinary shareholders&#146; meeting or an extraordinary shareholders&#146;
meeting deciding upon a share capital increase by capitalization of reserves, profits or share premium. At any other extraordinary shareholders&#146; meeting, a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the shareholder votes
cast is required. A unanimous shareholder vote is required to increase shareholders&#146; liabilities. Abstention from voting by those present either in person or by means of telecommunications if provided for by the
<FONT STYLE="white-space:nowrap">by-laws,</FONT> or those represented by proxy or voting by mail is counted as a vote against the resolution submitted to a shareholder vote. In general, each shareholder is entitled to one vote per share at any
shareholders&#146; meeting. Under the French Commercial Code, shares of a company held by it or by entities controlled directly or indirectly by that company are not entitled to voting rights and do not count for quorum or majority purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Statements and Other Communications with Shareholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the annual ordinary shareholders&#146; meeting, we must provide or make available to any shareholder a set of documents
including, among other things, our annual report, the annual and consolidated accounts, the statutory auditors&#146; reports and a draft of the meeting&#146;s resolutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of the Board is required to deliver a special report to the annual ordinary shareholders&#146; meeting regarding the
composition of the Board, the representation of men and women in its composition, the status of the preparation and organization of the work of the Board, the status of the internal control procedures that we have implemented, including those in
connection with the treatment of the accounting and financial statements and principles and rules that it establishes to determine management compensation and benefits. French law requires that a special report be provided annually to the ordinary
shareholders&#146; meeting regarding stock options authorized and/or granted by the company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights, Preferences and Restrictions Attaching to Ordinary Shares (Articles&nbsp;7, 11, 30, 31 and 32 of
the <FONT STYLE="white-space:nowrap">By-Laws)</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We only distribute dividends out of our &#147;distributable profits,&#148; plus any amounts filed in its reserves that the shareholders decide
to make available for distribution, other than those reserves that are specifically required by French law or our <FONT STYLE="white-space:nowrap">by-laws.</FONT> &#147;Distributable profits&#148; consist of our net profit in each fiscal year, as
increased or reduced by any profit or loss carried forward from prior years, less any contributions to the reserve accounts pursuant to French law or our <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Reserve </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French
law, we are required to allocate 5% of our net income for each fiscal year, after reduction for losses carried forward from previous years, if any, to a legal reserve fund until the amount in the legal reserve is equal to 10% of the aggregate
nominal value of the share capital. The legal reserve subject to this requirement may only be used to offset losses when other reserves cannot be used and, in particular, may not be distributed to shareholders until our liquidation. As of
December&nbsp;31, 2022, our legal reserve was &#128;0. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Approval of Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders may decide in an ordinary shareholders&#146; meeting, upon proposal of the Board, to allocate all or part of the distributable
profits to special or general reserves, to carry them forward to the following fiscal year as retained earnings, or to allocate them to the shareholders as dividends. Dividends may be paid in cash or as shares upon the option of the shareholders if
such option is granted at the annual ordinary shareholders&#146; meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we have earned distributable profits since the end of the
preceding fiscal year, as reflected in an interim income statement certified by its auditors, the Board may distribute interim dividends to the extent of the distributable profits for the period covered by the interim income statement before
approval of the annual financial statements. Subject to French law, the Board may declare interim dividends paid in cash without obtaining shareholder approval. For interim dividends paid in shares, prior authorization by an ordinary
shareholders&#146; meeting is required. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distribution of Dividends and Timing of Payment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In principle, dividends are distributed to shareholders pro rata according to their respective shareholdings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Timing of Payment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, we
must pay any dividends within nine months of the end of our fiscal year, unless otherwise authorized by an order of the President of the French Commercial Court. Dividends on shares that are not claimed within five years of the date of declared
payment revert to the French State. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of interim dividends, distributions are made to shareholders on the date set by our
Board during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an annual shareholders&#146; meeting or by our Board in the absence of such a decision by the
shareholders. Shareholders that own shares on the actual payment date are entitled to the dividend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders may be granted an option
to receive dividends in cash or in shares, in accordance with legal conditions. The conditions for payment of dividends in cash shall be set at the shareholders&#146; meeting or, failing this, by the Board. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Increases in Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share capital may only be increased by obtaining the approval of the shareholders at an extraordinary shareholders&#146; meeting upon the
recommendation of the Board. The decision to increase share capital through increases in the nominal value of existing shares requires unanimous approval at an extraordinary shareholders&#146; meeting. The decision to increase share capital through
the capitalization of reserves, profits and/or share premiums must be submitted to an extraordinary shareholders&#146; meeting applying the quorum and majority requirements applicable to ordinary shareholders&#146; meetings. In the case of an
increase in share capital in connection with the payment of a share dividend the voting and quorum procedures of an ordinary shareholders&#146; meetings apply. All other share capital increases require the approval of an extraordinary
shareholders&#146; meeting. See &#147;Description of Share Capital&#151;Shareholders&#146; Meetings and Voting Rights (Articles 6, 12 and 22 of the <FONT STYLE="white-space:nowrap">By-Laws)&#148;</FONT> above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Increases in our share capital may be effected by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuing additional shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increasing the par value of existing shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">creating a new class of equity securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercising the rights attached to securities giving access to the share capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Increases in share capital by issuing additional securities may be effected through one or a combination of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in consideration for cash; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in consideration for assets contributed in kind; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through an exchange offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by conversion of previously issued debt instruments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by capitalization of profits, reserves or share premium; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain conditions, by way of offset against debt incurred by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain conditions, shareholders may delegate the authority (<I>d&eacute;l&eacute;gation de comp&eacute;tence</I>) or the powers
(<I>delegation de pouvoirs</I>) to carry out certain increases in our share capital to the Board following approval at an extraordinary shareholders&#146; meeting. The Board may further <FONT STYLE="white-space:nowrap">sub-delegate</FONT> this right
to the Chief Executive Officer. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reduction in Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, any reduction in our share capital requires approval of the shareholders at an extraordinary shareholders&#146; meeting. The
share capital may be reduced either by decreasing the nominal value of the outstanding shares or by reducing the number of outstanding shares. The number of outstanding shares may be reduced by the repurchase and cancellation of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of each class of shares must be treated equally unless each affected shareholder agrees otherwise. As a general matter, reductions of
capital occur pro rata among all shareholders, except (i)&nbsp;in the case of a share buyback program, or a public tender offer to repurchase shares, where such a reduction occurs pro rata only among tendering shareholders and (ii)&nbsp;in the case
where all shareholders unanimously consent to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-pro-rata</FONT></FONT> reduction. In any case, we must not own more than 10% of our outstanding share capital. The extraordinary
shareholders&#146; meeting may authorize the <FONT STYLE="white-space:nowrap">buy-back</FONT> program for a period not exceeding 18 months. In addition, we may not cancel more than 10% of our outstanding share capital over any <FONT
STYLE="white-space:nowrap">24-month</FONT> period. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferential Subscription Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to French law, existing shareholders have preferential subscription rights to these securities on a pro rata basis if we issue
certain kinds of additional securities. These preferential subscription rights require us to give priority treatment to existing shareholders. The rights entitle the individual or entity that holds them to subscribe to an issue of any securities
that may increase our share capital by means of a cash payment or a settling of cash debts. Pursuant to legislation, which entered into force on October&nbsp;1, 2016, subscription rights are transferable during a period starting two days prior the
opening of the subscription period (or, if such day is not a business day, the preceding trading day) and ending two days prior the closing of the subscription period (or, if such day is not a business day, the preceding trading day). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the shares entitled to vote at an extraordinary shareholders&#146; meeting
may vote to waive preferential subscription rights with respect to any particular offering or a portion of that offering. French law requires that the Board and our statutory auditors present reports that specifically address any proposal to waive
preferential subscription rights. In the event of a waiver, the issue of securities must be completed within the period prescribed by French law. The shareholders may also decide at an extraordinary shareholders&#146; meeting to give existing
shareholders a <FONT STYLE="white-space:nowrap">non-transferable</FONT> priority right to subscribe to such new securities during a limited period of time. Shareholders also may notify us that they wish to waive their own preferential subscription
rights with respect to any particular offering if they so choose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a share capital increase without preferential
subscription rights to existing shareholders, French law requires that the capital increase be made at a price equal to or exceeding the weighted-average market price of the shares in the three trading days preceding the setting of the price (such
weighted-average-market price may be reduced by a maximum discount of 5%). However, within the limit of 10% of the share capital per year, the extraordinary shareholders&#146; meeting may authorize the Board to set the issuing price in accordance
with terms established by the extraordinary shareholders&#146; meeting. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Holding and Transfer of Shares (Articles 10 and 11 of the <FONT
STYLE="white-space:nowrap">By-Laws)</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that the shares once fully paid may be held in registered or bearer form at the
option of the shareholder, subject to applicable laws. Shares not fully paid must be nominal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holding of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with French law, shareholders&#146; ownership rights are represented by book entries instead of share certificates. Shares issued
are registered in individual accounts opened by us or any authorized intermediary, in the name of each shareholder and kept according to the terms and conditions laid down by the legal and regulatory provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any owner of our shares may elect to have its shares held in registered form and registered in its name in an account currently maintained by
Uptevia, 12 place des Etats-Unis, CS 40083, 92549 Montrouge Cedex, France for and on our behalf or held in bearer form and recorded in its name in an account maintained by an accredited financial intermediary, such as a French broker, bank or other
authorized financial institution. Any shareholder may, at its expense, change from one form of holding to the other. Both methods are operated through Euroclear. In addition, according to French law, shares held by any
<FONT STYLE="white-space:nowrap">non-French</FONT> resident may be held on the shareholder&#146;s behalf in a collective account or in several individual accounts by an intermediary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When our shares are held in bearer form by a beneficial owner who is not a resident of France, Euroclear may agree to issue, upon our request,
a bearer depository receipt with respect to such shares for use only outside France. In this case, the name of the holder is deleted from the accredited financial intermediary&#146;s books. Title to the shares represented by a bearer depository
receipt will pass upon delivery of the relevant receipt outside France. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with applicable laws, we may request the information referred to in <FONT
STYLE="white-space:nowrap">Article&nbsp;L.228-2</FONT> of the French Commercial Code at any time from the central depository responsible for holding our shares. Thus, we are at any time entitled to request the name and year of birth or, in the case
of a legal entity, the name and the year of incorporation, nationality and address of the holders of our shares or other securities granting immediate or future voting rights, held in bearer form, and the number of shares or other securities so held
and, if applicable, the restrictions relating to such securities. Furthermore, under French law, any intermediary who acts on behalf of one or more persons who are not domiciled in France must declare that it is acting as an intermediary. We may
also request the identity of the shareholders on whose behalf it is acting. Consequently, the owner of shares recorded in a collective account or in several individual accounts by an intermediary will be represented in the shareholders&#146;
meetings by this intermediary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">by-laws</FONT> do not contain any restrictions relating to the transfer of shares. Shares are freely
negotiable, subject to applicable legal and regulatory provisions. French and European law provide for standstill obligations and prohibition of insider trading. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are liquidated,
any assets remaining after payment of our debts, liquidation expenses and all of our remaining obligations will be distributed first to repay in full the nominal value of our shares (up to the amount of the
<FONT STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">non-liquidated</FONT> share capital). Any surplus will be distributed pro rata among shareholders in proportion to the nominal value of their shareholdings, taking
into account, where applicable, the rights attached to shares of different classes. Shareholders shall only bear losses up to the amount of their contributions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure Requirements for Holdings Exceeding Certain Thresholds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Declaration of Crossing of Ownership Thresholds (Article 11.2 of the <FONT STYLE="white-space:nowrap">By-laws)</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to certain disclosure requirements under French law. Any individual or entity, acting alone or in concert with others, that
acquires, either directly or indirectly, shares representing more than 5%, 10%, 15%, 20%, 25%, 30%, 33<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;1</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>%, 50%, 66<SUP
STYLE="font-size:75%; vertical-align:top">&nbsp;2</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>%, 90% or 95% of our outstanding share capital or voting rights or that increases or decreases its shareholding or voting rights above
or below any of those percentage thresholds, must notify us and the French Market Authority (<I>Autorit&eacute; des March&eacute;s </I><I>Financiers</I>) (&#147;AMF&#148;), within four trading days of the date on which such threshold was crossed.
French law and AMF regulations impose additional reporting requirements on persons who acquire more than 10%, 15%, 20% or 25% of the outstanding shares or voting rights of a listed company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a shareholder fails to comply with the notification requirements under French law, the shares or voting rights in excess of the relevant
threshold will be deprived of voting rights until the end of a <FONT STYLE="white-space:nowrap">two-year</FONT> period following the date on which the owner of such shares has complied with the notification requirements. They may also be suspended
for up to five years and may be subject to criminal fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that any
shareholder, acting alone or in concert, who comes into possession, in any manner whatsoever, either directly or indirectly, of a number of shares representing 2% of our share capital and/or voting rights must, by registered letter with
acknowledgment of receipt sent to the registered office, or any other equivalent means for the shareholders or security holders residing outside of France, within five trading days of crossing such threshold, notify us of the total number of shares
and voting rights he or she owns and the number of securities he or she owns that give access to the capital and voting rights attached thereto. This disclosure requirement shall apply, under the conditions above, each time a new threshold of 2% of
capital and/or voting rights is met or exceeded, for whatever reason, including beyond the legal threshold of 5%. If the shares have not been reported under the above conditions, the shares exceeding the fraction that should have been
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reported are denied the right to vote in shareholders&#146; meetings, if at a shareholders&#146; meeting, the failure to report was recorded and if one or more shareholders holding together not
less than 5% of capital or voting rights so request at that meeting. The denial of voting rights applies to any shareholders&#146; meeting to be held until the expiration of a period of two years from the date of regularization of the reporting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to publish the total number of voting rights and shares composing the share capital (if such numbers vary from the
numbers previously published) on a monthly basis. The AMF makes this information public. We are subject to AMF regulations regarding public tender offers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, and subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 30% threshold shall file a mandatory
public tender offer with the AMF. Also, any shareholder holding directly or indirectly a number between 30% and 50% of the capital or voting rights and who, in less than 12 consecutive months, increases his/her/its holding of capital or voting
rights by at least 1% of the company&#146;s capital or voting rights, shall file a mandatory public tender offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treasury Shares and Purchases of our
Own Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not permitted to hold more than 10% of our share capital in treasury shares or to have more than 10% of our share
capital to be held for us by our subsidiaries. Treasury shares are not entitled to dividends, voting rights or preferential subscription rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Repurchase and Redemption of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, we may acquire our own shares. Such acquisition may be challenged on the ground of market abuse regulations. However, EU
Market Abuse Regulation 596/2014 of April&nbsp;16, 2014 (&#147;MAR&#148;) provides for safe harbor exemptions when the acquisition is made for the following purposes only: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to decrease our share capital, provided that such a decision is not driven by losses and that a purchase offer is
made to all shareholders on a&nbsp;pro rata&nbsp;basis, with the approval of the shareholders at an extraordinary meeting. In this case, the shares repurchased must be cancelled within one month from the expiry of the purchase offer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to meet obligations arising from debt securities that are exchangeable into equity instruments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide shares for distribution to employees or managers under a profit-sharing, free share or share option
plan. In this case the shares repurchased must be distributed within 12 months from their repurchase failing which they must be cancelled; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under a <FONT STYLE="white-space:nowrap">buy-back</FONT> program to be authorized by the shareholders in
accordance with the provisions of Article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.&nbsp;22-10-62</FONT></FONT> of the French Commercial Code and in accordance with the general regulations of, and market practices accepted
by the AMF. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All other purposes, and especially share <FONT STYLE="white-space:nowrap">buy-backs</FONT> made for
external growth operations in pursuance of Article L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">22-10-62</FONT></FONT> of the French Commercial Code, while not forbidden, must be pursued in strict compliance of market
manipulation and insider dealing rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under MAR and in accordance with the general regulations (<I>r&eacute;glement
g&eacute;n&eacute;ral</I>) of the AMF, or the General Regulations, a corporation shall report to the competent authority of the trading value on which the shares have been admitted to trading or are traded, no later than by the end of the seventh
daily market session following the date of the execution of the transaction, all the transactions relating to the <FONT STYLE="white-space:nowrap">buy-back</FONT> program, in a detailed form and in an aggregated form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No such repurchase of shares may result in us holding, directly or through a person acting on our behalf, more than 10% of our issued share
capital. Shares repurchased by us continue to be deemed &#147;issued&#148; under French law but are not entitled to dividends or voting rights so long as we hold them directly or indirectly, and we may not exercise the preferential subscription
rights attached to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership of Shares by <FONT STYLE="white-space:nowrap">Non-French</FONT> Persons </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EU and <FONT STYLE="white-space:nowrap">non-EU</FONT> residents are required to file an administrative notice (<I>d&eacute;claration administrative</I>) with
the French authorities in connection with certain direct or indirect investments in us, including through ownership of ADSs, on the date a binding purchase agreement is executed or a tender offer is made public. Under existing administrative rulings
the following transactions qualify as foreign investments in us that require the filing of an administrative notice: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction carried out on our capital by a <FONT STYLE="white-space:nowrap">non-French</FONT> resident
provided that after the transaction the cumulative amount of the capital or the voting rights held by <FONT STYLE="white-space:nowrap">non-French</FONT> residents exceeds 1/3 of our capital or voting rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction mentioned above by a corporation incorporated under French law whose capital or voting rights are
held for more than 33.33% by <FONT STYLE="white-space:nowrap">non-French</FONT> residents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction carried out abroad resulting in a change of the controlling shareholder of a corporation
incorporated under a foreign law that holds a shareholding or voting rights in us if our capital or voting rights are held for more than 33.33% by <FONT STYLE="white-space:nowrap">non-French</FONT> residents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loans and guarantees granted by the acquirer to us in amounts evidencing control over our financing; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent licenses granted by an acquirer or management or technical assistance agreements with such acquirer that
place us in a dependent position <I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT></I> such party or its group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-French</FONT> residents must file a declaration for statistical purposes with the Bank of France
(<I>Banque de France</I>) within twenty working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding
&#128;15,000,000 that lead to the acquisition of at least 10% of our company&#146;s share capital or voting rights or cross such 10% threshold. Violation of this filing requirement may be sanctioned by five years of imprisonment and a fine up to
twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marketable Securities
that are Convertible, Exchangeable or Associated with a Stock Warrant </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we had issued several types of
founder&#146;s share warrants (&#147;BCE&#148;) as follows: </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Founder&#146;s Share Warrants (BCE) Plans: </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5.5pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:5.5pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-1</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-2</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B><br><B><FONT STYLE="white-space:nowrap">2014-3</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-4</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-5</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-6</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-7</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-9</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B>(G)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-9</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B>(S)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-9</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B>(D)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-9</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B>(C)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2016-1</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-1</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-2</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B>BCE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-3</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-4</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BCE-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:5.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-5</FONT></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Expiration date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">11/03/</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">11/03/</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:6pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">11/03/<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">2024</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:6pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/ 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">11/03/</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Null and void</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Null&nbsp;and void</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Null&nbsp;and void</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Null&nbsp;and void</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Null&nbsp;and void</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/11/2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23/01/2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/11/2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/11/2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/11/2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/11/2027</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Subscription or purchase price (&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Exercise price per&nbsp;share&nbsp;(&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.39</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Exercise conditions</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note&nbsp;(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note&nbsp;(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Note (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Note (4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Note (5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Note (7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives Note (8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Note (9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives Note (10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives Note (11)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Number of shares subscribed</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,800</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,700</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,006</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,426</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top" COLSPAN="15"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Beneficiaries </B>(remaining number of shares that can be subscribed)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Marc de Garidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Other</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>Cumulative number of cancelled or lapsed BCEs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,650</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,687</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,687</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,499</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,635</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>BCEs outstanding as of 30/06/2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">0</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">0</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman"><B>BCEs exercisable at 30/06/2023*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">0</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="right">0</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>BCE <FONT STYLE="white-space:nowrap">2018-3</FONT></B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Expiration date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15/03/2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/05/2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/11/2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/05/2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/05/2028</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Subscription or purchase price (&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Exercise price per share (&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Terms of exercise</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (12)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Achievement of objectives Note (13)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Note (14)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Note (15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (16)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Number of shares subscribed</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,930</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,916</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,750</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" COLSPAN="11"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Beneficiaries </B>(number of shares that can be subscribed)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Marc de Garidel</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Others</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cumulative number of cancelled or lapsed BCEs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,090</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,458</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,250</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>BCEs outstanding at June 30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>BCEs exercisable at June&nbsp;30, 2023*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(*)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by
100 for all BSAs and BCEs issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February 20, 2015. According to the exercise conditions provided in the notes below and assuming that performance
objectives have been achieved.</I> </P></TD></TR></TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Service condition fully fulfilled on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Service condition fully fulfilled on the date hereof. BCE 2014-2 has a warrant to share ratio of 1:100.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BCE 2014-4 has a warrant to share ratio of 1:100. 246 BCE-2014-4 are exercisable subject to a service
condition, which is fully fulfilled on the date hereof. 369 BCE-2014-4 are exercisable exclusively in the event of the achievement of qualitative and/or quantitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions), as set
by the Board on September&nbsp;8, 2014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">197 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-6</FONT></FONT> are exercisable
subject to a service condition, which is fully fulfilled on the date hereof. 328 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-6</FONT></FONT> are exercisable exclusively in the event of the achievement of qualitative
and/or quantitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions), as set by the Board on September&nbsp;8, 2014 and revised on November&nbsp;20, 2017. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">50% of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-7</FONT></FONT> granted
to each beneficiary are exercisable subject to a presence condition, which is fully fulfilled on the date hereof. 50% of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-7</FONT></FONT> are exercisable exclusively in
the event of the achievement of qualitative and/or quantitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions), as set by the Board on September&nbsp;8, 2014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Service condition fully fulfilled on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#149;&nbsp;&nbsp;&nbsp;&nbsp;33,687
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT> are exercisable subject to a service condition, which is fully fulfilled on the date hereof, </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;16,844 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT> are exercisable
exclusively in the event of achievement of the qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;16,843 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT> are exercisable
exclusively in the event of achievement of the quantitative targets (market conditions) set by the Board. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;75,000
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-2</FONT></FONT> are exercisable subject to a service condition, which is fully fulfilled on the date hereof: <B></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;75,000 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-2</FONT></FONT> are exercisable
exclusively in the event of the achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;50,531
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT> are exercisable subject to a service condition, which is fully fulfilled on the date hereof, </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;50,530 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT> are
exercisable exclusively in the event of the achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;33,687
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT> are exercisable subject to a service condition, which is fully fulfilled on the date hereof, </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;33,687 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT> are
exercisable exclusively in the event of the achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;16,843
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT> are exercisable subject to a service condition, which is fully fulfilled on the date hereof, </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;16,844 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT> are
exercisable exclusively in the event of the achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Service condition fully fulfilled on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#149;&nbsp;&nbsp;&nbsp;&nbsp;33,686
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT> are exercisable subject to a service condition, which is fully fulfilled on the date hereof, <B></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;33,686 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT> are exercisable
exclusively in case of achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;16,843
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT> are exercisable subject to a service condition, which is fully fulfilled on the date hereof, </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;16,844 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT> are
exercisable exclusively in the event of the achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;8,422
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT> are exercisable subject to a service condition, which is fully fulfilled on the date hereof, </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;8,421 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT> are
exercisable exclusively in the event of the achievement of qualitative objectives <FONT STYLE="white-space:nowrap">(non-market</FONT> conditions) set by the Board. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Service condition fully fulfilled on the date hereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>General note</U>: all of our BCE plans provide for specific cases of acceleration resulting in the exercise of said BCEs in the event of the occurrence of
specific events and in particular in the event of a change of control of us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we had issued several types of share warrants (BSA) as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Warrants (BSA) Plans: </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;1</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;2</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;3</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014&nbsp;-4</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;5</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;6</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-&nbsp;7</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-&nbsp;9</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">BSA-2015</FONT></B><br><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-&nbsp;11-&nbsp;
Sant&eacute;</FONT></FONT></B><br><B>Holdings</B><br><B>SRL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-&nbsp;12</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2017-&nbsp;1</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-&nbsp;1</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-&nbsp;2</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Date of general meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/02/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/02/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20/02/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23/06/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23/06/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23/06/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Date of Board meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21/02/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/09/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/12/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/12/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18/09/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22/01/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/05/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Date of decision of the Chief Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" COLSPAN="52"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Total number of shares that may be subscribed or purchased (<SUP
STYLE="font-size:75%; vertical-align:top">*</SUP>)&nbsp;:</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:7pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Sant&eacute; Holding SRL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Corinna zur Bonsen-Thomas</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Carol L. Brosgart</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Others</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by 100
for all BSAs and BCEs issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February&nbsp;20, 2015. Consequently, BSA 2014-3, BSA 2014-4 and BSA 2014-5 have a warrant to share ratio of 1:100.
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-</FONT></FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-</FONT></FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-</FONT></FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-4</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-&nbsp;2014-5</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-6</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2014-7</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-9</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2015-11-</FONT></FONT><BR>Sant&eacute;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Holding</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>SRL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2015-12</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2017-1</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2018-1</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BSA-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2018-2</FONT></B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Starting date for exercising options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">According to&nbsp;the achievement of criteria (see Terms of exercise)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">According to the achievement of criteria (see Terms of exercise)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">According to the achievement of criteria (see Terms of exercise)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">According to&nbsp;the achievement of criteria (see Terms of exercise)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">According to&nbsp;the achievement of criteria (see Terms of exercise)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/09/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/12/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/12/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18/09/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22/01/2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/05/2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Expiry date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/03/2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/09/2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/12/2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/12/2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18/09/2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22/01/2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14/05/2028</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13" ALIGN="center"><B>or at the end of a period of 90 days following the date on which the beneficiary ceases<BR>to work for us</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center"><B>or at the end of 90 days following the expiration of the<BR>beneficiary&#146;s mandate</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Subscription or purchase price&nbsp;(&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.07</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.78</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.78</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.29</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.90</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Exercise price per share&nbsp;(&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.73</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.79</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.57</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.05</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.60</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Terms of exercise</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">Note (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">Achievement of objectives</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="right">Note (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (7)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Note (8)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Number of shares subscribed</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,800</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,340</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,200</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,100</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Cumulative number of BSA or BCE cancelled or lapsed</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,274</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,600</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>BSAs as of June 30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>BSA potentially exercisable as of June&nbsp;30 2023,*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by 100
for all BSAs and BCEs issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February 20, 2015. According to the exercise conditions provided in the notes below and assuming that the objectives have
been achieved. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">263 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-4</FONT></FONT> are exercisable
at any time as from March&nbsp;11, 2014. 1,052 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-4</FONT></FONT> are exercisable exclusively in the event of the achievement of qualitative and/or quantitative objectives <FONT
STYLE="white-space:nowrap">(non-market</FONT> conditions), as set by the Board on September&nbsp;8, 2014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Exercisable by their beneficiary according to the exercise conditions set by the Board on September&nbsp;8,
2014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Progressive vesting in time fully vested on the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Differences in Corporate Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws applicable to French<I></I><I>&nbsp;soci&eacute;t&eacute;s anonymes</I><I></I>&nbsp;(limited liability companies) differ from laws
applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the French Commercial Code applicable to us and the Delaware General Corporation Law relating to shareholders&#146;
rights and protections. This summary is not intended to be a complete discussion of the respective rights, and it is qualified in its entirety by reference to Delaware law and French law. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under&nbsp;French&nbsp;law,&nbsp;a<I>&nbsp;soci&eacute;t&eacute;&nbsp;anonyme</I><I></I>&nbsp;must have at least three and may have up to 18 directors. The number of directors is fixed by or in the manner provided in the <FONT
STYLE="white-space:nowrap">by-laws.</FONT> The number of directors of each gender may not be less than 40%. In case a board of directors comprises up to eight members, the difference between the number of directors of each gender may not exceed two.
Any appointment made in violation of this limit that is not remedied within six months of this appointment will be null and void and payment of directors&#146; compensation will be suspended.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the <FONT STYLE="white-space:nowrap">by-laws</FONT> (unless specified in the certificate of
incorporation of the corporation).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Director Qualifications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, a corporation may prescribe qualifications for directors under its <FONT STYLE="white-space:nowrap">by-laws.</FONT> In addition, under French law, members of a board of directors may be legal entities, and such
legal entities must designate an individual to represent them and to act on their behalf at meetings of the board of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Removal of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, directors may be removed from office, with or without cause, at any shareholders&#146; meeting without notice or justification, by a simple majority vote of the shareholders present and voting at the meeting in
person or by proxy.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in the certificate of incorporation, directors may be removed from office, with or without cause, by a majority stockholder vote, though in the case of a corporation whose board is
classified, shareholders may effect such removal only for cause.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vacancies on the board of directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under&nbsp;French&nbsp;law,&nbsp;vacancies&nbsp;on&nbsp;the board of directors resulting from death or a resignation, provided that at least three directors remain in office, may be filled by a majority of the remaining directors
pending ratification by the shareholders by the next shareholders&#146; meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, vacancies on a corporation&#146;s board of directors, including those caused by an increase in the number of directors, unless otherwise provided in the certificate of incorporation, may be filled by the board of
directors or other governing body.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual Shareholders&#146; Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, the annual shareholders&#146; meeting shall be held at such place, on such date and at such time as decided each year by the board of directors and notified to the shareholders in the convening notice of the annual
meeting, within six months after the close of the relevant fiscal year unless such period is extended by court order.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or
by the <FONT STYLE="white-space:nowrap">by-laws.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholders&#146; Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, shareholders&#146; meetings may be called by the board of directors or, failing that, by the statutory auditors, or by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder
in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block on the date decided by the board of directors or the relevant person.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the
<FONT STYLE="white-space:nowrap">by-laws.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice of Shareholders&#146; Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A meeting notice (<I>avis de r&eacute;union</I>) is published in the <I>Bulletin des annonces l&eacute;gales obligatoires </I>(&#147;BALO&#148;), at least 35 days prior to a meeting and made available on the website of the company
at least 21&nbsp;days prior to the meeting. Additionally, a convening notice (<I>avis de convocation</I>) is published at least 15&nbsp;days prior to the date of the meeting, in a legal announcement bulletin of the registered office department and
in the BALO. Further, the holders of registered shares (<I>actions nominatives</I>) for at least a month at the time of the convening notice shall be summoned individually, by regular letter (or by registered letter if they request it and include an
advance of expenses) sent to their last known address. This notice may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any shareholder requesting it beforehand by registered letter with acknowledgment of
receipt in accordance with legal and regulatory requirements, specifying his <FONT STYLE="white-space:nowrap">e-mail</FONT> address.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> written notice of any meeting of the stockholders must be given to each stockholder entitled to
vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person
and vote, the record date for voting if it is different from the record date determining notice and, in the case of a special meeting, purpose or purposes of the meeting.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The meeting notice must also indicate the conditions under which the shareholders may vote by correspondence, the places and conditions in which they can obtain voting forms, and as the case may be, the <FONT
STYLE="white-space:nowrap">e-mail</FONT> address to which they may send written questions.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proxy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Each shareholder has the right to attend the meetings and participate in the discussions (i)&nbsp;personally, (ii) by granting proxy to any individual or legal entity of his choosing, (iii)&nbsp;by sending a proxy to the company
without indication of the mandate (in which case such proxy shall be cast in favor of the resolutions supported by the board of directors), (iv) by voting by correspondence or (v)&nbsp;by videoconference or another means of telecommunication
allowing identification in accordance with applicable laws. The proxy is only valid for a single meeting or for successive meetings convened with the same agenda. It can also be granted for two meetings, one ordinary the other extraordinary, held on
the same day or within a period of 15 days.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy
provides for a longer period.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Action by Written Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, shareholders&#146; action by written consent is not permitted in a<I>&nbsp;soci&eacute;t&eacute; anonyme.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation&#146;s certificate of incorporation (i)&nbsp;may permit stockholders to act by written consent if such action is signed by all stockholders, (ii)&nbsp;may permit stockholders to act by written
consent signed by stockholders having the minimum number of votes that would be necessary to take such action at a meeting or (iii)&nbsp;may prohibit actions by written consent.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Preferential Subscription Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, in case of issuance of additional shares or other securities for cash or <FONT STYLE="white-space:nowrap">set-off</FONT> against cash debts, the existing shareholders have preferential subscription rights to these
securities on a pro rata basis unless such rights are waived by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in a corporation&#146;s certificate of incorporation, a stockholder does not, by operation of law, possess preemptive rights to subscribe to additional issuances of the
corporation&#146;s stock.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the shareholders present at the extraordinary meeting deciding or authorizing the capital increase, voting in person or represented by proxy or voting by mail. In case such rights are not waived by the extraordinary general meeting,
each shareholder may individually either exercise, assign or not exercise its preferential subscription rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sources of Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under French law, dividends may only be paid by a French<I>&nbsp;soci&eacute;t&eacute; anonyme</I>&nbsp;out of &#147;distributable
profits,&#148; plus any distributable reserves and &#147;distributable premium&#148; that the shareholders decide to make available for distribution, other than those reserves that are specifically required
<FONT STYLE="white-space:nowrap">by-law.</FONT> &#147;Distributable profits&#148; consist of the unconsolidated net profits of the relevant corporation for each fiscal year, as increased or reduced by any profit or loss carried forward from prior
years, minus the amounts to be set aside to the statutory reserve (at least 5% of the profit until the reserve has reached 10% of the amount of the share capital) and to the reserve set forth in the company&#146;s
<FONT STYLE="white-space:nowrap">by-laws</FONT> (if any).</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Distributable
premium&#148; refers to the contribution paid by the shareholders in addition to the par value of their shares for their subscription that the shareholders decide to make available for distribution.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Except in the case of a share capital reduction, no distribution can be made to the
shareholders when the net equity is, or would become, lower than the amount of the share capital plus the reserves which cannot be distributed in accordance with the law or the <FONT STYLE="white-space:nowrap">by-laws.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, dividends may be paid by a Delaware corporation either out of (i)&nbsp;surplus, as defined in and computed in accordance with Delaware law, or (ii)&nbsp;in case there is no surplus, out of its net profits for the
fiscal year in which the dividend is declared and/or the preceding fiscal year, except when the capital is diminished by depreciation in the value of its property, or by losses or otherwise, to an amount less than the aggregate amount of capital
represented by issued and outstanding stock having a preference on the distribution of assets.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Repurchase of Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under French law, a corporation may acquire its own shares. Such acquisition may be challenged on the ground of market abuse regulations.
However, MAR provides for safe harbor exemptions when the acquisition is made for the following purposes only:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to&nbsp;decrease&nbsp;its&nbsp;share&nbsp;capital, provided that such decision is not driven by
losses and that a purchase offer is made to all shareholders on a pro rata basis, with the approval of the shareholders at the extraordinary general meeting deciding the capital reduction; or to meet obligations arising from debt securities, that
are exchangeable into equity instruments.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a corporation may generally redeem or repurchase shares of its stock unless the capital of the corporation is impaired or
such redemption or repurchase would impair the capital of the corporation.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">No such
repurchase of shares may result in the company holding, directly or through a person acting on its behalf, more than 10% of its issued share capital.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;with a view to distributing within one year of their repurchase the relevant
shares to employees or managers under a profit-sharing, free share or share option plan; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;under a <FONT STYLE="white-space:nowrap">buy-back</FONT> program to be authorized by the
shareholders in accordance with the provisions of Article L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">22-10-62</FONT></FONT> of the French Commercial Code and in accordance with the general regulations of the AMF.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All other purposes, and especially share
<FONT STYLE="white-space:nowrap">buy-backs</FONT> for external growth operations by virtue of Article L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">22-10-62</FONT></FONT> of the French Commercial Code, while not forbidden,
must be pursued in strict compliance of market manipulations and insider dealing rules.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No such repurchase of shares may result in the company holding, directly or through a person acting on its behalf, more than 10% of its issued share
capital.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under MAR and in accordance with the General Regulations, a corporation
shall report to the competent authority of the trading venue on which the shares have been admitted to trading or are traded, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all
the transactions relating to the <FONT STYLE="white-space:nowrap">buy-back</FONT> program, in a detailed form and in an aggregated form.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liability of Directors and Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, the <FONT STYLE="white-space:nowrap">by-laws</FONT> may not include any provisions limiting the liability of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a corporation&#146;s certificate of incorporation may include a provision eliminating or limiting the personal liability
of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any breach of the
director&#146;s duty of loyalty to the corporation or its stockholders;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation
of law;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;intentional or
negligent payment of unlawful dividends or stock purchases or redemptions; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any transaction from which the director derives an improper personal
benefit.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Voting Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">French law provides that, unless otherwise provided in the <FONT STYLE="white-space:nowrap">by-laws,</FONT> each shareholder is entitled to one vote for each share of share capital held by such shareholder. Further, pursuant to the
introduction of Law <FONT STYLE="white-space:nowrap">No.&nbsp;2014-384</FONT> dated March&nbsp;29, 2014 (<I>Loi Florange</I>), shares registered for more than two years in the name of the same shareholder are automatically be granted double voting
rights from 2016, unless the <FONT STYLE="white-space:nowrap">by-laws</FONT> expressly reject this measure.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Vote on Certain Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under French law, completion of a merger, dissolution or sale or exchange of all or substantially all of a corporation&#146;s
assets (<I>apport partiel d&#146;actifs</I>) requires:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the approval of the board of directors; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;approval by a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting or, in the case of a merger with a <FONT STYLE="white-space:nowrap">non-EU</FONT>
company, approval of all shareholders of the corporation.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under Delaware law, unless the certificate of incorporation pro</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">vides for the vote of a larger portion of shares, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a
corporation&#146;s assets or dissolution requires:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the approval of the board of directors; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;approval by the vote of the
holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dissent or Dissenters Appraisal Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">French law does not provide for any such right but provides that a merger is subject to shareholders&#146; approval by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote, as stated above.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a holder of shares of any class or series has the right, in specified circumstances, to dissent from a merger or consolidation by demanding payment in cash for the stockholder&#146;s shares equal to the fair
value of those shares, as determined by the Delaware Chancery Court in an action timely brought by the corporation or a dissenting stockholder. Delaware law grants these appraisal rights only in the case of mergers or consolidations and not in the
case of a sale or transfer of assets or a purchase of</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">assets for shares. Further, no appraisal rights are available for shares of any class or series that is listed on a national securities
exchange or held of record by more than 2,000 stockholders, unless the agreement of merger or consolidation requires the holders to accept for their shares anything other than:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;shares of stock of the surviving
corporation;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;shares of another corporation that are either listed on a national securities
exchange or held of record by more than 2,000 stockholders;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;cash in lieu of fractional shares of the stock described in the two preceding bullet points;
or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any combination of the
above.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, appraisal rights are not available to holders of shares of the
surviving corporation in specified mergers that do not require the vote of the stockholders of the surviving corporation.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Standard of Conduct for Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">French law does not contain specific provisions setting forth the standard of conduct of a director. However, directors have a duty to act without self-interest, on a well-informed basis, and not to take any decision against a
corporation&#146;s corporate interest (<I>int&eacute;r&ecirc;t social</I>).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general,
directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Suits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the directors of
a corporation in the corporation&#146;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action are borne by the relevant shareholder or
the group of shareholders.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The plaintiff must remain a shareholder through the
duration of the legal action.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no other case where shareholders may initiate a derivative action to enforce a right of a corporation.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A shareholder may alternatively or cumulatively bring individual legal action against
the directors, provided he has suffered distinct damages from those suffered by the corporation. In this case, any damages awarded by the court are paid to the relevant shareholder.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce
the right itself. The complaint must:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff
complains or that the plaintiff&#146;s shares thereafter devolved on the plaintiff by operation of law; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff
desires from the directors and the reasons for the plaintiff&#146;s failure to obtain the action; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;state the reasons for not making the effort.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Additionally, the plaintiff
must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>FRANCE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unlike companies incorporated under Delaware law, the organizational documents, which comprise both a certificate of incorporation and <FONT
STYLE="white-space:nowrap">by-laws,</FONT> companies incorporated under French law only have <FONT STYLE="white-space:nowrap">by-laws</FONT> (<I>statuts</I>) as organizational documents.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">As indicated in the paragraph below, only the extraordinary shareholders&#146; meeting
is authorized under French law to adopt or amend the <FONT STYLE="white-space:nowrap">by-laws.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, generally a corporation may amend its certificate of incorporation if:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;its board of directors has
adopted a resolution setting forth the amendment proposed and declared its advisability; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the amendment is adopted by the affirmative votes of a majority (or greater percentage as may be
specified by the corporation) of the outstanding shares entitled to vote on the amendment and a majority (or greater percentage as may be specified by the corporation) of the outstanding shares of each class or series of stock, if any, entitled to
vote on the amendment as a class or series.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of <FONT STYLE="white-space:nowrap">by-laws</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, only the extraordinary shareholders&#146; meeting is authorized to adopt or amend the <FONT STYLE="white-space:nowrap">by-laws</FONT> <FONT STYLE="white-space:nowrap">(two-thirds</FONT> majority). The extraordinary
shareholders&#146; meeting may authorize the board of directors to amend the <FONT STYLE="white-space:nowrap">by-laws</FONT> to comply with legal provisions, subject to the ratification of such amendments by the next extraordinary shareholders&#146;
meeting. The board of directors is authorized to amend the <FONT STYLE="white-space:nowrap">by-laws</FONT> as a result of a decision to relocate the company&#146;s registered office in France, subject to ratification by the next ordinary
shareholders&#146; meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the stockholders entitled to vote have the power to adopt, amend or repeal <FONT STYLE="white-space:nowrap">by-laws.</FONT> A corporation may also confer, in its certificate of incorporation, that power upon the
board of directors.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list our ADSs on the Nasdaq Global Market under the symbol &#147;ABVX.&#148; Our ordinary shares are currently listed on
Euronext Paris under the symbol &#147;ABVX.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_18"></A>LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ownership of ADSs by <FONT STYLE="white-space:nowrap">Non-French</FONT> Residents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the French Commercial Code nor our <FONT STYLE="white-space:nowrap">by-laws</FONT> currently impose any restrictions on the right of <FONT
STYLE="white-space:nowrap">non-French</FONT> residents or <FONT STYLE="white-space:nowrap">non-French</FONT> shareholders to own and vote shares. However, <FONT STYLE="white-space:nowrap">non-French</FONT> residents must file a declaration for
statistical purposes with the Bank of France (<I>Banque de France</I>) within 20 working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection
with investments exceeding &#128;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. Violation of this filing requirement may be sanctioned by five years of imprisonment and a
fine of up to twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, any investment: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
by (a)&nbsp;any <FONT STYLE="white-space:nowrap">non-French</FONT> citizen, (b)&nbsp;any French citizen not residing in France, (c)&nbsp;any <FONT STYLE="white-space:nowrap">non-French</FONT> entity or (d)&nbsp;any French entity controlled by one of
the aforementioned persons or entities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) that will result in the relevant investor (a)&nbsp;acquiring control of an entity registered
in France, (b)&nbsp;acquiring all or part of a business line of an entity registered in France, or (c)&nbsp;for <FONT STYLE="white-space:nowrap">non-EU</FONT> or <FONT STYLE="white-space:nowrap">non-EEA</FONT> investors crossing, directly or
indirectly, alone or in concert, a 25% threshold of voting rights in an entity registered in France; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) developing activities in
certain strategic industries related to (a)&nbsp;activity likely to prejudice national defense interests, participating in the exercise of official authority or are likely to prejudice public policy and public security (including weapons, <FONT
STYLE="white-space:nowrap">double-use</FONT> items, IT systems, cryptology, date capturing devices, gambling, toxic agents or storage of data), (b) activities relating to essential infrastructure, goods or services (including energy, water,
transportation, space, telecom, public health, farm products or media), and (c)&nbsp;research and development activity related to critical technologies (including cybersecurity, artificial intelligence, robotics, additive manufacturing,
semiconductors, quantum technologies, energy storage or biotechnology) or <FONT STYLE="white-space:nowrap">dual-use</FONT> items, is subject to the prior authorization of the French Ministry of Economy, which authorization may be conditioned on
certain undertakings. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Decree (<I>d&eacute;cret</I>) No.&nbsp;2020 892 dated July&nbsp;22, 2020, as amended on December&nbsp;28,
2020 by the Decree No.&nbsp;2020-1729 on December&nbsp;22, 2021 by the Decree No.&nbsp;2021-1758, and lastly on December 23, 2022 by the Decree <I>(d&#233;cret)</I> n&deg; 2022-1622 has implemented a 10% threshold of the voting rights for the
non-EU/EEA investments made (i)&nbsp;in an entity incorporated under the laws of France and (ii)&nbsp;whose shares are admitted to trading on a regulated market, in addition to the 25% above-mentioned threshold. Set to expire on December 31, 2023,
this 10% threshold could become permanent. The transactions falling within the scope of the Decree <I>(d&#233;cret)</I> No. 2020-892, as amended, benefit from a &#147;fast-track procedure&#148; pursuant to which the investor is exempt from the
authorization request provided for in Article R. 151-5 of the Monetary and Financial Code, provided that the investment project has been the subject of prior notification to the French Minister of Economy and that the transaction is carried out
within six months following the notification. Unless the French Minister of Economy objects, the authorization is granted at the end of a period of ten working days following notification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of such authorization, the relevant investment shall be deemed null and void. The relevant investor may be found criminally
liable and may be sanctioned with a fine not to exceed the greater of the following amounts: (i)&nbsp;twice the amount of the relevant investment, (ii) 10% of the annual turnover before tax of the target company or (iii) &#128;5&nbsp;million (for a
company) or &#128;1&nbsp;million (for a natural person). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Exchange Controls </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current French foreign exchange control regulations there are no limitations on the amount of cash payments that we may remit to
residents of foreign countries. Laws and regulations concerning foreign exchange controls do, however, require that all payments or transfers of funds made by a French resident to a <FONT STYLE="white-space:nowrap">non-resident</FONT> such as
dividend payments be handled by an accredited intermediary. All registered banks and substantially all credit institutions in France are accredited intermediaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_19"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Citibank, N.A. has agreed to act as the depositary bank for the American Depositary Shares. Citibank&#146;s depositary offices are located at
388 Greenwich Street, New York, New York 10013. American Depositary Shares are frequently referred to as &#147;ADSs&#148; and represent ownership interests in securities that are on deposit with the depositary bank. ADSs may be<B> </B>represented by
certificates that are commonly known as &#147;American Depositary Receipts&#148; or &#147;ADRs.&#148; The depositary bank typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank N.A., Milan
Branch, via dei Mercanti, 12, 20121 Milan, Italy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will appoint Citibank as depositary bank pursuant to a deposit agreement. A copy of
the deposit agreement is on file with the SEC under cover of a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> You may obtain a copy of the deposit agreement from the SEC&#146;s Public Reference Room at 100 F Street,
N.E., Washington, D.C. 20549 and from the SEC&#146;s website (www.sec.gov). Please refer to Registration Number <FONT STYLE="white-space:nowrap">333-&nbsp;&nbsp;&nbsp;&nbsp;</FONT> when retrieving such copy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please
remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge
you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, one ordinary share that is on deposit with
the depositary bank and/or custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not
been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary bank may agree to change the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-Share</FONT></FONT> ratio
by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary bank and their respective nominees will hold all deposited property for the benefit of the
holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary bank, the custodian or their nominees. <B></B>Beneficial ownership in the deposited property will under the terms of the
deposit agreement be vested in the beneficial owners of the ADSs. The depositary bank, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and
beneficial owners of the corresponding ADSs. <B></B>A beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only
through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or
indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit agreement.<B></B><B>&nbsp;</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of
any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as an owner of ADSs and those of the depositary bank. As an ADS holder you appoint the depositary bank to
act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of France, which may be different from
the laws in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain
regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary bank, the custodian, us or any of their or our respective agents or
affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>As an owner of ADSs, we will not treat you as one of our shareholders and you will not
have direct shareholder rights. The depositary bank will hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary
shares represented by your ADSs through the depositary bank only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the
cancellation of your ADSs and become a direct shareholder.&nbsp;&nbsp;&nbsp;&nbsp; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manner in which you own the ADSs (e.g., in a
brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may affect your rights and obligations, and the manner in which, and extent to which, the depositary bank&#146;s services are made available to you. As
an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary bank in your name reflecting the registration of
uncertificated ADSs directly on the books of the depositary bank (commonly referred to as the &#147;direct registration system&#148; or &#147;DRS&#148;). The direct registration system reflects the uncertificated (book-entry) registration of
ownership of ADSs by the depositary bank. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary bank to the holders of the ADSs. The direct registration system includes automated
transfers between the depositary bank and The Depository Trust Company (&#147;DTC&#148;), the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or
safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such
clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be
registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#147;holder.&#148; When we refer to
&#147;you,&#148; we assume the reader owns ADSs and will own ADSs at the relevant time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of the ordinary shares in the
name of the depositary bank or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary bank or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and
interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights in
all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends
and Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited
with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number
of ADSs held as of the specified record date, after deduction of the applicable fees, taxes and expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions of Cash </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon
receipt of confirmation of the deposit of the requisite funds, the depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the
holders, subject to the laws and regulations of France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion into U.S. dollars will take place only if practicable and if the
U.S. dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of cash will be made net of the fees, expenses, taxes and governmental
charges payable by holders under the terms of the deposit agreement. The depositary bank will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for the benefit of the
applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions of Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we make
a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will
<U>either</U> distribute to holders new ADSs representing the ordinary shares deposited <U>or</U> modify the <FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT> shares ratio, in which case each ADS you hold will represent rights and interests in
the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of new ADSs or the modification of the <FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT> shares ratio upon a
distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all
or a portion of the new ordinary shares so distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No such distribution of new ADSs will be made if it would violate a law
(<I>e.g.</I>, the U.S. securities laws) or if it is not operationally practicable. If the depositary bank does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and
will distribute the proceeds of the sale as in the case of a distribution of cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions of Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary bank and we
will assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to
exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the
transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary bank is not obligated to establish procedures to facilitate the distribution and
exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will <I>not</I>
distribute the rights to you if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not timely request that the rights be distributed to you or we request that the rights not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We fail to deliver satisfactory documents to the depositary bank; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not reasonably practicable to distribute the rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The
proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Elective Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior
notice thereof to the depositary bank and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary bank in determining whether such distribution is lawful and reasonably
practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will make the election available to you only if it is reasonably practicable and if we have provided all
of the documentation contemplated in the deposit agreement. In such case, the depositary bank will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in France would
receive upon failing to make an election, as more fully described in the deposit agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will
notify the depositary bank in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it is reasonably practicable to distribute such property to you and if we provide to the depositary bank all of the documentation
contemplated in the deposit agreement, the depositary bank will distribute the property to the holders in a manner it deems practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit
agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will <I>not</I> distribute the property to you and will sell the property if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not request that the property be distributed to you or if we request that the property not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not deliver satisfactory documents to the depositary bank; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank determines that all or a portion of the distribution to you is not reasonably practicable.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary bank in advance. If it is
practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the redemption to the holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary
bank will convert into U.S. dollars upon the terms of the deposit agreement the redemption funds received in a currency other than U.S. dollars and will establish procedures to enable holders to receive the net proceeds from the redemption upon
surrender of their ADSs to the depositary bank. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on
a <I>pro rata</I> basis, as the depositary bank may determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes Affecting Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, <FONT
STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of our assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive
the property received or exchanged in respect of the ordinary shares held on deposit. The depositary bank may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form <FONT
STYLE="white-space:nowrap">F-6,</FONT> call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the Shares. If the depositary bank may not lawfully
distribute such property to you, the depositary bank may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance of ADSs upon Deposit of Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the offering, the ordinary shares being offered pursuant to the prospectus will be deposited by us with the
custodian.&nbsp;Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in the prospectus. After the completion of the offering, the ordinary shares that are being offered for sale pursuant to the
prospectus will be deposited by us with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in the prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the closing of the offer, the depositary bank may create ADSs on your behalf if you or your broker deposit ordinary shares with the
custodian. The depositary bank will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit
ordinary shares and receive ADSs may be limited by U.S. and French legal considerations applicable at the time of deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance
of ADSs may be delayed until the depositary bank or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary bank will only issue ADSs in
whole numbers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the
depositary bank. As such, you will be deemed to represent and warrant that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares are duly authorized, validly issued, fully
paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> and legally obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All preemptive (and similar) rights, if any, with
respect to such ordinary shares have been validly waived or exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You are duly authorized to deposit the ordinary shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim,
and are not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares presented for deposit have not been stripped of any rights or entitlements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the representations or warranties are incorrect in any way, we and the depositary bank may, at your cost and expense, take any and
all actions necessary to correct the consequences of the misrepresentations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer, Combination and Split Up of ADRs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you
will have to surrender the ADRs to be transferred to the depositary bank and also must: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">ensure that the surrendered ADR is properly
endorsed or otherwise in proper form for transfer; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">provide such proof of identity and genuineness of signatures as the depositary bank
deems appropriate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">provide any transfer stamps required by the State of New York or the United States; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit
agreement, upon the transfer of ADRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To have your ADRs either combined or split up, you must surrender the ADRs in question to the
depositary bank with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of Ordinary Shares Upon Cancellation of ADSs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number of
underlying ordinary shares at the custodian&#146;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and French law considerations applicable at the time of withdrawal. In order to withdraw the
ordinary shares represented by your ADSs, you will be required to pay to the depositary bank the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of all funds
and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold ADSs registered
in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary bank may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares
represented by your ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept ADSs for cancellation that
represent a whole number of securities on deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will have the right to withdraw the securities represented by your ADSs at any
time except for: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed, or
(ii)&nbsp;ordinary shares are immobilized on account of a shareholders&#146; meeting or a payment of dividends. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Obligations to pay fees,
taxes and similar charges. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on
deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to
comply with mandatory provisions of law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder, you generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the
ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in the section of this prospectus entitled &#147;Description of Share Capital.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the depositary bank will distribute to you any notice of shareholders&#146;
meeting received from us together with information explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary bank may distribute to
holders of ADSs instructions on how to retrieve such materials upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary bank timely receives voting instructions
from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#146;s ADSs in accordance with such voting instructions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities for which no voting instructions have been received will not be voted (except as otherwise contemplated in the deposit agreement).
<B></B>Please note that the ability of the depositary bank to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in
time to enable you to return voting instructions to the depositary bank in a timely manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Charges </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Service</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fees</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares, upon a change in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT></FONT> share ratio, or for any other
reason), excluding ADS issuances as a result of distributions of ordinary shares)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS issued</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT></FONT> share ratio, or for any
other reason)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS cancelled</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of ADSs pursuant to (i)&nbsp;stock dividends or other free stock distributions, or (ii)&nbsp;exercise of rights to purchase additional ADSs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a <FONT STYLE="white-space:nowrap">spin-off)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ADS Services</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held on the applicable record date(s) established by the depositary bank</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Registration of ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and <I>vice versa</I>, or for any other reason)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) transferred</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely
transferable ADSs, and <I>vice versa</I>).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) converted</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADS holder you will also be responsible to pay certain charges such as: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">taxes (including applicable interest and penalties) and other governmental charges; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the registration fees as may from time to time be in effect for the registration of ordinary
shares on the share register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">certain cable, telex and facsimile transmission and delivery expenses; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the fees, expenses, spreads, taxes and other charges of the depositary bank and/or service providers (which may be a division, branch or
affiliate of the depositary bank) in the conversion of foreign currency; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the reasonable and customary <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the depositary bank in connection with compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs and ADRs; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the fees, charges, costs and expenses incurred by the depositary bank, the custodian, or any nominee in connection with the ADR program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADS fees and charges for (i)&nbsp;the issuance of ADSs, and (ii)&nbsp;the cancellation of ADSs are charged to the person for whom the ADSs are
issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC, the ADS issuance and cancellation fees and charges may be deducted
from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be
charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the ADS
service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i)&nbsp;distributions
other than cash and (ii)&nbsp;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held
through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices
prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs. In the case of (i)&nbsp;registration of ADS transfers, the ADS transfer fee will be payable by the
ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii)&nbsp;conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the Holder whose ADSs are converted
or by the person to whom the converted ADSs are delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of refusal to pay the depositary bank fees, the depositary bank
may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank fees from any distribution to be made to the ADS holder. Certain depositary fees and charges (such
as the ADS services fee) may become payable shortly after the closing of the ADS offering. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary bank. You will receive prior
notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and
conditions as we and the depositary bank agree from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments and Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may agree with the depositary bank to modify the deposit agreement at any time without your consent. We undertake to give holders 30
days&#146; prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements
that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with
applicable provisions of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the
modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right to direct the depositary bank to terminate the deposit agreement. Similarly, the depositary bank may in certain
circumstances on its own initiative terminate the deposit agreement. In either case, the depositary bank must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be
unaffected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After termination, the depositary bank will continue to collect distributions received (but will not distribute any such
property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a <FONT
STYLE="white-space:nowrap">non-interest</FONT> bearing account. At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction
of applicable fees, taxes and expenses). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with any termination of the deposit agreement, the depositary bank may make
available to owners of ADSs a means to withdraw the ordinary shares represented by ADSs and to direct the depositary of such ordinary shares into an unsponsored American depositary share program established by the depositary bank. The ability to
receive unsponsored American depositary shares upon termination of the deposit agreement would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored American depositary shares and the payment of
applicable depositary fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with any termination of the deposit agreement, the depositary bank may, with our consent, and
shall, at our instruction, distribute to owners of ADSs the deposited property in a mandatory exchange for, and upon a mandatory cancellation of, the ADSs. The ability to receive the deposited property upon termination of the deposit agreement would
be subject, in each case, to receipt by the depositary bank of (i)&nbsp;confirmation of satisfaction of certain U.S. regulatory requirements and (ii)&nbsp;payment of applicable depositary fees. The depositary bank will give notice to owners of ADSs
at least 30 calendar days before termination of the deposit agreement. Owners of ADSs would be required to surrender ADSs to the depositary bank for cancellation in exchange for the deposited property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Books of Depositary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank
will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the
ADSs and the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will maintain in New York facilities to record and process the issuance,
cancellation, combination, <FONT STYLE="white-space:nowrap">split-up</FONT> and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Obligations and Liabilities </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The deposit agreement limits our obligations and the depositary bank&#146;s obligations to you. Please note the
following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank are obligated only to take the actions specifically stated in the deposit agreement
without negligence or bad faith. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in
which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any
action, for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary
shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our
failure to give notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the
deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank disclaim any liability if we or the depositary bank are prevented or forbidden from or
subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by
reason of present or future provision of any provision of our <FONT STYLE="white-space:nowrap">by-laws,</FONT> or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our
control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any
discretion provided for in the deposit agreement or in our <FONT STYLE="white-space:nowrap">by-laws</FONT> or in any provisions of or governing the securities on deposit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or
information received from legal counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice
or information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank also disclaim liability for the inability by a holder to benefit from any
distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank may rely without any liability upon any written notice, request or other document
believed to be genuine and to have been signed or presented by the proper parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary bank also disclaim liability for any consequential or punitive damages for any breach of
the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary
relationship, among us, the depositary bank and you as ADS holder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which
parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to
account for any payment received as part of those transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>As the above limitations relate to our obligations
and the depositary&#146;s obligations to you under the deposit agreement, we believe that, as a matter of construction of the clause, such limitations would likely to continue to apply to ADS holders who withdraw the ordinary shares from the ADS
facility with respect to obligations or liabilities incurred under the deposit agreement before the cancellation of the ADSs and the withdrawal of the ordinary shares, and such limitations would most likely not apply to ADS holders who withdraw the
ordinary shares from the ADS facility with respect to obligations or liabilities incurred after the cancellation of the ADSs and the withdrawal of the ordinary shares and not under the deposit agreement. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>In any event, you will not be deemed, by agreeing to the terms of the deposit agreement,
to have waived our or the depositary&#146;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. In fact, you cannot waive our or the depositary&#146;s compliance with U.S. federal securities laws and
the rules and regulations promulgated thereunder. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the
depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable
for any deficiency if the sale proceeds do not cover the taxes that are due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank may refuse to issue ADSs, to deliver,
transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced
tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the depositary bank and the custodian may
require to fulfill legal obligations. You are required to indemnify us, the depositary bank and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Currency Conversion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay
fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable
cost or within a reasonable period, the depositary bank may take the following actions in its discretion: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Convert the foreign currency to
the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful and practical. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Distribute the foreign currency to holders for whom the distribution is lawful and practical. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Hold the foreign currency (without liability for interest) for the applicable holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law/Waiver of Jury Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
deposit agreement, the ADRs and the ADSs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an owner of ADSs, you irrevocably agree that any legal action arising out of the Deposit Agreement, the ADSs or the ADRs involving us or
the Depositary may only be instituted in a state or federal court in the city of New York. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>AS A PARTY TO THE DEPOSIT AGREEMENT,
YOU IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND/OR THE DEPOSITARY BANK. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the
right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under U.S. federal securities laws. If we or the depositary
opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will not be deemed, by agreeing to the
terms of the deposit agreement, to have waived our or the depositary&#146;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_20"></A>ORDINARY SHARES AND ADSs ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the global offering, no public market existed in the United States for our ordinary shares or the ADSs. Future sales of ADSs in the
public market after the global offering, and the availability of ADSs for future sale, could adversely affect the market price of the ADSs prevailing from time to time. As described below, a significant number of currently outstanding ordinary
shares will not be available for sale shortly after the global offering due to contractual restrictions on transfers of ordinary shares. Accordingly, sales of substantial amounts of the ADSs or the ordinary shares, or the perception that these sales
could occur, could adversely affect prevailing market prices for the ADSs and could impair our future ability to raise equity capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of ordinary shares outstanding on June&nbsp;30, 2023, upon completion of the global offering,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares (including ordinary shares represented by ADSs) will be outstanding, assuming no outstanding options or warrants
are exercised. All of the ADSs sold in the global offering will be freely tradable without restrictions or further registration under the Securities Act, except for any ADSs sold to our &#147;affiliates,&#148; as that term is defined under Rule 144
under the Securities Act. The remaining ordinary shares held by existing shareholders are &#147;restricted securities,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act. Restricted securities may be sold in the public market
only if registered or if their resale qualifies for exemption from registration described below under Rule 144 or 701 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, of the options and warrants to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of June&nbsp;30, 2023 and assuming no outstanding options or warrants are exercised and
no exercise of the underwriters&#146; option to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ADSs and/or ordinary shares, options and warrants exercisable
for&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares will be vested and eligible for sale 90 days after the date of this prospectus subject to French law, as
described above. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the <FONT STYLE="white-space:nowrap">lock-up</FONT> and market
<FONT STYLE="white-space:nowrap">stand-off</FONT> agreements described below and the provisions of Rules 144 and 701 under the Securities Act and French law, and assuming no exercise of the underwriters&#146; option to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ADSs and/or ordinary shares, these restricted securities will be available for sale in the public market as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (including ordinary shares represented by ADSs) will be eligible for immediate sale on the date of this
prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary&nbsp;shares
(including ordinary shares represented by ADSs) will be eligible for sale upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> and market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements 90 days after the date of
this prospectus, provided that shares held by our affiliates will remain subject to volume, manner of sale and other resale limitations set forth in Rule 144 of the Securities Act, as described below and subject to French law, both as described
above. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>French Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, and notably under the General Regulation issued by the French Financial Market Authority (<I>R&eacute;glement
G&eacute;n&eacute;ral de l&#146;AMF</I>), as well as under EU Market Abuse Regulation 596/2014 of April&nbsp;16, 2014 (MAR), any person that holds inside information shall, until such information is made public, refrain from (i)&nbsp;carrying out
any transactions relating to securities issued by the company, (ii)&nbsp;recommending that another person engage in insider dealing or inducing another person to engage in insider dealing, and (iii)&nbsp;unlawfully disclosing inside information
outside of the normal exercise of an employment, a profession or duties. The use of inside information by cancelling or amending an order concerning a financial instrument to which the information relates where the order was placed before the person
concerned possessed the inside information, shall also be considered to be insider dealing. These rules apply to all persons who hold inside information as a result of (1)&nbsp;their status as board member, executive officer, manager, employee of
the company, third parties acting on behalf of the company and having access to privileged information as party of their professional relations with the company during the preparation or the completion of a particular transaction, such as investor
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services providers, lawyers or public relations agencies, (2)&nbsp;their holding of securities in the share capital of the company, and/or (3)&nbsp;their access to information because of their
employment, profession or duties or their participation in the preparation of a financial transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under MAR and the General
Regulation of the French Financial Market Authority, it is also prohibited for a person to engage or attempt to engage in market manipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prohibited transactions include all transactions related to securities (stocks, securities convertible, options and warrants), and in
particular, (i)&nbsp;transfer of securities, (ii)&nbsp;exercise of options, warrants (including founder&#146;s share warrants (BCE) or share warrants (BSA)), exercise of any securities giving access to the capital, (iii)&nbsp;transfer of free shares
(AGA) and (iv)&nbsp;acquisition of securities. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a person who has beneficially owned our ordinary shares that are restricted shares for at least six months would be entitled to
sell such securities, provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting
requirements for at least 90 days before the sale. Persons who have beneficially owned our ordinary shares that are restricted shares for at least six months but who are its affiliates at the time of, or any time during the 90 days preceding, a
sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of our ordinary shares then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares immediately after the global offering, assuming no exercise of the underwriter&#146;s option to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ADSs and/or ordinary shares; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of the ADSs on the Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to the sale, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, in each case, that we are subject to the Exchange Act
periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice
provisions of Rule 144 to the extent applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but without
compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the
resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares subject also to French law, as described above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, all Rule 701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and in the section of
this prospectus titled &#147;Underwriters&#148; and will not become eligible for sale until the expiration of the restrictions set forth in those agreements. In addition, any Rule 701 shares held by employees who are French tax residents and who
were granted share options prior to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, may be subject to an additional holding period under the terms of the applicable share option plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation S </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation S provides
generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act. Accordingly, restricted securities may be sold in offshore transactions in compliance with Regulation
S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our security holders possess registration rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our officers, directors and certain of our existing shareholders have agreed, among other things and subject to certain exceptions, with
the underwriters not to nor publicly disclose the intention to, during the period ending 90 days after the date of this prospectus, directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant for the sale of, enter into any hedging, swap or any other agreement or otherwise transfer or dispose of any ordinary shares, ADSs or any securities convertible into, exercisable or
exchangeable for our ordinary shares or ADSs, except with the prior written consent of the representatives of the underwriters. See &#147;Underwriters.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect any release of ordinary shares or ADSs subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements prior to the
expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the ordinary shares (which may be in the form of ADSs) subject to such <FONT
STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morgan
Stanley &amp; Co. LLC and Leerink Partners LLC, in their sole discretion, may release the securities subject to the lock-up agreements described above in whole or in part at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_21"></A>MATERIAL UNITED STATES FEDERAL INCOME AND FRENCH TAX
CONSIDERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The summary set forth below describes certain French and U.S. federal income tax consequences relating to the
purchase, ownership and disposition of the ADSs to U.S. Holders (as defined below) as of the date hereof. This summary does not represent a detailed description of the tax consequences applicable to a U.S. Holder that is subject to special treatment
under the U.S. federal tax laws, including, without limitation: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities who use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of tax accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers in securities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding ADSs as part of a hedging transaction, &#147;straddle,&#148; wash sale, conversion transaction or
integrated transaction or persons entering into a constructive sale with respect to the ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts, grantor trusts or other trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose &#147;functional currency&#148; for U.S. federal income tax purposes is not the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expatriates of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax exempt entities, including &#147;individual retirement accounts&#148; and &#147;Roth IRAs&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entities or arrangements classified as partnerships or other pass-through entities for U.S. federal income tax
purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that received ADSs as compensation for the performance of services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own or are deemed to own ten percent or more of our shares (by vote or value); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding ADSs in connection with a trade or business, permanent establishment, or fixed base outside the
United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This summary is for general information only. Prospective Investors considering the purchase,
ownership or disposition of the ADSs are advised to consult their own tax advisers concerning the French and U.S. federal income tax consequences in light of their particular facts and circumstances, as well as any consequences arising under the
laws of any other taxing jurisdiction. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>French Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following describes the material French income tax consequences to U.S. Holders (as defined below) of purchasing, owning and disposing of
our ADSs and, unless otherwise noted, this discussion is the opinion of Dechert, our French tax counsel, insofar as it relates to matters of French tax law and legal conclusions with respect to those matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not purport to be a complete analysis or listing of all potential tax effects of the acquisition, ownership or
disposition of our ADSs to any particular investor, and does not discuss tax considerations that arise from rules of general application or that are generally assumed to be known by investors. All of the following is subject to change. Such changes
could apply retroactively and could affect the consequences described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, France introduced a comprehensive set of new tax
rules applicable to French assets that are held by or in foreign trusts. These rules, among other things, provide for the inclusion of trust assets in the settlor&#146;s net assets for purpose of applying the former French wealth tax (replaced by
the French real estate wealth tax as from January&nbsp;1, 2018), for the application of French gift and death duties to French assets held in trust, for a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specific tax on capital on the French assets of foreign trusts not already subject to the former French wealth tax (replaced by the French real estate wealth tax as from January&nbsp;1, 2018) and
for a number of French tax reporting and disclosure obligations. The following discussion does not address the French tax consequences applicable to ADSs held in trusts. If ADSs are held in trust, the grantor, trustee and beneficiary are urged to
consult their own tax adviser regarding the specific tax consequences of acquiring, owning and disposing of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description of the
French income tax and real estate wealth tax consequences set forth below is based on the Convention Between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the
Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital of August&nbsp;31, 1994 which came into force on December&nbsp;30, 1995 (as amended by any subsequent protocols, including the protocol of January&nbsp;13, 2009), or the Treaty
and the tax guidelines issued by the French tax authorities in force as of the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this
discussion, the term &#147;U.S. Holder&#148; means a beneficial owner of ADSs that is (or is treated as), for U.S. federal income tax purposes: (1)&nbsp;an individual who is a U.S. citizen or resident, (2)&nbsp;a corporation or other entity that is
treated as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States or any state thereof, including the District of Colombia, (3)&nbsp;otherwise subject to U.S. federal income taxation or
(4)&nbsp;a trust, if a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of the substantial decisions of such trust or has a valid election
in effect under applicable U.S. Treasury Regulations to be treated as a United States person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (or any other entity
treated as partnership for U.S. federal income tax purposes) holds ADSs, the tax treatment of the partnership and a partner in such partnership generally will depend upon the status of the partner and the activities of the partnership. If a U.S.
Holder is a partnership or a partner in a partnership that holds ADSs, such holder is urged to consult its own tax adviser regarding the specific tax consequences of acquiring, owning and disposing of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion applies only to investors that hold our ADSs as capital assets that have the U.S. dollar as their functional currency, that
are entitled to Treaty benefits under the &#147;Limitation on Benefits&#148; provision contained in the Treaty, and whose ownership of the ADSs is not effectively connected to a permanent establishment or a fixed base in France. Certain U.S. Holders
(including, but not limited to, U.S. expatriates, partnerships or other entities classified as partnerships for U.S. federal income tax purposes, banks, insurance companies, regulated investment companies,
<FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, financial institutions, persons subject to the alternative minimum tax, persons who acquired the securities pursuant to the exercise of employee share options or otherwise as
compensation, persons that own (directly, indirectly or by attribution) 5% or more of our voting stock or 5% or more of our outstanding share capital, dealers in securities or currencies, persons that elect to mark their securities to market for
U.S. federal income tax purposes and persons holding securities as a position in a synthetic security, straddle or conversion transaction) may be subject to special rules not discussed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders are urged to consult their own tax advisers regarding the tax consequences of the purchase, ownership and disposition of
securities in light of their particular circumstances, especially with regard to the &#147;Limitations on Benefits&#148; provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Estate and Gift
Taxes and Transfer Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a transfer of securities by gift or by reason of death of a U.S. Holder that would otherwise be
subject to French gift or inheritance tax, respectively, will not be subject to such French tax by reason of the Convention between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double
Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates, Inheritances and Gifts, dated November&nbsp;24, 1978, unless (i)&nbsp;the donor or the transferor is domiciled in France at the time of making the gift or at the time of
his or her death, or (ii)&nbsp;the securities were used in, or held for use in, the conduct of a business through a permanent establishment or a fixed base in France. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Transactions Tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Article 235 ter ZD of the French Tax Code (<I>Code g&eacute;n&eacute;ral des imp&ocirc;ts</I>) (the &#147;FTC&#148;), purchases of
certain securities issued by a French company, including ordinary shares (which may be in the form of ADSs), which are listed on a regulated market of the EU or an exchange market formally acknowledged by the Minister of Economy, after consultation
opinion from the AMF (in each case within the meaning of the French Monetary and Financial Code (the &#147;FMFC&#148;)) are subject in France to a 0.3% tax on financial transactions (the &#147;TFT&#148;), provided <I>inter alia</I> that the
issuer&#146;s market capitalization exceeds &#128;1&nbsp;billion as of December&nbsp;1 of the year preceding the taxation year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Nasdaq Global Market, on which ADSs will be listed, is not currently acknowledged by the French Minister of Economy, but it may change in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, a list of French relevant companies whose market capitalization exceeds &#128;1&nbsp;billion as of December&nbsp;1 of the year
preceding the taxation year is published annually by the French State. The last version of such list was dated December&nbsp;21, 2022 <FONT STYLE="white-space:nowrap">(BOI-ANNX-000467).</FONT> It did not include Abivax SA as its market
capitalization did not exceed &#128;1.0&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the global offering, purchases of our ADSs may thus be subject to the TFT if
(1)&nbsp;Abivax SA&#146;s market capitalization exceeds &#128;1.0&nbsp;billion, and (2)&nbsp;the Nasdaq Global Market is acknowledged by the French Minister of Economy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Duties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case where
the TFT is not applicable, (1)&nbsp;transfers of shares issued by a French company which are listed on a regulated or organized market within the meaning of the FMFC are subject to uncapped registration duties at the rate of 0.1% if the transfer is
evidenced by a written statement (&#147;acte&#148;) executed either in France or outside France, whereas (2)&nbsp;transfers of shares issued by a French company which are not listed on a regulated or organized market within the meaning of the FMFC
are subject to uncapped registration duties at the rate of 0.1% notwithstanding the existence of a written statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As ordinary shares
of Abivax SA are listed on Euronext, which is a regulated market within the meaning of the FMFC, their transfer should be subject to uncapped registration duties at the rate of 0.1% only if such transfer is evidenced by a written agreement. Although
the official guidelines published by the French tax authorities are silent on this point <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(BOI-ENR-DMTOM-40-10-10-12/09/2012),</FONT></FONT></FONT></FONT></FONT></FONT> ADSs should remain outside of the scope of the aforementioned 0.1% registration duties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Real Estate Wealth Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
January&nbsp;1, 2018, the French wealth tax (<I>imp&ocirc;t de solidarit&eacute; sur la fortune</I>) has been repealed and replaced by the French real estate wealth tax (<I>imp&ocirc;t sur la fortune immobili&egrave;re</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope of such new tax is narrowed to real estate assets (and certain assets deemed to be real estate assets) or rights, held directly or
indirectly through one or more legal entities and whose net taxable assets amount at least to &#128;1,300,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broadly, subject to
provisions of double tax treaties and to certain exceptions, individuals who are not residents of France for tax purposes within the meaning of Article 4 B of the FTC, are subject to real estate wealth tax (<I>imp&ocirc;t sur la fortune
immobili&egrave;re</I>) in France in respect of the portion of the value of their shares of our company representing real estate assets (Article 965, 2&deg; of the FTC). Some exceptions are provided by the FTC. For instance, any participations
representing less than 10% of the share capital of an operating company and shares representing real estate for the professional use of the company considered shall not fall within the scope of the French real estate wealth tax (<I>imp&ocirc;t sur
la fortune immobili&egrave;re</I>). Under the Treaty (the provisions of which should be applicable to this new real estate wealth tax (<I>imp&ocirc;t sur la fortune immobili&egrave;re</I>) in France), the French real estate wealth tax
(<I>imp&ocirc;t sur la fortune immobili&egrave;re</I>) will however generally not apply to securities held by an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligible U.S. Holder who is a U.S. resident, as defined pursuant to the provisions of the Treaty, provided that such (i) U.S. Holder (a)&nbsp;does not own directly or indirectly more than 25% of
the issuer&#146;s financial rights and (b)&nbsp;that the ADSs do not form part of the business property of a permanent establishment or fixed base in France and (ii) that the issuer&#146;s assets do not consist in at least 50 percent of real
property located in France, or that the issuer&#146;s shares do not derive at least 50 percent of their value, directly or indirectly, from real property located in France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders are advised to consult their own tax advisor regarding the specific tax consequences which may apply to their particular
situation with respect to such French real estate wealth tax (<I>imp&ocirc;t sur la fortune immobili&egrave;re</I>). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation of Dividends </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid by a French corporation to <FONT STYLE="white-space:nowrap">non-residents</FONT> of France are generally subject to French
withholding tax at a rate of currently (i) 25% for dividends paid to legal persons which are not French tax residents, and (ii) 12.8% for dividends paid to individuals who are not French tax residents. Dividends paid by a French corporation in a <FONT
STYLE="white-space:nowrap">non-cooperative</FONT> State or territory, as defined in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the FTC, other than those states or territories mentioned in 2&deg; of 2 bis of the same Article 238-0 A
will generally be subject to French withholding tax at a rate of 75%. However, eligible U.S. Holders entitled to Treaty benefits under the &#147;Limitation on Benefits&#148; provision contained in the Treaty who are U.S. residents, as defined
pursuant to the provisions of the Treaty, will not be subject to this 12.8%, 25% or 75% withholding tax rate, but may be subject to the withholding tax at a reduced rate (as described below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Treaty, the rate of French withholding tax on dividends paid to an eligible U.S. Holder who is a U.S. resident as defined pursuant
to the provisions of the Treaty and the beneficial owner of these dividends, and whose ownership of the ordinary shares (which may be in the form of ADSs) is not effectively connected with a permanent establishment or fixed base that such U.S.
Holder has in France, is generally reduced to 15%, or to 5% if such U.S. Holder is a corporation and owns directly or indirectly at least 10% of the share capital of the issuer; such U.S. Holder may claim a refund from the French tax authorities of
the amount withheld in excess of the Treaty rates of 15% or 5%, if any. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For U.S. Holders that are not individuals but are U.S.
residents, as defined pursuant to the provisions of the Treaty, the requirements for eligibility for Treaty benefits, including the reduced 5% or 15% withholding tax rates contained in the &#147;Limitation on Benefits&#148; provision of the Treaty,
are complicated, and certain technical changes were made to these requirements by the protocol of January&nbsp;13, 2009. U.S. Holders are advised to consult their own tax advisers regarding their eligibility for Treaty benefits in light of their own
particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid to an eligible U.S. Holder may immediately be subject to the reduced rates of 5% or 15% provided
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holder establishes before the date of payment that it is a U.S. resident under the Treaty by completing and
providing the depositary with a treaty form (Form 5000) in accordance with French guidelines <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(BOI-INT-DG-20-20-20-20-12/09/2012);</FONT></FONT></FONT></FONT></FONT></FONT></FONT> or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary or other financial institution managing the securities account in the U.S. of such U.S. Holder
provides the French paying agent with a document listing certain information about the U.S. Holder and its ordinary shares or ADSs and a certificate <FONT STYLE="white-space:nowrap">(BOI-LETTRE-000138-28/07/2014)</FONT> whereby the financial
institution managing the U.S. Holder&#146;s securities account in the United States takes full responsibility for the accuracy of the information provided in the document. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Otherwise, dividends paid to a U.S. Holder, if such U.S. Holder is a legal person, will be subject to French withholding tax at the rate of
25%, or 75% if paid in a <FONT STYLE="white-space:nowrap">non-cooperative</FONT> State or territory (as defined in Article 238-0 A of the FTC, but other than those states or territories mentioned in 2&deg; of 2 bis of the same Article 238-0 A), and
then reduced at a later date to 5% or 15%, provided that such holder duly completes and provides the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
French tax authorities with the treaty forms Form 5000 and Form 5001 before December&nbsp;31 of the second calendar year following the year during which the dividend is paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain qualifying pension funds and certain other <FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities are subject to the same general
filing requirements as other U.S. Holders except that they may have to supply additional documentation evidencing their entitlement to these benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the withholding tax rate applicable under French domestic law to U.S. Holders who are individuals does not exceed the cap provided in
the Treaty (i.e., 15%), the 12.8% rate shall apply, without any reduction provided under the Treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Besides, please note that pursuant
to Article 235 <I>quater</I> of the FTC (introduced by the French finance bill No.&nbsp;2019-1479 for 2020) and under certain conditions, a corporate U.S. Holder which is in a tax loss position for the fiscal year during which the dividend is
received may be entitled to a deferral regime, and obtain a withholding tax refund. The tax deferral ends in respect of the first financial year during which this U.S. Holder is in a profit making position, as well as in the cases set out in Article
235 <I>quater</I> of the FTC. Finance Bill for 2022 extended the deadline to claim the refund (December 31 of the second year following the year of payment instead of three months after the end of the fiscal year following the payment of the income)
and clarify the order in which the deferred taxes become due (the forfeiture of the deferral applies in priority to the oldest withholding taxes). Also, pursuant to newly introduced Article 235 <I>quinquies</I> of the FTC and under certain
conditions, a corporate U.S. Holder may be entitled to a refund of a fraction of the withholding tax, up to the difference between the withholding tax paid (on a gross basis) and the withholding tax based on the dividend net of the expenses incurred
for the acquisition and conservation directly related to the income, provided (i)&nbsp;that these expenses would have been tax deductible had the U.S. Holder been established in France, and (ii)&nbsp;that the tax rules in the United States do not
allow the U.S. Holder to offset the withholding tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax on Sale or Other Disposition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under the Treaty, a U.S. Holder who is a U.S. resident for purposes of the Treaty will not be subject to French tax on any capital
gain from the redemption (other than redemption proceeds characterized as dividends under French domestic tax law or administrative guidelines), sale or exchange of ADSs unless the ADSs form part of the business property of a permanent establishment
or fixed base that the U.S. Holder has in France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special rules apply to U.S. Holders who are residents of more than one country. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations for U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders described below of acquiring, owning
and disposing of the ADSs. It is not a comprehensive description of all tax considerations that may be relevant to a particular person&#146;s decision to acquire securities. This discussion applies only to a U.S. Holder that is an initial purchaser
of the ADSs pursuant to the global offering and that will hold such ADSs as &#147;capital assets&#148; (generally, property held for investment) under the U.S. Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). In addition, it does
not describe all of the tax considerations that may be relevant in light of a U.S. Holder&#146;s particular circumstances, including U.S. federal estate, gift, Medicare contribution tax on net investment income, and alternative minimum tax
considerations, the special tax accounting rules under Section&nbsp;451(b) of the Code, any state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax considerations, and tax considerations applicable to U.S. Holders subject to special
rules, including, without limitation:<I> </I> </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities who use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of tax accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers in securities or currencies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding ADSs as part of a hedging transaction, &#147;straddle,&#148; wash sale, conversion transaction or
integrated transaction or persons entering into a constructive sale with respect to the ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts, grantor trusts or other trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose &#147;functional currency&#148; for U.S. federal income tax purposes is not the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expatriates of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax exempt entities, including &#147;individual retirement accounts&#148; and &#147;Roth IRAs&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entities or arrangements classified as partnerships or other pass-through entities for U.S. federal income tax
purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that received ADSs as compensation for the performance of services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own or are deemed to own ten percent or more of our shares (by vote or value); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding ADSs in connection with a trade or business, permanent establishment, or fixed base outside the
United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes
holds the ADSs, the U.S. federal income tax treatment of a partner in that partnership will generally depend on the status of the partner and the activities of the partnership. Partnerships holding the ADSs and partners in such partnerships are
encouraged to consult their own tax advisers as to the particular U.S. federal income tax consequences of acquiring, owning, and disposing of the ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This description is based on the Code, existing, proposed and temporary U.S. Treasury Regulations promulgated thereunder and administrative
and judicial interpretations thereof, in each case as in effect and available on the date hereof. All of the foregoing is subject to change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax
considerations described below. No rulings have been sought from the U.S. Internal Revenue Service (the &#147;IRS&#148;), regarding the matters discussed herein and there can be no assurance that the IRS will not take a contrary position concerning
the tax consequences of the acquisition, ownership and disposition of the ADSs or that such a position would not be sustained. U.S. Holders should consult their own tax advisers concerning the U.S. federal, state, local and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of acquiring, owning, and disposing of the ADSs in their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used for purposes of this section &#147;&#151;Material U.S. Federal Income Tax Considerations for U.S. Holders&#148;, &#147;U.S.
Holder&#148; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of the ADSs that is an initial purchaser of the ADSs pursuant to the global offering and is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United
States, any state therein or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate whose income is eligible for inclusion in gross income for U.S. federal income tax purposes, regardless
of its source; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust, if (A)&nbsp;a U.S. court is able to exercise primary supervision over the trust&#146;s administration
and one or more United States persons (as such term is defined under the Code) have authority to control all substantial decisions of the trust, or (B)&nbsp;the trust has a valid election in place under applicable U.S. Treasury regulations to treat
the trust as a United States person (as such term is defined under the Code). </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below assumes that the
representations contained in the depositary agreement are true and that the obligations in the deposit agreement and any related agreement will be complied with in accordance with its terms. For U.S. federal income tax purposes, it is generally
expected that a U.S. Holder of ADSs will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treated as the beneficial owner of the underlying ordinary shares represented by the ADSs. The remainder of this discussion assumes that a U.S. Holder of our ADSs will be treated in this manner.
Accordingly, deposits or withdrawals of ADSs for ordinary shares will generally not be subject to U.S. federal income tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>U.S.
Holders are encouraged to consult their own tax advisers concerning the U.S. federal, state, local and foreign tax consequences of acquiring, owning and disposing of the ADSs in their particular circumstances. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the passive foreign investment company (&#147;PFIC&#148;) rules described below, distributions paid on the ADSs, other than certain
pro rata distributions of the ADSs, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). We do not maintain calculations of our
earnings and profits under U.S. federal income tax principles, and so we expect that distributions generally will be reported to U.S. Holders as dividends. Subject to applicable limitations, dividends paid by a &#147;qualified foreign
corporation&#148; are eligible for taxation at a preferential capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided that certain requirements are met. However, if we are a PFIC (or treated as a PFIC
with respect to the U.S. Holder) for the taxable year in which the dividend is paid or the preceding taxable year (see discussion below under &#147;Passive Foreign Investment Company Rules&#148;), we will not be treated as a qualified foreign
corporation, and therefore the preferential capital gains tax rate described above will not apply. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the preferential tax rate on dividends with regard to its
particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation (other than a corporation classified as a PFIC
for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation if: (i)&nbsp;if it is eligible for the benefits of a comprehensive tax treaty with the United
States, which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision, and which includes an exchange of information provision; or (ii)&nbsp;with respect to any dividend it pays on shares that are
readily tradable on an established securities market in the United States. We believe that we qualify as a resident of France for the purposes of, and are eligible for the benefits of, the income tax treaty between France and the United States,
which the IRS has determined is satisfactory for purposes of the qualified dividend rules, and that it includes an exchange of information provision, although there can be no assurance in this regard. Further, our ADSs will generally be considered
to be readily tradable on an established securities marked in the United States if they are listed on the Nasdaq Global Market, which we anticipate the ADSs will be. Therefore, subject to the discussion below under &#147;Passive Foreign Investment
Company Rules,&#148; if the income tax treaty between France and the United States is applicable, or if the ADSs are readily tradable on an established securities market in the United States, dividends paid on the ADSs will generally be
&#147;qualified dividend income&#148; in the hands of individual U.S. Holders, provided that certain conditions are met, including conditions relating to the holding period and the absence of certain risk reduction transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder must include the gross amount of a dividend without reduction for amounts withheld by us in respect of French income taxes (see
&#147;Material United States Federal Income and French Tax Considerations&#151;Certain French Considerations&#148;), even though the U.S. Holder did not in fact receive the amount associated with the withheld French tax.<I> </I>The amount of the
dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will generally be included in a U.S.
Holder&#146;s income on the date of the U.S. Holder&#146;s receipt (or deemed receipt) of the dividend. The amount of any distribution of property other than cash (and excluding certain pro rata distributions of ordinary shares or ADSs or rights to
acquire ordinary shares or ADSs) will be the fair market value of such property on the date of the distribution. The amount of any dividend income paid in euros will be the U.S. dollar amount calculated by reference to the exchange rate in effect on
the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder
may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
applicable limitations, some of which vary depending upon the U.S. Holder&#146;s particular circumstances, French income taxes withheld from dividends on the ADSs at a rate not exceeding the rate provided by the income tax treaty between France and
the United States will generally be creditable against the U.S. Holder&#146;s U.S. federal income tax liability. Dividend distributions with respect to the ADSs generally will be treated as &#145;&#145;passive category&#146;&#146; income from
sources outside the United States for purposes of determining a U.S. Holder&#146;s U.S. foreign tax credit limitation. The rules governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability
of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any French income tax, in computing their taxable income, subject to generally
applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Taxable Disposition of the ADSs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder will generally recognize gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition
of the ADSs in an amount equal to the difference between the U.S. dollar value of the amount realized from such sale or exchange and the U.S. Holder&#146;s tax basis for those ADSs. Subject to the PFIC rules described below, this gain or loss will
generally be a capital gain or loss. The adjusted tax basis in an ADS generally will be equal to the cost of such ADS. Capital gain from the sale, exchange or other taxable disposition of ADSs of a
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder is generally eligible for a preferential rate of taxation applicable to capital gains, if the <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder&#146;s holding period
determined at the time of such sale, exchange or other taxable disposition for such ADSs exceeds one year (<I>i.e.,</I> such gain is long-term taxable gain). The deductibility of capital losses for U.S. federal income tax purposes is subject to
limitations under the Code. Any such gain or loss that a U.S. Holder recognizes generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a cash basis taxpayer, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the settlement date
of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations between the trade date and the settlement date of such a purchase or sale. An accrual basis taxpayer, however, may elect the same
treatment required of cash basis taxpayers with respect to purchases and sales of the ADSs that are traded on an established securities market, provided the election is applied consistently from year to year. Such election may not be changed without
the consent of the IRS. For an accrual basis taxpayer who does not make such an election, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the trade date of the purchase or sale. Such an accrual basis
taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement date. Any foreign currency gain or loss a U.S. Holder realizes will be U.S. source ordinary income or loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Code, we will be a PFIC for any taxable year in which, after the application of certain
<FONT STYLE="white-space:nowrap">&#147;look-through&#148;</FONT> rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of &#147;passive income,&#148; (&#147;income test&#148;) or (ii) 50% or more of the average
quarterly value of our assets (generally determined on the basis of a weighted quarterly average) consist of assets that produce, or are held for the production of, &#147;passive income.&#148; Passive income generally includes dividends, interest,
and gains from the sale or exchange of investment property and rents or royalties other than rents or royalties which are received from unrelated parties in connection with the active conduct of a trade or business. Passive assets include, among
others, cash and assets readily convertible into cash, while our goodwill and other unbooked intangibles associated with active business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
activities may generally be treated as non-passive assets. In addition, for purposes of the above calculations, a non-U.S. corporation that owns, directly or indirectly, at least 25% by value of
the equity interests of another corporation is treated as if it held its proportionate share of the assets of the other corporation, and received directly its proportionate share of the income of the other corporation. If a corporation is treated as
a PFIC with respect to a U.S. Holder for any taxable year, the corporation will continue to be treated as a PFIC with respect to that U.S. Holder in all succeeding taxable years, regardless of whether the corporation continues to meet the PFIC
requirements in such years, unless certain elections are made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our analysis of our financial statements, activities and relevant
market and shareholder data, we do not believe that we were a PFIC for the taxable year ended December 31, 2022. Whether we are a PFIC for any taxable year will depend on the composition of our income and the composition, nature and value of our
assets from time to time (including the value or our goodwill, which may be determined by reference to the value of our ADSs, which could fluctuate considerably). We currently do not generate product revenues and therefore we may be a PFIC for any
taxable year in which we do not generate sufficient amounts of non-passive income to offset our passive financing income. As a result, there can be no assurance that we will not be treated as a PFIC for the current or any future taxable year and our
U.S. counsel expresses no opinion with respect to our PFIC status for any prior, current or future taxable year. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS, will agree with our conclusion
and that the IRS would not successfully challenge our position. If we are a PFIC for any year during which a U.S. Holder holds the ADSs, unless certain elections have been made by the U.S. Holder, we generally will continue to be treated as a PFIC
with respect to such U.S. Holder for all succeeding years during which the U.S. Holder holds the ADSs, even if we cease to meet the threshold requirements for PFIC status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year during which a U.S. Holder holds the ADSs, the U.S. Holder may be subject to adverse tax consequences,
regardless of whether we remain a PFIC. Generally, gain recognized upon a disposition (including, under certain circumstances, a pledge) of the ADSs by the U.S. Holder would be allocated ratably over the U.S. Holder&#146;s holding period for such
ADSs. The amounts allocated to the taxable year of disposition and to years before we became a PFIC <FONT STYLE="white-space:nowrap">(&#147;pre-PFIC</FONT> Years&#148;) would be taxed as ordinary income. The amount allocated to each other taxable
years would be subject to tax at the highest rate in effect for that taxable year for individuals or corporations, as appropriate, and would be subject to an interest charge on the resulting tax deemed deferred with respect to each such other
taxable year. Further, to the extent that any distribution received by a U.S. Holder on its ADSs exceeds 125% of the average of the annual distributions on such ADSs received by the U.S. Holder during the (i)&nbsp;preceding three years or
(ii)&nbsp;the U.S. Holder&#146;s holding period, whichever is shorter, that distribution would be subject to taxation in the same manner described immediately above with respect to gain on disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternatively, if we are a PFIC and if the ADSs are &#147;regularly traded&#148; on a &#147;qualified exchange,&#148; a U.S. Holder could make
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election that would result in tax treatment different from the general tax treatment described in the preceding paragraph. The ADSs would be treated as
&#147;regularly traded&#148; in any calendar year in which more than a <I>de minimis </I>quantity of the ADSs are traded on a qualified exchange, including the Nasdaq Global Market, on at least 15 days during each calendar quarter. The ADSs are
listed on the Nasdaq Global Market, and we expect, although no assurance can be given, that they will be regularly traded on the Nasdaq Global Market. U.S. Holders should consult with their own tax advisors regarding potential availability of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder makes the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, the U.S. Holder generally will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over their
adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously
included as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). If a U.S. Holder makes the election, the U.S. Holder&#146;s tax basis in the ADSs will be adjusted to reflect these
income or loss amounts. Any gain recognized on the sale or other disposition of ADSs in a year when we are a PFIC will be treated as ordinary income and any loss will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). If a U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election in respect of
a corporation classified as a PFIC and such corporation ceases to be classified as a PFIC, the holder will not be required to take into account the gain or loss described above during any period that such corporation is not classified as a PFIC.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A timely election to treat a PFIC as a qualified electing fund under Section&nbsp;1295 of the Code (&#147;QEF Election&#148;) would
result in alternative treatment. If a U.S. Holder makes a QEF Election for the first tax year of such U.S. Holder&#146;s holding period in which we are classified as a PFIC, then such U.S. Holder generally would not be subject to the PFIC
rules&nbsp;described above.&nbsp;Instead, a U.S. Holder that makes a timely and effective QEF Election will currently include in gross income such U.S. Holder&#146;s (a) pro rata share of our ordinary earnings as ordinary income and (b)&nbsp;pro
rata share of our net capital gain as long-term capital gain, regardless of whether we have made any distributions of such earnings or gain. The U.S. Holder&#146;s basis in its ADSs would be increased to reflect the amount of such income
inclusions.&nbsp;Generally, for this purpose, &#147;ordinary earnings&#148; are the excess of our (a) &#147;earnings and profits&#148; over (b)&nbsp;net capital gain, and &#147;net capital gain&#148; is the excess of our (a)&nbsp;net long-term
capital gain over (b)&nbsp;net short-term capital loss.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder that has made such a timely and effective QEF Election generally may
receive a distribution <FONT STYLE="white-space:nowrap">tax-free</FONT> as a return of capital to the extent that such distribution represents &#147;earnings and profits&#148; that were previously included in income by the U.S. Holder because of
such QEF Election and such distribution&nbsp;will reduce such U.S. holder&#146;s adjusted tax basis in our ADSs to reflect the amount allowed as a tax free distribution because of such QEF Election.&nbsp;A U.S. Holder that makes a QEF Election would
generally recognize capital gain or loss on the sale, exchange or other taxable disposition of its ADSs<B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, a U.S. Holder
will only be able to make a QEF Election if we provide such U.S. Holder with certain tax information annually, and we may determine not to provide such information. Furthermore, if the IRS determines that we were a PFIC for a year with respect to
which we had determined that we were not (or believed we were not) a PFIC, it might be too late for a U.S. Holder to make a timely QEF Election, unless the U.S. Holder qualifies under the applicable Treasury Regulations to make a retroactive (late)
election. U.S. Holders should consult their own tax advisors regarding the making of any such QEF Election. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we are a
PFIC or, with respect to particular U.S. Holders, are treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable year, the preferential rates discussed above with respect to dividends paid to certain <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders would not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder owns ADSs during any year in which we are
a PFIC, the holder generally must file an IRS Form 8621, or such other form as is required by the U.S. Treasury Department, generally with the holder&#146;s federal income tax return for that year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders should consult their tax advisers regarding whether we are or may become a PFIC and the potential application of the PFIC rules.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of distributions and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries
generally are subject to information reporting, and may be subject to backup withholding, unless (i)&nbsp;the U.S. Holder is a corporation or other exempt recipient or (ii)&nbsp;in the case of backup withholding, the U.S. Holder provides a correct
taxpayer identification number and certifies that it is not subject to backup withholding. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional
tax. The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the holder&#146;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely
furnished to the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information With Respect to Foreign Financial Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders who are individuals may be required to report information relating to their ownership of an interest in certain foreign
financial assets, including stock of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> person, generally on Form 8938, subject to exceptions (including an exception for stock held through a U.S. financial institution). In addition, certain U.S.
Holders may be required to file a FinCEN Form 114 (Report of Foreign Bank and Financial Accounts) with the U.S. Treasury Department each year to report their interest in the ADSs. U.S. Holders should consult their tax advisers regarding their
reporting obligations with respect to the ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The above description is not intended to constitute a complete analysis of all tax
consequences relating to acquisition, ownership and disposition of the ADSs. You should consult your tax advisor concerning the tax consequences of your particular situation. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_22"></A>UNDERWRITERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below,
for whom Morgan Stanley &amp; Co. LLC and Leerink Partners LLC are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of ADSs (including underlying ordinary shares) and ordinary
shares indicated below: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley &amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bryan Garnier Securities SAS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bryan Garnier &amp; Co Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LifeSci Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closings of the U.S. offering and the European private placement will occur simultaneously. The
total number of ordinary shares (including in the form of ADSs) in the U.S. offering and European private placement is subject to reallocation between these offerings, as permitted under applicable laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and the representatives are collectively referred to as the &#147;underwriters&#148; and the &#147;representatives,&#148;
respectively. The underwriters are offering the ADSs and ordinary shares subject to their acceptance of the ADSs and ordinary shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the ADSs and ordinary shares offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and
pay for all of the ADSs and ordinary shares offered by this prospectus if any such ADSs and ordinary shares are taken. However, the underwriters are not required to take or pay for the ADSs and/or ordinary shares covered by the underwriters&#146;
over-allotment option described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the ADSs and ordinary shares directly to the
public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS and &#128; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary
share under the public offering price. After the initial offering of the ADSs and ordinary shares, the offering price and other selling terms may from time to time be varied by the representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs and/or ordinary shares at the public offering price listed on the cover page of this prospectus, less underwriting commissions. The
underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the ADSs and ordinary shares offered by this prospectus. To the extent the option is exercised, each
underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional ADSs and/or ordinary shares as the number listed next to the underwriter&#146;s name in the preceding table bears to the total
number of ADSs and/or ordinary shares listed next to the names of all underwriters in the preceding table. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per ADS, per ordinary share and total public offering
price, underwriting commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs and/or ordinary shares. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Ordinary Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting commissions to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by us, exclusive of the underwriting commissions, are
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have informed us that they do not intend
sales to discretionary accounts to exceed 5% of the total number of ADSs and ordinary shares offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list
our ADSs on the Nasdaq Global Market under the symbol &#147;ABVX.&#148; Our ordinary shares are listed on Euronext Paris under the symbol &#147;ABVX.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and all directors and executive officers and certain of our shareholders have agreed that, without the prior written consent of Morgan
Stanley &amp; Co. LLC and Leerink Partners LLC on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending 90 days after the date of this prospectus (the &#147;restricted
period&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any ADSs, ordinary shares, or any securities convertible into or exercisable or exchangeable for ADSs or ordinary shares
(such other securities, including any received upon grant or vesting pursuant to a free share plan, &#147;derivative securities&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">file any registration statement with the SEC relating to the offering of any ADSs, ordinary shares or
derivative securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enter into any hedging, swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of ADSs, ordinary shares or derivative securities, whether any such transaction described above is to be settled by delivery of ADSs, ordinary shares or derivative securities, in cash or otherwise.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we and each such person agrees that, without the prior written consent of Morgan Stanley &amp; Co. LLC and
Leerink Partners LLC on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any ADSs, ordinary shares or derivative securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our directors and executive officers and certain of our shareholders, the restrictions described in the immediately
preceding paragraph are subject to specified exceptions, including, without limitation and subject in certain cases to various conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transactions relating to ADSs, ordinary shares or derivative securities acquired in open market transactions
after the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of ADSs, ordinary shares or derivative securities (i) as a <I>bona fide</I> gift; (ii) to any trust
for the direct or indirect benefit of such person; (iii) as a distribution or other transfer by a corporation to its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shareholders or former shareholder or to any wholly-owned subsidiary of such corporation; (iv) to such person&#146;s affiliates or to any investment fund or other entity controlled or managed by
such person; (v)&nbsp;pursuant to a qualified domestic relations order or in connection with a divorce settlement or (vi) by will or intestate succession or intestate distribution upon the death of such person; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">surrender of ordinary shares to the depositary or the depositary&#146;s custodian for the purpose of receiving
an equivalent number of ADSs in lieu of such ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of ADSs, ordinary shares or derivative securities to the company in satisfaction of any tax
withholding obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers or sales of up to 1,000,000 ADSs or ordinary shares (in the aggregate for all of our directors,
officers and affiliates) used for the primary purpose of satisfying any withholding tax or other governmental withholding or payment obligations pursuant to equity awards granted under a share incentive plan or other equity award plan that is
described in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of ADSs, ordinary shares or derivative securities to us pursuant to any contractual arrangement that
provides for the repurchase of the ADSs, ordinary shares or derivative securities held by such person in connection with the termination of such person&#146;s services to us or such person&#146;s failure to meet certain conditions set out upon
receipt of such ADSs, ordinary shares or derivative securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise or exchange by such person of any option or warrant to acquire any ADSs or ordinary shares or
option to purchase ADSs or ordinary shares, in each case for cash or on a &#147;cashless&#148; or &#147;net exercise&#148; basis, pursuant to any share option, share bonus or other share plan or arrangement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of ADSs, ordinary shares or derivative securities upon the completion of a bona fide third-party
tender offer, merger, consolidation or other similar transaction that is approved by our Board, made to all holders of our securities and involves a change of control of us; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the establishment of a trading plan on behalf of our shareholder, officer or director pursuant to Rule 10b5-1
under the Exchange Act (&#147;10b5-1 trading plan&#148;) for the transfer of ADSs or ordinary shares or the amendment of an existing 10b5-1 trading plan, provided that such 10b5-1 trading plan does not provide for the transfer of ADSs or ordinary
shares during the restricted period. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morgan Stanley &amp; Co. LLC and Leerink Partners LLC, in their sole discretion,
may release the ADSs, ordinary shares and derivative securities subject to the lock-up agreements described above in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the ADSs and ordinary shares, the underwriters may engage in transactions that stabilize, maintain or
otherwise affect the price of the ADSs and/or ordinary shares. Specifically, the underwriters may sell more ADSs and ordinary shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is
covered if the short position is no greater than the number of ADSs and ordinary shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short sale by exercising the over-allotment
option or purchasing ADSs and/or ordinary shares in the open market. In determining the source of ADSs and/or ordinary shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of ADSs and/or
ordinary shares compared to the price available under the over-allotment option. The underwriters may also sell ADSs and ordinary shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any
naked short position by purchasing ADSs and/or ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs and/or ordinary
shares in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, ADSs and ordinary shares in the open
market to stabilize the price of the ADSs and ordinary shares. These activities may raise or maintain the market price of the ADSs and ordinary shares above independent market levels or prevent or retard a decline in the market price of the ADSs and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ordinary shares. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any,
participating in this offering. The representatives may agree to allocate a number of ADSs and/or ordinary shares to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective
affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging,
financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they
received or will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the
underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and
for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective
affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such
securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our ordinary shares are traded on Euronext Paris, prior to this offering, there has been no public market for our ADSs or ordinary shares
in the United States. The offering price for our ADSs in U.S. dollars and the corresponding offering price for our ordinary shares in euros was determined through negotiations between us and the representatives, and by reference to the prevailing
market prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors, but is not lower than 85% of the volume-weighted-average price of our ordinary shares on Euronext Paris for the 15 trading days
preceding the day on which the offering price was determined. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the authority
granted by our shareholders to conduct the global offering, the securities that we are offering may only be purchased initially by (i)&nbsp;French or foreign individuals, legal entities, including companies, trusts or investment funds or other
investment vehicles of any kind, investing, as a main activity, or having invested more than &#128;1 million during the 24 months preceding the considered capital increase (a)&nbsp;in the pharmaceutical sector; and/or (b)&nbsp;in a growth stock
listed on a regulated market or a multilateral negotiation system (type Euronext Growth) considered as &#147;community small and <FONT STYLE="white-space:nowrap">medium-sized</FONT> companies&#148; in the meaning of annex I to the Regulation (CE)
No.&nbsp;651/2014 of the European Commission of June&nbsp;17, 2014; (ii)&nbsp;one or more strategic partners of the Company, located in France or abroad, who has (have) entered into or will enter into one or more partnership agreements (development,
<FONT STYLE="white-space:nowrap">co-development,</FONT> distribution, manufacturing agreements, etc.) or commercial agreements with the Company (or a subsidiary) and/or companies they control, that control them or are controlled by the same
person(s), directly or indirectly, within the meaning of Article L. <FONT STYLE="white-space:nowrap">233-3</FONT> of the French </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Commercial Code; and/or (iii) any French or foreign investment services provider, or any foreign institution having an equivalent status, likely to guarantee the realization of an issue intended
to be placed with the persons referred to in (i) and/or (ii) above and, in this context, to subscribe the securities issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the Corporations Act, and does not purport to include
the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
offer in Australia of the securities may only be made to persons, or the Exempt Investors, who are &#147;sophisticated investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the
meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the securities without disclosure to investors under Chapter 6D of the
Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of
12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or
otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring securities must observe such Australian on-sale restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take into account the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate for their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Relevant State&#148;), no securities have been offered or will be
offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Relevant State or, where appropriate, approved in
another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of the securities may be made to the public in that Relevant State at any time under the
following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of the securities shall require us or any of our representatives to publish a prospectus pursuant to
Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes
of this provision, the expression an &#147;offer to the public&#148; in relation to the securities in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to
be offered so as to enable an investor to decide to purchase any securities, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who receives any communication in respect of, or who
acquires any securities under, the offering contemplated hereby will be deemed to have represented, warranted and agreed to and with each of the underwriters and their affiliates and to us that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) it is a qualified investor within the meaning of the Prospectus Regulation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in the case of any securities acquired by it as a financial intermediary, as that term is used in Article 5 of the Prospectus Regulation,
(i) the securities acquired by it in the offering have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant State other than qualified investors, as
that term is defined in the Prospectus Regulation, or have been acquired in other circumstances falling within the points (a) to (d) of Article 1(4) of the Prospectus Regulation and the prior consent of the representative has been given to the offer
or resale; or (ii) where the securities have been acquired by it on behalf of persons in any Relevant State other than qualified investors, the offer of those securities to it is not treated under the Prospectus Regulation as having been made to
such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the underwriters and their affiliates, and others will rely upon the truth and accuracy of the foregoing
representation, acknowledgement and agreement. Notwithstanding the above, a person who is not a qualified investor and who has notified the representative of such fact in writing may, with the prior consent of the representative, be permitted to
acquire securities in the offering. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MiFID II Product Governance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of each manufacturer&#146;s product approval process, the target market assessment in respect of ordinary shares has
led to the conclusion that: (i)&nbsp;the target market for the ordinary shares is eligible counterparties, professional clients and retail clients, each as defined in Directive 2014/65/EU, as amended (&#147;MiFID II&#148;); and (ii)&nbsp;all
channels for distribution of the ordinary shares to eligible counterparties, professional clients and retail clients are appropriate. Any person subsequently offering, selling or recommending the ordinary shares, or a distributor, should take into
consideration the manufacturers&#146; target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the ordinary shares (by either adopting or refining the
manufacturers&#146; target market assessment) and determining appropriate distribution channels. For the avoidance of doubt, even if the target market includes retail clients, it has been decided that the ordinary shares will only be offered to
persons who meet the criteria of eligible counterparties and professional clients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>UK MiFIR Product Governance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of each manufacturer&#146;s product approval process, the target market assessment in respect of the securities has led
to the conclusion that: (i)&nbsp;the target market for the securities is retail clients, as defined in point (8)&nbsp;of article 2 of Regulation (EU) No.&nbsp;2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act
2018 (&#147;EUWA&#148;), and eligible counterparties, as defined in the Financial Conduct Authority (&#147;FCA&#148;) Handbook Conduct of Business Sourcebook (&#147;COBS&#148;) and professional clients, as defined in Regulation (EU) No 600/2014 as
it forms part of domestic law by virtue of the EUWA (&#147;UK MiFIR&#148;); and (ii)&nbsp;all channels for distribution of the securities are appropriate. Any person subsequently offering, selling or recommending the securities (a
&#147;distributor&#148;) should take into consideration the manufacturers&#146; target market assessment; however, a distributor subject to the FCA Handbook Product Intervention and Product Governance Sourcebook (the &#147;UK MiFIR Product
Governance Rules&#148;) is responsible for undertaking its own target market assessment in respect of the securities (by either adopting or refining the manufacturer&#146;s target market assessment) and determining appropriate distribution channels.
For the avoidance of doubt, even if the target market includes retail clients, it has been decided that the securities will only be offered to persons who meet the criteria of eligible counterparties and professional clients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any other material in relation to the securities described herein is only being distributed to, and is only directed at,
and any investment or investment activity to which this prospectus relates is available only to, and will be engaged in only with persons who are (i) persons having professional experience in matters relating to investments who fall within the
definition of investment professionals in Article 19(5) of the FPO; or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the FPO; (iii) outside the UK; or (iv) persons to whom an invitation or inducement to engage in investment
activity (within the meaning of Section 21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as &#147;Relevant
Persons&#148;). The securities are only available in the UK to, and any invitation, offer or agreement to purchase or otherwise acquire the securities will be engaged in only with, the Relevant Persons. This prospectus and its contents are
confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person in the UK. Any person in the UK that is not a Relevant Person should not act or rely on this prospectus or any
of its contents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No securities have been offered or will be offered pursuant to the offering to the public in the UK prior to the
publication of a prospectus in relation to the securities which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the FSMA, except that offers of the securities may be made to the
public in the UK at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the FSMA, provided that no such offer of
securities shall require us or any of our representatives to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the securities in the UK means the
communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities, and the expression &#147;UK Prospectus
Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in the UK who acquires any securities in the offer or to whom any offer is made will be deemed to have represented, acknowledged
and agreed to and with us, the underwriters and their affiliates that it meets the criteria outlined in this section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>France </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any
marketing materials relating to securities may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article <FONT
STYLE="white-space:nowrap">L.411-2</FONT> 1&deg; of the French Monetary and Financial Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may only be offered or sold
in France pursuant to article L. <FONT STYLE="white-space:nowrap">411-2</FONT> 1&deg; of the French Monetary and Financial&nbsp;Code to qualified investors (<I>investisseurs qualifi&eacute;s</I>) (as such term is defined in Article 2(e) of the
Prospectus Regulation) acting for their own account, and in accordance with articles L. <FONT STYLE="white-space:nowrap">411-1,</FONT> L. <FONT STYLE="white-space:nowrap">411-2</FONT> and D. <FONT STYLE="white-space:nowrap">411-2</FONT> to <FONT
STYLE="white-space:nowrap">D.411-4</FONT> of the French Monetary and Financial&nbsp;Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors are informed that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither this prospectus nor any other offering materials relating to the securities described in this prospectus
has been submitted for clearance to the French financial markets authority (<I>Autorit&eacute; des march&eacute;s financiers);</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither this prospectus, nor any offering material relating to the securities has been or will be released,
issued, distributed or caused to be released, issued or distributed to the public in France or used in connection with any offer for subscription or sale of the securities to the public in France within the meaning of article L. 411-1 of the French
Monetary and Financial Code (other than public offerings defined in Article <FONT STYLE="white-space:nowrap">L.411-2</FONT> 1&deg; of the French Monetary and Financial&nbsp;Code); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">individuals or entities referred to in article L. <FONT STYLE="white-space:nowrap">411-2</FONT> 1&deg; of the
French Monetary and Financial Code may participate in the offering, as provided under articles <FONT STYLE="white-space:nowrap">D.411-4</FONT> of the French Monetary and Financial&nbsp;Code; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direct and indirect distribution or sale to the public of the securities acquired by them may only be made in
compliance with articles L. <FONT STYLE="white-space:nowrap">411-1,</FONT> L. <FONT STYLE="white-space:nowrap">411-2</FONT> 1&deg;, L. <FONT STYLE="white-space:nowrap">412-1</FONT> and L. <FONT STYLE="white-space:nowrap">621-8</FONT> to L. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">621-8-2</FONT></FONT> of the French Monetary and Financial Code. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold
in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection 73.3(1)
of the Securities Act (Ontario), and are permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the
securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts <FONT
STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in
connection with this offering. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or the
DFSA. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or
verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The securities to which this prospectus
relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this prospectus you should
consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (i)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Hong Kong and any rules made under that Ordinance; or (ii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding
Up and Miscellaneous Provisions) Ordinance (Cap. 32)&nbsp;of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to our securities has been or may be
issued or has been or may be in the possession of any person for the purposes of issuance, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to our securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the
Securities and Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Israel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Israeli Securities Law, and has not been
filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the securities hereunder is directed only at, (i) a limited number of persons in accordance
with the Israeli Securities Law and (ii) investors listed in the first addendum to the Israeli Securities Law, or the Addendum, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers,
investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time
to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are
required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No registration pursuant to Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as
amended), or the FIEL, has been made or will be made with respect to the solicitation of the application for the acquisition of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the securities have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in
Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or re-sale, directly
or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Qualified Institutional Investors, or QII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in
relation to the securities constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, Article 23-13 of the FIEL). Disclosure regarding any such solicitation, as is
otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the securities. The securities may only be transferred to QIIs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Non-QII Investors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that
the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in relation to the securities constitutes either a &#147;small number private placement&#148; or a &#147;small number private
secondary distribution&#148; (each as is described in Paragraph 4, Article 23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not been made in relation to the securities. The securities may only be transferred en bloc without subdivision to a single investor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has
not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may not
be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor
under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions
specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is (a) a corporation (which is
not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b) a
trust (where the trustee is not an accredited investor ) the sole purpose of which is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in Section 239(1) of the SFA) of that
corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under
Section&nbsp;275 of the SFA except: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or
to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; (ii) where no consideration is or will be given for the transfer; (iii) where the transfer is by operation of law; (iv) as specified in
Section 276(7) of the SFA; or (v) as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of its obligations pursuant to Section 309B of the SFA, we have determined, and hereby notify all relevant persons (as
defined in the CMP Regulations 2018), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of
Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is
not intended to constitute an offer or solicitation to purchase or invest in our securities. Our securities may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act, or the FinSA, and
no application has or will be made to admit our securities to trading on any trading venue (exchange or multilateral trading facility) in Switzerland. Neither this prospectus nor any other offering or marketing material relating to our securities
constitutes a prospectus pursuant to the FinSA, and neither this prospectus nor any other offering or marketing material relating to our securities may be publicly distributed or otherwise made publicly available in Switzerland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_23"></A>EXPENSES RELATING TO THE GLOBAL OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the costs and expenses, other than underwriting commissions, payable in connection with the sale of ordinary
shares (which may be in the form of ADSs) in the global offering. All amounts are estimated except the SEC registration fee, the Nasdaq filing fee and the FINRA filing fee. Except as otherwise noted, all the expenses below will be paid by us.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>EXPENSES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> *</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be completed by amendment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_24"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of our ordinary shares (which may be in the form of ADSs) and certain other matters of French law will be passed upon for us by
Dechert (Paris) LLP, including certain matters of French tax law. Certain matters of U.S. federal and New York state law will be passed upon for us by Cooley LLP, New York, New York. Latham &amp; Watkins LLP, New York, New York, with respect to U.S.
federal law, and Gide Loyrette Nouel A.A.R.P.I., with respect to French law, are acting as counsel for the underwriters in connection with the global offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_25"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2021 and December&nbsp;31, 2022 and for each of the two years in the period ended
December&nbsp;31, 2022 included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers Audit, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and
accounting. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offices of PricewaterhouseCoopers Audit are located at 63, rue de Villiers, 92200 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Neuilly-sur-Seine,</FONT></FONT> France. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_25a"></A>DISCLOSURE OF COMMISSION POSITION ON
INDEMNIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to our directors,
officers or persons controlling us, we have been advised that it is the SEC&#146;s opinion that such indemnification is against public policy as expressed in such act and is, therefore, unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc609070_26"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the Securities and Exchange Commission a registration statement (including amendments and exhibits to the registration
statement) on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under the Securities Act. A related registration statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> will be filed with the Securities and Exchange Commission to register the
ADSs. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules to the registration statement. For further information, we refer you
to the registration statement and the exhibits and schedules filed as part of the registration statement. If a document has been filed as an exhibit to the registration statement, we refer you to the copy of the document that has been filed. Each
statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by the filed exhibit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
completion of the U.S. offering, we will become subject to the informational requirements of the Exchange Act. Accordingly, we will be required to file reports and other information with the SEC, including annual reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;20-F</FONT> and reports on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> The SEC maintains a website that contains reports and other information about issuers, like us, that file electronically with the SEC.
The address of that website is www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are exempt under the Exchange Act from, among other things,
the rules prescribing the furnishing and content of proxy statements, and our directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In
addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will send the transfer agent a copy of all notices of shareholders&#146; meetings and other reports, communications and information that
are made generally available to shareholders. The transfer agent has agreed to mail to all shareholders a notice containing the information (or a summary of the information) contained in any notice of a meeting of our shareholders received by the
transfer agent and will make available to all shareholders such notices and all such other reports and communications received by the transfer agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a corporate website at www.abivax.com. The reference to our website is an inactive textual reference only and information
contained in, or that can be accessed through, our website or any other website cited in this prospectus is not part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc609070_27"></A>INDEX TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Statements as of and for the Years Ended December 31, 2021 and 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_2">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_3">Statements of Financial Position as of December 31, 2021 and 2022
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_4">Statements of Income (Loss) for the Years Ended December 31, 2021 and
2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_5">Statements of Comprehensive Income (Loss) for the Years Ended December 31, 2021
 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_6">Statements of Changes in Shareholders&#146; Equity for the Years Ended December
 31, 2021 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_7">Statements of Cash Flows for the Years Ended December 31, 2021 and
2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin609070_8">Notes to the Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_2"></A>Report of Independent Registered Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Shareholders </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on
the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying statements of financial position of Abivax SA (the &#147;Company&#148;) as of December
31, 2022 and 2021, and the related statements of income (loss) and comprehensive income (loss), of changes in shareholders&#146; equity and of cash flows for each of the two years in the period ended December 31, 2022, including the related notes
(collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its
operations and its cash flows for each of the two years in the period ended December 31, 2022 in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board and International Financial
Reporting Standards as adopted by the European Union. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits of these
financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to
error or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emphasis of Matter </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 2. Basis
of preparation to the financial statements, the Company will need to continue to rely on additional capital from investors or lenders to meet its forecasted operating cash flow requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers Audit </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuilly-sur-Seine, France </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 28, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor
since 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_3"></A>ABIVAX SA STATEMENTS OF FINANCIAL POSITION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of</B><br><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>7</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>8</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables and assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables and assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>11</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premiums related to share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>13</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>16</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible loan notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.1&nbsp;&amp;&nbsp;15.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.1 &amp; 15.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.5</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>22</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible loan notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.5</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>17.1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax and employee-related payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>17.2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><A NAME="fin609070_4"></A>ABIVAX SA STATEMENTS OF INCOME (LOSS) </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros, except per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19.1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19.2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial gain (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>21</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>22</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of outstanding shares used for computing basic/diluted loss per
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,455,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,092,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic / diluted loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>23</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2.75</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3.18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_5"></A>ABIVAX SA STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Year ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Items that will not be reclassified to profit or loss</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>169</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>235</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and losses on retirement benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Items that will be reclassified to profit or loss</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>169</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,283</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,506</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_6"></A>ABIVAX SA STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; EQUITY
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands of euros, except share date) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros, except<BR>number of shares)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES<BR>ISSUED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SHARE<BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PREMIUMS<BR>RELATED&nbsp;TO<BR>SHARE<BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RESERVES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NET&nbsp;LOSS</B><br><B>FOR&nbsp;THE&nbsp;YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL<BR>SHAREHOLDER&#146;S<BR>EQUITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,320,271</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>42,073</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,851</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(37,633</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,733</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>169</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,283</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Appropriation of 2020 net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs related to capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercises of share warrants under the Equity line agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercises of share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shares based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction on treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,764,051</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>168</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,361</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(42,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,934</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,506</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Appropriation of 2021 net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increase from issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,530,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs related to capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercises of share warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shares based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction on treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22,313,185</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>223</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>150,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,771</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,189</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_7"></A>ABIVAX SA STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Amounts in thousands of euros) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ajustments for:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Elimination of amortization of intangibles and depreciation of property, plant and
equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Elimination of Impairment loss of goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Elimination of retirement benefit obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>16</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Elimination of share-based compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>14</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(-) Net gain on sale of treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>21</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(-) Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Effect of unwinding the discount related to conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Decrease/(increase) in derivatives and liabilities fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Redemption of Covid 19 conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>17</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows used in operating activities before change in working capital
requirements</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(44,381</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(51,933</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Decrease / (increase) in other receivables and related accounts</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase / (decrease) in trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase / (decrease) in tax and social security liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase / (decrease) in deferred income and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Changes in working capital requirements</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(667</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,002</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(45,048</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(53,936</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acquisitions of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acquisitions of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Advances related to CRO contracts</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayment / (disbursement) of the advance made to the Nice CHU</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments for the acquisition of Prosynergia, incl. acquisition related costs, net of cash
acquired&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>4.15&nbsp;&amp;&nbsp;10</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Increase in deposits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Decrease in deposits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>9</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest received</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,232</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12,026</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows provided by (used in) financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Capital increases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>13</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs related to capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Warrants subscription</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayments of KREOS <SUP STYLE="font-size:75%; vertical-align:top">(2) </SUP>1&amp;2 bond
loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net proceeds from the royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net proceeds from OCEANE issuance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net proceeds from sale of treasury shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayments of conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments of the lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows provided by (used in) financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>82,679</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,211</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Prosynergia SARL (or &#147;Prosynergia&#148;) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Kreos Capital V UK Ltd (or &#147;Kreos&#148;) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin609070_8"></A>ABIVAX SA NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1. The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 1.1. Information on the
Company and its business </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABIVAX SA (the &#147;Company&#148;) is a <I>Soci&eacute;t&eacute; anonyme </I>incorporated under the laws of France on
December 4, 2013. Its registered office is located at <FONT STYLE="white-space:nowrap">7-11</FONT> Boulevard Haussmann&#151;75009 Paris, France. The Company is developing innovative therapeutic approaches (drugs and immunotherapies) to modulate the
body&#146;s natural immune system to treat patients with chronic inflammatory diseases, viral infections, and cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred losses
since its inception and had shareholders&#146; equity of &#128;7,189&nbsp;thousand as of December 31, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its drug
candidates which are currently under development. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s future operations are highly dependent on a combination of factors, including: (i)&nbsp;the success of its research and development
activities; (ii)&nbsp;regulatory approval and market acceptance of its proposed future products; (iii)&nbsp;the timely and successful completion of additional financing and (iv)&nbsp;the development of competitive therapies by other biotechnology
and pharmaceutical companies. As a result, the Company is, and expects to continue to be, in the short to <FONT STYLE="white-space:nowrap">mid-term,</FONT> financed through the issuance of new equity or debt instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is focusing its efforts on the following points: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continuation of the clinical development program for obefazimod, with priority given to the treatment of chronic
inflammatory diseases. The specific order of priority is as follows: chronic inflammatory bowel disease (&#147;IBD&#148;), starting with ulcerative colitis (&#147;UC&#148;), followed by Crohn&#146;s disease, and other indications.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continuation of other therapeutic indicators of obefazimod according to the relevance of scientific data and
research into potential derivative molecules of obefazimod. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research into new molecules aimed at treating chronic inflammatory diseases and major viral infections
(&#147;Modulation of RNA Biogenesis&#148; platform). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, due to the lack of progress made in
the negotiation of a development partnership, the Company made the decision to freeze the development program for ABX196 in the treatment of hepatocellular cancer (see Note 3.2.Significant events for year ended December&nbsp;31, 2022). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 1.2. Date of authorization of issuance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
financial statements and related notes (the &#147;financial statements&#148;) have been prepared under the responsibility of management of the Company and were approved and authorized for issuance by the Company&#146;s board of directors on April
18, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Basis of preparation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for
share data and per share amounts, the financial statements are presented in thousands of euros. Amounts are rounded up or down the nearest whole number for the calculation of certain financial data and other information contained in these accounts.
Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Statement of compliance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of the Company as of and for the years ended December 31, 2021 and 2022 have been prepared in accordance with both International
Financial Reporting Standards (&#147;IFRS&#148;) as issued by the International Accounting Standard Board (&#147;IASB&#148;) and IFRS as adopted by the European Union (&#147;EU&#148;) regulation n&deg;1606/2002 of July 19, 2002. The term
&#147;IFRS&#148; refers collectively to International Accounting Standards (&#147;IAS&#148;) and IFRS as well as the interpretations issued by the Standing Interpretations Committee (&#147;SIC&#148;) and the International Financial Reporting
Interpretations Committee (&#147;IFRIC&#148;), whose application is mandatory for the year ended December 31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preparation of the financial
statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of the Company were prepared on a historical cost basis, with the exception of certain asset and liability
categories and in accordance with the provisions set out in IFRS such as employee benefits measured using the projected unit credit method, borrowings measured at amortized cost and derivative financial instruments measured at fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Going concern </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred substantial
operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. For the year ended December 31, 2022, the Company had a net loss of &#128;60.7 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, the Company has financed its operations through the issuance of ordinary shares with gross aggregate proceeds of &#128;336.8 million, of
which &#128;130 million of gross proceeds were from offerings of its ordinary shares on Euronext Paris in February 2023, bank borrowings and structured loans for &#128;65.0 million to date, reimbursements of Research Tax Credits (Cr&eacute;dit
d&#146;Imp&ocirc;t Recherche (&#147;CIR&#148;)) in an aggregate amount of &#128;26.6 million, and subsidies received from Banque Publique d&#146;Investissement (&#147;Bpifrance&#148;) (including &#128;13.5 million of subsidies and &#128;6.6 million
of conditional advances to date). As a result of the level of available cash and cash equivalent of &#128;27.0 million as of December 31, 2022, the February 2023 capital increase amounting to &#128;123.3 million in net proceeds and the reimbursement
of the 2022 Research Tax Credit in 2023, and under the assumption that R&amp;D needs are being substantially increased in 2023, as the Company continues to make progress on its lead drug candidate obefazimod, which has started enrollment of patients
in its UC Phase 3 clinical trials in October 2022, the Company expects, as of the date of issuance of these financial statements, it will be able to fund its forecasted operating cash flow requirements throughout the second quarter of 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects it will be able to extend its financing horizon beyond the second quarter of 2024 through additional dilutive and non-dilutive financing,
which could include a combination of capital increase, venture loans and convertible bonds. Based on the above and the actions the Company has taken, management has concluded that the substantial doubt about its ability to continue as a going
concern has been alleviated beyond 12 months from issuance of these financial statements, and these financial statements have been prepared on a going concern basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Impact of the Ukraine/Russia Hostilities on the Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of inflation, particularly in
relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given these developments, the Company has decided not to include Ukraine, Russia and Belarus in its global Phase 3 program for obefazimod in UC. However, the
global scale of this conflict cannot be predicted at this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stage. The Company, therefore, cannot rule out an adverse impact of this conflict on its business, including in terms of access to raw materials, logistics, the performance of clinical studies
and in relation to any future financing the Company may seek. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2b maintenance trial of obefazimod in moderately to severely active UC is the
Company&#146;s only clinical trial currently in progress in Ukraine. The Company has, however, terminated a few trial sites since the Russia/Ukraine war began. The <FONT STYLE="white-space:nowrap">12-month</FONT> assessment was carried out in all
the Ukrainian patients before the war broke out and these patients are therefore included in the <FONT STYLE="white-space:nowrap">one-year</FONT> maintenance results that were reported on April&nbsp;6, 2022. Ukrainian patients who completed the <FONT
STYLE="white-space:nowrap">two-year</FONT> Phase 2b maintenance trial have been transitioned to the long-term safety and efficacy trial that is still <FONT STYLE="white-space:nowrap">on-going.</FONT> None of these sites are located in the Crimea
Region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, or the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic. The Company is also evaluating the possibility to
include a few Ukrainian sites in the western part of Ukraine in the ABTECT Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Together with its CROs, the Company is making
considerable efforts to ensure the <FONT STYLE="white-space:nowrap">follow-up</FONT> of patients who are unable to come to the study centers. Monitoring takes place through a remote monitoring system that was established and used successfully during
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>New, revised or amended Standards and Interpretations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applied the following amendments to IFRS that are effective as of December 31, 2022: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendment to IFRS 16
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Leases&#151;COVID-19-Related</FONT></FONT> Rent Concessions beyond 30&nbsp;June 2021, whose application is for annual reporting periods beginning on or after April&nbsp;1, 2021;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IFRS 3 Business Combinations &#150; Reference to the Conceptual Framework, whose application is for
annual reporting periods beginning on or after January&nbsp;1, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 16 &#150; Property, Plant and Equipment &#150; Proceeds before Intended Use, whose application
is for annual reporting periods beginning on or after January&nbsp;1, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets &#150; Onerous
Contracts&nbsp;&#150;&nbsp;Cost of Fulfilling a Contract, whose application is for annual reporting periods beginning on or after January&nbsp;1, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Improvements to IFRS Standards 2018-2020 &#150; Amendments to IFRS 1 First-time Adoption of International
Financial Reporting Standards, IFRS 9 Financial Instruments, IFRS 16 Leases, and IAS&nbsp;41 Agriculture, whose application is for annual reporting periods beginning on or after January&nbsp;1, 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company did not elect for early application of the following new standards, amendments and interpretations, which were issued but not mandatory as of
December&nbsp;31, 2022: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 &#150; Disclosure of
Accounting Policies, whose application is for annual reporting periods beginning on or after January&nbsp;1, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 8 &#150; Definition of Accounting Estimates, whose application is for annual reporting periods
beginning on or after January&nbsp;1, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 12 &#150; Deferred Tax related to Assets and Liabilities arising from a Single Transaction,
whose application is for annual reporting periods beginning on or after January&nbsp;1, 2023; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IAS 1 Presentation of Financial Statements &#150; Classification of Liabilities as Current or <FONT
STYLE="white-space:nowrap">Non-current,</FONT> whose application is for annual reporting periods beginning on or after January&nbsp;1, 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback, whose application is for annual reporting
periods beginning on or after January&nbsp;1, 2024 (not yet approved by the UE). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the impacts resulting from the
application of these issued accounting pronouncements and concluded that impacts are not material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3. Significant events for the years ended
December 31, 2021 and 2022 and subsequent events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 3.1. For the year ended December 31, 2021 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share capital issuance and unsecured senior convertible bonds exchangeable for new or existing shares (or &#147;OCEANE&#148;) issuance&#151;July 2021
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received a gross proceed of &#128;85.0&nbsp;million on<I> </I>July 30, 2021 through (i)&nbsp;the issuance of 1,964,031 ordinary shares
with a subscription price of &#128;30.55 per share, and (ii)&nbsp;the issuance of &#128;25,000&nbsp;thousand in OCEANE, maturing on July 30, 2026. The proceeds of the transaction mainly serve to finance the progress of ABX464 clinical trials in
chronic inflammatory. Note 15.3, &#147;OCEANE&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> BPI subsidies &#150; March 2021 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 5, 2021, the Company announced the interruption of the phase 2b/3 miR-AGE <FONT STYLE="white-space:nowrap">Covid-19</FONT> clinical trial due to lack
of efficacy. As the Company terminated its financing agreement with Bpifrance in March 2021, Bpifrance made an additional payment of &#128;3.3&nbsp;million in October 2021 to reimburse additional expenses incurred by the Company and agreed to waive
the conditional advance of &#128;6.3&nbsp;million. See Note 15.5, &#147;Conditional Advances&#148;. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 3.2. For the year ended December 31,
2022 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acquisition of Prosynergia SARL &#150; April 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 1, 2022, the Company acquired 100% of the share capital of Prosynergia SARL (or &#147;Prosynergia&#148;), a Luxembourg biotech company, in order to
strengthen its portfolio. The terms of the share purchase acquisition (or the &#147;Prosynergia SPA&#148;) entered on November 15, 2021 included an early payment of &#128;325&nbsp;thousand made on November 25, 2021 (see Note 10), an additional
payment of &#128;2,925&nbsp;thousand made on April 1, 2022, and possible <FONT STYLE="white-space:nowrap">earn-out</FONT> payments for a maximum additional amount of &#128;4,000&nbsp;thousand based on the potential evolution of the Company&#146;s
market capitalization, a listing of the Company&#146;s shares on Nasdaq or a M&amp;A transaction incurred before March 31, 2023. In addition, the Company granted a loan of &#128;1,400&nbsp;thousand to Prosynergia on December 1, 2021, which term was
at least on December 31, 2025 or at an earlier date in the event of a breach in the Prosynergia SPA (see Note 10, &#147;Other receivables and assets&#148;). Such prepayment was repayable in cash only in the event the transaction is not completed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Considering that Prosynergia only owned patent rights but did not enter into any employee contract, research agreement, collaboration agreement or <FONT
STYLE="white-space:nowrap">out-licensed</FONT> agreement, it does not meet the definition of a business under IFRS 3. Consequently, the acquisition cost of this group of assets was allocated between the identifiable assets and liabilities acquired,
pro rata to their respective fair values as of April 1, 2022, without recognition of goodwill. Also, the &#128;1,400&nbsp;thousand loan granted to Prosynergia in December 2021 was included in the acquisition cost to be allocated, as it is considered
a prepayment for the acquisition of the group of assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Merger with Prosynergia &#150; December 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;12, 2022, the Company completed the merger with Prosynergia under the French legal procedure called &#147;Transmission Universelle de
Patrimoine<I>&#148;</I> (universal transfer of assets and liabilities). All of Prosynergia&#146;s assets and liabilities were transferred to the Company and Prosynergia was dissolved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Impairment of ABX196 cash-generating unit </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first half of 2022, management took into account significant external changes in the hepatocellular carcinoma (HC) treatment landscape. These changes
are expected to require a new, lengthy, heavy and risky internal development process (use of a combination of compounds). In this context, entering into a licensing partnership to fund the completion of the clinical development of ABX196 is the
option being considered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, due to the lack of progress made in the negotiation of a development partnership, the Company made the decision to
freeze the development program for ABX196 in the treatment of hepatocellular cancer. This decision led to the full impairment of the ABX196 goodwill, i.e. an impairment loss of &#128;13,586&nbsp;thousand related to Wittycell&#146;s goodwill and
&#128;45&nbsp;thousand related to licenses. As of December&nbsp;31, 2022, the value in use and the fair value less costs to sell of the ABX196 cash-generating unit (&#147;CGU&#148;) are nil. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forfeiture of AGA plans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AGAs granted in September 2021
were subject to vesting conditions including the completion of a M&amp;A transaction on or prior to July 31, 2022. As the <FONT STYLE="white-space:nowrap">non-market</FONT> performance vesting conditions were not satisfied, the Company recognized a
reversal of related compensation expense of &#128;1,026&nbsp;thousand and accrual for social taxes of &#128;205&nbsp;thousand in the financial statements for the period ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Repayment of the advance made to Nice CHU &#150; August 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#128;4,000&nbsp;thousand advance made to Nice CHU was reimbursed in August 2022 for an amount of &#128;3,302&nbsp;thousand. The remaining amount of
&#128;698&nbsp;thousand was settled by way of compensation with a payable due to the Nice CHU related to the recharge of third-party services expenses that had been invoiced to the Nice CHU as part of the miR-AGE project (see Note 10, &#147;Other
receivables and assets&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in governance &#150; August 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;16, 2022, the Company announced a transition in the chairmanship of its Board of Directors. Philippe Pouletty, the Company&#146;s founder and
Chairman of the Board of Directors since the Company was created in 2013, informed the Board of Directors of his decision to resign as Chairman with immediate effect. However, after many years of successfully leading the Board of Directors,
Mr.&nbsp;Pouletty will continue to support the Company&#146;s development as a member of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending the appointment of a new,
permanent independent Chair, Ms.&nbsp;Corinna zur Bonsen-Thomas, an independent member of the Board of Directors of the Company, carried out the role of interim Chair (see Note 3.3. Subsequent events). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Company completed &#128;49.2&nbsp;million cross-over financing with <FONT STYLE="white-space:nowrap">top-tier</FONT> US and European investors &#150;
September 2022 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 2, 2022, the Company announced oversubscribed financing of around &#128;49.2&nbsp;million, led by TCGX with the
participation of Venrock Healthcare Capital Partners, Deep Track Capital, Sofinnova Partners, Invus and Truffle Capital, <FONT STYLE="white-space:nowrap">top-tier</FONT> investors specializing in the biotechnology sector. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financing consists of two transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a reserved capital increase of a gross amount of approximately &#128;46.2&nbsp;million through the issuance of
5,530,000 new shares with a nominal value of &#128;0.01 per share, representing 33% of its current share capital, at a subscription price of &#128;8.36 per share; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an issue of royalty certificates with a subscription price amounting to &#128;2.9&nbsp;million. The royalty
certificates give right to their holders to royalties equal to 2% of the future net sales of obefazimod </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(worldwide and for all indications) as from the commercialization of such product. The amount of royalties that may be paid under the royalty certificates is capped at &#128;172&nbsp;million.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds of the financing will primarily be used to fund the advancement of Phase 3 clinical trials for obefazimod in ulcerative
colitis, expanding the Company&#146;s cash runway to the end of Q1 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related transaction costs amounted to &#128;3.3&nbsp;million and were deducted
from the share premiums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty certificates are recorded as financial liabilities at amortized cost (see Note 15.8). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Company announces first US patient enrollment in global Phase 3 program with obefazimod in UC&nbsp;&#150;&nbsp;October 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;11, 2022, the Company announced that the first patient was enrolled in the US into its global Phase 3 clinical program with product candidate
obefazimod for the treatment of moderately to severely active UC. IQVIA, a global premier contract research organization, is responsible for coordinating the Company&#146;s Phase 3 clinical trial for obefazimod in UC. As of December&nbsp;31, 2022,
the undiscounted amount of the advance payments made by the Company in relation to the IQVIA agreement is &#128;12,187&nbsp;thousand. They were recorded at inception at their fair value (discounted amount) and subsequently measured at amortized cost
calculated using the effective interest rate method. As of December&nbsp;31, 2022, their carrying amount is &#128;10,471&nbsp;thousand. The repayment dates of these advances are scheduled between April 2025 and July 2026 (see Note 9). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 3.3. Subsequent events </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Company
announces successful oversubscribed &#128;130.0&nbsp;million cross-over financing at market price with <FONT STYLE="white-space:nowrap">top-tier</FONT> US and European Biotech investors &#150; February 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2023, the Company announced the successful pricing of an oversubscribed &#128;130.0&nbsp;million financing with high-quality US and
European biotech specialist investors, led by TCGX, with participation from existing investors Invus, Deep Track Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point Partners, LLC, Deerfield
Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others, by way of a reserved capital increase of &#128;130&nbsp;million through the issuance of 20,000,000 newly-issued ordinary shares with a nominal value of &#128;0.01
per share, representing 89.6% of its current share capital, at a subscription price of &#128;6.50 per share. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related transaction costs amounted
to &#128;6.7&nbsp;million and were deducted from the share premiums. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in governance and management &#150; February-July 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2023, the Company announced the appointment of Marc de Garidel as Chief Executive Officer (&#147;CEO&#148;) and Interim Board Chair, effective
May&nbsp;5, 2023. Corinna zur Bonsen-Thomas will step down as acting Chair, a position she has held since August 2022, and will remain a Board Member. Prof. Hartmut J. Ehrlich, M.D., will retire from the CEO position, which he has held since the
Company&#146;s founding in 2013, and will stay on as a strategic advisor until the transition is complete. The Company expects to appoint a long-term Board Chair in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;17, 2023, and April&nbsp;18, 2023, the Company respectively announced the appointments of Dr.&nbsp;Sheldon Sloan, M.D., M. Bioethics as new
Chief Medical Officer and Michael Ferguson as new Chief Commercial Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;11, 2023, the Company announced the appointments of June Lee,
M.D. and Troy Ignelzi as new independent members of the Company&#146;s Board of Directors, replacing Joy Amundson and Jean-Jacques Bertrand. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Creation of Abivax LLC &#150; March 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;25, 2023, Abivax LLC (or &#147;the Subsidiary&#148;), was incorporated as a<I> </I>Limited Liability Company<I> </I>under the laws of Delaware.
As of the issuance of the financial statements, the Company has full ownership over the Subsidiary. The Subsidiary will host the Group&#146;s operations in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash less exercise of the Kreos A&amp;B BSA &#150; May 2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2023, Kreos Capital V UK Ltd (or &#147;Kreos&#148;) opted for the cash less exercise option of the share warrants they held (as defined in Note
15.1), implemented through the repurchase by the Company of 43,070 tranche A share warrants (&#147;Kreos A BSA&#148;) and 43,070 tranche B share warrants (&#147;Kreos B BSA&#148;) and the issuance of respectively 67,887 and 31&nbsp;696 ordinary
shares, as a result of the exercise by Kreos of the oustanding Kreos A&nbsp;&amp; B BSA. The operation resulted in the derecognition of the derivative financial liabilities corresponding to the Kreos A&nbsp;&amp; B BSA, amounting to
&#128;424&nbsp;thousand as of December&nbsp;31, 2022, and in a capital increase including share premiums of &#128;829&nbsp;thousand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4.
Accounting principles </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.1. Goodwill </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 4.4). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In respect of business combinations prior to January 1, 2020, in accordance with IFRS 1 exemption, goodwill is included on the basis of its deemed cost, which
represents the amount recorded under the prior basis of accounting, French GAAP, (&#147;Previous GAAP&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.2. Intangible assets
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to IAS 38&#151;<I>Intangible Assets</I>, intangible assets acquired are recognized as assets on the statements of financial position at
their acquisition cost. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments for
separately acquired research and development are capitalized within &#147;Other intangible assets&#148; provided that they meet the definition of an intangible asset: a resource that is (i)&nbsp;controlled by the Company, (ii) expected to provide
future economic benefits for the Company and (iii)&nbsp;identifiable (i.e., it is either separable or arises from contractual or legal rights). In accordance with paragraph 25 of IAS 38&#151;<I>Intangible Assets</I>, the recognition criterion
relating to the likelihood of future economic benefits generated by the intangible asset, is presumed to be achieved for research and development activities when they are acquired separately. In this context, amounts paid to third parties in the
form of initial payments or milestone payments relating to pharmaceutical specialties that have not yet obtained a marketing authorization are recognized as intangible assets. These rights will be amortized on a straight-line basis, after obtaining
the marketing authorization, over their useful life. Unamortized rights (before marketing authorization) are subject to impairment tests in accordance with the method defined in Note 4.4. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development costs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to IAS 38 &#150;
<I>Intangible Assets</I>, research costs are expensed in the period during which they are incurred. Development costs are only recognized as intangible assets if the following criteria are met: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is technically feasible to complete the development of the project; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is the Company&#146;s intention to complete the project and to utilize it; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it has capacity to utilize the intangible asset; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there is proof of the probability of future economic benefits associated with the asset </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there is availability of the technical, financial and other resources for completing the project; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there is a reliable evaluation of the development expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial measurement of the asset is the sum of expenses incurred starting on the date on which the development project meets the above criteria. Because
of the risks and uncertainties related to regulatory authorizations and to the research and development process, the Company believes that the six criteria stipulated by IAS 38 have not been fulfilled to date and the application of this principle
has resulted in all development costs being expensed as incurred in all periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other intangible assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other intangible assets mainly consist of acquired software. Costs related to the acquisition of software licenses are recognized as assets based on the costs
incurred to acquire and set up the related software. Other intangible assets are amortized using the straight-line method over a period of one year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.3. Property, plant and equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant
to IAS 16 &#150; <I>Property, Plant and Equipment</I>, property, plant and equipment are recognized at their acquisition cost (purchase price and directly attributable costs) or at their production cost by the Company, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, plant and equipment are depreciated using the straight-line method over the estimated useful life of the asset. The principal useful lives applied
are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>DEPRECIATION PERIOD</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Buildings</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office fixtures and fittings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3&nbsp;years&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Equipment</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Industrial materials and equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 to 10 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Technical facilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 to 10 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Furniture and computer equipment:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 to 10 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IT equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size:4pt">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;3 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Furniture</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office fixtures and fittings estimated useful lives correspond to the Headquarters residual estimated lease
term. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The useful lives of property, plant and equipment as well as any residual values are reviewed at each <FONT
STYLE="white-space:nowrap">year-end</FONT> and, in the event of a significant change, the depreciation schedule is revised prospectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.4.
Impairment of goodwill, intangible assets, property and plant and equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill and intangible assets not yet available for use are not
amortized and are tested for impairment annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company assesses at the end of each reporting period whether there is an indication
that intangible assets and property, plant and equipment may be impaired. Pursuant to IAS 36&#151;<I>Impairment of Assets</I>, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
criteria for assessing indication of loss in value may notably include performance levels lower than forecast, a significant change in market data or the regulatory environment, or obsolescence
or physical damage of the asset not included in the amortization/depreciation schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of impairment testing, goodwill and intangible
assets not yet available for use are allocated to each of the Company&#146;s CGUs expected to benefit from synergies arising from the business combination or from the use of the intangible assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An impairment loss is recognized when the carrying amount of a CGU, including the goodwill, exceeds the recoverable amount of the CGU. The recoverable amount
of a CGU is the higher of the CGU&#146;s fair value less cost to sell and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">value-in-use.</FONT></FONT> The total impairment loss of a CGU is allocated first to reduce the carrying
amount of goodwill allocated to the CGU and then to the other assets of the CGU <FONT STYLE="white-space:nowrap">pro-rata</FONT> on the basis of the carrying amount of each asset in the CGU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An impairment loss on goodwill is not reversed in a subsequent period. Impairment losses on intangible assets and property, plant and equipment shall be
reversed subsequently if the impairment loss no longer exists or has decreased. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.5. Financial assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial assets at amortized cost </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other financial assets
(advances, loans and deposits granted to third parties) and other receivables are <FONT STYLE="white-space:nowrap">non-derivative</FONT> financial assets with fixed or determinable payments that are not listed on an active market. They are initially
recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS 9 &#150;
<I>Financial Instruments </I>requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each statement of financial position date. The amount of the loss allowance for expected credit losses
equal to: (i)&nbsp;the 12&#151;month expected credit losses or (ii)&nbsp;the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash and cash equivalents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies
investments as cash equivalents in the statements of financial position and statements of cash flows when they meet the conditions of IAS 7&#151;<I>Statement of Cash Flows, </I>i.e., when they are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">held in order to face short-term cash commitments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short term and highly liquid assets at acquisition date, readily convertible into known amount of cash and not
exposed to any material risk of change in value. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.6. Share capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary shares are classified in shareholders&#146; equity. Costs associated with the issuance of new shares are directly accounted for in shareholders&#146;
equity in diminution of issuance premium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s own shares bought in the context of a brokering/liquidity agreement entered with an
independent broker are presented as a reduction of shareholders&#146; equity until their cancellation, their reissuance or their disposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.7. Share-based payments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its inception, the Company has established several plans for compensation settled in equity instruments in the form of founders&#146; share subscription
warrants (&#147;bons de souscription de parts de cr&eacute;ateur d&#146;entreprise&#148; or &#147;BCE&#148;), share subscription warrants (&#147;Bons de souscription d&#146;actions,&#148; or &#147;BSA&#148;) and free shares (&#147;Attributions
gratuites d&#146;actions,&#148; or &#147;AGA&#148;), granted to its employees, corporate officers and scientific consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to IFRS
2&#151;<I>Share-based Payment, </I>these awards are measured at their fair value on the date of grant. The values of the equity instruments are determined using the option pricing model (in particular, a Black and Scholes model for the BCE and BSA
plans and a Monte-Carlo simulation for the AGA plan) based on the value of the underlying equity instrument at grant date, the volatility observed in a sample of comparable listed companies and the estimated life of the related equity instruments.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes the fair value of these awards as a share-based compensation expense over the period in which the related services are received,
i.e. over the vesting period, with a corresponding increase in shareholders&#146; equity. Share-based compensation is recognized by installments in consistency with their graded vesting schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and
<FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and
<FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions at the vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For share-based payment awards with market vesting
conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions and there is no <FONT STYLE="white-space:nowrap">true-up</FONT> for differences between expected and actual outcome. The measurement of the fair
value of BSA, BCE and AGA incorporates the market-based vesting conditions as described in Note 4.16 &#147;Use of estimates and judgments&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.8. Financial liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to IFRS
9 &#150; <I>Financial Instruments, </I>borrowings and other financial liabilities (excluding derivative financial instruments) are measured at amortized cost. Financial liabilities that are due within one year are presented as current financial
liabilities in the statements of financial position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial liabilities at amortized cost </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borrowings and Other financial liabilities (conditional advances and royalty certificates), other than derivatives instruments, are initially recognized at
fair value and subsequently measured at amortized cost calculated using the effective interest rate (&#147;EIR&#148;) method. The transaction costs that are directly attributable to the issue of the financial liability reduce that financial
liability. These expenses are then amortized over the lifetime of the liability, on the basis of the EIR. The EIR is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability to the amortized
cost of a financial liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalty certificates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty certificates meet the definition of financial liabilities. The Company concluded that they do not include embedded derivatives related to the
variability of royalties that are based on future net sales. In addition, the Company concluded that the prepayment options were separate derivative instruments as their redemption price did not reimburse holders for an amount up to the approximate
present value of lost interest for the remaining term of the host contracts. However, their value at inception and subsequent dates is nil and has no impact on the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty certificates are initially measured at fair value (refer to note 15.8 for valuation model applied).
They are subsequently measured at amortized cost calculated using the EIR method. The EIR is calculated based on future cash flows, estimated on the basis of development and commercialization plans and budgets approved by the Board of Directors of
the Company. If there is a change in the timing or amount of estimated cash flows, then the gross carrying amount of the amortized cost of the financial liability is adjusted in the period of change to reflect the revised actual and estimated cash
flows, with a corresponding income or expense being recognized in profit or loss. The revised gross carrying amount of the amortized cost of the financial liability is calculated by discounting the future revised estimated cash flows at the original
EIR. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditional advances and State guaranteed loan &#150; &#147;PGE&#148; </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting treatment for conditional advances and PGE is set forth in Note 4.9. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Leases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting treatment for lease liabilities is set
forth in Note 4.12. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial liabilities measured at fair value through profit or loss </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BSA attached to Kreos 1 bonds, the conversion option of OCEANE and certain prepayment options of bonds are derivatives instruments. Derivatives are recognized
initially at fair value at the date the derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. The resulting gain or loss from change in the fair value is recognized in profit or loss
immediately, as financial expenses or income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hybrid instruments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OCEANE bonds are hybrid instruments. A &#147;hybrid contract&#148; is a contract that includes both a <FONT STYLE="white-space:nowrap">non-derivative</FONT>
host contract and one or more embedded derivatives. Embedded derivatives are required to be separated from the host contract (bifurcated) if: the economic characteristics and risks of the embedded derivative are not closely related to those of the
host, a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative, and the hybrid contract is not measured at fair value through profit or loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separable embedded derivatives are required to be measured at fair value, with all changes in fair value recognized in profit or loss. The initial bifurcation
of a separable embedded derivative does not result in any gain or loss being recognized. Because the embedded derivative component is measured at fair value on initial recognition, the carrying amount of the host contract on initial recognition is
the difference between the carrying amount of the hybrid instrument and the fair value of the embedded derivative. If the fair values of the hybrid instrument and host contract are more reliably measurable than that of the derivative component -
e.g. because of the availability of quoted market prices - then it may be acceptable to use those values to determine the fair value of the derivative on initial recognition indirectly - i.e. as a residual amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair value measurement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When measuring the fair value of
an asset or a liability, the Company uses market observable data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 2: fair value calculated using valuation techniques based on observable market data such as prices for
assets and liabilities or similar parameters quoted in an active market; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level 3: fair value calculated using valuation techniques based in whole or in part on unobservable inputs such
as prices in an inactive market or a valuation based on multiples of unlisted securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 12 Financial assets and liabilities,
Note 15 Financial liabilities and Derivative instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.9. Research tax credit, subsidies and conditional advances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research tax credit </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company benefits from the
provisions of Articles 244c of the French General Tax Code relating to the French research tax credit (&#147;<I>Cr&eacute;dit d&#146;Imp&ocirc;t Recherche</I>&#148; or &#147;CIR&#148;). The CIR is granted to companies in order to encourage them to
conduct technical and scientific research. Companies that prove that they have expenditures which meet the required criteria (research expenditures located in France or, since January 1, 2005, within the European Union or in another state that is a
party to the Agreement on the European Economic Area and has concluded a tax treaty with France that contains an administrative assistance clause) receive a tax credit that can be used for the payment of the corporate tax due for the fiscal year in
which the expenditures were made and the next three fiscal years, or as applicable, companies may receive cash reimbursement for any excess portion at the three-year period following the fiscal year of the expenditures. Only those companies meeting
the EU definition of a small or <FONT STYLE="white-space:nowrap">medium-sized</FONT> entity (&#147;SME&#148;) are eligible for payment in cash of their research tax credit (to the extent not used to offset corporate tax payables) in the year
following the request for reimbursement. The expenditures taken into account for the calculation of the CIR involve only research expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CIR is
presented under &#147;Other operating income&#148; in the statements of income (loss) as it is accounted for as a government grant as defined in IAS 20 &#150; <I>Accounting for Government Grants and Disclosure of Government Assistanc</I>e, and as
&#147;Other receivables and related accounts&#148; in the statement of financial position until its payment is received. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Subsidies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidies are <FONT STYLE="white-space:nowrap">non-repayable</FONT> grants received by the Company and recognized in the financial statements when there exists
reasonable assurance that the Company will comply with the conditions attached to the subsidies and the subsidies will be received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidies that are
upfront payments are presented as deferred income and recognized through &#147;Other operating income&#148; for the amount of the expenses incurred as part of the research program to which the subsidy relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A subsidy that is to be received either as compensation for expenses or for losses already incurred, or for immediate financial support of the Company without
associated future costs, is recognized in the Statements of income (loss) as &#147;Other operating income&#148; when there exists reasonable assurance that the subsidies will be received. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditional advances and PGE </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company receives
conditional advances to finance at below market interest rate research and development projects. Due to the innovative nature of its drug candidate development programs, the Company has benefited from certain sources of financial assistance from
Bpifrance. Bpifrance provides financial assistance and support to emerging French enterprises to facilitate the development and commercialization of innovative technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Funds received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as the Company has a contractual obligation to
reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. Each award of an advance is made to help fund a specific development milestone. More </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
details on conditional advances are provided in Note 15.5. Receipts or reimbursements of conditional advances are reflected as financing transactions in the statements of cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The difference between the present value of the advance at market rate (i.e., present value of contractual cash flows including principal and interests,
discounted using a market rate as effective interest rate in accordance with IFRS 9) and the amount received as cash from the Bpifrance constitutes a subsidy within the meaning of IAS 20. Considering that these advances do not finance fixed assets,
these subsidies are presented as &#147;Deferred income&#148; in the statement of financial position and recognized in the statement of net income (loss) as &#147;Other operating income&#147; on a systematic basis over the periods in which the
Company recognizes as expenses the related costs for which the grants are intended to compensate. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The incremental interest expense resulting from
the difference between (a)&nbsp;the market interest rate and the (b)&nbsp;below-market rate is spread over the contractual period until the last repayment and recognized in the statement of income (loss) accordingly, using the EIR method. In the
event of a change in estimate of contractual cash flows due under the conditional advances, the Company recalculates the book value of the debt resulting from the discounting of the anticipated new future cash flows at the initial EIR. The
adjustment is recognized in the statements of income (loss) for the period during which the modification is recognized. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the statements of
financial position, these conditional advances are recorded in &#147;Other financial liabilities&#148; as current or <FONT STYLE="white-space:nowrap">non-current</FONT> portion depending on their maturity. In the event Bpifrance waived the repayment
of the advance, the corresponding liability is derecognized and treated as a subsidy in the statements of income (loss). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The benefit resulting from
the low interest of PGE loans is also recognized as a subsidy corresponding to the difference between the present value of the PGE at market rate and the amount received as cash. The accounting treatment is therefore similar to the above-mentioned
accounting treatment for conditional advances. PGE are recorded in &#147;Borrowings&#148; as current or <FONT STYLE="white-space:nowrap">non-current</FONT> portion depending on their maturity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.10. Employee benefits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
employees in France benefit from retirement benefits provided under French law, which consist in the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensation paid by the Company to employees upon their retirement (a defined benefit plan); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments of retirement pensions by the social security agencies, which are financed by the contributions made by
the Company and employees. As they meet the definition of a defined contribution plan, the liabilities are presented as Tax and employee-related payables in the statement of financial position. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with IAS 19 &#150; <I>Employee Benefits</I>, the liability with respect to defined benefit plans is estimated by using the projected credit unit
method. According to this method, the cost of the retirement benefit is recognized in the statements of income (loss). The retirement benefit commitments are valued at the current value of the estimated future payments, discounted using the market
rate for high quality corporate bonds with a term and currency that correspond to that estimated for the payment of the benefits. The Company applied the decision of the IFRS IC, published on May&nbsp;24, 2021, that concluded that, in the case that
no rights were acquired in the event of departure before retirement age and that the rights were capped after a certain number of years of seniority (&#147;30 years&#148;), the commitment would only be recognized for the last 30 years of the
employee&#146;s career within the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The difference between the amount of the provision at the beginning of a period and at the close of that
period is recognized through operating expenses for the portion representing the costs of services rendered and financial expenses for the net interest costs, and through other comprehensive income (loss) for the portion representing the actuarial
gains and losses due to changes in assumptions and experience adjustments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.11. Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions correspond to commitments resulting from litigation and various risks to which the Company may face in the context of its operations. In accordance
with IAS 37 &#150; <I>Provisions, Contingent Liabilities and</I> <I>Contingent Assets, </I>a provision is recorded when the Company has an obligation to a third party resulting from a past event that will likely result in an outflow of resources to
the third party, and for which future cash outflows may be estimated reliably. The amount recorded as a provision is an estimate of the expenditure required to settle the obligation, discounted where necessary at year end. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.12. Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As lessee, the Company assesses
whether a contract contains a lease at inception of a contract and upon the modification of a contract. The Company elected to allocate the consideration in the contract to the lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components
on the basis of the relative standalone price. The Company recognizes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a corresponding lease liability for all arrangements in which it is a
lessee, except for leases with a term of 12 months or less (short-term leases) and <FONT STYLE="white-space:nowrap">low-value</FONT> leases (value of the underlying asset below &#128;5.0 thousand). For these short-term and <FONT
STYLE="white-space:nowrap">low-value</FONT> leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease
term. The lease terms used by the Company reflect the <FONT STYLE="white-space:nowrap">non-cancellable</FONT> terms of each contract, plus any extension or termination options that the Company is reasonably certain to exercise or not exercise for
all of the leases periods covered by the extension options. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Company incremental borrowing rate for the asset subject to the lease in
the respective markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company remeasures the lease liability (and makes a corresponding adjustment to the related <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. The portion of the lease payments
attributable to the repayment of lease liabilities and the portion attributable to payment of interests are recognized in cash flows used in financing activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are initially recognized on the balance sheet at cost,
which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentives received and any initial direct costs incurred
by the Company, and expected costs for obligations to dismantle and remove <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets when they are no longer used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are depreciated on a straight-line basis from the
commencement date of the lease over the shorter of the useful life of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset or the end of the lease term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are assessed for impairment whenever there is an
indication that the balance sheet carrying amount may not be recoverable using cash flow projections. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.13. Translation of transactions
denominated in foreign currency </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to IAS 21 &#150; <I>The Effects of Changes in Foreign Exchange Rates</I>, transactions performed by the
Company in currencies other than their functional currency, which is the Euro, are translated at the prevailing exchange rate on the transaction date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade receivables and payables and liabilities denominated in a currency other than the functional currency are translated at the <FONT
STYLE="white-space:nowrap">period-end</FONT> exchange rate. Unrealized gains and losses arising on translation are recognized in net financial income / (loss). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.14. Current and deferred tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the French tax authorities,
using tax rates and tax laws enacted or substantively enacted at the end of the reporting period in accordance with IAS 12 &#150; Income Tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income
tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the statement of income (loss) unless it relates to items recorded in other comprehensive income (loss) or directly in equity, in which
case the tax is also recorded in other comprehensive income (loss) or directly in equity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the statement of financial
position date. Considering the level of tax loss of the Company, no current tax expense is recognized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deferred taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the Company&#146;s financial
statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time
of the transaction, does not affect either the accounting or the taxable profit (tax loss). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deferred tax assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that it is probable that
the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which the deductible temporary difference, unused tax losses or unused tax credits can be utilized. See Note 4.16. Use of judgments and
estimates and Note 22. Income tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.15. Accounting of Prosynergia acquisition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From April 1, 2022 up until the merger completed on December&nbsp;12, 2022, the Company owned a 100% ownership interest of Prosynergia and as such, controlled
Prosynergia. The Company had power over Prosynergia, was exposed or had rights to variable returns from its involvement with the entity and had the ability to affect those returns through its power over the entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Prosynergia were therefore included in the consolidated financial statements of the Company from the date control was obtained,
i.e. April 1, 2022. Prosynergia was merged into the Company in December&nbsp;12, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Considering that Prosynergia only owned patent rights but did not
enter into any employee contract, research agreement, collaboration agreement or <FONT STYLE="white-space:nowrap">out-licensed</FONT> agreement, it did not meet the definition of a business under IFRS 3. Consequently, the acquisition cost of this
group of assets was allocated between the identifiable assets and liabilities acquired, pro rata to their respective fair values as of April 1, 2022, without recognition of goodwill. For this purpose, the following approach was applied: first
measurement of any identifiable asset or liability initially measured at an amount other than cost in accordance with the applicable standards, deduction from the cost of the group of assets of the amounts allocated to these assets and liabilities,
and then allocation of the residual cost of acquisition to the remaining identifiable assets and liabilities based on their relative fair values at the date of acquisition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, the &#128;1,400&nbsp;thousand loan granted to Prosynergia in December 2021 was included in the
acquisition cost to be allocated, since, in substance, it was considered as a prepayment for the acquisition of the group of assets, which is repayable in cash in the event of <FONT STYLE="white-space:nowrap">non-completion</FONT> of the
transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The potential <FONT STYLE="white-space:nowrap">earn-out</FONT> payment to be paid in the first half of 2023 was measured at fair value on
April 1, 2022, for an amount of &#128;1,446&nbsp;thousand, and included in the acquisition cost. This earn out is triggered in the event the Company&#146;s market capitalization is in excess of &#128;300&nbsp;million (evaluated at certain specified
record dates), a listing of the Company&#146;s shares on Nasdaq or a merger and acquisition transaction prior to March 31, 2023. The amount of the <FONT STYLE="white-space:nowrap">earn-out</FONT> is equal to 1% of the difference between the
Company&#146;s market capitalization and &#128;300&nbsp;million, subject to a maximum amount of &#128;4.0&nbsp;million. It is, as the case may be, payable in the first half of 2023. No amount will be payable in the event the Company&#146;s market
capitalization is lower than &#128;300&nbsp;million. The related financial liability is subsequently remeasured to its fair value at each reporting date. The gain or loss arising from the change in the fair value is recognized in profit of loss
immediately. As of December&nbsp;31, 2022, the fair value of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability is nil (see Note 15.7). The remeasurement results in a financial income of &#128;1,446&nbsp;thousand over the year ended
December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The allocation of the acquisition cost is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(Amounts in thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;allocated&nbsp;as<BR>of&nbsp;April&nbsp;1,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash prepayment made in 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan granted to Prosynergia in 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash payment made in 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition fees (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Earn-out</FONT> measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total acquisition cost allocated</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,562</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,571</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total net assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,562</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of which &#128;451&nbsp;thousand were disbursed in 2021 and &#128;15&nbsp;thousand in 2022. Acquired cash
amounts to &#128;41&nbsp;thousand. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition cost was mainly allocated to Prosynergia&#146;s patents US 10,464,903 (filed on
March 20, 2017 and granted on November 5, 2019), EP3 429 998 (filed on March 20, 2017 and granted on September 1, 2021) and continuation US 10,745,357 (filed on November 1, 2019 and granted on August&nbsp;18, 2020). All patents will expire in 2037.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These patents cover alternative synthesis process for obefazimod and a family of close chemical analogues. They also cover alternative forms of
obefazimod (salts thereof and crystalline forms of said salts), the pharmaceutical composition comprising them, that could be of interest to the Company for future development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 4.16. Use of judgments and estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
order to prepare financial statements in accordance with IFRS, estimates, judgments and assumptions were made by the Company&#146;s management which could affect the reported amounts of assets, liabilities, contingent liabilities, income and
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These estimates are based on the assumption of going concern and are prepared in accordance with information available at the date the
financial statements were prepared. They are reviewed on an ongoing basis using past experience and various other factors considered to be reasonable as the basis to measure the carrying amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assets and liabilities. Estimates may be revised due to changes in the underlying circumstances or subsequent to new information. Actual results may differ significantly from these estimates in
line with assumptions or different conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This note provides an overview of the areas that involved a higher degree of judgement or complexity, and
of items which are more likely to be materially adjusted due to changes in estimates and assumptions. Detailed information about each of these estimates and judgements is included in other notes together with information about the basis of
calculation for each affected line item in the financial statements. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recognition and measurement of impairment of CGUs. The main assumptions used for the impairment test include
(a)&nbsp;the amount of cash flows that are set on the basis of the development and commercialization plans and budgets approved by Board of Directors, (b)&nbsp;assumptions related to the achievement of the clinical trials and the launch of the
commercialization, (c)&nbsp;the discount rate, (d) assumptions on risk related to the development and (e)&nbsp;for the commercialization, selling price and volume of sales. The sensitivity analysis in respect of the recoverable amount of the CGUs is
presented in Note 6. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">measurement of share-based compensation granted to employees, corporate officers and scientific consultants, such
as BCE, BSA and AGA, which is based on actuarial models; these models require the use by the Company of certain calculation assumptions such as the estimated vesting, the occurrence dates of a change of control or a M&amp;A transaction dates, the
expected volatility and maturity of the underlying equity instrument (see Note 4.7 and Note 14), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fair value measurements at inception and after of derivative financial instruments resulting from (i)&nbsp;the
warrants issued concomitantly with the issuance of the straight and convertible bonds to Kreos on July 24, 2018 (or &#147;Kreos 1&#148;), (ii) the prepayment option attached to the straight and convertible bonds issued to Kreos on October 2 2020 (or
&#147;Kreos 2&#148;), and (iii)&nbsp;the prepayment option attached to the issuance of bond convertible into new or existing shares in July 30, 2021 (or &#147;OCEANE&#148;) (see Notes 15), </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fair value measurements of financial liabilities at inception (see Note 15), </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amortized cost measurement of royalty certificates, based on the following assumptions: (a)&nbsp;future cash
flows, estimated on the basis of development and commercialization plans and budgets approved by the Board of Directors and (b)&nbsp;the discount rate. The sensitivity analysis in respect of the measurement of royalty certificates is presented in
Note 15. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fair value measurements of the call option resulting from the equity line contracts entered into on September 30,
2019 (or &#147;Equity lines&#148;) (see Note 13.2), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CIR based on internal and external expenses which meet the required criteria incurred by the Company during the
year (see Note 4.9), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recognition of deferred tax assets: availability of future taxable profit against which deductible temporary
differences and tax losses carried forward can be utilized and whether sufficient evidence exists (see Note 22). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The main critical
judgments made by the Company&#146;s management impact the following item: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence dates of a change of control or a M&amp;A transaction dates used for the measurement of
share-based compensation (see Note 4.7). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5. Segment information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assessment of the Company&#146;s performance and the decisions about resources to be allocated are made by the chief operating decision maker, based on the
management reporting system of the Company. The Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identified the Chief Executive Officer of the Company as &#147;Chief operating decision maker&#148;. The Chief operating decision maker reviews on an aggregated basis the incurred expenses for
allocating and evaluating performance of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates in a single operating segment: R&amp;D of pharmaceutical products in order to
market them in the future. All operations, assets, liabilities and losses of the Company are located in France. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6. Goodwill and impairment test
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill relates to the acquisition of Splicos SAS and Wittycel SAS occurred in 2014 (i.e., prior the transition date to IFRS), which were merged into
the Company in the same year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill from Splicos SAS and Wittycel SAS acquisition corresponds to the &#147;Modulation of RNA biogenesis /
splicing&#148; technological platform and the &#147;iNKT agonists&#148; technological platform, respectively, from which derived the lead drug candidates of the Company: ABX464 and ABX196, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS 3 was not applied to acquisitions of subsidiaries deemed to be a business within the meaning of IFRS, carried out before the IFRS transition date, i.e.,
January&nbsp;1 2020. Due to the application of this exemption, the previous accounting for business combinations in accordance with French GAAP remains unchanged (no identified Intellectual Property, Research&nbsp;&amp; Development
(&#147;IPR&amp;D&#148;) assets are recognized in the statement of financial position). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of the goodwill resulting from Splicos SAS
and Wittycel SAS acquisitions were, as of December&nbsp;31, 2021, &#128;18,419&nbsp;thousand and &#128;13,586&nbsp;thousand, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance
with IAS 36, goodwill is allocated to CGUs at a level corresponding to the lead drug candidates. Thus, goodwill from Splicos SAS and Wittycel SAS are allocated to ABX464 CGU and ABX196 CGU, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill impairment tests are undertaken annually or more frequently if events or changes in circumstances indicate a potential impairment, in accordance with
IAS 36. The carrying amount of goodwill is compared to the recoverable amount, which is the higher value in use and the fair value less costs to sell. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
of December 31, 2021 and 2022, the recoverable amount used for the impairment test of each CGU was the value in use. This value in use was based on a net present value calculation, using the following assumptions as of December 31, 2021 and 2022:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cash flows are set on the basis of the development and commercialization plans and budgets approved by Board of
Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A discount rate (or &#147;WACC&#148;) of 14% as of December 31, 2022 and 13.5% as of December 31, 2021,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A risk of development is taken into consideration by applying probabilities of success (or &#147;POS&#148;) of
reaching future phases of development to cash flows related to the commercialization phase. Those average probabilities of success of R&amp;D projects are based on public sources (INFORMA databases). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the commercialization phase, selling price and sales volume are estimated on the basis of the potential
market and the observed performances of comparable drugs currently on the market. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impairment tests resulted in no impairment
charges as of December 31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first half of 2022, management took into account significant external changes in the hepatocellular carcinoma
(HC) treatment landscape. These changes were expected to require a new, lengthy, heavy and risky </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
internal development process (use of a combination of compounds). For this purpose, entering into a licensing partnership to fund the completion of the clinical development of ABX196 was being
considered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of this change in circumstances, an impairment test of ABX196 CGU was performed in accordance with IAS 36, resulting into an
impairment loss of &#128;10,986&nbsp;thousand of Wittycell&#146;s goodwill, based on a fair value of &#128;2,600&nbsp;thousand, recorded in the interim financial statements as of June&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, due to the lack of progress made in the negotiation of a development partnership, the Company made the decision to freeze the
development program for ABX196 in the treatment of hepatocellular cancer. In this context, the impairment test carried out as of December&nbsp;31, 2022 resulted in the full impairment of the goodwill resulting from the acquisition of Wittycell SAS
and other assets included in the ABX196 CGU, i.e. an impairment loss of &#128;13,632&nbsp;thousand as of December&nbsp;31, 2022 (&#128;13,586&nbsp;thousand related to goodwill and &#128;45&nbsp;thousand related to other assets &#150; see Note 7).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Sensitivity testing as of December&nbsp;31, 2022 and December&nbsp;31, 2021: </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has conducted an analysis of the sensitivity of the impairment tests to changes in the key assumptions used to determine the recoverable amount of
the CGUs to which goodwill is allocated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding ABX464, as the product is currently in development, a clinical trial failure or a failure to obtain a
marketing approval could result in an impairment. The results of the impairment test indicate a headroom level that is high enough so that any reasonably possible change in any of the key assumptions (except clinical failure) would not lead to any
impairment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding ABX196: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as of December&nbsp;31, 2022, as above-mentioned, the net book value of the CGU was brought to zero after
recording an impairment of &#128;13,632&nbsp;thousand. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as of December 31, 2021, an increase in WACC of 3.7 percentage points, or a reduction in sales of 22%, or a
reduction in POS per phase of 10%, would result in the recoverable value being equal to the net book value. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7. Intangible
assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets are mainly comprised of the intellectual property underlying: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exclusive license agreement with the Scripps Research Institute, University of Chicago and Brigham Young
University for which the Company paid a milestone of &#128;45&nbsp;thousand in September 2019 as a result of an IND filling of ABX196. The value in use and the fair value less costs to sell of the ABX196 CGU being nil as of December&nbsp;31, 2022, a
&#128;45&nbsp;thousand impairment was recorded during the period (see Note 6). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The collaboration and license agreement with the CNRS, Montpellier 2 university and the Curie for which the
Company paid a milestone of &#128;40&nbsp;thousand in September 2019 as a result of the entry in phase 2 of ABX464. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patents acquired through the acquisition of Prosynergia of &#128;6,529&nbsp;thousand (cf. Note 4). The patents
are not yet amortized, similarly to licenses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licenses and patents recognized as Intangible assets as of December 31, 2021 and 2022 are not amortized
while they are not operating in a manner intended by the management. As a consequence, and in accordance with IAS 36, those assets were subject to an annual impairment test as of December 31, 2021 and 2022, which did not result in the need for an
impairment to be recognized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PATENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GROSS VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,529</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,673</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PATENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AMORTIZATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(66</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LICENCES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SOFTWARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PATENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NET BOOK VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8. Property, plant and equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables present movements in property, plant and equipment including the right of use of assets (or &#147;ROU&#148;) as of December 31, 2021 and
2022: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BUILDINGS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FURNITURE</B><br><B>AND<BR>COMPUTER<BR>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>OF&nbsp;WHICH<BR></I></B><B></B><B><I>ROU</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GROSS VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of January 1st, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>593</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>447</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>194</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,234</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>636</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>62</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(16</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>593</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>402</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,230</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>682</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,472</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(593</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>438</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>344</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>1,561</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BUILDINGS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FURNITURE<BR>AND<BR>COMPUTER<BR>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>OF&nbsp;WHICH<BR></I></B><B></B><B><I>ROU</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DEPRECIATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of January 1st, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(222</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(741</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>(243</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I>)</I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(244</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>16</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(134</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>(470</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I>)</I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(481</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>(414</I></TD>
<TD NOWRAP VALIGN="bottom"><I>)&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>593</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(259</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(378</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(171</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(808</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><B><I></I></B><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><B><I>(290</I></B><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><B><I>)</I></B><I>&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BUILDINGS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FURNITURE<BR>AND<BR>COMPUTER<BR>EQUIPMENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><B><I>OF&nbsp;WHICH<BR></I></B><B></B><B><I>ROU</I></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NET BOOK VALUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January 1st, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>394</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>212</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,270</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Right of use assets relate to buildings, vehicles and furniture. The net book value of right of use assets related to buildings
amounted to &#128;147&nbsp;thousand and &#128;1,224&nbsp;thousand as of December 31, 2021 and 2022, respectively. Acquisitions over the year ended December&nbsp;31, 2022 mainly include the right of use asset related to the new Headquarters entered
into in July 2022 (see Note 15.6), as well as office fittings and IT equipment. Disposals over the period mainly include the right of use assets related to the former headquarters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9. Other financial assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other financial assets
break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OTHER FINANCIAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advances related to CRO contracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits paid under the liquidity agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits paid on Kreos 1 and 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposit paid under the Headquarters lease agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,342</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,708</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advances related to CRO contracts </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Advances amounting to &#128;12,187&nbsp;thousand were made during the year ended December&nbsp;31, 2022. These advances are related to CRO/CMO contracts for
clinical studies and are to be recovered at the end of the studies after final reconciliation with pass-through costs, which are being invoiced and paid as studies are carried out. These long-term advances were measured at fair value on initial
recognition, using discount rates ranging from 0.19% to 7.16%, and are subsequently measured at amortized cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At inception, a prepaid expenses asset
was recognized for the difference between the advances&#146; nominal value and fair value, and spread over the term of the advances, at the rate of recognition of the related R&amp;D expenses (see Note 10). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10. Other receivables and assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other receivables and related accounts break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OTHER RECEIVABLES AND ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses - non current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> other receivables and
assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credit (&#147;CIR&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance made to the Nice CHU</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance payment for the acquisition of Prosynergia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses - current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current other receivables and assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,784</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other receivables and assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,784</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,268</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research tax credit (&#147;CIR&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CIR is recognized as Other Operating Income (see note 4.9) in the year to which the eligible research expense relates. The Company received the payment of
the CIR for 2021 tax year in the amount of &#128;4,204&nbsp;thousand in 2022 and expects to receive the CIR for 2022 tax year of &#128;4,448&nbsp;thousand in 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>VAT Receivables </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Value-added tax (&#147;VAT&#148;)
receivables relate primarily to the deductible VAT and VAT refunds claimed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advance to be received </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;20, 2021, the Company amended the research agreement entered with the University Hospital Center of Nice (or &#147;Nice CHU&#148;) on
September&nbsp;25, 2020, which consisted in the conduct of a study to test whether ABX464 could prevent the development of severe <FONT STYLE="white-space:nowrap">Covid-19</FONT> disease in the participants. The Company agreed to advance amount of
&#128;4,000&nbsp;thousand to Nice CHU corresponding to the expenses recharged by its third parties for the year ended December&nbsp;31, 2021. An amount of &#128;3,302&nbsp;thousand was reimbursed in August 2022. The remaining &#128;698&nbsp;thousand
amount was settled by way of compensation with a payable due to the Nice CHU related to the recharge of third-party services expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advance payment
for the acquisition of Prosynergia </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the context of the acquisition of Prosynergia, the Company made an initial payment of the acquisition price of
&#128;325&nbsp;thousand on November 25, 2021 (see Note 3.3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 1, 2021, the Company signed a loan agreement with Prosynergia for
&#128;1,400&nbsp;thousand. Prosynergia committed to reimburse the loan at the end of the contract, on December 31, 2025. The purpose of the loan was to allow early repayment by Prosynergia of all its existing indebtedness and was a suspensive
condition for the acquisition of Prosynergia shares provided by the Share purchase agreement entered with the shareholder of Prosynergia on November 15, 2021. For accounting purposes, this loan was considered as a prepayment for the acquisition of
the group of assets, which was repayable in cash only in the event the acquisition is not completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, there is no more loan
recognized following the merger of the Company and Prosynergia on December&nbsp;12, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prepaid expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses as of December 31, 2021 include costs related to the acquisition of Prosynergia for &#128;451&nbsp;thousand. During the year ended
December&nbsp;31, 2022, these costs were then included in the acquisition price of Prosynergia which was allocated to acquired patents (see Notes 3.3 and 4.15). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses as of December&nbsp;31, 2022 include prepaid expenses related to CRO contracts for amount of &#128;1,714&nbsp;thousand (see Note 9). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11. Cash and cash equivalents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash
equivalents break down as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH AND CASH EQUIVALENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents (short-term investments)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash (bank accounts)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12. Financial assets and liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value
hierarchy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B><br><B>RECOGNIZED&nbsp;IN<BR>THE&nbsp;STATEMENT<BR>OF FINANCIAL<BR>POSITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS/ LIABILITIES<BR>AT FAIR VALUE<BR>THROUGH PROFIT<BR>AND LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS AT<BR>AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LIABILITIES<BR>AT&nbsp;AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other financial assets (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other receivables and assets&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion
(4,&nbsp;Note&nbsp;15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial liabilities&#151;current portion (3, Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Trade payables and other current liabilities (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tax, employee-related payables (5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,323</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,664</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,932</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,732</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B><br><B>RECOGNIZED&nbsp;IN<BR>THE&nbsp;STATEMENT<BR>OF&nbsp;FINANCIAL<BR>POSITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS/ LIABILITIES<BR>AT FAIR VALUE<BR>THROUGH PROFIT<BR>AND LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS AT<BR>AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LIABILITIES<BR>AT&nbsp;AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other financial assets (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other receivables and assets&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,488</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,488</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B><br><B>RECOGNIZED&nbsp;IN<BR>THE&nbsp;STATEMENT<BR>OF&nbsp;FINANCIAL<BR>POSITION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS/ LIABILITIES<BR>AT FAIR VALUE<BR>THROUGH PROFIT<BR>AND LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ASSETS AT<BR>AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LIABILITIES<BR>AT&nbsp;AMORTIZED<BR>COST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial <FONT STYLE="white-space:nowrap">liabilities&#151;non-current</FONT> portion
(4,&nbsp;Note&nbsp;15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Financial liabilities&#151;current portion (3,&nbsp;Note&nbsp;15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Trade payables and other current liabilities&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tax, employee-related payables&nbsp;(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>66,620</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>58,424</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,858</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fair value of cash and cash equivalents is determined based on Level&nbsp;1 fair value measurements and
corresponds to the market value of the assets. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The carrying amount of financial assets measured at amortized cost was deemed to be a reasonable estimation of
fair value, except for the long-term advances made to CROs, whose fair value is determined based on Level&nbsp;3 fair value measurement and is estimated based on future cash-flows discounted at market rates, using credit spreads ranging from 16 bp
to 476 bp as of December&nbsp;31, 2022. As of December&nbsp;31, 2022, an increase in the credit spread by +100 bp would result in a decrease in the advances fair value by &#128;240&nbsp;thousand. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The carrying amount of short-term financial liabilities measured at amortized cost was deemed to be a
reasonable estimation of fair value. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fair values of Kreos BSA A&amp;B, OCEANE conversion option and royalty certificates are based on
Level&nbsp;3 fair value measurements and are estimated based on models and assumptions detailed in note 15. The fair value of other long-term financial liabilities is determined based on Level&nbsp;3 fair value measurements and is estimated based on
future cash-flows discounted at market rates, using the following assumptions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the debt components of Kreos 1&amp;2 bonds, a credit spread of 1,058 bp as of December 31, 2021 and 1,475 bp
as of December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December 31, 2021 and 2022, an increase in the credit spread by +100 bp would result
in a decrease in the Kreos 1&amp;2 bonds fair value by &#128;209&nbsp;thousand and &#128;68&nbsp;thousand, respectively. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the debt component of OCEANE bonds, a credit spread similar to that detailed in note 15.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, and 2022, an increase in the credit spread by +100 bp would result in a decrease in the OCEANE
debt component fair value by &#128;648&nbsp;thousand and &#128;476&nbsp;thousand, respectively. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the conditional advances and the PGE loan, a credit spread of 850 bp as of December 31, 2021 and 1,475 bp as
of December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">An increase in the credit spread by +100 bp would result in the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December 31, 2021 and 2022, a decrease in the PGE loan fair value by &#128;102&nbsp;thousand and
&#128;55&nbsp;thousand, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December 31, 2021 and 2022, a decrease in the <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> conditional
advance fair value by &#128;61&nbsp;thousand and &#128;31&nbsp;thousand, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December 31, 2021 and 2022, a decrease in the CARENA conditional advance fair value by
&#128;58&nbsp;thousand and &#128;37&nbsp;thousand respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December 31, 2021 and 2022, a decrease in the Ebola conditional advance fair value by &#128;3&nbsp;thousand
and &#128;1&nbsp;thousand, respectively. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As of December 31, 2021, a decrease in the <FONT STYLE="white-space:nowrap">Covid-19</FONT> conditional advance
fair value by &#128;161&nbsp;thousand. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Social security and other tax payables are excluded from the tax and employee-related payables, as this
analysis is required only for financial instruments. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 13. Shareholders&#146; equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 13.1. Share capital issued </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to shareholders through the optimization of the debt and equity balance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, the Company&#146;s share capital amounted to &#128;168&nbsp;thousand divided into 16,764,051 ordinary shares issued with a par value
of &#128;0.01 each, fully paid up, after taking into account the various capital increases that took place since the inception (see Note 13.3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December 31, 2022, the Company&#146;s share capital amounted to &#128;223&nbsp;thousand divided into 22,313,185 ordinary shares issued with a par value of &#128;0.01 each, fully paid up, after taking into account the various capital increases that
took place since the inception (see Note 13.3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share capital does not include BCEs, BSAs, and AGAs that have been granted to certain investors or
natural persons, both employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> of the Company, but not yet exercised or acquired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Treasury
shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company held 8,600 and 12,000 of its own shares as of December 31, 2021 and 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of outstanding ordinary shares (excluding treasury shares held by the Company) was 16,755,451 and 22,301,185 as of December 31, 2021 and 2022,
respectively. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 13.2. Equity line instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity line agreement with Kepler Cheuvreux </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
entered into an equity line agreement with Kepler Cheuvreux in September 2019. In accordance with the terms of this agreement, Kepler Cheuvreux, acting as financial intermediary and guarantor of the transaction, committed to subscribe for 730,000
shares, at its own initiative, following a schedule lasting no longer than 24 months, at an issuance price based on an average market price weighted according to the volumes traded over the two trading days preceding each issue, less a maximum
discount of 7.0%. On September 24, 2021, the Company extended the agreement for an additional period of 12 months for the unsubscribed shares at that date. On October&nbsp;1, 2022, the agreement ended and the 300,000 outstanding BSAs lapsed. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER OF<BR>BSAs<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>MAXIMUM<BR>NUMBER<BR>OF&nbsp;SHARES<BR>TO&nbsp;BE<BR>ISSUED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER&nbsp;OF<BR>BSAs<BR>EXERCISED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER<BR>OF&nbsp;BSAs<BR>LAPSED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER OF<BR>BSAs<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>MAXIMUM<BR>NUMBER&nbsp;OF<BR>SHARES<BR>TO&nbsp;BE<BR>ISSUED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>FOR THE YEAR ENDED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF DECEMBER&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DECEMBER&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF DECEMBER&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BSAs granted under the Equity line agrement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(300,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Considering that the Company could terminate or suspend the Equity line agreement by buying back the BSAs or increasing the
minimum exercise price and that Kepler Cheuvreux was committed to subscribe the shares if the conditions are met, the BSAs granted to Kepler Cheuvreux under the Equity line agreements were <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
commitments rather than derivative instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 13.3. Change in share capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increases in the share capital for the year ended December 31, 2021 relate to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The completion of a capital increase of &#128;59,982&nbsp;thousand on July 27, 2021 by issuing 1,964,031 ordinary
shares with a par value of &#128;0.01 per share and a subscription price of &#128;30.55 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exercises of 167,749 share warrants for the year ended December 31, 2021 (see note 14), resulting in a
capital increase of &#128;1,522&nbsp;thousand by issuing 167,749 ordinary shares with a par value of &#128;0.01 per share and an average subscription price of &#128;8,49 per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exercises of 312,000 share warrants under the Equity line agreement for the year ended December 31, 2021 (see
note 13.2), resulting in a capital increase of &#128;8,094&nbsp;thousand, net of commissions, by issuing 312,000 ordinary shares with a par value of &#128;0.01 per share and an average subscription price of &#128;27,13 per share;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Incremental costs directly attributable to the issue of new shares were classified as a deduction of shareholders&#146; equity and
amounted to &#128;4,153&nbsp;thousand for the year the year ended December 31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increases in the share capital for the year ended December 31,
2022 relate to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The completion of a capital increase of &#128;46,231&nbsp;thousand on September&nbsp;7, 2022 by issuing 5,530,000
ordinary shares with a par value of &#128;0.01 per share and a subscription price of &#128;8.36 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exercises of 522 share warrants for the year ended December 31, 2022 (see Note 14), resulting in a capital
increase of &#128;3&nbsp;thousand by issuing 19,134 ordinary shares with a par value of &#128;0.01 per share and an average subscription price of &#128;0.14 per share; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Incremental costs directly attributable to the issue of new shares were classified as a deduction of shareholders&#146; equity and amounted to
&#128;3,280&nbsp;thousand for the period ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distribution of dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company did not distribute any dividends for any of the periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 14. Share-based payments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has granted
BCEs, BSAs and AGAs. These plans qualify as &#147;equity settled&#148; under IFRS 2. The Company does not have any obligation to purchase these instruments in the event of departure or if a specific event does not occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Valuation methods of BCEs, BSAs and AGAs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value
of share-based awards was determined at grant date using the Black Scholes model for the BCEs and BSAs and the Monte-Carlo simulation for AGAs plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
assumptions used to estimate the fair value of the instruments are presented below and include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected maturity of the options </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected volatility based on the historical market share price available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected dividends based on management best estimate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risk-free interest rate based on French OAT rates measured at grant dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Share price offered in case of change of control (only for the market condition applicable on the free-share
plan) is based on Monte-Carlo simulations and taking into account a change of control premium based on the management best estimate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BCEs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the data relating to BCEs as well as the assumptions used for the measurement thereof in accordance with IFRS 2 &#150;
<I>Share-based Payment</I>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>GRANT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>DATE</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TYPE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF</B><br><B>BCEs</B><br><B>ISSUED</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF</B><br><B>BCE<BR>OUTSTANDING</B><br><B>AS&nbsp;OF<BR>JANUARY</B><br><B>1, 2022</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>LAPSED</B><br><B>BCEs</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>EXERCISED</B><br><B>BCEs</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>OF&nbsp;BCEs</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>OUTSTANDING</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>OF&nbsp;BCEs</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISABLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>MAXIMUM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER OF<BR>SHARES TO<BR>BE ISSUED<BR>IF ALL<BR>CONDITIONS<BR>ARE MET</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF DECEMBER&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2016-11-07</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-01-23</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BCE <FONT STYLE="white-space:nowrap">2017-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-11-20</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-03-15</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-21</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BCE <FONT STYLE="white-space:nowrap">2018-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-05-14</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Total BCEs</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>702,821</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>429,767</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,340</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,093</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>222,766</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>541,309</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6.5pt; font-family:Times New Roman" ALIGN="center"><B>TYPE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR&nbsp;VALUE&nbsp;OF<BR>THE&nbsp;UNDERLYING<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR&nbsp;VALUE<BR>OF THE BCE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BCE&nbsp;PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>STRIKE&nbsp;PRICE<BR>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPECTED<BR>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPECTED<BR>MATURITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VOLATILITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RISK&nbsp;FREE<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-4</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.54&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.77%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.96 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.77&#128;-3.15&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[-0.1%-0.18%]</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.95 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.38&#128;-2.72&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.39 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-7.05</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.11%-0.44%]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-2</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.22&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[4.01&#128;-4.56&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[-0.14%-0.1%]</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BCE&nbsp;2017-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.22&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[3.83&#128;-4.56&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.04-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[-0.21%-0.1%]</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.22&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[4.01&#128;-4.43&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-6.64</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[-0.14%-0.04%]</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.22&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[3.92&#128;-4.43&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.26-6.64</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">[-0.18%-0.04%]</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[3.81&#128;-4.28&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.14%-0.37%]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.31&#128;-3.11&#128;]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[5-8.06</FONT></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.05%-0.53%]</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">BCE <FONT STYLE="white-space:nowrap">2018-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.03&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.75&#128;-3.11&#128;]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[5-6.4</FONT></TD>
<TD NOWRAP VALIGN="top">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.08%-0.3%]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-4</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.03&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.75&#128;-3.11&#128;]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33 &#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[5-6.4</FONT></TD>
<TD NOWRAP VALIGN="top">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.08%-0.3%]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.03&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[2.88&#128;-3.26&#128;]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33&nbsp;&#128;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10&nbsp;years</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[5.5-7</FONT></TD>
<TD NOWRAP VALIGN="top">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">[0.16%-0.39%]</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BCEs include a service condition under which the beneficiary must still be an employee, a corporate officer or a
scientific consultant of the Company at the time of vesting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise rights for most of the BCEs are vested annually and have the following vesting
terms: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">25% of the award vests on the first anniversary of the date of grant for all currently issued BCEs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the remaining 75% of the award, the BCEs vest 1/48th per month over four years from the anniversary date of
the grant. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most of the BCEs plans (all BCEs plans except BCE <FONT STYLE="white-space:nowrap">2014-2</FONT> fully vested as of January
1, 2020) include or partially include <FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions (obtaining financing of &#128;100&nbsp;million, positive results on clinic studies, signature of informed consent in a clinical phase,
signing a license agreement, FDA authorization). The level of achievement of the <FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions are taken into account in determining the number of BCEs allocated initially and reassessed at
each closing date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a change of control or a M&amp;A transaction, all the BCEs will become immediately exercisable. A change of control is
defined as a new investor/company holding directly or indirectly more than 50% of the share capital or voting rights. As such the probable vesting date of each plan corresponds to the weighted average of probable change of control dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For BCE <FONT STYLE="white-space:nowrap">2014-4,</FONT> BCE <FONT STYLE="white-space:nowrap">2016-1,</FONT>
BCE <FONT STYLE="white-space:nowrap">2017-1,</FONT> the vesting terms have been modified by the Board of Directors on February 14, 2020 to provide for the possible exercise of the instruments, even if the associated performance and/ or conditions
included in the graded vesting schedule are not met, in case of change of control. Since this modification affects a vesting condition other than a market condition, the modified vesting condition was taken into account by adjusting the number of
equity instruments that eventually vest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BSAs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following tables summarize the data relating to BSAs in accordance with IFRS 2 &#150; <I>Share-based Payment</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>GRANT&nbsp;DATE</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TYPE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER<BR>OF BSAs<BR>ISSUED</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER OF<BR>BCAs<BR>OUTSTANDING<BR>AS OF<BR>JANUARY 1,<BR>2022</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>LAPSED<BR>BSAs</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER<BR>OF<BR>EXERCISED<BR>BSAs</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER OF<BR>BSAs<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>NUMBER OF<BR>BSAs<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>MAXIMUM<BR>NUMBER OF<BR>SHARES TO<BR>BE ISSUED IF<BR>ALL<BR>CONDITIONS<BR>ARE MET</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>AS OF DECEMBER&nbsp;31, 2022</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2015-12-04</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-11</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2015-12-04</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2015-12</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-09-18</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2017-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-01-22</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2014-03-11</FONT></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-5</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Total BSAs</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>247,798</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>148,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>147,917</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>147,917</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>325,384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BSAs include a service condition under which the beneficiary must still be an employee, a corporate officer or a
scientific consultant of the Company at the time of vesting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise rights for most of the BSAs are vested annually and have the following vesting
terms: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">25% of the award vests on the first anniversary of the date of grant for all currently issued BSAs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the remaining 75% of the award, the BSAs vest 1/48th per month over four years from the anniversary date of
the grant. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the BSAs plans include or partially include <FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions
(positive results on clinic studies, signature of informed consent in a clinical phase, signing a license agreement, FDA authorization). The level of achievement of the <FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions are
taken into account in determining the number of BSAs allocated initially and reassessed at each closing date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a change of control or a
M&amp;A transaction, all the BSAs will become immediately exercisable. A change of control is defined as a new investor/company holding directly or indirectly more than 50% of the share capital or voting rights. As such the probable vesting date of
each plan corresponds to the weighted average of probable change of control dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For BSA <FONT STYLE="white-space:nowrap">2014-5,</FONT> the vesting
terms have been modified by the Board of Directors of February 14, 2020 to provide for the possible exercise of the instruments, even if the associated performance and/or conditions included in the graded vesting schedule are not met, in case of
change of control. Since this modification affects a vesting condition other than a market condition, the modified vesting condition was taken into account by adjusting the number of equity instruments that eventually vest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>AGAs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize the data relating to AGAs as well as the assumptions used for the measurement thereof in accordance with IFRS 2 &#150;
<I>Share-based Payment</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>GRANT&nbsp;DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TYPE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>AGAs&nbsp;ISSUED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF&nbsp;AGAs<BR>OUTSTANDING&nbsp;AS<BR>OF&nbsp;JANUARY&nbsp;1,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>LAPSED&nbsp;AGAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>EXERCISED&nbsp;AGAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF&nbsp;AGAs<BR>OUTSTANDING&nbsp;AS<BR>OF&nbsp;DECEMBER&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2021-09-21</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">AGA&nbsp;2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>155,000</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Total&nbsp;AGAs</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>155,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>155,000</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(155,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>TYPE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR&nbsp;VALUE&nbsp;OF<BR>THE&nbsp;UNDERLYING<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FAIR&nbsp;VALUE<BR>OF&nbsp;THE&nbsp;AGA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGA<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>STRIKE&nbsp;PRICE<BR>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPECTED<BR>TERM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DURATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VOLATILITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RISK&nbsp;FREE<BR>RATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGA 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.60&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.92&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n.a.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n.a.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AGAs granted in September 2021 are subject to a vesting service condition of one year following the grant date. The number of
shares that will be finally vested under this plan will depend on the following conditions: if a M&amp;A transaction is completed on or prior to July 31, 2022 and the price per ordinary share of the Company retained in the framework of the M&amp;A
transaction is at least equal to &#128;100 per share (or lower than &#128;100 per share) then 100% (or 75%) of the shares initially granted will be vested. The AGAs are forfeited if a M&amp;A transaction is not completed on or prior to July 31,
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These conditions qualify as both a <FONT STYLE="white-space:nowrap">non-market</FONT> performance condition (occurrence or not of a M&amp;A
transaction before July 31, 2022) and a market condition (number of shares depending on the share price offered in case of a M&amp;A transaction before July 31, 2022) under IFRS 2 principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The level of achievement of the market condition is directly included in the unit fair value of the free shares and the probability of a M&amp;A transaction
before July 31, 2022 is included in the estimation of the number of shares that will be finally vested by the beneficiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2021, considering that it was probable that an M&amp;A transaction would occur before July&nbsp;31, 2022, 100% of the shares originally granted were included in the calculation of share based payment expenses. In addition, the Company recognized an
accrual for social taxes related to the AGA 2021 plan of &#128;205&nbsp;thousand as of December&nbsp;31, 2021.The total share-based compensation expense amounted to &#128;828&nbsp;thousand (&#128;389&nbsp;thousand in research and development and
&#128;440&nbsp;thousand in general and administrative, respectively). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period ended December&nbsp;31, 2022, the AGAs were all forfeited since
no M&amp;A transaction was completed on or prior to July 31, 2022. This resulted in a reversal of the related compensation expense of &#128;1,026&nbsp;thousand and the reversal of the accrual for social taxes of &#128;205&nbsp;thousand that was
recorded as of December 31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Breakdown of the compensation expenses accounted for the year ended December&nbsp;31, 2021 and 2022 </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B><U>TYPE</U></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPENSES&nbsp;RELATED<BR>TO&nbsp;THE&nbsp;YEAR&nbsp;ENDED</B><br><B>DECEMBER&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EXPENSES&nbsp;RELATED<BR>TO&nbsp;THE&nbsp;YEAR&nbsp;ENDED</B><br><B>DECEMBER&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>(in thousands of euros)</I></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BCEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AGAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social taxes related to AGAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1&nbsp;032</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1&nbsp;369</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 15. Financial liabilities </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCIAL LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Borrowings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,458</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Convertible loan notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,191</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,332</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos A&nbsp;&amp; B BSA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane conversion option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Derivative instruments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,932</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances BPI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalties certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,659</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,549</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> financial liabilities</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,573</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Borrowing</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,608</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances BPI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT> liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,112</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Convertible loan notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,224</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,585</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,797</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.1. Structured debt financing with Kreos subscribed in July 2018 &#150; &#147;Kreos 1&#148; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 24, 2018, the Company entered into a Venture Loan Agreement, a Straight Bonds Issue Agreement and a Convertible Bonds Issue Agreement with Kreos
Capital V (UK) Ltd., (or &#147;Kreos&#148;), which provided for up to &#128;20,000&nbsp;thousand in financing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the agreements,
Kreos agreed to subscribe for &#128;16,000&nbsp;thousand in <FONT STYLE="white-space:nowrap">non-convertible</FONT> bonds and &#128;4,000&nbsp;thousand in convertible bonds, to be issued by the Company in two tranches of &#128;10,000&nbsp;thousand
each. The tranches were issued in July 2018 and May 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The convertible bonds were convertible into new ordinary shares of the Company at
any time from their issuance and at the discretion of their holders. In October 2020, Kreos required the conversion of all the convertible bonds they held (2,000,000 for Tranche A and 2,000,000 for Tranche B) and 464,309 shares were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each tranche bears an 8% annual interest rate, plus <FONT STYLE="white-space:nowrap">3-month</FONT> Euribor, including a floor at 8% and a cap at 9%, and must
be repaid in 54 monthly installments, after a deferred repayment of the nominal value to 12 months for the first tranche (&#147;Tranche A&#148;) and 6 months for the second tranche (&#147;Tranche B&#148;). In addition, each tranche
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bears exit fees of 9% of the total drawdown amount (i.e. &#128;900&nbsp;thousand per tranche), payable upon the last monthly installment (exit fees remain payable in full in case of early
redemption). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the agreements, the Company has the right, at any time but with no less than 30 days prior notice to Kreos, to
prepay or purchase the <FONT STYLE="white-space:nowrap">non-convertible</FONT> and convertible bonds, exclusively in full. The prepayment will be equal to (i)&nbsp;the principal amount outstanding, plus (ii)&nbsp;exit fees of 9% of the total draw
down amount and (iii)&nbsp;the sum of all interest repayments which would have been paid throughout the remainder of the term of the relevant tranche discounted by 4% per annum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreements do not contain any financial covenants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with each tranche, the Company issued 110,957 tranche A share warrants (or &#147;Kreos A BSA&#148;) and 74,766 tranche B share warrants (or &#147;Kreos B BSA&#148;), each, for a global subscription price of &#128;1. Each Kreos A BSA and
Kreos B BSA gives rights to one new ordinary share at an exercise price of &#128;7.21 less a discount and &#128;10.70 less a discount, respectively. Both Kreos A BSA and Kreos B BSA are freely transferrable among financial institutions and are
exercisable over a <FONT STYLE="white-space:nowrap">10-year</FONT> period from the issue date. In addition, the Company granted to the holders of the Kreos A BSA and the Kreos B BSA the option to sell to the Company, upon each exercise of all or
parts of the Kreos A BSA, at the put price defined in the agreement, a proportion of the number of the warrants, for the sole purpose of implementing a cash less exercise of the Kreos A BSA and Kreos B BSA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting treatment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Kreos 1 financing package is
issued at market conditions: the net issuance proceeds reflect the fair value of the instruments at inception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The straight bond tranches are split
between i) a debt component (then measured at amortized cost), and ii) a premium corresponding to the initial fair value of attached BSA (then remeasured at fair value through profit and loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BSA attached to all tranches (both straight and convertible) do not meet the &#147;fixed for fixed&#148; criteria (non cash settlement option which may
result in exchanging a variable number of shares, for a variable price), and are accounted for as standalone derivative instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuer
prepayment options meet the definition of a separate derivative. However, their value at inception and subsequent dates is nil as per Schoenbucher model, and has no impact on the financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Measurement of Kreos A BSA&nbsp;&amp; Kreos B BSA </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Kreos A BSA and Kreos B BSA are measured at fair value using a Black-Scholes valuation model. The main data and assumptions are the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Kreos A BSA - July 31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;year<BR>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;year<BR>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of outstanding Kreos A BSA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Residual maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of issued Kreos A BSA (in thousands&nbsp;of&nbsp;&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,478</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Change in fair value of Kreos A BSA for the year
(in&nbsp;thousands&nbsp;of&nbsp;&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(699</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Kreos B BSA - June 1, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;year<BR>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the&nbsp;year<BR>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of outstanding <B>Kreos B BSA </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">28.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Residual maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of issued Kreos B BSA (in thousands of &#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Change in fair value of Kreos B BSA for the year
(in&nbsp;thousands&nbsp;of&nbsp;&#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(494</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,376</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, using the same assumption with an increase of +1% volatility, &#128;+1share price and +1% risk-free
rate would result in an increase of Kreos A&amp;B BSA fair value of &#128;16&nbsp;thousand, &#128;176&nbsp;thousand, and &#128;69&nbsp;thousand respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, using the same assumption with an increase of +1% volatility, &#128;+1share price and +1% risk-free rate would result in an increase
of Kreos A&amp;B BSA fair value of &#128;6&nbsp;thousand, &#128;78&nbsp;thousand, and &#128;12&nbsp;thousand, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.2. Structured
debt financing with Kreos subscribed in October 2020 &#150; &#147;Kreos 2&#148; </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 13, 2020, the Company obtained a straight bond loan of
&#128;15,000&nbsp;thousand from Kreos corresponding to two tranches of &#128;10,000&nbsp;thousand (&#147;Tranche A&#148;) and &#128;5,000&nbsp;thousand (&#147;Tranche B&#148;), with an option for an additional &#128;5,000&nbsp;thousand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tranches A and B were paid in October and November 2020, respectively, with the following conditions. Each tranche bears an 8% annual interest rate, plus <FONT
STYLE="white-space:nowrap">3-month</FONT> Euribor, for the first 12 monthly installments, after which the annual interest rate is increased to a fixed rate of 9.75% for the following 36 monthly installments. Each tranche is to be repaid in 36
monthly installments starting from October 2021 and November 2021, for the tranche A and B, respectively. The agreements do not contain any financial covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each tranche bears exit fees of 4% of the total drawdown amount (i.e. &#128;400&nbsp;thousand &#128;200&nbsp;thousand for Tranche A&nbsp;&amp; B,
respectively), payable upon the last monthly installment (exit fees remain payable, in full or partially, in case of early redemption). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
terms of the agreements, the Company has the right, at any time but with no less than 30 days prior notice to Kreos, to prepay or purchase the <FONT STYLE="white-space:nowrap">non-convertible</FONT> exclusively in whole. The prepayment will be equal
to (i)&nbsp;the principal amount outstanding, plus (ii)&nbsp;exit fees of 2% of the outstanding amount in the event of prepayment occurring between the 18th and the 30th installment or exit fees of 4% of the outstanding amount in the event of
prepayment occurring after the 30th installment and (iii)&nbsp;the sum of all interest repayments which would have been paid throughout the remainder of the term of the relevant tranche discounted by 4% per annum. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting treatment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Kreos 2 straight bonds were
initially measured at fair value, which corresponds to the net cash proceeds, and subsequently measured at amortized cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the prepayment
option is a separate derivative instrument as the redemption price does not reimburse Kreos for an amount up to the approximate present value of lost interest for the remaining term of the host </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contract. However, its fair value at inception and subsequent dates is nil as per Schoenbucher model, and has no impact on the financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.3. OCEANE </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received a gross
proceed of &#128;85,000&nbsp;thousand on July 30, 2021 through (i)&nbsp;the issuance of 1,964,031 shares with a subscription price of &#128;30.55 per share (see Note 13.3 (changes in share capital)) for gross amount of &#128;60,000&nbsp;thousand,
and (ii)&nbsp;the issuance of &#128;25,000&nbsp;thousand in OCEANE, maturing on July 30, 2026. The proceeds of the transaction mainly serve to finance the progress of ABX464 clinical trials in chronic inflammatory diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The OCEANE bears a 6% interest rate per year, payable semi-annually January 30, and July, 31 from January 31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The OCEANE shall be convertible into new ordinary shares and/or exchanged for existing ordinary shares of the Company at any time from their issuance and at
the discretion of their holders. The conversion ratio is one ordinary share of the company per OCEANE, representing a conversion price set to &#128;&nbsp;38.19 per ordinary share. This conversion price will be updated (decrease only) 18 months, 24
months, 36 months after OCEANE issuance date to match the volume weighted average price of the thirty trading days that precedes the update subjected to the following floor threshold. The floor threshold for the
<FONT STYLE="white-space:nowrap">18-month</FONT> update matches 85% initial conversion price (&#128;32.462 per ordinary share). The floor threshold for the <FONT STYLE="white-space:nowrap">24-month</FONT> update matches 70% initial conversion price
(&#128;26.733 per ordinary share). The floor threshold for the <FONT STYLE="white-space:nowrap">36-month</FONT> update matches 68% initial conversion price (&#128;25.969 per ordinary share). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OCEANE terms and conditions anticipate a conversion ratio adjustment in order to preserve the rights of OCEANE holders with the following achievements made by
the company: issuance of new shares with the preemptive subscription right, attribution of free shares or securities for the benefit of all the shareholders, number of share multiplication, shares consolidation, increase of the nominal value by
incorporation of reserves, profits or bonuses, distribution of dividends, premiums or reserves, mergers, scission, repurchase of shares above market value, capital reduction, creation of preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting treatment and measurement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the conversion
ratio is adjusted 18 months, 24 months, and 36 months after the issuance date of the OCEANE bond with the weighted average price of the shares and is subject to a floor and a cap, the conversion does not result in the delivery of a fixed number of
shares. Consequently, the OCEANE bond is recorded as an hybrid instrument which includes i) a debt host contract accounted for at amortized cost, and ii) a conversion option which is a standalone derivative accounted for at fair value through profit
and loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At inception, the net cash proceeds reflect the OCEANE initial fair value. The fair value of the bifurcated option at inception has been
measured with a Monte Carlo model using a Longstaff Schwartz algorithm, with a 53% share price volatility, a 1 400 bp credit spread assumption and a &#128;31.50 share price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July 30, 2021, the issuance price of &#128;&nbsp;25,000&nbsp;thousand has been split between i) a financial liability for &#128;17,839&nbsp;thousand,
and ii) a financial derivative for &#128;7,161&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, the fair value of the conversion option amounts to
&#128;5,929&nbsp;thousand, based on the same valuation model, a credit spread assumption of 1,400 bp, a share price of &#128;28.55, and a price volatility of 77%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, using the same assumptions, an increase of +1% volatility, &#128;+1 share price and +1% risk free rate would result in an increase of
the OCEANE conversion option fair value of &#128;114&nbsp;thousand, &#128;337&nbsp;thousand, and &#128;243&nbsp;thousand, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, the fair value of conversion option amounts to &#128;142&nbsp;thousand, based on
the same valuation model, a credit spread assumption of 1,475 bp, a share price of &#128;6.18, and a price volatility of 44%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022,
using the same assumptions, an increase of +1% volatility, &#128;+1 share price and +1% risk free rate would result in an increase of the OCEANE conversion option fair value of &#128;17&nbsp;thousand, &#128;97&nbsp;thousand, and
&#128;15&nbsp;thousand respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.4. State guaranteed loan &#150; &#147;PGE&#148; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2020, the Company subscribed to a PGE from Soci&eacute;t&eacute; G&eacute;n&eacute;rale with an initial maturity of 12 months at 0.25% and a five-year
extension option. In March 2021, the company exercised the five-year extension option with a <FONT STYLE="white-space:nowrap">one-year</FONT> deferral of the principal repayment, with the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rate: 0.58% per annum excluding insurance and state guaranteed premium, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State guaranteed premium of &#128;138&nbsp;thousand to be paid by installments over the contract period starting
in June 2021, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reimbursement by yearly installments from June 2021 to June 2026. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The benefit resulting from the low interest nature of the award as a subsidy was recognized as other income during the period ended December&nbsp;31, 2020 for
an amount of &#128;377&nbsp;thousand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.5. Conditional advances </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(In thousands of euros)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>CONDITIONAL ADVANCES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RNP VIR &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CARENA &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBOLA &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> &#150; Bpifrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total conditional advances</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>RNP-VIR &#150; Bpifrance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> contract, the Company was eligible to receive up to &#128;6.3&nbsp;million in conditional advances to
further develop methods for the discovery of new molecules for the treatment of viral infectious diseases through the development of the &#147;Modulation of RNA biogenesis&#148; platform. As of December 31, 2022, the Company had received
&#128;4,032&nbsp;thousand, of which &#128;1,756&nbsp;thousand was received in September 2017, &#128;346&nbsp;thousand in August&nbsp;2018 and &#128;1,930&nbsp;thousand in November 2019. The repayment of these funds is spread from the date on which
the repayments are called by BPI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 25.2. Commitments under BPI conditional advances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CARENA &#150; Bpifrance </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the CARENA agreement,
the Company was eligible to receive up to &#128;3,840&nbsp;thousand to develop a therapeutic HIV treatment program with ABX464. As of December 31, 2022, the Company received &#128;2,187&nbsp;thousand, of which &#128;1,150&nbsp;thousand was received
in December 2013, &#128;1,008&nbsp;thousand in September 2014 and &#128;29&nbsp;thousand received in June 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The repayment of the advance is spread from the date on which the repayments are called by BPI. An
additional repayment is provided for based on the income the Company generates through this research and development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 25.2. Commitments
under BPI conditional advances. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>EBOLA &#150; Bpifrance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Bpifrance and Occitanie region joint aid agreement, the Company received a total of &#128;390&nbsp;thousand (&#128;300&nbsp;thousand as of December
31, 2017 and &#128;90&nbsp;thousand as of December 31, 2019). The reimbursement is spread from 2019 to June 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> &#150; Bpifrance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020, Bpifrance granted the Company with a conditional advance of up to a total of &#128;15,869&nbsp;thousand under the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> agreement to complete the miR-AGE study to demonstrate the efficacy and safety of ABX464 for the treatment of <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients at risk of developing severe
forms of the disease thanks to an anti- inflammatory and antiviral effect. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the project failed, the repayment of these funds were to be spread
over five years from March 31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had received a grant of &#128;1,587&nbsp;thousand and a repayable advance
of &#128;6,348&nbsp;thousand. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In view of the study results and the recommendations of the Data and Safety Monitoring Board, the Company terminated
the study on March&nbsp;5, 2021. As Bpifrance had recorded the project as a failure, the repayable advance of &#128;6,348&nbsp;thousand paid in 2020 was recognized as a grant. As of December&nbsp;31, 2021, the Company had also received the remainder
of the grant, amounting to &#128;3,279&nbsp;thousand. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A valuation of conditional advances was made using a market rate of 8% per year as of
May&nbsp;31, 2020 (see&nbsp;Note&nbsp;18). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.6. Lease liability </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(amounts in thousands of euros)</I></P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>LEASE AGREEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LEASE&nbsp;LIABILITY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;214</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease liabilities mainly relate the Company&#146;s headquarter and to a lesser extent to vehicles, parking lots and printers
(Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease for the Company&#146;s corporate headquarters in Paris, France at 5 Rue de la Baume, 75008 Paris ended in August 2022. A new lease
for premises at <FONT STYLE="white-space:nowrap">7-11</FONT> Boulevard Haussmann, 75009 Paris started in July 2022. It has a three-year duration, with a tacit renewal option for approximately two years and the possibility to break the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contract one year before the end. Per Management, renewal and termination options are not reasonably certain due to the forecasted development of the Company, which may lead the Company to
relocate at the end of the initial term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021 and December&nbsp;31, 2022, the lease liability of the headquarter represented 92%
and 97% of the total lease liability, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expenses related to contracts for which a lease liability and right of use asset is recognized
under IFRS 16 were &#128;250&nbsp;thousand and &#128;424&nbsp;thousand for the years ended December 31, 2021 and 2022, respectively. They were recognized for (i) &#128;244&nbsp;thousand and &#128;414&nbsp;thousand as Depreciation expenses and (ii)
&#128;5&nbsp;thousand and &#128;10&nbsp;thousand as Interest expenses, for the years ended December 31, 2021 and 2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expenses
related to short-term lease contracts and low value assets that are not included in the valuation of the lease liability amount to &#128;25&nbsp;thousand and &#128;331&nbsp;thousand for the years ended December 31, 2021 and 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.7 Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT> liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT> liability is measured at fair value using a Black-Scholes valuation model. The main data and
assumptions are the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Prosynergia <FONT STYLE="white-space:nowrap">earn-out</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;April&nbsp;1,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;and&nbsp;for&nbsp;the<BR>period ended<BR>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0,27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market capitalization (in thousands of &#128;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403&nbsp;118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135&nbsp;952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary share price (&#128;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to maturity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25&nbsp;year</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,01</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability (in thousands
of &#128;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1&nbsp;446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April 1, 2022, using the same assumption with an increase of +1% volatility, &#128;+1 share price and +1% risk free rate
would result in an increase of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability fair value by &#128;12&nbsp;thousand, &#128;132&nbsp;thousand and &#128;17&nbsp;thousand, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the fair value of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability is approximately &#128;0. Using the same
assumption with an increase of +1% volatility, &#128;+1 share price and +1% risk free rate would result in an increase of the <FONT STYLE="white-space:nowrap">earn-out</FONT> liability fair value by an amount less than &#128;1&nbsp;thousand. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.8 Royalty certificates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 2,
2022, the Company completed a financing of &#128;49,162&nbsp;thousand, consisting of two transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a reserved capital increase of a gross amount of &#128;46,231&nbsp;thousand through the issuance of 5,530,000 new
shares with a nominal value of &#128;0.01 per share at a subscription price of &#128;8.36 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an issue of royalty certificates with a subscription price amounting to &#128;2,931&nbsp;thousand. The royalty
certificates give right to their holders to royalties equal to 2% of the future net sales of obefazimod (worldwide and for all indications) as from the commercialization of such product. The amount of royalties that may be paid under the royalty
certificates is capped at &#128;172,000&nbsp;thousand. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related transaction costs amounted to &#128;3,280&nbsp;thousand and are recorded
in equity, since entirely related to the reserved capital increase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, following a change in the estimate of future royalty cash flows, the
certificates&#146; amortized cost was remeasured at &#128;3,287&nbsp;thousand, using the original EIR calculated at the date of issuance. The change in estimate resulted in a decrease in the related interest expense by &#128;100&nbsp;thousand over
the period ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair value as of December&nbsp;31, 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this date, the fair value of the royalty certificates, calculated using the same model as their initial measurement, amounts to &#128;3,307&nbsp;thousand.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Royalty Certificates is based on NPV of royalties, which depend on assumptions made by the Company with regards to the probability
of success of its studies (&#147;POS&#148;), the commercialization budget of obefazimod (&#147;peak penetration&#148;) and the discount rate. In addition, royalty projections have been adjusted to reflect any difference between the company&#146;s
value derived from management projections and the company&#146;s market capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sensitivity analysis to key assumptions is presented below:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Fair&nbsp;value&nbsp;of&nbsp;royalty<BR>certificates&nbsp;(in&nbsp;thousands<BR>of&nbsp;euros)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">POS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-5&nbsp;points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">+5&nbsp;points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Fair&nbsp;value&nbsp;of&nbsp;royalty<BR>certificates&nbsp;(in&nbsp;thousands<BR>of&nbsp;euros)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peak penetration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-5%&nbsp;(worst&nbsp;case&nbsp;scenario)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">+5%&nbsp;(best&nbsp;case scenario)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Fair&nbsp;value&nbsp;of&nbsp;royalty<BR>certificates&nbsp;(in&nbsp;thousands<BR>of&nbsp;euros)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-1&nbsp;point</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">+1&nbsp;point</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.9. Change in financial liabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in financial liabilities, excluding derivative instruments, are presented below as of December 31, 2021 and December 31, 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(Amounts&nbsp;in&nbsp;thousands&nbsp;of&nbsp;euros)</I></P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>FINANCIAL LIABILITIES</B><br><B>(excluding derivatives instruments)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;1&nbsp;&amp;&nbsp;2<BR>bond loans</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Oceane</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conditional<BR>advances<BR>BPI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lease<BR>liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Prosynergia<BR><FONT STYLE="white-space:nowrap">earn-out</FONT><BR>liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty<BR>certificates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26&nbsp;233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4&nbsp;623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11&nbsp;193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>42&nbsp;449</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25&nbsp;000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25&nbsp;000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5&nbsp;537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5&nbsp;856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: interest expense and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes : classification of the conversion option
as a derivative instrument</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7&nbsp;161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7&nbsp;161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes : subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4&nbsp;459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4&nbsp;367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non cash changes: additional leases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21&nbsp;110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18&nbsp;816</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4&nbsp;742</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6&nbsp;770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>214</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51&nbsp;653</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(Amounts&nbsp;in&nbsp;thousands&nbsp;of&nbsp;euros)</I></P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>FINANCIAL LIABILITIES</B><br><B>(excluding derivatives instruments)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;1&nbsp;&amp;&nbsp;2<BR>bond loans</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Oceane</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conditional<BR>advances<BR>BPI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lease<BR>liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Prosynergia<BR><FONT STYLE="white-space:nowrap">earn-out</FONT><BR>liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty<BR>certificates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9&nbsp;410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9&nbsp;806</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2&nbsp;456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4&nbsp;006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: interest expense and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3 738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: recognition of <FONT
STYLE="white-space:nowrap">earn-out</FONT> liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> changes: fair value remeasurement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non cash changes: additional leases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12&nbsp;982</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19&nbsp;957</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4&nbsp;838</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6&nbsp;783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1&nbsp;384</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3&nbsp;287</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49&nbsp;231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excluding issuance fees of &#128;87&nbsp;thousand for the year ended December 31, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.10. Change in derivative instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in derivative instruments, are presented below as of December 31, 2021 and December&nbsp;31, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(In thousands of euros)</I></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><B>FINANCIAL
INSTRUMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;A&nbsp;BSA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Kreos&nbsp;B&nbsp;BSA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OCEANE<BR>conversion<BR>option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3&nbsp;177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2&nbsp;019</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5&nbsp;196</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(699</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(494</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2&nbsp;425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2&nbsp;478</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1&nbsp;525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5&nbsp;929</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9&nbsp;932</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(+) Increase in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(-) Decrease in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2&nbsp;203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1&nbsp;376</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5&nbsp;787</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9&nbsp;366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>142</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 15.11. Breakdown of financial liabilities by maturity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maturities of financial liabilities are presented below as of December 31, 2021 and December&nbsp;31, 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(In thousands of euros)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>CURRENT AND <FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> FINANCIAL<BR>LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>LESS&nbsp;THAN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>FROM&nbsp;1&nbsp;TO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>LONGER&nbsp;THAN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>GROSS&nbsp;AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>5&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>5&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oc&eacute;ane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances BPI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,585</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,237</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,003</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Of which current portion</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>11,345</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Of which <FONT STYLE="white-space:nowrap">non-current</FONT> portion</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>50,240</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(In thousands of euros)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>CURRENT AND <FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> FINANCIAL<BR>LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>LESS&nbsp;THAN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>FROM&nbsp;1&nbsp;TO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>LONGER&nbsp;THAN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>GROSS&nbsp;AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2 bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances BPI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,797</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,224</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,150</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Of which current portion</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>14,224</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Of which <FONT STYLE="white-space:nowrap">non-current</FONT> portion</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>35,573</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 16. Retirement benefit obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Retirement benefit obligations include the liability for the defined benefit plan, measured based on the provisions stipulated under the applicable collective
agreements, i.e. the French pharmaceutical industry&#146;s collective agreement. This commitment only applies to employees subject to French law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
main actuarial assumptions used to measure the retirement benefit obligations are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>AS OF DECEMBER&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>ACTUARIAL ASSUMPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2022</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Retirement age</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">65&nbsp;years for key management / 63 years for other employees</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Collective agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">Pharmaceutical industry</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Discount Rate (IBoxx Corporates AA)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.90%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.65%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Mortality rate table</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">INSEE 2016-2018</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Salary increase rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">3% for key management / 2.55% for other employees</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Turnover rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Decreasing&nbsp;from&nbsp;5,80%&nbsp;at&nbsp;20&nbsp;years-old&nbsp;to&nbsp;0,05%&nbsp;from&nbsp;55&nbsp;
years-old</FONT></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Employee contribution rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center">45%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in the projected benefit obligation for the periods presented were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RETIREMENT&nbsp;BENEFIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OBLIGATIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>745</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>693</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Actuarial gains and losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 17. Payables and other current liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 17.1. Trade payables and other current liabilities </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>TRADE PAYABLES AND OTHER CURRENT LIABILITIES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued invoices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Trade payables and other current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,558</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,475</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No discount was applied to payables and related accounts maturity does not exceed one year. As a result, fair value
approximates the carrying amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decrease in trade payable and other current liabilities is mainly due to the end of the research collaboration
agreement with the CNRS (French National Centre for Scientific Research) and the University of Montpellier. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 17.2. Tax and employee-related
payables </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax and employee-related payables are presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>TAX AND EMPLOYEE-RELATED PAYABLES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social security and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other tax and related payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tax and employee-relates payables</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,200</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,300</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 18. Operating income </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>OPERATING INCOME</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credit (&#147;CIR&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,962</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating income is composed as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research tax credit (&#147;CIR&#148;) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
carries out research and development projects. As such, it has benefited from a research tax credit for the years ended December 31, 2021 and 2022 for an amount of &#128;4.2&nbsp;million and &#128;4.5&nbsp;million, respectively (see Note 4.9). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Subsidies: </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidy income primarily relates to
Bpifrance agreement to finance the <FONT STYLE="white-space:nowrap">&#147;COVID-19&#148;</FONT> project. This financing was granted under the French Future Investments Project. This study was conducted with the participation of the University
Hospital of Nice, which directly manages part of the financing of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2021, the Company recognized as a subsidy: (i) &#128;4,459&nbsp;thousand
corresponding to the conditional advance received in June 2020 (discounted amount) which had been waived by Bpifrance in April 2021 (See Note 15.5, &#147;Conditional advances&#148;), and (ii)&nbsp;an additional payment of &#128;3,279 thousand
received in October 2021 to reimburse additional expenses incurred until the termination date. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 19. Operating expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 19.1. Research and development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expenses break down as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PERIOD&nbsp;ENDED&nbsp;DECEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>RESEARCH AND DEVELOPMENT EXPENSES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sub-contracting,</FONT> studies and research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of the following items: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel expenses, including salaries, benefits, and share-based compensation expenses, for employees engaged in
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">sub-contracting,</FONT> collaboration and consultant expenses that primarily
include the cost of third-party contractors such as CROs who conduct our <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials, and research related to our proprietary platforms, as well as investigative sites and
consultants that conduct our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with contract manufacturing organizations (&#147;CMOs&#148;), including
manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to regulatory affairs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocated expenses for facility costs, including rent, utilities and maintenance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to the implementation of our quality assurance system. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2022, research and development expenses were &#128;48,295&nbsp;thousand, as compared to &#128;47,781&nbsp;thousand for the
year ended December 31, 2021. This increase was primarily due to the &#128;20,841&nbsp;thousand increase in UC expenses, following the strong progress of obefazimod in this indication since 2021, as the Company completed the Phase 2b clinical trial
in early 2022 and initiated Phase 3 clinical trial in the first half of 2022. This increase is offset by a decrease by &#128;13,943&nbsp;thousand in transversal activities, as the Company completed existing studies, a decrease by
&#128;2,021&nbsp;thousand in Crohn&#146;s Disease research expenses and a decrease by &#128;2,834&nbsp;thousand in Rheumatoid Arthritis expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 19.2. General and administrative </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses break down as follows; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(amounts in thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>PERIOD&nbsp;ENDED&nbsp;DECEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>GENERAL AND ADMINISTRATIVE EXPENSES</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>General and administrative expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,492</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits and
share-based compensation expenses, for personnel other than employees engaged in research and development activities. General and administrative expenses also include fees for professional services, mainly related to audit and legal services,
consulting costs, communications and travel costs, allocated expenses for facility costs, including rent, utilities and maintenance, directors&#146; attendance fees, and insurance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, general and administrative expenses were &#128;7,492&nbsp;thousand, as compared to &#128;5,580&nbsp;thousand for
the year ended December&nbsp;31, 2021. This increase was primarily driven by other general expenses, as well as an increase in consulting and professional fees. The &#128;2,233&nbsp;thousand increase in other general and administrative expenses in
2022 was primarily related to financial and legal consulting fees. These increases are partially offset by a decrease in personnel costs, mainly due to a reversal of share-based compensation expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Principal audit fees and services: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory Auditor, certification of individual financial statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other procedures required by law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>166</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>840</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 20. Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s average workforce during the years ended December 31, 2021 and 2022 was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>HEADCOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Key management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 21. Financial gain or loss </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>(In thousands of euros)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>FINANCIAL GAIN OR LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on Kreos 1 &amp; 2 straight bond loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on convertible loan notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,064</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,022</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease/(increase) in derivatives fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease/(increase) in other liabilities at fair value through profit and loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,509</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,118</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial gain (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,052</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended the year ended December 31, 2021, the fair values of the Kreos A BSA, the Kreos B BSA and the convertible
option related to the OCEANE bond decreased by &#128;639&nbsp;thousand, &#128;427&nbsp;thousand and &#128;1,231&nbsp;thousand, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year
ended the year ended December 31, 2022, the fair values of the Kreos A BSA, the Kreos B BSA and the convertible option related to the OCEANE bond decreased by &#128;2,203&nbsp;thousand, &#128;1,376&nbsp;thousand and &#128;5,787&nbsp;thousand,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 22. Income tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax
rate applicable to the Company is the French corporate income tax rate, i.e. 26.5% and 25% for the years ended December 31, 2021 and 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reconciliation between theoretical and effective tax rate </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros, except percentage)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory French tax rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nominal income tax using statutory French tax rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,250</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,185</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CIR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs related to capital increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease / (increase) in derivatives fair value and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-recognition</FONT> of deferred tax assets related to tax
losses and temporary differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effective income tax (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deferred taxes balances by nature </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>DEFERRED TAX ASSETS BY NATURE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax losses carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,743</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>77,558</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kreos 1 &amp; 2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oceane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>680</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,063</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,130</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total deferred taxes, net recognized in the statement of financial position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company incurred tax losses in the years ended December 31, 2021 and 2022. As the recoverability of these tax losses
is not considered probable in subsequent periods due to the uncertainties inherent in the Company&#146;s business, the Company has not recognized deferred tax assets beyond deferred tax liabilities arising within the same taxable entity under the
same taxable regime and with consistent timing of reversal, after considering, if applicable, limitations in the use of deductible tax losses carried forward from prior periods applicable under tax law in France. The amount of accumulated tax loss
carry forwards is related to the Company and amounts to &#128;232,167&nbsp;thousand and &#128;308,829&nbsp;thousand as of December 31, 2021 and 2022, respectively, and do not have any expiration date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 23. Income (loss) per share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic losses per share
is calculated by dividing income (loss) attributable to equity holders of the Company by the weighted-average number of outstanding ordinary shares for the year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diluted losses per share are calculated by adjusting the weighted average number of ordinary outstanding shares to assume conversion of all dilutive potential
ordinary shares. All existing instruments giving deferred rights to capital (e.g., BCEs or BSAs) have an antidilutive effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros, except share data)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>BASIC AND DILUTED LOSS PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of outstanding shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,455,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,092,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted loss per share (&#128;/share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2.75</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3.18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Potentially dilutive instruments (BCEs, BSAs, AGAs, Equity lines, BSA Kreos 1, OCEANE) have been excluded from the computation
of diluted weighted-average shares outstanding, because such instruments had an antidilutive impact due to the losses reported. As of December 31, 2021 and 2022, the number potentially dilutive instruments were 1,873,216 and 1,707,037 respectively,
giving rights to a maximum number of shares to be issued of 2,186,551 and 1,707,037 respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 24. Related parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate compensation of the members of the Company&#146;s Board of Directors and to the Chief Executive Officer includes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>FOR&nbsp;THE&nbsp;YEAR&nbsp;ENDED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(In thousands of euros) </I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>COMPENSATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed compensation owed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable compensation owed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contributions <FONT STYLE="white-space:nowrap">in-kind</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost related to post-employment defined-benefit plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attendance fees&#151;board of directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>738</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021 and 2022, the liability related to post-employment defined benefit obligations (corresponding to
the legal retirement benefits obligations) for members of the Company&#146;s Board of Directors and Chief Executive Officer amounts to respectively &#128;141&nbsp;thousand and &#128;149&nbsp;thousand. No other post-employment benefits are granted.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other arrangements with our Directors and Executive Officers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into an intellectual property assignment agreement with CEO Hartmut Ehrlich on July 7, 2021. The purpose of this agreement is to transfer
to the Company all the intellectual property rights held by Hartmut Ehrlich on certain patents of which he is a <FONT STYLE="white-space:nowrap">co-inventor.</FONT> No compensation has been paid in respect of this transfer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 25. <FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet commitments given </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.1. Commitments under collaboration, research, service provision and licensing agreements granted by the Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration, research and development, and licensing agreements, and licensing options related to the &#147;Modulation of RNA biogenesis&#148; platform.
</I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Exclusive licensing agreement with the CNRS, the University of Montpellier and the Institut Curie</I></B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December 4, 2008, the French National Centre for Scientific Research (CNRS), the University of Montpellier and the
Institut Curie granted the Company four exclusive licenses. These licenses cover the use of their technology and products by the Company in the field of human and veterinary health relating to the use of synthetic products modifying mRNA splicing,
for research, diagnosis, prevention and treatment of any possible indication. The licensing agreement includes low single-digit royalties based on future net sales to be paid by the Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Framework agreement for research collaboration to create a cooperative laboratory (ended
December</I></B><B><I></I></B><B><I>&nbsp;31, 2021)</I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December 11, 2008, the Company, the CNRS (French National
Centre for Scientific Research) and the University of Montpellier entered into a research collaboration agreement for a duration of two years in order to conduct a common research program in the fields of screening and development of <FONT
STYLE="white-space:nowrap">anti-HIV</FONT> and antiviral compounds, anti-cancer and anti-metastasis compounds and compounds targeting certain genetic diseases. The term and content of research programs have been changed by successive amendments in
force until December 31, 2021. Each party retains ownership of its previously acquired intellectual property rights. The parties are <FONT STYLE="white-space:nowrap">co-owners</FONT> of the research results. Since
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
this agreement ended on December 31, 2021, a hosting agreement was signed with CNRS in 2022, and renewed up until December&nbsp;31, 2023, so that the Company can continue its research program at
the CNRS center for the year 2023. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Collaboration agreement with the CNRS, the University of Montpellier, the Company and Evotec</I></B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In support of the development of the cooperative laboratory, the CNRS, the University of Montpellier, the Company and
Evotec International GmbH have entered into a collaboration agreement on the development of the &#147;Modulation of RNA biogenesis&#148; platform, effective October 19, 2018. The molecules generated in the framework of this collaboration are the
property of the Company, the University of Montpellier and the CNRS under the same terms and conditions as the research collaboration agreement on the creation of the cooperative laboratory. The agreement ended on December 31, 2021. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Research collaboration contract with the CNRS, the University of Montpellier and the Institut Curie</I></B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Concomitantly with the research collaboration framework contract relating to the creation of a cooperative laboratory
the parties have signed a financial agreement defining the financial terms for the exploitation of patents. This contract was signed on 15&nbsp;April 2009 for a duration of one year and was subsequently renewed up until March 31, 2022, In December
2022, Abivax and the Institut Curie concluded a new contract for a duration of one year, renewable by amendment, granting Abivax access to some of the Institute&#146;s equipment and consumables. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Research and development contract with license option with the CNRS, the University of Montpellier and
Theradiag</I></B> </P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The CNRS, the University of Montpellier, the Company and Theradiag have set up a collaborative
project called CARENA, which has been in operation since February 8, 2013. Its purpose is to conduct joint research and development programs in the fields of obesity, HIV and <FONT STYLE="white-space:nowrap">HTLV-1,</FONT> in connection with the
funding obtained through the Bpifrance CARENA project. On February 18, 2015, Bpifrance accepted the reorganization of the &#147;CARENA&#148; project proposed by the Company, following the abandonment of the obesity project. At this time, Theradiag
is no longer involved in the collaborative project. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Under the terms of the collaborative project, the Company will have the exclusive
and global exploitation rights to the proprietary results of the CNRS and to those of the University of Montpellier as well as a share of the common results of which the CNRS and the University of Montpellier are
<FONT STYLE="white-space:nowrap">co-owners.</FONT> Furthermore, Theradiag granted the Company an exclusive and global license option for exploitation of its own results as well as a share of the common results of which it will be a <FONT
STYLE="white-space:nowrap">co-owner.</FONT> This option may be exercised by the Company throughout the duration of the contract and within a period of two years after its expiration or cancellation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive licensing contract with &#147;The Scripps Research Institute, University of Chicago and Brigham Young University&#148; with the &#147;Immune
Stimulation&#148; platform (ABX196 product) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On 11&nbsp;November 2006, The Scripps Research Institute (La Jolla, California, USA), in agreement with
the University of Chicago (Chicago, Illinois, USA) and Brigham Young University (Provo, Utah, USA), granted the Company an exclusive license in the field of human and veterinary health on its technology and products relating to the use of iNKT
agonists for research, diagnosis, prevention and treatment of all possible indications. In consideration for the licensing rights granted to it under the agreement, the Company must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay The Scripps Research Institute milestones at different stages of clinical and regulatory development of the
first product (the milestones amount to $50&nbsp;thousand at IND filing, paid in September 2019 and capitalized, $300&nbsp;thousand at Phase 3 and $500&nbsp;thousand at IND approval) and low single-digit royalties for vaccines, diagnostic tests and
therapeutic products, according to the amount of net sales, and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">give The Scripps Research Institute, University of Chicago and Brigham Young University an equitable interest in
the Company (as of the date of these financial statements, these three academic institutions hold 0.41% of the Company&#146;s undiluted capital). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contract shall be terminated at the expiry of the last licensed patent in force in the last country and/or ten years after the last marketing of the
product, service or process derived from the <FONT STYLE="white-space:nowrap">know-how</FONT> or the licensed equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.2. Commitments
under BPI conditional advances </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance CARENA contract </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the development of therapeutic and diagnostic solutions targeting alternative splicing and RNA interference in the fields of virology <FONT
STYLE="white-space:nowrap">(HIV-AIDS,</FONT> <FONT STYLE="white-space:nowrap">HTLV-1)</FONT> and metabolism (obesity), SPLICOS (absorbed by the Company on 31&nbsp;October 2014) has entered into a Master Support Agreement with Bpifrance as well as a
conditional advance contract in the name of the &#147;CARENA&#148; Strategic Industrial Innovation Project dated December 16, 2013. The Company, acting as project leader for the CARENA project, is associated as part of a consortium contract with
Theradiag, a company specializing in in vitro diagnostics and the development of theranostic tests for monitoring biotherapies, as well as at the CNRS and the University of Montpellier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CARENA project aims to develop the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HIV-AIDS</FONT></FONT> therapeutic program with
the compound ABX464 up to the Phase 2b study, as well as a companion test set up by Theradiag simultaneously with the clinical development. Beyond the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HIV-AIDS</FONT></FONT>
program, the CARENA project should extend its pharmacological investigations to another retrovirus that could be combated by the same approach: <FONT STYLE="white-space:nowrap">HTLV-1.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is committed to reimbursing the received conditional advances up to &#128;3,840&nbsp;thousand. The Company will also have to pay an annuity of 50%
of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale of the prototypes, preproduction and models produced under the project; The sum due to BPI under this provision will be deducted from
the repayment of the conditional advances. In addition, if the advance is repaid under the conditions outlined above, the Company will pay to Bpifrance, over a period of five consecutive years after the date on which the repayment schedule ends and
provided that the Company has reached cumulative <FONT STYLE="white-space:nowrap">pre-tax</FONT> revenue greater than or equal to &#128;50&nbsp;million, an amount equal to 1.20% of the annual revenue generated from the sale of the products developed
as part of the project. This supplementary payment amount is capped at &#128;6,800&nbsp;thousand. The total period, including fixed payments and incentive payments, is limited to 15 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> contract </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In pursuit of the CARENA project, focused on the clinical development of a drug molecule and demonstrating the validity of an innovative therapeutic approach
targeting viral RNPs, the Company has entered into a Master Support Agreement with Bpifrance as well as a beneficiary agreement with conditional advance for the <FONT STYLE="white-space:nowrap">&#147;RNP-VIR&#148;</FONT> structuring research and
development project for competitiveness dated December 16, 2016. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> project will further the
discovery of new molecules aimed at the treatment of multiple infectious diseases by the development of the antiviral technology platform. The Company, acting as project leader of the <FONT STYLE="white-space:nowrap">RNP-VIR</FONT> project, is
associated in a consortium contract with the CNRS and the University of Montpellier. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is committed to reimburse the received conditional
advances up to &#128;6,576&nbsp;thousand. If applicable, the Company will also have to pay an annuity of 50% of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale of the prototypes,
preproduction and models produced under the project. The sum due to Bpifrance under this provision will be deducted from the last payment (and if needed from the previous payments). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the advance is repaid under the conditions outlined above, the Company will pay to Bpifrance, over a
period of five consecutive years following the date on which the repayment schedule ends and provided that the company has reached cumulative <FONT STYLE="white-space:nowrap">pre-tax</FONT> revenue greater than or equal to &#128;25&nbsp;million, an
amount equal to 3% of the annual revenue generated from the sale of products developed as part of the project. The supplementary payments amount is capped at &#128;5,500&nbsp;thousand. The total period, including fixed payments and incentive
payments, is limited to 15 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bpifrance Ebola </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bpifrance and Occitanie Region joint support agreement granted on June 2, 2017 consists of conditional advances to the Company for a total amount of up to
&#128;390&nbsp;thousand, based on the success of the program (respectively &#128;130&nbsp;thousand from the Languedoc Roussillon Midi Pyr&eacute;n&eacute;es Region and &#128;260&nbsp;thousand from Bpifrance). In September 2019, the Company decided
to terminate this program, due to the existence of a vaccine in the process of being licensed for this indication as well as changes in the macroeconomic climate for public funding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reimbursement of the conditional advance is spread until June 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.3. Pledge assets to Kreos </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the
KREOS 1 &amp; 2 bonds, Kreos benefits from first-rate collateral on the Company&#146;s principal tangible and intangible assets, including its commercial fund, intellectual property rights in its principal drug candidates, as well as a pledge of the
Company&#146;s bank accounts and claims. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.4. Other commitments related to research and partnership arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company regularly uses the services of subcontractors and enters into research and partnership arrangements with
various contract research organizations, or CROs, and with public- sector partners or subcontractors, who conduct clinical trials and studies in relation to the drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December 31, 2022, the Company&#146;s commitments amounted to &#128;194,731&nbsp;thousand. The cost of services performed by CROs is recognized as an
operating expense as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.5. Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease for the Company&#146;s corporate headquarters in Paris, France at 5 Rue de la Baume, 75008 Paris ended in August 2022. A new lease for premises at <FONT
STYLE="white-space:nowrap">7-11</FONT> Boulevard Haussmann, 75009 Paris started in July 2022. It has a three-year duration, with a tacit renewal option for approximately two years and the possibility to break the contract one year before the end.
Per Management, renewal and termination options are not reasonably certain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 25.6. Commitments related to Prosynergia acquisition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into a share purchase acquisition on November 15, 2021 for the acquisition of all the shares of Prosynergia (Note 3.3). The acquisition was
completed on April 1, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition price included an early payment of &#128;325&nbsp;thousand made on November 25, 2021, an additional payment
of &#128;2,925&nbsp;thousand made on April 1, 2022, and possible <FONT STYLE="white-space:nowrap">earn-out</FONT> payments for a maximum additional amount of &#128;4,000&nbsp;thousand based on the potential evolution of the Company&#146;s market
capitalization, a listing of the Company&#146;s shares on Nasdaq or a M&amp;A transaction incurred before March 31, 2023. The accounting treatment related to the possible <FONT STYLE="white-space:nowrap">earn-out</FONT> payment is set forth in Note
4.15. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 26. <FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet commitments received and contingent
assets </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum amounts receivable by the Company after December 31, 2022 under the
<FONT STYLE="white-space:nowrap">&#147;RNP-VIR&#148;</FONT> and &#147;CARENA&#148; and innovation agreements entered into with Bpifrance, subject to the provision of evidence to support the forecast expenses and the achievement of scientific
milestones, are &#128;3,255&nbsp;thousand and &#128;1,853&nbsp;thousand, respectively. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kepler Cheuvreux&#146;s commitments under Equity line
agreements: see Note 13.2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note 27. Management and assessment of financial risks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal financial instruments held by the Company are cash and cash equivalents. The purpose of holding these instruments is to finance the ongoing
business activities of the Company. It is not the Company&#146;s policy to invest in financial instruments for speculative purposes. The Company does not use derivative financial instruments for hedging purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal risks to which the Company is exposed to are liquidity risk, interest rate risk, foreign currency exchange risk, credit risk and fair value
risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidity risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liquidity risk management aims
to ensure that the Company disposes of sufficient liquidity and financial resources to be able to meet present and future obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
prepares short-term cash forecasts and annual operating cash flow forecasts as part of its budget procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prudent liquidity risk management involves
maintaining sufficient liquidity, having access to financial resources through appropriate credit facilities and being able to unwind market positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s operations have consumed substantial amounts of cash since inception. Developing pharmaceutical drug candidates, including conducting
clinical trials, is expensive, lengthy and risky, and the Company expects its research and development expenses to increase substantially in connection with its ongoing activities. Accordingly, the Company will continue to require substantial
additional capital to continue its clinical development activities and potentially engage in commercialization activities. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of issuance
of these financial statements, the Company expects it will be able to fund its forecasted operating cash flow requirements throughout the second quarter of 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects it will be able to extend its financing horizon beyond the second quarter of 2024 through additional dilutive and non-dilutive financing,
which could include a combination of capital increase, venture loans and convertible bonds. Based on the above and the actions the Company has taken, management has concluded that the substantial doubt about its ability to continue as a going
concern has been alleviated beyond 12 months from issuance of these financial statements, and these financial statements have been prepared on a going concern basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest rate risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is exposed to market
risks in connection with its medium and long-term borrowings subject to variable interest rates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to a significant increase in market interest rates over the year ended December&nbsp;31, 2022, the Group
has performed a reassessment of its exposure to interest rate risk. As of December&nbsp;31, 2022, all the Group&#146;s financial liabilities accounted for at amortized cost bear fixed interest rates, except for KREOS 1 bonds, which interest rate is
based on <FONT STYLE="white-space:nowrap">3-month</FONT> Euribor plus an 8% margin. The <FONT STYLE="white-space:nowrap">3-month</FONT> Euribor being capped at 1% as per contractual terms, the A tranche being repaid in full in December 2022 and the
terms of the B tranche loan being November 2023, the Group has limited exposure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign currency risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is exposed to a risk of exchange rates fluctuations on commercial transactions performed in currencies different from the functional currency of
the Company entity recording the transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this stage, the Company has not adopted any other recurring mechanism of hedging to protect its
activity against currency fluctuations. From time to time, the Company may nevertheless subscribe currency term accounts in order to cover a commitment in currency as described above. The Company may consider in the future using a suitable policy to
hedge exchange risks in a more significant manner if needed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Credit risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The credit risk related to the Company&#146;s cash and cash equivalents is not significant in light of the quality of the
<FONT STYLE="white-space:nowrap">co-contracting</FONT> financial institutions. As of December&nbsp;31, 2022, substantially all of the Company&#146;s cash and cash equivalents were maintained with one financial institution in France. While the
Company&#146;s deposit accounts are insured up to the legal limit, the maintained balances may, at times, exceed this insured limit. As of December&nbsp;31, 2022 the Company maintained &#128;26,844&nbsp;thousand in bank deposit accounts that are in
excess of the legally insured limit in one legally insured financial institution. The Company has not experienced any losses in such accounts and does not believe that it is exposed to any significant credit risk related to these instruments. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The credit risk related to the Company&#146;s other receivables and related account is minimal. In particular, the credit risk related to advances made
to CROs (see Note 9) is deemed insignificant due to their credit ratings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>ABIVAX SA </B></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>(Including Ordinary Shares in the Form of American Depositary&nbsp;Shares) </B></P>
<P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g609070g03a03.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" NOWRAP><B>Morgan Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Leerink Partners</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top" NOWRAP><B>LifeSci Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Bryan, Garnier &amp; Co</B></TD></TR>
</TABLE>  <P STYLE="margin-top:85pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (the
25th&nbsp;day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in the global offering, may be required to deliver a prospectus. This is in addition to the dealers&#146;
obligations to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;6: INDEMNIFICATION OF DIRECTORS AND OFFICERS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under French law, provisions of <FONT STYLE="white-space:nowrap">by-laws</FONT> that limit the liability of directors are prohibited. However,
French law allows <I>soci&eacute;t&eacute;s anonyme </I>to contract for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, provided that they acted in good
faith and within their capacities as directors or officers of Abivax SA. Criminal liability cannot be indemnified under French law, whether directly by Abivax SA or through liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain liability insurance for our directors and officers, including insurance against liability under the Securities Act and we intend
to enter into agreements with our directors and executive officers to provide contractual indemnification. With certain exceptions and subject to limitations on indemnification under French law, these agreements will provide for indemnification for
damages and expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding arising out of his or her actions in that capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These agreements may discourage shareholders from bringing a lawsuit against our directors and executive officers for breach of their
fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and executive officers, even though such an action, if successful, might otherwise benefit us and our shareholders.
Furthermore, a shareholder&#146;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these insurance agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers or
partnerships, be insured and/or indemnified against certain liabilities in their capacity as members of our Board. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any
underwriting agreement we enter into in connection with the sale of ordinary shares (including in the form of ADSs) being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and
persons who control us within the meaning of the Securities Act against certain liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;7: RECENT SALES OF UNREGISTERED SECURITIES.
</B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding share capital issued and options and warrants granted by us since January&nbsp;1, 2020.
None of the below described transactions involving any underwriters, underwriting commissions, or any public offering in the United States. Some of the transactions described below involved directors, officers and 5% shareholders and are more fully
described under the section of the prospectus titled &#147;Certain Relationships and Related Person Transactions.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Shares
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the shares issued since January&nbsp;1, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<BR>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>shares<BR>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<BR>number of<BR>shares after<BR>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<BR>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<BR>capital after<BR>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<BR>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">07/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,019.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,203,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,032.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">11/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,032.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,219,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,196.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">16/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,196.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,222,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<BR>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>shares<BR>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<BR>number of<BR>shares after<BR>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<BR>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<BR>capital after<BR>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<BR>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">17/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,222,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">22/01/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,226.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,224,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,240.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">11/02/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,240.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,225,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,256.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">17/03/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-7</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,256.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,228,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,282.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">29/07/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-7</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,282.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,230,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,308.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">30/10/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Conversion of convertible bonds</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,308.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,995,356.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,695,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,951.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,951.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,983,789.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,620,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,315,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,155.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">09/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,155.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,386.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,315,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,159.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">30/11/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,159.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,316,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,166.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/12/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,166.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,623.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,318,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,183.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">08/12/2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,183.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,320,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,202.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">04/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise&nbsp;of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,202.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,321,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,212.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,212.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,322,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,220.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,220.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,324,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,240.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">05/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,240.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,325,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,253.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">07/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,253.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,327,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,273.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">08/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,273.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,343,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">11/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,343,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">12/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,437.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,344,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,447.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">22/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,447.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,346,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,462.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">28/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,462.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,347,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,472.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">28/01/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,472.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523,343.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,394,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,942.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">01/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,942.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,397,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,972.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,972.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,002.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">09/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,000.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,404,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,042.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">22/02/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,032.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,406,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,062.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,062.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,408,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,085.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<BR>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>shares<BR>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<BR>number of<BR>shares after<BR>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<BR>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<BR>capital after<BR>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<BR>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,085.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,810.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,411,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,113.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">03/03/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,113.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,895.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,411,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,117.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">25/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,117.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,531,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,317.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">26/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,317.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,249,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,581,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,817.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">31/05/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,817.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">519,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,601,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,601,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">03/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,017.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">573,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,623,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,237.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">15/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,237.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,626,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,262.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">24/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,262.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,646,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,462.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">25/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,462.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,651,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,512.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">29/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,512.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,661,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,612.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">30/06/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,612.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,671,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,712.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">01/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,712.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,673,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,732.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">02/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,732.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">539,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,693,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,932.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">05/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of Kepler BSAs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,932.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">944,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,728,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,282.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">22/07/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issuance of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,282.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,981,506.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.692.268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,922.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">06/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,922.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,731.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,693,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,933.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">09/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,933.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,327.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,696,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,963.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">09/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,963.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,696,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,967.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">10/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,967.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,292.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,706,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,067.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">20/09/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,067.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,282.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,709,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,097.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">18/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,097.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,710,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,107.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">20/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2016-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,107.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,245.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,713,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,137.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">20/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,137.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,005.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,717,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,171.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">25/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-1</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,171.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,718,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,181.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">25/10/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2017-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,181.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,719,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,191.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">30/11/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,191.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,740,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,401.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">operation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Prior Share<BR>Capital (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Premium (&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>shares<BR>created</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<BR>number of<BR>shares after<BR>issuance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nominal<BR>value&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Share<BR>capital after<BR>transaction&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;price<BR>per&nbsp;share&nbsp;(&#128;)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">21/12/2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,401.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,048.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,764,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,640.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">08/03/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2018-5</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,640.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,444.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,764,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167.643,85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">30/05/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167.643,85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,783,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,831.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">07/09/2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,831.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,175,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,530,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,313,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,131.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">20/01/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-4</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,131.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,331,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">27/02/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Capital increase through issue of new shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,331,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">10/05/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2014-3</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,315.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,347,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,479.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">24/05/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-KREOS-A</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,479.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488,786.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67.887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,415,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,158.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">24/05/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BSA-2018-KREOS-b</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,158.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,830.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,447,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">19/06/2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exercise of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BCE-2014-2</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,547,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425,475.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>    <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transactions described above
were exempt from registration either: (a)&nbsp;under Section&nbsp;4(a)(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did not involve any public offering within the meaning of
Section&nbsp;4(a)(2); (b) in reliance on Rule 144A promulgated under the Securities Act in that offers, sales and issuances were made only to &#147;qualified institutional buyers&#148; (as such term is defined in Rule 144A(a)(1); or (c)&nbsp;under
Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances Under Our Equity Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2020, an aggregate of 335,316 ordinary shares were issued upon the exercise of share warrants and founder&#146;s warrants
issued under our equity incentive plans, at exercise prices from &#128;0.01 to &#128;11.14 per share, for aggregate proceeds of &#128;1,617,997.53 (including a premium of &#128;1,614,443.37). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2020, 241,762 share warrants or founder&#146;s warrants issued under our equity incentive plans were cancelled or became
null and void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also issued on September&nbsp;21, 2021, 155,000 free shares allocated to employees. However, such free shares became
void in accordance with the terms of the free share plan. We further issued on July 11, 2023, (i)&nbsp;1,382,796 free shares allocated to Mr. Marc de Garidel and (ii) 100,000 free shares allocated to Dr. Hartmut Ehrlich. The issuance of these shares
is subject to the achievement of specific performance and/or service conditions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales and issuances of the securities
described in the preceding paragraph were exempt from registration either: (a)&nbsp;under Section&nbsp;4(a)(2) of the Securities Act in that the transactions were between an issuer and members of its senior executive management and did not involve
any public offering within the meaning of Section&nbsp;4(a)(2); (b)&nbsp;under Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans and contracts relating to compensation; or (c)&nbsp;under
Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;8. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exhibits to the
registration statement are listed in the Exhibit Index to this registration statement and are incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following exhibits are filed herewith or incorporated herein by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>DESCRIPTION OF
EXHIBIT</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">By-laws</FONT> (<I>statuts</I>) of the registrant (English translation)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Deposit Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of American Depositary Receipt (included in Exhibit 4.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Dechert (Paris) LLP as to the validity of shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;8.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Dechert (Paris) LLP as to certain French tax matters</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Venture Loan Agreement between Abivax SA and Kreos Capital V (UK) Ltd dated July&nbsp;24, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Convertible Bonds Issue Agreement between Abivax SA and Kreos Capital V (UK) Ltd dated July&nbsp;24, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bonds Issue Agreement between Abivax SA and Kreos Capital V (UK) Ltd dated July&nbsp;24, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Warrants Issue Agreement between Abivax SA and Kreos Capital V (Expert Fund) L.P. dated July&nbsp;24, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*<SUP STYLE="font-size:75%; vertical-align:top">(1</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Put Option Agreement between Abivax SA and Kreos Capital V (Expert Fund) L.P. dated July&nbsp;24, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bonds Issue Agreement between Abivax SA and Kreos Capital V (UK) Ltd dated October&nbsp;12, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Subscription Agreement between Abivax SA and Kreos Capital V (UK) Ltd dated October&nbsp;12, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Terms and Conditions of the OCEANE Bonds issued by Abivax SA dated July&nbsp;30, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Terms and Conditions of the Royalty Certificates issued by Abivax SA dated August&nbsp;31, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Share Purchase Agreement between Abivax SA and Mr. Fabrice Harari dated April&nbsp;1, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Master Services Agreement between Abivax SA and IQVIA Ltd dated December&nbsp;17, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to Master Services Agreement between Abivax SA and IQVIA Ltd dated September&nbsp;9, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Drug Discovery Services Agreement between Abivax SA and Evotec International GmbH dated September&nbsp;1, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manufacturing Agreement between Abivax SA and Delpharm Lille S.A.S. dated November&nbsp;24, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Development and Clinical Batch Production Agreement between Abivax SA and Seqens dated March&nbsp;11, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to Development and Clinical Batch Production Agreement between Abivax SA and Seqens dated March&nbsp;2, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">State-guaranteed loan agreement between Abivax SA and Soci&#233;t&#233; General dated June&nbsp;16, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No.1 to State-guaranteed loan between Abivax SA and Soci&#233;t&#233; General dated March&nbsp;15, 2021</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>DESCRIPTION OF
EXHIBIT</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19*<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Royalties Agreement with (i)&nbsp;the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie dated December&nbsp;18, 2008.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">List of subsidiaries of the registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers Audit</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Dechert (Paris) LLP (included in Exhibit&nbsp;5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Power of attorney (included on signature page)</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">*</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by Amendment </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions
have been submitted separately to the Securities and Exchange Commission. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Financial Statement Schedules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All information for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission is either
included in the financial statements or is not required under the related instructions or is inapplicable, and therefore has been omitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;9. UNDERTAKINGS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery
to each purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers
and controlling persons of the registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of
the requirements for filing on Form <FONT STYLE="white-space:nowrap">F-1</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Paris, France, on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Abivax SA</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>By:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the undersigned directors, officers and/or authorized representative in the United States of Abivax SA, hereby severally constitute and
appoint Marc de Garidel and Didier Blondel and each of them singly, our true and lawful attorneys, with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the registration
statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> filed herewith, and any and all <FONT STYLE="white-space:nowrap">pre-effective</FONT> and post-effective amendments to said registration statement, and any registration statement filed
pursuant to Rule 462(b) under the Securities Act, in connection with the registration under the Securities Act, of equity securities of Abivax SA, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to
all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of
Attorney. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons
in the capacities indicated on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>TITLE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and chairman of the Board</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(<I>Principal Executive Officer</I>)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc de Garidel</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer and Board Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(<I>Principal Financial and Accounting Officer</I>)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Didier Blondel</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinna zur Bonsen-Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"><FONT STYLE="font-size:10pt">Director, and member of the Audit Committee and the Appointments and Compensation Committee</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Carol L. Brosgart</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sofinnova Partners, represented by Kinam Hong</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director and member of the Appointments and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Compensation Committee and the Audit Committee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Troy Ignelzi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director and chair of the Audit Committee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">June Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director and chair of the Appointments and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sant&#233; Holdings SRL, represented by Antonino Ligresti</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Truffle Capital, represented by Phillippe Pouletty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director and member of the Appointments and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, Authorized Representative in the United States</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g609070g00a15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00a15.jpg
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M 0$! 0$! ?_  !$( 'H"4 ,!$0 "$0$#$0'_Q  ?  $  00" P$
M    " 0&!PD#!0$""PK_Q  \$  ! P0  P8$! 4"!P$!   % P0&  $"!P@5
M51$35)25TPD2%-07(5?5%A@CEI<B,20S-7-ULK0R4?_$ !X! 0 " @,! 0$
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M2B)1$HB41*(E$2B)1$HB41*(E$2B+YXAW_KAG_RI'_ZUJ^L-+^[4_P#L0_\
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M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7SQ#O_ %PS_P"5(_\
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M118$$=01T(ZA=9^"^XOTGV7_ &)*?VJN;TLNKZS7?_&;.^)75_9]?WU(O?\
MTU;/P2?@ON+])]E_V)*?VJGI9=7UFN_^,V=\2G[/K^^I%[_Z:MGX)/P7W%^D
M^R_[$E/[53TLNKZS7?\ QFSOB4_9]?WU(O?_ $U;/P2?@ON+])]E_P!B2G]J
MIZ675]9KO_C-G?$I^SZ_OJ1>_P#IJV?@D_!?<7Z3[+_L24_M5/2RZOK-=_\
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M#MQ -H2^VP%I[&1@X+#M8ZZSV0^DX80Y7S)["%N@V.+EZK#[/?X>"Y7DY7Y
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MVYG.C!=0OGD1,9 Q;-B'#"+M7E2S'Q]P Z#=2),,<!]8 $D]>A!T&GW>WJL
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M\?>2^"2(H\?PJ1WQ"QXAC&7$8$]1TQU [=/M5Q*6N) !S8D@@="[H<#@3A[
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MZX=CACVQP.&/V[J.W&5K[5TUGG!YM;A_U!*G1I3C^X,"6TIM"=.S=D,3@6M
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>T9ZL3\^Z]VB)SHSU8GY]U[M$3G1GJQ/S[KW:(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g609070g00m61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00m61.jpg
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MW_=_I8_^D)__ /E(KY_&K^#N%_\ 4Y3[V5_0?S\[RZWIPB<(IA4[@[4FSZ&
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MV$I(I4CR*+BU;/U]78:GX[ Y4ZS,RRI8,&'%2L)\[G?TF<?;2GYD&#9@7_\
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M.WLSG';^7LSG\_'SN='3.9P?_P!Z4_,M;$RF<F29.:3:3)#B6)"29)&EQ++
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M*XVV>(#G>CC$\KD8CTV2:'5IJY+[R%J[(MH^O.21+!Z36(DP</E'4AGQ[9)
MN//+#8+TMV,AIN7,9C*5AY648/$!SO1QB>5RQ1,?7ML7$2$NT&PJ5,LZ1ZAY
M"O$TK(42P/TZXI@N,PGD.3:A9TO5NQ)C*4^#+JR-(XC274M+/$!SO1QB>5RE
MO<B)ZU*_NW\.X>(#G>CC$\KD[D1/6I7]V_AW#Q <[T<8GE<IDTWAIMMK&<JP
MVA#>%*[/"5A"<)QE7@X2GMSV=N>Q.,=OY,8Q_=R*KD+JMZ9 W4]&H8^?>9%
MG:XM-?O=3N-<4TB\4Z]578^M;N*/5B8^_B%#<EA:78Z*;CS8LIJ?7[R49<1E
MAM^&0(&@R=(@07?<;5P;_P#DO;^/;KHNI]4%<IU5 ;HZJMM.5D/1;&F.3A]3
M&U]A["72W5L;8@AX0JI@-C3Z4]+C5I4JSLC(\\FEL:_%K8<M7R@W:&1I']Z
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M\6I;:NR2<J+-U(#LIRNT:J7I0B.&)IL(5W9=WI%:L;*Y@9802=?L:),QL6]
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MT0LD,7LJ(X6U,#+F:/:F:O)K1\8!-[ LX.T VR$*^TV34*\6.5-0#9 @@((
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MOV*LW"9L*NG'7'1V<Y)@;^1GWD))1X"@]PFR;(,Q$+NJE\=O>D;L%1WQ3/\
MW*=C4#;:8]P_@],M#G._ZR%7DO28T/NBPLAV#W2WTRF6Z^3#F0N2A=,]T87K
MS1]@ 3AOR1[K[,X%'M5GCAI27/'"X]B-QX*V&2DU#[M[TC=@J.^*9_[E.QJ!
MMM,>^'9E[Q?B#HG?0JP52R"NGK0XN=2B)(Y6V1UOEPX0^PDJAC7B+ F.S#1E
M981KM<S7]>>6XID!2R4^MBH\46XU'9=O>D;L%1WQ3/\ W*=C4#;:8]\.S'WB
MMKP>L_XK-/\ V[)>S\=O>D;L%1WQ3/\ W*=C4#;9X]\.S'WB>#UG_%9I_P"W
M9+V?CM[TC=@J.^*9_P"Y3L:@;;/'OAV8^\3P>L_XK-/_ &[)>S\=O>D;L%1W
MQ3/_ '*=C4#;9X]\.S'WB>#UG_%9I_[=DO9^.WO2-V"H[XIG_N4[&H&VSQ[X
M=F/O$\'K/^*S3_V[)>S\=O>D;L%1WQ3/_<IV-0-MGCWP[,?>*+DZ/U0&B:31
M?1.AB99"1.&B,ZV2Y4MA8"03E@GX[ST5:XTH+*-&) F6QEN4.>*$'(;S*YC^
M7';WI&[!4=\4S_W*=C4#;:8]\.S+U_\ M-:J_/2U?\PUCU=&_2.J"X% 5Q<-
M?FY<90"JB&*[70_B%!\M^;0]<B0JU!B83AEFMP!]?PCS/ APF';WI&[!4=\4
MS_W*O8] VVF/G#TR]XI+%T=O&")LX*!TS=.0\/=*\:J=J'#['(@13M:L1.QF
MC@6>W$BLX='E#-PM9>6QCP4NE+(<(Y[)A2:\\[>](W8*COBF?^Y4[&H&VTQ[
MX=F/O%Z9NBM[&&IB;%TY=/EHDE8B(ILA8;,X2G'58< O29Q=QP>EF42(O5:L
M.E9_B&Y!)5;KZ)BW6@8IN&[>](W8*COBF?\ N4[&H&VSQ[X=F/O%N!NJ>I ,
M3!$PVA=$"%5J98RP>$+MCP\=%L-M:\FL-J5#B0&D2;44A.38$JP2<O$G(98T
MRI_.#!',AV]Z1NP5'?%,_P#<IV-0-MGCWP[,?>*P?!ZS_BLT_P#;LE[/QV]Z
M1NP5'?%,_P#<IV-0-MGCWP[,?>)X/6?\5FG_ +=DO9^.WO2-V"H[XIG_ +E.
MQJ!ML\>^'9C[Q/!ZS_BLT_\ ;LE[/QV]Z1NP5'?%,_\ <IV-0-MGCWP[,?>)
MX/6?\5FG_MV2]GX[>](W8*COBF?^Y3L:@;;/'OAV8^\3P>L_XK-/_;LE[/QV
M]Z1NP5'?%,_]RG8U VV>/?#LQ]XG@]9_Q6:?^W9+V?CM[TC=@J.^*9_[E.QJ
M!ML\>^'9C[Q/!ZS_ (K-/_;LE[/QV]Z1NP5'?%,_]RG8U VV>/?#LQ]XG@]9
M_P 5FG_MV2]GX[>](W8*COBF?^Y3L:@;;/'OAV8^\3P>L_XK-/\ V[)>S\=O
M>D;L%1WQ3/\ W*=C4#;9X]\.S'WB>#UG_%9I_P"W9+V?CM[TC=@J.^*9_P"Y
M3L:@;;/'OAV8^\3P>L_XK-/_ &[)>S\=O>D;L%1WQ3/_ '*=C4#;9X]\.S'W
MB>#UG_%9I_[=DO9^.WO2-V"H[XIG_N4[&H&VSQ[X=F/O$\'K/^*S3_V[)>S\
M=O>D;L%1WQ3/_<IV-0-MICWP[,?>)X/6?\5FG_MV2]GX[>](W8*COBF?^Y3L
M:@;;/'OAV8^\3P>L_P"*S3_V[)>S\=O>D;L%1WQ3/_<IV-0-MGCWP[,?>+#(
MC.L N/GB2FH=+D!A2%*'$8$N[$'XLV!-8<C2XDEE<;*'H\F.ZXR\TO&4N-K4
MA6,XSG'';WI&[!4=\4S_ -RG8U VV>/?#LQ]XHR0UQU)EB+18IT^=/A$FP5A
M'&9\VR.R931<:T):'ST/.PEK3(A8  7(JL9[&) 0/*;PF2,A/,.WO2-V"H[X
MIG_N4[&H&VTQ[X=F/O%B.ZOZF)!,\3EZ.TE-<LEJJ]\+19MUG2H3]YIL *+K
MMP0R]$4IH^-&UBJ1(TM#F$1L58')BLQYT9V4^[>](W8*COBF?^Y3L:@;;3'N
MK_1V8^\6E<T/NAXT0LC_ $M],KY\J-(!R1B062^0FBBJR+A(=(E.CUNN0YBR
MY53\=2O%+R2G9RG_ 'I_PW;WI&[!4=\4S_W*=C4#;:8]\.S+WBD8#7?5#5S$
MHX"TII0=.D5\/56<1;K,CQ1]=!33!2")&Q6(;3,5A96P&"<Y["53",R6C,Z2
M^S &LPW;WI&[!4=\4S_W*=C4#;9X]\.S'WBFG@]9_P 5FG_MV2]GX[>](W8*
MCOBF?^Y3L:@;;/'OAV8^\3P>L_XK-/\ V[)>S\=O>D;L%1WQ3/\ W*=C4#;9
MX]\.S'WB>#UG_%9I_P"W9+V?CM[TC=@J.^*9_P"Y3L:@;;3'OAV8^\3P>L_X
MK-/_ &[)>S\=O>D;L%1WQ3/_ '*=C4#;9X]\.S'WB>#UG_%9I_[=DO9^.WO2
M-V"H[XIG_N4[&H&VSQ[X=F/O%@D175^7BYA%-0:6(0\R(4K,67=9[["I Z9'
M(P7E-.1E(4N+.BQI3.58SX#S+:\?WIQQV]Z1NP5'?%,_]RG8U VV>/?#LQ]X
MM(BC=4#9J#8D:)T0@Z-E'9T LFW34SHDRSM1&+#(8D8C>,;=--0839%>,]LI
M,2/AWPO$M^"[>](W8*COBF?^Y3L:@;;3'OAV8^\6I@ZMZEA\EF2UHW2+N8%T
ML.PPC$FZS7X];N5NA&85L/5UM<3M%3[*BS6MXT_'5AR:_;K2IQ7BSQ%M]V]Z
M1NP5'?%,_P#<IV-0-MICWP[,O>+UM:BZ@&6I[#73?TYML%1,0"4918'$M% <
M,>'$M!R3>(/@3Q;@FNU\3,@2\/12 L"$'3VI,(3 8CNWO2-V"H[XIG_N4[&H
M&VSQ[X=F/O%OPU1ZM016SG(&I-08+W C#)'B#M](KD2EC!4,(*AH5B*A,<<,
M&P6F84%E*&&WWI\]:7"),C+E.WO2-V"H[XIG_N4[&H&VTQ[X=F/O%)/!ZS_B
MLT_]NR7L_';WI&[!4=\4S_W*=C4#;9X]\.S'WB>#UG_%9I_[=DO9^.WO2-V"
MH[XIG_N4[&H&VSQ[X=F/O$\'K/\ BLT_]NR7L_';WI&[!4=\4S_W*=C4#;9X
M]\.S'WB>#UG_ !6:?^W9+V?CM[TC=@J.^*9_[E.QJ!ML\>^'9C[Q/!ZS_BLT
M_P#;LE[/QV]Z1NP5'?%,_P#<IV-0-MGCWP[,?>+!G"NK\FF*@CJ#2TY$*=$)
MQ42KL0>0P0@.X?@S6T.1E)Q)AOX3(BN]GAQY"&WVLH>;;6EV]Z1NP5'?%,_]
MRG8U VVF/?#LQ]XM(.HW5 (*QC@S1.B(!B$*(@XA*+;IC,N,'+ETGR@UAY$7
M"FX9 TALI,81G"'YS;<AS"G&T92[>](W8*COBF?^Y3L:@;;/'OAV8^\44'Z/
MWV/'116.G;I_FPAX>?6AC1&SNS%#*K.9L,-NK0''8'C&*\*%6VS@0(WPE-!*
M]838,;F,,+$(TEV]Z1NP5'?%,_\ <IV-0-MGCWP[,?>+>D]9=1QIF4P8Z>NG
MLJW.-2+'.R2LKTYR<<F!)%7EDYK\F&Z]+E2ZI,EU*4N0X[B149,BK/877WG!
MRG;WI&[!4=\4S_W*=C4#;:8]\.S'WBVE<J75M54&<"=2:@1(L1\C9STYZ^D7
M9Q<V3\2T].G2/)4Y>7'@1!X> C.,-P HL6*BH:A0(S+;M[TC=@J.^*9_[E.Q
MJ!ML\>^'9C[Q2/P>L_XK-/\ V[)>S\=O>D;L%1WQ3/\ W*=C4#;9X]\.S'WB
M>#UG_%9I_P"W9+V?CM[TC=@J.^*9_P"Y3L:@;;/'OAV8^\3P>L_L[/[+-/\
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MQ'BY #ZUUN6WV*8Z0;]K$/I3%ULXC54,L@P5KDBF["M)>60AGX%M ' 5UM$
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M/$>+G54]^1T__"PO]B+M_+_&<U0WM'A#A;&GHZ9O=*OU#,>(\7.JI[\CI_\
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M>D. E/.N"Y\.'.'+6M2H4R+&DQLM/,-+2JB;!>E<!:;EJ51*BN8+(KUA1E$
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M?A'%438+TK@+3<G?6=ZFB?6[WX1Q5$V"]*X"TW)WUG>IHGUN]^$<51-@O2N
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M7K%;_5N4<Z6]+=<#&^:)M?JC*"IKE8TAU%ZW06A6*JG2 Z3MB?T17&IPY30
M+6H-A4$MNI]\^6EL@A4..LB(8!AA5:+1! 4A++B!$%_EE;WZQ96M;4.G3JGU
METAU>@T"M@8/6+5@;=,N'47BWU9K.TIQZ\B2E\V2X9*A;'9CZ;JT'9N=DA7
M;5+6+*+0#K9*8WA^6Z0D%HG47U:Q >JK\=:HNI:_]T5HF]1U4$ER-=F[FL-J
MWW>B8YNGD]98,5^P^YJ5"P)NY=T#.BBI%AI CJ[B *+49(XW9<3<'A,:+D'D
M]5BIR?-U0K/^54/*JLZAHK<N@QVI_=,& VHVE;O8E%R44F_MIRQOT#+%;*N;
M#J,:5$&.5FEPUSP,G2@BRPJ:J$@L6$;/L<FPV.1(B>:W:Z4&36_D^!T/?H+M
M+G@144IFJ_=.:W105:)[ DR6*W3NG:N2&1MHH)"Y'0,:H:/#;W4/O%N&%6T[
M@ W6L;QLU0/'QZZK;ZEL<*'L![!L&&54R$LOJ$7VESG$5.=ZQ;BD^G;K]&[)
M,6^N79R>2</;GACKT8L.NC5G@TC875#T8W$$'K,DY4T]WA3/3QK'=E6-5R"+
M$U]=NQ67&0<A46L'PY'LN(KU6@-?>2.>A27<(7KKK_3;J(K(+ECF^*;TD]38
M(X4JHL?:7D=8Y/5P09T];'F!P "<&)"A9&#L*/)F+K4FO1S=J$+(!TXD--LD
M&2^O1E!__A>\_<-\%!2ML]T=!;9J=9-L;6DMD[7MD\.D4^IZ8LVMQM;MNX]Z
M.:,K.R;!(LE6.+@B:,9TL!V'*H=?OY?6XG6\P^:>7#V$[8B1*H:AK+S4'N];
MS7'14O6(']5KVR[EJ6NQ]]QZIKC;6BA&A3=DH]!$:SC:_P!9=0^M6=AE&[<#
MM<N_BLHZ=8MWI:8][JE2';GJJK*3K1*Q3[5"CRB5:=+P7UE[R'#2 *BXU/Y+
M[9<+2G")PB<(G")PB<(N-]NZ:V38]Z@MH:]FH!H311NJKM,<*^1*-ZMLLZ]3
M[Y$KS,5_+L/9-:-HUK9=?6$I%P-@XCVD/F7&8/$%9*@NU0-GX'6N?=2:IZRM
M?ZXUEK<@RRS3J!JO1VNR=7K1[7RO/-?&:OU56-@1QD\W!?=1? &Q:_LHLDA*
MF#*U8=:6MN)YP+7)T&SKTA(>=[_O/EJK\Q!1P)JCKSH6N -/UR["KDX14P8E
MF3#)ZG6WY6(Z8M):UCI*)F@''2Q %M"O7,G73A:78%2JX.C02\5N)&K,51*G
MA^C7:3&'XZU]$]+P-DC*D0@[2(S2Y]FYW1P42).5YPC)J$RQ3IU31-55XT(1
MA^"&DQAN$-PV)"&H;:97E#^%RY!0[MWW5\U;7")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PBU%@B>< )N!B(F?Y:()1/(5X8RB9Y3#>9\D7B2MN-E,CP
M_$JQ(<0QG"\^-6EOPLX(N!V>G"RR1NL))^LV:2;J72V(T7?FAY?6\E9H00I,
M@.?':JL)9YNST?8D&R/9=(V-L[7*=:ZNO$$[BP$H-6ET\J3I&FM[X_&_1ZRM
MCI_IPV=KO;VO++*G ETNIZY@TB8(A#:V"'*8'"[1'#V*!!IL*N1 5XC*(#@-
MII=>K<32%AB3)U_"B:U=!0P<LC[],7/U/U1_%_?W"B<(G")PB<(G")PBI[J&
MIYK86A-U4.M0F2%DNFJK_5:Y%D2(T-A=A/U8H+!K=F2UML0FV"DJ)(5,4O"H
MF&LR&L*=:0G)4:0^*HG=7347NQ3;]IUB.UYKZ]7S5+=&=N\JHM2K1<D'7I[]
MV!6HY73M7/R(TR%6-6UX$8)'R/=H3!L<(*.CMRH<U@CZG5Z7Z?NY\E)=(ZCM
M--V'+NAD2*#RB6EM9ZWO4B,-K\-%PNFO,S785PK<@(5*''0,B-8CXN5$V)-G
MG1R(->AUY<48T5>+$)?:2-S](Y!SEUEPHG")PB<(G")PB<(J<WG43=UIH(37
MH#9 D-V_H*Y+;<DQ(GB0VOMXZ\O5GDM/S'66_*&ZQ73*8S"%^-FR%MP4]B9*
MU)*BJP\P0N4T=+=XN4'<%:W6-I6U*Y>K^DX'Q=@=0L,X,T=W/L]!>Q5DE)"X
M(C9%4Z:;12J90FSN2AFFV$$4%5R8V!6J>>(]VBJJT[Z]#_W+JS5]0-UBX=0)
M4G ;@C+]N 9<:MEJ1$=\J#,:1TW1YTIUB*ZXJ"^_:J79'51Y"6WGF7&"#B?&
M35I02'E7:5<?"B<(G"+S_AG_ *\?^I7"+QPB<(H!MBOS[;JW9-5%Q6II2RT&
MX !L-]QEEF40,5XB/A1W7I*D1VFW9,AI"W7EI:;2K*W%82G.>%1I#]#P]<8E
MM-;M8LEBL1:LA=N5<E3ZM6F]46?-%(5MVG#-<U$8W3&$V!,-^)9A^YHEMO=G
MF*/IIETU^68KQ!)(^%K*!!-3M$377I]6[1ZU8>F=(3Z7?]6V*%49=.$:\Z<5
MZ4*YL+]-,6&S> YJ:94'\V*K3Y16?(K4.H6 +8(UB6^"'SG(RM?-H@$SI,N2
M_P!6_P#!=E<*)PB<(KIB_P#-H_\ XAG_ -FGA%\&E;%TUJ[0^I]N=26^^J\/
M+V4,W=8)4ZD7:>5"B@.BXEKMEY,3(+D0@;0R%U]5YU@=C0L&2IAZ!+@A($PI
M)'"I'3.AJC2=TA4;XN8WX;I3ICF^$\+'#'SF2P;CY.I"9,?,,.X3P9(_(R4Y
MFD[EF<J;S*2:E,N<2F5*F4:9R&"RPSVOI6Q^F^)&/V'L5\#T<45R^#\&=E?-
MY3"&)DUEIVU\^P-@Z?RHE920G,UDFG2\[E&9/(D&,F2##+64T"VUU_!UKTOD
MY,J# ZY]ARI\$U&K<\<SU0T]1$?9)A,H$BUPB/\ )L3(%@D&@9L,T$F,,E%%
M@Q89B+Y:-F,,\G]P,T\6:<?:$WTM<=]]4Z\,Z'^!I/J"U.*/TT.'ZZ#B]9&Y
MI\6ST$KLH;:H'494Y=-Q51Q?5P:)-D6)IE41&+')W%0G:NZUAZ$;BFHKL:7C
M,T4@@[@9IXLTX^T)OI:=]4Z\,Z'](#OZAI-[R_\ SAN6^5JKIG1(\D7UQ;%1
M+\1%D^2JZHJ<F1Y-.A5 C"D>)S'PYXB8/V%09\5WP?%R(5XJ$IE2V+*%<FNX
M&:>+-./M";Z6G?5.O#.A_@:3Z@MO8]%:&IT>-*MW6-MRK19H"?:X<FQ]1];!
MQY=7%BYALG9(SQ.#%;? #@H^>7GF&E+'1!<&80D26XD9YY#N!FGBS3C[0F^E
MJ=]<Z\,Z'^!I/J"U&-5=,^3*:YCKBV+FPK'3#" ..J*G>>5B1\.PD9Y1(OR?
MRY0Z"/J-KG3)V&,QHT.L6&2\ZA@*27&=P,T\6:<?:$WTM7OJG7AG0_P-)]07
MMQJ3IN5AC*>MS96<2F8,B+G'4]4<XDQREPSKT:^QG$;L>9(WY*J/!=;\)$NX
M)S6HZG#6,PN.X&:>+-./M";Z6G?5.O#.A_@:3Z@M4B@]*;CK+#?7K=7'I "!
M:V&4=5U%6Z_5RKXR,,LC+:496X (R38:/ ,(PH=,?+C&H\EQR?$2Z[@9IXLT
MX^T)OI:G?7.?#.A_@>3Z@L\WJCITK=MB4:P]96Y =IG4EC8\846Z@!0]2Z+,
ML0ZI#K0N5*$-0FA)BRE880))=DHP;(J?CBL2UPY>&'<#-/%FG'VA-]+3OKG7
MAG0_P-)]05FC.D"EFQH\R&ZB.I$N'+P8A,45&;FCSQI,;/CMRH) ?.B@G8LV
M#-BNM28DN,Z['DQW6WF7%MK2K+N!FGBS3C[0F^EIWUSGPSH?X'D^H+.]Y;7?
MCXZG_P!K?]/<=P,T\6:<?:$WTM.^N<^&E#_ \GU!/>6UWX^.I_\ :W_3W'<#
M-/%FG'VA-]+3OKG/AI0_P/)]03WEM=^/CJ?_ &M_T]QW S3Q9IQ]H3?2T[ZY
MSX:4/\#R?4$]Y;7?CXZG_P!K?]/<=P,T\6:<?:$WTM.^N<^&E#_ \GU!/>6U
MWX^.I_\ :W_3W'<#-/%FG'VA-]+3OKG/AI0_P/)]03WEM=^/CJ?_ &M_T]QW
M S3Q9IQ]H3?2T[ZYSX:4/\#R?4$]Y;7?CXZG_P!K?]/<=P,T\6:<?:$WTM.^
MN<^&E#_ \GU!/>6UWX^.I_\ :W_3W'<#-/%FG'VA-]+3OKG/AI0_P/)]03WE
MM=^/CJ?_ &M_T]QW S3Q9IQ]H3?2T[ZYSX:4/\#R?4$]Y;7?CXZG_P!K?]/<
M=P,T\6:<?:$WTM.^N<^&E#_ \GU!/>6UWX^.I_\ :W_3W'<#-/%FG'VA-]+3
MOKG/AI0_P/)]03WEM=^/CJ?_ &M_T]QW S3Q9IQ]H3?2T[ZYSX:4/\#R?4$]
MY;7?CXZG_P!K?]/<=P,T\6:<?:$WTM.^N<^&E#_ \GU!/>6UWX^.I_\ :W_3
MW'<#-/%FG'VA-]+3OKG/AI0_P/)]03WEM=^/CJ?_ &M_T]QW S3Q9IQ]H3?2
MT[ZYSX:4/\#R?4$]Y;7?CXZG_P!K?]/<=P,T\6:<?:$WTM.^N<^&E#_ \GU!
M/>6UWX^.I_\ :W_3W'<#-/%FG'VA-]+3OKG/AI0_P/)]03WEM=^/CJ?_ &M_
MT]QW S3Q9IQ]H3?2T[ZYSX:4/\#R?4$]Y;7?CXZG_P!K?]/<=P,T\6:<?:$W
MTM.^N<^&E#_ \GU!/>6UWX^.I_\ :W_3W'<#-/%FG'VA-]+3OKG/AI0_P/)]
M03WEM=^/CJ?_ &M_T]QW S3Q9IQ]H3?2T[ZYSX:4/\#R?4$]Y;7?CXZG_P!K
M?]/<=P,T\6:<?:$WTM.^N<^&E#_ \GU!/>6UWX^.I_\ :W_3W'<#-/%FG'VA
M-]+3OKG/AI0_P/)]03WEM=^/CJ?_ &M_T]QW S3Q9IQ]H3?2T[ZYSX:4/\#R
M?4$]Y;7?CXZG_P!K?]/<=P,T\6:<?:$WTM.^N<^&E#_ \GU!/>6UWX^.I_\
M:W_3W'<#-/%FG'VA-]+3OKG/AI0_P/)]03WEM=^/CJ?_ &M_T]QW S3Q9IQ]
MH3?2T[ZYSX:4/\#R?4$]Y;7?CXZG_P!K?]/<=P,T\6:<?:$WTM.^N<^&E#_
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M^9;^[P\Q-I1P@+ GDD3T:/\ ,M_=X>8FTHX0%@3R2)Z-'^9;^[P\Q-I1P@+
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M.,XSC.,XSG&<=G"*&@Q="K$D7,K6K*-7I8, .J824#$!A,D/5A")38FM"WX
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MR[0<EW8[%,7:.,L, J\UUZ=*TVP.FO4.T<;G&7$W;L =R6>#>YSM5LMVI=C
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M/]EX1.\X/TQ?T*?[+PBUY<T+)"B0Z)8"(*5/@3(<8T+&LODA#\F.XRT3'L'
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MD/CY\H1F0X\^X"(2X;T\"^^ZX](#28+[BU+<4K):35\7JT.$3A%=,7_FT?\
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M^,@1/*Y,LP'.].\L[]%$^;>_C\9 B>5R99@.=Z=Y9WZ*)\V]_'XR!$\KDRS
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MXYR+!AL.+6W%82AD")Y7)EF YWK.389:<]J8T%.>U>>U++N,]KJL+<SVX?\
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-N_OSSQ+R"L Q 7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g609070g00m62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00m62.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ,X"70,!$0 "$0$#$0'_Q  ?  $
M 00# 0$!            !P4&" D#! H" 0O_Q !7$  !! ("  $%"P<'" 8*
M P$% @,$!@$'  @)$1(4&5<3%1<:6%F6F-76UQ88(9.5T]0B.#EXE[:W"B,Q
M-D%V=[4D,C="474E4U5Q@9&9L]'8)D-'4O_$ !T! 0 !!0$! 0
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MMN2/UXUS>-MZ.#6HX.ZTT[L#LRV0KG*I16SU0YVIL?6B.8INO&=?%QKYBQ!
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M]SK-\!+J$@(R%=NC:2P;-"'T8K7?TQ@I2%&5EO/0RL8W6=!E6Z>*'-B'^#W
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M(4VC=1C<K;>TB8DR4,Y-%#H[]*C%19CE1R:Q6Z24"L]2?$ C@*/9GG+>.W<
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M;US/I-GA-LX-4H+!!-1;G32#P*WT:52"EH%A]D/VU$KC,1#L26FP/MJQPW%
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M4[%5S<IJ?)''9A@4ZJ!G$TI;K::UGOF"Y0"7.1=A$/*F:Z++F,&.9J-4 0'
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MQI!6::._MV9N3>_V414SXM+>3?VU/G;7Q'AW5G<LO5[^J2=R&5+777[:&P+
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MHI#UT/!^'KN.V?!&'PRKU)P%=I:PK>69/C0[W!Q2.WQYD^VMERKB8A+0<+5
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MS8K] HG[45%VL(-Z9M*$K51XBL5S",<CFJJ+7Z+6*^VK$EJAWJRRQS;=.&A
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M^JZ=V([9=>=&;<C%[-J)_4FY]DDJ%'LEAKP,W<:M8=9B:\6-)K9,1,)*$0[
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M9F[[2V-JTAL&6+.1M>5*0#86$B1HLAIF=96;&!L#$6R%F)+'I8\?'@R1\.%
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M5?7:&$L$IM.'U>K$W9PJH5A@4HJJN^N?%WOS^=]:RIXJ*<4IQ2K'V!7_ '^
M/^XH\Z<.\Z;#\F/*M?F)SZ1'3Y/TY]W9QGS4X_ZS[;/E_1CE35R5/$M4N3-%
M\:5B80B8(0)L!3ST9,V))B*D1O<?2(^)+*V<O,>DLR(_NS6%^Z->[QWV?/2G
MW5EU'G(5>7:BIQU938J+Q5B%#Z3Z\@ZEI6EV;IL/\CZ#3NIE+K\GW'6+=HS
MZ=7Z'L/6TPK9F-:,DC$D\8%AX=Q@D%O5Y X>^NBA*.7/V@J<IT=F6:\'%O)\
MU5Z:HNDB)G\;CR^,F2[,^+\[$RNTWU;J9ZQ!;3,M]N:+5Z)V,@BD0P^J6!&(
M_94C$(VO!,%\&:Q!YZM+'P&JU*.PR,HOB.[)V6]L$@1*3)LZ*=_AXN'?X*C2
M7>R3;HY[_P"KO</#PY9=[*KXU[I2O:YO&Q;^+-V,F8V:.UR-/1"N*TR&@MZR
MK3U7".@A]?K0'WO7/@ON2"[#CTJ!Z7YF!$,1!0F%@B9*J\>7%P?-4*N:(F2;
M,]NW/:N>W-5K(2K W+"<A#4X5AE2_=IBT_\ ]4-G.%/J\O\ W5+QY&6\Y_1[
MLZWC/Z,\ARY)^?:B^+>HB9KE^?SP]_):R\;;;9;;::0EMII"6VT)QC"4-H3A
M*$)QC]&$I3C&,8Q^C&,8QRS5^L'^Y'^O'1C^N;4_\(MS<J;^M^ROW52[]7]I
M/OJ+O%[_ )B.T/\ >#6O^(%>Y[%N"?UG63^RWC_*9=?-W1:_U&XG_M^&_P#/
M[?7CCY^@E?D%3BE.*4XI3BE.*4XI3BE.*54! _WV*C!7ID =[YD(0_WP*2D0
MAD#TV2U&],(S'?(U$@1?=/=YDIS.$,1T..K_ )*,\M2"]+@.?5E-J0D+J@,4
MIRZMCGZL(V[2%?HZ(V)M>]4:FU:R(D?IN7%BZX$;IF0"/TQ*(T,8&N*T>ND&
M>J-$ 6EIF(Y4:,;7.5<D6MMMWZ1:G:*-DZ,/44UA5]"=A-QN;-K6[P&V*EMH
MMIRJ#9H^JCGP-0JDRB2F+ 2&/W(1,1-)+#E'8((K&ECWBC?A%MW2+ZX*@N94
M!>IN*,*8?;9IF&Y5BGV(&()QAFG%9*GSQW0;H@3-MT@:C"D@#2R@/&9H5^L+
MUN*X59)259(RR<,VO F/\8/Q);<:P<56G%<K"%KC&C6N.2#:;66QE;.DQB7>
M&5II+H<EX8,H98[Y3(EO'A\6&1LHT%UU=*:*J.3?7@$'7?REA;*,6#LG58)J
MF G,UNH'?2HS)]PE7<E%-LK9C1H18JS%B/2I3&]MFZM$99XTB[VZX'GI&Q9*
MD):@1% Z)@^<6-<)3>F[A&T'NB(&7J$5R.>\@([B/:QC^4O?0_W F(YD/#UY
MLT2T+-W/X$1;]*N#93+ANC6P$RSP5^#K1-UHF3W2('3*M:Y@AAE2F#$XIF1%
M/Z0;<@>\SZC- D"R54WG;BIF*:-N#ZI!ZXRWQ^V(1U"ZTT1ED@4YIF-"158%
ME@G,S8CX>?,B9?D1]\+=)L)>F&I'NK#!G89@ COC1FEGEQ<-I;$2*J3%$,,D
M3G/(LXL,D9!D;($-Z-:[DC[B>+(_2;UFV D:1:\<7:5,%-FNCVL&YV9\?%09
MS76ULDLB"=K!A2UQ[D&;KA$B',+3(RABNJ5H7V<UUUE-V>MLGKR6UZQ(L(/W
MV("1 ?8 D59H$]"# NO29\QNJEX99$%MIMIU^0P,<F,3,2D1<D^.83<&7;&4
M>%,=%MH+JYD23J!'/(M4@\(HE6.>6P0UG (!2N57-8QQD&X:L5^#%W++HNZ7
MA[<UFW.W-GWN58&$N$'IL\6)#OT6+<@':DR+;R',VURQ2V@:QK7$(R,XS#(5
M!3 /ZZ:NV.9[E4RC0CE8*=6ZE>]@U Z9-K*+O-6U394 ;? O<14:)#C'CT)Q
M!:O/U5FOPQ,G#HB=!-)<028T!<77NT1]SVXW,D::#&T^V6JX18\9 );)U\AK
M*@%MA$(\CXL4B*"6V<LLAV92!%C*BA=U\?<\PQB*7NPV>Q@G6R5N86J]W^T3
MIDUTIU[M>%KCTC=P7T*B$ <^>%6RX#[6VWAB$1T0P)B.22.8"G2O3UEV-'T[
M4L6NM6PYTVKG9"K6258(Y4,J[/5ANSFJC814L2AU%6(QDRHHDI )Q28*0AAZ
M=BPM.+83SX-T;$$.T.Q!/Z0F08VZ%+PA-ALB/!(2VMF+#CSXIV2%:LT3U8\X
M2@>&2U7-'TJJ(Y>OE[C.#[CB-N#K2VZVVZS-R"W[HEKN1+B.5$=>GVUMRF6F
MX1#14<EKD#0HHLH$H4F"1&//T^QSF-P&I^KX\O2^R=X'?='@]0M=(US7A#;J
MV$&KI=HUB-J>(/LYQ(2( 5FIEY,B/&=B2I94D"PB5B&R19>]1N%[>S$5GPU%
MR;(N$&Y7>7(5J.6-;K:^)&1HFN^(IY4V<!C7O:1@P!DJH]8X3F^#V?# BX,Q
M)C>?F2':+I9</6^&U[AI-O-Z'/FJ^01BH1L2!;;7+(\8W"*:5)A(TJ!'(8[+
MO;/575<>HRMW:(2?MVJ@H^^47:E9L!;,BV:7W'3PQJ0,DF) F/!S/HMQF#(C
M]<(O1?<GL2\BIDJ*5F0HL?@[%CB^.GCPWB=8D"^236NYV29$CZ,'$6'[A)CL
M.R.P[R(*YV\9B-EB:_2;JT.,;P#(]_K6*]RW"S+07&N!FSKMA:''OMCQ/;;A
M+4EVP;C"T0YI8Q99(@P:^R7<L83K><@M!^NZ6*4<DP1#AC/2'<"GQD1A<9^6
M8-@*] 9>HV\0S+I*R&QX 8V\5LFHP@."TN>2C)<D$2L-A",J\UQ;N6VG.A3=
M)L&@8CD>T<>-*EE<VYX:D.0,.,6496@AW^3)*Y!!?HL" CE=EL1,U3CEW$L7
M*^,(;P$++FP($=CK+C:(U\FXS00(S72KCA*%!"U3R1HXDB4%B-SR<KM%KKZV
M7UFJ^E]MT@$8K<O8.J2EUM.M(-P8VK5*(F^[!H-@A52^0S)\C#(B-4!0YA[,
MN$+-CGR2@\F&\_:I>)3TL1K;-C*;B*PW*5'F#M-\!;H5X+;W6.=<UM=IND0D
MZUDCQ0D">^29$=N@0\8K I(81K8(]!K)&[Q'N:VO!V*[) F6TM_PO+O-SPV"
M[LQ3:[&E]Q!8IX+5?0S9\@4B'A6%#EO4H(LV.24L5X7$NA4*\L2F[NZL ZA;
M>X%=IS5J&+ZS60 <@P+:[ D$3^J[2?%UIF:\L<C$9<X?,L=3.AB,93;!RIF)
MDV7$A38C##MW#>-Y5P@8 EW!8)DQE#EQBE@-*P46^08IYCAM0RZ:#*.'/BR
MO171I\<8QO(-[W-QL;;E\"TW7=<M]F9=(KMS6Y0)P 75X"2)^%[I.BVYAGK'
M35J:.:X6N=#DC5&3K3+*8P@G$QK\$N>G5X93BE.*4XI3BE.*4XI3BE.*4XI3
MBE>L/P/OYH-L_P"/-R_N5K?GPQT27]/H/_#%O_S&[U^JG05?U1W+_CB\?Y1A
M^LK+W_2$]>/ZM78;^^FFN?/_  +X4^QU?7?"G@7[6UG#R*FG%*P%[0^'WKKM
M/L,=L:V7>ZUPF-J8ZHM0*ZD$J"Y#&E#95J4YDD,F2/27'3C[3F$NX:]S99\U
M&%>?E7IV#=U&[8+M1;3!MUNEA+.-.4LM9.M0A@QPN8FI,-N@C8S53-NEFYV:
MJF67C>Z#N+6/=$O8+Y<KM=H,B/;06QH8*0]2X0),N2TCNF(Y7ZQSICVNR<C=
M%C<D1<U7'#U,^DO:MM/]74OL+G6=?_$7<2R^.=SFN%[%K"?*+$7BMO,J>IGT
ME[5MI_JZE]A<=?\ Q%W$LOCG<YIV+6$^46(O%;>94]3/I+VK;3_5U+["XZ_^
M(NXEE\<[G-.Q:PGRBQ%XK;S*GJ9])>U;:?ZNI?87'7_Q%W$LOCG<YIV+6$^4
M6(O%;>94]3/I+VK;3_5U+["XZ_\ B+N)9?'.YS3L6L)\HL1>*V\RIZF?27M6
MVG^KJ7V%QU_\1=Q++XYW.:=BUA/E%B+Q6WF5/4SZ2]JVT_U=2^PN.O\ XB[B
M67QSN<T[%K"?*+$7BMO,JY&?!LTQ'>:D1]M[78?8<0\P^S^2C3S+S2L+;=:<
M0#2MMQM:4K0M"L*0K&%)SC.,9Y#MWW$#VN8^QV1S7(K7-=TZYKFN3)6N19*H
MJ*BJBHJ*BHN2U4WH7<*L<U[,28D8]CD<Q[5MK7-<U45KFN2&BM<U4145%145
M$5%SJK&?"*UI8G&G;!O3=IUUC+N6'#)  3<9S(RA3^6ES1+ZF\O*;;4[E&<>
MZ90C*_.RE/DL1]W2[Q$<V+AO#L9KM'22.&4%':**C=)!G:BZ**J-SSR15RRS
MK)E=#38)RL=-Q?BV8YFEH+*D0I"LTU17Z"FBO5NFK6J[++25J9YY)70A>#MJ
M$:_B4.W'MX?)PA;>)$)VL17\(<3YKB,/,!6W,(6G^2M.%>12?T*QG'+I-WJ^
MF;H%L%A*Q51581LQ[<TVHNBZ0J9HNU%RV<%60]##AF._6 Q1B<),E;IA?;QO
MT7)DY-)D1KLE38J9Y*F_75SX-&D\YSG.U]J9SG.<YSE%2SG.<_ISG.<@O+G.
M<_ISG/\ IY7U_P#$2;UDLOCG<YJTO0MX3555<1XC557-55+:JJJ[ZJO2>U5K
M\]3/I+VK;3_5U+["XZ_^(NXEE\<[G-.Q:PGRBQ%XK;S*GJ9])>U;:?ZNI?87
M'7_Q%W$LOCG<YIV+6$^46(O%;>94]3/I+VK;3_5U+["XZ_\ B+N)9?'.YS3L
M6L)\HL1>*V\RIZF?27M6VG^KJ7V%QU_\1=Q++XYW.:=BUA/E%B+Q6WF5/4SZ
M2]JVT_U=2^PN.O\ XB[B67QSN<T[%K"?*+$7BMO,JU5]Z.KM9ZL;6JFOJ8>L
M=IB6&ACK4N0?;'J()(3K)9 GH49 J'$:6Q[D%CN-IRTM]3[[N//RG*$I]JW-
ML93,:66;=+A%B0B1;F6$C(JE02B'$B2-8]3D(Y':4AR*J.1J-:W9GFJ_.VZ]
MN?6_<\Q';K+:IDZX"G6<%Q<^:@%,ABSIT35#2,(359HQ6*U%:KU>]R9JF2)M
M(\//P]&]>-AMZ;T#(=OSJ&25$HI)E*VZ.VM.'(M@L$5S&4KN*TY2Z.'.IRFK
M)RF1(3FQY0@!XSNJ;J:W59&&L-R%2V(K@W*Y!=DMQ5%5'Q8KVK_W!%S:4K5_
MENUC5Z4S63]";B>XHVR-BXOQ=%1UY<C#V>T'8BI:&N1'#FS1NS1;HY%1P .3
M_LY,GO3IY4;#W*\\!KZCK7YCPSNL*3J;(F#>$ED2LS$/8M[V6TR,[,:VWY^&
M,PLM9QBYLMR\(4E2?0\>@9QEC.<<5.:Y9<'@3A^SYJH0OPJ>H@H9$#- +I)&
M0Z_6JRU%F72>\A0NFZUT'JRII<6EEMW,D#7>L>EI<24E:77SE3<($534'#T8
MDJ=)?9WMJK]Z[^>_X*[MB\+;J-:0!*M&JS;9(HN#V)7I[2;H6:=>&[.IMFI-
ME;P\WYKC;B!]UN)$4XWE&1YFR3)2<.1X .&)5&DN>>>W^*+]R>*LN*)I.A:X
MO6TMBU6!)@V7<<FISKVI#[; LH1I@B2!#%4AH+$,:V;4'D,BB1Y<9XV4$"*T
M$FD'0E4K0X2IGO=[_K^>#YU6I;XJ*<4IQ2G%*<4IQ2G%*<4K%J_5Q80_(]&9
M7Z"0\Z;$]S1G*&_=%9]WCX\W'D3[B]YWF)_[K*V?]N>7FKFG?38OY_.W.K+D
MR5>)=[\]ZK)]P?\ _4N_JU__ (Y55-/<'_\ U+OZM?\ ^.*4]P?_ /4N_JU_
M_CBE9$ZMKV1HEPM);RF86SC+6%8\BVH#2LX:QY,_I3F0YYSRO_\ IO$?.<>5
M/++US5>]LJZQ,DSX_P \6?VIPI4I<IJNL'.Y'^O'1C^N;4_\(MS<J;^M^ROW
M52[]7]I/OJ+O%[_F([0_W@UK_B!7N>Q;@G]9UD_LMX_RF77S=T6O]1N)_P"W
MX;_S^WUXX^?H)7Y!4XI3BE.*4XI3BE.*4XI3BE=\5/R**#2F(< AD;/AS\0"
ML5$X7.S#D-R,0R4)>4HF0).6_<9D5:L(D1UN-*SC"\YY:.+7@,#6%%KA$%K0
M/49Q:QBLU@2(BJ,K,](;T158]$<B;*OQ3K%E1I2!!(6,<)T!*$AXIU"1I-3)
M"Y4:8!='0,)51"#<YBJB+4]P.S%W EILBG ZA2*L4C;'AEM:UN-9$T(G%VW5
M85,V!&?@&+.7-L1SM>&C(3# \_"9 +'1)5:0'E-Y=5RY<&VV4 ;+A*N%RG ?
M:" O$Q\/X4"^PSB7&U/:6/"CQGNC2S&(YQHI72D*1DQ9#%T4[P&Z7>X$LQ+1
M!M%EM<H6(@R\-VX5Q2PR18LM@;/?QD!+N<N:P<V!&C!&R//"R Z.(MM;#*U7
MNO@;W>W,/,'3KD>G$R!W8NFMEJ62$E7&Q9?033475PD4U&/14M5X .8;&NPI
M?ILLG$3YY$A)F9S*YK#;FV'2QXL5K[@ 46T8ALR(&0!'&CXI<XEZ.=SXI%=+
ME&>XS2#U8PD7(0F#R96[C[M>,8\N=-<.SR3S<180Q+G)B2G-BS,"M8+#,6*T
M4\2,M\".-L=P2ZXLD2*LF04RZVKXH'=!<RU5>1N&J 2=9I</L-.K8^M8N-??
M=M'860]/M"BU@!W2)8A0A,Z2[Z(0 ^E%Q,-*8T:)+=>5,CZVZ[G:#@S68?G2
M03+B3"8YA9GP?*8V%A-C10DCQ)-N)$.=1,;K RM".<F;WD&UNK?N[!NR*:ZV
MPF+[5 DVVS!W0#VX%N2\0'NN>Z 1Y[HLN?!O(KC%B:\C]2>!K9<02(,0BN>I
MAP;M[;-=*;H'[9TK#M-!)#E5D^B<0M]CMI.+L$&MN1(L(2Q6^>7M3L#$V+">
M&8L1*:1QEA3CR8K+S8V)TU@L4L&'2V+$9(-T"9)D51A@1( 'VJ2BL9$DQ( H
M\%I=6\C3=*!&'XR(U7N:IB<1B[%=NDXRCXKP6*Z6&3&6VST/(NUQNLD5_A*T
MA+A"N%WD2[HX"&$%\9+A(-(_1JY[1,>V,*5K#VCK=@U?L=(L*5USO/<I6>K>
M-FJ@J&2JNX@4LPW8L#L8G6@9-U,S/.8<(7 73@Y<9;I7N6,8!AFD5].BB8*F
M1+W:%/)!=\,X> ),-0IQR!G8?E#CK$URZJ$85^>*-D*WGN!XYH#-)?Y3)<LN
MNJN&Z?;;AAC$2184O#N.,8RCKC>Y6J(&1:L7P2RTN"1TU]TC'PHR1-TCWB-9
MXDN-=BZ*90H:);TM>S=T-N6%R9.APJ;4K 0TX(T#+M-7%%FCZM3B(K4+%7BR
M#1\W#&*)0V&(A8V*@P;!-B(7%R5;C29C4C-A;G=AB-&(A+A/B"Q!(Q2R#-.!
MT7X=.]Q.G2,C18Q#($CG$!&.0D0;U1^H5[!N;J[GNRXMN#CG$&SVJX2<(1,"
M&NMLBRV7!<+1!M#\&"),GS0Q5DA8P,N;% ">8+5$LIHR%:2,*AM9(?4>Q].G
M(3TZN7"P4V_AW6,86L1>Z*T='0E2&?2H2W@EAKMH.A#/HTMF?#>]YRL-3_O;
M('$-U<+&LB_6C$$8C12[?$N%JD-<N22+9<W1BD1CM B-DQ)<*-)CZ8W"(W7@
M)HZYA1<S:,5-AX3Q%A"<!Y[==[A9[]#<Q,UB7RQMG1PJ5B% Y\*X6^YS84Q1
MF8<+^E)0=/I<@)'Q%WM?A<S;S@&5$KXC>0P@)V'51B2#E;*19Y5LZA3,,F1(
MRF)8PPWF<(FKG/2A^7YD)IWWMGS84B7X9M9AV!LIA)<C#1A'M,XVJ28%X@.B
MJCB "%CAFCNU1Q()HRZ R.;KA#(V!8YOT4V+70"!@1,;QI$3$%KC(=UNDBD2
MFS6N8&3(D%&6-,;KXAE.\@%>4+7+&.8!(W!V4]6S0>Q RTT<;KY4<<#$6'E9
M?@%A,QD@.G,>Z>>W[M$F1V9#7GH4G#C:<J3G'Z,[B3$C3(TB') ,T:4 T:0%
MR?%* XW",)V62Z)!O<QV2HN2KDJ5SD*YW"W38=PA2SQYL"5'FPY#'JKP2HAF
M2(YF([2;IB,-A&Z3532:F:*FRLC+CVUNNPLD(UXH^K[,#)$-BV-ZMS0=CC"8
M][VH<"V"Y[#&OBK8/."K;/(5\<B,H:9B@1X_,X7#!-#RA*-+Y&WX$MUIU3[;
M<[U#E!%:(C9HY,1\A]LLD:1$M]I,T\ L4\ 8I15>AH[Y12ZHY)3C "]GHEWW
M6+UB#I@5[L>&+E!D2,0W%]N/"N(XH[YBB="N%XQ!&?%NT>;$NQY$".T2QI@H
M,>.LB,&"P$N2,M(?[%V2;4]W,%7Y16[[X8H]7LQI]MIF &UY0IHDN. B,)D.
MRWY$R96ZB):R^AAH/6ZPJ&ITW(/N/!;[,(PQ3L-N U@+;A=URFPH[7.<63=K
MH(\<TJ1FQHVL&.9/.[15[I$R:A$;&;%:DC#?NAW$UJQJ.4\LJ]XZ99+9<ICV
MM9'AX?L1HDN/ B(A'E(0Q;=:HC5(@VQ+=;%"KYI)[GP\;N=A7G-.*4XI3BE.
M*4XI3BE.*4XI3BE.*5ZP_ ^_F@VS_CS<O[E:WY\,=$E_3Z#_ ,,6_P#S&[U^
MJG05?U1W+_CB\?Y1A^LK+W_2$]>/ZM78;^^FFN?/_ OA3['5]=\*>!?M;6</
M(J:<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*QVLO6C7MT
M[!5SL+;HV#]@I-)%U2F!)K#3@<&2@G[&<=MBVUY7Z>9;]_&8P;#S:& KL5XD
MTF02<'R175P\7W2WX7EX6@OZ5BW&XFFW"2-SDD2 DBQ8S8**F6KCKTNY\C15
M72$>T*JT2%8;B)^ K)=<:0<:W,?3LVU6F/;K5$,QJQ8APS9TMUR5JJNNE)TV
MT<731&17#>=J/.X)(V1/.4KMZ<4K4L.\3I0*SDJYLW5CX-(Z;LN9,,P#]8:J
MB*G3Q3I^HG*E=U6HO5]BQK\%EBY<2*B=2K]77A]K'6S6 (M!"#CJJM'?R7>X
M]G'XE3+;OIOKGE48C_&*#%U/$A^H[-^3)2W:7,569D>D@77IW8VE>F6TK%$L
M8@2=F/#=R#R';)T%3:]"].KUR<UY;(\ BJ97BW%2K-[:G#FO!FBN]63<]NW;
MO5E^_P!T$69_JT]3A@6G4WLJ)W'8(NTMDRH1"E@XNK8PQ5=K[$BN6:"+GV#;
MK!61;Z*B39Q\M%%J%NFD@39Z!(!#U4Y;^?!Q<?L3>7OY<=<FINV>Q+P_V2"D
MM.$3MVT48A1PM7U[-KY$-L2MF[[LBI5^V5/84NXR0!.,H=0Y,^Z5(G"J^U*&
M:#6JN.ZYL,IVAR+LHJ>+[\MJ?G9W]^H_[0]Y[GH"A:VN0ZNZL+VVU4+L->B&
MC+!9[?4=HVB)I[3]_O@]C5@B\U:B7.PS&+E7:32SX23K#\I)\6^.6,>($!ZN
M1FRE$3//?X-O F:\/S9\*;U1X \6NBQ;#7*'?M2;!AVLM:QE4D&JZJIJJ$AF
MP[V3I6IVX:T;MT.P9KUDB/C]BLI;ADLL5<G#0-(6%2\3%/S^?#4Z*][>S]6?
M%^<EXJSNZO\ 8VO]IM6P]LU:J6NH@"4UB.-A7!(9!28Q(KX _B4E ,L9B(Q$
M4=4!(-YE9PT>#&&X+I$0@:9)*A4RV9I\U9$\5%.*4XI3BE6/7=EZ_MCJ&*Y<
M !9Y^4[#AMQ2#&5DGF4$G5J$8<4C)B,ID.6?:FB_2X;\<9/D,/N,Q'W$*56;
M):JU3QKIBTG18 :RP2D*EE9C$1#C88*4LA7T=+JTN2G8%?"&3<IB,AY]H6*(
MSE-^C0Y#C:E6S4=NZROU@L]5I5XKMHL%,=PQ:1@4@U/?"O\ ITX6XS,6QYS.
M'HQ463$S&FW7%P2HT@,F)8GPI,=I2KB-W"K5N4,@'K )%3S4J%"$P)LYAF<1
MD$"PT%#1#AY7Z2^ATR8$C,O-M*8;F$H3#KC:Y+.%J5<?%*<4IQ2L'.Y'^O'1
MC^N;4_\ "+<W*F_K?LK]U4N_5_:3[ZE;MC7.O]FT1<H7:$X)K6D8KE?)7$\=
MM#U-$#,Q+$+R#>G6)B7!7 ;=L#@N*WY9+:9,B0S%5Y^'O,5TN#KIB*SX@A3<
M*L>2^-;)%#&.*R:1Z%C%9(:R,1A&D7I=2JN;%5J(KTR5N:<?C["^%L887GV+
M&;=+#LA\,TW.::WHUT66&1&<LL!!$&B2F"V(]$>JHQ<T=DNFGX._ %^41I;Z
MSI#[U\]MZO\ H@NYUP^J\3F=?.W8\]#)Q"^N-TY_3X._ %^41I;ZSI#[U\=7
M_1!=SKA]5XG,Z=CST,G$+ZXW3G]/@[\ 7Y1&EOK.D/O7QU?]$%W.N'U7B<SI
MV//0R<0OKC=.?T^#OP!?E$:6^LZ0^]?'5_T07<ZX?5>)S.G8\]#)Q"^N-TY_
M3X._ %^41I;ZSI#[U\=7_1!=SKA]5XG,Z=CST,G$+ZXW3G]/@[\ 7Y1&EOK.
MD/O7QU?]$%W.N'U7B<SIV//0R<0OKC=.?T^#OP!?E$:6^LZ0^]?'5_T07<ZX
M?5>)S.G8\]#)Q"^N-TY_3X._ %^41I;ZSI#[U\=7_1!=SKA]5XG,Z=CST,G$
M+ZXW3G]/@[\ 7Y1&EOK.D/O7QU?]$%W.N'U7B<SIV//0R<0OKC=.?T^#OP!?
ME$:6^LZ0^]?'5_T07<ZX?5>)S.G8\]#)Q"^N-TY_3X._ %^41I;ZSI#[U\=7
M_1!=SKA]5XG,Z=CST,G$+ZXW3G]/@[\ 7Y1&EOK.D/O7QU?]$%W.N'U7B<SI
MV//0R<0OKC=.?T^#OP!?E$:6^LZ0^]?'5_T07<ZX?5>)S.G8\]#)Q"^N-TY_
M3X._ %^41I;ZSI#[U\=7_1!=SKA]5XG,Z=CST,G$+ZXW3G]/@[\ 7Y1&EOK.
MD/O7QU?]$%W.N'U7B<SIV//0R<0OKC=.?T^#OP!?E$:6^LZ0^]?'5_T07<ZX
M?5>)S.G8\]#)Q"^N-TY_3X._ %^41I;ZSI#[U\=7_1!=SKA]5XG,Z=CST,G$
M+ZXW3G]/@[\ 7Y1&EOK.D/O7QU?]$%W.N'U7B<SIV//0R<0OKC=.?T^#OP!?
ME$:6^LZ0^]?'5_T07<ZX?5>)S.G8\]#)Q"^N-TY_3X._ %^41I;ZSI#[U\=7
M_1!=SKA]5XG,Z=CST,G$+ZXW3G]/@[\ 7Y1&EOK.D/O7QU?]$%W.N'U7B<SI
MV//0R<0OKC=.?T^#OP!?E$:6^LZ0^]?'5_T07<ZX?5>)S.G8\]#)Q"^N-TY_
M3X._ %^41I;ZSI#[U\=7_1!=SKA]5XG,Z=CST,G$+ZXW3G]/@[\ 7Y1&EOK.
MD/O7QU?]$%W.N'U7B<SIV//0R<0OKC=.?T^#OP!?E$:6^LZ0^]?'5_T07<ZX
M?5>)S.G8\]#)Q"^N-TY_3X._ %^41I;ZSI#[U\=7_1!=SKA]5XG,Z=CST,G$
M+ZXW3G]/@[\ 7Y1&EOK.D/O7QU?]$%W.N'U7B<SIV//0R<0OKC=.?T^#OP!?
ME$:6^LZ0^]?'5_T07<ZX?5>)S.G8\]#)Q"^N-TY_3X._ %^41I;ZSI#[U\=7
M_1!=SKA]5XG,Z=CST,G$+ZXW3G]/@[\ 7Y1&EOK.D/O7QU?]$%W.N'U7B<SI
MV//0R<0OKC=.?T^#OP!?E$:6^LZ0^]?'5_T07<ZX?5>)S.G8\]#)Q"^N-TY_
M3X._ %^41I;ZSI#[U\=7_1!=SKA]5XG,Z=CST,G$+ZXW3G];4^CD;IX*U;80
M?2R]U*]ZVAWB?-L,VHWQS842!<R(0$F7$EEWB!)V+)6&A!7\#\OH0VTM$A+6
M,R%*5Y%CVYXQO%WCSL;1SQ[HL 4>.AX#+<KX03R'C5H1B$UR(8QT4FBJJOQ5
M7)J(GN^YGA+ N"K!(LNY^K/@9US//D-9<CW16W"1'B"*KI$@QB,T@1HV0M)&
MMRTD:BO<JTZ]_P!(3UX_JU=AO[Z::YQ/ OA3['5Z'PIX%^UM9P\BIIQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K\PE./+Y,8Q
MY<^7/DQC'ESY/)Y<_P#CGR?H\O\ X?HXI3R8Q^G&,8S^C'E\G^S'^C'_ ,/+
MGR?^'%*92G.,8RG&<8SC.,9QCR8RG.,ISC'^C&4YQC./)_HSC&<<4JBV&M5R
MVAIU=M=?"6:OD\,I) K"*@&@Q!,>0S+CXG#"3$F%+PQ*C1Y+.'V',-2([+R/
M-<:;4E2OL!7:_5 \&O58&'K0 8VMH:# #(08./:=><D.-P1@YB-"B-N2'GGU
MH88;2MYUQU6,K6I65*J_DQG'FYQCS?)Y/-\F/)Y/)Y/)Y/\ 1Y/)^CR?Z/)Q
M2K!USJO7.H@<BM:RI@"D IA#!:8-K\!J#'EDTC!@1$Z7YGE<DRF@H4,'8>?6
MXM@6)&CV<HAP8S+2E7_Q2G%*<4IQ2M4FQ?#&Z\NPC! U?K)2(=L-6D2J*):
MCJ@S<-_1!6NSQVMU*7!F@J??]D6>8#FGYM#C54'9;2XU.DUALB1)S9RJD<J<
M"+\W!O\ 'P9;,]ZNY>_"?TQ>+=?K2J^7BO1;E&C#@U.KP;78NE:[$P-&]H=
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M\$#'P(-P@??G\_G93-.+@]>2(J^K9WUSKHU[PJ"E9U_\'0GM1L&$#CZ5LFH
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MJZ93# _:%_-V>G;,U?L'%S.N1YEL/C]7:1UWI(?1K)/4]D>=JYD=1BUIGPS
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M*CW#1&N*J,3)5727:E5#UI/A\?*NU7^T"7V9SG?AZS=T8WEK[*]"['C=L_\
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M?K':^9U]L=1]A_\ #FP_^6[=J_\ N]?2=I6-'E\SL+;D>7_3YOBG>'HGR_\
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9G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g609070g00y99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g00y99.jpg
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MU30V.+8*&1HC)$%8&#<Y46%WMR4R0E.11O_$ !X! 0 !!0$! 0$
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M_NU.:_Y]]6^\4Z0?%'W_ ."ISO\ T=];^[4YK_GWU;[Q3I!\4??_ (*G._\
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M6,DJ02A4FMRTAAD61PAD) B*"4I'I#TBH!+D*"!F?;Q5[<C^X+-M?QK1G$0
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MD[]Y7^R3T>K*L[03=Z*[@0/1&X-EI ;MP;(9@=.0SIW3/YOT\_T;=KC^E?\
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M*RH;LI):.X&5BK&'1!S9Q++<1Z>;99:^0!B,OP8Z"W3!+!I)<(I/_FF DS(
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M-\39&S5$1@KQV2L X#@27#A6=410K^5<I^5 Q$-88>66R#?AI]ZM=%3F%52
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MOJISNN.#A[Q_"G-B#BI>[3QIS_>=7MO*J^JG.ZXX.'O'\*<V(.*E[M/&G/\
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M!ZAZ?Z@2<V("@G)5 ACQ#!HBYCF@4R,7<A'])CZ]Z;A^09 $D@9DDRWT2C?
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M/U;03/:6SQ7H.I$LL$>(7-ED<<L$4L,_GRP3PQROV>S^ECC:U_G_ .?SVO\
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M(-VZ2:*2>..">&.-K6M4DL2S$DDYDDDDD])).\D]9J@      &0 &0 Z@!N
MKGU2JTI2E*4I2E*4I2E*4I2E*4I2E*4I2K(5[17D]*4I2E*4K1RC?'/8<.=7
M'I+9(1B=(XD\CB;59C9R_@^631./9*65,X$+ML5%2B:>> *X])NIDG<XG;-2
MMXI2E*4I2E*4I2E*4I2E*563B\X?L^)W1Y[42<N0@^9DM'25I"Y#W.I-N0B[
M8G="X[$J&NK=U9#N&.??Z?<KY=T[17L=I=2I?)Q#OY5MGRFFCW!BU:=KDW[:
M^?>Z?:=TM_Q&/8MG^NV/8OVOZNVO^NN;Q3D^<2NOC/QL0_@TCT-1K/Q,]^EK
M4Z<^C1W9=-;[#L;%A;Z@VQE_",^GKM#\;+=HZI^C+ISW]58WF'XX1\V^*K7<
MT#\X#W4_Q%9_.@<$?>!]A3F'XX1\V^*IS0/S@/=3_$4YT#@C[P/L*<P_'"/F
MWQ5.:!^<![J?XBG.@<$?>!]A3F'XX1\V^*IS0/S@/=3_ !%.= X(^\#["G,/
MQPCYM\53F@?G >ZG^(ISH'!'W@?84YA^.$?-OBJ<T#\X#W4_Q%.= X(^\#["
MG,/QPCYM\53F@?G >ZG^(ISH'!'W@?84YA^.$?-OBJ<T#\X#W4_Q%.= X(^\
M#["G,/QPCYM\53F@?G >ZG^(ISH'!'W@?84YA^.$?-OBJ<T#\X#W4_Q%.= X
M(^\#["G,/QPCYM\53F@?G >ZG^(ISH'!'W@?84YA^.$?-OBJ<T#\X#W4_P 1
M3G0."/O ^PIS#\<(^;?%4YH'YP'NI_B*<Z!P1]X'V%.8?CA'S;XJG- _. ]U
M/\13G0."/O ^PIS#\<(^;?%4YH'YP'NI_B*<Z!P1]X'V%.8?CA'S;XJG- _.
M ]U/\13G0."/O ^PIS#\<(^;?%4YH'YP'NI_B*<Z!P1]X'V%.8?CA'S;XJG-
M _. ]U/\13G0."/O ^PIS#\<(^;?%4YH'YP'NI_B*<Z!P1]X'V%.8?CA'S;X
MJG- _. ]U/\ $4YT#@C[P/L*<P_'"/FWQ5.:!^<![J?XBG.@<$?>!]A3F'XX
M1\V^*IS0/S@/=3_$4YT#@C[P/L*<P_'"/FWQ5.:!^<![J?XBG.@<$?>!]A3F
M'XX1\V^*IS0/S@/=3_$4YT#@C[P/L*<P_'"/FWQ5.:!^<![J?XBG.@<$?>!]
MA3F'XX1\V^*IS0/S@/=3_$4YT#@C[P/L*<P_'"/FWQ5.:!^<![J?XBG.@<$?
M>!]A3F'XX1\V^*IS0/S@/=3_ !%.= X(^\#["G,/QPCYM\53F@?G >ZG^(IS
MH'!'W@?84YA^.$?-OBJ<T#\X#W4_Q%.= X(^\#["G,/QPCYM\53F@?G >ZG^
M(ISH'!'W@?84YA^.$?-OBJ<T#\X#W4_Q%.= X(^\#["G,/QPCYM\53F@?G >
MZG^(ISH'!'W@?84YA^.$?-OBJ<T#\X#W4_Q%.= X(^\#["G,/QPCYM\53F@?
MG >ZG^(ISH'!'W@?84YA^.$?-OBJ<T#\X#W4_P 13G0."/O ^PIS#\<(^;?%
M4YH'YP'NI_B*<Z!P1]X'V%.8?CA'S;XJG- _. ]U/\13G0."/O ^PIS#\<(^
M;?%4YH'YP'NI_B*<Z!P1]X'V%.8?CA'S;XJG- _. ]U/\13G0."/O ^PIS#\
M<(^;?%4YH'YP'NI_B*<Z!P1]X'V%.8?CA'S;XJG- _. ]U/\13G0."/O ^PI
MS#\<(^;?%4YH'YP'NI_B*<Z!P1]X'V%.8?CA'S;XJG- _. ]U/\ $4YT#@C[
MP/L*<P_'"/FWQ5.:!^<![J?XBG.@<$?>!]A3F'XX1\V^*IS0/S@/=3_$4YT#
M@C[P/L*<P_'"/FWQ5.:!^<![J?XBG.@<$?>!]A3F'XX1\V^*IS0/S@/=3_$4
MYT#@C[P/L*<P_'"/FWQ5.:!^<![J?XBG.@<$?>!]A3F'XX1\V^*IS0/S@/=3
M_$4YT#@C[P/L*<P_'"/FWQ5.:!^<![J?XBG.@<$?>!]A3F'XX1\V^*IS0/S@
M/=3_ !%.= X(^\#["G,/QPCYM\53F@?G >ZG^(ISH'!'W@?84YA^.$?-OBJ<
MT#\X#W4_Q%.= X(^\#["G,/QPCYM\53F@?G >ZG^(ISH'!'W@?84YA^.$?-O
MBJ<T#\X#W4_Q%.= X(^\#["G,/QPCYM\53F@?G >ZG^(ISH'!'W@?84YA^.$
M?-OBJ<T#\X#W4_Q%.= X(^\#["G,/QPCYM\53F@?G >ZG^(ISH'!'W@?84YA
M^.$?-OBJ<T#\X#W4_P 13G0."/O ^PIS#\<(^;?%4YH'YP'NI_B*<Z!P1]X'
MV%2=7:UR5*4I2E*4K1"O<>D:%]MS<[OS6GO<N_._>=7<^_X+W;D"R7_ <C=M
MW'G+WW_Q/?7-OO+]#OVE*WNE*4I2E*4I2E*4I2E*4I76C\K7_@NF'[X0#_,3
M>E*DS</]Z&'[L@OY?.NEPG_=3_Q7_<M=!AG^[?YC_N6HIK9UL*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*[.*X>N/I2E*4IV;7_5>UZ4JF&UN'*73OBXX>-[B=
M\[ AD'UC')J-GNF0L\DPB,;,?NLFKB"+.8X.)-1"K=F4<DWLR[Z;K<Z&H*(A
MGR+E@P4PPL,B*P5G0,W0I8!CGT9 G,Y_D%7!'(+!6*CI8*2!Z]Y R&[?OJYW
M9MV.SV;=C_S[/S?_ -J_,#I.56U^TI2E*4I2E*4I2E*4I76C\K7_ (+IA^^$
M _S&WI2I,W#_ 'H8?NR"_E\ZZ7"?]U/_ !7_ '+7089_NW^8_P"Y:BFMG6PI
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K7I<:4
MC44D\B10P=*@(\:-)-E,\DTW"@H:Y?8(**8VRRPP6R0LGGGC:^6..5\K6O>U
MK5:QT59NG14G+]0SH3D">H9U6[@8XC2W%OPHZ<XBCL9'0XMLX,:*/(T)?.20
MX5F*EL@CF"+9\\20<N,540R;G/)5+"^*B^:=K7QPQO>*VF,\$<Q4*7#$J#F!
MDS+TG]51Q.9(U<C(L#N'JR)'_:K95/4E*4I2E*4I2E*4I2E*4I2E*4I2E*4K
MLXKAZX^E*4I2JVJJ;]R=*V;&XVW:J$U$$,%=:EW&2+2\LS!)+JK6F:-E+8BN
MUD&>=DT\,V79O;M4KXN+<&[<M=:1%>X>L33,JF7 +R5TC-_):JQ9,5C!T;<+
M=DE4!0C1R0ZP]D5Y(:I"UC?O(($=RN-VBAI=GQW+HJ;-=ESNB]J,\\GR!)=3
M&.0(TN%/Q4JYG0Y$M.Y0J0(DY4L+Q9&Q+_)13 3C'LUEG3X$U"(IM;"6S5[>
MR%T>ZYYJJKJJ92VG)6VO<-N9,:B6YQG$C-/<WYA,5S;7!]"W^(EGDELX[1(H
M1;1I*='0S=I&9B5URHN[3$K6/"':UPC#EA@ML/699K6>#\>X^/:"Q0WLEV\D
MQN97C7,2%46,*H7!M5.(EN,96N>!.%4QC3/.SG697-YFM:+.3&:;K/"8I8Y.
MN46J0-?/!!.V1!WCG9!+.^+2^O1^7<=O&AO;&4K;IF9, O&F=AALER1)(N*:
M)E-S&MF["-<Y9-,1J=&$Y$B\BGN92+*^1&N) ICQJT6,*;]+<% <-;1C^+R-
M=*--LHH] .PSE%E ^+S 2-Q(YX*$,6+6SY1-ODU34=V1P[Y43:YJKY-\,UNW
MRP0R66NEC>R=U5+X]O?T*'6&&(S%6F,::UE0QJTFB-,JC,S("V9"LS%1N))&
M=<1((UDD$(80B1Q$'<2.(PYU89U"JY"Y L%4,=X49Y#)5+5E*4I2E*4I2E*4
MKK1^5K_P73#]\(!_F-O2E29N'^]##]V07\OG72X3_NI_XK_N6N@PS_=O\Q_W
M+44ULZV%5'XW5&.6A'XXALMAJAL;G>KA.4GD&<K80HCDOL&/+V@FPI)"R <]
M#H+LNS:^OI%*4#8IL.;27%)XJ0;NE A3'NLM407"9N@S.D%/I#T792"J/^*S
M9C+/U]!LDRT#FVB"5&9SR_&&YB-X#?BDYC+2WG+<>M2<!H4<X./E"Q=X]E&Y
M?P[ZQV3.8MEJWB(E^V=.0:8D=!/3 E]IF96'P621IVFK'1TFE>L9"*R;121$
MVYT6DLSEMGS_  V"FWNAEHM"C,NKF9XU8QYYHV2D'<"R-GHDYC<V9@(&KF W
M% Q&BY9 =7GZ!R4C>,RA'HD@[]+.IQXM(G)!F.ON%?A3B.T<2HL',^(V0WU;
M+P*9>,2$2+(1C02DJ)[6VE"DW40/;E6QF3\(SD3U8TTTV4"JB%A#\I>I;@$:
M,$"R9@-*3&P)5@"L6D7=<U,ATB,\R(R ,LZOD5O1CC!SWN<F ((W)F7905+G
M2RS).K(RRSK]G8W57$V9^3QW2[C)D8]W[N$Q&MI1].83$2HCS:X0^*(X<UI(
MF(:0,&%GD"VEK]BR)XMVZ2MI##L<E%EK)Y]T-JYS:29,-:[+(-)@?1@F)1@I
M !5U&>0&]:J<G$3Y$:;Y$!F&7X*4E3D1GHLH!_*M6NXH8_KU>)02#%9&%"FK
M)2%+4T+G.RIOK76$S/QZ(.4[,I[*HDW=''Z,2C>1*5!1:C_OQ8D(O(&J"Q
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M*;IRBV-L3\_A&RG;=^T'O1S-5TWDFO8XF/<D6Q9HR&YE;HC+'51!\&IG_/\
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MBEGSQ6#1)B.P(XKM\@Y%T_6B;:-QY5&*H*J3T_E_Q]>?[]];3%N&0%$M@K;
M'R@XY>7V(=G[9B34=D4$,I0MN0@;"]L\)KIMV5B^[Y4Y#X!VH9B+9L S=08^
M(9'S!Y3/^=_Y/R_D_G=EZ8%PS-H'L@EL]OL*4%CCX1S<1:$DFS@6U *31U,'
MR"31RJ[P9ORN;\BQ?7!<B1QMD[R? 8N#4Q[CDIGNR_GU^-2$0U82*R*6R5_/
M3F9$G#)+!X,Y;#0S%WK@7,%V9 ^Z&.&S7!,R25*AXRLQ=%6U[M&,6#-5\7KS
M(N4*JI_/T?\ ]J"27!V*1@\> P\K&(4<UND:(ZOM!H !@T582MU%V<9#%Y:(
M:8''4CR#-6#95ADL[[BQ,-PLQQ'.YE"8(:CBJY[^CZ>G\N_\O7EG6_L>&&(6
MUZ_UR:(*DPQ.VJACE$>)%Q\<G$=-N8^K#HFS"L$LV#=BJA'[)GG5[*NWV9<H
MB.R#A&\<!QY3/?F-QW_M_7_/^-: +X)8B.>"";B>SDX8MD33FQHT\3Y3V$RD
M376F4L;2#D2X0<IC(C&M\GRC)P-?1T,/G,T"QR/"$5(NYBZF?Y!_/_?P%;>%
MX:$(S&S#(?)\B\AM%=)Q.,D"8@<,9M@W#K)"LPUD,/\ )2&3TQ@]D!@FZF[[
M-6W*F1@O<(. -%FPUJIG_P!]WJW[J];OAE4+O903D.PGQ<O,A\RB4C.91]HD
M:):UGKD<J?@]W:Q%X@Q08-0@=A$70EF.8QE+ R]2"/2\C+$5E,\NC\AZ]X]?
M17XUX95LW3 J?V ]D)W$L[?24XH :L2DT9/9+K:7.FAIUD0(8-'2A/5,5#-%
MP[9D$ PM4M&HW&0__P! (1]3/J'J/[>G]G1^\UL[729;$#ID(XF2?)VM+,B4
MACB@6Y"-S&4-'@4LQ-9H6(BW#2T7+,2CR&#W>1((&>DAQM0(Z/Q6*D@Z@]?Z
MOY_G=6Z!=5" Y6/$[$B;U*-'MLRD<-=][78XR/;$K?R1Z:RP30PSL_CC,Y)X
MP!6PSQO@"DYE)Y9RX<8K8*I6J$M$")(*,QJ2OW"T<<S_ &++V"(]7N)%RPVE
M IC$Y.+,/%4,K]NW>['F"P9=EVN3,8UC+3)13O-U@LI7HCNDB F?6GA668FR
MRB19R4>JA1Z%S)8]T5C'BF(JR:C,(@/C.E(0S8N&3IR[<%B4C*__ $[#$<TQ
M57/U?SZ_&M+,<*;=T7E1,-L(\,;RPW(2)8020?'AA(+,SKF5S"'E$5C[+/&-
M%Y)<:XQ81A2*IN08SFO*;2L,0((KJ9]?Y/R= R'\_KK;PW#P'&.3BR\C(ND2
M4FBDB&M4&#!@D&QC.ZC.^E1^%D\5K.DBLUD! <HK?%O9G$F8(6V1Y69$Y ;5
M2O1'.&N,1]W+'V)HHNZD\DU@5PR3P3;MQ +4.R2.SX7%1S%51XS8#&QLV;:.
M&H9$.$2'/^U#  SK%RZ>J5Q#_"]$#Y^$R5P3=Y%X9+IY*6Y%X.%D"65M@;:B
MVX2;86060P<@7S$S"H]%AAMEDH\:P.Y<%BGW^\&F@JJY_P _S]/ZZDL7KMR"
M:OQP21*,&A"VUWUWMQ3!Q(&!_9TX=S? B+**6LDW91YX5*(("EV+I$GV!+EZ
MMW49G9XJE1<QX9V-^C)8]+%2;O3@=$'KC!C'!H\2 9-(R3C[-:XD@X/8OB+9
MUG%9$D\<.KXHFX%%G;5!MFW=Y.E5)Z?RG/\ +G^S\OJ]?ZJS!OA\&OEM8)AY
M"X#"-3CX2QB;/D<6Z-!,($0:/FF$9F'<T#T=:SAD/'Q':['NA1E-8,S3CZ#8
M$JN0)/E,_P#]_+_/[Z]DUT+CL _KJ4R&:FL3L)#,QA%<2EF/8G73.1Q"9W)-
MPUB"P@;D]E<*"O'[,BRD3-4<@@U;)M"PT*?&* Y?S_A^X_SE6 /\,J!T1J +
MAL"2AF6I 4 #L40UEFC<BKKR1PJ4CG&;/E/)FJT-DX($;R(3)$)6T<#&C1 5
MD&?IO"9!5/YWU.T&B:$$B@*',7KAZ)C D6 !=])HX+M @08S%#&2JJ..-W:J
M+9GADJ[6MW9=913+*V./:88*5MM*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2H>F^GV$VEB,V='"8^0@(28BVOWC'-="T**R(@V)G91@@@\;MI$Y?/
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B*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g609070g01b19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g01b19.jpg
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M.;#:^1NM=([>TEM<W&KW)BJPKS4>1VI;Y O%0OG(6O4<A9K[M7:M#8FE[2(
MRQ-\AYHI6,!,^@.W#5Y-6"\T.Q<"NM:A%O(YA-I9-I<D9>0.3LW,BF3,[-RS
MDB[LC=G+I<\$J3=58JK0^O$S+)=-;HN&LO>(2\CM($DI JO-V<M?2]\H"4X1
M*Y0FS%T5RW=35)L99R^?-P,HL1(Q'1=;'!,]O+ES YE0W=IU;6M>OMTN]"SS
MDGC6B.A#K0HI7J=7ZR:XJS8Q=FF@@%H*G!4\H<%5^L%O.UU?:2)(QD//PV.N
MM-+,67.$O</UV;5H\[$B*"2<HBHFNZ7<)6B(9(72RS=-%0B:2BSA/%M '&D,
M)0,:+UQ/I^77R#-)TX<M>R,Q /+%<6=)NDBI)3E4!NFDNHHF<ZB:**F,<B&+
M,6HE"(L"[;Y*:DC;WV)JBV7/8K6\^9,;3E9N.R]-1J$6NUNVMPCX^4?06Y7J
MG/I-+2BL47=U1@U.QHKP -6CP8J<-3H2XHK#\*P5ELBF1I0RF39JR-*++FFC
MAJPF9GB;1K+K5SEW.96#@CMW5P[E+D[A#'K*KHJI(I%/A*"4_"3?3=B69NF*
M[AV$RM"$O2</)>#91PN]LW*6TKF H&;MZ(-ID@5!;%))HJ)G54,7!3$2^\15
M[88UH9%K@>K6S#0]EHF6M-Q(T^=(GM)2VX^@>!UU:8#F)7@YDNJ:='-,O.*8
M8A)90A77CZ8,5!4,NJX;5.(IIMVJ;HA2#> "=9\W.&#_ $0 0.(@ ")ZB(1Z
M8<71 (5)-%>A0 YUESH&$P7"."DU6*.%E&@D !&@%I'F_P WA6^R_)'B@9KV
MJKS;]1:ZVWJ0M!)TNQ5-N"[>;/;C,&Z%;J!(646=C0J31 PR!6C/FZ3751]B
M7Q!F3%DPPBG>\V34DZ4BM&DM,6C69/I;,DSINT'(F!FW;I':IM%DT%$3'=O%
M3G72PRK +%GB@,!U0#J5HR3-2;211)DY<,&CYBH4[=5 "BY6<'*X.X2.LFH!
M6[9,I$E, 4J.W.,$HE3$?YP:$[]A<FN7YG>.KKW1#^R:KI:X$CQ>P5&Q5%H]
MBQ;PAC:M2IU?L1Z!-A5*ARZ;4H;K$*/*7 I<4Q<APHO9(+)):U63'D%F4I3,
M&;Q%BXFK5-%)!R@Y%'$2DQW+LBR")R'<O".G)@,<Q0.[,DU442;G%-9LDS+.
M)ZI,63ELJ[0E[@ZJBJ"J *XV8E(@V,DLJ4Q$&PMT"B!2F$K<#N"$45*!X1U=
MR1[0\[L77U#LM7/+2<M<C598Y)U1%  U63BR)JMIWG>21M\ V/!UKDU**G]?
M:_FN+:!17P3Q/7SS#S\>6JVF$CL2BQ>O$'"("DW"8I)%F)EE@0M"HY;RAFFD
M5<3K.) 5-%Z])05C%6!-Z @4Q(K6<WM4J[:MED%1!1<S)1060))8Z2IHKS)P
M=44<!)&<"=5JU,."F IB=H("(&C0:GRJ[0XCJ/!LZXAJ:4M''B)L8_BCW0!9
MM!O70!MHCN4-APOPRDU84)K=JKFK*?&'OZ^Y*'=9-6PP1OUXL LM6[4+YKFS
MMB23+$HWE2;SHS)'7;19O.0:K2U.5JT3M25PHJNW7F+HQRO9$C,!;ID9,T3I
M+ME.,A.[5'8@HI<<ZTI!VKK9RDM+!<)OC3!,!4L^*)$TET63<""UFZK,%U#N
MG*I#HK$V+4FRN8,+D]4+S<JO-&5/;VIN((/>.T*IK.\S,.6N&&Y8R*2(AT6Y
MT&LV4)4K59IE9:VR7;K86TT*<?JP""' #K6Y;*QHF3"S)[/N6;5P11S+)E:9
M:4R]R_:%HV,K9P':IW;1XX05<MVY7 RY(5U6[PB+A8ZJQVP-G&QB\GQ)RBY<
M(&(W?L9$E,GJ+-R/X\J<\%L0K9PU15(@LL9$'Q\4FLV,H@D4B9%\>C=3L\MO
M[RVG3M@QM[$+/9;)5S%2;CW,C1E4RI&G3=1@SCHZEMS]6:4L[,<,<8F.E*?=
M==MV_7+I6'4C]SO<^&\;ZZK;:62B7NF1I.1N@@X2<B+4CL'3E($G)R(G=B28
MS5N)E41*";IJ]%L^!,[E%JT(<$0[%95_,GJ#HLR.LLLBHA1P9L+=!3&(%,H5
MN!V4N7 "* 83MW+0%V@G*@JX<F**D>A_728[5#I"'2$.D(=(1YB>E"KGL.]I
MW]1K:O[/79>QE3=NS7+3:-&/#M2_BAAZ4*N>P[VG?U&MJ_L].QE3=NS7+3:&
M/#M2_BAAZ4*N>P[VG?U&MJ_L].QE3=NS7+3:&/#M2_BAAZ4*N>P[VG?U&MJ_
ML].QE3=NS7+3:&/#M2_BAAZ4*N>P[VG?U&MJ_L].QE3=NS7+3:&/#M2_BAAZ
M4*N>P[VG?U&MJ_L].QE3=NS7+3:&/#M2_BAAZ4*N>P[VG?U&MJ_L].QE3=NS
M7+3:&/#M2_BAC'&.TJHMA$% %@X$]I4<!'!TT0:"&.!FS"8@P))1G89$64&S
M6'X9 =/AO/1)L*6R]&E1G76'VG&G%HSFE9YP@HFLC/[.HK(G(JDJE/4$U$E$
MS =-1-0@@8AR& #$.40,4P (" @ Q@H=-5,Z2K915)0ADU$U$,--0AP$IR'(
M:I3$,41*8I@$# (@(" QJE!YWZ0U5!G#-9=FYV@VO1Q26W.)PJ5V>5[K$8E-
M9C-0F)9!H- AHFR6(3#$)AZ3AUQB&PQ$:4B.RVVGDO)5,YB<BC^U$E>G3*)$
MSN[1)N#)D$PG$I!5,<2%,<QCF M $YC&$!,(B.EJBS9%,1FP!J0Y@,<K=H1$
M#F H% QP3*7",!0 H":H@4 *%P $;YZ4*N>P[VG?U&MJ_L]</L94W;LURTVC
MDX\.U+^*&'I0JY[#O:=_4:VK^ST[&5-V[-<M-H8\.U+^*&+:<=N14#D6!L!Z
M!I[D/IU%>+L"'!7(G3MDTX>+K?AHFX(5\39<8D&!#6%^3/D(W^):F)7&5^_3
MGJJF$O-+U$TS.Y>\QA!/AR]VF[3)0PEP5#IW$.-*@4;Q+08V$/A@(X)RT&E#
ME$HCP5RA%A^J^,X=(0Z0B$M^[OAZ H[%ZG:QW;MIE\]  8J^@M8'=MWAI9"*
M0E)+/U:NXS/: Q,#U,3RRL>3Q)4L>PY^^EM]<U@R%^N*!7+)J($,IC7[DC1"
MA1*&""JGS1..%4I O$ ,.0!C$YL *X)C7TH0HF'AH&;?BF/I0JY[#O:=_4:V
MK^SU<=C*F[=FN6FT:L>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_
M%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*
MF[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]A
MWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,
M>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_
M9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##T
MH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=F
MN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._
MJ-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E
M_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C
M*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]
MAWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT
M,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5
M_9Z=C*F[=FN6FT,>':E_%#$Y<?N9HGD)=IU(@\;^9.HWH-<G615FY \;;MJ&
MDRFX) 2.4&@V>QXQ!E6.4HLB9!"M_P"JI0^ 6F-_XH>]UPG\G-+T2K&F,G=@
M90J>*83%%VL&$4YL,R2?S@3# P3'R 8Q _*",R*88B& H6@5J<@E#* 4J.>_
M)H 8N3U3QLATA#I"'2$.D(=(0Z0ATA$$\A-\PN/%,&76?JK>VWV2EGA5=-:X
M]ZIL&X+I!<FBC1;!PG6JWC,Z#6(R0BX$TZ[_ *DC%284>O\ QQ-CKG2]B,P6
M,B5TQ:"5(RN,F#HC1$P%.0F 513YIE1P\(I O$A3FR%&,#GP K@G-4:4(43#
MD$:B 9KLND0BG7I0JY[#O:=_4:VK^SU;]C*F[=FN6FT:\>':E_%##TH5<]AW
MM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>
M':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9
MZ=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH
M5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN
M6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J
M-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_
M%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*
MF[=FN6FT,>':E_%##TH5<]AWM._J-;5_9Z=C*F[=FN6FT,>':E_%#&HG.T"U
M#9['4+A9.SI[1"P6W7SQ>30[.;[/F_E;!2I)^(S .R:F8G07R%=D&8$9B$4?
M$2(;L^&RW&E+=93A'7)1DTP;H.6J%I9&BV>@D5XW2M"DF@[*@83HE<I$,4BY
M4CF,=,%2F AQ$Q0 ;XT*$:K+(.%F6-7:BH9JLHU*=5N94H$5,@H8!,D90H 4
MXIB43%#!$1"Z-N]*%7/8=[3OZC6U?V>N-V,J;MV:Y:;1OQX=J7\4,/2A5SV'
M>T[^HUM7]GIV,J;MV:Y:;0QX=J7\4,/2A5SV'>T[^HUM7]GIV,J;MV:Y:;0Q
MX=J7\4,/2A5SV'>T[^HUM7]GIV,J;MV:Y:;0QX=J7\4,/2A5SV'>T[^HUM7]
MGIV,J;MV:Y:;0QX=J7\4,/2A5SV'>T[^HUM7]GIV,J;MV:Y:;0QX=J7\4,/2
MA5SV'>T[^HUM7]GIV,J;MV:Y:;0QX=J7\4,/2A5SV'>T[^HUM7]GIV,J;MV:
MY:;0QX=J7\4,/2A5SV'>T[^HUM7]GIV,J;MV:Y:;0QX=J7\4,/2A5SV'>T[^
MHUM7]GIV,J;MV:Y:;0QX=J7\4,/2A5SV'>T[^HUM7]GIV,J;MV:Y:;0QX=J7
M\4,7ZU5L)C:^OJQL.-4-@T)BT079S=0VK4"-!V"#2U,DP_);/4"_<2!3EYBY
MDM19?^,7#?C2<?O'T]43IN+5PJW%5NN*1L$5FJI5VY[@&J2Q/FG+?2H9P$,H
M1M*;"*!J&"N8P4,'"&:)!ZX\90Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0
MZ0ATA&EWG8-4UP+AEK9/F1FB95@&&'B 9^U6(^:DQIDYL17*I5!ANSV,FD:.
M)EGX ,00E10XHJ8DM,C!D^7'Y31DY?*'3;$*84TS+*G461;H(I%,4@JKN'"B
M3=!/#.FF!UE2%,JHFD4144(4W'<ND&A"G7,8 .<$TR)IJKK*J"!C 1%! BBR
MIP(4YQ*FF<2ID.H8 (0Q@CGZ2&O?R=WU]5;D_P#<_P!<[8-[V^3_ 'AD'Q..
M)LLU[5,^19S[A#Z2&O?R=WU]5;D_]S_38-[V^3_>&0?$X;+->U3/D6<^X0^D
MAKW\G=]?56Y/_<_TV#>]OD_WAD'Q.&RS7M4SY%G/N$/I(:]_)W?7U5N3_P!S
M_38-[V^3_>&0?$X;+->U3/D6<^X0^DAKW\G=]?56Y/\ W/\ 38-[V^3_ 'AD
M'Q.&RS7M4SY%G/N$/I(:]_)W?7U5N3_W/]-@WO;Y/]X9!\3ALLU[5,^19S[A
M#Z2&O?R=WU]5;D_]S_38-[V^3_>&0?$X;+->U3/D6<^X0^DAKW\G=]?56Y/_
M '/]-@WO;Y/]X9!\3ALLU[5,^19S[A#Z2&O?R=WU]5;D_P#<_P!-@WO;Y/\
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M=3;/.J973S^UR]8$0PN;^7(&[YI?6=0I0-NS'JW7&),0UN))"WR21@:D8X.
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M'M6Q-C4*\27RU.-E!CP:CZ#N>AFJ#:5TS9&LKE9:JY'OAK8(R#!N]8C#+W"
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MT,-K=;82X\I,+*6D*>=:92M>4IRZXVWC.5K3C,#^#'(P$H#:N9@)Q$I0%BS
M3& HF$"@*M3"!2F,(!4<$HCD 8R+^'):HQ3F+8"1F*F &4,69S(2IE,8I ,<
M00$"@)S%( F$ $QBE"\0".+T\>TO4#0/UKL7]CZG:PR7OJFGD#3VL8[>>T_>
M'(>59A[&'IX]I>H&@?K78O['TVL,E[ZIIY T]K#;SVG[PY#RK,/8P]/'M+U
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M*(2V!\"-AY];;>9$Z?*C0H;/A>,DRY#$9E*WG6T*0C%2+;58<F7#EV:OQ9<
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MT1"M>L8U]Q$ROF&H3"+IZ]?!# -F 1RY+\G\>&.2'RQX[RW'$YVU2(K#KL+
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MY]^4<ND8^AG%+G8+-Q3[00C+(1BB#"\$]DU E%GS,6 3:GLE(DNU.LD69MB
MAC!!F6EU$T@,A2Y&%R(S+B,FNI+J]M'R4P(P<JN$W8/3:ZM-)7*3A?9%G-U-
M=I+3<Y')%YDP9/7":P&*LX:H+* 91(AB@0= -<$<M?Z9*"-0->&%0:B4!&N4
M0 1O".2V\3^;-RL@>UDZ-&;- (D2&)FM7^JS)D9N"0F%8SCY4W<RQLI);G3Y
M*VY)@F0?:C9CCF7&AD*%#CS.-235QG<R9S9W($RO9>BBBT6):&4++)$0<K.T
MC*.WT[=OG2A%W"HE5>.G"A$L4V3,1J@@@D,@Y,8#"2\,@X91&X:Y1.(C>.41
M'1D  #6B'"?F<5BJ@$:I)F0%*%+S ?V)3%P<9!#WQ(/"(>;1Y,VD,+E21HE#
M;24#A[[L.&EF,M3>:QQJ'ZMCM(6[F3K+-Q%H(MU+22,R #+VZC1A@HC-L44&
M3155JT*4@%;-SF11 B8B6(ULX'*0<WY9,P4#\K,%P: N".8+POYK5N$9&U^M
MD0@^QQ$P;!!%;+J$"(;A)PZE,,K'BVIIJ?&3A][&&)276L>-7W)_?9[\V6HG
MJX2U!\UETL=,6TS1!O,4&EIY,W1?( !P!%VFE-R$<) !ST(J!BAA&NO@#=R6
MH 40 ;A #D !#0(85!#>&-A3Q=Y_IG)))^5N"*!B0R9V-OUWRM(M,C$Q,'#_
M ,L/&XCIF)3-2C"OWLU*9>.Z2G#N+$-2O\(4%P<@$Y!R5J#(JX6REH+%: J"
MX-P4V:PP3!< 7 H#<N +!^, #1.(=UK0U<E<86M*UI7#TW\,:20X)\N2KS3\
M^@1I#K$2% 9RJZT%"688^,U#AQVFVK$AMMMF.RVC&$(QE:L*=<RMUQQ:J-QJ
M":L+HY5'%G4U#$11;D$9Y9XH$1;I$113*4LR*4I2)D*%P )AJ<PF.8QAQ%JX
M'*30'](F8*!^5HCH_0 Y5^KB)^N]$^).M&U[U6N]E+EVS_Q2&M5^U_XB>M#Z
M '*OU<1/UWHGQ)TVO>JUWLI<NV?^*0UJOVO_ !$]:'T .5?JXB?KO1/B3IM>
M]5KO92Y=L_\ %(:U7[7_ (B>M#Z '*OU<1/UWHGQ)TVO>JUWLI<NV?\ BD-:
MK]K_ ,1/6BXG"/B/NK4FWWKYL<$/K8>#6"PR,U@\%,S"4XJN(VVAAH'/(-L,
M1V67GI#TMUC.5>):8:>\8XMCV;4-U'[;V0MD>?VEE[>6,F\K>-4B!,&+U=RX
M=F1(4J9&#AR5--,A5#J*+'3&H$(F0^$8R?(;-U$U,,X8(  @%X#6OZ(CDWXO
M1H3&//W(U6/X<\A+ G/_ +-"UU_T9SGK[$/D)^@'G-'.+^5^D/HBQ/6$91_,
MXPK&4JQC*<XSC.,XQG&<9QW9QG&?P9QG'X,XS^#..D(J7= &:\>EQ$)RF&]G
MRN!GN_!Y*\I6<-XS_LQW,+CY_ESAO"\_@7CK<4:AOA</7K?6-)@H.\.2-4ZR
MC&'2$.D(F?4M?\=(DV&0C_%Q?"AC_"Q_#(<1CRE]/\O^*97AE.>[*59?=Q^!
M3?X-9QS>$>O7-&P@9^+K3T^>/Y?O\NO'W_<NW?\ NR%ZM&?T1.OTI;_GJQP'
M7TE*^!]_DDCRG[5O;X\SL?4W'D2[=QMP"$Z'?X,T6WK&P5&P'K=)V6<J=1*4
MF[<C..<WRN4'X]; ADMFD;8U1J "LKPPJR1GW-J56J>+8M;Q\'!DOR#IN"@U
MOX!]'MN#I ?@ILX3+G%2DH7Q+N@Z22.FXME-D9$+3Q*,].,6.#A,*P%9;C2I
M! W#2F*5EN/3X^,,OHQU<6>^GY'^N)9_K4(J9W]#3;]6/_\ 2JQFX/\ '(M'
M_)FH?_BGL?JHS!PCYBQ99QX \YH\..:"5(Y0;?PM*DYS8(2L85C*<Y2L '6A
M6,9QC/@K0I*TY_@4E6%8SG&<9Z_,+5M 0U5+9 (" [(-QH(" T-+F1BC?F$H
M@(#D$! 0N&*=S_7J<(?](15_KRN-$.D(=(0Z0B4Z)L(37 1JJ6BKOVNM%K#5
M;<B'!/\ R:GQ;%4&3T,:[YQR(.(>%3!UE+P2X[R)F3(;=C/028V3&PZOM<AM
M$SEK!]*9K*E)O+'DQE,X!%"8;&.$9C)B3!%L;7(LGY3M%VTS>(/&^((JH4R1
MT'395(#FS*8  2F*)BB)34 <$:EP@"^@W4,-0I4;J"%(FV-RY--O0BTNJ-3K
M$@P^2)OO'5YKDMN;N$_N6<[ K#HA](LZLV;2)BG5%)^(@B)EO(Y]R1E3/>$M
M6!\4R#M64$7F97JCITJ=^89:L5>V<PMLX,A*C,SE:S S]]K1%^+IP"+-+!UL
MH=03$VZX&H"):C6HW_-'\8*MQ:#0<(:5J-P9(P"N2;CA&.Z_59$D3$,U\G'@
MK-AX4I#-?HARE1&%*"TP37'7FE&&BT93M46)Q@5!#D0909AYIRO'5,,9RF=2
M4J*LTGLN<IMQ?,T%03ET@?R-%,18R1G+#')KTKM(32@6@:U09N6+MMC"GQQM
M_P#1NJ TJ 4H02 %Q0+D&O\ 1I< " A=&5<Y/Q,$U&H=&)0"+MJK-EGIBW.&
MR,,MU2MB*V($EAS%*8QF%$:@D2D=H1(#Q//!?$N9"G-AP\>)RSZJ2.N1>HR%
MRW<GFTJF;@$ITB1J]+*):SEC-F[:IR1, 02*@Z=IE9J,DM>O 670<%9,TT9Q
MP5P@*(?.*:F$%!P2@4 &A0J 4,(4P0J;)<$89?)L\L,D%D.\H<BK*JZ8;MAE
MNP/$_,>'TVT^J N%Y,IMIP4Y;DP\I\7F=.>@X<3G"B+G#-JHOS,@8:R.+8LJ
M&5@@:8K';X'8(SL4106XH8H2D,T-. 1$,''KG;X0" N3P*PB&#2[!IE&_P#%
M EDR9L+ANWXVUGENI!U15=((>3.V-5U?88O+T<I\J7;]!V [&CFLUIU3%&R0
M@X@LU%<)^4U%=7(S8W)^,2NK9/5>$LP%V:1.!2/,AGATTY\=-ULL:T*%HCII
M/1EAQ)(1<H B23F046(F<5!F9G'XT<L??7!&E<+^E>!L,#W#3^C4*8-!TUK?
M$)U_9(8+6;P*562N#]SFNNKLX>T1!+S G'?)8K,R-(JQ>7* NEO%D33 DM7I
M1Q,6#"DRVF(J,YZ/+[2L64KGK096["8SI<QQFC.:HM#IM JJG+%TE)2\558'
M=X+E\FT>2Y5^"2""JQ$T@KJ X 4Q<$:F_* P -/S1^:-0K>-!"M T1,".6A>
M(8%E( (XYYN(UL@[*/7Z><L9-L'=+#='Q9*R*"PI$L0_+/Y@#8;\1S(F'#;4
M\Z4E///Y[F&J\\2>M7:#!^?6SF6.#*S"T#A_,G16$[F,[4:.IF+)!19FHK,-
M;M45$3:S10*)S.U5#J1LQXU 0 UPE$1$XB8:&$P@)J (@-:  UIEO$8^X>_J
MN8UV; VI%FA6.17&J\Q.%K&DI$Q S7,"FP9"B!H=.4V@_+B.HM4=GS1-8!N8
M1 -$Y7BV(TH:H,J>6<?L)J6:(3-66%ER:[06KE5<&UFF\D;J"X?-EQ*68+(G
M+-DR:S738& K=ZZ5 B:3&E$@E'" U*5 0&M"8(90R"-:TH(%NJ8:4ANK;6EU
M:N/BXD23@KBO7"JP2L0@Y 7%$7!X3->7A3",O8DC)PZ:MM*%8P08-O,O/14C
MV4R^ERFUBTIEJC5%%4'>QTYE*+M%P9N9)G.3-%CF 4PP\:V7;+B4 $-<)O3D
M.=(&Y 5UE/@@(7UP3% :TH!J>80'AKE"E_'=]NF[D>O!3(JN0!]UL]GLBX#U
M:JI4H*7:#,XO+8A6J97\'\/M^7*AX(-28SZX[,="4,HBQ&H\3VV+Z=S">NA:
M2UNVGDUFDS,W/+)2[=-#31ZX>*IH39:7!, .37!D0<%53.*94P I"I(E3&4$
MPG&A0 QC&I@E$0PA$;C"%<]*U 8D8;R%& ;&Z? U.U0&\U.BUM(AS9/AC"*]
M?UG%2$?*F+ IPN+9:^0$-1LG*](C15RYB9:X1<;"FN0$=D;:HK5A,CS"7RB;
M($V(D,L!F>TV$U<FL[*]AV>RR3>2M$9I+G+,B0OY:HDB*RP+"@\;(+F;ES!4
M $1 I@N*%,.X<$N"&$&"&$40I4!H.6@@ TC$6#?"3HUMENM+'$_-=CP0EY+)
M(12EBM6OZYJTH31$\W0'!0QJIAY\N$*Q()OHL15R4Z36-9CC6.%,;? _:D3+
M+!;.M:S('*PNP<(NYC-;.RVRKIT5'6R!FC8DI9.%D6H*NE F3LZIW1FQ$VI(
M,KA9"T&@U&M:B8I2#F"@8("-/SA$1$0NBN_7G,:H=(0Z0ATA#I"/TX<04J1Q
MGTWA:5)SFGQU8PK&4YRE<N6M"L8SC&?!6A25IS_ I*L*QG.,XSU^HNHX AJ8
M6+ 0$!V&2&@@(#0RRQBC?F$H@(#D$! 0N&+IO_4I_HQ'O*N_<1J#8M?EN3$1
M.30:G;(V%33#E7O)^-6ZCJBWZ5V!=31"?4A\T<#C0]@!='.#,6!R,Y8;>FK5
MH"@B3*X%3O2XWA7-O!FSU#TC%)!5P[) G*(SJI7RY$JNK:PG-,T@!R'=+0TV
MS<F@=0:]>IL.M*Q)"WZ9M[7O'ZK-62FMP+3)G:U!8</2A^N3#@%$_.NX+L@7
M7\U*\ #OQW1]][*%VN0Q52"6=T&0J6FHU.&4.H<E4N26Q43B[7==L:T%U^&B
M3"V568-]XI5RX3:I%A7^!&(U&N;"FN-5VP#PJ%#>?1OUKG'(.71=$8!KEV,5
M-H$(A++$B0NGTG0E21=R\3>@VQ&!MCTA2+[KPF,R AUQB)9[5IO0E6MUN72P
ME?G6(=4'8A,=,=(.""")^=7?J(W4S"-?!41RW19NTE>!^B=R,UR?K2]@SU$I
MFI]NU*QTJ#N&SUL_C89%VI5FJ5@)22I?Y334Q>+5=NYVGR $JO$6]?"]AS(A
M([5#!D6B+Z9J9,V;AX<NGP1Z=5JQ@[A7 %NK!*,9K=I""K'7C$/*E1"H,W!8
M)B2452TH6J-.@2H\IC*T(5EIU.5)3GOQA&.2,UTA#I"'2$.D(U^S5^/913HQ
M]SQ"LN-O1Y.&\.JC/M*_ XEO*V\+\)M3C*T^&GO0ZKN5C/=G$@-! =$0(5"D
M1C\S2/RB5^B<?:/6>,WN?]T88O?YOWP^9I'Y1*_1./M'IC-[G_=#%[_-^^'S
M-(_*)7Z)Q]H],9O<_P"Z&+W^;]\2G7@<>NB8PN.KQN&<*6\_E&&U2'W%94Z\
MI&%+\'PL]R4)\-?@-I0CPE>#WYP$:B(Z8S *!2/$'F-R>VSQ+[-/8^T=)EX5
M<V#-Y>\D::,LLP2-..5^+8.8^^G")(<,,Q9X:02S$'N0HRB@^?%CXF.2<1E2
M&6%M][U.9%+K16H;L)HF=9F5JX<J(%4.D"QD4RX!#J)&(J4F$<#&Q9R&'! N
M$ "(#V"S$O;3*:I-G9!40Q:ZIDP,8F&) '!*)B"4X%J-1P3%$:4K2L?F=]-'
MVF_M3&_=WIO[NNOH_P"3"PNX"7ELS]]CU#L4L_N<3Q[KV\/31]IO[4QOW=Z;
M^[KI\F%A=P$O+9G[[#L4L_N<3Q[KV\/31]IO[4QOW=Z;^[KI\F%A=P$O+9G[
M[#L4L_N<3Q[KV\/31]IO[4QOW=Z;^[KI\F%A=P$O+9G[[#L4L_N<3Q[KV\/3
M1]IO[4QOW=Z;^[KI\F%A=P$O+9G[[#L4L_N<3Q[KV\/31]IO[4QOW=Z;^[KI
M\F%A=P$O+9G[[#L4L_N<3Q[KV\/31]IO[4QOW=Z;^[KI\F%A=P$O+9G[[#L4
ML_N<3Q[KV\6)J?/[ME;OK'YV:YR6AS*TX/V68A#I$7C6,N!<-IP)"LNT"P*F
MDZI#L1N%2J[.:.FE"X$I]L4U+F,,/M0Y.6J1S9#4S:O]CEY$<JX'8I'.4T[.
MV25F:ID&":KHCDR"1W2Q122!0Y0%02E$0$Q:\!63651<:V4EX@H!FY1, OC)
M%,Z.*;<IU2JBF053E$A,(P5-0+A$*Z3?^TZ[836ELN-/M&][HV1HNRK)J$[/
M&ZLU,4KRMAU0S-!&*T,L$+6CHHJ000'R<18\*2Z]+82B0PTMIQ*L\MG834V?
M-VSE"4M<!VQ0F21%)A,4U@9.$BJIKJ(F? HF3 .7",8H 4:E$:A&Y"067<)I
M*ILT1*LW3=$*9PY*IB%2 <BADQ< 8I1*8*B8  !N&^,)&[5CM=Y!"8,5O38,
M.2+-B*X;41T]J^!'KQH[+;@B1]BD2M8-- Y,Z2ZAJ,T35&<>SG/BTJ[L];3:
MG^IP4A5-BF1BJ)*KI8$S?G,LDB43J'0*5^(K%(4!$PIX0!G&,QL[9@"@;6B
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MBR,B#"F93F7#BRLHQG",R([+^485W95A.74*RG&<XQG.,=W?W8[_ .#K&)$
M'* #PQUO,H;\4C/\PB_Z+I"@: X@AYE#?BD9_F$7_1=(4#0'$$/,H;\4C/\
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MI[&U_!JDFJ*U;VHG,GLPLN\(*:*\P9G6?+-VYS($,NHBF%2@*9BHE444.5(
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M/BU?4C[:[;#LW\.-Y7P.N2486C*E810'LX3A6,JSAIPVAMW.,=^<-K4E"_\
M6J5A.<YPVF-C@O"1V,$0O #2]S@B(7@ U(8*".6I1"F8<D/DZ<]U,?%J^I'Z
M?="[2H&[=+ZRVQJQIV-KR^4T(?J4%\:R'DBP\F(A# >4*C+=B#I093;@J5#A
MO2(4>1#<:A29,5++[G7WLF/9YTO(CH-VPRD^L"MVA2E:HIM@!)(C8A"D*1N"
M928@I4R 5+!+@$I@AT]TU58N5F:Q2E5;J&2.!!J2I+@$@@ 5*(4$MP#@B%0
M:@$3<B[1QN$6BIUO=M2EVL[<M9[9#1LP*39;?\G]+O6;3,?<!ZR2:["EJK%%
M@VV7I.19+$]XIT$]'%6G+P\'6;$="\6- 5S?QRW<5?-GO\]KQLKLQ;U!!"B]
M2VU#+M2->/J4*I>Y6[E6U5+8VG]]TZ,=FR&Y\JO6+;%DK^EYT@\V]'V1?AYZ
MMM2K Q+A2)M=1-!"_P!(4T< Y:5S5C9X?(+LFZ,>;(5^MUN+/K=$5;A4BK:^
MM4^(/JN@7"V1TVJA1<9_*7H>>&F8S,ZO!_#L2]%:Z#6&=+DM:F'ED*&]&4!R
M_P#_ %EW^&-#F[A[. 66GAWM D:M1=?TVL1CUYM(K8]4CZXJVM@?,C6MHI=,
M#BHQFT5PW01O#_;U(N5:#1Z@'V#7Y!^!.-VCO6(L;T?OZ^&)H:^_*.80H(C2
M_1G"F<!T4NF[9O)#L\-DV^3#VM5+4_;6Z&3#65XEK[981VHB]6D>35LQ3K,4
M IAP =LK\WB]R2>JC:):B3PV#98=7*/UW966K.B  0R9[LU]::;Z7AS5O"+6
M\8>4&K^0,JT5W3@=F)KW7%3HN0)6)F/"@.XG67:FO"M4@@(<)N +C40]I\N#
M9F"298$984U) OJ$-0YI!$#4!ORQ;?I$0Z0ATA#I"'2$.D(=(0Z0ATA'YUNW
M T._K?@7L,M6=@;/,4\CO@9=)FMBZ:-/HM5,;*V/8[I8[ .G#Z"/OD5+UPM!
M%B"R:O),1'Q8UP?(G7L"E0_4]1XY0MH@!A*43RY^0E1H)S F0V"4!&\<$AC4
M *T*(Y &.V6*H$]3J-*MG(  B 5$2@:X+JC0!N"HT 1I=6/Q4=?6L>R0Z0AT
MA#I"'2$.D(=(19I/*?8XWC]3^/=2*&Z?6PI?:4ZVS =A?B?. +V;BFMR:\9A
MQH<5]@3!8J;L:9#R3FPCT8L\Q/A-LQ_%R*$;/,5)RYG+E-)RNJFP*V*JB!M9
MJ,=<X*R1C',4RAQ< 8IL64Z)DP$AQ$U2UPRUN=ZJ^5*150Y&Q4@.2N(,WQU%
M"")A 3F%6H#@E$@E"@B(U"[;G:I822/FX.AVXI6S;OL.Y2F7MCQ)L1E^P<A+
MWO%4,-)>UHFUA#D"!>5TN 6@6Q%4ARP J_#]>P;5.LKA[JX:G_S$DCS83$0E
M2,L3HR,4P@C)FDJ RI0?"W51.=H#HR9F^N#%649G>G0(AB:GL<^:F0ST1*FT
M3:EH@)34(Q19U. .,6<AA1!42BGC! YD3+F3!/ C8=VASH'7AS7 +7MK=%O$
M)3M>,7/9E8V':LB"U$TW02X:\6JV:8G6,XS%%:;%KIZ=>E=1CJH@BR-P*+":
MU6X0[F*6+QSQ-ZJ];E4P"@LFU8N&;?&)NYF\34:MV\T(@D)E)DH#G7B<Q.XP
M!/C$U%USGWFD8'7(N==/"H&&1)NHBGAE6=+%.BFF[*0@B9T8%<>5R*F#A813
MJ*&-(SG:G.9ND2SIT]8WH8VY#=IP(Y#=DB=97MB"]W7'>3(DW;?FW8<*Z-D'
M;E)#3M1-"!Y"4*'PI6=AH,Y?).<+Y/PUJ=#9) IE&IY><22HI6X,E)4VE0J)
M-@>B"<U!)L54LQ%4Y 4.8H,\4 $C2%G0Q0IZZ3 QDA;&$K0 3Q!FB3,3%2QX
MX+P") <KH3&*!C"&($E"Q33C]R6D:.DPB20$@L2K6P&-DU%8PIY@S"-O4ZUT
M<Q"7+CQGWH+$J%9!AR 1B-2) TA4(@Z/#2R=EDA?9YS(@FQ3$QQ4R+LQ8N<8
MF*V&D#EN[2.!1,!3F*= Z1R&$H'(Y.<3U1*FI:/F&O $H* 0JB MU0,3&81
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M>)03 S-@VHJU I"N"$*L8RJ0)\$DSF2&)2*W4<?-=&.55%<55!PIB=' 7PQ
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M'OT.SV5]R/\ [+?WB/Y^YJN8'KMXV?I?:'W9=/EPLYN5._%L/?H=GLK[D?\
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M;JK8!@)8JK/EA"K-MO'SWNZV)4/7 VV3YIA1,-98<09)?GRD*#IRT ;[AO$
M\%V>D6C@; T[C@S8-A<?N.] E4D<.M9FL\=9\+5%*K[]ZK^QBL">#.#*U.L.
MOQ-I1LT*0G3($>7,/+N<58]YN-=_&PXR(OK>/AO\&_DR13[8W);7I755GO\
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M4X6.5)!"8F,NLH($21(I+)DW(=50P@5,AEUD40,80+C%2%K4P17?=6O^S^Y
M7J!LS9NU].F[U6Q>O(.O;/G:FMLF-4$=;;,SMD1:M8$)4F7+I]L,6V,!^51F
M ]E9X/5*X&DLIA1)3<W1L#.]QIKR<[]C&[9F5!=LK+J7_P#C6V?_ /JQ%E;X
MV]GS7JGLJF2.28:R"-E:MD:4DK/;YU@F75=72;6>NSM3JBP,4''2UFRV,D02
M9LD:RV1"<LPT&<04*C+;!3O<::\G._8P&<RD0ILI+O+6W!VW0'3&\WK6G"K8
MENW<?L?*@.JK\C@V0NZ-50=X:FA:_NC2-81-2Q)ZGFX&;_7RPRM# \X61JM[
M!/P+&''&H^4/-O-O-@IWN-->3G?L8C9B4[J2ZZ_^VM?:QLX8)Q+BQJCFV<O6
M=I':;N@7O<9:MC\AM?%S"[H$H4W6HB&F )R"J@6JPJI-=;77*G6J[#)'%2[8
M9R1M1FP&2[8*=[C37DYW[&)V8E.ZDN#-_;6W#VWKP1U3=.X0S-HZWVO4=_:K
MU27UM8KA;8M>UE>M @J9:;3L)\#\N[5;0!*OF\2[K;! !FJEM@!I0._?),I8
M@,*SPXEA+8E-@IWN-->3G?L8C9B4[J2Z^G_CFV;)_P 6,1MS5?9[;YL9PIN+
M:&D-AU@^9G7"=K>T['UD:HKNQ2FIV]&SMB."B<R8ZNTL:JABJL!?1):BUO,2
M89$Q6#1<A.<;!3O<::\G._8Q.S,J#)-9<' ^; .G+C=,15'XM<!&Y))Z5RVG
M$62$&R,M1W^2&M(,@68N^H:_HB]6P<?!PA-LQ9[AJ^O(KY.;.L$Z(-E$R5CK
M$ !9\#3 UL%.]QIKR<[]C#9F4[J2X/\ ^:UNOK=^-N"L;$UQE[+YE%-C)O&G
MTC-=WPY=J$%8W74H :GP#\ZX&9>M00\:<A,Q-41+!?K>=!T=6'(->DFWQ@1Z
M!6V(0.,V"G>XTUY.=^QALS*MU9=?E_GK:_\ _P N7)?&/JW%OLT:X[5RD[<%
M"N-PJ>Q*7LB!?K9O>CR+;,):[I^O]>TD$6D!9P,00JP&BZJUU6<"W R7R\>J
MQ2UAG%[(1.FRK8*=[C37D]Y[& SF4[J2X,MVO6U KE_XL;M?=0\ [Y+&1,;S
MUC1M=C-$[MXZ-Z8UELG2-#U6YKCD-*&$]KM-!@8EDX'.V([7*;8VS5<L860-
M/4X00'HCK(VM%C;!3O<::\GO/8PV9E6ZLNR@/]N;90R?\7-6--'\=N"8:Q0+
MN(Y6CX]_9ED;">N4C>.HY!*\["<L6[K?6-EW&*T.B#7K1KZU\B=M':9 K42L
M4R*]8( TS5#8&L5<2';!3O<::\G._8PV9E.ZDM\M;774N_&Z  (E2ZT/@/>)
M>H)$_<^LQ4;1E+ Z^UT+ [KI4(8*JM9W!QSW<%'/LR"LQZ9Y%<N+6JF$/.R,
M.+!1SHU:E.%_*XS8*=[C37DYW[&&S,IO_P!J2Z__ .=;:!#MN_$!&>'79M'(
M)4%+Y%#6JD? 7P,?IT7D-KMD"9([%T[NW01^WREY;6;8M36I]^WJJ#I XS!$
M1VFJ\1>#22HGRZ2V"G>XTUY.=^QALS*KO]J2ZZE/YZUS" A_Q=(1OM5T7P>J
M)TA91W+EY\U;&;7'VO.D\B]:,O;HC6RRVRYR(FPU"H@U2!XNVWJWG!(RCJI0
MQ.3TL(3ADZNS"!16P4[W&FO)[SV,-F93NI+@SW/6UV;MM<VF-7C<6.SU:0+5
M*Y-CB<V/#@@+"3F;WU(U,O5$CTWC?1R&NK4T-%CQZ:I81/$S1,@X]68-;M3Y
M"H2'(=F@Q+%8X91L%/-QIKR<[]C#9F4[J2WRUM=>/_J[X_Q !B7J=0>$&O@E
M^#4GDJ#JK^PM9T[5A&QU[D950EK" J%<-NWJL$ZN>%%8<L18(-CW7<Y#\S/E
M,(C$P+&$1TH='EQI[8*=[C37DYW[&&S,IW4EV41_MK7*-*_\3>#>B'T\6^ 3
M0O,2%RKABS$R<7/GK6*W5HL<9L=T(;OHO(D;>9HZ+5VZ>'/5C;.N:O8P<&GU
M:LU-Y$>8,L-9/#B,N,ZV"G>XTUY.=^QB=FI5NI+;@$ #7K;((4$/ZW.'AT1@
MI/$C@4*$)BT?D[1X\N"#LD>$$V-MZD;#UL=MUEU+N+1TR\;&JD2QTVTVXFYK
M#>5WJLX>)V'4!Q&%@/)?:25'J(R&P4[W&FO)SOV,1LS*=U)=X'K4!I<-/ZS-
M2Z+"@*MP\":%TKHASDKKHA#TL,@1AUTD;:H*[39C$NB6G7.P[38W9)F7&G6'
M9U;V!L-=F(/-//-'+A-L,!;)>' E,M@IYN-->3G?L8;,RFM=E)<%];GK:F6N
M3&Y-Z.]KRH<#=:CK ,";IUU,C6,W5;!.\Y;] MN-D*?H_37'P5F.L+90V/$J
MU]HFA)E-R4R<N&FBY-E4=)-<9IL#.]QIK?\ _M[SV,!G$I'_ ,TEWEK;2(]M
MWXBFS\?.!=CSMI+'*,;66-NQCX\C%KV]-1X8J0N[WYG:>RQE+\^"SCT./LS8
ML=BW6U\\[8B+))OQ%6G5H6X\/=;!3O<::\G._8PV8E.ZDN\M;5X\;7T1N0JA
M\2QURO\ <9G,@;:%[5N&N;KL0+:MMZ(GP+"5U5/J9.F1\$AM<#VF$$'2Z6)C
M_)9-A>J#8HI;X,"O0'K40G);!3O<::\G._8Q SB4C_YI+O+6WM<HYXGJS[-U
MSL_:W'$-K:^TW8)2L;0M%XLL.DV4-:G:]46-"[HIJ["<\QS9R!0Q=JNE6 1Y
M$Y3&)9,S%CQ</*2_XGG(,'TOET\5?LW3)-Q+V[1 SM!5L"[DTXE;H$4<<4@J
M* W:.%C 0#8*:1C&I4*\19XT>O92FS=-W9T7JSA8K99-<4D EDP0%53%&,!"
M8YPBD FIA'4*!:WTVGC]W^7<@,Y_EY$W;N_VL5VEIQ_U>NO&"F#OE ><?3%T
M7\K](?1&%N#3FAKU*VD-;7C55[(16=O"F$J4S4[%(4U#&[4AQD8SAN'+5E@9
M>DL)0M;7D9Y:)3\>3E(/G!3.&3@T='H" _-&N8<H:!T]/IS6@:=:?:;>9<;>
M9>;0ZTZTM+C3K3B<+;<;<1G*%MK1G"D+3G*5)SA2<YQG&>L8RC[Z0ATA#I"'
M2$.D(@6Z_P 8/1/_  /W=_U=:=7#7Z%F_P#>I3_[^*UQ]*2[^[S'SLXH9VL5
MXC:ZK''JUR3#=>\BVQ*&H,V*OZU.:\:Q<0:]?OQ++G:E8M]?9+KC6]XF%8&"
M(ECE 1%T>BG(@:">$G:>+,*WT_?INIP<'AI%N]ODG3/!?:!A\>5$OEN)MV)/
M"CP:)73@QV=I\G*<'F:_ SF""*PENYC$0T+.8@R8V]"CYRRPCJXL]]/R/]<2
MS_6H15SKZ&FWZL?_ .E5BV75/%G%?^.[CK6M;2ZRPJ4\WO3E<XU&0MMI<AU'
M)S<*FV$N/*0TVIU>,-I6ZM+:,JPI:DIQG.+B>?VU#]3V>_[!+(K)3_95?UG.
MO^\OX\/9_9O<PLU(97KU&I&RX-RY+4[FELR+K^%JJ(1#;HV1QOY0:EY!UL:"
MY,#]UZIN4<1<;1HXP,M1JG0PEC@3KB7 :_IMD!CGIE,&?)ES!3CW]^+?"#-<
M( (7UR5 0O"_3Q!41B4K%V7UPF:1OX5C4FA4;G-=D0-XB"[4"9@OOXY'M:YO
M&N2DR!>;>,EW=T3,K)@/5EW^S3Y)PM6DY'FUOQVWHV9B,*_*-,(!#@J(] W1
MML?A7?XYFCF)G$NA[.KD#5UGUD)I&U;+H#7\[66QRNV0FP4[Z2YQSUG3]>AT
MG@3 BNE;%J*F!]M"5:=H&&AQZ69*64:@(A??G"@WB A2\*"(\]PU&\,]P-+\
M.H&J+)S_ #=*I>M]1F^1>U7BNH[O0JU71)T%2IG$SCGKG+DEP"-'S1;4'=]&
MV+</D\E_Q$DG*7:LH\X'WWUHQ$:TOK=Z1]%(H5N/@SR]V4;V3LNJ!]<51JY<
M.]B<#@6FI<K,<T TQ9^)15X60<OL6U2*>ID7S'<A!FJU&I3D]6O&4W5B]+C+
M13<.O7GC(#  A>(@!@-< 90',%-%^6D1]Z-/D:]1T!@>MM>AF!'(NP<@5BK5
M:*6 /[0UBUIK0>M[MQ*O@KC_ %G76F -5Y-%*(7:LKM6IN:'$K>NJ+8MG!+W
MLNSV0ZVA4*Y<U,F^-!"M1NNT#>(!=EVKD!V=?+N]7/?EP9*:]OL+:&TZ/LM0
MI@=269ETCU[5_,K7U$IUSJNZA&U=2%0.FY>X>/*)<<W6)\<W5=3NGJRQG8HX
M4_-0 P!U'_ET" WT'.&7+%S= <7>6NL^1O(K;5FV;I5YS=E8X]-D;4/US:2B
M"7S7W?D3B32(=/SLFN,UG-9U;=];5$5;(TIX83?%>>WJB\56>Q*1 B%  *Y1
M&@C7* 7UH&C)3PZ*D;2X';\O0RZ :KI>H5(&1Y!<CKC0AI&Y4U,.BF]WUK7@
MZA<FQ3 I1),2Z:BL50MQ]QN)AJ]+?V _. N2B+QA*$ '?K<&G,']'@R!HH'@
MBY>J>(Y'7>WRU^!ZSH&NYEQYAVC;167KX76J^)&:3I.AKEIK70AZ& AC<$;%
M=C%L(74K!F0YC\0C?[^4F%6I0H-!<1 C< ;U.>MW@NXXGCESJ;:VZ>)?,'30
M K4#-EW'QMWQK#6PQ 6?5$,6;8&M+95:U'L-B(6NQ0WHJIY<?'FD60XIIC&'
MYV6$M=T5M +A#A"*#VSL^]N:*.QK#Q**RB<\Y4-N)O!.3-HNKY8^P[6W#P"P
M=&ZWINIQFDZ?5Q$O2W&>\8>@U4IKJ<2MLHA8)UZA7:YR[0I&6%4*#I :Y<@&
MRUKG$,V2.L,TWVI^-=D8%AV(3F[;<UIH >FW#=I5]O7K@RNU_C/$W]1D4"&-
MJYPENB[6>J\GC%9VT*OFJ8T(1LBG#_G!%/P(N*.B/FZ!SW?:I0:Y NJ WW9<
ML:/!XO=IJ"LUHM54V-YEO]\U^-3;+?.V%6VP]C56^,MHH ZLS:@D-9?(MLL;
M;FZL+!=KYD68.'&4>W.SI9%%A4S<4*ADI=4:<8<&8!X_#$_[HUAVB93AT"I>
MG[1-$[Y<V=NXK *G=C1I%NINLRK>[)7'"O7&Y0S0.%=C-%?+:6A7\GY_L[$M
MVN3WS0W>8YHW"N: 8-;\EVG> 1SY0J.]F +@C!V/1_:,MVFRV"!M.Y'*C9MC
M64Q8:()VI6JX7:UW#Y,G#5$J^JSDNOYC4.?\QQ,5BQRGIB7RT89-J4HKA_S,
MJ$A4."ZF3>\]:W\$9@'Q[YLZ]T9V=.J]<V5JNNZ,X[Z2UCN.(!N@P<"%[,H<
MOC6,.V*S,R1SB]GZZ9U=3N0-*CUH7A#LRQW*KE4"6I'F^[ZY0J B;?$:75NO
MW[KZ>"N7(-7J7Q5[4W7.I*?K?76R54@-51U.!PJU)OX2W&(5M$:]N8V3?*P5
M:)4V&*TZ-MA36ZI&M#$VT-XEU8\:)ZVV,-)/5RW(")1&M^6N2E=[*.:H9JCE
MTQ+ GBQS@U#;JPWIZ;(:I!7E7R/WCM5EK:KS<ZXUG:O*HW8(PXJZ1-CF4E)_
M'#Y/#Q#Q /?<B+'*-KB?(.QAQ=@.HD1*.8?Z( &:@@ !F&^HU'^-VN#>+?:*
MEA8LHN]W"B7,[1H R^GW-JU,I>8!1B'S&LS5$K&PFH]DL9#5M6N>Q>/P&J.G
M2ZK%,#UTK:23 FR233CR(J%X90S<-U1S#?3P9HD,;HSM. ]DJ49K<Q8R)@;#
MK94;83M] 2HX,2_9^/\ 8MKRMG@8@(>O8E;LM1'<AZ+KJH"6,MTBP6.O31T*
MN"T ;11T!$HYA#+YAIGX*^F^+"=GAI+D'J,-N<SR063E; V9:-5GB)8W?A6P
MRY\[5./NJ]<WZPK+AQPR) "GMBU*UF*@$\DBJ%5&<$B8%5MMINK!$080&E/-
M3..C>IX>.+/<;O\ )Y8O^/OE7_\ %#N'JXGG]M0_4]GO^P2R*N4_V57]9SK_
M +R_B)>7F_=):DS6ZWN?45JVX.(Z\W/MC$$%4*C<Q0FM:QB4BB69HP&L]C#O
M$)MS([TJFO:^*&"CT8A,M<A=ER!K4,D<AT\6@!7C ./^%\5/3R]X5,U5F>WP
MOMS(75YO5@L76GM!::&62I;C); KVNM9ZWJFM2%JA79N]@SNSX<L'9*K5GZ&
M%%&BLD3?$RWWX,A$B AGO'?$:AIX+OW1$FSN3_"3;<!5"B\&;=92-U(\9:)(
M:E5C5>F#)4#<=F\#;4Q3I!L5?QNQ!+NJIG,?1%HD4BUC:Y1+'<@Y"MI.^9XD
MBQH#T>?KPP !#.&??#(.]00&@Z8G+C[MS@WLZS:@T5KOB/+4MFJV&9KTA<]<
M:B.QJYJH?K'6X1J_$K*8O-FML<9?=?DZ'1O-T_$W:DJ"*@ ]B5,(*@CW5H"
M@ B(Y1OWQJ-W@XM$>B(?0.CJ\)LU>!:AUN(K-SKD&H6NJ#J: B5$_5ALJRSH
ME?)U1F BNRA*9EQM,E^"L9EB8\>).3$/JDKSTC&.G'XV\=HBQ#D70>EHSE?J
MTZC 5Q]649E82DDYI$D2IXA38)*AM6($2Y:?.K\++(F7-)D94B(X_-DN.HFH
MZ1B:>D1#I"'2$.D(=(0Z0ATA#I"'2$4JY_\ )*T<5>-Y_:5+"@SEH4>KU6$,
M61J5)!Q'CTEU,@A/@PI4"201'A1926(B)T5"I;L=Q];L=IV,_P"BZEECV5N+
M7-9),7#ELQ!J[>N#-!3(Y4*U(7!224435(D)U5""<YDE!!,IRE #F*<OC6KS
MJCS/4MU.WUJ)*S9/9IK^7RQF28E549(J/E#X;A=%!5!5<$T4E 32*ND JF3,
M<QDRF3/^>GTRO*[\F-#>[@A\5]?5FUWL'W5:7E5#W"/@;;F:KO<MC>0W?Q:'
MIE>5WY,:&]W!#XKZ;7>P?=5I>54/<(;<S5=[EL;R&[^+0],KRN_)C0WNX(?%
M?3:[V#[JM+RJA[A#;F:KO<MC>0W?Q:'IE>5WY,:&]W!#XKZ;7>P?=5I>54/<
M(;<S5=[EL;R&[^+0],KRN_)?0WNX(?%?3:[V#[JM+RJA[A#;F:KW<MC>0W?Q
M:)>-]HQVBM:\F\_Z/U@(\K$V0VWY?J8G'RW!IP+Y3VM,S"[9C, C7*]ELR9#
M3O)C \>_&DR8#;<J/EV@;:D&I"\P]:VBF[C%N&;8V*G;<V$K,'6LF(IT8?C4
M7CNK=NX2PVZRI3E(J(D/@]N>_A'_ (2$MQ>O[)2%IC6DQ>EQ]FGJ>"A)V.R<
MU!;"FX:W<2^7B5X\9KXMXW0.FHH@4%$\**X7;$<NB4V(.'T[1LV?/E1X4&%%
MUF3?E2YDIU#$:+&8;M2G'GY#SB&F6FTJ6XXM*$)RK.,=7BOX/FI^BFHLL]M&
MDDD0ZBJBDW;E(FFF43'.<QF( 4A"@)C&$0   1$:!'5D/PQM6-RLBW;L;(+N
M'"J:""*4A>G5665.":229"S83'44.8I"%* B8P@  (C'>L/:[<Q:J<*UL_2]
M$#C8.=(&%8"]>R'W(4^(XIF5%=<BW!]A3K#J5-.X;=7A#B5(SG"DJQC4TU M
M3M\V0>-7UI56SE(BR"H3-,H*)* !B'*4\N*<"G*(&*(E"H" A<(1OF'X7NK3
M*WSJ7/V%CF[UDNHV=(#)ESF172,)%4C&2G)TQ.F<!*<"G'!, E&@@(!Q2NU]
MY@PAPHM+IFBV!QO$U0J6O7,WQ<W Z1Y)-RUA-MRO'D\G_%+\-*/WW^M\+'X>
MLB?@_P"IZJLN@F^M(99L*8+IA-4:IBL3&)X59?3YY/G!01NRTC!7\,#5G0;M
M7:LOL>1L^!<6BHR-U@K@V4Q2^!2;B/XM3YAL( OR5"^,9Z97E=^3&AO=P0^*
M^MVUWL'W5:7E5#W".-MS-5WN6QO(;OXM&U#^U=YN%8=7(#-;Z8GQ+K:B-'JC
ML36)!_)^W"&JN^1KXUINV*>D$HK5UJBEL8;QE7GV EO*U.*2C@JZA6IH@H]2
M6FL_24ES%&9/BJ3= H-6#@STJ+M8PL *5$YI:^ #5NULJ)J  "-HW_"QU=':
M,L7;2:RJZ4ZFKB22HR4@=GU_-FA98=PP;E+-Q,=RD6=2H1)@A77R %$1,(!M
M<CM).T-BMVEYW2>K\LTB P3MK[&I2LID!!DPIY-J01>C6MYME/FL26*NI\)3
MD<4*)DWT-0!\R0SP2:CNI(H+$I;0S?"F2IT6!33QN0SI4BB2)B(E.P*)AQRZ
M"!1H '7711()E54R&ME?PE/PC$BS0Y[*2# DK<CJ:G)9IZJ1@@HBX<E4<'2F
MYRD#6S1TZ.4!$R;5JY<J%*@W64)%7IE>5WY,:&]W!#XKZO-KO8/NJTO*J'N$
M=5VYFJ[W+8WD-W\6C*!^U[YAGRHL((I6C)I0U+CP1<1O7$U"IDF4_P"3,H0X
M];6V4HR]A2%ONN(89PAQ;SK:&W%)T.-0#4\:(+N7#^T:2#9,ZJZAIJB()D(7
M#,(@5@)A'!O I0$QJ@!2B(@ \IG^%_JT/W35DTE]D%W3U5-!JB61N@%9553%
MD ICS<I  3U*8YC%(2AA.8I2F$,<YVR7*]MQ;>:SH-66UJ1E3>NYKC:LH5E.
M<H<1;%(<1G..]*T*4A:>Y2<YQG&>MP?@\6#$ $'5I@ 0 :#-$0$*A6\!8 (#
MI 0 0&X0K'&-^&5JO%,8HMK%B)3"41+)71BB(#2I3%FXE,4:7&*(@(7@(@,;
MI6NU,YVW(+8K%5=4:FL *I1ER[(5%:F,3(0AAH>1+O+EO-6A24YCAQ!<Q);1
MX;D8.*)E7T-CQ\N2S7/-0_4NE[EFS?3J=M73\X)LT%YVV34<&%5) H)E,QK0
M[A=!N01H4[A=% HBJJF0UU+?PJ-7R<,YC,)59ZSC]C*4S*S%TULT_51:$*W<
M.SBJ<LU$*IM&CMXH4N$=-HU<NCE*W;JJ$VM':(]H^X7A 4Z"U_YY(@$VB&.S
MI@\F2^"5/C"4S\(59L> E1B= "ICN91*4:(#P^&,DIT2*]P!U(]1X$%'0VFF
M6MT76LE%0M T$A76*.OBJ@R&M&Z:K@3A5,&Z2KC#Q*2ARVH?A%_A*&=H, L9
M*->.& 3-%N-E)D"AV(KI-07H,T#!J[709@D<2K"]<-V>+URNDD>,S':]<P@,
MB-&*T[0\9R:-&F(><:\E/LRAI:&U.@2X[\>WNLNH=8>2EU*',N193<B#+0Q-
MBR8[5TWU -3QT4YT'MI3@FLLW4#91(IB+-U#)*IG*:7E,42F*(E$0P5$Q(JF
M)DCD.;K3S\+[5G8*)I.V%CDC+-FSM$=A7)R*MG:)5T%4U$YP8ARG(< , &$R
M2I5$%2D6243)B?3*\KOR8T-[N"'Q7UOVN]@^ZK2\JH>X1Q-N9JN]RV-Y#=_%
MH>F5Y7?DQH;W<$/BOIM=[!]U6EY50]PAMS-5WN6QO(;OXM#TRO*[\F-#>[@A
M\5]-KO8/NJTO*J'N$-N9JN]RV-Y#=_%H>F5Y7?DQH;W<$/BOIM=[!]U6EY50
M]PAMS-5WN6QO(;OXM'H5V;?:2;FY)[WFZ?V;5]<1Q1*FF[&,*TH"0KD^"3 .
MP%*:FMOF2L0A!F0Y,AO*<,1Y3$E$=Q$E;.765>5:KVH]9RQUF$Y_)7DV,LE,
M&S1="8.47:2J+HJH 9,2-D%$E4U"%&N$<AR"8!(!L$P>]_@[?A(6TU2K<JV2
MM3+Y#K=Q)WLP:.Y2S<L7#=PP,@82+%5>NTET%D55 H!$U4U2D,"AB"<@^K''
MSO\ *]_9SGO[^15[_HP$J"<8_P";">OF8_Y&\0/.(Q]PE_*_2'T1/T^!"*09
M@PE%CSAQ&+(@SX4MI#\69#EM+8DQ9++F%-O,/LN+:=;6G*%H4I*L9QG..L(R
MBG^NKS/U'MR!Q@)PRY>MD/+R.K+<0;(1TCJVP#GGETB3,(0DLV%^M*A.#QI$
M;.E-(%.184UUB>/<@IS$*EPL@Y]\=.]UX1P :&P<V;>"E:;\7+ZPC.'2$.D(
M=(0Z0B!;K_&#T3_P/W=_U=:=7#7Z%F_]ZE/_ +^*UQ]*2[^[S'SLX\T>UEJ(
M>&2TI<@9&\L;*N$^VT"*#&WBSUZE6 )!J!DLJ:10YS8X4TT19Z>J3)/UU2+_
M #S%GPDA#?K9)D1%L5-IXM2WW74R[_\ TF'F&GGOAM:$\-X'[)'2214Q('\1
M[C"D%SKHI\X5>BZ;(L.DC+P(D9!O%9SC:I)%T,8*BG);KRQQ*=#RS*=N+/?3
M\C_7$L_UJ$5,[^AYO^K'_P#I58MQU3Q9Q O'#./F_LB>_'A(WWRGPM/_ *2<
MKY.;=>1A6/X4Y6TXVZGOQCPFW$+QWI4G.;B>?VU#]3V>YI!+0'B$!#A 0BLE
M/]E6_6<Z_P"\/Q\P@/ ,>5 M[MDA.NJHV5G62S7HE2J#8B,M(;B=%E"MVF]!
MT":6UQ;6(PX.!:XWU_>_SA"]AG:G'G;D9@8$.4*W$02\28]/%M\W@OIGR5&_
MAI0 #)=?EBW.AHO:#-;#V0O:=A"SZ66GQ2]2C;  Z[\TU49&Y$\F@DRK4I6H
M&Z]:)$LAQ[%\;;.P0V1/M>&3ADLI4V//=-5T.C$:7<_$&G?KDS176,KM;(!W
M5C<XT<(BRVJ))>[R!](XPF6 VTY\W=;9RM'Q$NRZX>7 JU?C:'DZPDUN[189
MZY$;BF^$IU96N%6T+J9+^'@R9M.4,F>(XK6RNUAFW2BT)L5?$7D-1ZO9CC%Z
M%<9'=8V&*6W?NX&9/[BL%5J]7L5<41U17*K*HU)TP]).UVR1@,>_SB\4H5+G
M$3\WGS5KD#( B.>M:^"-^KJ^UG)8I4J42O(<.$-.F"$2UA.).+M=H3-IX'0B
M%4V:BK#"%7%!<M&N>\BL2=5O5H_*H55US+,67-Q=%9L2'S:#=0?#_P UX?X0
MOWX@X:#[80,[;KV)$WZ+L.[HU=!O4TG#XJ'6D6ZH:[VJW-$:TJ2+()JZ^/#&
MT2X(:@C8"-5W<=JCE;E%KD-;^4EL&H?-OS:,NG/EOI3)4-X1NBY 97:-B=OZ
M?FG2-SMNO;!R"Y(YV;5H8?C76JI3M(XW8;KFA%OVU, M?BL$5I 4 OB*^*%P
MKI9CEC,M6/9D C%%Z^@H#3-H+IRTOY\^2ZX+ZQK)Z1VGEEW_ +/ !7+KKK1A
M?9E,#56U,1N+A^93]>0-K#@]KL^O))4 1+3'++J-^;<'A^SZA=)M;,^2B1CI
M,A!)!W4+KLXWUR^#BYZ1B.,P#M$+1R'T!=>6(6Y0AM0TY!3;6QCVAH.IAMLN
M/%WCKBZ>''I15S9!;9#W)6+R %F(JT%-9!:L)IS],1 B34$SR X/SJ#P9:Y;
MJ9LFF^_AC4[,'[6 HU5:V7(&[#7+IJ2WMWR- !\=8<6#=; 0W2)+4^Q2X4^J
MV$&+"45O2<K6=FHQT@0D7<O<YMQ2=#,Q*X'0"E0R9:CEXL^^%^@-^NAEKKVH
M.L,9%$ &W:WJYEWC)J^OIJ@[BWL"W#I4K;G'C7ENDZTG&($MZ25MFNCNUS9*
M3N:%8ZY4S$"*^W9V_)%0TH7::C>(Y0OH(W^&E*98VQLYVQ; XDS)$6.:5FZA
MT;+E3FH'%<3$IUM0:XX1MS1JB,83:57_ &62K$OD&;\[&S%>UM7+.'(5>M:O
MLH;.K;9;$/F\XYAR7TSAO!3+OA&P6)[M:8NKYMJA$KP4V)"L^FHH;6=<JO$F
MON6>MQ>-3)'92C]KL,N\B*'/LG(::D*9-BF-BP <L,]#K-;$ZZ/N7FG(!@U$
M!I2^@U-3+ER5&@9J!OWQ;?D75^1LW:N26FIU@"R;*!XWTX!=P(VD&9.LZ:SR
M26[R](06]D"#M,&V"RZ=L% *@D$@9Z2?=UE)=&AB$ZL1X$U$!3/O^:[G\\;#
MQ_>YU/TO1KNZVM+-35:\UUC="2;9AG:"KLBJ#$;">:9HZE:K:GR+4DD_$: 8
M;KC<=Q"(;+#"6V6T!I4:9*W<$6$%M;K1?R"C4_5LK5DC,R0*9%B;9 OXG#+>
M(L 40E2S1&NV#)%W*C<RP1HE9P&;;Q5F:R=4[FX,HB/SY6WBWVBTZI;5 *I^
MQ#Y(O8MJE =F$[.K-4L<_D9<Z3R@ :RW2U*:W,J'+T?J>S&>/UJK4TC$%; #
MDB\O#NLWPVI*F%JR,ZENWJ9KJ5K3(-]:YZ4NJ(Y;;:(T5REK>[K<8N5;O8IP
MANZFFF+J=MT&T5FQ%!'(CF'=-D;, P(%LLKE4JMNXEWO4^E!,$J.K))4TA3Z
M3BNQH6K&Y0I$"(4"_-?=O%NR!G 1&_2.41K[4=(QATA#I"'2$0)QNSC.O+%W
M9[__ ,^^5?\ \4.X>KB>?VU#]3V>_P"P2R*R4_V57]9SK_O+^(EY6\CM>Z2L
MNMJ=;-&V?=1O;@&PUJ!$K@_6$EN#5K-N/C;HLL!//[+MU2BK 7+8>_M1P"@>
M$Z1ASX8]\F=B(A 6GD4\6@!7. 4TUWQT;PQ2D1SQX2V2%6XXWB0\_P#+366K
M:-614[7_ !_&MSJ[L1OB;9(FG2KA2XQ1=;J%95S&TY/F(L,D?K@B7AVUFLS"
MY(;6TVE$X(Z0SZ=_>SX/FB)M=<T.*<VE5(_$XWZL%[BY#B>*-BY%M%JY4YM#
M163=<[,>NG(L-LI99Y,53:C0.66K6-4@IT>%3(QW5-D-$HB)3.2UG1(E&N?.
M :<IO.(" Q,>L^T=T=(L,0GKSB<9J(ZP><)$L@@7J>CW&1N39FZ=(:F;$3X[
MAP9 PQ<9NS=>V"YW^>>3'DL0(;:LGY$ 5Y6B*4NK?EI?00H(U]&3TQ-5.[4?
M4]X7KD@*U/N:#2]FW?5=%"7XW"H$&MCB.V*'I"^AYECRQ?IL^O#AD7D)K@'.
M(F(D(83M$F?6JJ0L-AD5,3:T,$=[((Y\PB%,E*W"-V:^)&Y:\RL\=7:IBN"@
M5X^6>E]U[!K$&&LJ:*V:WU)[5=>T_6JX.JZ2!$S#V9?-I@ZJRX*'DITV80%1
MP;;\R4AE]$ %>;KQ7UT -T5UT?VE-NW!O71VG9>N1--'[#U?KBP7N[GX%K%C
M*CN=Z?RCJFT>/,<85S -P]D_+CC=9(=''6P>"1 !4S92[4\NY1J?2K$B1+<(
M[^D,EU!XAOIGI'KWTC&'2$.D(U:WV1%8$+G80V]*==;CPH[F580ZZK/A+ROP
M,X7XMIE*UJRG..]6$([TY<QGJ2A4:<<8F&@;^:(D^> U^*Q?_O?]HZV8 :1Y
MNB,,,= <_3#YX#7XK%_^]_VCI@!I'FZ(88Z Y^F'SP&OQ6+_ />_[1TP TCS
M=$,,= <_3$P52P-V4,P2PE#3_A+8F,(SG*6937=X24^%G*O 6A3;S??E6<-N
M)3E6585UK$*"(<7!&P!J #Q\,>#G:)DMEWOA3?MDV_9A0L$7R>V-0@VMV*Q3
M!M:KXW6N_MH:WK9)DS"!(N4\G@#2H^):B=BD09,LM.>5"PMN#F-[I^#S0-45
M$+@_V+,]-1'!;C=?X<F88^5?PQJCJ-.!RAV32*ZF2AG85KO[^F/S;=?><?DU
M#I"'2$.D(R84FZ$,"3+#+$AX03@$V8\I'C8K[L"4U+;9DM]^/&,.K:PAY'?C
MPVU*3WX[^M+E KENNV,8Y"N$54#'(."<I52&3$Q!OH<H&$2C0:" #')9.C,G
MC1X0A%#M'*#HB:H829S-U2*E(H6H81#"0"G"H5*(A6/12'S U<"L%W(UJ'M.
M&WMJ^[FV=:2\V#5Y9S7=DVAK&[T,..I3/RD3&MS-7)7XH>GV0M,I4^QH% 8K
M8<')AK(+\D4L!.W326HO5)(H:0RNSTE9-TE7J;:;,Y+.9;,W"TQ-K3#EYGJ,
MK0:I,T$YDDT%=T<7#DB@)!]#(ZKMF&+^=N):C:A$MK)[;"TTT=KH2M5]9^96
MFLU.9$T;R8FR()S9.6.9ZZ?+S!VM)EY@5JP2*S9*I&<&[A#FKJS$:>[7==$0
M!;&R1UN8EQPT)N8<<'WV@6GY?3YH^ZCP5>V#(%U,N,=CPJ2>=:Q8)D =>!H(
MB>'%M:6IS/!.D5Y-T7:&PZS Z9W"@IM@5E<U8A*DDU9:LZ=RDB[YNL!E)DU*
M;6J:JLL6<HM5D-Z^K19<$G!Y=9YRP=C:)O-2JD9H@N],A/9#--GEUV\Z;,6$
M^.UE+IL9-&2/S%!^LW;SMLQ</F[KKC^76FR ",.MH?:JBD[9SNP;"9"X@>?6
M9&=GW"U2)8 XY>Q\6&2.T8Z'I$Z2S6AUB'H'D?"NIP+(!AJ[DK8*T*3HZK!Q
M(\2G)2REJW<XW6IB;"R]B4CIL65JG41;3-JXF29#/%6BHJH_[.;.".7#O4WU
M6[(+L4D)LTM2+I:TII_,'C+6^OB*!:6;S115@]-/&Z2+A])'S.2KJ$EK>8-R
MH.:SI\S49,Y?_0G-:CA+5$LTJOFK$5S96"AL[\B:76W2PB7O:F[(/"8E>38+
M)%#Q)5""G*!&@H.3DJ@$&QTF<H9,(*P<ZG$R<LE&9';9HAK(R#9KLE,7@-W"
M=F9C)VJYW>M&9W"A)HY:S0Z@MDJ*I"J1(%DT@&66K3)&<T2F:LO>S!V,R3=/
M7VPDEEYG3-6W$IM$_:), ?S%)FDK(6CV0IHE>KU17*@HOK=9<0P,+EYKJ2%G
M)/TXV[89=,$ SCT(#4<P-CK$U7:]7CU&W+Q,@+$TZ-FYTPU$FC81:4W*I,..
MD U+'5LV%Y*E@9N1PD+28-BM23%PY;%4=/\ &R@%WTC>F?L %-4%Y@<)=,6R
MB:RJ!!),5#ZZ$BKQLYX*6JY9U5FL#^3O3OU).S9O3(L)2*%HC-)7:F6)RB;&
M!9 S23I&G,G>HKMD7:I59,B0&!54)<\98+;'*FH6\GH<C4(MU"-ZIW'9-J)@
M/!Z= CTL8<%:(ABJ-KYIN0;%E1U.D:F**#D;,%ALSV20S!('EM$R-CE2*P\P
MEZ%IT9@>6N33RS[.2"J5Q,%33%9LO:=1>9S8PD;+H*S D]0!PBR<*&2,BMB7
M("*9XX%JM5*43=W85S*4IRR)96U\QM0#<[.3MTY.V>MK#(M)'("E4>M73>4'
MLHY%HXF;-(JY'+<'+(2E53C8Y7+'4\<27@"*G8D$!E=LC $S!IU%I4785LNN
ME+]IPZ<OM4JQ? &FLC8EO$D8+-8Q:'#;%=E0B?D,ZR2C4#B)V%GQUT%7#]H*
M2SIH9TW4F$SF*DI8RZT<KM V;2M\^;BZF)ECL%T5#/18E;'=D40!1)H1NI8J
MZJUE$VKI!I*IB#AK+YB1B]1D\BDR=H9K.;%SZQ[Y[/I7*W8,9.1NE-VKA$DM
MV4,]3EZJ#G$+3!1XAN_TUM972W/B[369 NB'[SF5A12JU24.KE>7R4U!LZOO
M%((L<6ESHM1U[5]D@%PHHPVI4J[%(\4>1C6 ZJ16_)Q.9=+RK,7A%IFUEF+_
M !+Y\19V[[#K025V5%5=5!-([^;/9.Z!119N!22Y$YU43M&H%N_EHLU.9N=M
M,Y:HVD3^>"J&NI7*5&\N8#JC62M++SN46S=VJLE*;/RRT;$R*39Z(JSIRFDW
M<IOGHJ0KNO<%/G;YJ-R&7!Z[U=K6LJCE<019UN;2AU@@WBI%1PXA:+,?F6XX
M/&6%=[C'5&HL.6<-)%Y2-<'2,M=CLY9^8)67?RY:7EEKT9PG,D,:LV,E,5FB
MDM?(*JHLF;5-@U56:!+#M@;G43;-A7JL"Q,+IEL[7RA>W<HG+:;FG<L)9M62
M.L0U?%7DS>8(3N4ND&[B:3*8*S9\W;3$T\2?"\315>O"M1!N9NH)<=<.2]4-
M4&L4IFG-D_D9G3: J28.J*$8^16G+%KW8DC&)@PD](5<[1.KUD8=)C),F3&
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MI,9#F7,)0O&5L/)4I*<^ ZG"T_AQWX<:<Q_!W=^)BX(QD4V$$1K=?XP>B?\
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M4@J.GDP]LK#(>78Q"*2V\?<T!*-1OK2O#^57G ?/&_UWGYQ=MM3A)JW#N88
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MHQY^?+/LW_8?B_I?^]^O-/Y0JTWY]KO+93["/)OD&U$OJXDG&\][A\L^S?\
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M&KL(6OEWI\84<+!DR<D1P@G(%DV!Y*9'9AS'1TYN.\XJ(_AN:AI"%!RT&@W
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M+%N5(=V13+&NT4:! 4W,S;JYFR!BM<CTU-@KT@;@43(Z]8=5Y0QYPD6?7B4
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M ,M!83C;^^=&WQO;L4[$X_5O6@> ?SK&9%MUNFW*M;,(1P]09IHMRT#AOSB
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MH6\[;:SCD7JP["9WW X\8V]I#Y<]D+[>TG]6#WW>]-H6\[;:SCD7JP["9WW
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M9>JYY+RLOE['WZ9(HLV@V,'L+DWLO855:#R0EV*VELC.K5U&2W81RIALPY$
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MTM\N26(JN6;1RZ1EZ;QRX),BD:N")R5&:+%(H5B!2357#$A)65+%E,-== F
M1Q$;1*@T(=5!%54C<BRBA70%25*5B1V<"F*A0'A\+!*T F" C4%0*$4FX[:
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MQ"I@(/Z@0I#&*4M<$"F,4 H(@. 6VD(#4&KP! H% 0;-@$"@ @!:ZYK@@ B
M!D !$,@C!_\ P?7M(97GGRG;^B9'RCD1)=A\?MO:CWGZ5 =P_!DF?&:O5YTD
M0GL8>B/3O'N1W<8<94A>._H&K%8DN*P99-BX@IBH4ETO#$E.%#E2H_\ Q93!
M<8"4 P7" A +:R$,"C1X&+ 03HU;!@ 8*"!/YS\T!"X0+0!#+'TK_!]^TB5+
M605N'1:I[HARON35;=VKF6X!=3E#H1<G.K_'+$.(4I#@U2\PEI5E*F<XSG'3
MY8;$8($V,FV "H+ 38V78(+!D5 NOZ J&90 P@S##LUD-,'6CS! V&!=:MJ
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MSC-<M&\^G2+9?&I8A7'()RHJ:F-1#$JX11QB7XL^$3YL2#1P " &* #E #F
M!K<-0I0:A=&!QV97(?"%-X/ZNPA2DK4C%DLF$*6C"TH4I/R/[LJ1AQS"59QW
MIPM>,9QA2N^OVKVJ-02[(65P1$!$NR<SH(E 0*(AL-01 #& !R@!AIE&(UDM
MI)]H?5CY]&1R%_'NK/UCL?P=U&U=U1>[[*<I3+X-#62VDGVA]6'HR.0OX]U9
M^L=C^#NFU=U1>[[*<I3+X-#62VDGVA]6/K'9E\ATI6E)_5R4N8QA:<66R82O
M"584G"\8I_<K&%8PK&,XSC"L8SC\.,9ZD/P7]4< $ F%E0 U , 3.9@!@ :@
M AL-0:" "%<@A6&LEM)/M#ZL?/HR.0OX]U9^L=C^#NHVKNJ+W?93E*9?!H:R
M6TD^T/JP]&1R%_'NK/UCL?P=TVKNJ+W?93E*9?!H:R6TD^T/JP]&1R%_'NK/
MUCL?P=TVKNJ+W?93E*9?!H:R6TD^T/JP]&1R%_'NK/UCL?P=TVKNJ+W?93E*
M9?!H:R6TD^T/JQ_4]F/R#RI.%'M5IQG.,95FQ63.$XSGNRK.$T[*LXQC\.<8
MQG.>[\&,YZD/P7=441 !F%E  1 !'9*9#0,XT"35&F6Z^&LEM).,>B/:#36O
MW-5ZLHVO'B""LBJ5^&+E$6FE,,RYB,*>F.QVEYRXB-F2\ZF-AS/C?$8;R[W.
M95CK[8L59XUD[*2&SAW)7:DHER+55R0@D(LL%3K'3(-3%2QIS@D!OGXL"X?S
MJQ9)DQ9"DK7!  KI'/$F==HC.'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'
M2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$8*T-V)VMGVJ@\+CVIT.2:K<D
MWY1D/&..1'4"Y)1,5F1)<@1YJF7I3+#*W7F6UM(\%2\*2#*%<F>(&M!IES1Y
MR=F"'V<(UIL]-TLX^S '=M6Y@2O,@B^<BVH:1>@W>7)<F1DLNBK!.1#+PL-R
M$OM3UEI$F/XTBM:,STJ&\'-F],8DK?73SYX]..L(SATA#I"'2$.D(=(0Z0AT
MA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D
M(=(0Z0ATA#I"'2$>6//P#NHON/B0[0+A7ZT-QL^'!JC$UPME>=CNHDS_ #S9
M&(D13$BO1@8_ =F,P[(E.M%SS#S/DT[..MA*4-6N2_@H.3?RWYLL:SUJ7)EN
MX;LO48]26,OY89S)0TW)RTWF0VPXMYA#^48RZAEUQIAQUI+GA);<6RRM:,84
MIIM6<HQKC9'+TA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(1XD=KU?+Q2RNA44ZYV
MNIH(C]CJ((K5B+@DSE19-)Q&5,2+F1<251\/OX8R_A>6L/.X;RG#B_"V$ !K
M4 ')E\,:U,WA]$>0]?V;R&M+Y*,#VQLZ6\)!&K+/2[M Z/PR&KT!XF7E(61L
M,1N2[&A,.O-P8JGB$Q2<,08LF0I#2LZ!H#B"-<;!J^^;KV/?:[2E[VVF$0=D
MR67"ORXLDSR-N*/ED'',1IEJ"PW,J1$4VGRLL.BHRO#DB8PRA:\*!H#B_=")
M=>KG(&9/D8JG(V\6L)(?6*KY(=L^0Y,)6.)7:$>-")T*!L,H-AQZU(V$%!'S
M08]9AK)CQD<<X42A]4=0- :<@9*B'H&'7KQQPL4/F-,+! X_;MM*2CR\-PUB
M=QV,JRRMV&$EQ,3E#RDE<-N;FP#X[$EUO$1I?CY4U^(,:\O5%"Z XN'>WHF@
M]>N2_+DC32^.5(0 1LDW;MX4-"URK6@]F+MX]*D@!UW'C2=29,QF#2W()$_%
M+05#H"\9?=4[G"L(2G*NIH70&?,&:M?-$>B-]E5K?<N740E3Y&[",V0_0J'?
MBT0OLE($2!@7\=KUX3!7+B[2/V%$[!?9($*RU9:E4G"V?&DPS4\?W.8@  :_
M-"X1#)H\'FK$B'HYPK'%&I?*F4#"3T[TMT8T5>0Y,!3]LGXJ 8PE&U2]5Y),
MM\H7(Z)]D<V_4TQAB6<IBL3&GI,WQV)\0:^;?<'%HK7-FP1@(4Z\ ^F.H+J'
M+@AA+#VU]CQB4P>!>'04;3*N)8*6(_J@8,%6:3)MD%(!,@/N&HGFYK#9E.$3
MV(,B/'7'/R:^^;H#/FT5WMX84$?XAO=(=0&.5%-Y62(H?,#>MI(EC<DOB$%A
M;6N,F3*%P:AK2ZC3 Y;,US!..:![3K<MJ/$;7*%PUR"9IN ,@EI8Q\W0'%OB
M'G"%!Z\ #YAC1Z7:-L'6;26LO(_:H6MU.)4G)Q*LV:U7:>].N<V'$%PHXK%P
MKS:T0</3%''\DO'0),!0Z-#(3Y+#"IP0T!Q?NB(DKY#\FB:J\S5-\[$+R#L0
M7*R\9V!8*H,:68'Z2S @QI)*VO$7R#UBWC60&(\T.*3G&6""759>)P0<?-O&
M@7#3)^EO?\HQ-!\W/3I"-2DC>3^':VB%NC8*LVN'59(2$4V<>@FR63](I]T)
MR!H2!934HB,!,7,:RIZ(IPO/B^'-0!BR(AD:'D *.8.+?$-&6[K=6!"G7> ?
M3'\/0.30.S5NEO;NOZ+,8K6P+*7CD-F6,6)K\76Y?8,6PY=-/V%QB7'0%UZ0
M.-2,LPW7/*FQJ(:Y+:5OQ0M]P90#(%]:4\\33)O@(\5>B,LFD\R$N.-2]K7,
M6XR*;)OI+[C/"\LJ6/,$UCE8FF6<KG,0P1!UQ3/C1ZD-^,CSWF4/N,S@AH#B
MB(XR=8Y7P(LYUO<.P7Y(2!+G'FE[2,M16&8]IM%:3-&36;1+S*!8Q5I<V;8#
M,:N#1KDB$.E.8E$@F2ZA<E K6F3/=0,F4:W1-!Z^'H&L=UVD<N4/,#$;:V1Y
M\78R-<7'E[*L8T4_,2QJI-<C#",ZQ,D)A.S%-LU\9&B3 0R#&\9'(8+2H"B[
MX**%T!Q5IERT = [^]DJH/7P=,:23QRJ%3J&.?VW?9$K8LMF  ;';6LQ)34]
MX/5K#Y$3;A%GGH<MH#=:R4=CI:?=2R31'2E<^/*AL30N@.+AWMZ(C,D@?+$,
M02+,[FM8F<ILZ0\F(;DL,>3\F:V..$S%PQ#46\M778<>MF&UK;C++8F140<B
M4RY4-E]0- <07<.C+".)(CEDH7(,)W%:UCX0Z26(2&MUE7V8 ]#<J0,DNOL'
MW8TE%EA0I<^L^;GIJC,5I.8V/'2H;,D %'( 7[P0I&Y&:-R9$08__P"H"\2#
M+4%R986OG,,LUNM*&D>046R1)UES<'')<H'#X_FYO>/"2(T]Z;+@LR&W!XAZ
MT1\W0 >#+DWM_/$T'KX>@8U$Z)Y3U-T S:]UW0$[8=@.Z[BL.[1NDQU!.%93
MU3,$_&P9<@;)$!#5=G1B;D,B_-CY>'*5"\"<TKI0N8 &ZMP=;[\D*< 7TOZY
M SQT;4WR:J669,_=]U>"OV^)44%XVTK8XAAPJ9MX4$7FP?.?ET48<>H5ODP<
MY9<E)B@WGY4>.W-%+(30N@.(-[IB(D$WKOE/%?&L5G?-VMZGW[)%+^0;&N$=
M\.[6[-N,/(E)&^>)1@D)>$:8L1IJ9%&IF.RU*K\(9-G,1W2$?-T &3,&>G/\
MX I^^)P1X>#P] QH-=@\K+'+N$./N6V#G:,=F5RP*+[G,PV6R0V.5FDL07DG
M'FR<:"-"%B3LN"I]AV)"\&(J3*EP(TN:!H"__EX-[?B(V&%3>7;D]$4KM^Z!
M(T2>W$LTR9M\XO%2;D$I L;),M(/8QW'I,20@ W%>?\ +\I:S(<@LOMOY4+D
MH%^2[+S>>G'$T&_>RQMD^A;]C0RJH/(O;9,W')SQ@2N,6(VR1.>;ZB:M+I)3
MCNQ\11XQ[(Z' BYR[+)N>5RWW!;+L"/")J!H"FF@=>O$I=X:4S]>O#'L777(
MJ@";FY-VI9J,* #K)9&X8:^'&%6<X.C12)QJ&(BEADK$MM<V)DT4FQ4/XS*B
MS6&"<1]$KH( -*A7P>&_KEB(D%B@[]F49F\PN2>S94.5K4':XT--CMZ7';T<
M<;GLZW\<JX> AUJJ/L615B4C",X?9@*#-^,Q-Z4"N0,M,F:E:Y,E;H='IZC?
M&H3*7S)A3GH+NT;YX4=V.V^^O;-GB,L8E(J#S#DI! G#E0DN1;E$FH:FQH\E
MR&&M,IMA;->GJ0H70'%^[>A'5I#.];);K#23G(;9@0^-& )U>'";R8.S+JY:
MFQLROHK;)*]U5LF@@'+03+ \7()W"=$DM,!*>8GHE0XJ@9:!3.-+@\-!YZ<,
M*=>OHK&-8'\K9*'_ !.X[<N3%&"ILH>G<IO)**0/ Y-F!UF3"P;R\S8BX"%-
M)P8CB4Q'DPYD',])2)(@-*%T!GS!FA'';87+*E ;!9#6U[[D363+P$K)@;8L
M<]M!"*^%ASV6'V"ZHDAX>0L(D?,A-R,DD279OBX3K 4Z^-4+H"\*_P!$>C1?
MHI32$300KO;X=>HZ!B8:!KC>5^B5F1'Y.[.%N%;XU3#C+EAM\_S+!9UJ!V 9
MM#"D6^&F?#'3;&+I\:!E4;!,I+&S6B;+91N%%@0 !'YH7!7)P[U<VB[/  KP
MUR;VG1X(^<ZXW>BN9M<CE1L6*#;HM)LLF>\<NZV8=EN$YIUVHRDQK;(DX0#J
M3S5KEFH\>0X^U(B#60R7I*)&%PW8(5J( % J-,X:;[LN_"F_F >"HY_!?S9P
MB)]H$=R:_BSIP_D#MP\-C3*PF 4?N1.-"/C;2W<VXQ0+,KFP+D (P8I"B&(B
MI@JR%F9*GTQWL#28DN/8D  <P;]V3C !YHB.2ZC^4&O*@1M=NW9?!:H<NF,1
M0BMC7A1,FS<9.R![<B.E4QM#619/6%CB26Y&6T3&F<$AC\P:Y#E35"Z SY@S
M4Z0A2ZO6^O1&>Q0.:?C<(5LG8'BL2IT5V2SM>S36VLCW;:EY_+, I+FO1W(U
M/FDXJHL20Y+%%JT0CMN1SX]3JA= <7[M_P X9;H1WP>N.8I53L>7M/90X@Z"
M)%Q4%&RK#.5,>&DQ413,B4U8VH3 YX=/E'//<"07A1X(]Q$I++[[2,*%T!Q!
M"@Z.H98TD;])!RTZS &MW[%%P-GCXQD,>B;"M9*$T(>@H).RG''SHH;A<.&X
MWDB]*+00P23F5%LAH&L0>4)4+H#BT>#B#/FN$*J<\<\Z)R=59-I@Z]N/9YN+
MJF(1)FR;U\MP_$@6.!F+,N2RVT<)0<*<  #!&.\T6E!2.(2&@9LQDD$644#0
M%]+J:?!IAUZY8VE^C<K \NQ-6K>=O#0Z]6;V;7-A;9/'/.)6CAMN3)5;&L1;
M"PJ3.49TQ<0Q*0ESQ EJ)@GC!!+XV&2BA:5  R@&3@WM!@'J,30?/S5Z!C*:
MTUYR?V*+U271NS<8J!LZR%ARI23&P"<6O5P;AMF-89$EH_&:FRBY!HC#'A<9
MAH4AL7-=+(BE5+@2(%"MQ;@J.3T5S>'+==  K3+EZ.G>S:8JG(W7O.)(?BR=
MN;8CR8SSL>0P_?;@R^P^RM3;K+S3A9+C3K;B5(<;6G"T+3E*L85C..F"&@.(
M(B.'Y\]V^N+:?O!MOVOTH&@.((0^?/=OKBVG[P;;]K]*!H#B"$/GSW;ZXMI^
M\&V_:_2@: X@A#Y\]V^N+:?O!MOVOTH&@.((0^?/=OKBVG[P;;]K]*!H#B"$
M/GSW;ZXMI^\&V_:_2@: X@A#Y\]V^N+:?O!MOVOTH&@.((0^?/=OKBVG[P;;
M]K]*!H#B"$/GSW;ZXMI^\&V_:_2@: X@A#Y\]V^N+:?O!MOVOTH&@.((0^?/
M=OKBVG[P;;]K]*!H#B"$/GSW;ZXMI^\&V_:_2@: X@A#Y\]V^N+:?O!MOVOT
MH&@.((0^?/=OKBVG[P;;]K]*!H#B"$/GSW;ZXMI^\&V_:_2@: X@A#Y\]V^N
M+:?O!MOVOTH&@.((0^?/=OKBVG[P;;]K]*!H#B"$/GSW;ZXMI^\&V_:_2@:
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M)HM?Z=6CPQ;Y8[-E J$&W<%&$CAN!#(/QJM5\Z6.1*Z*'02#TJ(F,0G-#HD
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M@Q9IT2YSG&3I_P X[+JMGCOSE,-M33L>30]BCR+Y!UF.4\1F&*GE95A#12D
M(9O-P#D\(<^_ 0'/YPW^@>HA'U=@V^M9UR?;#>ZYOEU:LT(0-@!;59"#TR3=
M"6T(%AF1".([$1#D"S:XMT&:B0O"9$MN63&R5L.P))6:[W-31EW[^:F:(Z]>
M*.&AT7;-[6)?)[6+#G[&!9-C1\8W-)V/(\]88^O8LB9"DD!,-B*:B3C3+#C9
MAUQ,6*F,5;&1RL)YU6E:Y,]U_@&@CQ1(!7T<8!Y_-&P*UGR/L XO&D[**EF[
MF)KBW0[5K>D()NV,IJ4:%'7!J;.@Q!4>:'W+7B\I^(HXC+R'&R+/<APE%5 .
M?-G"M?,-<^>^M\4$>O!TQBZ;KW=T\&F= VR0CT06]/<@SJ[8+([%7D+0'2P<
ML&ARV0L?,1<, *K#B<R(M@ .--19X6*F!EK$Y-&30 YQSTWZUKX8>'/O\?6^
M.( (Y%7>HBRT"[0\,&5#]J,E9=EE1[,EZCF;)K6CHFS\-N*"1XA5-S@U%K+P
M\+%:P6EEIT*'&'*CQ<(UNJ%WF'10<U?XQ/F&_BJ'3'\'ZSY&B2%CM078*F#1
M4"$.2RHVVFV)=N1*"WVTC(80GY"S#,S0XO5%NE0"42;@+#D!8T2O&WILD<PZ
MXO/HNI_^07;^BL1?U\_-ES1W96M^3$ >5BN;.3@8&JQ4.B/B_DF8A +7HNP!
MUC C4R6H[/=786HKZ(G29V8(Y0VKIB#"DX20 ><HJ'4--//4.M84'KO1K%[U
M?ORO5"^3+/;7)U3CV!T@<;<L)E42W&)2*24+EQK)2#"P7QA5DI)"7(D^39/^
M+@EPS9V* =GCIZ NS@%XTWL@Y+@\-X>&O'Z8[8VC\B!P(85K]\=BB%4B';T+
M"6@G!C1:S'#"#[[KTF/$BP2+P)&MZ.)+Y'RBBH%A&TJM.OJ*0&X0Y=U#P:-\
M=ZE8F_3HS^$/-X!H&6-B(ZDY&UV,X/D[;@Q! F3/?)N0[_8UCJ_FL"+5"D$Y
M3<,>J1WP(VB[("AN"HTZ>M=&AMPF5P)%=E$(J Z-Z@ '13^EO!>(CGA?D&[A
MWOX9M%T8W86F-W%8^4VJ^0+,2BPR4@X+(E2"Y(^SUBQ;EK[%/C3'8*XA6>EG
M5FSC(AUJ2R!:?S8$LRV2)^.]8UV\%;PR7U HUWJX0</"%P0'AIOUI2O0/@C)
M733W(\HJ4)M^R(=F:($L ST9ZUG[$B#FM&=R3ESBL-H1,E*B![+K[;KKLR!%
MF2T%%F9N&W&K [+F $,WFW@]%.+>@-<_6\?36.\0UAO@-'@NO;A(J.@V#,XK
M 4<..#*6S5X^UM=6]TJ0<<<5.9$4OCP1'I37A)]98&*;!L1\MQ0R#:H!F#*%
M,@UR#HTF#+GW\B@W>G-E#S%]$:!4!'(&Y.S6 6SIKB:E:9P%N7\N"SJED848
MS?294.Y!3,(E8(^!2"MKS/B-/O\ _DR/@:T^6G#84R;@_A=E *:,^3T ,1UX
MHS9#4W()F#%M<[80SRF@0+), M)NTMXG"A5Z%LEF:L#B-%<B924#:-N[,/'E
M32IH>K0ALW##+@B$Y%0\/!?FNR5SA=O\,30>H\/1S<$9:5ISD#!LMP% ]B29
M*KG8+]5C;^3QALG:)=**GJ"^&.P0C9Z/,L14>1,Q6*N))V":.JQ<F^3S!JTF
M3/>5#+P4KQA?3@ONOIGA0:TSWY,N@>NB_)'RO7G(V:W-9';+*O0[: BS2\4U
M;9@V62K-MA2#QXN6CMRR8]5?78]L645-<>)J*D)MK/3) =F*6,J:FX<P:,@!
M>&7,&CB -$+]_3Q_QYXC(!JW;S!VSUVO6#$61JA*+^W*'&##(I,]L'\I196O
M3&(.&X9DB"%8("GBB0KJDP4Q7GHTYM$7+3OT >NB^HPYL]_7/SQG\<4+O!FG
M,6<_5QPX(-M3LHE (/%UR;+71FU)GR3C1_)HJUEGI6H;<F7(D.1QL6'#\<W.
MED), 7-BH7;]*< B >F( .O@$?1ES9XP0KCR5-4BK7H>?@/#S='M]K*CL)8;
M+A)5<:WK+'QU1Y<Z'%E!2T/1Q5;YG$YJ4/>F/M(#3U0HV"2MXAZ>#TF"[G#*
M$TNKO=/1_&,@2XN6T1"(/D;34(LD86DQY2%KL.1OR>@5";<)]QBED@,MD@+$
M.!)B17!<:<\8DH2Z$;(PY$.1*F(_=S]>B.<SQ/V&-7!A,OB%&G(\Z-/#$)\:
M!(38P=@L :T!QDQ+LH7+CUF($28)%9\X5%=AR_!'8G/-9;4S5T\/@S9_XT"$
M=$KQDM0F"N2_8ZOA4&02;.3)$B>."!L1XVJ\C(4J41@Q33)N>3VU6A4P?-KL
M&&$=?Q*)%6XD8V\$BH;X#QZ='!I&N]G<_7KFC4JOH78=L"3C\*(-A0(B!2V,
ME2+<193!:',),8@+;0_&0ML; DS5H(R!ZG^YB! Q-+2X@]^>OFZ;]&>$2%!X
MF7I<B>P0,5I"O-)A^M8%$%DEVT\)B$E/@A/C68+37D),:L87($'H<1A3K<L6
MHQ$SAW+KUZZ<D(PC?%W9,K&7!DJK%V53@L2.^-*S'VGXIHNP 0;>\,6TX'!P
MCCS@J1/L+8?$R9"(-@VBZ84A:%>OHX0RC2MPAIA3KS5CHCN.%W+PVB(TQ39@
MU^(0,LSVC,S,==3'1CKSUQ[E"DOM@U2*V8&8C.LMV1DE%\GF (J7$.J#=S<^
M3S@/ ,*=/%_"/JU\=;94 CYLJ4!18T" N1+>ES4,PR$]XGL1D.-K,AA4QTFX
M;":TL)R"\7B5U.<LH$K1@G-#L%50K3IWND(4'KX>@8^PW&C8!ZNA[$/(5%:#
ML2#-@"7#CK9E3!',%<7+T;R#,=E:H<UP@M*I?>U$@R?&>#(>&QR#3O!6%.>Z
M.NSQOV(Z@%A;M:C2K47@ ZM!EF\,2;"3EDAXV5'@+5&\D:R'R6&3"F2,J#C$
M"8EZ!Y>MB6U':=X*CP0RQV6^-&P9#$>7$EUTA"DD!,=N6-?-DD-"#E+@; %6
MB<Q! R)HL)-JQ*.0CL%(L.Q.Y;G,-@%NC2"8KKSB WYZ"&:Z$<9SC^:KUK!T
MHB23FP3Z%MBWE68<>/(BCI^JC&X!4X7&E.D8K<^#/1JAR9YTQXB0Q'++Q'%$
M)$)J//BH>;PU !#-=E"[S9IIDX!'@I6OFC+E>*NP0KC_ )>>H2(T!9?!F>R>
MG28@1@'&OSQ*60\G#.R76&9&KK\/:0,C$)4J977,Q8ST,F$EDU0'FYZ4\X=0
M&%!Z^'H&L="?Q?V8*=)123M7B$!:BL:0.R<Q)EJ*#"%['("H\BBR8R211S65
M\?%)?D,Q'XM===?EQLD@B"<A?D'K=??FO *CGR9!A3KZ.8<O1'<<XH;7:Q+\
M<BM,KC%/,[2'#B4XGS<'R8+*8C_DN8N&UM#4'X;DR1$27KQ0--"><I!%J%A7
M)O\ 4./^-(4&M,_I\T<Z>)NS'I$9J(2I4^.]&\LED(1V4_"$Q7&J]Y&^3S@5
MB2VU/F688.CN1HTI#4C+\N>J&':P46J'6^HWU"[.%.HQ%.N31IX?3DC%O\;K
M6,K1>SG[#5!,473)-MQ$;FS2LUUYL;0#4*OOI&P'X\0D5#[&!S(,CRB0-PK#
M[4N9&1A+V4(S6L>-;VS8E45$MHT++.VS4X AYUD ($6) VD>V$(;FB73EB I
M/EP4:BLS$5D8Z^7L$@R^.@LQ' ,B1.@1IE#,(Y=%-[/7+F\T@%:<(!QUZ(S8
M[C %*/C1$78LCY2$].#-H1AWF&LRH[I>P5VF%*W2U(';%G608^7-7@2 8+6*
MKA,2DX=+"!I:+C#?4B(7W#<(@-^@1"N3PY1T5K"F;@YPJ$=?8'%]NAM2VUW-
M98A%&D%OM)!('QHAD#K@IL&P05/>=R"ID:*]7S%:A26T1E3'50C2T1VO&BU.
M//S#3GRY]%^6('H\WHBI/2$.D(=(0Z0ATA#I"'2$.D(=(0Z0CV^[:#_SQQY_
MWMV=_P!JHG6M//X/3&Q3-X?1'B_7ZX1LKY*.-=%M."@1JQ2LE30D(VL>!@.D
M9S<)TO,A-D";D=E:1X:"J05*2,IC#X<E]6$=;.O/3P9<HW1KC9]2PUSMBU:.
MBW$J$K,YU[-P#IF><0*(L*5*<F1W8,B*]$[T,J8>(.2HT(:P\Z0)/LCHTIQ+
MK?\ O\V>$6D+:JY#MRITX7MD^P(?L4:QPW+)L*1'-3(L8#73&=C);JIRW S
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M^RIS+;I[.3#B5$,YD=.O-3S7<%T(Y6MD;$8CL1&;[=&8L4/*KT:,U:3C<>.
MG>3>6@V&43L-LAYGD4/RH8VE,*1Y)&\:POQ#7@/2-1WQT\,(Y<[/V4IQMY6P
M[SEYID3':=S;3^7&F ,I^:#8;<R0\)#(6;*DRQ+:<X0.E2'Y$-++KSBU/X>
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M*'2*Y<I4Q3RI#N5J!DI=HA4<M;],8P;>;L&R3R(N-I%9-SHA0SD;8"T')<G
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M#GZ(>ASWIZSM3?GKA\+],,- \W3# '2'/T0]#GO3UG:F_/7#X7Z88:!YNF&
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MW'F1"+@SAN:EVJ:RQ8]?2),=RNAW!Z[7:2D 5%'NX4[()!R8)A4N4XK,=$@
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12$.D(=(0Z0ATA#I"'2$?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g609070g03a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g03a03.jpg
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M 0$! 0$! 0'_P  1"  Q ,$# 1$  A$! Q$!_\0 '0   P$  P$! 0
M      D*" 4&!P,$"__$ #L0  $$ @$#! $ !P(/      0" P4& 0<(  D1
M"A(3%!46(2(Q.'BW%S88(R0F,C-7='5VE[*TM=C_Q  = 0 " P # 0$
M        !P4&" ,$"0(!_\0 11$  @(! P,# @($" L)     @,!! 4&$1(
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M^2 *6K-2U#(+8)C)<9*7TAJJUE+!X[(R#'^(FU[ K%<L@-I8MH+@5\H&>8$
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M_8P9^_6C/2]?WVYC?\K:5_\ ;;*ZAN^7_=M.?T^3_P#SI==#N1_BL3_27/\
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M]MY^TV2%K"GZ3:!B"8<_LB7<BF?MO,^W4N7I\^9FJ^,V_-IZQW!8XJD5KD+
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ML&(6&AE##[\#V\[AX;26&M8[(U<F]S\FZZ!TE56*A3*M-$"4ON5CAD'6.9B
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MM9J&Z\IBR%@A85!J_0LV"9:(\C83=;8G(XR:65I7#8Y,+LS7"O*X;'T<F6/
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:T='1T='1T='1T='1T='1T='1T='1T='7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g609070g27m05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g27m05.jpg
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M 0$! 0$! ?_  !$( /L!?P,!$0 "$0$#$0'_Q  ?  $  @(" P$!
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M,8ZNT^!1)[RMI33[Q-6U5R'^A9>!JD=2B,O'\';)V-_Y\>0=!Y\%OV!T+B)
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MD82<9[2<I.UTYZT',Y5?U.*5D%:MMJI<F6:IUFL%3F2HJMBRU:F9&"DRMUP
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MQ6^M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*53/O\
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M$)23]@>94+%T^1K&"RY?D-QWWQ856=EY:,)1(DWF2Y$90T2"0S'=2COR""D
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MJ6M9"4H0DJ4I1. E*0"5$G@  DG@5^D06."QB(JG*W)\BXD3.8$">\J7O6$
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M9KT%* ("E $;2 3@ISG:1GD9YQXSSYH550I%$BJ'*FJ)!53*<P$4%,1%,5"
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MFDFV+Q.ZQ^T#U!ZTW5Z5J.YO,6GN$Q+%%>4F&RT%;FA(VAI,I:,)4 6FHR'
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MG@!!+[BF +!+1XF]Y1 2 4!$_D (!A$ %2H%_P >_7>6_P O-W6I;>Y/_P"
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M7:-,B%K(G[Z;36LEH5X$2@9,:I2FAYR19J%'_B^]*MFM?0*4!,=U+-R%#W&
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MJSN+?LM0RR5EHF/@X&*AS(59?0*T9"M56L2EJM4BXAZA586PW6SP<9(*]J2
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M_51IQ2G%*<4IQ2G%*L5UW23KLG<]D>ID,TQRJN)R&^8A5$7&AV XUO/&IB"
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M%(RR$1&E SJ;GWI""4PQ\!#-WTP^ A@4,U9*D2 RQDR&H6IM00=+6&YW^X*
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MT?/.(K/Y^$8Q+S[*YAQ5#!\?7QGU\5Q77SL+T&WS'LBG([-LNK:UFG<VJ_\
M=,[QA9RKF^P=D^O$3?6M0,V5S>+:IH7#%+;]L-IC6+CJ+=Z.]%B6?7B9,L<=
M42""<Y]?/J <>OU&,?.L>W:=P/K'IN08Y,]!,=7ZV7Q]IV@.-'J]8R<&M"T7
M(<9M.J2]V=8@UI(^8M.ETE2KAJAK#$S;"SN86L_956,E"2$DH,G///C!/D$@
M8!_'Q\LFJ_TKOKUR=46K;Y =3XVMVS";)T]RNI5*L/J9&,\]HGJ6UW![53;%
M$S#*J0JC%!FGK3:&N51AHAPS";KDZLQ7?LW[*>*\TP<XSY"B>?.T'S^7%77F
M-8SK0>\MCZ>ZCU]QVP.;!UAE-(C[Q.VK/;U;['G->TZI0;NB7_)Y>K)SL'5)
M6VS06RFF;V*YP$J-<>R<Y&U2>1;,S*8(3N!/G'XX)\_=_.K9U;#\5HURL&BT
MG(,NI^@VPLF2TWNK9_4Z_<K*2:DV\U,%L%GB8EI-S)9:9:-9:3+(OG(/Y-LW
M?N@5=(IJE5#)^9KZI3'<CG(^J1,WEN=3$51)9">I$;*TJMR+"GSK9T5\WFJN
MT>1JR$!+(/2E>)2,4FT>)NB@X*L"P ?BH9/S^GX?*I'XI7&34-%V*(E("<8M
MY.&FH]W%RL<Z)\C9]'OT%&SMJN3R F3705.F?P(& #>2B!@ 0E9T*)<H4NW3
MV&Y4*='>B2XSHW-OQY#:FGFECU2XVI23@@X.00<&H$!0((R",$'U!KK7]I.O
M,QUZT5S!B5R\ILX9Q)T>=5*)@>10*A\L8[6*4$QF(0RJ;20('L%9,[22*BBA
M((IEY@]6.F\WIOJ5V 0Z]9)Y<E6&X+&>_$W#?%>6 $^^P%+2S)2,%:2S*"$-
MR4)%&?9+*RGRD\I/S&?!],CP<?0X (%5JYB^OC3BE.*4XI3BE.*4XI4@951U
MM)T2H4A-;Z5&>F6Z$D^$Q2EC(-L!WU@EE#' 2%2B81K(22IC![03:F\_CEQ:
M2L*M3:DL]C#G9;GS6T2Y!("8EO9"I%RFK4KX0B' 9DREE6 $LDD@<U]H[#LI
M]F,PA;CTAU#+3;:2I:W'%!"4H2,E2E*("4@$DX !-<GL-X1T32;7:F*/TD*Z
M?E85B/\ !B%C*E!MT82JQI$S"/Q_10$?'H*% "@*Q53B4#'-S'/434Z=8:SO
MU^81VH$F9[M9XV"$Q+';FF[=98J4^$=BV18J%@  N!:\94:[']/-*M:*T7I[
M33:4!RW6YH35(QM=N,C,FXN@CE25S7GRWDDI:[:,X2*C3EEU>=.*4XI4G-,<
MT200S==A  ^#6Y"4C*"FSDHITK-NH9VP8R13D0>J?:R-'<@D@X/+BQ^ 4G2B
MX)(ME5"WJQT]U=);T>Y&M8D?IY+FP]+(CS8+Z[B];GHL:9O2U)6(28[\M#;J
MIYC=HMOK="&V5K%I/:YTQ'<U2W(N)C_H7&B2]1J?B3&40&9S,E^*4J<CI][4
M\S%6XT(0D=P+92V5K=0D\-8\^M%8=UQK(,DUB7".:2U6?1[A)XPGF#QZO&I+
M,7"8A_F$DFKE@Y:N2-W;5T@=-P@F!DS'IUWTG>[+(M#$N,AQ.H(C$ZQR8KJ)
M$6Z19$AR&AR*\DCXDRV78KS+R6GV'FREUI *"J>M>I;1=F+H]&?6VJR2GH=W
MCR6EL2;=(88;E+1(:4#E*HKK4EIYI3K+S3B5-N*(4$R1,]:=1@UXA!PA57QI
MI6QIME(&[U6Q)($J$(:QVA=^>#E'_P!$E!PI0?/06 JWM5;(H(K.739%6\+A
MT:UM;7;>TZU8Y)N+EV0RJV:CLEV0TFPVU5WO+LI5MFRO=V[;;DB3(#@#F'&6
MVFW'GV6UVM!ZK:0GMS7&W+Q'$%%K6ZFXV"[VQ;IO4\6NTMQDSXD?OKGSR8[!
M;RWEMUQQ:&F77$1U8,[M=6?6R.GX\D:XI;B/:38K.FYD0=RYBFB6K%PDH=&0
M<2;,5I5BBU.H=>(9/Y$H V9N#DM&[:0OUCDWZ)=8B8;NG'8C%R+C[2FN_<"E
M4!B*ZVI;<MZ;&+DZ,VRI2G($>3+X:CNE-T6W4]FN\>S2;;)5*:OS<EZ $,N!
MSLP@H37I+:TI7&:B/A$.0MX)2W-?CQ22Z^V%8/RV:N"G%*<4IQ2G%*S:CWZ<
MH3]ZO&$CY.)FF*L-:ZG8&24O4[E7W("5Y 6B#<^6LI&.DS&#VG CEHJ)73!P
MT>)I."7[TXZF:QZ4:FA:KT5=Y%JN<1UI:TMN.IC36FUAP1YC3;C9<;W#+:T+
M;D1W"'HSS+R4N"QNHG3C1_5/3%PTEK6SQ;Q:+@P\RIN0RRZY'+S9;4['4\VZ
MA*BDX6A:'&'T?JI#3K1*#7O>^I4',04WL_65K(/JE%MU);1L8=.59:[9,AY
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MF#_,"H0G/3FS:V[-ENZW;9>PUVNN1VRM7>KM[-:J ]KOZEKRFVE<O B&^9-
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MM/K.JR4KENLSN;TN\VK)YJ+D9&R9U8+ID=^VEGF%F<1[+Z0+ZC3<HTMS]K1
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$%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g609070g27m26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g27m26.jpg
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M 0$! 0$! 0$! 0'_P  1" #0 E$# 1$  A$! Q$!_\0 'P !  $$ P$! 0
M          <$!08( PD* @$+_\0 2Q   00#  $ !0@%"08% @< ! (#!08
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M>Z*\*]"/0VR2[H?J&W;VQOV.C ["V;4KH,H)^4N6H&N4BQKSKF5C@*ZGH[K
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M^O'5'WBS_J8^DYX!?9AEOP91?SAC\>_P:/U/G]P=/_MG'SU^)/UXZH^\6?\
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M>O[I,M8L[!-%O;6*7RC[>[C^!YG\G9S,<\_#N].>V/7M]>>>(G'^U\0G>'S
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M_=-"-,(9WEH\6'P6[+Y!JC\M]<T>NW0%ZQ$)OT;:[@U [ULDJSFPWSBF8/\
M=?W'RA 0R;SICOX&/?;#9]9])@NZ8]>?CZ_S3/I''IG%)>43UB"ZQ VWGD%8
MZKU&[ZZ4F#(F)@%RJWC;#8STI$2L<H8QT,H=M(A(#^DNK"3H=!S>UD.D4[/B
MH>Q1U=0V_3E#9:GJK>_C.-!MVX@M3OI6*CMT[=:5.-+5C"FUV<$2(A0O"98;
M$ODH9!",B9=_$\^Z?YXF./H])^F8].8]><+E^WMV3EU7YS9*'7Y4RA.6%JBV
MI)\P&5 Q5F,5(&Q1<8R4H:<9!+7IZ&6>_P"R%[@9LADYG1;9N%N==#L^E-5T
MUL]!K[;NGRV(:#;#8N(;KZFT?-A]1U4&RJ^"'3!TBL'PGRUBT+ 2X7R2SN6(
M$,3V=W87<43$%/,Q/$^O$_#U](]...>9&.\N)24$M+\E08,NTWCD(W(+79=R
M\NU\HQ0+;8XLV/%-*0,%+N#--:._G7Q2"!Q7AV06$DB%[(_Q@MVD[9EGI^@W
M:[WHY?1NVV?MEP?::B!%:KRZ@S"DW24(18GO8IC%*-2T!#4NGE\S!<C'<:_+
M(N9]8^$%$?")X^//,3,<^D>DPWRGK)O+D7T1N"C[#%=%HDO0YT XDP);8$HX
M,_HP(L%Q#S)0[PR/U5:6VZRXZWZFW-MO-:7TEU>_I2.H%!0K;&KU)H+G3]^O
M88],C7MDL_.0ZN8F#5FJ(XF"$P(Q]TI%@4P.0[_3F#"0F/Y)XGF)_/''_P Y
M_DF)>J'EA)5 +E80U'C"D<IJO0ZK$[<F36DR(_27F7IDDY/PKJT.!;2^B+;9
M=UII#J/BUF+9VMW<=-XN6=-7Z40K156QTGJ.H]34DKKQBROJ8P9=:^/)*1)$
MPR*@@4=HF/G$Z0[CG%TC"X[8GRQ8,>L^OF3///\ -S]&1Y9.UM6_FM-HMDHT
M-)S7/HR1KM2NZI*4'D1*R>0LA$9(Q8SC4;*$Q>W%(B#W4M(#]2'%A/N[?6_K
MNSZX#<=,Z70[/14K5WIVK8UNGWDV;2[*=7883(JV:JR&M;;5DIBG8* %/$$2
M&')D<LL[@$"$9D(X$XYB>WX\3'/$^OPGZ(^B9YF;],^1;TSU;FO4BJ+ %N\X
MK]9K@U:E27Y2&EPZJ,2+%DF>\'9<;/0DA)7O4:<81(##%-C)0A3"[^[XDLN]
M6],]5NT.O<?36NU>M7K+;3M4KB=2IJJK7=RUD-B(9#>^.Y8V%J:*H$9649;/
M>L^V/W,0&!GF8F!](_-Q/']$^O$_#)\XSY,QUK[3P!V[Q]7H5;Y9*=4D%V-^
M>F'&]BWN/G3W6I FQRA[Y).Y<L=K9"B"2S'GO>(0,SIQK70>B?%"MMNM_#T]
M[6U73^LZ4M=66"V;-A=(?)W];86#"RW9V[+&MFXY8>;+&N<P^Z(4'<,55NB6
M*[H$17)SSR7\+F9YDIGF>?\ ;,S_ +,BR.\H3J/,<Z!K=0B&Z]R>Y7&XA1FI
M\F29L=JLJ30GI(N6;;7_ .$ "$J8A@0O;=2,I6S9>3=7\1K4ZOBF_0W.FZ^L
MTU,-=TCNMSNDU?E%EH-EMMI#T'9=<$)_P.NALKI(1R<*F9?<M&7F9(+Y#RX$
M8[5R1<3//)%$Q,\_1$<\#'$SQSR13/,879.^M6_GT=1+)0(26<JL[<):@V%^
M5E6CZP)=I1V9EXHT810PEC'9D7=%@*-0.VRZ.,V0.4&D@0G"[/Q!'<].UM#L
M^GJ-P]3?W%SI[8LMVPL:M.\M'=N4WJ3*D[)862AU>7PL0):@8IR88EDDL[@@
M)&)[9*0+UB8@R[BB8B>"]?6)GX3]$QZ9;+GW26M?,8OE#,6J/J\7:F[<(,7+
MDS:(@QF')B$Q=726,T]7Z^_\<=)%P^BCQ]R9'M@;C@V_@E6F[Z\N;?I>ITD-
M6:^JJ;8-PE3KC+T4W!2;3]DU4.4!Z_7,FQ8M.I>;87[4WNKS62/D2)A$$+^
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MC)AS<LJ8QC//OZ2+_F3)_P"AZK__ &.?/#\)?_O-;_H+4_\ ]+&8FY_CI_\
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MW.W2%0J[#Y@D<'[^"&@2IR0E3CU-#"AM[L\*((XM]AA3BI,@DEE$<EHK'5M
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MVU9EY;Y7)+N-L;*TUJAA0""(,$#[QRJ6&9E+W3'J/N^DQ/;)1S$SSZ\S/_\
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M473VXZ4O4]6K<;E&\M=-;RRBLFW4VW3U34[1>O+9$ L51V-1E]=GSFDI4")
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M9T0^G@_H>X3_ 'E3_P#A=>>F_P &/_*'J;_0U;_?ASPW^'+_ )(=#_ZR7O\
MA99YC<]FY\T\8QC&,8QC&,8QG:[Z/I7.Z1:8GG'7GZ\'&^9-1L?+I<&:C+%\
MY@Z5;"=UWG4G4Y >N$PD<]8NB1<CN07+30*&P8VJ6(-7K:'4_P -\58V^RI6
M-OH ML=X>WZ>ZKMKNIS29L:(>U[=-Y)VPLN&IJ7I\J$5FS+6WJC(]XNWU3X!
M3T]I-E4Z=ZM9KU5_&'4['IFVBY6V/RFG2[1LZ[IZSJK"]:VD@]AU!6L^>5JZ
MB!17U>P3,R*^_P".7^*XG,JKY%DVBA,='[AQ;R+Y!RH>NDMV1X:"J$_9G-$7
MX&&KTG&'E-733( =?EREO- @O?% ::+*20B.ZZW9N;W204MH6GZ;ZBZ1W^\.
MX$TQ.SL*M*.S5-LVTN4!:Z2:RT@( F-'L;)+#LF'2_A<KIK6>(3=GHE]1=:]
M&>(G2/2ZZ#1V)KHZB]LY\S?IIT+-9S W, A5"VTF"A!>:CL:R&1-_?N=<HZ[
MY.^D.YO<XV!J_68D6+Z_RGI]@+FQ6@("BPM6E^EUXF-1*L0LJW)4IDJ4A778
MMTH=(DR0DQ;21T,:UTMM]YH>C/"?<:YUJ]HGF_I_>:6J%8Y;:V5B]7T]L&R@
MK"23L2!-D8? 'WUP\L2DB+=>O.GNE>K/$O\ "!Z<W-:AK.JZBJO5W2W4VP;=
M4"-?I*.KM]2:]M>+2Z=D+&F!EJF15I:$*NLA\C"X7C7BIXO<N[M5XVYS?!R8
M>H](E?)8*'E 9FRSN]-5:G-2_/AH10#J&J)\QY..-!2;89B5E>A3990VX27A
M&'7H"\ZWZTW?3%YVNK=4!8OZ='1S+"&UZ=;WKVP)&U.SYHR6S^4DN6SRZE=*
M-56!9^THLE$6L=X6^&72W7&KK[F[T*RGJ>H[?B,FG:1<V5V>S5ZD;>A52\@H
M#1?(MBNY,/OW+5K?W6-7[%;I 9T;OX_>,_";CR?Q ;M7'X@ZS=QY7YM$WRU.
MRMZ$GA9CB\P^'1)2*"&M T!&2<<EL=DI3L&\T8IO:7A_;()V]0ZJZQZFU^]Z
M_*CU!873Z:WGAP&KHBG6,JG6ZCK"W9I>PZ1VG(=)&2X&R,KB>1/@ [;KH#PW
MZ'W'2OA*.TZ0IOV76O2WC.S>;0[.[5>5<Z.N&G1V:J5[)=&M:KP*P9)4C%LC
MP0=S&2>O-NX9SNC^/O#;()R4N^5GN'&PYB>[_'RU@;3R/KK'2U#VAR9<!0=7
M4P-4J&F:NNJ2@\5J6D'#9-,@Y*B>TQM=#J;;;/JOJ:H>^#67>FNH65JO2KD5
M)^7M"6G[J0UQ;*K<VKU_NNQ>23Y0J%IE4(9P7/\ :]#]/:7H#H?8)Z3=O=;U
MMT>JY?Z\KVK\?BGU6'4?9LSN&B':^*&JU,CK9U=I=6+5B6V/:)M*Y#:)[Q"\
M:6O+ZB>.MCYI?:["([ 6U"6LMHF#HG4.6IXL=9ZW5M7==PD2[/:+)>J\,2[/
MP$; *^'M-BK[;D8\!5HR/TL>ONL2Z!VG5M3<ZNU9G0 5BBL@M;/2[J>HE4KE
MV=9&O4%*E3UELPBK:=:B3I5+<PX6W7-Z:?A+X;CXM:/P]V/36]U](.KFA3VK
M0;1T?4W3$=&/V>MU?RU.XL-V>SV.\UZV%?H5J$]FRV&N@JYHU=:OK9Y=BS"?
M![P4(E*$WSPANV>5#9U8"BYZ*CX8DJ_P#@[* ["9(R(*I!H4@QD<@Q2'=((=
M!::$0EIK<.@CK_.5XF C:3MAFAT3*[K'U7ML &KLP92RHM*6PJ3!9&"^8F0A
MI$R9(N<>+2K<>"?@>RUHAZ?8.U\4!?K$UKU:O3:W?426$)V#K%A$V!4QP+8Z
M1*(82!%(P([%<4C(H:J^AZDH'G\ 'N>[#U ZUVN)C9;1:;#&=8@JZV1)2+<B
MX N4L,-!QVI#Y78)?4U#BL0B8J,#2&G4>I'/.]X_IM;6TR*N@TBJ%%[D>7-1
MVDM6R!*92+834L66^5[.0#!6&%9E[F2R>B=&5JJM5^")8H:"@J;_ %=U._:;
M6I6M>=%^KU30UXLL6!L$B;.PJ4D18]K!IR%-2Z45:R83%T,\9.$]DZAXTREH
MI\=2U]6\HO+ZCW]R'FK,&-?6N=S<]+TF,E'Y>?-<!E[%. IK9AE>)@G2M33X
M\<@%\>+2#27UGU-T]I>L44M@W8QH^B^@=EJHL5Z;#UA;:M5K[)Z KU5"VO4K
M-]L6NV%D0]F W2T3?YMRWPUZ%ZPZE\-[6SU%;3%U1XG>+6DWY4[NS2O>AT_<
MV%S2UK1V[[B1;V%U ZYSM>RD;(N&NO"3"K"(/YIQGAD_-]U8N/ [E#S7)_"'
MJ/1['6;U'3G.4/\ 8^=6T6. M-4BHB[R\E&U^4B"]Q$D&88_%.S49+F10NE,
M[;&V3<=0]35:W3)T.J==8K;SQ)TNHIW=6ZKN)#I_;T&-;2O/L:VNEUM%A?M"
M3!0O&NY"WGP426E]-]'=#W[G7 [?H/<5+O2W@MU-U#L=9NZUSIT3ZOZ>VJZZ
M=IJ:M/=W+-:A:J-]DLJ<TZI7*UIU5?(3"Y!\7/&WD_D9$0=\F?' :E4[IDQW
M>$&57+%=K+&LOU+EP<C5TUEUXQXJA,UJT0LL8@VSV"5DKG.3+T,/"2U=$6NM
MXGK;K#>](OLZROU>>QV&FK],V3BW4UU-Q#>W3%79N"*Q#:'<I6$+E=.JA.OK
M5QL'91;.(N9[PQ\.NE/$.I3WUSPY5IM1U);ZWIJ^3MAN=E6$]3TRI^L'6$33
M;H0UVSIVG"[97[5G<7K;*BZ5K7JF==5\,\8N'6ZL>#L9<>-1S<?WOFOD_OM?
M3W9&]@R%0,Y:FR.5:TB$ILC-4K4G$N0@GRC\HQ#H4BG3C! >DOE()I]2]9]2
MT+OB4[7]0NEO2^XZ+_%S2PK5L3L%[N:@WJ3 FF5ZXEXV3\KR; L3S!@R9$)"
MIT1X:]$;;6>"=7<=&UA1UWTYXE_CGU,3]XBQJ'=,#L2U>S4R-DO5:VS5*BKV
MCVBH2K$08&F(-HLIZ#XU<UZGSKQ :DXV6DIV2\4O*Z]UNJIFK3+BW[I5!L7P
M])@X6K2=H%$%]^X6_:Y"LU4NK"V8R/?^5G-,&F.[GVO6.XT>VZ_)#D)JIZYZ
M'UER]->E79JM/M*G?LK-B\BDQA]L+&@FY>7>.DMH^SC)K6.2:'PXZ;ZGZ>\(
MPM5K=F]8\*_%'>:[51<V=I6^ZCT6P$-+1IZRSLU)5YDN9M'ZW6-UB=DY!^UE
M .<>89R[AWC9U0Z^UN-YW9.9='DAZ.718[M\%/P='F;/6N;RDUU+G6GX*V2<
MCR]ZZ&L;Z)3):S''.CPP3<> %(P LG#S.1W74O6&D5J[;MO3W.H2>R7LW=-6
MJMK95Z5S<)K:3;R-FBE6Z'7+/Y)V->FM0G99YK6IML18KX?ICHCPXZH?O=;6
MZ=V/3745I>E=I*_6U&_1TMO9ZWIVQ=ZGZ>$Z.VLV.F"W#@GJ'36MDYY!30*$
M)L:]5FE;U:\/H>%<IGF+;EI9=N5+\7K6_3=*UI14<BT6&N4VVST=ZOYQDL2K
M3LA#+*;WK8X5A+]>];6E:-WZ_L68V/A_0CN'7;'K6B.QF.?+=-*I;V%"J[^"
M2V7:JK$ 7[YE1?T1,3R[PBJ4RTWB_MI@2W&F\,MH>GYXEE8=G?U^HVUZO_#!
MRM7=?4EHS$K3?=\)*)B2*R3)F>BIZBV20>4%'>7E)9";?=(?% 85SU2WFA4N
M*4T*TH@AM3J&=(1MY]"EZ]MU.U8>X"%^.&ED 4#'=!;(F2(@)M/Y5X$CF(@C
M+L HB2YGM&>/09XV/6-LN_!;ZH%K'M37\6=*"!8;#4@)T,$8*@ID%#+&"1"'
M;'><3,<E',3=1\O7^HTZ]563YZ$";>XCF DM:1IH5N:DISEUDZ++QEEL3$=6
M(J(FI.5A^@K@YE\6.A3I(J#"L4E(GRALKLO.Z3H$=)L-9>3MF-7J[&Z.O1.L
M<UTUMU3U-=U.H3KK[%9*+&JBS7$W6%)"RRHE*D*1Y>J=4>+9]4:?>:NST^E#
MMY4Z95:VB[JANV+W3&RZBN5]EL KZRK4NV;=3J J5PU5Z;[#:2=A8L/M.M>;
MV8^.-0AKS5O1(U2QA2)4/,5#S]T5\E3EDK$FRH&3G9<1T&=JDK"38*W"0AV'
M]#2#;1P!),>4V^(:ZTOCG5^PL:V[X\7J;4A8KWO"R0\^M3NI*&)JUV"VK>19
MK-B 89#WJDEM &A(FN)CTKX=ZFGN]7^"AJMBFPVI;T_CQYGLMW8ZVRN46;=M
M1HO:NU2NHDF)!;/+>(/KM;7:)J<0S&_!/&S@UTY#XF*L7(H60L7;N(^:$S<[
M?\KWAB:9F^.3+H=!F8846T,5X \)I J2E+A"!Y#>DZ=']1).B,MU3UAU/KNH
M.NHI[^RJITYU)X=U]=0\C6'6*MU#6AFTKV#.D5MJF%)]D19 E>O!<@$AK?0?
MAST+N>DO"GY0Z2I6-AUKT5XQ7-QM_:]V%T;O2%V4Z.W36K9A00](0J&S-,P=
MQ$2$0UL-U^Z'POCG/O&3F%P30;U;5=4\<OGL#U>KQ"SX>L]T'Z"I,Q%6JT/V
MT.'B*W!5MC5%*JFJN063)2(TP*298=Z;&VO4]3=0;7K/=:_Y4UE"-)U=\FLT
M5ZQ"K%SID]5'D/HTAH,L6+EFX7RFN]-T%@E1US!=3U/0.H.A^C]!X:=-;>-#
MN]M/5'AW\M(ZJUE2;%/6=<+WW^&5=KM#VR:E/74=:'R(S51K&-;9L+MJ8[8<
M"N*/-:'AQT^*]J8TTBU] \1>066^*3ZMDR4Z%J=JD=8))>OUG)*8K-<@]EO.
M^L@Q8FI$A;KQJWG,YX<V'G/6]$I*:.JZ^Z@IZR)] 169[+>=43'P%->[;L^6
M(^XN&2D($50,:MXT4Z:Q\+=JN C:[_PEZ1V6]F(CS+-Y,7=77V%F8]2LW-;K
MZ?FF?ONE,6#DB=)EI#G2<XGC&,8QC&,8QC&,8QC&,8QGH9] ?_YIY2?^@XW_
M -QT_/*'X47^(Z*_\7J'_P"C2Y] ?P$O^T^)_P#X'1__ -SJ;/1OGD;/H?G"
M2,.8.^(6PR4(4RZ,2,2TA\<D=]"FGF'V74J;>9>;4IMUIQ*D.(4I"T[3O>MS
M 9K,6+(@,"$P,"D3 QF"$A(9B1(9B)$HF)B8B8GF,D8M;EFIH U30);%L$36
MQ9C(F!@42)@8S(D)1(D,S$Q,3GF4].%0*)1+#XYMTBE5*FMR4+TU<BW5:W#U
MY$@L4ZCI%6:F("#24H9+[Z6%/Z<VSIYW3>TZ<7[7LK\&S:[/9U.KIV6QO["4
MV--"9O7+%N50:]E)PN;#&2$'(C)0/'=VCSSQ''S8_#8T.CT>P\.QTNFU6G&S
M3ZE*P.KUU/7B\E.TD*ET5$IALKAAP$GW2$&<#QW3S#WH6*;4+OY0= BKI5:W
M;XL?@MED!XVT0<9/@,'M="Y@,T<R'+"ECM&-CEE,-DH;2\ADDAI*](><2K8/
MPBMA?UO1>J?KKUR@\^J*:C=2LNJM)1:G=&2B8@UF2R-8'(3,C) !3'(Q,:A^
M!II]3NO$S?U=SJ]=MJR^A-C877V=*M?0#QZ@Z96+P3:4U8N%;6K%@C!P#&#!
M0)E$^L.*B8N"C0H>$C8^'B(T=L..BHH,>/C0!&4^RR*$"(VR**.TG6DML,--
MM(3KU)3K7Z,\,/>^RYEBRYMA[C)CGO8;7-84\D;&LDC,RGU(B*2F?69SZI5:
MM6C734I5D5*E98IKU:J5UZZ%!' *2A0@I2PCT$ $1&/2(B,K\I97QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8SHA]/!_0]PG^\J?\ \+KSTW^#'_E#U-_H:M_OPYX;_#E_R0Z'_P!9
M+W_"RSS&Y[-SYIXQC&,8QC&,8QC+XJSV59$:6NPSBRH9K3$02J6/41%,Z1IO
M3,:]LC;@+6F]:;TV*II&D:TGU>SK6LMHI4X!RXJ58"P7=8"*ZH!Y<]W<X>SA
MI<^O)P4\^O/.7T[/92RLV=C>EM,/+ILFW8EE0(&!@*QRSN0';$#VJD([8B..
M,J4W2XI+,/3;+*DZ1!W%R!J9V4T6?&;4E>XXPG16GB@=J2E6Q'UK']I*5>[]
M>M;R2==KY6M4T*4J2WSTJFJB5J=Q,><L/+[0;Q,QY@Q!\3,<^N58W6YAKK$;
M;9P^PCV6PZ+]J&OK<P7L[F0WO:CNB"\DR)?,1/;S&6HB6E"S2)(J2D"9$M)"
M"SR#"7C2D%L.#%((*<<4^\DD9UT<A+CBM/,..-.:4VM2=UP0A:P2M*@2N1D%
M L!6$@4&$@L1@1D#&#&8B.TH@HXF(G+1ENTUS++;-AEAL,%MACF&YHM E-%C
M2*3.&+(EL@BF# B N1F8FH"L,_&MBLQTY, ,A$DF!-!29HK8A9HV@S"A4,/M
MI')+#UH4E]K2'7QM:8=4MK7LY(RI5=)DZM7:3 !;"8E9RQ:S\Q:SDAF3 &?N
M@"7(B?O#$%ZY41L=A6%05KURN"&,<D46GJ%+7+\ES5"LQA;&I_<F&$01K]PI
MD?3*T6Z7$%H5@*V64-@%E8X3(L[*#M!CN;1M; K;)2$#LKVVWM;3*4(5M"/6
MG?LI]5,]=KVD9LH4F&TH-I'509,..>",B7,F4<SP13,QS/$^LY75NMR@%+1M
MMFE: E:5JOVE@E9<<K4(-@5A/:/(A$#/;',>D90[L$\J(<K^YN7W NG?*;L)
MN2-W$.27L^Q\H.1NWO@UG>Q^I\6IG9'L_J^\]7Z,J>R58L1;BM7BT*O)&SY*
M_:(3SSY4.[?,A7/KY<%V\^O&6\["_-0J$W;<T#?[2=*;+O9"L\<>T%6[_))_
M'IYLA+./3NXSE*L]D.W#;-L,X7NNM,L5_94L>1N"8'<0Z.S#;=(7N+:8=;;<
M9;"]PAIQM"T:2I*=Z@%*FOVGRZE9?MA$5OL0H?:B.)$RL]H1YY$,R)2WNDHF
M8F9B9R=FSV3IIR[87FSKA -?++=ADT064& 4Y)D^RB!") *.R!(8*(B8B<^9
M>R6*P;2J>GYJ;4AX@A&Y>4.DMH(,><(+?3LQ][:7BB'77R'=>I;[SCCKJE+6
MI6U>G4J<Q5JUJT2(!,5T*3R"Q@ &?+$>1 !$0'X",0,1$1$9"WLMCL)B;]^[
M=F#8R)MVGV9ACC)C61+F'P;6$1L*/>,R(BF2F9S\#L5@CFPV8^=F0&8\H@T!
MH.4-%;!,+8^%*+#0P^A(Q1(W^[D$,Z0Z\Q_-.+4W^KD64ZCI83JM=I. %-)B
M%'+5K/O6MDD,R8 ?O@!<B)^\,1/KD$['85A2%>_=KA7:QU<4VGJ%#FKE36I%
M;!A36*F5L8$"1KF0*9'TSF+M=I/;':.LL^:T(;\IBMES,B0V-);<=>W(#H>)
M6EDWWK[SOQ;>DO\ O'G5^\]IQ>]RKH4529*IU%DQ7DL)==(2:>!'RCD0B25V
MB(^67(\",<<1'%1NVVKQ6+]GL'"E_M21;=LL%5GN(_:%P;)@']YF7FC$,[C(
MN[DIF>==TN+I\C*N6RS.2DPVVU+22YZ46?*-,M^Y:;D3%%;(.;:9_FFT$N.I
M0W^HG6D_HR2-;KH4E$4*4)KR15TQ51"D$1=Q2E<+[%21>\4A S)>L^OKDY;K
M<D^Q:+;;,K-P1&W9*_:E]H1'M$;#I;YCQ$?=&&D40/I$1'IE"%89^-;&9CIR
M8 9"*?.#:"DS16Q#BAO@R3!D,/MI8*(#UH5\AK2'GAM>X<6IK]3*K:E5TF3J
MU=I,6*F$U*V2Q0'Y@+.2&9)8,F6"!<B)^]$07KE!&POUA4-:]<KBAK'I%%ER
MA2YJ_):Y4+,86UBOW)C B#-?N%,CZ9/-]\D[-=>-\8XT,"168CCL!<*VW(Q%
M@DD.7.,N]A:M,N/:(]"&!"6AYAOVHQA&_<#B*VR4V<3I)J=7U?1U+6]0]1=0
MFP+MCJ"UK[DJL5$S&N=K:I4JYTFS), CKEPXI]\CB" EARN=ZWWB/LMUT?T=
MT<I#-93Z1H;;7"^IL+,%N:VZOCL[@;2O K4T N#)55Q^YK24K:+V<.B#D6VU
M-JB%MV:P-K@%MN0*D34DE4(XTA#;2XA22=;C5M(;0AM0>V5(0A"4[UI.M:V6
M:%&8L1-*I,6HF+4363,68F9F8L<A^[1,S,S#.Z)F9F?CFDQM]J,U)'9[")H2
M)49B[9B:1 ,"!5)AO^#2 B(C*>R1&(B.(B(SZ1;[8A4PI%HL2%6'16I]2)N2
M2J<T=ZOC=3&]$ZW)Z,]E/Q6C??Z(]G7O?;]6L3KZ$Q7B:528J2$U8FLF8K2O
MGRYKQ(?N,KYGL\OM[>9[>.<C&WVPS<D=IL1G8>;[?,7;,3>\[CSO;.&_X3YO
M$>;YW?YG$=_/&7.@W^Q\XG7IVN/LZ6?#3=9G(PYM9$19*M9HU^'L5:G VW6%
ME1,Q&DO#OI9?&,%=]Q(Q9@$J$">-1VFJJ;BL-6X)<*L5KE9RY@+%.]3<-BI<
MJLD2A;Z[@$PDA-9CWI<MJ&-4=SH=_L>G+QWM<8<OIW=;>JO$F5-CJ]E794V.
MMO)$UDVI<K--;(!BW*+LL5G(M)0]=I5:;#H!^''G)H2!>V]K4"S,27R2AEYS
M;FQ_@EE*8<;UO?Z?>H6IS>O;<VI>]JW7BC4EHV#K5V6A@?\ "BKI]HDA&!@O
M-@(*)XC^#,1'PB(CTRUG:[&$,IJO74T#DXB@%RS[((&4E*_)EL@0\SZ]PS)3
M[Q3,S,Y8,NLQ^9,-=+B&T(P);+,*S'L[' 9&GI1AH)A24HVP(VT4E S.TH0G
M;;.D(VE"=;3ZDZUJR/6ZYA,)E"DPFEW-(ZJ")I1,S!,DES)E$S,\E,SS,SSZ
MYDU[O<I%()V^S4%</+0"[]H!0OB([$B+8A8<",=H0(\1$<<1&?;5YNK&F=,W
M"TLZ';=:'TU8)9O3#3ZD+?;9T@O7NFWEMMK=0CV4N*0A2];VE.]0G6:TN[NU
M]$N^1(^:E>>X@B8&2Y7[TC$S S/,C$S$<<SD1WF[#L[-QM0\L3%?;L+8]@LF
M",0X=':)D(R<#Q!2,3,3,1E&S9)I$>Q"$2<F;6VY1N7=K)$K)I@BCD[UITAT
M!@MEI!3[7M,.&L::-TTM6FR$*]2M5"IUI<5D$)7<E,UQN@A,V@5/P 6DLBD!
M+@H67<ONB.0F/3*0;*Z* I,M6GZT;0VSUC+=F*+71,=[#0MH##6#R!."!= S
M/:R)XF+K?;Y8^D6)VRV8EMXO4?$0D<&(UL:+@J[7(L2#K=;A O;<T#"5^$ "
MBHP7WCKB!AD.$ODEN$$O4=7JZFHJ#3I@0K\VQ9<QA=[[5NX]EFY<LLXB6V;5
MEK'N9Q$29S " 0(#<[[?;'J/8ELMFT3=[/4I5TJ'RZM'7:ZLJEKM=23R4(I4
M*:$UJRNXBA:X)IM<3&GAN9#,/C&,8QC&,8QC&,8QC&,8QGH9] ?_ .:>4G_H
M.-_]QT_/*'X47^(Z*_\ %ZA_^C2Y] ?P$O\ M/B?_P"!T?\ _<ZFST;YY&SZ
M'XQC/,=Z=J[UV7ZOQ"B1T@P78:53;5+V01AQ#JHMJY24'\B#&>QM7PYI U<*
M/V([[#Z0"H\O:-,&CN.>S/P9-;;KZ/J39M405-CL*->FPHF/.+7IL^TF'/[Y
M8G<6KOCD9:#0B>Y9Q'S4_#CW6OM]4]$Z.O86W8:;4;6WL4K(3FJ.XLT?8EN[
M9GRW,7KFO\H^#A#$-D>QRR+$O05Q9KWDUU.:;94J.C^$RL641K6_8:-F.@<_
M+ 94KU>K2GV(.26C6]ZVK0Z]ZUO25>J__"9>L>C=)6DHAS>IT/ .?4EU]5M5
MM*(^/ E93$S]'?'/QC,5^ _5<?B3U1=$)FO7Z'LU6LX]!=<WVA<@)GX<F%&S
M,1],+GCX3GJ>SQ)GU QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&=$/IX/Z'N$_WE3_^%UYZ;_!C
M_P H>IO]#5O]^'/#?X<O^2'0_P#K)>_X66>8W/9N?-/&,8QC&,9V=>#%8ILS
MQ?ODY;*?'V)^N=?\2!(N1:Y+3^K6@&/M5YMT?:(:$C+4RE.P[.$#'QTP,T6I
MM3"6GODX]Y"!7^,>)EW8UNHNEJM#8.J!<Z?Z]983.^V&CI-;1UFO;1LV742_
MQE-C7-KF01/?)#YRAY,/3/@?K-/<Z-Z\N[745]B>NZN\)U5; ])Z?JG9HK[3
M>;6OM*=*MM0B)3LT(KU[BQ;(>7 G[.\XA3)@ZAXI4::(N46_NJTF)@?(3S,/
M:KG-D5N2:+"Y;Q>J].@J!3+T;4Q;*^HGUZ@-0DND^)K18=@*BJVT8AR.S :7
MKC9UQU[QB]LGVNE/#Q,W-Q-Q,K9N^HKVEM;78ZQ5XZ8P$_X5[2B56+BV5%ON
M2$PW-NZG\*]'=9MJISK-+5H]?^,-@==TY&MLBU/3/1VKZDI:#3[M^J3LF$WT
MH^Q6X?4UK57V5=:+1*OB+\.>:%4-?*')8!K4IY.<A=1?78FOKZ-$P-I\/[QV
M22Y+\X]1J%[EB9\>/J; /NDQ95H3$RS];:-5N);E?XA;D-I&]%#2\CHS?06K
M%]N-0^U2Z_UO3R=][)YQ1Y 53;>)O,N"G+ZXW)7^[DK>#_3;='/2DVTB-GQ+
MZ2.-\56@74-2CM/"3==7V>E?E&*PE[4V^JOJEH[(JLV?LEL]<+YFJ,/0WASP
MQ@>(G[?T&\!P,I6N 7"<CX[<<B0YU7^N\IO-]FW9R9W4Y,6T3<1*5:)%A*I$
M0D1896!L8LLV"0EE[:=@L>(/4Q&^K0U.L9:3<ZIU]5K?.E6WM:'>:W5UHK5_
M;DG2K/1=>RS>L6;%1-JHQ$M"2&)U"EX/=$"NI>VV^WBJ-K6]!;>[7K^SC8Z=
MH=6=+;O>WCO7)U5E6SN5+>LJJI:NI3I["S0V"K<(9 %Q>I+Q;I-KIW/+T>/>
M9.#K'BQPN_S%'Y77:.WTV0B^@]FZ'4;#90F0*O&,7CYEQL6T7)2$Z'\N2CLM
M!B2]MC8@%M]F@KK;94=AM=8H]8FU=ZWZFU5?9;RWLRTRG:GIW4["I383KSBU
MGRBYY+2JLSV5 HLG7H.>V1F]L>&&DVVGZ?WMA6]L4=9X7]#;VWH^EJ&DCJ:Q
M6W_6/4.HO[)0(U=8-W.GK50=8L741=LE:I+M[2O41# U7[5PBJ<^Y'QSIE1G
MY.<1?@F0K6+-OL1<Q5[HU6("R2E>*IQ$)'R(4=L*P1\K6K*)-6:)LT#("&[=
MB']LCG;OTYU/?VN_ZATU^JFM.K83*+*P&^O>UQ7;5--L-@%EJ6.AE1J+M,Z]
M-].THUP-@>XU<MZTZ%U73_271_4NIOVKT;Y((VJKIA5MZS<CK*&QLT&:AE*O
M817\F_7M:W8JN[.KLJ-A3N^H?8M\L.>,D%;NK=EI<8-96Z]R^U%\SJ$U7!AG
MXT]^!HG29J.EIA#,9+R<E*7*0HXLZE.F8B'*%E9QK5DBB4UJ*-P4=9VJ&CZ>
MV#CIE;W5%>YOUKAF+E!:VFHKM17DGH2E&O5LF5?WUBP#$5B]C>$W'KVPO#2C
MMNJ>L-/75LAU_3.T9TSJ;FN4HJ[SHZ+J*Y7MW(76N6;-G<6-*J_QV5*C56KH
M_*55WR=5=4UOQGY>[*1VW@>A2WP07(B)2%)FHMC<R=V;Q-MO?8F.C5 U1!83
MU;L]57!N(<U(.6.-D1D-L1)0;JY&2YUENA0V!;J42QF^!%D*SB]F5T]UW0Z6
ML.=#;Q+8-RE>BR,QY0U')9,G8!@PJIK?#7I@[=:31U!:A2NDCM4VW:H>UOZQ
M\*=KUY5KUY1JA:D];L]9[$0EYY;"L]<0NJU9$^![O0(^'BN;S^[5!PC[7(86
MY#5:]B$*D)@Q-WZ''OUV%;KM+T#*IT16]*?W<" 'UJEV@7I8@)CU [/K=JVP
M[<5?8;-D2W]G7'>U; A5=<ZW4M&Y9FYLO-1[ESW8UXM&(KDP4"POW71-WH$4
MZW3M^=I2I&'25+<+U>^4R;%MT;KJ!#-=3'7Z:$6HAFNY/Y78ADS<!!VF)#A$
MS?.(EE/A80BD<S*>Z3'?%6IMSCO-5-V<X3R@OL*WHAABI-(?][!0<77'Q6$I
M9?A$JC%L[9>VG>OS4$OG%&=GN@C3MD*,CU#N8*DL^BM79GM(KY2/;9LON P^
M2&SPZ"[AYS<OE%H1X,L'2]-M/J-$LV@ETATY([-RO$W>4Q[P7J@@^ZC2K:XU
MKB .CS6D.P^,R6AU+FMAL')>AT*%JCU)Z;Y2^/M=LG,IJ+A;'+<WL!AEOW=N
M>*1.B2$I)\RLS#@$I42WUO"3<(TBOV#9UDI\F2Y9;2_N:E3>ZK:6;X[+3=$]
M56Z>YK/LTZ^XJK70^3=M$U6*0G=4RAJ;ZQ@65K)3;J>73V"0'(Z+5=.;#8=)
M]0:*EJ2TO4OBAT#K]ETU<JTMA;Z<V#G;:=UT_,7DV+5GIK9+)%G4M,C3<I#%
M"_YVQU-EA:SVT.OWGJU1Y[$S(45&2%W<KDC.G\\J%"W7#;%=%0A&BAZN6\F6
M@H&)'BY 5V3D].C./2S++4>TXO2MRH,MZS1W]M8KM>Y.MBVFJK;[#:>V*J:Z
M+(>6=Y<2BU:>;U&*42)P*"*6E$<<VVR:&\ZJU/3U2XFK6L;LM=8O/Z?U.BG7
M.V&YFBR&KUC3BU1HU%5;"CLV>Y9LMB(H$BYNO6N$MU2M5BQTV!Z06W,$]0/G
M!IB+U)C5FL4.V(I8)Q\M$0P##9!,C%STA-.&C ,18Y<,#IIQ+?RM+V^AZGF]
M<NT]C:TZYKAI553KO\@[MW:49V+%*18L-*0!+ZJJT+-I/-=AO(\^0BZZLZ%'
M5:W6;'3T.HW#;;U.Z\NW6BTK6ZS1;6-,A[[=2G7 6-L5;]BX3U("LMM-, 4#
M[7;N'//'X&W<>L?2#Q+H@J'B)2Q1ZXYL54+,1T'T;EE-E01?<Q$NXT0)&W6>
MDC)"4D(A8C\='J#@YF-:E3&:6VZK;0Z@IZ=1ZZ5V'HJ.ATG%BNZSJ-YL4-9W
M6$1(,;KJJ5I2E\,%S89:KN)"RN.GN@*^VZ0V'4=A>Y%M2K:V")KPJ:=NO2ZA
MZ7T]E"I"G;D&*K[J_8<^U8J$HZ]>4T;E8;3PE>S^-G,ZR#U\F,CN@6)ZEB=X
MKD,*9-1NC';'QSKO*J?\Z4(BZHA*@#:MT HDZONL%[C"HLHY4R\P^RW&X*GU
MCN;C= #G:FH.Q9TO;LL76=*QI]0Z#>;#V*9=?F?-7=U0 JW!+\X'K7%<3 I=
MM6R\-^F]:CJQM:MU!L#TZ>NM=34ZY6AQ;'H_JSI?4?*<#6U4<H?K-\UCJ! V
M:S:K7S;-9@-?$U<=B-^35=KCE] 'V1V3E=19@R1&4="=%LA%,0W/A1C-#=YR
M2/&[FMJ^'DDLHD-QA*#(8A#^E%WX]06)Z,MW(U3B@>G=W?*R#"G4B=,-C,U&
M/+:#MP-T5HCO1)2J'!*[ 2'"\5/2-2?$O7Z\M\A<LZQZ7U(4F* >H"7L6:80
MOHK!H2Z=8NM-SNA=B %\5F"VHR#@FW2H>._-YN/ILC*KO.S9:BU7ID^E,K"!
M1+D<=YC/>,<Y  H16-D@NEQKP=H EUE/-Q)@IL:[&R;)C!,=0V'5NXJLV"D1
MK/+1LKVGJS*++'PY7A['6E6TTINP#!!PG2:B%Q+UL6X7)("!MSJ?#WINZC46
M+1;R76=)J^I=A$6Z2*AUG^,!>&=V@@1UDM0;JQIVE>V33&HU3JY5K(-6VOS2
MOB]5&2X%R2$ZE6@K_<QHN"EHNLD6VN5)M[O)_*I2IV%*(J,.(LL;6Q6[='#A
M'.SIY!]>A/FDZ#/#VIJ5'6MXPM0EFCN-U>N-]JN^X%"W>(>EU;Q%ZK,V'K"F
MZX<T'&Q(U5"JU8]O%M4Z,U+7AAJ@=1*RKJC6)WVY55HVJVM9M==J0/KM_2UK
M5[#BK6>>QK:Y0[6LM+ROO8_7TODHT7@V@X_,\*YI5H*X25B Z>S,4?FD-<+'
M7&9V"9^3[#.]@?YL%#(GGZ(H"2C%5XB"NZ92-'(:6])N51Q8T@$:<+=UNI]S
M>M:]-1NE*ML]S9H4[A5+12VI5Z?#<,L35':0U+XMC:ULH<83 HB^,&IBE'87
M>A>FM71W%G8(ZF&WH^FJ6WV.N"]0#R-A?ZN9TXFF-X]&2+%;Y.90W?M-=;!(
M[1:HI4]+GJS::\<J/)3<ZU(GWMZ8*E+3 PI@[M8 !#>K/CE$]<AR96."J0[<
MA_ONU0L@%'JAG38YU$FDX<X=[4CC:W5^S36JDI.L&N"*5JRLQNM:P;G5[]#8
M!#FWRE7[GQ94QT6(6Z)3*C48^3F;OAWI+5V\-FQO#N-M[.A3<LM770D]=X=U
M>K*;;59&I6-B/.YI6$UYI$ZN0VH>MZSBQK_U#B7S4@*U8::B:M449&3!5FD6
MD%/$U@VN"45%CC[76G:[#R])(@I>[10I)1[LY590:=KCU<M\ULHC:-JTG4GM
MUJY4V,UJ+UNKA224@(75VV;.:C:-T;=BOL@M(UKS %#6NI.M<&Y0K=@Q.@]3
M]%?)5#6W]-%W:U75KK=G8$6FS6.UJM'&Q1M-:6OJ6]*=&UNJJFM>5W5V57M<
MS7;>YYK.S..5^.$=>N9%WF3'NX[PX(L\*]'-B*B9B(1VGE_*I42.]U#2R62
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M,^OW)*&75MI(:]>][]V\E.G$>O>]^RK7Z<Z<LY8M9R)!)@)R!?O@DAB9$O\
M]PS/$_RQG#'+%3FJ%@M%;6+%H?O&"!2,,'X^Z<1!#ZSZ3&4V3Y3QC&,8S8/@
MWE1WKQD=M#W#KZNC.7-N':LJD5NH6'Y31 *DUQ"=ZM=?G4B?"*F9+>M@Z%V_
M\3O1.WM-,::U3JCHCI?K,:0]2ZN-F.NFP5.)N;"IY,VH3#YYHVJLL\R*Z?\
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M9@7$3BFIF8UL+>I62UN-UM,=O1Q6M@)VC3>TA>IW_==;0E*-Z8]WK:-:3O\
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MP>?EP4+]*E6K7#L$BCE2 (^Z281G,E-[N>J-INI &,]CIJ$Q5KZEG8'5#S2
MFSW;"[>ML\P@">U]IH+@1%(K"(',4^<MC]KV_G!-^W[SWOM_*I_M>]VU\/MS
MVO?^OWFV/YGV_7[7NOYOU^Q^KE]['3XX]EK<<=O'D*X[>[OXX[/AW>]Q\.[U
M^/KF)^4]ESS\H7>>[OY]K?SW]GE]_/F<]WE^YW?'L]WGM],Y6+991OBMM3DE
MM1D(16WUNE.$.?():TK*B67"-NN#!$>SM#S(RF4N,N/L+];)#[;DIT*9]D%6
M3PNR%P($!"/:EQ, \A"!@V!SR)'!3!0)Q[P#,3AMMFOS>V]9F74CUK)-I,+V
M!LQ+*@$R2)2&=O:8*D(("-<\K88E;AY64$:0P+)'C,MNK>;9',(9:;><6,XM
MU#;;B4(=6X$&M;B=:4I8@RM[VIAK:*QH0PI)B5&4C R1K BD8AD0,S,3,C$-
M;$1/I$,9$>AES;KMVTB(*LV% )28@MS $3(EE)B(E$04DE)241S)*7,SRL>.
M9R=FWO5[V9E7?9T^E/O)$M?LI*6EPI.O:>WZM$N)2X_K7Z'EI2ISVE:UO4L5
M:P_O:Z(YD)GA2XYE<3 3Z#\0B9@)_@Q,Q'$3DQ7[Q_O[ELO1D>]8<7HTH)L>
MISZ,*()G\<HB2YF,X-RDGL[Y3W(G;DO:TKY0V61L[VM-Z:TKXO;GQ'M::UIK
M6_>>O3>M(UOV=>K)O(3Y7D>2KR>./)\L/*XY[N/+X[..[WN./CZ_'))M6I?[
M5-E\V>8GVB7,E_,#V1/G=WF<P$0$3W>@QV_#TRM^<UD]VXS\X)OW3OO?>M?*
MI_NW/?;4I[WB/B/97[U2U[=]K6_>;4K:_7M6_73]BI]T%[)6[A[>TO(5W1V\
M0/$]G,=L1';Q\.(X^&5_E/9=I!\H7NPN[N#VM_:7?,R?</F<3WS,R7,3W3,\
M\\SEN#.-CWOB #"@2/84W[\,AT9[V%^KVT>]96A?L*]6O:3[7J5ZM>O6\K,4
MMP]C5@T.8GM8 F/,?">THF.8^B>.8RV2]]<_,KN:AG$CWI8:C[9^(]P2)<3Q
M',<\3QZY5)G)M J 43$H@)O:%-AID"TBMJ:>T0VI ^GM,IVV0E+Z-I1K:'DZ
M=3ZEZTK*<U:TLELUT2THF"9*ERR8D>R8D^WNF)'W9B9]1]V?3TRK%ZZ*A1%R
MU" D9%,6'0H9$X8,BN#[(D61!C,1$P<04<%'.?#<Q+M!*C6I21;CEZ6E8#9Q
M* EI<5M3B5"I=TPK3BM[4O6V]Z4K>]J]>\C->N3(<2$DZ)B8;*@ED2,<#,,D
M>Z)B/2/7TCX9 ;EL$S6"U9&O,%$UQ>T4S!3R42J"A<P4S,E$CZS/,\Y<P;=8
MH^738&94QV=9$=##F#"'C)"/2Z,L+3X!)+CJQBQA'76H\I/K>C'%H,CEBR P
M98]%NOIMKS4)"QJDP6,KK 5I=(G#.UH!$0:S,1)H3[KHB5N@U&Q9W"=OL46X
MOC;<=X$DE-QS#=8KP2Y3WH8PBE;5J(P0V.3K$4.KRJPM+5XWEYF.QC&,8QC&
M=I/HS_!SF'FB9V0?I-FOE<1SH:A/0^Z.=7@E&*M3MP0?J2W/5RPZ<2QJO";$
MT+H3:-O$^^V_I36FN*>,?B5NO#M?3QZ>EJ[D[<]H-B-DNVR%Q1'7RKR?9;=7
MB2]K9YG?YG/:';V\%W>G?P;O!+IGQD=U@OJ/9;W71T\O1'3G2/UZ9=.T+;B^
M+/MVNOP4!&O3Y7E0KCO9W]_(]G:W]1;XN_M.[Y]^<\_AMG#ORF.M/T+TO]FV
MW[7SU-^1!X9?6;KO[;T__=W/MOT%WBTEQ"G>E]]<;TK6UMIG^>-[6G6_TITO
M^31?L^O_ (>OV=[U_P#3]/Z<@7X3'6TQ,#INEHGCTF:NV*(G\_'RQ'/\W,9,
M/X$/AA!1)=2=>$,3$R,7^GQF8_-W?BY/'/Y^.?S?GS=[QW\!?%_QC-:G><<_
M;+N;3:VD7VXFN6BV,)<0IIS<848AN-K[CS2W&2':W%P[A3#BV2E/-*VC.;=6
M>*/6G6:RK;?:DO7E,%.KUZXI4"F)[H\Y:YEMJ!*(((N.L0!1!! E'.=J\/O
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M&?U8_%_=_HNY_P"26/K.O1\?; X1^.XO_/C\1.L?JWMOLC/ZL?B_N_T7<_\
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M,\P13\(^,_1&3!4O%WK-DI//>JR%>DZQR3HO4!N7Q'1)&$G3HI)C;P+=ALB
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MW2ZQK<#*^NQBL)VI\F!U\)ZY<=E.MJ=>C_B&VTZWM:DZ_3F9]JJ_NW^$U_\
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M@-G,EO=!:'?54-J[>YT]<Z6=HB9J%5&V*U]MZ+5BPX+"V!6F] J,[HPLO:!
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ML$I*(FMZNZ;!A]9EEB^DF49;Y<MB=E[W8 G,%RWUF8;SQS,E)Q,SF0^/G?\
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=,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g609070g29f00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g29f00.jpg
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M*#,V46=RE*6FM-'2XR-!9FAS=J>R)3(T.%)TL[4D0D5&6&%#<9'_Q  > 0$
M 04! 0$!            !0$" P0&!PD("O_$ &D1  $$ 0$#! @+$ T("04!
M 0,! @0%  8'$1(3%!4A"!<8,516E=,605%5DY26H]35UADB)2=35V%E<7*D
MI:;1TN,C)C(U9&9G@9&AL;/P"20S-++!U^$W0D58<W1U=O$X1$92M#:"_]H
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M7;S4*T\Z?$&MNT-LR&"K,TM:^))*XAG6-?->%!R8\8+2QG!5&RBH1'N4+P[
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M44Y'!TAZ?V;U6TRLK(=C7:AT>L9I;,VH[N,&.K%G2 G6';4<RKB\Z)4C!9Q
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M(\27&*B)RD>2 H7*UCE8KF-5/EA8UD&VCI%GA4PFE&<:L*:.8!PNXA'C28Q
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MM''41)-U >R+9(39G.FSX5>"OAOE*&-J'6D$=*>7(/,33$L<:0VP,-\&BO%
MZ5\:]8*UJ^R'+NU05.0F!IN##%S;'70&O)>9!ZKE1I<T@K=IY^WQL#X-E%1@
MTT!W#4>6F+*8D9:VUUOTLX$RK8E:ZT1"N-&*0XX<N5;#X(LT!H\905HXL!_*
MEAG?(%*WJYG&QS,-W0;+?0\R567SW7;*%S@CC3@ BGL*Z#0&Y6=62XTN:DNZ
M//MA)&!9161#0$:P94$5A+-9J'TW>MIDX-N\I&Q%4,3/A!QEB$^(V+((H&@"
M!6 6"2PTXQ-)V2SW7:\!*H=A$L#YU$?2W!D-QI<9>>'::PZ8YL:M8M2EH<1)
M!HA^<NAGMM5! 4$ED@4<0(<*MHBJA(AW%%:-52M5['IIV5#LX737/HUV1NH5
MH8D@,.-81$A,L8=!H*1*CRH189I9Y5E9W6J8Z*&PBLCR*,B- 1HRCS)4G7_1
MN5IU*B9M;M(/%0-4,D[5!OL&TO"R/K<:H?N,<[5<A5S$IS=96QH@RO1Y(0M%
M*C9,^/)GUZ4%#1X=EKM#!86)$@MLHH)4Z.&"6K)!:<73%XVO?%G\Y0?[VLJ2
M&EN9)CO 9@GL%+'(D/Z,FG]CTNGI1=*NI)\J#5S)5H&^CV9(LCT.:5?;CG5:
MPE,B+=%U"*-7C)#EBE1R'84]>2'#' 2&LM#1]D;<H-2N0@E D:K%/:OL-]O5
M6:%0-C^6.O"1B*]?J_+&T>=CR'9O+,*5/3"A9>F)"N1/**-$><E0W.J'T]#:
MSZZ0$K;P[;N)5UDUQRT_,+8,=[:N6,UD)>DG5CBL$I2<(UD-)S1Y&I 'TUH0
M>HM6T-5<PY(":6BOTQ87UY5LB@U'TSIZ3+$Z^KS1Z4^^D9=L"4Z!#QF2&X7/
MQB>Z:]0 3I:]:VUE=1>00XQ&VW;$U%8VQV,]:+%2I&S=CL@XK@@M9(1.IL":
M FE*6T9HYH&4'1!1,;L%NU%+$ 7':5DZVZ;@@ODM#1WT,#GZ&B1(L*)8LI:A
MTDB2 1"!GOD6JV*(L>RCR0%(<)JI8((DI)O7T'9?Z%[65I):&/,%JRT2I=&L
M;&=9V%,34NHV0A+$EV09-6R)0I3*YLRDFP94<,63&OVV<J? 62']>=)5@>P/
MC&J'7H23A!_5KE+V:X&L-_U_$J&9#&-P62^O7&K:ONLBP9'R$>-:T"=DD,VP
M%'!)%9J<R'I1;;7D1O*OC6<LJQA-NTL:9),2JM23^!WH?AU;:^;=5S(B%:O(
M3)36BYC*=)Y?GPR2,_3^R>P?S<<VBKPMFR'Z8=3:F="L+^@%4(1GHNLKQUS6
M:9NGV'(/3G5;!<60MK!'!2+T486KNYJQJJNEZ$1UW(BEZB_3:3FTQ8>PA9P\
M4MB8KV;H^AM(>//J3$F9&?B1(I,$^F$O#!%EF0/(P(W.VT[-O)8+0-NQ\>>V
MPL>8O)4GC1005>WHYBN60X4]S!O:0CPRF*1O$%SF&"5^>8ZSJ]+5TJADZ=(&
M74DIZ7I00=01IT^5;()ZW)$:D,9ZEA2C>((Y,%Z!<C)#&$CR #S)%VK^BK*U
MM.O:P$UX;:I^UM1Q]8S'+O-<&M4PY3;)BVAH'CB0F-F((M$<:Y8+,;(3W<*E
M#([.!#4>:LK#ULO4\-U)+NCRS014=^^Z&E:)IEL(MA$YA(+S=BO0DB$\J184
M80FJ@S/=SA7#0'1W-?H:R;JBNTS$KHUK(U3I(>F3.NS/C-IYU/8]*PH_.R<G
MR42S''=/LILB0_B-%$SF;1F65(-)5?0LG5=?)['B:GF6LE:[<T(;(;#*!; R
M^+HMT>J3&RQOEN+CCZ5:=C*HP-A8<&,R."P3MBLER"P94)HEJ:DFZH9>2@U!
M+T< ,& Z0X52"3%<T]G7-G.IC=&F<6Q@U"6<EZ2))N6DEBQ(==)(,K@[^BJS
M09-+5\G48M*FM9%K;-B-D:@DPI['Q:.Y?5,U)&6ZBL!36FH5HX(^9PH_-X89
M]C8V\,)0LDY>S0.E3)T$T']8"179VW]DYCE3.T[,V\+U6%=V!@3&M8F9L\ 2
M*GK)A%?1K1IC%1!0XP"JO7FW3I-\LV0T#TKKA(LETA-4MF"T_3\8(]'#5I[R
M0E4LA\$XZ64$$6)OEK<N>LZ40DN:VL@"'5P^7Z[H#96LZ"V&N@25QM7:C4<J
M9JBQ:^-I>&Z_YJ.TB'U- DRIU@K:]NFV-;500B@U;[RV,6]LN9^:UN2+1:[.
M@'":&A46$TD..9+MGV8 M)*3@?"9/,J6T;:BQ,,L-EVEJ;)(;Q,0I27L9S[#
M 4RP82R2.-(6)&609\=8CBF4+%*1T5R(Z,YY.)SH[D10JJC5$5N[/S=;I%;:
MV;8(6QX26$U(<=DML]@(J22I'"R<Q5;-:(7 QLMJJV2C4,BJCT7(]S;R/QQC
M'&,<8QQC'&,<8QQC'&,<8QQC)E0Z'8MBV*)6ZW$R_+?SWR3)<[I,(9"2I*7R
M!!]*589C,X5C'N84Z\ZIN/';=D.M-+\QVN;7-%[%-%V.N-<6*1*^(BA@P0JQ
M]I>VCV/=%IZ>*Y[%DSI*L<O6Y@(H&&F3#1X<<YQ^L[%=BNO-O>O*S0&@*Q9E
ME,5#V%@="#J-/5 R,9,N[N8QA$B5\1"-3J:^1+D/!!@@DSI,>.3UUU;K !JJ
MMM@@J<R)3^42#1=Y&$RB\_".YR^XG&588C-8RIN%#0I3<9G.>U3TAV1(?_F]
MV_;>M8=D%KF1J[5#VQ(,5I86F-.1B.?7Z<IU+RC(@7.:Q94V0J--:616,-/D
MHBM''A@APHO]2'8X]CKHCL:]G\;1>D1NF6$MP9^K-42Q-'9ZHNVA0;YLAK7$
M;$@1FJ\%15"(\%=%54<25.D3I\S)//#\]_QQC'&,\Y2YD37MQ60P=JPRZBH5
MPM"YE7,S"X\852[+),-MRI@&>,+,ICONM3&\PYS&5O1FVWLN1UNM+Z6KE1H4
MR+*EU\>UC";O+7RBR0@DHX#F-:0D0P)#48]S2MY,K%5S&H[>Q7-7IS1)4ZD;
M%AV4BHDFC1D%8Q!132(RM43W*,4P,B,]2,:X3N5$]$81SF\+T:Y._5FPFJ*/
MV5%?BN2O*JC.AQJFPP8KXO.I.!WHI-Q\LTZL6TT(R>@>&P4N2,.DF6\QW$JP
MXQ,Z=NFU ;T;QN(EA4.C 5L6+(Y&6DN,X<ASY+'K&:V,LP/+"1ST>=B*QR+Q
M,T-24;KDU 1A&BZ.N&RI".ERHW+PUARFECM9&<U)+G2>9FY$RM9PQW.1[53A
M?L*=L71U)KULFB-<66//<RD0"#)9/##G?IS6Q)(F3#(2]A6@0$<#-OZXB&S1
M$?:\V*4#,*@T\<R8D25=O,F[,20;$L:BG#*Y4BPXK1S(\SC,RZ+&>(Y;FPC1
M'16OHQ2Y9P6//B1)2AK0,E/>[AX4':FR?6AE7U>0+465-E*^'(A\ 7T8Y0R
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ML8T. %\>O"1T>OA1(<2%%8XQF1^>3)TF3D/GC&>ZXXQCC&.,9Y@[%_=_=_\
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MGKD$!8T*'&.99)X\6. TAV_B.406#(9V_>N\KVJ]=Z[][LM'-7-K/M<\>?-
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MRNL]CNW?9]IZ;JK5FPO2%;05RBY_81X.G+AL-A7H-IY,>DU'8RPQ4>K6EED
MV,%7,0Q1\;=_8:$[(7L=]I>I8.C]&;=-06NH[-"]'5L@FIZ1TYX6*1\>))OM
M.5D,\M1HYXH8Y#I9VL>H DY-_#G)>ULX0O/K;ZGSV)5GLS34YQGLQGW,X\8>
M[C]_'/!%UXNY?VFZ"[R__CB?"\_1S-'(KV)Z*=9)O<U-Z7JHJ;U3K1>;=2IZ
M60'UY<_)5ICS%Q]Y\@.V(OB-LZ]S"?#<ZKT!IXY:]]T:_!,>O+GY*M,>8N/O
M/CMB+XC;.O<PGPW'H#3QRU[[HU^"8]>7/R5:8\Q<?>?';$7Q&V=>YA/AN/0&
MGCEKWW1K\$QZ\N?DJTQYBX^\^.V(OB-LZ]S"?#<>@-/'+7ONC7X)CUY<_)5I
MCS%Q]Y\=L1?$;9U[F$^&X] :>.6O?=&OP3'KRY^2K3'F+C[SX[8B^(VSKW,)
M\-QZ T\<M>^Z-?@F0=S>6<+7CUH-%Y[%JQVYUZCMS[N?Q_\ 2OX^<RNTU=Z_
M2_V8]]?_ ,29ZO\ YW)ENSY%:U?1MM"_<IWM3/W=[_RF</7RS\D&B_S>H^]>
M4[9J_6_V8^Y)GPW+NU\GCMM"]TS_ ()CU\L_)!HO\WJ/O7CMFK];_9C[DF?#
M<=KY/';:%[IG_!,>OEGY(-%_F]1]Z\=LU?K?[,?<DSX;CM?)X[;0O=,_X)CU
M\L_)!HO\WJ/O7CMFK];_ &8^Y)GPW':^3QVVA>Z9_P $QZ^6?D@T7^;U'WKQ
MVS5^M_LQ]R3/AN.U\GCMM"]TS_@F: 7;JM7$NELA)Z;.DZ9F-9#4;$F9IE$B
M;)[R1DM]_E/8/IR])=[GOCSO<)[XXI2^YQV]G)5NTE51B)H#9JJJUNY$THBK
MUM1=R(D[TO2^QG51=FB.BQWKM VF,1P!.5&ZL5K&[V-7<U%@]34[R)OZDZLZ
MZ]U"6^VH(.5?I Z7["@2P]))J#:"?(^ QXXLN<?>DXBG7<M-LAP!LFXI>,83
M!$D).>QJ*\I$A!UI9V:'=7;,MG\U(S'$.L71SC<BQD>3+<XB#F.5J-C0Y9W*
MO>%',1?G1N5,$[0]76. VQVH[1(*R7M''25K1@.6>^3%B,:-20FHY72IL2.U
M$7K-) -/GB-1;P5W+LL)7UVPOT5]-PVLMN,MNG9G3S,8%LJD.HCQ^_S%F\,L
M(?D.-QV7'5(;=D.-L-J4\XA&=F3JB^APEL96RK0@(#58CI9=%$;':KW(QG&1
M9?"Q'O<UC'.5&N>YK$57*B+JQM*Z?F3DK8NUK7I[!S7.;#%K@3I#T8U7OX!)
M#XWJQC7$>UB*YHVJ]R(Q%5.HCNO88B,[,)]&G3+!BL,09,A^3H)QIJ.R2$E#
MT!4E2C^,1U2PP0P28:>[AUR(,G/)1W,9WN:'U5>1AO+(V6Z!",;!$(\FCE:T
M;#QI$P*D59OSBDBQ))V-=N<X<<SD;N&[=4&DJ*41HH^U;:"8CWF&Q@]:-<XC
MP28\(R#1(/SZ"ERXL=[F<36ED!8KMY&[X1GJV<QVYSTQ](V,8[.WMTFC'9VX
M[<=OX0^YVX]W';^/'XN1';(=X@;->KO_ +5$ZNK?X;ZG7]S)CM9-^N%M.Z]^
M[]MJ]>[O_P#V/I>GZF5<KJG(09:H$OI:Z3(\Q"VVU1G-()P]A;R4K:1WORA[
MK*G$+0I"<8SE6%8[,9[>92;0CA*H2[/-F["HK6J-=)?/\3D16INY[O57(J*B
M)UKOZLQ"V<@,)#BVC;2WA5'.0C=7[V<+%5'+Q<QW;FJU45>\FY<FAC<&T*]-
M>''.B;IR$SHX(C9Y$6?T[3HST>O!W'&2YB0ATTG+$ 3):=B%'W>X2.FMKA3.
M\RDJ9Q*RM3:@A%>"7LHT-&,.&>P(,VB##<.%%<YLJ2]'2TX QGM<.0]VY E1
M1%X2)PY$Q=+Z=G":>'M<UY)"^:"N80.N0D:2=*:U\6*Q6Q%XS21N:6.QN]3A
M<AA<8UX\YL[<VI)&,&8_1#T\/B95?(6N.2:Z<"3D)ZM"FH#Y(ZW)27RTH7"C
M%1<J3,PKO+40F.EJ5B-.BNNF:DU$2.R4S9-HA\8D(UBP[=#G43H,=H7GEH])
M7"H!#D1R/)OX4'( 3?P%&YU'Z9TV.0^(_:]KEDH<T%:2.[7D=#,GR7&''AN&
ML7B208D:2)@MW$XL<XD3E D:T=VYM2L0"96Q]$/3P"&!DPUEIY;IQ)0(@U,^
M4F!$5-D22[;4;#A!QL:K+JDX:).-#WN]S7$,*K,U)J*O">3.V3:(B1XJ"62:
M1H<X1 0Q$"-2O?*:UB.,K0*KE3A.YH7\)7-8J'IC3EB:/'@;7M=3#RU*D4,;
M78#%D* 2G*@F#B.<]6@:XZ(U%X@-<=O$)JO3'?LN%?\ XR](GYE6_2+D'VRE
M\0=FGN43X=D[VL4^N#M/]UJ_ <>RX5_^,O2)^95OTBX[92^(.S3W*)\.QVL4
M^N#M/]UJ_ <>RX5_^,O2)^95OTBX[92^(.S3W*)\.QVL4^N#M/\ =:OP'/J%
MY^S<_!V.,8XQCC&.,8XQCC&.,9KMM_JITGHFX56C[,M+H([;ZEL.\C4H%$)\
M*)6=8@7;'92!>9"8>:&K>@1Y35?AO_\ QMC(1)8X/'ERX[K2>IH]&Z@U'!FV
M-1#23&@S:NN+O,(1'R[>2D2(( R.:XJ-*YBR2-_8X@GL+(<,;D=G/6^J:6BF
M18-G*4!Y<2PG#1!$(QD:L LB20SV-<@U<-KTCL=\_)(QXPM>]JHG;3>JOI[N
MM;!V2)MFC 4GM;C-NMU^Y6FOU.X"=;%QL S N-CJAHG%-UX"X**#)[A(M$BQ
M(\8A#<?>;[^WC-L_1NIZ^7)B/I;&2L:U-1NDP8<F;!-; ,2.2!%FQPOCRI*&
M"42!"]Y'/&]&M7A7*P]4Z?FQ@266T$"'K16Z1YDJ/$F!K3"&9DR3$.1AXX%$
M4;U(9C&-:1BN<G$F2B/U :'EIJ:XN[-1R47XH1"45<?9%.>3=#0@FL*5$5-3
M9E6+$4&&&W!)" 'S,EPB;:X$EIN4G+6--VF=2,6:C]/W;%K BD62.JI[5KXY
MQ(<)YN^.G- F J&$4_)L()4(QRL5'9M-OZ)_-%9=5+TGE(""K;*&[GIA%4)0
MQ-QEYR41D4)!AXWL*BC<B/3=F.Z/UH=,&Q[,'J=.W-1RQ2Q!)9^MJ4<@#XED
M@P[5>:>XBN/DWX>3TIPKK2\28\<2W,5)!5Z58V,K!NQ)\B4L=!:OJHAYL^AL
M0!BR&1I:<W(5\0A(5=.19;0M)S9B!MJYCW'4?!)E,BN1)#7C9'0M9Z8L908D
M.YA%+( ^1&53C&R2QDN=#5(SBN8LAZEK)SFM"C^($=\EJJ!S".F[?4CT[.PQ
M!%K?>EW8%@58D@9S>T:.N&;54&FG[8D1)2<RR2S5V)##UBQ#6]D(R^RX3\&0
MZA2H]=*:I:0XG::OT+%2(LD:T]BA(Z3W.;!4[%C<04F.8YL3E$;SAS7('C5%
MW;R:CT\K D2^IE'(62@"):058=8:(Z6@7(?A(L5KFND\"NY!'(I>%%3.R)U&
M]/<]RLM0=[Z:FNW1;K5.;B[/I,ARV.,E"8-YNM(9.+4=6T;"F0[B1>)2D%1)
M,>K&)<&4RU1^E=4#26XFF[YC:]$6>KZ>P:D)'!#(:LM71T2,CH\@!T4W BA,
M$J?.$8YQNHM/O6,C+VF>LU52&C;.$Y9:M*4#DC(AU4ZH<)@J@N-4*(HU^?&]
M$G]<NM-N*%.U&VUFTMH&@C2G*X>%'$)#VD<DO62REC)<I*1MC$J24!3\YQ%+
MCE)FCW9$;.'>1DJOGP5X9T*7#=RTF/NE1C1UY>&502P;C,8O+13(H9(_W8"H
MHRM:_JR0C38<Q-\27&E(@@&58QQ'3D90^6C%WB>Y.2D"_90$_<F'\^-7-Z\Z
M;W>*OK2F6C8-V*H"5*F@R-BL)5<>7,S"%"HSDJ6ZU"@,2B$^3EMO+<0>/BRB
M$^4MF'!BR);[+*[JZOF6T^'65X5D39\@46*%','RAC/1C&J0KF"$S>N]Y2O8
M(3$<0CV,:YR4G38M;#E6$TJ B0P$D2"JU[^ 0FJ]ZHP;7D([<FYHQL>0CE1C
M&N>Y&KB\'U+ZB(0(TFU6%>H24TJ<#PJOO"-G4=J(RJV)$'C3X0-=EB7;&,'A
M#X8G-,5Q985!9GICSID8A%G0XLQ)TE>"(]L.*EX$88YR3-//2\A"9+.>-';(
MD5Z';$,61&D!&"6@#D</B&-XWC>^+!J6H(-KI4CH@CRG"R+=M6HE$=&"&09P
M0SE"Z0(8) 2O-'4HF-?PO>U[2,9Q']4W3P6ME5IPK<6NR1*]A,'*-.@7"NRP
M%U:\H9E64,J1Z.3<%V0^V;@3(;H(-(F$VU1W<KCX[A6,"Z.U0"%-G&HK00JV
M1S>Q&6!*')KUYJR8AIT9X4-$C+'(PB29#!A5')N=UIOH/5&GC2XL,5Q7%)/#
MR\$@YD9\>:G.'Q5%$D-*HI,A##>Q0!<\J<+M[>I<JHW4QH0A'8)!=M:_L5;[
MDVHK=*Y;ZX=I%7P %"3<[ROMHPG)!5?NQAT1*AJ-38B):"4'O2L^&1>_6/TE
MJ03W!D4EG%E[XZ!@2H,N-83.<F-''S&$8+),S<:.=CTCC(K%$3>G[&_AO;J6
MA(UI VU?(C;C*6;&F1CPHO(""9_/)8BN!%WB.%[.6>Q'H1FY?GV<5?>NH726
MN=98W#:]H4:!KF4+FE0=H1:03XRW-PPY$]B#2Y;9#P:VEYXP20?%"03TZ<3\
M%=3#9=RA7<XZ[3&H+6W6BA4]B6U8889,-8<EIH*O.*,I+!BBXH(!&.)ISR6C
M&'C:I'-WIF2=J"EKJWI>79P1USA/*"4DH#A2T8$AT9">A.&68@A$<(0%(\O"
MO UVY<Z*_P!1ND;#)B#FMFTD4<(2;.P.K1^U5T-9B35.EFH=BG0 $PH@G*'#
M%UTZ[,EM1E-Q&!!)R7X/X!+2Q=)TMJ&,QYEJ+ T8;(;BRXT*4>(%T]D=\419
M(PJ%A3)*C(-BOWO<<2,XN49Q6@U%22'-&EG"$<CI2#C'EQPR2-AO,R00<=Y4
M*X8ECG5[T;N8T)%?P\#]U9$ZA=!$,5E4#>&H)J;JP7E4U4395,D8MD6OJEH/
M2:SEDTO!U@(N!.07>%^%-C50Y:9BF<QWL(QOTQJ42S$)IZ\&M>X#)Z/J9[%@
MOE(Q8S)G%'3FSI"$&H&FX%,A&*-'<;=][-04).:\G=U#^>M,^%P64)W.V1U<
MAW1>$R\X:!6/0SA<:#5CN-6\*[JH1OC1U@=JC '<NJC;]\EE8%'9$;#J))VY
M3@2T-FX55;AEWEV&6'<<;;*QA"9CP]:T(EH94I.,V'TYJ&*DUTFAN8[:U@26
M+CU<X*0!R458Y)JD U(K#HBJ%Y^3:5$56*Y$RX-[22%B-!<51W3WE'!:&PB$
M68^.J(=D1&&<LAX55$*T/&HU5$>C=^0*]=5FJ:'8"M2DMW>TVL,9)A9M9U_1
M++>#W?Z]3*GL"US(XNO09DN2-J=5OE)G'9K+:D(G6P!7A^"%D(L",R5=HRZL
MHH9K%KX<(\<,@<RSLHE=&X94^;60AN-**-C#39M;8#CC<J*HX4F47DH@G'30
MG:JJH,@L1W/94H)B@?&@09,X_%'AQ+"6]HHXWO<.)$GPGG>B*B$E@CCY221H
M5C+_ %MZ,AF+8(G/7L?BI>7+4@O/UU;8H$R2UK3D["O "O%7AJ8Y*S@*0F59
MGJTKP<[,&C2V1L";(&36&=MFS_41 0CB;7%6;T<YH!VD)\F.*UG]%U\J4%I5
M>*')L59$;+^>CC*8"%(-IAN=K.UK1L-+"1TX?-.?-<9]?+: Q:V'TA-CQRJ/
MA)*!!XI2QEX3O$,JC&]PGM;MG'D,2V&)45YJ3&DLMR(\AAQ#K#[#R$N,O,NM
MY4AUIUM25MN(4I"T*PI.<XSC/.+<US'.8]JM>QRM<UR*CFN:JHYKD7K145%1
M47K14W+G6-<U[6O:J.:Y$<US516N:Y-Z*BIU*BHJ*BIU*G7G=RW*XXQCC&.,
M9A*Z_NAE?[*+_5V^>::D_?>1]X#^Y9G<T?[W"^_+_>.SYK/5)&7)'5*1893W
M;KU1IK+2.U*>Z<<BO(0GNE92E/=*5C':K.$X[>W.<8[<\^L_87.1NPZ(YR[F
MMU)J)RKUKN1"@55W)O7J3U.O/AWV?['$[(R:-B;WDTII5C4WHF]S@2&M3>NY
M$WJJ)O541/3S7>^=,^ZM;().6FHQN]"'2<<D]6[93+PS#D@I5@AV&*^[2;#8
M6VY59?JQ[RHBJ5B36V(&99QJ!$D1'W_T;5ZRTY<*%L*>_B.T+PMF0;&M<1DI
MD4D1[6V42(JLF,FQ>9/1."8XJ,C*4C7M;^7+W9KK/3K9#K.I$K(CI(Y#JVUI
MKMH2036 + 1'4MA8(TM:^KG=)B54)7#!RLYH!$$\D6#Z4V^?<0V)UE>I67&K
M,XTYFL%X\=_--"3[':([$J5$8C/S@H47.G3!S+JY^$L=Y;C.27667-V1J33\
M5%4]U6,W.A(YO/8[WM2QDBB0GN8PCGM%(D'$,9G-07SW&YZ,:YR1</1>KI[D
M;%TU>%XFV3FN6LEC&_H>$>QLQL*43!//#A1C'+'8]Q]S$8T;B/8QU$0U1L<0
M"?LAJFG0(B.3IHC+Y^&H%(>E;!@V\E3G80\MF&1(#3L*AVQZ,9@Q) AK(AQJ
M5.8>DPFY.45[42)+8<:PBRCN#8GX8I$E,:RI+ #8-(4'*!$:*2T@M?'*]DA>
M<(Y@G-81683Z4U'$@OL9E/.@Q&2J:'QSPK!(\NH 6\FG<&/+Y&0>-.#16KQS
M B)$:L1S2G8\@6DR/;ND_?\ 28IV:7H#D^'67)31^53['4=@1Q+HXC8!)=F<
M[1#UC3'> $*N<CV1AS*7JYF&ATXB Q-@.RH>!KK2MB^,./:M$28C'163XD^J
M<=I@Q3QW#2SBQ%<V4*;&?#<GSLSE%;&4KAE:SH[;95KVE%./+H5.&M<5D\M1
M8U-^R(^/)L(DMAW4<^Q0;X,BKG#L6.W/K^1:^:@&& XN,).K]F0HTN;,UW>H
MD. "A6B=+DU$^Q&AUHDJ0D=8I;[H]#4<%/5$EIA%WEH'RE19&&)#F67.YFF7
M5,1XQCMJQY"RB0A#9/BN>28%&*:(-K2JY\H2$&I([44K$>SB8G$W?S!-,:E"
M(IS:>O!!!"#9',2IGL$&NDJ1(]@4CHZ,'"D*(J!E/5 %41$81RL=NN8'3FR;
M#=(VO&*P^%N,N*Q-8#7:>*UZM4:6EA4!Q<N]SZX/9R3S*BMB6WI:'"K\J,P.
M1)>D-(7AE:AIXE<^V=-;)KV/<-TBM$>V3C&KN51!U@I97<BC'N.K6*T#6/>9
M6-8Y4V8&C]26-R/3XZPD.W()AV0[H\73[N2+R?(.<6]/71V<Y4HFQ6O*UTIY
M1LCH1[VM7JB:>VI-L-2JC.OK:D]?3*Z_2X,H).@IM)9H@V*D10<R:U'@$4Q"
M#K<:=)C2G(D%2N[F/L-XRO%Q-04@XD^<ZU@+%JXZ2K$C)(RK" X2G8^2,3GE
M"I!-5XV/8A"HFX;7+U9:+2&J36%35,T_;)/O9CH%, D(X4M)3#MC$'!,9@P2
M4"=[1G*(K@@W\1B,;O=E4UI#<+T>"^UK.[K<*2HT04-37"GCTNJ6.*%F9(BO
M^#>/"@W(\*4D.EH ^0,83#<0_+;<RA"L;M2Z?:\C'75:B!8\AS+,!S8"#, #
MF'E\?-@&Y60%C0%*P[E(BM&J;U3*W1.KWC 1NFKM72BC%%CI72N?2U+'DRV%
MB0.3Y[)C<WAR2.E@CDC,0+D>5KE:BT&=3;*47@@(=)L1@X1JXJYQ1%>&R+&2
M\F#3<9P<6D0@22,B$P[X;$:=;F-L/Q)$EB+,:8DNH:SE2]IT 642RB1XP9IZ
MY\B69D,//8RO:8#"2E$PCF\F16J-7-(QCGC<YC5=F!=)ZD66" &DL9DV161;
MD42OC$L9/1DQ!K'ED#!200+'\L)KVF:,@B%8(S!D<C%[YNF]JP6XSZM?VJ9%
MEQ*=,9G!P\LZ.[G8 058Z=$=(A6Y\*.6/"#@J3$"R)#1=+DUJ(_!:F87'1:/
M4-&17MZ5@C(,E@-XI$@<4R+523P[ B!DJ(K@19$8["26L='5!N(TCA[GKD/H
M[50&B>M!:F$8-0=AX<,TZ/NOH46QJ!/D0FG".5.B38I!0B/;+1QFB(!AMXTH
MI&JMH1&R3TO6]]BLABD0(7=D4^PLMBC4_(Q,$026X.2F"4FJ-!DQ($K+4N3D
ML,PRTO,^+WW(R\I2*%H[BK>Z0$DF.UEA$<IXXN64L@*-,JE")(\A2%9Q#9R!
MN)R<D_AUR:6U,%DDAM.WHF0Y(H4QY*BP8R+,.L9 1)+G1T0$DRS8:" 56E(L
MN-P,=RXN.KQI[:20UXL,F@VD:%ULTPN\D3(B6$C5UZ2;K5=9&S5%FX65&U%+
M?749 Q\/&D0R."JX"1<69-CX_1!2+(K(C+6":3<.<E8&/(')?+:R-,EN,- *
M3=&0,"6O.GJV,I!<@A5.\8WYO0AJA(=W8%H;2-"TXP;KN1,B%A#KWEG5M<R,
M99;0JLU95O7)S :/F(&1SIP$BB,8>-^3&<YCC&.,8XQCC&.,9W1Y$B)(8EQ'
MWHLJ*\U(C28[JV9$>0RM+C+[#S:DN-/,N)2XTZVI*VUI2M"L*QC.,,F-'F1S
MQ)8 RHDH)8TF-)$P\>3'.QPC .$K7#,$PW.&41&N81CG,>U6JJ+GBRI4&5&F
MPI)X<R&<,J)+BF)'DQ9,<C2@D1SB<PH3A*QA!%&]I!D:U['(Y$5/8_I2ZKX^
MRX<?7NP9C,78,2*IH45=RAB/<XS#6>WM_P"JVU8F6TY7*C(PE!)M*YD-&'$R
M8[/Q8[+OL1Y&S$\[:+L[AFE;.Y9G%MJD*//(T5)._OI^Z(73ABO1D62Y7/K2
M.9#EN43HT@OWI["7LU(VUH-;LOVGS@0]IT(3 TMT91QXVO8D9B;]_P"X$'5,
M<+%?,B,1H[837SX+&E;+B@VCY\W,^K&.,8XQCC&.,8XQF.G/VQS^.K_FSSD'
M=]?NK_;D\S]PW[UO]B9PY3+L<8QQC'&,<8SSW\:7T-O,V3U@H^B]Q;C:U5]5
M7AR"!W#SCQ5F9XOAQ8\J0^O(UR;A]+<=SN8N7UJQA"5*QUE%(N(MG!D4"S$M
MQHJPE@">>7Q.C/:7D1#81[UY!Q>)$8[</B<NY$54G["/2R].NCZB2$M,2+%2
M:EB5@(? UX7"Y<I'C8Q.<-%P*Y[=Y.!$555$7(W3(=W8"3=)&EPP2>3SXN;?
M)$K $!E!98G5-BU<$FLM&K $\='GXUD/31HB!&,399$3"1B \RIV++[+0$O5
M<1+9^EHD0\A>0:\\B;$B'CR9%?=U\-(#94R+SJ8]DZ66/&"R24AXPD0+V\0R
M<OM"AZ2F+4LU9+E@CIR[F1P09DR/)BQ[*BL9O2#HD*7S2$PD"$&1*.2*$8)1
ME4S'HT@IWMZ];[LL>[58_H%FME9P-H%8"E8K-RD1AE)(;$&W& -#HC%BE48!
M2[I3X<84;89F9D,BI0<<14G$I/)C4]QK&>VVKYFC6P9)HC(<R17P+0@P51[F
M/9A!&1D@]<V(6TK1,CRF,)QMCDC ,NXB9"Z7IM%UY*FQA:U=/C"EK,@Q["PJ
MADD6P*.15&D2E)&CV3Y@ZFT*^3$>X2,?('*.!%4>51'J8ZA0+OCFT:R<85!L
M0L=**6P!=8R$'FJ9>! X'/(%"#"6IZZ[LF628@/OMRO X@:2TWB!AW$G,?7N
MM(CDDV&GG,44Z. DBQB6HTYXVMM8P(ACR"L1I5A7A#,"]Z$1@XQ&H@4<C\0-
MGVAYC5B5VH6/0T&0<<:MF5)'+#=:5$F1,"",%RN$DZA&!YV,4?*DE#<JFX>3
MOVR=M;8:T]LBE;(UV7EDK%$!Q%7ZMF9%EI*81(IJN</EGK2!L)^L'BJ8VLXH
M8*W*D3I4!1F:P/EB,HGCBNW?:DU&W3%Y5WM%*(><*(+IF!*?/J4%(/IXH2S+
M"',F5\R3P40XL5"/,0*RBC"2-N,&1IT&FM-.U30VU#>Q!QX!)9.AI\5E?;J6
M/&U((XX==-@PK"%&5^H"2Y;AL"(R1!/.*4B@/&C-_MG5*8'1:B9U.:!^2=GK
M$T; 8K]@<7Y5TZR7&4P\#&3)<V&=*+G7YT>;\2Q"#N!XX,W)PQ';><D:-S9;
M0I0&5LK3<N*M;/KC $R'->O2%9.LR#=$ 1Y1S#N+;N#*YHPSN1#&1_"Q'*Z0
MI*S9S%.^SB:EB2^DZ^Q$<SYL)J=&VE?5!>V9($(18<=H:5IXG.R :ISRG#XW
MN:UE::WAN2,-,T4%H8!7/*JE[",VX&&"VBSD%B[WF8%LEJE((ECUDJ2X11EW
M$\9+(Q@K4P1772P-)(;@@0R2]6ZH&"341-'0X72-3=2K*)%BS[ RQ[A2Q9UB
M5#2)<ZM<*0UZ& 0XXR$CPG2(J'!RQ\,31^E7GB7,W6DV=T=;4<6LF2Y==7 2
M13<E*@5HU!&A0+-"QG-Y&0(!)3A29S8TM8YU #I'73?]!!B]=C>G*>.P&KY6
MGN-QZQL*>LC;"XJ";D6^1B*1?@2[NV&BXF2&T)>A.@61T"<+4#K0.(,MCV^L
MZ6)'I :','FL(]6J,@71G'L9,<,MUD_DS/"6V2*-"O:B.$Z&P 2QUBP(@X]Y
MZG15U,DWLC7@#K+G1K1%?84@$!619!H;*MG*@8850Z63DF.7@*V:XYA2.>6$
MLLBR72Q;;L2=F4*#T^PP!7,:JZD.UVLLW<T5J,>OF6[@/#!JP]93#:52"%5D
MDGSR!,Y<F02L!0@5FE+2F>O4MIVI9S;ZG#HL4.2K*_34N% ;;2Y-:R'*2S#%
MBUZSI+4XS0'G?,2.92$/,D'D%D6'+.W*B#IB NG[HVMRS8R$LM30YU@^HAQK
M0DV*ZKD2Y5BV!%<J#!8CCLA.DA:,<>#'!&#'KE"FN@#3^P[/7IUG"@6Y(R"[
M8&.\.F0,$Z1=J0R(9M:0%7(%(MFLGDN(G12=AR $DDA8#OA1',=EMU:.&A:8
MN["$:?$AM( +IK.!TJ&&8=U: <JQ2'7FD#G3NCXQ1GF\SCGYJ%W*&X&M<J=W
M-U315\X-=+FJ.09L%_&V)--" VSD$BUJS;$$<E? Z1DA)'@I-E1UEF;R8.-R
MM18M;:E8:+8)U6M8U8@^-1"7.'.2(DI<;!$?%*1,+>@OR8V5N09L9Y3:'E+9
M4YEE]+;[;K2(ZRK9M/--76(%C3(Z"4P5>,BL0X1R!;WB>0:JX)1N5$<JM5W"
M]&O:YJ2-99P;B$&QK3I*A2%*@3M84;2<@8D<NYIF#)N:81&(Y6(CT;QL5S'-
M<L<YHYOY]H'/HQGR_P <8QQC'&,<8QQC'&,<8S2?J!Z"M,=2MW<O^QS.Q<',
M QX$>V L @:/#1 H+80D$^+CR*W/<:FA"VRCMV@/R'Y2<W,?6B<QN7" 0!B/
M0-,[2+_2=>E;5 J^;K(+(*LF,<I3OD2:L\EIG,EB1PY *F-7E:UK/\P++"-6
M$DD,O%:@T'3:EFK/LC6/+H 8!I'D!&,+ @L @<)KHQ%1X2V1YHU<YZ<\'&*]
M'LCC&ENQZGQI!95^5,,;!( 6[WY? *1))51NIU6;+M=#M5@!BFH5-B'2=<L^
M-;U:J$X5O.V>:-H$>=1ZH1KE=*$(,C+VSM0H%K& K!R5K>C)-BP,U9LT8X5E
M"BR#N)/?&#*A]+39H208T,9K-X[&:*7+"(K<?:_I%*Y[S6! ).Y_'@N+%2)%
M>Z5 E2 "1D-ARQI25L2(5DL\IXH#'PHA(T<I&._8?0!J2$==-LW3;"FY[@,L
M?$.FZBY!LEUJVT=A;LJ^P2L[-'Q8V+,!VSLL_?X\((=#TTA98H.>=JA90MM+
ME";2[LD9L=T"F11-D C';'G-)$KYE-5Z>F5@1I8\T=$DTE3&K'$D1CSQ1'R!
MQIH.654JS0-2PZF29:JCW ,<+C0U')FQ;2PNXM@5_,4DMD@MK*18-8 X89)+
M //%-R2(MBE^IMZ+(Z^3K@G9MISQ"*\(K+1%1JGPRS0JN=/I+IPK#"/%=&@"
M%,URG6&XV,9"<$.#%7V[V<^0@SXLJ")'[+-J^HQ6?2H8E,,ZR3RU$D><0"FE
MZG%JN8Y4-8E-Q2I\6!%,1#H9*VNAQ1$&]A#%P/V<49*_HXLFT(%(XHS2*:(P
MS11]/ETW&:BB@C%NC0Y,R2)BB42SYLJ009&O8(<C&= ^J@82TC@5TVD"-V^L
MURJEKN#)4<-:\#PVP7=@G7(JQE B@&7MBK;!TW8<=8!T6=H%2J]9BCAC0YV3
M*U#;2;F0>&217TTF/!ERY@*^0*Q/"Y616)61D>AK-\IS:I'29]6Y)+31K.;,
MEO*92HQFP+0=4 ,H8)MH \N-&BEF@)!#*08;!; ZLY*O9'1;%4!#L6K'<(\"
M)%C-&)!JYV,*?ZG8+U\0LIH%?"EE5"-4XGK:DW)H&FCJ>HCQJX5LUM"37JH,
MN%B/0-T;$VWMI46IGJ=4YINS!&B%<E2J]&*<F)VU$UF*)'D5H8B$CSPVUA =
M)6P1MBV/ E IVRIIH,6,33]71TB.G1I\T<>'(44MC)3PY&1-G@J\DDX)Y9*L
M-#+6PIJ YBJP5-,C&LW1XHY<@X[JQM[9&Q#PXCSR@(2,]\9A<VPZ8.GBK=+V
MEZ9J&LSYQ]=<"AHA^X&,=IRYFQ8(57O'A52G9"VT," HD"!&9DR6*[50P&LP
M7E#@T3&.+U?JB9K"_GWDL8XR2I$A\:"#JCP(YI)I7-PHB-15<>0:3)-P-=*F
M'DRR-0IWYU>F-/1=,4T*HC$?(6. +)$PW^GFG$ 4?ERKO<J(T0!  +B<V/%"
M",Q5&%F9)V9KNL[:U_<-:7*/*DUB[@"%=,H@S'AY!N(084UX4-(,9P_ )P7<
MMS1TUKM<B36&)"<*RWC&8JIM)=)9P;: YC9E?)%*CJ4;2B5XG([@*)WSI0D3
M>,HW=3QN<U=V_)&SKHUM7S*R8U[HLZ.2.9!O<,B,(U4XAD;\\,C%W/&].MCV
MM=U[MV:Z&.B^D7* 2C[.V7N;:Q,Q1MR:](V"[66L)(YKV[1^LA=C:%#ZK2ZQ
M5ZOD+#U/6LUN)4J\!#H(3;,:L NPF[&2(N]3'U]80"A?45-#2B!8T-H*-7Q)
MBBYUI\MN:*XQ9MA,F3.</NI:2WS94DZB'$CQ318T40F\\?1D&:,K;.RN;4AH
M-Q7DD39,9"<WNV5@Y""'%A18L7D&54;FS(D< 4(^2:0*0>24CK8.Z%-5QB;]
MB*6W9EEM9.UTV[V*TF"5,C$[+9Z1N>L;P%DB,&NT8%78*9=EJ $*3@UP&"'/
MUB(N/&B1#<AX\O*7:+<O"V*&#41(0H4^OBPP"GO%$AV-!,TZ8(22[&3*)P1)
MTF0$DJ1(*V8]'.>^.UL9,0]#5;2.D%EV<F627#G2)1BPVEDR8-S&NQ$(R/!!
M&&CY,.. K(P #=%8K6M8=SCK=Z_T4ZFK.H[?ID83M[E7N>O]4ZY(RBJJ:;)Q
M1&G*0!H51(0HQ>F3:VX96*K@V<4>*UXG ?,X<F0QT!K#$5C!*U_=S+N%?&%!
M29 L[JU$P*3XX7GOK&39SA$>">.6@$-+*(+0R@E;'X1D*5>)[LT?1=3&J)=,
M(LM8LR!55Y'%YF<C!4\&/ B$8TT)\93***(A7%CE&XR*]@QIPL;2VWHFU[<-
M/T'3D^_[=CC=? [Q5X%Q;L59*WDS6-E52Q4J[@#L^T4VP G(!FNV69 C+$UT
M1.KC4,6S59@.-"2PN^%M M(-[97PJVD<:SD5TPL%8LL-<"94S8EA7R8PH<^-
M(0@)4,9'H>4<<ISS.FCDO(KDMEZ+KYE/ IR6%NT=>"=&',21&+.-&LHDF%-C
MG)*AR *,T>4\;5#'"2,U@FQ'@:SA6#F?4W]%G2L@C-LFTV8Y(5LX%8!0L]5P
MS=G";8D;&DV0*?.BJ7#N<L%$=VC9G P!JSQ@<9_$&9,'$)S<R3.D8^U7448+
M!#B4[G!-428IC1IAUAR*5E4R+(C1C6#X#)+VT\-)$ET-\E[>4&,HAJ-@]$VS
MFC.5Q'R;1&D%9@D"$>*%)0;9UBZ2"0<4)DUX&.LY*ACI*:!KD&]XR$1[WT[7
MJ;VG_P $DSM@[?+1ZK,FE5CR,O5R@UD.3B!66Z?L(&-JN,#497!+.5^9-"#@
MBC5?AC1]A275";?S<NU:\_S[DZNC"Z:P8>5$RX0\6.,0&-C19+[E\CFZ$ V4
MP<@LA(\IY2Q5!RBMRU-G-1_FB$L+<K8I'F49'5?(R3D(9[I$B.RJ8#EE&98[
MW@&!31V"'(0JL1V5E*]3GTS1S^M;)$N>V#D_69=LJ-CV4M1B@DLV/M(^Z5P/
M+#(U]%&5H)4;..:,5R#K>+1<QIC\IV8]/6[C*++#:G?6,6VB/@4L<5L%0E=$
M!8A.!2PRU\L[)"VCS2Y$Z&5P)9+9]EQC:QHVB1%WWPMG=-"D5LEDRV,2M*A1
MMDE@E"9!RAS8P7A2O:*,")*&AHPZUL'@>KE>I%7)F>Z/QU@NMWNL;9FP==GS
MMVM=HK-MU=/ "+@ !;+USJZC[/HS\JUUBY"7A%F*:HKUMBFX(R!:P!5N JMF
M0;X9B7*T(VN2Q:^OKWU%9:QHU?"B2X-R.2>#)DU-K<6-18M9"EUYVGB!NI4%
M\<IBPI(7%26"0V0X;-P^D!R)LZ:VRL*^0>;+E19=62.&9'!95U7!LX+GRXLP
M3@R2U4>6PXQ#E1RH-8Q@."U[K!8>ANMR5; * ME;&E%K'C:9VE@;K/K1VCZ_
MV7M?6,S4IW8D? ^HB=@V@HW42$^#B'<[_8H:VR19<=$(@1429V8NT.4SHP,F
MIJF B]#QK"37CEQ[&SJ::X'=QZM_*S3UD,*SA")RD"LBD10@1ZD$+DG:\C1$
M9RV!065BXTGI21#!-)&/!K[*UJWU![!O)Q!6$HJ0WD'P39\EBH4JM1A"<HW=
M*O X-9  ZV+PZD;7PXP&.2\YEUY,$3"8@1,.NYQC+CN(\=O#CF<8RM?:K.,=
MO.!DR"2Y,B4944LDY9!5:G"U2&(XCU:WTDXG+N3TDZL[2. <8 (PD5!1PC -
M%7>J#$QHV(J^FO"U-Z^FO7EWY@S+CC&.,8XQF$KK^Z&5_LHO]7;YYIJ3]]Y'
MW@/[EF=S1_O<+[\O]X[/FN]4B?7&ZIY\EON<N1ZG2WV\*QG*>[:C/.)[K&,X
MSE/=)QVXQG&<X[<=N/Q\^LW87M1^PV*Q=^YVH]1-7=W]SB@1=V_>F_<O5U+G
MP\[/XCA=D;,*W=Q#TKI4C=_6G$P,AR;TWIO3>B;^M.KT\Q,[UD[QGW>Q7P\=
M8M9.RW,9;I8VVNG+&!APAQ"X37*"*&E3<CP#7!2+>K($*U5MY3$@).7"9D1U
M*>?=]^;L]TT*MB5<6*Z &'7F@#- ;&ARB$** -+0Y@1F<K;@?60Y()RM1S9(
MD(YCT1K6_G-VV+6YKJQO)TYEK)L[B-:FC6SIMC!"&-(MSNHHD:5-)S?3LD=Y
M8PI56UZL?".H6$&JN>ZM1UG;9<@OQ2@^G'91./;A]F,%8-A\:6L-<HNX(Q(,
M94/LP^#&CQG=Z;&G02-?@@[#F84B9(&B$<9#CMXNUW1-*T@#6,5@'0"PXX"Q
M.0@R:]^GWADQT+"*1[WMTS4"*&623$Y,!.1C">8CUSIMDU6X#Q2H]1.+)':Q
M[*9*!8<YM(=N+5PY$.8L>SC@&P3M;ZA,"37@@V'+21+(FR!QQ#;8=H=5%^VK
M7(E4+U^A@ <(O43<6#4PQ48Q'F4V9M0B-;C,2SQ*-#A2)VXKA(FP8;$>*GM%
M,#FA\6#EA_:I=$5='+).!+M)4DL>?&>6?) =SAV Z0)E>X<4+R$8/3]>T92.
M>]?V=Q5*\J.;H:GVIW^J:X-7+KZ*!"!,J9P@U4.5&8PU.;5$B,T;#3Y(Q!(?
M5]N0P!,&-%6,P#0" K'ULOK%WB3MMLN1VQ>4A6VVB':'6;'+L!J !\7RKG,A
M5NKQYYYY86I17KV;S'!-/N,,)3"PTM&67LR,;-GVF@P(%=&B<S! A$A-=#9$
MC%E*5E<,DR:\45J2)[VUD;CE.:CG*I%<B\3>#,7;!K>3:VUQ.L.D95M:!LWL
ML2V$T$#FY;@P*ZK&>>]T.I$^\F\G!:]PV(@4:Y%8]22B?UQ[2FB"0-NHZM'C
M2%55568$*O'LBA+:G+?(0<%U^;:YE;;L$.5>+!+$398>9& 29*' $$9W*\.:
M0MFM(.0&2L^[*84Y)SBDEQ>7.J-@,6,>6.".8L4@ZV(,XQR!OE,8K913;T5L
MH?;?J@T23";4Z8!&/5K5L &OG\UB-5UL]LV+ -:FKFSPDN[ L,I89A0"%1T
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M6H<6QNJAV(,AQ=??)LQR$SQ/)=:+1Y4%C ZJL&@#)2*4@#QR2V/#PGX(XS2
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M3+#X:>9KIYL:?K_AJ9++28QT:.F,REYA2([,Q#C"<4BKL(Q2!+$*KAR9$/C
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M\BILHHX93PS-'815FPWHU"--%:22-Q4Y-7\' Z))XV$X",8)Q',0:M<N,-E
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MAOWK?[$SARF78XQCC&.,8XQGF#L7]W]W_P![+#_[M+Y+M_<L^\9_L)G;0?\
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M\BO%)&5B(45+!0BO5QU)H#V706L(A+649\AD]DDK@"5[DG5D*K5T=SWD?%(
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M9\$(7![5\<%X%K(;=V'!8E'8=DV?=F]MN;*BTP"?.V!\;3*TS4G)6J:,_#6
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M)_OG9W:?^KW?ZGM[>S\?^;MYJ3O0/S0_*>BO@X$XN#HCCW<2?N>+JW[]W?\
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M ,.G] ./I+?RH?DICZ:W\GOY28_8S_PZ?T X^DM_*A^2F/IK?R>_E)C]C/\
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MD0I)(HA&*6(%!&DV4&KBHKCE$YS"RK*(KG(-.3"IR;G\F-#4Z?5/J9(%1K%
MTILV;6UU0;;9Y;!6AQUBXCNG=9[Q.1'Q[]F1+D2P%+V3%8<\"0^P2/C_ !?
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M'=T;'O6;:!Y&HOE/CYG%MV]?]F'E_4OR.Q[5KU$_&/4GG):O0?CNZ-CWK-M
M\C47RGQ\SBV[>O\ LP\OZE^1V/:M>HGXQZD\Y+5Z#\=W1L>]9MH'D:B^4^/F
M<6W;U_V8>7]2_(['M6O43\8]2><EJ]!^.[HV/>LVT#R-1?*?'S.+;MZ_[,/+
M^I?D=CVK7J)^,>I/.2U>@_'=T;'O6;:!Y&HOE/CYG%MV]?\ 9AY?U+\CL>U:
M]1/QCU)YR6KT'X[NC8]ZS;0/(U%\I\?,XMNWK_LP\OZE^1V=,CU+SJ&BLN/N
M6/4V4-X[I6$V.TY5V9SC'N8S2,8S[N?W\<Q&[.[8X 3ROI=H2M8F]4;2T*NW
M;T3J1=4(GI^JF9!?Y-W;P8C1,U!LOXGJJ)Q7^I43J15ZU]!R^DGJ99O:V-]?
M&'5OG!9O0SD;\T"V)^LFT?R'I_Y5YO\ S,SL@/&#97[H=3?(S'M;&^OC#JWS
M@LWH9Q\T"V)^LFT?R'I_Y5X^9F=D!XP;*_=#J;Y&9Z+]+O2S7NGX$J=/5#/;
M),QDMG[&TVM4:#'4I+F05=S(::?8%MN)0J5*<:8EEY#:)$IMAAJ'!A_@GLC^
MR2O-N-TV%";+I=G]3(4E)0%>ULB:=J.&EU?( A FL2,<]L:,PIHM4![P1B&,
M67,E_2;L5>Q2T[V/% Z?8.A7^TRZC-9J#4HAO?&@1W*TBT&G%D"%(!5"(UKI
M4L@@3+B0QLB6( !0H$+;/GYBS]=8XQE--_['+_\ +/\ _I+YAD?ZN?\ \$O^
MP[,@?]*+_P 1G^TF0#G*Y.8XQCC&.,8XQG!S]K<_B*_Y<\H[O+]Q?[,O'_I!
M_?M_VDS&7.8SM<<8QQC'&,<8QQC,=.?MCG\=7_-GG(.[Z_=7^W)YG[AOWK?[
M$SARF78XQCC&.,8XQGF#L7]W]W_WLL/_ +M+Y+M_<L^\9_L)G;0?]3B_^7#_
M ';<AV%*PG*<*SA*LXRI.,YPE64]O<YSC\6<I[<]F<_B[<]GX\\NWJB*B*NY
M=V]-_4N[O;T]/=O7=ZF_-G<BJBJB;TW[EW=:;^_N7TM^Y-_J[L[?")'N_P"7
M>]UG$?/^57[L=.,8PQG]5[K.,)3C#6?U&,)QV)]S'+N4)U_/OZV<FOSSNL:;
MMS%Z_P!PFY/G?W/4G5U9;R8__P!&?N^4_<M_TB[][^]^[7>OSW[KK7KS\P^]
MA"6\/.X;3G*DMX<7A"5*QG"LI1V]SC.<*5C.<8[<X5G&?QYX0A$1&H]Z-155
M&HYR(BKOWJB;]R*N]=ZIZJY56,55<K&JY=R*JM3>J(J*B*N[>NY414W]Y43U
M,_5R9#F4J7(>6I&<92I;KBLISCM[,ISE6<XSCMSV9QV9QVY_?X4A'*BN(]53
M<J*KW*J*F_<J*J]6[>N[U-Z^KE$&--Z(QB(J;E1&M3>B]]%W)UHOJ+C$B0E6
M%I?>2M/==RO#J\*3W79A78K"NW'=8QC"NS/N]F.WA"$14<A'HY-^YR/<BIOZ
MEW*B[TWHB(OJX48U16JQBHN[>BM;N7=WMZ;MW5O7=ZF_.7A<K&.S$F1C&4J1
MG'?G.S*%+6XI'9W79W*G''%J3^+*UK5G&5*5G->6+NW<J3=N5N[C=NX557*G
M?[RN<Y53O*JJJ]:KE.2%W^3'OWHN_@;WT1K47O=]&M:U%[Z(UJ=Y$SHRI2NS
MNE95V8PG';G.>Q./Q)QV_BQC_-C'N8_S<L557=O55W)N3>N_<B=Y$]1$]3+T
M1$W[D1-ZJJ[DW;U7OJOV5]-<_.4RN.,8XQCC&?:YY2&O?OU>)]ASZ6=-6?A/
MO,?S6?*WHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5
MXGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW
M'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHB
MN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3
M[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XG
MV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E
M(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\
M']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S
M'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV'
M'35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:
M]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']
M]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\
MUCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''3
M5GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^
M_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/
MYW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UC
MHBN\']]/YW'E(:]^_5XGV''35GX3[S'\UCHBN\']]/YW,36N_6R$;DQXQ;O;
M*6X^4H\!&K[,J80I6>Z<AK5GMSG.?=5GL_S=F.<%>ZLU!&LC!#8< VL"K6\U
MA.W*X37+UOC.<N]55>M?N=6=?4:;I301D+"XGJ\B*O.);>I'JB=33HG>^QFC
M^YO5(:;HJ[/T&[$KDX=CCAY1Q02I5V?!\&)-K=C83(?DPG,NX2C/?$=XQA.>
MS&%*_P WMNS?8UMLVIZ9'JS3%OIQE66;+@M2SD B2N7A.:TV\(J22Q&;WIP.
MY55<F_>U,_..U?LD=A6QK5Q=%:OK-5.N0P(-D]:B ^;#YO8,>\"(<MW%>I.%
MCN4;R2(U=VYSLQ3[<)J#W_LGS&J_WISO>Y4[(WUYT9Y19\G<\U[N;L8O6K7O
MD5/E)CVX34'O_9/F-5_O3CN5.R-]>=&>46?)W'=S=C%ZU:]\BI\I,>W":@]_
M[)\QJO\ >G'<J=D;Z\Z,\HL^3N.[F[&+UJU[Y%3Y28]N$U![_P!D^8U7^]..
MY4[(WUYT9Y19\G<=W-V,7K5KWR*GRDQ[<)J#W_LGS&J_WIQW*G9&^O.C/*+/
MD[CNYNQB]:M>^14^4F/;A-0>_P#9/F-5_O3CN5.R-]>=&>46?)W'=S=C%ZU:
M]\BI\I,>W":@]_[)\QJO]Z<=RIV1OKSHSRBSY.X[N;L8O6K7OD5/E)E/+]6"
MU,N.ZF,1V.A_*>QM2J+5NYQGMQV]O:25C\7;^-.>89'8I=DBX)&ANM%H56[F
M*MB/<B[T[^_3BIWM_?1<R@[.CL76E8XU3KYPT5>-K:7K5-R[MV[4K5[^[TTR
M/^V\T#X8V#YBU/\ 3.0W<E]E)Z_:'\H ^3&2?=V]B;ZQ[0_(R_*K'MO- ^&-
M@^8M3_3..Y+[*3U^T/Y0!\F,=W;V)OK'M#\C+\JLVZUOU4%=L5,==*1=FRH4
MAA2,]H<$U-'36L)S)&%8>1V7()&)E:</1W.W"FUM28[C\.1'D._ES7[]K6S+
M4\_26L"OK;>"J.3_ #"K)$G1"*[F]C6RD@(.9 E(URA.S<K7M( [ R0G +]A
M;-+39+M;TC7:UT,X=K26*.8N^98"FUTT2-YS66L-9KB0;&(YS4/'(JHYCAR
M$/%. Y9WZ[^Q/C#_ #2#^[.<9VP]8>N_XOJ_@6=[Z!]+>M?X;8_"\>N_L3XP
M_P T@_NSCMAZP]=_Q?5_ L>@?2WK7^&V/PO.B5N'8R(LE:;%V*0P\I.?% +/
M8I+:LXS[HS./<SC&?=QV<Q'VB:Q:$SFW&YS1$<B]'U:[E1BJB[E@[NI4]/JR
M\6AM+*0:+5[T5[$5.>V/>5R(O_W>0OU\-H_&C/T-7_NGG/=M#7/KY^+*?XOR
M8] &D?6A/;UE\,QZ^&T?C1GZ&K_W3QVT-<^OGXLI_B_'H TCZT)[>LOAF/7P
MVC\:,_0U?^Z>.VAKGU\_%E/\7X] &D?6A/;UE\,QZ^&T?C1GZ&K_ -T\=M#7
M/KY^+*?XOQZ -(^M">WK+X9CU\-H_&C/T-7_ +IX[:&N?7S\64_Q?CT :1]:
M$]O67PS.*]X;1PA><6C/;A*LX_Z&KV?=QC/[XGLY1VU#7.Y?HYZ2_P#9E/ZG
M_I^7,V?Z15[$6H3<KFHO^?62=2JGJ3-^0#V0>WOC=_,%8^Y>0';:V@^,'XJI
M/BW.I[5^AO6/\9W'QACV0>WOC=_,%8^Y>.VUM!\8/Q52?%N.U?H;UC_&=Q\8
M8]D'M[XW?S!6/N7CMM;0?&#\54GQ;CM7Z&]8_P 9W'QACV0>WOC=_,%8^Y>.
MVUM!\8/Q52?%N.U?H;UC_&=Q\88]D'M[XW?S!6/N7CMM;0?&#\54GQ;CM7Z&
M]8_QG<?&&/9![>^-W\P5C[EX[;6T'Q@_%5)\6X[5^AO6/\9W'QAD(7U*[LPM
M>,77.,84K&,>3M3_ !8SGL_^A<YAVV3:1O7]L?IK_P!CT/J_^EY,MV4Z!5K5
M6@3>K47]\[GU/_4<X^R6W;\=<^;M3^XN4[<FTCQC_$]#\5Y=VJ= ^L">4[GX
MQQ[);=OQUSYNU/[BX[<FTCQC_$]#\5X[5.@?6!/*=S\8X]DMNWXZY\W:G]Q<
M=N3:1XQ_B>A^*\=JG0/K GE.Y^,<>R6W;\=<^;M3^XN.W)M(\8_Q/0_%>.U3
MH'U@3RG<_&./9+;M^.N?-VI_<7';DVD>,?XGH?BO':IT#ZP)Y3N?C'//V\=<
M?5(.N=L'P]HY9B0K(;B16?(O7CG>H\<E):9;[X[4ENK[AM"4]VXM:U=G:M2E
M9SG,IVW]HNYJ^B+OL8J_0FC[ZL:J_P#9GJK]Q/2ZLZR)L<V<$BQWNTZJN> 3
MG*EQ?-155B*J[FVB(F]?21$3(O[/#JM^57/F1KCT0X[;^T3QA_%-'\69L=IK
M9MXN+Y9O_C7'L\.JWY5<^9&N/1#CMO[1/&'\4T?Q9CM-;-O%Q?+-_P#&N/9X
M=5ORJY\R-<>B'';?VB>,/XIH_BS'::V;>+B^6;_XUQ[/#JM^57/F1KCT0X[;
M^T3QA_%-'\68[36S;Q<7RS?_ !KCV>'5;\JN?,C7'HAQVW]HGC#^*:/XLQVF
MMFWBXOEF_P#C7'L\.JWY5<^9&N/1#CMO[1/&'\4T?Q9CM-;-O%Q?+-_\:X]G
MAU6_*KGS(UQZ(<=M_:)XP_BFC^+,=IK9MXN+Y9O_ (UQ[/#JM^57/F1KCT0X
M[;^T3QA_%-'\68[36S;Q<7RS?_&N/9X=5ORJY\R-<>B'';?VB>,/XIH_BS':
M:V;>+B^6;_XUQ[/#JM^57/F1KCT0X[;^T3QA_%-'\68[36S;Q<7RS?\ QKCV
M>'5;\JN?,C7'HAQVW]HGC#^*:/XLQVFMFWBXOEF_^-<]XNK&CWF]TFE0J@"-
M74($VG5['M#6E;MD.DG]G:W@#K!&(U$4>)GJH'P\U9)U7M4D.<M-="V4?69E
M<)%&HI5QE_\ ?VB["NKK"P).D1X$B133(E/;2X1+"+46Q2Q7BG&C!C3#JUT0
M<R$P\>'*/$++'+$%SP(K?G/JN%.G0H3(8#30@M(LBTK8TMD*19UHQR&DB".4
M\4/$DE\64X)Y48,D<9\8A4:56NT*J.G_ %0*@6Z 5H;M@$PRU6#BP@"WWW75
MZU]2*Q%WMU3W0;KW:4NQ$#>R2YNCZAO^I:B&LFJ94IF;81D(0:L-DJ=:P0;]
M)G7NS*S@D#9,C&(&8<TB3 K;2NL[&8[3FC:\MI3,BCCU((]C>5EW-D1+IC'#
MBF(>/%B3I?).X.)3Z_@3&%@+($PT40@1YD^OG5\&,V]U3-'7VKI!#V1CP:FP
MJ8@)-4][7R1,$>1)B1D(B-J[U1,GY$;*MIS8!78-/I&P*^+&0YW3"!,"25QV
M%T^PGS+PEMBPZOL9^/1XV["8:9B36\2*T) 5%TE3K&=*E3AUQLM%TA4PH]8"
MLGV-9*,8@]828Y@P*O4Y&@:=71;F)&?8OT\&0SAEJV8:5.04Z)& &.;5[0R)
M!LI4BP+81(-A'&)C], *$LNPT^Q3.%PR:R3(;!;=D"_CC(Z,*/$4D.0<ICR6
MK _5'K$8K\79;=U;@"X'21()QI$CI2=H):W5?:&H;#U$6^-+JV8.S KZZN)N
M,4!5'&SP*;+7:B@PI 5/U_5PFI-D;*XH)3ZA:Y2&+K=H7M;K1+,$&93WD72T
M%[)G*U$AJ3#P"29J+&DC8D()@E05G,D;$4&T:0:.VS;-08AZ2<1KG:46O++C
M6E1(U%,:^+P687<T%,:"(J' ]ZRRB*Q25T4%0%K'JHXNLQ9A'8!"QV672P#)
ML61B=-<5 VPSM.:O*W>54W0U/#P<V<5MQ.TJUK]-BF$J1A.0TJUQRU;4T:S;
M(E['C3'L#6"B0V6$ET<PWZL>I8H[ZX#7LG-/..7F9J-::79K%8*QW\X9"<&7
MOCI<"+M0%%:\E@21)?"CM.(C--L0<@E/5EG/B*&&)G.A6W2D:OYR\L+=R+I3
M2QE0ZW473NOFR;!TRO8<JWNT"O; J=IDM1C&A!3[56$;+W2J<SO7R5Q#)&MC
MYUC.T>C _2[CVK99F%><28[KR!KA' :=LVB5E\E6R"VSE5LV&Q7 U*9KIAZG
M3_)NT[SU7B!5)<#U%^RW[6W+(Y*[A<UJE068,/7DBPIEL7S'0(\^+*>B&H1.
M2**RNE>EYS1&%-9=&OHTY.F5U6\S)W$U5Y-2>JW/&L]3QQC-1>H#K5TYTVWR
MH:^V&W:'"ENIE[O." $<-G"@ NE!YI.# -JE&1Y')W8<T83K>N1 <<7DV*RC
MY(QSQ?\ Y%YWM],Z OM65LZSJUAH&#/K:[DI)2C-)-8'&$A(_  HDC58S!EV
MIY!0,B1"M,G*?/-;R5_K2GTW/AU]BDI23(<^=R@!B(*.*$%Y1L/Q&&7E[!XB
MQJX01F=(DC>)>3ZG+UU'KGZ<;+4@%H,75.OY!O7T+9$NL7=A,0]6P\P!7[2L
M-8'P;QZMLW4=7[56RQ:DCK 2LP^";&R9 U+$IIQ59VSO542;*A@KULVQ[,E4
MR77N5\:6=DJ5";(BMD-C2W5YI4*6 %@6,*(4D<K&E5S'(E(>N=.2HD>4:;T>
MX]>.R?%G-X#Q@OCQY:@D."IXS9PH\N,8T$<@LD;#C>X?"]%68QNK?ISEN5IA
MG:07PFV6)ZIB8;T$]%G,V%F]S=7)&'X,D2S+J3TS9(Z=0Q;EK9"L%[=%>KXI
MV843X-S1?HG53$EN=32."%%;-.1I([QNBK6CN5-&(PSF36CJ2CLC)"=(<""]
MLHS1A7CS<;JS3KUC-;:!XI<ET03%'(:]LAL\E7R4AC@H^(Y]D(D 2RFA::6Q
M8XE>7<W,8TOU0CIGNYH,+BV<S7AMAJ[5M#VVY5^96*E*%S2^SH07$@P2RW@0
MY8@.HKI?@;IMD9"F46+"-*ELO3VH.)>PV8ZMKH\@SX8)18LQ81X4"4.9-89@
M*<A^  =_+I%DWE?6R$C.,0=B\L?@<T3B9%PMH&FIQ@B;)-'%(BI+#+FQWQ8K
MA/-:,#Q%)N0*R(]1-GA4Z"8^"T9N)'$0:9+@=773H37!9'[+@RY9!BV2VQS(
M.U*+185'9$R;1/+B/$6"8(>,BG@DK! U$'PY\4N-DC7YC$V.XY$%T1JD*$<6
MI(Q@G0F*5TB&@7DL7'9#$$_.>1D%,^-(9R0'D(-X"L*T;AN1)-FK=.E5C1V3
M'/(V6]!H"5RK&04$Z4\PN0Y0 Q-.!W&9@V$:8;A*]KVJM+!ZR.F@D_78L3:H
MI4NTS&1PF(^(M$.4@A)NUFUM%@F8TP&P_6IDO8-.L]+AQ;(V)?EV</*"QT.S
M^],.7DT)JP393WTQN"&-Q3O:>&1BB97Q+9Y /'(<V6-E9.B6#WQ%,UD,[)#E
M07$Y+1ZPTV58[66@E=*>T0FN#*8]"/FR:U@S->!KHSWV$.5"8V2@G/E!>!J*
M3<U<L:^VOKO:T)TEKJUC;:/8&U4L].$XDNPVH5WK(VZ5?+DEQAIE$LK4S06Q
M('*7@C%$&0\V=%C,E("I$+9TMI3$05I"+"*XTT#1GX$>I*Z66!,W,1RN5@)L
M>1%4J)R3SQSC&][@E1DK7VM?:L4E=*'+&T<4KB!XE8C)L84V+O<K41'EB&#(
M0:KRC0F"][&M*-7<=M[+!Z;UG=]J66(5G@*%72-E+P@;,208DP1K67GV1S$^
M:-A.RUIQV-(DSXC.5?\ 7?1CW>5I*F1?6U?31'A')LI0H@"2'/8!A#.X6N*X
M8RD:Q%[ZL&]WJ-7%M9 IJV;:2F%)'@1R23, UCC.&)-[D&TCQL5ZIWD<1B>J
MY,U_O'7/H2I*3!#ECFQ+%G9%?U<Y5Z0"ER"K-A.VFVTUV6J0>\0AG@(&PT&Z
MB3YF&4E0QQ:MSPRUJ+Y8A.]+7[.]2344IP1ZN(E5*N$F6,AC0NBQH<&>C$;&
MYR=LF3&LZ\T:.\+"%#+'(1$ CB-Y^=KBAB;F!,:PD+91ZM8L(#W%20>5+AJ_
MC/R 7 !(@31',PKV#-&(!5Y;A8MSKW6UTZ'*W6+!,NK]9D6FA:\V'"K9\"<Q
M84B-G8H+%:'1V1$$N.L-@P7VA0JZ3$T\G8WAU@M0,:^KOA2 J1BE;/M4QY<R
M*.O;+;"LK2K)+C28_-5/4=).EE<XY %BQN0I[*4$TX45I8T*05J;@E1F6/K7
M3IXT60^:Z,Z5 K[!D<X#\N@K/F#8PFH$91R)'+6D",4,0LAPY$L W=91\7[C
MKEZ4,@6K/C=%=P">7CN"*A]D2WX-D"/M"BJVU!,/M@&:Z3C&Y-B<:0!BC$3Y
M<DBTR*)JANUYK3G*Q.@)7.41547*Q>+C226'R*+SCA62Z4%\=D1%62\RB&P3
MG&"A*^C?2O()*Z9C<@JIN(HY")PJ <KE53D>)(Z1BM.Z0J(!@D(]Q$:(JL[K
M/UK=-M4K#EK(; 7(@>3]_L$6-"K-J<(SO6Q8OCUSK[<>2%BMP;B*5K#8,=50
M-/B[ Y(I]APF!WL3/=CVP] :KFS$A"K$:7G-9&>XDN&@A],/K65\I7MD/4D
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M\",<J4#76#TY..&(RMECD$@)!H.2$8%6&064;7:Y5&>"!X$01(?M!:!;X4H
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M[--I>D-K>CJK7&B;-EE26@U3<Y$',KIHD9SNJM(J.>Z'907O:R1'<YS51PY
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MP[UE#1$%)CM%#*-T,(0,QW4O4^M9:[FV$U0S!"$720K$O60VS/6FTZ_U\S3
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HQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g609070g39i77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g39i77.jpg
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M%0F75^E_64+- @8 P!@# & , 8 P!@# *J"_UX&_O4=_S:.;5C_SMG^E6_\
MWH$QZKTKZSI8]_TQW_O*_P#Q=\]%5OY6K_\ )/\ ZF;T>B]"^HELQDC & ,
M8 P!@# & , 8!5@'^O0O][#O^<1S<T[^<+'],M?^_ F/5>E?6=LL]Z&^, 8
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M5O3NHQKU:-2,YN5*A.?BXTY<M1U=DJ:A+*?,\O#<4XILPV2'/1!%^)(H;-2
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M3C)Q<H3BW&<'C,9Q;C*+33PS">64 P!@%5!?Z\#?WJ._YM'-JQ_YVS_2K?\
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M_P#WE)_^MOL_);5?YTU+]/O/\14.@9_CR_K2^MEFYH%1@# & , 8 P!@# &
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MQKGZ[:?N\>XJ/?/^TOV1^!0ZA_G#=_[913[ X^!+@_XQKGZ[:?N\>XJ/?/\
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!&G^43_ $]?WN,
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MT7T4,H]7]+_1^C\[\6!A]SVZ[=#(&"!@# & , 8 P!@# & , 8 P!@# & ,
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M1J4JD=I0DGA/*5?SEQ\D8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MJJRK.DTDDDB]O)7#HOHQ1@T2.]R[FZL5R02B@?:3[GM!;RJRIF:.>3(7AC#
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M/3J=2KR5'2I5+CW;"-1TZB@W5DH2PXO%DW!B:<15CH<V-D\Q.:*.EI2,Y_\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M.C1IQC3I4X[1A%9;>6[@SEY\D8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M):!@'Y,D^<*<\J+O'SUPNZ<K;\\[JKJ[[[<\[;<Y)ADL2DET4FO69OP5& ,
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MJ](!+\['SNB@UFU3.A_8WD<YC*X2*BK 8B8#"NRXP+Z^2C%@6)$%' $T>?\
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MSY>-=?.%;;>;K_5QYVVVWDX_'MSSY><G*[EZ_:"'U<Z^O"OPPW\(QE=R]?M
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M[#W 5V_FS*WI&-F6CEMPS7=:A5HZS#+-U4GHA5&\K":?/MOGR\-_-RK&W?\
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MY2QOOL7P/\-6J=Y<:E,TNJT)_<LU%]A7UA3(VM6HD]-/O@ZEK6@S!G>*Q6$
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M@<@Z2&^LWP3DI<J6<1BDV_Z3[\=FV%\AT83_ "B?Z>O[W&#&08 P!@# & ,
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M2@)1]V&:Q7MG.K##=7>Z].URH!F%?1<PWW?=A1$KII63+R%Y9;$<?*TXLF2
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M>VVZ><^E9WQ7)IXO=-5U,.RD3F]767&5NNPD\1U;G'T" 2RRU!,\A];AU83
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MY-R=*%2$:M'+?)2K1I9?BN9Y]SUR=4# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M_P#DIT(UEM426P&>OCJ88 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!&G^43_ $]?
MWN, @P!@# & , 8 P!@# & , 8 P#BKXE73>U>VO86J@T*K&II=&E^G7<&M2
M,[N\68?PFK)G9TJZ\#8C,(VX!ACCYI;<=9#Y)+8#KHV'\O-8T;:(R.,.EFYY
M@,U.<8P>6T^>+275I)[>AO"?F['C!CF6>%EV/,%9K&6UIU08KPG..T5DAIC)
M7<XXL\])NQW0$WU$X;RX0A'7P!@A')D[;S$B78R,Z\D80F]VU8AR89)E((:S
ME=Z^_P!_NRJ12Z/.(KLPN6:G_P".PIL+\)"W@>PMWJ9Z\5RW&SJORVT J5A+
MAT >-:]Z4=DNL#ZRMV[F,C5$K3M>4W?'I)-VNPUR@QC,&'-%YE,C:&CQU)*J
MI/I)[-9>,Y<XRQZ$HX7IZ8*]"/"ZOFOBCIP*>=1Y8?>4A 86#NZSX5.)E;%3
MR&"](&W5C[G5=CVZ0(4\I<Y.6'-F$4SL@39.!DIG ,M5IL\78RL8(\9%KI);
MMM)K#S/FR\YRTMELO2C%E8^#;;T+*P>3E].KY,A&+WE5F(1?Z%OI'HF#L+J"
M!Z[2EY"5(Q1$!CHN6"[!B<;M\,P 5O"@A,F)"<O'PHW'6)ER2P2ZJ:QY2VQV
M;M2;6=^F'C=MX;70R# /"6N"(SVC#3^8TB3XKEITO(O[D^@RW>]X"WZK4!&:
M?EU#5([4"IL.*,N\S'RI^2J/I!&5FS&PIV@4@TF*/V!%D'C8[[/^EMLD^9MI
MO?=K;"[UG)L]X?/AWDNDYR+$T7-9M6NO2KKK05C-Z\&/A&TZNVH97:9F4VN8
MU4#"DSG!X/.A(D:>,\J2G= 6JQ>H-F#9CIR*U)J>>N>>4EGLBTMOG3\QU8P8
MA@$HF/8(N-W:3%FD[5\OI'2;9'1PIY?Z_/6UTX4W\O\ M\[;GR_[<^=1TC2;
M>\JZC;Z7IU#4*^57OJ-E;4KRLI?C*K=0I1KU.;MYYO/:;$[N[J48V]2ZN)T(
M8Y*$ZU25&&.G+3E)PCCLQ%8)O/HFN, 8 P!@# & , 8 P!@# & , 8 P!@#
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M[]%WI]@J1V?;I1Y)'?42V%G&"<5LWFIT_%>,X[7\B];/JEP:XP!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , C3_*)_IZ_O<8!!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# (T_RB
M?Z>O[W& 08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P"-/\HG^GK^]Q@$& , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , C3_*)_
(IZ_O<8!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g609070g56a56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g56a56.jpg
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MA,QE[K&N&YK?"9 E"T*F0==^?A8D*4ZQ)L)FC+<C[P>$Y(+>3*6;W]5D CT
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M(&GS%-]*S<D!,H=$\-5-UG+IS]-G0S%EN04C(Z%@&M&_D\Y7Q^.EC].6O"O
MK-J;6=2U2VZE7P<$N-X5Q -*U9XMF:+<R$LY-!K^6K9D.].AB37;S7<Y68'A
M8*\7!@3CKV+#F+'A:1R&%&N#AZY2?G"CC%YJ&I!WXO[6]K2@!Z J5?"83VAZ
M"5!'W#%S"I#,-6O9-2&D9'%9XT7=2(,HY,L94OJ_.0\AKI%AX_0<#>D3/I/O
M)4&C<,^'QUP-QLA;N:?UEDS1G&V"KQ8+PH8+-.<8@*T13K,\ V8/X1.;D-&
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MD]F<IV).5H<3R/*<W++?BGQR:3NTG9^%#^H?5JOQSP1!^O5.Q,8_F44L%VQ
M5]&A;9::P0E@Q!I'E)H.2UU(PLKC)")*:8UTC;K=58-HRW54SOSM:FU#=G$M
MO-Y2R2%6S1C,]VP235+@^:M@WE-WX+0O[NRS]9XLS%>;,VW&O@<+5A(=;%8\
M$)6 VY1%4#"+V:T^<K&VC!FXZY/TP;=09;N-H[NK%<@U+)PB<(G")PB<(H4O
MZCP_8" ?P,4F%@5Z\8R2-3.+SRKY"G&YK$9;$"J!@":$NWC N&>ZHN4<H/@\
MA"&@11@X<M7XU;&Z:B4KALL7"W?#!U:5Z$P'JV*>0 YZEFM9&XC")&$Q%AO%
M]X% 41AS:,H$;9V>.RF-'E*O@T[%JI*)@V V:16#9 >N1B"(.4H$'+9VVD,H
MBBG!Y1G!]VVITT\8\"9+[SIM?-_I]D%+>6NO?M#\]JO:SLRMU6:M.NQ6L<VJ
MW:HM8<YKA=6.J1_-<;;9USH\V(;.T4E-<HGK^Y-FJ2P^%?!-C(XEM/<&1\7^
M#1R#92).?\8^,_"HWF8['\/;KWBT&B[LH!M&U8OX2V3RGC?P]\EXZXJ+W>?>
MF^/E#FGI> >#O3?F7%X'UMM+BXF9UGVGCRIEZ N&.3&7W'936].O$!ZW6&4L
M2=Z2>4%HO7BL]=BY?F5.@^AU2P'Y*PRY,B6>/7@5%TP"(AH\)'L-F+BR?6V5
MB;%GJU<70EB,W<SM$=&F]>N.Q=:E$E;P:)7"U*$*(QP%&$2O&97*8LY\;73:
M4QTA9 -@^0N1R>*JXBW.Y:8YB!J/:D,_/N-BO:E.V2<R2E(;2@-AB'"/"\-+
M>)"BW4-$!'D^G;N;1RPD;#CMFJ03K:F_%N48*YKC,;5KAM1"%)F8T[C+QTN1
M2/5H3,NY2X5EGTTD8^353E6Y2<O&T4L:5.-0]%Z)Z#7,Z\"1>Y&\QVO2S$LJ
M*Q"Q"+0<-\8HUXM6YIQ;L\<^A,;*N,<K=J5D-IK0;KUL/QC=JTJG-/4;&-C2
M"D&4GFQ:<R2,[GYQB;.T@%O&31!:#V1 5)5:+01:'7"L^LLB<LBD,;D$H?6$
MKEDS&R<=G2"X'-YN?.S,RYDKU0<O'G&NR&HJ-B,Z*;*V(M?9@5NC<:OCY$Q^
M=R&?!&8[4H/:R-:M4)7GO<XY5 !J"C7@TV/'K<M@O5M=ST=C)UK=5SW6A=Q%
M/#&E&==IM7IGL6(&A_DW#&R4MDCFD\7$_5P!AL^\AQKHK5$7N@9>3"26$O*A
M78&Y^QS<:\)QO>/[S6\J>!4I*A*S9&*H$MHN-B\?:$8^TT*)EFQY5RX)&2@_
M=(8C9V-7Y*QBB8B8*35B87%8*1(C.QVJ8C)FRM8C2>RXVL$L'E \G&XY!:,1
MB'/<CW0=-40Y&&2B:VYQY3(Y:,)3#S3V,G0%CSC=F TW# (HS%%IM.)7=YDG
M#:#:P>PWB3M)*+I4KU8D3H76,MZUQGKI.I?*KL3B9@VRC5@2F5!RUKP850DG
M:6$QBC*7%%8U]7<KJ(N57<O(O+MB$65V^<Y_A.4K'O9\;:A!$E^KG;&<IU:V
M)>R(4ST:U8HL=<+F:\J,[,JHVL>&ULF(;1A8K-"PWZ.&Y70MU@MCL*5X4CX<
M.(M6#Y%@$+$-HQQDO5H8L[6H@B<CA\$L4"$E*0+#S _7Z#4$L(((H:YSMJBD
MFEC;/H].V$],:8SGT?T].<8].?1_3T\TL[[N[^=W?][K:;-LS-YF9OW+]>45
M4X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$4;V345>6ZE"$;$CNLB2K
MBR(?;L,UV*&A?T+8<">*D(E(L9"DANS_ &$NUU5L"RF7H5[ZWJ$1KQ/&NF+^
MAD[V,>V]$[@>]0M8RT[#$3G:-V#0L@?G8$X&+%F;G!\!8;;CG%^M6=RA4OM6
M:V+G6J7*]^O_ 'A!\W;JR>8"_P!W.''P2=WYN?$.79.$FZE#2/2#JPE'89$=
MJC&/(Q7\-NROHJ#*'Y@8&L(;V+(M"MS@G;8K(GFAMM-G[%JLNJ>P3=AL)?(1
MQP';J*);RCZMU"Y[5GQD2-B[:Q-VR88:HB3M8.$QXHT9#!!PRJ0G*,6#S<2[
M[GB5V9VCVTWA&#7 ]"$@U:^2J@%,M@D(U\O*,\B*49EDQ8V91B[N7CD/;8+C
M9W9\ 8>-;IP.C\ICS>M9.KK,=JJ6-R(A=5Z%IYAY1I4H8J F&L0I9+R<1DO7
M;LP]1C!:-2 208"<,@6'.X,8-'M+R>N]43/7.]^NW@OC%@@AB<..GPY<8Q9,
M9:(Z$*E@5Z(H/8&<)(3)QFX6,0A)6L='Z?@(XFIF?PCP%REGD<D2UQ8R<R4)
MCMSN2LA)4D23!F$HYP'PBWYN$(1P:0]./'$Z)QOKB60B@>>X+V18\=@+'L78
M,:NXKM;B&-K;(:.AUIC[;D$3L9J*VVG 9R0?Q,^DPW<$AZJC7Y9*[!JC7,1G
MS@I6"T^:H43W9X.C8Q(VQC[8R#Q)CB8T-FC(K>"%C"%D+S9AS9I;/;&T_I*4
MPX@C '::=RV&K'+6PY*?A[;WY-*%V%\H+<8;V1RE,!&CO.#\.[33MT/ZJ9F.
MDY1JW+ RD^H\HBQ$36PPD30*];E >:2*(P4/+&,+T(0%O&@(P8ZP!^4=A!B(
M,KE^(5=,G$6VL-1>"O4?(\8GAEAO,M2D:RX\ZQ?&PWN%K3M\%R1S$)'GMHE(
MYA\!6C.,CT9P?A#66I<)&GC2-$=FV,#$Q'-^+2-6&>-;CJQ"*$)<UO(<&%-Y
M#>47ZIAX].H TQ-S36H\?*3Z.6C$RHEQ.K)=Q4""NU%TWMQM7$.=3!:*U,XL
M-%\[TDY*KP\0)OL.%O0\3^54]?LGK;4Q!5!2R752/CK(RQIT(V3&Q+Q?&2O6
MHU6L9*-%X1\''D"V1PX6_1?9MN$=*8&!+)(T/_B@W0$&]FY( AY)I-?:G7E8
M<-"5MIRY^=(=><]W_2;=U,D<IJE*;,G+4#!!T-(M:GA-;2&6$Y,:P-8513:,
MA?1$<2W/FW 4>/B;8_('3J0+)($G+=RJL>+/4FC?9O%GRF5R@@XXI9VH2R5N
M^"L.N+G)Y+*."%F8V"*)9SLR ",0L\AQE%F".#REQ7X<?CL>0MT8X5YQHUJ9
M3S,3@A1Q[%D"$^=(XX0 Q2RD5V:<F=W*231;:F] ^-CK7&F4BG<D62O$S94J
M[$SP+,$)5.FD)0B/:<Q)B1G:'P\?8AF!,3KZNI:G!7%L11@+E4EC**.Z!-@Q
M729HY1F=>9ZQ,%,#/B!4*V#IEK/7ISMO9T\*N,7A-J=$5R88WJSW&QMF9*X+
M#NTASFSR> Q>D,.&)K1G;)$N'RUH=ACV8UFKYLAIDYBO"V2K$LJECP5[X(P.
M8#-M.$':+3S*^A_5>9L1[$W6CK&P:N:?JD 3$6!9D>/QR%T#*'DSIYM&Y$!F
M(XX .063D'A<7,1+]I,7*RV42IX@TUT;ZP]?6&HJLYS%?C_>WLGD3#+2H'">
MUF:\*N4D<!JI F#<KPB(E4L)58LVX@PEO)29],X2S&$2TY?W=2A1%,=JX$H:
M^+-*QCV"85B!1%K&G(D+ YQL2=]B%G%F98H_\;W4!_&\Q/->R]@&7>6(Z,:A
MKSOP(3E:%N.V)"T LW/BK.:'IQ&)Z0&MB,FBTM)&8\2(9=OE!N'9$BLZN(:Z
MU/ _A/AM:98PHQ%SN(PQAUGQD9PQY:@"8^0*=BG DH5[%88C#APP8G ,<8]$
M](X&8>8\%L1&\K<B<WD\H*9VORC.Z.R4=R);(+4XM,P+$R!G/BD\.*<WE(0K
MI=UM VN/N<#7JX*:#'@<JU9A)K/A-?[2"/0W6O0,K=U*/E#>K'\P#0?1.+C)
M8]ASB0LQ*2"")'79LWW2LB:JSIL=/%FNL:J2!1RD:K3+=Y@UI[QJT<E.O+(P
MJEN.]@E:%J()D=W>&TI,]V/3V(%>CD!5'%8A(<XQ'9M#J<Z&NU41WH0.U&5@
M=9F# \J[FB-F9I]3;6EYCRFDX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A%Y]?([T=[975V;FMV]=(PBD:6IBG:;C4R7DL0'86C$]:=JZJ
M["L$V162#"+=:(0FZ8E8#5PZ;(Z/B8 =K'/I@RP4'I[IT-J[3>*P%/$YRP[B
MCE,KE+%5J]HFUFG+3N1PDWF.N2$HVK>*LTI1C)W@,Q.?YH4VF^K-7:;SF1S%
MG)8D+,3Q?C\>&PY@0W#:CFZ65BT)FA-GKULC7M1=V9I3%!@N0D7@T!63T.[@
M@J#9T16/7XW]' C/?(Q5IZ)V?'FQJ%R:;W8]/]>G>X]QV(K&!1886@N&YQ"Q
M5(W9UA11REB)M8Y$%3!99>8H:QTR;,RS&0S0N,PM'"R(;.//(5H%/$P#FX\<
M<)D+ED@[G$%Z+'Q]*RS^$R/9B(;1B[FF<\/&1QE+%E: B:G+1*"Z*)*QK.1D
M7$N\'RM.J"$ZNQ(VW#<MUY-S#! Y)N]JM>G_ &AL2]@CRV(S.'=/G.V<7GT]
M3VMX:/U?54VZ!"JX-IDVT6L! RX"OKX:K@CL68:J[FG"SXPX%/HN^7*N,>Z3
MZ>HX<T,:>I'*!TT>E3=L82?!D9:S+>$XY6*4A1+##RB<-B;LPHM <20L0B.,
MWX@S-O)CE>#9E0)G06K7^70AQ4HZ7A3)QQ#:8CCEDXN(H8[N1WD1X2!)R/6]
MET.[JB1D$*B8)-V-X)]".T/7F,6OO<<>=OZHL52XYB=IY*2'-K*W);,Y%1[S
M6 Q*11QM+58M()"!('DP*T=7/1^<GK'2I26QEMU)XE]8Z?S=C&MBS1AD:+8N
MJ'*. 7@+0X@9>+W;(#RK-9 $T N9CQ":(CIC40X59CK68Y%M+YG$@O>,!/*C
M;?(')0YXGACS>)<;+P4!@Q.X2E%(O-.)RBE.K.E'98T)J6.RV$6O%:?SW-AD
MWFM4';& 1;:,5&(ZTV'#)\_1:P[L+:Y',,G-EDXVT-0UC99]_*7VI.7O(F*&
MR$H@C'Y#5>!$7)GK6\;8R?16W3J9$- UEK&2+GJ-JE!Y6L)CA^%5* SR%;G0
M#"O'FZT;)" ')[VEIS,%'1$>M>!0Z0UK-BB6X$#AH#P]NM:DT:^6O2\&LW)A
MB2M"X61Y<9Y5QP-.+09;O3CR#$**K.KXS3L\)R^M:^NU.LI\-NX22EL-E>O:
MZ=R6KP#DK).S$3B418-J':0!6.3L9#K)G3U-TWKHP2A@P*]U2E\9JC1<,Q?R
M!\I3'6OW<0^0IDQ)1UK=;HY3KY T1@P%FS8G+,3NL>F2U0IP>+WA0LD+!WC+
MV U7/&4Z0J%J=BI5R34K4,D.=BN?QY:-2%(ALP %>$<7&HX;,*]RU+=J9)UA
MCDRN1CI_V71NC:[0PF:"; 5\F<VE[&2N[70>BPW2V442;#YWQ#<SU:,[1AS9
MZHI<A#&X7:9NGB*+M</L*:HN$,6Z38!\4V**2H6DV@:E:=>..>!"ZJKY@1=O
M"O VL-9CCV(T+;E\%C!WC$O.2>,LA\09ALD^2'"P.T^L;)XF>\TH#TZ;%E'N
MU?PKF>9E><;SKL/PB4OTG'P-Q-7,=U*[GXZXGX* H2W(5<C<+3+?L=8YSM0R
ME:?;PK%KE;2"V&U?PE"VV@_=.;PGZ0+*S*;3:CY 1$OMZ:PV8"'CTHQG":DT
MKX]#<-F,9;Q<BY66"HAT[*MT9'9Q4@XR5VW+&RGO4M\V-JM2IEP#+!LKQ3+&
M Y1,,%J'Q06L+%WZ^18>/;+W"YN!VSQ 9&);S5*[7V@[6:W'/PBS8QA9#D^/
M=HCE*4=O'C_K6SZJZ]-XQ:B,N%$UY_8AZ+1";OPI ] H$;DKM[%8=ML G=GC
M1PP<TV4>!8ZG8DSVB@D@SC&QYUJ'UU3UIK._C\CFY6,<]8@XTJ(;%FI L W+
M@:\86+3,:GCR3).3-$IWHU6LEA.PP8\[UYYI:G=HXI@W6/"<K5LH*]F0YEJU
M2FE(%=^:M780A"+O(86MV.8'.(.=ES?5=GF*+(DX1.$3A$X1.$3A$X1:RO*#
M8TJKVI85O%.V4,ZM+F)>N@6TE;Q6)/+;!,ANSDA HU;+*(6$7J0MOC*;K^+@
M<'.%DT\X1;+#/[;K.?<GU&O=R5MK&F[6H6%5:0O!H-9AC33(T87+&-G9I"R0
MFZX^#&MA&[]<F)U16&ZSMGJT:S@SE?"N2P[$8TG!*^*$.*54-Z->V2A-^IWL
M#K$(S=47AUNL-%6S8VOC6K^4=0ZNL,]*IXJXAXM.,6:+[%S>"#CD_DXNQ[B'
MV#8,L"M[9-B-6DBE,3TD)X1@A*"D;%R!@ &-BPT;=$QM'IY=KZFR%(->FS6B
M/8QY,'4N$#2KDHXN=*E6++&B+Q K67"$CPKC.0)#$D,D^B%ZVVD*IL#2MF/:
M=Z\&#=AEK-:!;1H6\A&W;.-KQ1\)3@8Q1\1IA@6 H1F.$3=#Y5=8_P /)<C3
MXJ<Q^Y:N:=E7%=+VT/#2(Q.S$0M^PIFP;N-4RIW4OI(T]UZY*$7^![]&5-3[
M@>WRQ:!S+^2UA7Q,^4X4,H2F;%Y&6!C>;&S* 5,5G&4JDY1=QAYKF'9KXX0X
MX/6D&,Y<<BBA8:8/D8: ).B.R+(THYEZCWHC,2R2O?MV(,[,0K$8W74G.7#)
MC1*\&>,1DG6J*>3;O+9CZ>O:]KK5R/=5EV%[N4^%=P;5T0,=6(C'I]6E*UR;
M3:H)NG<QE%U H[,RR(A?,L(1=RX""R#;#M#*$]9T#I''PIPO7GC.-_":3RA8
MW.& M163T[^5OB>3O&-6OB3'JC<D?!AV(Q,2$N&7%$!UCJ6Y*U*I4XH2IY74
M= <JO%,F$KBM4\=4(T69Y6#Y$8;)&&[V) DXH2;B;;JQWDB[;[TGF1)6E I'
M#'U]TG SG9P<QJ'7%9 9Q4TOF<Z"2$AIOIU^CSD=-@</C8D_+'3S,,:SG>+V
M&TQ-6PUPKSGH73397F'Q]P%J&&RUP. G/)OX>:IDJU2F4(W9\T>,ZA;1RAK1
MAX5*HUBC+P21(MUPU?GO%W/-<JEKSRF.JDS$&H-X&.S1/9LC*3=L4%X6!UPC
M+8>7@S67!<CX1&$GQEUV[[3,^P-!7:;7#@ DWZ8T$EV8NV*!$3 6MZF(]S;9
MBJ-KQ>O9-A-BLYG8M2)/I :V'' U>1@S(9.U#GA@D/Z]Q'3.G9X7,XD+%,6I
MJG,O@,39,XBW\D/2V-LRQUB[7WFT:9&LP"+C"6[8$"M,H2%+MU2SV;CE,7D2
M/ 0[.GL7XXR(!L0=2A/4%X#7@U3,T'>R-P3*1XD'5"0IHC-" ][O=:NZUW3/
MR#3KKW8$]"3").9)?HV,1FNPL%*C(8!KTPV<0]S88QSB&7[3AA$!KH'>G)_'
MY_7=JR@HGO6YX>,V8KYQ//:4Q-715/-4J9:MF(,,2Q8O&MC);-=%*-J-(D?"
ML-E!.;<L TC4KV.KB=KX2$XV;(\/J+(V-56L3:LCL <N4@$-0=:<*XJI&E7E
M;A+P?*8\C"V%(EH5JI=.3>H6,.%UNQYJA;%3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$7GVMBE;H(>4-.<CJAL-\ >=J.L=@#]6-:JD*
M7E-=PF@2D#E]XRKL!KC!*$V%6KHL2  Z>;2(!'I0H!CRSV 3)S(G\DTW3C<K
MBH<GSU)Y.E T-.Z@I3X[[#RM>[;S0[E;$5L*_P#=VZ-^(AF-E) ,>NQSQA=J
MQ!"N^K+V.R,]9^$PH6I"EF\+;CPTWGCSU*V+G5/DC97;CKVZ<IR$/'Q*(1W$
M%Y5;#EF9I:\A8SR"C;M;M.II"S7D$L.N6%DD'X-P7? H).>K(JSYPK6S/1IG
M*(/':Q\9JFNEAN-DDCZ@0TNHB^U2>HXC-$DT63$REJ2&/C<I7IT(0+$4#7*F
MHB4*;7Y/+9S='("R-YB/NX6*)FE!W@ZOM5PU5#(M'!3N2K6ZD;DY#D20JUG"
M0N67IQX=^:\>2)1J/!MF*XR.[2VFRJ39J/D]W;T](UC':, ZL^JY=;0497X6
MP9<YK'L39E]&94#J^QXM&G#(*RBU7TJ3KR(,(G=Q('3C5(18.CQRSDNR7R62
MX^6@&EE ,+3QXX_(UL:4ETM*M'(82AAA5C9"C8L-,L[&0RH[MJ=G$P-E).2D
M\(R!NSP=QM9[4#.3-">[1/>'"J*U8E2RUS)D,.E; %XCB"ECIU 0#D9CQ\>;
MM<4HFV65R\/Y")5>7::.2WZ^WPHVAW#!M8L.B$^-T%*J%)T;(QM#"8F\7=-J
MG$RQ[)',95'JPC<]<I"9ZR().1O\-O</6MM5+HJMB=/&K>)X$"^F#2LDLT@Y
MFOF1Y@!,P6S%HRR1*T:\3M-K3!Q4*C@+4)X1#@?O/#51LEF@G\:2&5L^.((5
M[1<6;&3QIH8P8)O)J,#R-(+Q>OSN1G88H[,.9EQ-B<2C'?\ A?4=> 3AWV8C
MMM1R6]6"@\I640NF0U<OUV4I!,2/J85'ZB-1"Y*X<U]*Q[H+?)"I&<HN-S,&
M$?/%11V"R5=,%=6;&B[>I6NTXX$^-/6U$.8\A9Q0,A'.>-^=GDBGR8;6+O1N
MUIL7#CR<J^+C6F8(R!N 9S6X ZIK8%ZMI\P*^&QA9Q)3!D"TGQ3XUH1HC%1+
M7OU'J&A,>3G1@:^]B(BS@6L5V'N\Z0EK4-=5J;?W9&9O$;-S'W[.2!;'/.Y+
M-_5&2(R-"%Y"7)QZ*FU'<CCS03(4V<E #Y8):E&XF6:N)(R*.U]2ZL'CA:BR
MD,58J6:'/PD M$,*]3^\ (A1 $,]D+0 >10/.N>=8LAN6L[ F.+;'TX2\3"8
M^61#9!<YJ43#MED:SM I(#(4DP@(\C"C K1,*!X1FT#[FC.3VJYCJFTX1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$57[>[<U-2<EL
M2*S3649*5AUHF7:^39#AD'[;-5P4LL&.:CEE"+79W)OGB&_S,/NF@BX1]7?8
M@EG.=<9!C--9++ HV:G@_-Y#/5=.5^=*\)>,;@F*'G&:$N&OP/\ I%9Y/%]V
MX'[5#7\[1QQK8+'/<=+#V,X;FQM)O JTW&3@=YQXC<47X1NS,[=?&RAIQY**
M!:6$Y@3F.W$BR$S^H:QE%DYKW=2KH;,+XBD0E=4CI/*D2RN[).5)S<$%^=M1
MKUN#..-$I)N'&O!1,C*1T)F948W8GQ;S)2R>0KT/#6;(VJN&LV:V2)7K.)FF
M]9ZAB\,B0D8,7<#%G @X1[ZOQ<;4JLA7VB.U0IFM^"N]*O8R@*YZ,#':;\+'
M:R(?%&$F$1]C<W"4)S["Y>],=HSM$UHZ>0F0#:V']6;/[-3B[$T=GH&)!Z[.
M"F*[9Z.;>E[N+28Y(MGSUFD1*+RHY!8\,#+_ $P[>M>&+T@?+Z?EEZ=L!+Q-
M18_ 5,2[M UDMX))QE DMH,1Y\W*$)/ <:X;AR%CS482Y9#4H<9FHXVU6+"G
M'"7<S9R6W$( ZA80>,H,W$\&CQ-*4>.;F+5% ;\Y*49.Z^=N:[[$')3$ T6M
M&MYW$HY$)L_@5Q0M2#RM[ )_J4Q#9X'9X(%69*-'' 0PP]=%_@J&)CG R1BP
M[_*+=6PS6FKV$#7LEL8^_3LGM5(7<7::W6A=I<WX53+/@'(9PL44]GAS91SB
M0!"CWDU[BL[4RQ# &&[4L@#7LSJWZ[UCRJVN/P>R./'.,PD<1([M+C'.#P+
M<MF>$:7[Q$KQ[NV/U]B<2'8H^&4V9E\7MA7=TH_LR;1&TV=9SAQ$MTWWT:O7
M4>/J&8>@4V';KFI7%3ST627 ZLE'4ME=)#Q&DJ&;LVI^-K>4%6L8UFBT*%2S
MCI7ZD;.\.<:\8+"M2'QM$5>R&!!L;C:,;CM23R6H[>+ "'BVOCR'#>?BX[ED
M%V-.RX'XN!Z@BN2NT^!W(<)90FXFB\L]*]_NO@(\4C!QY*A$@ W;8]'R(0^
MHIOH^2JFK'=US.?ED-"2FZ-6L:O;M)<WEB6%U7K$P(00%;/W2C1"R'HS-&".
MP&%<H38FCEP%@9W@8>1R,<35I#=QLSY&>1E*J]9]FC,19.3@BTI71-48H1)A
M)(\"BR-O&F'(3-(4Z-*>1L6IMQ]5*-*,;#';=Y1(-F'Q2>+8'!O)M0EC0N;2
MZ(P^[RK^%"*VE.T#0KUNK-Y#!;<?/V$"L$.U0D*T>'0HDJ)+*&3<RD<4UA*(
MU?,[1C*BS%-W>7- YFC;J5K-K$CA;+?K>&2NNU0%S&0A.Y2+)P,<EL;$&PA5
M067MN2/@;V&:3QM:VL<9;KV#@KY*<ZXZ9_!6J,]DM:_.4*MH<6*XH5YO CD)
M8,#P9H/X2P7>+2X4>\I'7.7-JL<Q2.73)\VI%K FR*$>KS4RM!XG4UC8J^T)
M!8&PXXX;AQ$%DF%5"Q(6N<9/QB:;F.+FUWXMJ_YGY/<Y6ED8V3XJOXNL4:CN
M>]S36[.3HOD,<"EQAC(I;@-F&,D13@1WB>(8P)*%!:TQ)VI. .1-X:"U99A5
M.<>L"C<\"NEM<!'88ZQM^<G!R1E!FD%RO*$93AU2[C5CW#CIJ55:#G@\ )2C
M[MN6E@@(D(/CY,T=/1CH"<BTDE@%P[10:;X.QMX483"*KJM&TICH9=XV35B=
M1Z7R&ESBK9$M.9BN>,A5BE<H9UY1@2)@V 5C1B\I-S)XCG5LLTI5CEC"3M(X
M/4%//A(>D*U 4&%*)#C&PRP-%Y0D(H3'%*3,SL4,IQ.!WC$PAO*+/;'F-J<3
MA$X1.$3A$X1:P?:?BO<,\GWZ+YE\9YDG1N7?FF_>XO@71S[>B/ZIT]I^*]PS
MR??HOF7QGCHW+OS3?O<7P)S[>B/ZIT]I^*]PSR??HOF7QGCHW+OS3?O<7P)S
M[>B/ZIT]I^*]PSR??HOF7QGCHW+OS3?O<7P)S[>B/ZIT]I^*]PSR??HOF7QG
MCHW+OS3?O<7P)S[>B/ZIT]I^*]PSR??HOF7QGCHW+OS3?O<7P)S[>B/ZIU\>
MT\#^KMI_J$^3OU-O6];3_4MF'J[>OG.=_6U^F/1GU\YSG;TXSZV<YSGT^G/*
M]')[[^/--[MML_C@6[;=G_R>3R*G/-MMS)]O-S3[+[]I^*]PSR??HOF7QGE.
MC<N_--^]Q? J\^WHC^J=?./)Z(QMG?'0KR>8VVQC&VV.ELQQMMC7T^KC.WTQ
MZ<XU].?1C.?1CTY]']^>.C<^_--^^!?!^#)S[>A/ZI_Z\KKZ]I^*]PSR??HO
MF7QGCHW+OS3?O<7P)S[>B/ZIT]I^*]PSR??HOF7QGCHW+OS3?O<7P)S[>B/Z
MIU)50=]A]OV-&JX1ZB=]:V5DRQ!'6;6_U?DT!KD%]'B"!?*LFES\FNT#(O,#
M\CAZBR.^'1=X/8:^A1UKMBWMX.52N2P^5P=AAM%^9J9(9[$^*<8;#%&+/-VX
MN*3,_5!I2\BY1,TI-'FRQW\LANT6ZM^M_)YOUKMKS[OL:+L!Y7R_57N];"C(
M<,(YF-&=;I'9=?N<$V_SG#)G*AI%LU<$6&,_(DVFJ6-V3C_8[[;;?UYPI8:5
MT$3MD\-5:4I1YF[D!USMPOMQ2%*+NT9=L7WZVZTF7@?;FRR_&$'DW[V4/^T_
M%>X9Y/OT7S+XSR[Z-R[\TW[W%\"X\^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW
M[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GW
MZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WH
MC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-
MR[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO
M<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\
M"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE
M\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=
M/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\T
MW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\G
MWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^W
MHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ
M-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?B
MO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%
M\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+Y
ME\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J
M=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\
MTW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\
MGWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^
MWHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9X
MZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?
MBO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W
M%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+
MYE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^
MJ=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[
M\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=6JJKLJU
MM6GII<*-'=E*^1A6\HT4K6U:>+P>X91_"\=92+?>%P!Z[7?R+0]J]P%B^S9=
M/!J1-7HE'U%FVV^8RUCGJVPU'NXX[FYK:S5MP-4%SI''_?'9FB/F]N,N[?H#
M=IOU.NR,^*+RX)MMO^C*+M)]FWZH]K[]C>=U57VGXKW#/)]^B^9?&>2?1N7?
MFF_>XO@77S[>B/ZIT]I^*]PSR??HOF7QGCHW+OS3?O<7P)S[>B/ZIT]I^*]P
MSR??HOF7QGCHW+OS3?O<7P)S[>B/ZIT]I^*]PSR??HOF7QGCHW+OS3?O<7P)
MS[>B/ZIT]I^*]PSR??HOF7QGCHW+OS3?O<7P)S[>B/ZIU2/LU:-0]H92^ETD
MZG>9^O24AHZ;]<INE5W4Y04SGE0SL@B9)QB1)RH!,EF^61I#0F.(QM< 0WRH
MY&%G!4&\="U<LP%S(Z>KPK OZ'NC!EZF=J/D<B0DJ>3IP<0[ 'K6*K2XQ.XY
MP.QH-M$@F$:,2-CF9P%/-&D<QLO4F7&V<39:ES,(VJ%F7.3"5CUK#MPD9IPF
M%Q2=]X$>8Y/!Z[Q-T"<7G<TXLGJUY='%12.Z.O%I06GXIU:D6(K,<]>JEK"*
M0UY=@PG%4BF# 6>0-60-V$"F P)(V*(/,LT(:,FH89.6<T2.(Q52A<T@V3!B
MLYC[F3L7H^$U?'>3R%FU#$DA:<?-%I7&!*=RL0H)R-X,\'G(I(H&E8RR60LW
M#Y!Z!<CB;M:@"4>8L>*J%(%>61A.JT^<':JN5HU;$!&BP^?:;18<+3WM=E*=
MAK&96)/>D?EW1RI2%H]=IC#@740NRB%C51;'S%R< 2U)ZU)2)HY#G10F3QLS
M#)'$B[ Z+8J.WA >FH/5QW#FRF$HRHT\OH]]LOC\Y5M&R?':HY+&\<0FK/ @
MP2B4)"5SBM LBF$DVC"$W:;363PE'+6X6[4<@W_LV]B;%<481KVZ-]H.41VD
M*9HR&48SA+6, D"CB\I3AO!^;UY["5WU]DLKG>.J/F9N2Q9;%(77KFP+HZGO
MCTE%5Q7F2ZL.@87$2%0D*T!BWAXP4>.U@[J12 P07*2,X6=X142XYN5S-5ZU
M/P[1&+HUK-J[&EBLC(("7KO--:N&\)-;+(Q(!$.,6+$ 10B, 11W9^6*Q%?%
M&/:Y[+9"V<%:I*UD>:*:%2ISCUZP^8!6'$<)%).4G'(Q23>9BDEL[8;5LGZ8
MTE?[3L=4GBU\DE?3EA RD#9C(STC/CHHW3-E52165)#4W&2.LP?-5UP"Y/!C
M#+< LHSR+^7V^=XN<CE-3Y;#2P62U;@+M.=P=R1+&:C.S)PB88Z[D?\ 0>K"
M3,9AN+C8S-/G-FX5;TM,X#&Y2.6H8R=2S"J2K& 01@!F*1YD.T&CQ\_)G<3S
MYSA<;O'@W_245AK7'3?NWV.[/71XY/((VA=ATIMU^AL)C?5^UY.YE@<^VV V
M':LX;OV$2'PV:2JO0\(K9$7&G4D5:1L&\07E"^NS7961+:>II/!X#%:DP\K=
M++>.K5H]ZG7C6("7/4<=4E MF=JK7O%MWW(>(&D<L91KQ?B9K(>!\)U'E\SD
M:D6KV\=XJKU@S.9SC*W-V[UF,@@A7L'JCK4V@&1GB$4F<SL\=^I%Q3KB*K=:
MMT^J_FJ=-6LFJ.214\^Z90=<C#L4BX?.(&%:Q_6KDZ[F8K38@IF2+6M"+!-R
MY=N.?R(P0(C![MOVDU+FR7VOO=T+&4J^2KV PR^0:%GQM&$;A9'?)/>JE=H-
MS#8VW2%6:4X %"!)QEUPT9BX4Y4V/F'BQJ!@ED+'RG7\6O-ZHXA?'>"6(-QO
MSSWJULMAVA,Q9SA"49>H^;4)09H,?AW3?S+OB0*M[VJX>X-=5RR#A$!V&MT;
M=<X?I/HL,C)-G(6$S&)XBA<<^9;AABZZ*B3Y]HT(M8O+Y'+YD10VLGHF S7L
M/D)Q%?WBYL)C"8FG!X6#6!R!.J1_"13A)BD9G9X0>4)7^-TYCL609:\LK*8J
MF3IP<DH,["RM^&1LS:00!G$L;$&YB<)1YN#NSM*7#./<=6;4I;J?+;#GL0Z9
M^7J:3.S D1C4CD4WZ4B!SQ8'"%CC@&F[;U;$:T'2:0;K2!^J:GTX92FQ)#MJ
MVU,RQXFAJGGKU#;R>HZU&E9RFCZE6@:S8 "IF+,XL:VPHF>,LA;ODKA:(8,*
ME4G7H@_2<5:#R=UV87 4<'8MV@/D;-FX, 3&LAJ0DXJSD<32C2J4X&+N6;DM
M68GMEZN</)FV5UO:?BO<,\GWZ+YE\9YBG1N7?FF_>XO@61<^WHC^J=/:?BO<
M,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"
M<^WHC^J=/:?BO<,\GWZ+YE\9XZ-R[\TW[W%\"<^WHC^J=/:?BO<,\GWZ+YE\
M9XZ-R[\TW[W%\"<^WHC^J=;"Z[F>EB06)SI.,3.%IRP$/.Z1.Q(\XB4ZCNI!
M#5? F61EVHJY!'6?K?(D!BZJBC1?79+;;.=?3R!L!\'.4#D";FIRASM<C% 3
MA?;C$1F9IPEVQDS;.W6NZ+\3,^SMNV^TFV=OP=O(_P""S/G2JIPB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBXSQZS'H;NG[M
MLQ:IYTUW<O%TFR&FRF^J:>NZRV^B>N5%-]4],9VQG;?;777T[9QC)%R?[_[N
M$3A$X1?.V^FF,9WVUTQG;77&=ML:XSMMG&NNN,YSCT[;9SC&N,?USG.,8QG/
M"+ZX1.$7\SG&,9SG.,8QC.<YSGT8QC']<YSG/],8QC^_/"+YT534]/R:FF_H
MUTVSZF^NWHU4QZR>V?5SG^SOK_:TS_=MC^N,YQPB^^$3A%QW#QHSPCEVZ;M<
M.'"35#+A=)#"[I?.<(MD<J[:X4<+9QG"2.GK**9QG&FN<XX1<CA$X1?/KZ9W
MRGC;7U\:XVSIZV/7QKMG.,;9U]/IQKG.N<8SG'HSG&<8SZ<9X1?7")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G"+0YY)1]))=X^N4D[_Q!:9^/YCUJND;'V\B@\OL6G0?;Q[.(
M&H*(V3&8F'/M=3Q"FDI6,JTE*A:[9(QD^WB^R4A6^4U?U_7]?XKG'?9^%]I;
MLW4^S[;/V=>_;MO^SR;JC5P=P>R] ".J%:]+AUN=7.MZ_54-.^OL1[-0XS,I
MM:UH$;^D$51I.QD258=EK7, A];(1(Y$ZNJP_ +8%P:QP9I,L.&1#:)ABY;-
MU\6SOQ/Q;/ULS-N[MULV[OU;ONV_7YU9UQV \@!6Z%RF+YFP:"R/RL7%T/'U
M6,I:HEP46H]UUQF<^B5K,Y8^K%:;$I7!I\(')1J0DSRL,+I:-ALK!R+9RZT<
ME3:.S_A#B[?+NW5V]FS_ (/_ (JMWC=N[MX5@/4.!L.S5U.*ZK'H):'92\0>
ME&UU/+'EES55>88 5ZZD"4P@;*5NWS@*=*"R#9"1LK,D+QNALC-&9APY/(E6
M7#O)]F=G=FB[.[,S.S]?EZV;;\/P4*1?M?VG[2 &D4M.>RZZ8*,[,^'*ZZZ,
MGH9 QTG!/YIVP<(VT#>[5+3-419@A$U8L$TDL+R[MAW59%)T -6Y("FA= <1
MV9G9V9FZB,[;O_U.KM=^M]_PWZNI;S>U=@]NE.\52U)0]CGX=7(SJ3=G8Z41
M(-7=?21&X+!J>T*D%0^I'\QF<4./X>QL!A*RH LXC9(6<T"K$'H18>9;LC@P
MN#;<+OMU[LS=?G9]_P##^*T^4SY)^\[_ *ZVU-+/NF4O7JT1ZJ)2&31RGH8G
M->K=WVU;"T:LR&FWI[KE":6K.N@4>U6'G-+:2[ V=3&XK,JD#&=C9"!3<ER>
M+,_9U,[LW7_G,W8_4^[N_F9F9^KL75N^]?=>PJ.BT-O"]IK5,//PWR-Q!2X(
MI0<7G\@[$VO5,Z'Q3KQ0\B;*4* '#4K"JX\4DS,E!JEI296NW'H;Q5*&%U'+
M=H5=H[OPMU[PV9WVVW;=W[7?J?J=G=V;?K=_)QNKMC=IZYAU0PFGG[VFRD]"
M> :BI!/AE(0(S+6E?6+U-EXVUMB3^60<K]/$8FX8C\#'TN^ETH&_23'II,Q;
M\F)($EP[RWV?KF_;Y>+J\OE_BIADG>+O5#@P"+V=?UHUY$H!8'DO@'^LE'.K
MD)L"77K9?6.UV\6ZQUI/(H&J(]"8HRL:%?3LC?O81#(&\L3,>W'Q*2Q]VD^(
M[%1VCU[,V_Z'4[[-^DV[[.[^1WVV??;M=]F=7?L#MIV9;^*+HMV*%34D G5X
MQKI2][.]AP%8 YL7INN;>BL:+73? FM&<9*0[*XI\^31RFXA12(Q1K(5SB\;
M5&!<-M"H\6XI-YGELV_;L_4WX[_AUOY%0V$IWOW0[4>-0[==@RRU:BK3N%W=
MUJ.Q9/0E7"P=]U;25>127U/?,GB)ZK-8^$D4K+N)-686;18##44FL7;6-4;:
M&R\BVDF"KU1:6S-N\6WZWZM^UNI_WL^_7U/YE9CN)W([OU[Y&Q]+5]*F5?UJ
MT>=4$JC@1N%Y,QOLP/LJ;DAU^*/WH>B;2LHJ1B(MON 8.*ZGE8"JJ<LQTWLG
M4Q$RKQPT*C,W#N^[_P"=OMVL[-U>5NKROO\ J9]^I0U&^WGDU" 8%:;&=RFZ
M3MOQ?R\# - %Z.KL3'@,JZAEK#VZN+""$+@L;L!^?EKJ,CP;UF:E+H5.0[\8
MV%"6\@PO(BA5VB_X?YCN^[OMQ,V_X;-O^O?R^158BW9SL>)L^\>Q57W]95XF
M)%U'\<L+L_M,;ZT@VA6B(;+^R5FZ]D))&:IB]816)3Y?K^/E,F(Z#U8=(58K
MKNL*GJDF>P0^NZ?U_7ZE79MHL^S=<W9MWZ^J.V_E;=V_#S=7:TCW#Y!^^,9I
MYI)X3V0-GJK ]B.Q4-K:_B%40.HK([8U7#JVJN05W(01^;=5;(ZSY=QJPCMF
M0_\ A_2-4@4[))1P:A4T@&NP<M>JOV^?^OV*C-'?K;K=FZFZVB^[M_UF?;;9
M]]WV\NZN+&^[G866=O(=%[%NJX^N(HPTZ/D*/ZSO.H@67/\ LQ$[MJT+*KW,
MV4^T E)979Z"SXE(('+#$+M./Q*@OX+<&)B$F+1UOJ\IOV?X?N_P_AY539MN
MQG[=WW[.OJV;J\WEWWWZMNIU2EYY*/(&(J.TI\UN&3G+<&]3>[-H]E:8/=;X
ME$H[X[K7J-9'>A1,=D1&NV#F5XDCS+N-)@+7/VDO.Q[%:?"?F(;11/:O_/\
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M Y%/;#!,PK"0SL%IF=V)N# @EXQ#EV\2WEVS*3NM#HW5J@BL3:+[[.[;>?\
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M2NZ:_NOLE$9K$8%-(G IP[CT*=#QLMK""5T$3N)6NA97L%;9?,WF, <O *S
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M 9@PLN(C5R%( 9WA)@S,& B%%$FW!(@X'#,D&=Y0B4<I,S3B[]#6JTK)*<;
M96P@#:+58L'L#K6"'%7L$"TN<@$Y:MD8BRBT"3KFA"3R%-FY_.I=Z<(M%CGQ
MU]Q)=,[)*67=\$-PGL#?M6=@+$B4:+6''W->DZEN=^2 0\&0,JRX/8H]S0Q*
M(P=R_2C53B-3E"5H^4B#HH9DDKV+GQ1ZMF[&=NO9^WR]G5U^=Y=3OYMERZ0Z
MB^4N+,X1"+"[2A&U;@89URAY7$5L0\9FOT;!&G7T9;>C"222J,/7!F1:0[L
M\%2C=P..$&UI@&1Q\X<AP#JM2H[QZ]F?R_AY]NIG_%O+Y/+UL\J6YU.[IMNQ
MMD7)UUM"%QD?:]XTG*I0M*)C(T3"-15-!:U"+0-D-;00PQ^8%C&EV*9C;PD_
MC6RDK#E=F;<R4(&8R3=MF9V[&?S=KOOV_A_/R=L>TEU#\BM+;14<'M:J< SD
MJZ^D+5;CIF=&MVHVMJ]\9D%L%[& N*A<,2"TGCO6;MI"A<=;+0L6D*MZ,'=W
MC$B2*M(N57E%W?J?R[=7GXMO+^+>?K;RJ<NL%"^0>M[9JDI>?8T+:-6"NO</
M#6@.<&W1 \8OA2,)[6,[',]J^ C'L77L=P].0^2)KQLXPAZ Z)N1";5!=%X5
M'>+[[-MYNOR>3]NW4_[UA]'=1NYRMX47:7:JXH_8@NE2<[,I!F$O=GFQ6<2R
MJQD)+6(+%[53!6 (2<D6QTM$*V64*;T^)?/F 6;R%*0/!XXCNW7MY?P_X[O^
MWL[&6W3A<4X1.$3A$X1.$6+3*0:QL \(8VUPZWU^:L-,^C/KO5\;82V]&?Z;
M:H:XW<[ZY_Z6B.VOI].<<(J=;[;;[;;[[;;[[[9VWWVSG;;;;;.<[;;;9].<
M[;9SG.<YSZ<YSZ<\(L4ELXA4!'(%YW,(M"A+IZF-;%);(!,<'."*R#ARDP0>
MF';-LL]5;-';A-JFKLON@U<*ZIY314VU(LA:/&A!HU?L'3=\Q>MT'C)ZT72<
MM';1REJLV=-7*.VZ+ANX1WT5072WW252WU43VVUVQG)%D$?,+@##$JAZ<[-%
ML;*)XSZ/EF^^,IN$,_[O]JCMOIC.?3ZNV==\?UUQPBN@T=(/FK=XV4PJW=(I
M.$%,?W;I+:84TV_^WIUVQZ<9_KC/IQG^N.$6O7RH_P"#23?\9NIW_JMI?A%"
M7G<_[,J]/_'Z>_S>A7-D<DW^G6)_^SDO]VVED^CO](*?_P!%K_PIE_G_ '/8
M"W2G")PB<(G")PB<(G")PB<(KM>..W:\H7NWU\MZV)#_  I7<'EQ I*9#]$G
M#OT6Q7BQ\:DO]$QL88./?6>O6J/R0X8[6U^5^4V3PEHHIIBVML;=R^ELSC<<
M'PB[;KP'7#S@A<Y.-@)';G#D$*&T(2?>9(MU;;[NS/$YVJ>[B+M6M#G#F%&(
MX<4(<3L6$G;B)*$&ZHN^\I,W5MVJX?6GR5IZ]GNL^EHBJ;Z^=7JFN:4VP=!T
MC4I2.@7<M,0&10QO/9,(CZ4MF$ED6HM\W!-ED$W&[9@[W3V9ZHHZJ-\:SFAW
M\0YQZ!,GF<]D<97QPBY7(C.:-8=P%J5,!#/7K !SD)%=G=N*<6=IN[[2BLA@
M/_9V0\'E:O9&S5'6A.W9B2;"B897 .4W$(8^*+S=GVWE%NO?MF2KNV?6*%=$
MCM.O.Q! H_EW2*VJV5J>7IWV^<1KL(;DA.3B1$>@D5A[7KN.B+I?#-P!M0Z]
ME5DJG2:;<D<BP%N8RE&7].YZUJT63CAH#'6U5CKS9"L^'@Q\,((P$(:U8LRS
M4[$6><38\4:]%@C>0Q6#2%O;6,;D"YB%IJ,8Q%EZMCPD7@3,2E <1RF0Q"O>
MD5FXFG6&PP-".\8%F\-^ZMGNQUX.3^"6CGM%(9OURUM/I[*@/C[2J>0$A=5Q
MJG&()E8 Q^[F8D=7\/3CFK LJ'2J8X6TM=<M@9+D?HC9P0:]6.TMFA4[>/\
M$ *N:\7ZEKFUB^0",F0/DY%E3)"%4D[EES\8HDED10?',-R5GYUFA+A6Q-Z
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MT.+2H&X0RL-R;;J$W;=WVWW?=MV;\>I_WM^Y?DRZQ>5%:5+CC?;2.8KE5O6
M1 @%DQ)G/&41!775A*=M=E7%4N1K^<EZ= V<DQG^<LRKZ02]C&C?SL6BWD
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MA[>-L/F#EO\ 3^!GT0Z(80&,GCDB[:-5[^YKS26/R1,1;S0!7PV:E(H6!<+
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M27]=4],8THO3:W;Z::)Z:)IZXT33UUTTTUQZ-=--,8UUUUQC^F,:ZXQC&/\
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M/1%4ELDPT?*.$QS'1O(^-LCXI;!M;+'%-?)DY4HOPA)>( -9[!6BS.6<  A
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MF5LI-)I[!46K262+L]5\"@(PBT;&Y"5/C";\<!'Y/8C9-OZ\O:[=G7U]3_\
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MV''CC+=Z9'VVS\U.CV [CP_NRE\A/JUKK[ PK\*@OV''CC+=Z9'VVS\U.CV
M[CP_NRE\A/JUKK[ PK\*@OV''CC+=Z9'VVS\U.CV [CP_NRE\A/JUKK[ PK\
M*@OV''CC+=Z9'VVS\U.CV [CP_NRE\A/JUKK[ PK\*@OV''CC+=Z9'VVS\U.
MCV [CP_NRE\A/JUKK[ PK\*@OV''CC+=Z9'VVS\U.CV [CP_NRE\A/JUKK[
MPK\*@OV''CC+=Z9'VVS\U.CV [CP_NRE\A/JUKK[ PK\*@OV''CC+=Z9'VVS
M\U.CV [CP_NRE\A/JUKK[ PK\*@OV''CC+=Z9'VVS\U.CV [CP_NRE\A/JUK
MK[ PK\*@OV''CC+=Z9'VVS\U.CV [CP_NRE\A/JUKK[ PK\*@OV''CC+=Z9'
MVVS\U.CV [CP_NRE\A/JUKK[ PK\*@OV''CC+=Z9'VVS\U.CV [CP_NRE\A/
MJUKK[ PK\*@OV''CC+=Z9'VVS\U.CV [CP_NRE\A/JUKK[ PK\*@OV''CC+=
MZ9'VVS\U.CV [CP_NRE\A/JUKK[ PK\*@OV''CC+=Z9'VVS\U.CV [CP_NRE
M\A/JUKK[ PK\*@OV''CC+=Z9'VVS\U.CV [CP_NRE\A/JUKK[ PK\*@OV''C
MC+=Z9'VVS\U.CV [CP_NRE\A/JUKK[ PK\*@OV''CC+=Z9'VVS\U.CV [CP_
MNRE\A5_N&&=L4"HD9U1DO5^KH,L.45D^;'JF=2N39DJKI1/8@ ;0J?P6-ZLL
M"DF"6R1=D\>JNT-_6=X:X12TM#V;%J;$LG-8(T6@TSEF:;09W=HM(DI2:+/*
M3M%GV9Y.^V[NK^K2IT1R%2J5J8I3<DA50"KCD1XQBY)0%"$7F\80B\G;B>,8
ML[[19F[;J5UY+=;:S/1.33_2S9E-[4L^Y9U,&L61A0LA,[8ECZ7R),'%DC$@
MR&#-7[[=%@T6-DEL)ZY4V7TUWT;H=*N59_A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$5(>V]Y]98F
M5A%(]D:NQ:L?L?49(E!1VN(K8]?Q]CI:E7T^%DLP%2ISNGJGI9URUT"8[B 9
M\LQ4/*&U&;4((-%1Y59GZW;R?O['?_!G?]GZMZ:C>\/0XZS.221]7&(R.V/6
M4:G9!0A3$$)RP]UZ,06O),6L:V8_\PU8M:[!0T?3+S^&V\DG<R(1Y""-\09F
M4BNT? E79_X[=;^7?L;S]K]?9V_MDPMV,Z"5Q5E?W6_ZUCHU&K0F9&MX*BPH
M&N<2D\,JP3)#3R3,@XA59WO"XD(BLC= 1^JF98^RRT8PN'%2)4.S(E3KZ^OL
MW[7\[[/^]W_5YU@\@[<^-]TYG) WUC'FU8G*+9HJTRCOKQ5Q!2.:=?CD1GUR
MA9&J^=Y>F857!N5QR>OTP:4A&FC.V3$+9R60M-M=2JS2\C[=3/V[=O9^U^Q-
MNV_C5W791QSUN -1-A.J\K[+\OU_JP/"C553ITY@U9S60G3+IC'FU2'G%(:Q
MB,QN1N6LW41K@&R:5MJR#Q_&I-I>=^K?L??K\O9Y>O9_U_K69-_()T5KL<.F
M$9J\P):#:S<VHN6AM/Q0<ZB%;"Z6!R4N=?[L2#!VR:A:A@$3 .QHK#TDL+BD
M2B(M@01% V*)-GZF\[[=OF?;^#O_ (NN,<[/]*ZMKBH["'=6& FLKE-]CW,A
M5%T_68=Y"#U6#"9.S%9)&1VRB<I-SR4U<)!,2L1=2(--5A$<D^LE(@&D?).B
MIL[[MYF_A_PVW\NVW7NMB]-6]&KP@^LXC#$^'0;RB=0<['Y2Q:CY'&)K6DT/
M5[.HP90'/RPE5]'Y=&C(M1\$,& 1+1KH1"ER0QTU>+$=MOZ\_6I4X5$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$6+3DF["PF8F&#QP/?"8M(";)^SB1J?.V+M@)=
MNF[QK!8WNE(IJX;+):+(1( HF:D:NFH<5OH^>(;8)_7F6HOK'VP[/V'>?7BN
MIL8-.1L@97V\LC8OUIFL'B!^#0J<WW'JHF "TB T4FM85B#(Y51\6 7A]=QI
MK"8S9,C,"M"5J4P):4Z_\?\ EY_Z\W8N3MLSO^INUNW9G?=NWJZ_V[>9UBKW
MRP7AD1+3,:Z<2"=,@-E8B(QW$'%I$1Q(>)FW8F)RP4Y+O*='!])L'&4=&IEN
MV!D)$$U!6]'4V[XF]%:I'ZIMV=;=?_+M_?\ PW[.MN&!\C'<Z/N "<MZC2.Q
M"<CD<5BQ5*&C)=$HA$B+FT.S4:,CV3B1P=8ZXD3@'6E>M&R14@[#;O3#=ZDX
M::%1B<B>7]W_ !_K]J;-Y)>?;?\ 9M_CUO\ MV[5WI[R(]S6#R.$M.GK8:#V
MC,YES\/NM;!8I),(U+8,KKZ%LS*55LV,4E3B40%]B3Z$Q[\8D/*@F#<LU6W<
M/G9'9F_^;?\ ]=GZOXMY]G6QJCKZFMKUE0\X,4)9$;?6RP-+3)MLI#6(^FW
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MC,(9XJ28GXJ"<JRZFH%W0H)[&G3^(5SH7%-&L2%F(MD&6Q%RKL^_;MU/UO\
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D1PHPS&[.^_@I^UV\X_P9>\[GBU;43A$X1.$3A$X1.$3A%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g609070g59g59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g59g59.jpg
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M@I*B_]H # ,!  (1 Q$ /P#[^* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"BWI+_^A?D1_P"*"/\
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MD&(%PP1;O']D;.U\78D>0SNM9NFDC:^*CS-/'^!/&W\&&/;VY=M[@1C0"@%
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MRH*.5,EU4R3A\^.DH:FJCF5%!+F_+)4W[WA6HPW%DZYCS?5)L,Q"PO*#[.C
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M&@(QBF0#CDB#%9PAD'S5S4Q>7Q=8YXXY63QM:U@/-![.X^91S6L)E)_:;Z,
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M^P/^Z*__ #(_D1;M_K=JSY7+?M]/OGL%_)7%/T^D_A#[Q?Q+^7V!_P!T5_\
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M>.(D(VS9$4L!RJ[-=7,L5LZ"**Z2N[))6:7DK=T;E*%10"@% * 4 H!0"@%
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M;&6[Z^\OGM;H[62;O\Y]6^K[6ZM=NVILWX=\?YQJ'9?*>7S!P;7&S:1Z,@4
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MV? [V->FE/@-^Y4R1:;KD9X==GP.]C7II3X#?N5,D6FZY&>'79\#O8UZ:4^
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M1:;KD9X==GP.]C7II3X#?N5,D6FZY&>'79\#O8UZ:4^ W[E3)%INN1GAUV?
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MXU7++%(@%/A73T458JY89XINV+M=#/+#*V*E[XW[)(::Z-6>C,EH!0"@% *
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M*B;31%:,+/DC26;+%FAU]GUY[!P1*UU:ZOU]U_U=;=[=>Q9>K%10"@% * 4
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M/<+6A5K_ $+Z4NOZ_I*1NZ@]T3ULG%$TO33]=T;"ZL8Q0"@% * 4 H!0"@%
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M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'0*%181@Y*FB3
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M3#9KB%2EESC>R9", HP>BA6WND8M"_5.19-.'HO;+&$76 AOYJ[]E_O*W_\
M6U[_ $O]R^E6A04 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M'#AN7.T<X^B_IY=O_1-UT^?Y=79].EDETZ=.G1]6TWV5K0\#-6F=/;UX8Z]
M1+8\')1_A?S.-\DHYLF,0B$%V!+8W+354VU5;*#:SFFPH+!HP0V"_P"1;[1$
M-"RXPA&-78' EG-GS,KA:0W=/SZPVZ];)-:+2&[LKM&^.A04 H!0"@% * 4
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MOPM\+4 [+?A;X6H!V6_"WPM0#LM^%OA:@'9;\+?"U .RWX6^%J =EOPM\+4
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M;5+O?N[OM]=/6'+@N[W3;C2M9)9(5$G:WGU7==^A9W@WZ0?=_(OE*AI;9/\
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M(C*BS%X.C,^][]8NG73]6B)<$#LOP4X8+Q.SZN*S?;H];/8E;7GI$N76UI-
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MJ***M%,\KP]FO)1-(Q1VNGK!"W[VNOK]'L1>.K%!0"@% * 4 H!0"@% * 4
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M![]M?/!7'!9!6U[?QHKI).6R^%\%VKI%%TV42<(I*X&K]&$[=4?DJB$7G G
M#, 0R2!<#$</V%&&J;UAD9B,A%RR,D5&JULD57 22A!)L?=7#/% B.:.+8WS
M1QO8TGW)3:[=/+U,CH0* 4 H!0"@,][M1[H@KP#;Z=<<SV6B]$.[4>Z(*\ V
M^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B
M]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>
MZ(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V
M^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B
M]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>
MZ(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V
M^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B]$.[4>Z(*\ V^G066B
M]$?O=N/]$%^!;?3J;O5^K%EHO1#NY'^BB_ MOITN]7ZL66B]$.[D?Z*+\"V^
MG2[U?JQ9:+T0[N1_HHOP+;Z=+O5^K%EHO1#NY'^BB_ MOITN]7ZL66B]$.[D
M?Z*+\"V^G2[U?JQ9:+T0[N1_HHOP+;Z=+O5^K%EHO1#NY'^BB_ MOITN]7ZL
M66B]$.[D?Z*+\"V^G2[U?JQ9:+T0[N1_HHOP+;Z=+O5^K%EHO1#NY'^BB_ M
MOITN]7ZL66B]$.[D?Z*+\"V^G2[U?JQ9:+T0[N1_HHOP+;Z=+O5^K%EHO1#N
MY'^BB_ MOITN]7ZL66B]$.[D?Z*+\"V^G2[U?JQ9:+T0[N1_HHOP+;Z=+O5^
MK%EHO1#NY'^BB_ MOITN]7ZL66B]$.[D?Z*+\"V^G2[U?JQ9:+T0[N1_HHOP
M+;Z=+O5^K%EHO1#NY'^BB_ MOITN]7ZL66B]$.[D?Z*+\"V^G2[U?JQ9:+T0
M[N1_HHOP+;Z=+O5^K%EHO1#NY'^BB_ MOITN]7ZL66B]$.[D?Z*+\"V^G2[U
M?JQ9:+T0[N1_HHOP+;Z=+O5^K%EHO1#NY'^BB_ MOITN]7ZL66B]$.[D?Z*+
M\"V^G2[U?JQ9:+T0[N1_HHOP+;Z=+O5^K%EHO1#NY'^BB_ MOITN]7ZL66B]
M$.[D?Z*+\"V^G2[U?JQ9:+T0[N1_HHOP+;Z=+O5^K%EHO1#NY'^BB_ MOITN
M]7ZL66B]$.[D?Z*+\"V^G2[U?JQ9:+T0[N1_HHOP+;Z=+O5^K%EHO1#NY'^B
MB_ MOITN]7ZL66B]$.[D?Z*+\"V^G2[U?JQ9:+T0[N1_HHOP+;Z=+O5^K%EH
MO1#NY'^BB_ MOITN]7ZL66B]$.[D?Z*+\"V^G2[U?JQ9:+T0[N1_HHOP+;Z=
M+O5^K%EHO1#NY'^BB_ MOITN]7ZL66B]$.[D?Z*+\"V^G2[U?JQ9:+T0[N1_
MHHOP+;Z=+O5^K%EHO1#NY'^BB_ MOITN]7ZL66B]$.[D?Z*+\"V^G2[U?JQ9
M:+T0[N1_HHOP+;Z=+O5^K%EHO1#NY'^BB_ MOITN]7ZL66B]$.[D?Z*+\"V^
MG2[U?JQ9:+T0[N1_HHOP+;Z=+O5^K%EHO1#NY'^BB_ MOITN]7ZL66B]$.[D
M?Z*+\"V^G2[U?JQ9:+T1[502?/KL#G9R&U/SND"<_P!MN'7%9KR0OH^-@]3Q
M'0&U(%FY1TCWH4U!LP3:0Q+EQK#D0XEK=Z<831O><:96$+A1Z\7:#B#DTP?7
MW%[*W3O9-WNFG>UUTRY;675WN_H,LUOZ;- SJ1'?NV^-!S56DQQK09&=;%M+
M)V^$0?4_)F$3PUK"<JISS1.JE)27'3^,Q+6\]'Q7,GKQE?9<7F$#VUL0/B[:
MX X;-J][7M:W5IJ_GH[KSZ=CT1/IC)JIL=G 9-PVE<:5$PG7)#9R>$QG9DKK
MS86T^,A7E!'(JY(-] MM8/(X$C;<1#9H=)[1CDY'2Y\?<QS5<KBD,+R%81EZ
M=UU?1:J]KOK=:VL^AQ"/3"[([S\=XW*.':S)QNK4?';D#(D85L[8FR'<(T_R
MGV??6NK7C)\$XTM883FX3)L3D6RH].9EJR,#6K1J U[/-ERPHW")"<O?KV;6
MG97?=]/9WOUO:Q/?-@OR?"\J>$\$T_ROF&G()R<V1L'5TKC(;5.B9E@ QU[Q
MXW'NE*4 #&P]=R<Y<N=,0,.$(LR!!T';B<W.8YBU?*>TVBWM:]/WID*UHKJ]
ME==__P H5K[2J?$GF/R9D.TN0>U^0^R=IM^-.DMP\ZAQ1]FQX-"=+L]<<=M@
M[8C@)GD.#%6O,/,G&HW$&SQT3=1M-B5-!'#P@3=QEYFZ=/I>W!,222M:[4+:
M^=FNTGIE\RG\3]+GRSEW#OED1*REQ&^38>>\.=MZ0]@U, A!N/\ 'WEOR&U%
MK(UJ(4!W?& ,#ETMTB^.2W69'9TBN0B)-[)8@?>RC.^#@F@[K3]WKPO<64*;
M756M$G:[ZPPMWZ=;/O;O;IW-_G!XYN>0:>)$=[&=FF)ME.C22/\ :PKQ76E(
MX"D)C^+!@FKQ ,'=5YBLG7O @SN^(*3#%9^[P+)I#< F%I,;M?I9^Z]O_P#7
M4N/0@4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0%6.9LH
M;Q/0,E?K[XSXX*/C<,!L=G(D8C'U\"IJ6"& N%-YE/(U,8? %]EOUF^ODY^=
MBYM"'Y27WXT8*DVC&^+Z_7WDKOVO[.O[C7GKGE;NB:>C;X2SIYL(F0VKO[D)
MH7COL';J(V.,7J3,AR06UQLR0@7,>:IQ(M>31N('XI!]B@1@H+*UI-']D@@(
M5(JQ!-!+2S->2S=.]K)NWT/T]IQG=R[V#[G])M ]X\O1&HX;!V'"E_IR:1.-
MQ:!A=/ MTS?;XAK"FTDV&UV*('RW9C2/1&%2O<$T8$PH"3GUY1'XG'Q@@0(;
MB4E:%I7=XD[W=[*%]KK5]//4ZWH]N6&ZMDRCAN(V+L0GL_#>/&3F2C.WCAM&
M%6+;8W#/E-!=9B9X -P\<-C,L R^.;:*1=ULB.#PH+:241A$U8QJ,J$W(%@$
M22O9></T9H6[=_*UO6[-X%"@H!0"@% * 4 H!0"@% * UP>DPG_('5NJ=2SG
M2>R@NN@C3E#Q2BFTDLXG[_F$TBFS^4>DM7KQ"-''95$1#A9 3,9$K+2BP"0&
M"+%NR"!<P?MY LD+0I-NZO\ -B:]C4+:>QF^_-E[51Y<<7M$:XD#"+-Y?IOE
MWNM^[-L7#V.RF4ZC%:@UUKN&R9NP<L"Q")-Y!R"4V%(A04J&+/%8&#P;DT4+
MN\<Q%NC?M27TW=]K?2:PS7(#G P]&Q+]KI<C BVS=7<\]MZJV=L?/63) _-H
M+%/2$.]""8OKL.F=SCFLACD#FBT<."C2?D!\39WCH]QD;?8S,<+VASI6Z.&%
MVOV;@3][\].OLZ/:MQVV=,CW(SG-IV2F'4B Z@VIJLQK\B\Q1NX!QG;NCH5,
M2$!5<(I)^UX1R9-Y2<&*./XG32/3 ()RRS;#6BJ@HUT7M7[VBYU"!0"@% *
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M(CXQ;]U,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W
MSQ:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@>TONI$?
M&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+
M79<#VE]U(CXQ;]U,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;
M]U,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+
M@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@>TONI$?&+?NI
MD6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+79<#V
ME]U(CXQ;]U,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU
M>W SQ:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@>TON
MI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@>TONI$?&+?NID6KVX
M&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(C
MXQ;]U,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ
M:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@>TONI$?&+
M?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+79
M<#VE]U(CXQ;]U,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U
M,BU>W SQ:[+@>TONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@>
MTONI$?&+?NID6KVX&>+79<#VE]U(CXQ;]U,BU>W SQ:[+@XJN5-.<M](5N;7
M'-4CJ':L7UOJOCTGL[* Q>636$;JROL6/(ZKO,W<MAG(R)H2G16&PFTH1(!+
M\=9B!B$R7&#EEFLN7+NAPQYCSM.S2M>WU]WF9E+3@NFW%:]KKH[]LO2*UNN9
M=.J7DV>O!_3,\<-FQ(=(=<:RWO/#\AV+JC6\1US$6^D#\SD[_>,'V5/M7&$7
M([>*\(C; \(U/,69D%.IE%=@:_+M&[38T+B:#CVO"<Z:NKOM;MUOV\_70CXJ
M)/JTEU^<[I=+7[I:^Y^3L<P_TLNLX_#'AZ;Z_P!JRUW%K<AIMMHAJ^#1EN&T
MAH[2?)S97'7+9VQ&,FVXL2(#,2FOBOM#76KK8$N.MH[)Y:R@0(0EB(8E&O._
MMLO;[_<'*=[)I7RV3=VVX5%967M\TOWDP'/28Z!!-3;M2-;>*I@SG,< JC'H
MB&.OB+WA"UP=[7S##ALK7?DT) FHG;77L[:[@WGGC[^;Q?#MSM.9>WSV(^+B
M]G:!]7;\/M>]E[]#/M&<J;<T..I[;/%K*-QR16.OXH RVL1@NRXLP/!\PKTA
MD>4XZ[AF04@U5#%.Q%D*V*T-#R*B:1IBQ5;+L5"BS*Z[]NO:_GV(<.2*T5[>
MSH_/5:]^AJZ0])?S70T9P^V@7C6A'1GEYL?9T9#C=<<?>3NXR4,C^KX=L<V^
MSRUIK.=R/8LW+EBT$3QNZC;9,?'0+UX7,M+LA;Q^E7-%TZ)WOVOY?29/BH+Q
M*[^;EO>*&%/-[6DOH)9Y&^E<-<82G#F/3EIK)R1V7&PNU^4;R4B)OHLSKO2<
MDVC!]/B)#!-2[5+M=BM9AA(IR_E1*$RI H='P?5.S'[L>W59(*-I<35NBU?E
MTOY7\_\ [[$0RE$HW>R3M#U33:3?=)IKHDK>;2[M)Y]KWG+R'V-S=V]H%A'(
MT.U5JGD.EI[(J/XN<IIZH6 H:NU_L5^3-\B(@17X^ZZD*N4S<#VXN98LUF#=
MJ(?OF"B$B$9NRBB;LETO:]GVUO<AP0J!._7+>SBA76[5E#^$^QM_JYB% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"B7%#?>\]J[RYI
MZUW5&(%#\-$;(UB @(*#ER4E5;1&>:H!S]FM*I20'!$S,E>X%T'I) 8"8"@#
MAPK'V#R0H#<)&5K"VVT^EK;EXX85# X6WF3O?IU3MT1K5G'IE7$5#<*V+B4:
M5C$RY-;A@NR-@);!D R+-=;\+MD\H'NJ(8D!'DS@][)ME.X)@J6DDC3R7CL1
M:078TMD;4(T=0P2_KG?3VM/W0WLU[>B9D4J^:R;4*:Z7ZQJ&[;T77HO=[3;I
MQ-W+)-QP?85IK@PO--2[_P!ZZ*D;\2UNQ&';:OV*:"Q>1MF=U5[,W$A@F<4,
M&F2:F3=A('A=BTO=HV0O>\+O>_DVO?;S,4:2:MV<,,7NNNJ^A]O.Q:.I*B@%
M * 4 H!0"@% * 4 H"B?/;?>\^/4#U;+M.QB!$PYSD%Q[U[M"2S4L2L[C4.V
MKOW5.IEFL.B8X=GC)).>3GKW%%^4/ A,58BWI51,X14&"%ZQ-I77T^JZ?27E
MPPQ-IM_@Q-6U4+?5Z=#,-T[PG\6Y%:#T7K<&(.%9WK3DENJ1,3#NPO$\!TB%
M@,7C\%'GE$'B$9>2S9V[($\=R;,6:L* 1DVA<6KD2361-V:2]KM]#MN%"G#%
M$_)PI>]OK?SZ),U]%.=7,T=P3+<@+PG1JFSXER_V1H[:CM Q)[PB$0V%\RW7
M'=#"!A5Q*9O8QQZQLT%L21Y] VN*=GDT)-<72#:%D*YHK/5-IO3MS;ZW+N"#
M/:[LX%$M6W!F^A>=OH-CVD-S22:;KY:Z:E> ]9WHC8T#QBA4<UR9^\M<;5U3
M%9Y'T2Z5U54[GP,G6G,<770]6F^""H^2523?/GF-KI]6M/W]=C'$DE"U_O)W
M7M3:Z>^U_?<M'4E10"@% * 4 H!0"@% 5^Y2SB4ZUT1/IW$MA:GU,^B[,86+
M;.W8R,EM>P.(-S8V\VDQ " )!2,E-CHG<QG#XUB<"MCTOR!C'Q)!FY7Q4A]%
MY+VORY?L)A2;2:;]B[M^2]BU>A3P?RJY$C>"^E]J;#BPB*<A-X;CU;I.+ID8
M88B0UH/W5R08ZHU[M:1ZU.'C)J&E76GRXO;9;6I<^1=A9,ME"R*Z6>"[=O6[
MRK5NR^GS?U9=P0YXDG=0IMV]BNTGYI/I?I==>A2S#TI?(3-;ES-28J,QJ'ZB
M"<LMAZA@Y75ZS1U-H)P+Y$Q> ;J8C]G-]NG\C<CD, 6?X2$?(]7:UO$I5-HH
MK!GTX&Q>5J9USQ7;7;RO[UT]^OOZ&3XJ&\,/5MY;M/LXX;JZMV7D_.W6USZ$
M&KE%ZU;/&^5\V[M!%RAG?'+"^:*Z>*J65\,[8YXWRPSQO_#EC;+'M[,K6O:]
MJRG'.>@% * 4 H!0%/2? ?B>9W$[WH5U:J_G1"8X[&(CW,]V4IJ\ELG"-]T<
M=DD='WF/]BS_ &)W<M89></( M*,L+8N<BN3W'%S:KAA?6WZRZCB2LGT]RO;
M2]KV]E[']Z_X'<7-8LX@/B4!/X,M?3Z([*@;:0[9W'-4H7)H!$)- H,WBV,T
MG\@]Q0^'P^8R0#&]=#?9]?!V9/.[*,(KMV:S><JTT?=^78AQQ.]WW33Z)=W=
M]EYOS[F.R3T<'#*6MP[0WIW-1D(>["=+,1^Q=K!6,J8[5VJ5W?/XIL9F%G(]
MMM+7LAVL;*3176VQTI3 &)-ZL@*C;$=E[%:,L.F[WZ]?I)^,C[YM/)=+*R:Z
M=&ETNK,]!?T>W$9S.YAL=QK FM*9RXVL\.74VEM^\=;/]YBFH?;Y.+PJT]M"
MX.6V(V9,G,G+0L  )$##)D?R=XG&;4BBRPZ;OD9XK)7Z*R[+LNR;M=V]MR9M
M'<>-3<<PDG ZH!&!B4VESN>S0Q*9Q/-ES"7S%Z("Q]:02B=[,DTOFA]_@"CH
M(,UR*GG2;$6)8L62;=LABG4I)=D1%%%$[MWMT71)+W)))?0NY$,AX \4Y)KW
M4.KG6OY*'B&A"\E/:@3A.Y=X:[DD&*S%N<9R=T+G<!V/&ITO8TRDIYB];DI(
M^:YL2CIEBC@URQ1Q95T5NW;J_,E3(TVT^L5KW2:=NW1IKIY=#^F_ #B+B*GX
MDSJ%"=8;0UX+U1."VU9IL;;\K,:^"M)8R&1Q&:;2E\OEX5%JC.)4I9\!.#"B
MKPLH17?*D&S%RVC+#H/C([IWM9W5DDD^G6R27DO(ZL/]'YQ=U_L)/:$*CFTH
MS+>\,;ECZPCDQR<:Q4_)(I&XW$ YJ6Z^PW#_ &?S)_W:B$:#EEI7&#-Y&T$-
MK2*Q52ZN:A0PKJE[?,.9&U9M6ZK\&&_7VVNN_DRZ-6*"@% * 4 H!0"@% *
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M>.-F[5LX?/5GYDD4)/1+=_K[6_UM_P#T6DH0* 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
$% ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g609070g60a60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g60a60.jpg
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M 0$! 0$! ?_  !$( )<"70,!$0 "$0$#$0'_Q  >  $  04! 0$!
M    " 0%!@<) PH! O_$ $,0  $#! $"! 4# @,$"00#  4#! 8  0('"!24
M%E32U0D1%5*5$A-35=,7(9,C-C>V(B0E)CAU=G>R&!DQ0311<?_$ !X! 0 "
M @,! 0$            ! @,%! 8'"0@*_\0 4!$  0," @@#! 0)"0<#!0$
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MXV/KRVE:XS.8UWDXXH[W'H$6YC7$R"RIL0@;(5!2$.F%I1)4=A^-\01 )@U
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MY7MCC>]K6O?_ /%KUZ1]$+FL^DC11SW-8T5T]W.(:T?S"K&9) &>69WKQ?\
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MZ*$HB41*(E$2B)1$HB418Y,<Y<G$I.IK]O''<[PCYC*&-9B])CHDXE.(]Q<
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ML=>["9B&3) ?*&5[M3;=\A>Z=%-SON;[[W\>*O#G0VC7B:Z+O3&J'23DO(Y
MY2<ZZB"Z;@_,86MKB7'%\%0^6*I>5:\<.(%(R2ELGIR%KK18FNZ!JYL<B7/$
MJRN^,7&M_*%)P^X]:.>S1:"JZN6E[O4T"<RA76;@/G'5]=*2!8!F6S@JT?54
M!JQ')W>/J!U,QF8_)EGDA<ESQ/FO: <:^.FJ%1*^K=!:4UJN!=OWX): :K@L
M.5"OBH(?%BCT2I'00[,<[)1D2*CC]PSR16> A@\0XS4'LFS=,A).\D_$WX^I
M\RJ^6\?]#SZ-2Z&3O2>HYK#]@29.:SR*2W6\-D<:FTR1:"F",MEP(P&>"Y))
MDF(((R3/&6KTK@T#"F^+NR(]I@B2YXE5;71VE&2S%RRT_JUHX&.8*\&N&NOX
MFW6'N]7LG8S6CIBJD(PS:.==C7[X?!5V^2:L29/';0!D/0<+)YDN>)\>N_S\
M5C)3BUQD.1XC$37'/1!>*& @:,EXP4U%K\A'BD;CDB.R^/1\B%=QY8:^" I9
M*)+* PIRV58"Y%(CIMBW0)%R#EP2YXE>C;B_QI922 3)GQXT8TE^J K.-ZME
M;;4L!0DFM8Z/Q<X, $ .)1_ I#@K'!Z\P9BXZZ',6V+MSBBAA9=6V9+GB<]^
M:_MMQCXV,Y!KJ6M./>CVLJU '3CNI9,VU/ D)!JZ/H]1=$%KHTD Q)0D.E=T
MZNF,C3D8R3ZEQ^E"W[RGZB7.>9SWY[_BLQB^I]60AV+?PO6L B#X''7D0"O8
MO#8Z =B(D1-^)2$7%N10YHL/CKZ1_P#;[P(TS1&.C?\ VJNVS?\ ^WHH6?T1
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41:7PXW\=T
MRNSCJ>A-+IG-VL%Q6YC.&K8/B5VX+<IYHN1NSB.(*SR?,'"2BB2[.5+%FZJ:
MF>"B>6.>5KE-SQ.6[DK^"TUJ*+ =?16+ZOU[&8MJ9\L3U=&(Y#H\"CFNB*X4
M_&UGL(!"A[05%G2@"5R<+DL%:,L[C)":9?JZ<F\36)<YYG/?SSOGQSS^*LX/
M06GX?K^VK=>:_B>KX%B?&29.,:TC@*%!DC(N0BI*F[2%A!K8;@HY(!6";S/%
MI919DEBUP42P30ND4*ZRO2NFYW-(5LB<:EUG,MB:V65<ZZGLK@<6D4T@+A=3
M%5=>%2DN*>'(JLLKA@HJJ"?,,U%,<<\\LLL;7L16</QUX_QRVTK1O1VHHWEO
M'$CCNA6.:XB %QMJY=L09E,]E.1 =FXFZI!J6*-WBTE5)++I$7V"F>5G:]LR
MFY-KDFV[E\%?PFH-41J<F=G1W6D" ['D0,;&3\\#Q("-EYF.AVXUH+!DY$S8
M(EGHE@T#!6C5@X=J-D6H4,VP3L@)')MBBYW7RX+8M$2B)1$HB41*(E$2B)1$
MHBU_CJ;5>,3;P+'6>O\ &#-)&E,&D+QAD<M$VLM;S3_$="4MXY8;8.C(T=A_
M]_4C:;/$FG-/^].#K$Y_UZB7/%6N<Z,TOLYO*V>R-3ZZGS2=#8D'FC690X!)
MF\J$P$N5D$'&GT3+!XF48P\\=-&XRU>8JH@RY<D2&X-GCYRLJ2YXK^#VF86?
MGVH-B+HO1YC2#:9LX,.$*M& !!I.(ZTBY5J]&8,LOW&[04Q;IB4&:[%)DIC\
M[XK)6Q2Q)^]9O>)16\JQG5XS'[S?"/YQ+"8W##KRK"*JD4S"D9QD/3?5\8^H
M712*9AK/+#LR*2;[)M=SABK8BL+?5.L&8$-%6.NX0PB\=E>,[ QMA%@C$ 'F
MN,E=S2TM&AFC)$<SD?C%^]EMS2#; AE)W;@_DXN65S=W)<\4@.J=8ZJ1D;?6
M.NX3KQ"8R<C-98C"8N%BZ4EEY?!ND4E!Y,*R98ECY!)HU2=EGUEWRZ39NDHM
MDFBGCB2Y.\W\/EP6?41*(E$2B)1$HB41*(E$6FGW'+CV3D&P):2T1IHA*ML"
MQP3:<F?:OA#N0;+"B,VB@D1L RN#4(S(6+48,5!P^1.231EFR:9-D4LFR-\"
MFYXE9<7UEK>0.Y:_/:^A!M]/XFS@4[>EXH!).YK!AV9U0?#):X>L%EI)$V&<
MHDV;..F<WH=KG(CN2#/"Y<A=P4+7[3BSQC'CM7"&''+0[(3H\JY.Z5%M-0Z^
M;#M0&WCO!^[,:N9(Q[!MK\JZ?)IO7)")I"7:[M/!RJMDMACG8IN<\SGOS.?Q
MXK>]%"41*(E$2B)1%K_Q$:^X7V+OW2LFSY].ZQ[3EU[)XB-?<+[%W[I39\^G
M=-IRZ]D\1&ON%]B[]TIL^?3NFTY=>R>(C7W"^Q=^Z4V?/IW3:<NO9/$1K[A?
M8N_=*;/GT[IM.77LGB(U]POL7?NE-GSZ=TVG+KV3Q$:^X7V+OW2FSY].Z;3E
MU[)XB-?<+[%W[I39\^G=-IRZ]D\1&ON%]B[]TIL^?3NFTY=>R>(C7W"^Q=^Z
M4V?/IW3:<NO9/$1K[A?8N_=*;/GT[IM.77LGB(U]POL7?NE-GSZ=TVG+KV3Q
M$:^X7V+OW2FSY].Z;3EU[)XB-?<+[%W[I39\^G=-IRZ]D\1&ON%]B[]TIL^?
M3NFTY=>R>(C7W"^Q=^Z4V?/IW3:<NO9/$1K[A?8N_=*;/GT[IM.77LGB(U]P
MOL7?NE-GSZ=TVG+KV3Q$:^X7V+OW2FSY].Z;3EU[)XB-?<+[%W[I39\^G=-I
MRZ]D\1&ON%]B[]TIL^?3NFTY=>R>(C7W"^Q=^Z4V?/IW3:<NO9/$1K[A?8N_
M=*;/GT[IM.77LGB(U]POL7?NE-GSZ=TVG+KV3Q$:^X7V+OW2FSY].Z;3EU[)
MXB-?<+[%W[I39\^G=-IRZ]D\1&ON%]B[]TIL^?3NFTY=>R>(C7W"^Q=^Z4V?
M/IW3:<NO9/$1K[A?8N_=*;/GT[IM.77LGB(U]POL7?NE-GSZ=TVG+KV3Q$:^
MX7V+OW2FSY].Z;3EU[)XB-?<+[%W[I39\^G=-IRZ]D\1&ON%]B[]TIL^?3NF
MTY=>R>(C7W"^Q=^Z4V?/IW3:<NO9/$1K[A?8N_=*;/GT[IM.77LGB(U]POL7
M?NE-GSZ=TVG+KV3Q$:^X7V+OW2FSY].Z;3EU[)XB-?<+[%W[I39\^G=-IRZ]
MD\1&ON%]B[]TIL^?3NFTY=>R>(C7W"^Q=^Z4V?/IW3:<NO9/$1K[A?8N_=*;
M/GT[IM.77LGB(U]POL7?NE-GSZ=TVG+KV3Q$:^X7V+OW2FSY].Z;3EU[)XB-
M?<+[%W[I39\^G=-IRZ]D\1&ON%]B[]TIL^?3NFTY=>R>(C7W"^Q=^Z4V?/IW
M3:<NO9/$1K[A?8N_=*;/GT[IM.77LGB(U]POL7?NE-GSZ=TVG+KV3Q$:^X7V
M+OW2FSY].Z;3EU[)XB-?<+[%W[I39\^G=-IRZ]D\1&ON%]B[]TIL^?3NFTY=
M>R>(C7W"^Q=^Z4V?/IW3:<NO9/$1K[A?8N_=*;/GT[IM.77LGB(U]POL7?NE
M-GSZ=TVG+KV3Q$:^X7V+OW2FSY].Z;3EU[)XB-?<+[%W[I39\^G=-IRZ]D\1
M&ON%]B[]TIL^?3NFTY=>R>(C7W"^Q=^Z4V?/IW3:<NO9/$1K[A?8N_=*;/GT
M[IM.77LGB(U]POL7?NE-GSZ=TVG+KV3Q$:^X7V+OW2FSY].Z;3EU[)XB-?<+
M[%W[I39\^G=-IRZ]D\1&ON%]B[]TIL^?3NFTY=>R>(C7W"^Q=^Z4V?/IW3:<
MNO9/$1K[A?8N_=*;/GT[IM.77LGB(U]POL7?NE-GSZ=TVG+KV3Q$:^X7V+OW
M2FSY].Z;3EU[)XB-?<+[%W[I39\^G=-IRZ]D\1&ON%]B[]TIL^?3NFTY=>R>
M(C7W"^Q=^Z4V?/IW3:<NO9/$1K[A?8N_=*;/GT[IM.77LGB(U]POL7?NE-GS
MZ=TVG+KV3Q$:^X7V+OW2FSY].Z;3EU[)XB-?<+[%W[I39\^G=-IRZ]D\1&ON
M%]B[]TIL^?3NFTY=>R>(C7W"^Q=^Z4V?/IW3:<NO91XW]R&UCQHA8R>;5>2=
M *<F<5UX!90R!S;9<I/S6;$/I45C@&&:] R65F2AHC^EDR;#0[E11QFFE:WZ
MU,+97)M]F2HUI<;"VXG,@  9G,JJU[OG7NQ8FPF+?.6P,>2?.A[,1NO7\XT3
M,E5FA%F)NKX%V^ A<OP9.B1!BS&D,PN+(FN\;)CUW.2Z5L@<#R/ Y'R0M(X'
MF#<>8_>JJ6[UU7!]AZRU1(I:R:[!V])B<1@T9:HNR;]\<$P"8;.=(%,1J#K"
M.-<X7 I459$9!F-'D%!>0]BY<$7#9JLN+@>)_P#.:!I()MD!<GY@9<<RLPSG
MD&P".)-G,XIA&VCS,<ZD&<B#XA&Q!-QBT48N"UWEF"+S!WEBUS:J.,5\7&6*
M&6%E;VQI<<1YI8\#Y*YWD(#$LT 7.!['7[#,JQ"W)LK%GHM+/]"A)H.NOUCE
M@GG>V&;Q%'-OAG?].2EK_P"53<<>?RXJ+'AR^?!4&,WA>;!V5PE\7S%L'[T4
M^)8GQ63!F4'(JN" UV\L[NW;OV#=!9=ZS64P<-44555T\,$\\K1<<1PW^/!3
M8\#QW>'%8_?;,%QDY6*JEUFRP77X#9[Z0NQ91I L8=)2Q\.*?M]B.&:4(>O,
MG4:).'H9H>6,#!:@LP18M19H2[>+B]N5[^%MR:IM?F1;QN!?=O\ N>!5;*-C
M1:)#8H8(KDR R:2J)0Z/O(P!-R]!R5F[]$='W;G.,,"MAT=57<)*OY40Z:-A
MV67U L49L<<G%EP+<S8?- ";\@2;Y;M_W_>J]M/(,\<(-6<SBCITY>LQK9LV
MD0==PX(D6&14>P012>9J*O7PS#,DS:IXY+NF&&3Q!/-OC=2RXXCS"6/ ^17N
ME,H@O=_9"5QM:XK%GF4LD<%J7&X$'*K-AD_M@ZRZ/%\\16:L\G'[=G+E)5!&
M^:J>>%EQQ'FECP/DO-&;PMRH@DWE\775<@LI0V31/B55'$9Q^?ZI$AA@[RR5
M!8_*_P"HNG;(?;Y7^;BWRI<<1QW^'%+'@>&[QX+V(2^)"6Z[LI*(Z-:-D!CI
MRZ(&QC-NW:FEU&P=RNLX<III(%G"2K<8LIEBF_7342:Y*J898VFXXA18\"O(
MC-H8(<N&1:71@6\:-WCQVT(GQ3)RU:#V34B_=.$'+M)5%NQ'OV+]XNIABDV9
M/&KI;+!!PBIG%QQ'FIL>!\E6^)8YU[(7]?"_4R0U0R.'?56/7D Z/Z/WBK)G
M^_U#H:E^XG^X^034:I_KP_4K;]6/SFXXC=?Y<?@HL>!WV^?#XK7DQWYI: #!
M!B7;.AP@8>G,&UH)>7--7R3N=;*?,A\&CEK#<GF:+V1*D&CAIFXQ2:I"\U#3
MQPV#MW+Y&-8<1P4AKCX'<3PR&_>MNU*A*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$44IOS9XVP":;=UR<GCM_/-%Q?6LKV7#X?#9M/)($;[AD.
M46UD#9A(5'CQ(_,YB9R9(BH4 :DI1=H7"%'(MN+,#WB]2X D9Y"^[[^G-7#'
M$ BWO$@7(&[,G/<!Q*PT+\1GA^?<Q%!AM51)O,M>&=G#RA:%SL"*$1D SW.0
M+(3!\<C8Y.%25BRXY[Z7=Q*4V$R-I_A)-$7@UNY'H(NYUAT)W'POZ'R34=P\
M;;QF<MV>?XS<QQ"D9)MR0:%ZO8;@F#HO&H6^;0EQ=0M'C:1P>IL$N! 1M@5C
M:3%8V.)*&I*)'$6+EE@L(<*K_4L6R;1RHDN +G)5 )-AF<^F9Z!8/N+E5IO1
M<ZUOK.=OIVZGFV&DA)PR,:\T_MS;I1<)%"\/ R*1GT=4PB96AL8$F)]$F#N3
M3#(&"P7+IXV(7LW=W0$@?^"?L4AI()%K#>20!?,V%R+G(Y"Y6FU_B5</$[[-
MP0V.<?N-5EQX0PV8ZPV@JI*GA+:CW1R:VJE<X>DTV\(9[@&%-=&3^M7,G! 9
M(,>-S1%@V3P=*1KC[^/P4[-^60S%]XRROGGEE8Y^!"DQJ_=NMMSXG'&M#]Y2
M-CR$-6(&F@\BW#W4GD(!;(CK)L^>M6R;DBK!Y5%9(_8)VNY%L),%L03;N'ED
M,)!!W<NN?W^*J01:^5[Y>.1M]H(^2VO4J$HB41*(E$2B)1$HB416LX<"1@*7
MDDE,"X]'8^,?FCQ\X0:"0H0,+:JO298N4?K-V(T8.9(+.WS]XNBU:-457#A5
M-)//.Q-^Y1!0^(9P^<:?U)O9+<X*^M]\[-3U#IDIFR,HE=ESI3:#G4'TZ(QA
M8>G)"S)&9,W%GAE 5<2P 86E#YXW *)D,JZPL#X'=YJ^S=<MMF!<C@+7SYVZ
MK) O-?CM(YK+-=A)@2(3*';)BFJ2 /"(RM!P3ETNG.Q]<,TXPH[#MVTI$!YA
MIO<0V5'02SX7%F^JYT8-N684)F05:PO;F!YDC]Q\E&HZP.68)WC(  Y\+@BP
MWYA;T/[)A\9FT UX:)J-9;L_Q5X+&XL"#A,KX*$H')'^X^;ME6 [H1KA)?#Z
MBY:]7EE^RS_?6QR3M:XN!QW?)5L<SPW_ #6L5.6/'9'<D]T(MMB));-U5J];
M<FT ZI)-(=K?7J#UHS5,SN2*_HCD4733?-"JHDX49%D(^X;R)PR2".6S]:-8
M7M?=OX#=X_-6U76!L;$V'/X!:RC/Q"^)DR#Z(D,7V6N;C_),U, NHC;"'S)4
M6?SA&UX_HTR4(/+ ;)1L"XVU+X=" AF17&,#I66 E12KH>Y6>MXUAESO;Y*=
M1UW"V;0"1XYB]K<;7RY%2>UQL.+;8A$>V-"'BY.'RUGF4C)=9B[8)G >3IP@
M-D Y%ZDBNN#/M44S,>)63LW, GPXLTRS:/4,\I!N+A5(L;'>-_I\O%9O4J$H
MB41*(E$2B)1$HB411G@O,#C[LC>,QXZQ";.R6U8/C*K%A;B'S43'B3J OHN,
MV&,B$\+QYC!9P8UT3FT0'3X1$)$:(Q%_(1S,XV9.+N$T(U@3;Q5BQP:'$9&W
MB/'=<;Q>QM?TO@:GQ"N)J4HW'#O\13"Q_18Z5$INU::SVD^1(IP26!X!.F6N
M'S*&.&6W#$+G\A 0.5 ]7N)<7!S(V+C;]DB5>(MLHUA<B^Y3LW6!MD;>(ROF
M+\+C,7WC-693XE7#E!CK)^ZV:::8;3*R$,+:N]6;8;$H8]B6TA6CY1EN46M"
M<'^CF(#<IT-K F4VXWAHQO,23<9U>6.*ZZ+7;S\MWQ[)LWYY#+/>,[@N%L\[
M@$@;R-RG;5E1*(E$2B)1$HB@K\0CBO*>7FE(GKB(/H4U*1;>.H]MJL=@N9<Q
MBTC':VD?UU]%R)&"+-I8,P/)6Z'ZB%=-'S/%3-=LZ07P34M5PU@!EOOGR5F.
M#3<WW$96\?CEY@J"&R/A-RO<T"=1J;#N.<<=">'W,#CYKL*#3V?L&-P?9G(.
M5:JDT#VX*,[74D$O:$X<M#978B];OOJS"YYHE&LD6]G6&%=0Y[MV5K[_ )W6
M42ZI%K_CM<;V%PT$$>Z ,[WW>'BK1/OA#;/G.Y)9+L=H:HCPJ3[#Y,S^VZ!D
M1D.7*%ECR4X;S+C/:*^*[ND6"T=U%(SPN40QK]73L3"CAK2V$8(Q[!8^U#Q'
MCGXY^?VYY\4$H#;6.X#5_P!SW7:P-KYDC(G*W-8T8^#MLH_JZ6 UGG&J'2 U
M/- R,+KO4H>=Z[U-&KZ*TWL?42NPP3C%D>');5V4SV,KE-<9MJ39<+>Q&.!8
M>]#ES+<?L .U#;>-XX^ (\^.2C: $'WMQS-B<R#;?N%A;,'>MH0WX6NXH],,
MGIS8''.2WDVK]5Q4YNZ^DE8]O/3Y_77$U]QE>#^,8^*OP4-U?$"Y!:^Q@C<<
M[&C8B^.S$,UAA-(TU(#&H?$BW496RW?;GO/!#*#G9V\D"^1N[6]XFY)ME?GO
MRSC5(OA4;RU^)TO</!N,TR<MMY<*P!O4T"@!H+Q^)0WC%KWD(-*;UW8$*W6?
M$)ILDCL0($ECL:(/*1X:(C"2ZNP\FJEJ:I%MQS&0&60WG]ZG: WN2,G$&_O7
M<6G5&=K"V7[EMD?\'W:@:)0YDELS4$C?PN!\>V>.OY+%9&KIN5FM/<P^0/*,
MCJJ0 K7>.D]%-Q6ZA6O((VZ4D0#)0"/%7T:6;-< ]VH<MV0&1W7O?R4;49Y$
M7+C<6N+M:VXW9W;?PW[^,]B'#Z8&./7%C4V;K34)-Z+Y%Z4WE(!6J888AFJ$
MA>M=JK[%*0W7L86(&7XW#-DXL''OG[ENW)$4ES:XX$@_L&86U39HX$$]?54U
MAK.-CFTC?<YBUR>JY]Z_^"7E @>L<AQ/2#.=:]U?P+C.$T%0==B8OL'B[RZ/
M\@MM3\<52%)E&Q7:L&(BX&V,76P-N<QN#,^X^AIHIVKJ'B-P'SN3>]N%@K[7
M?>Y%W&U_^)NK;X Y_$>%[K3VIOA#;EV9J8BEL$5IK2ZY@-N:%% #:)E4I[ML
M9->?4%Y"X$>0Q%K=R//M(_ =28 =9-FBYI2[&?Y.'2T<9-%@J\:A(SL,MQ^/
MCEPOT5C* ;7)W9Y9686^[GXDY_#QNIJ.OA6Y9<HL]@CK:(':45WM'=V(KL]=
MN6&]04-C_'!#CQGQ&CQ8?=M$Q_&LF/;9EU@;;%HT:ARYR)8Q!RJ[1E#>VIGX
M6O?G\.%OOR5-I[MO>UM6PSRO>Y<?&_#AQ4?C?P6ME+:F#Q]3=<0V5/XENA@0
M"X;-$$%81(.-^M=!2OC=Q\U5*\,Q$H6SD6KXC)G\[4D"@ W@2GDEG5VN8]<^
MRDPB"P\<[_*UO@K;;/(6!&=K?C%P<3X9$C=]OCLD1\&T/C.H5*9FYU!L)&+[
MDX[3 @ZEL,?R$Z>UKH_X?67$AS!'I"5Y2<J\;%]GMQ6T6HX[(#C3)D.:KFB)
M.3MDWB@L)\1X=!;?\?7DHVMMUQ>^XVWOUMPRW?#/(6"P/4'P;MJZYV5Q_F![
M;T EK75NIN.L0+&7+*4HRZ-G=!:-DFGE .MW3=!J]R@$Y5,Y&2#4O)18U@V.
M39@4@TM5.,G8IJ'C]_O\%)F!!LVURX@96]XWSYCD/GDOT9\%LQ$X;J05%5^/
M#DGK76?PW61X";A#Y&%[*W!PPV'M22[2F\JP9A7#E6^W(KLI6-('W(XG(UFR
M1 8>3N,?9?)J'+=EX>!-SO\ D4,H)-P<R\WOF YH  Y B_6UU]!]9%@2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%QB@_PT=\:*W'OS<.G^4:,
M[>[AU<PC+B/[_@L4?-Y/)R>^)QMB?(3R2ZMBL%F2H4E&9N=AD+E#(\0E,/L?
MRQ<LY#&(1 HJ*QZA%\[W'CXYYWW^' W68R-(:"RUC?W3R %KY7!%S<6/)7R,
M?#%<#N/NB]3FG6H5Y[ S4TRDVTV<-7?&8KK)]+MG[0UYH75[F1-2<A*:SA\R
MF,<@Y:TWD%G<JT\TV)&2+6UMHG&;9J9 97\3Z>N_Y*#(-8FQL;>[?QL 2=XN
M1?<-]CX+-CW'_DV-X!D]/[-E2^\=U9[*UV<P="I :E[C&-CN0L EN0[&7S$;
M')!); HT,)%W+\R,8N&3>R@-E@Y8"&"[F2#JD',^?B% +=<$9"Q&>6>J1Q-K
MY?-7'G;P9F?*Z>:TDT/>:3C#J,BQP/\ Q4E45E[K?.FU&&SH9/U9GH.6 C[<
M0RD!!A&GD?6&%AH>R:[ML27DI 3B1BQ$YMS?+=;KX(Q^J",]][>!RM8C[#T6
MJ]#_  PB6OY5/,MQ.-/;NUD#UEM35>C]>G(Z6LW.!-D<I))RN:%MRKEFAH>S
MD,2ER\-C85_$!13]G"..IJCBW+O6P9D#.-B+6'G?,^'R4F3(:MP<B3S#=4VY
M$9Y\AX76W^*7$#?_ !VW$W+D]R!#FDW.L#&,E@@;,N,9%]W3![!3TF/BH#]'
M2BT9CPJ6CMF%(F:8G5SS2&3F-ZES#-(CK2,KV-:0=^5MW/+[_!0YS7#=[U]^
M6[/>?'*V5K7!/B5TOJZQI1$HB41*(E$2B)1$HBHB0T<9'/A!@>R*B2C1P/)B
MR35!\.(L'B6:#MD^9.DU6SMHZ04S1<-G"2B*Z6>::N&6&5\;D7,)+X?DAMPW
MA/'%>3PA>;PWE$QWJTG"@A]FS;1?'G^QYA%HL,4S:Y%V;TI%QK"*.K)?M#G4
MB8LW3F^8YJBJG35]VV5^/#._V+('V>76-BTBU[?[A;G\\UX\F^!DWGD[F.T>
M.)#6ND)PN-C9( 8C:IC7TCFFPS<S)N]M2_84ZAT6)'@A;'7R[N*:ZD,>:G"[
M3_%#>Z91-KALDB]R%I)N,OOG\.MU+7@ !UW#._C8>  )L<\S?@%O^6ZWV2OO
M7@R>)=5-<=7QS<@[:4];,VHYCD>.:J! 6QMT/35QLPQE4A:/5&K-HFJDVS4N
MA_T$D\<KS8W9R!N?DJ7%G\R+#YJ\.>,+5US!(\B5TX>M"S_&0WHR3PI8&FH]
MD9XYLL/,GD@-X9M,A)8<Z!BL ;W AU#US^A!)7'-FE:V+5SO86M;YWNFME:Y
MO>_RM91O%?#N;VXJPK0LG1UE)9Y&]J;E,--L.0KCZ_K[6N^^2$IVQLA+51-<
M6X,Q[8;O7IUG&@A=NY%-0<]% )XW=JNH>#35C5.J!E<'?ROG;<K"2SB[.Q %
MLLR  +@Y$7W[\E(+AMI3>NCHUL:.;IV:+V$Q?[ 6?:N8AWA9Z/B$!:A!(IB+
M9H%@X7"),WKEBL^::UCR3^'0%OE@)C)=^S5S_9EH(&9OPY*KRTVL+99[A<_
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MCW'OCA!=@0:&-]J"8'C$-FO]5R<P35"[;C<?+!UR!+./GT) 5B)9K<K  D7
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M01*91*42S1*!]4=IQC&-E;=;%#&98WI:SP@0@"X(S(!\<LB3S'@?'*_%=8N
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M/TF3O-/)=JD]LU;6=IH*)XN;-T++6S_93_216G"'1%+*2Y)16.)Y3.U[3#+
M&,PREELF>0[*TEOBUM<[;(?GFQO8IU7S9YY-K_[#*^%R+^&4+APT]>5#HG&6
M$GR ,XIE(V0$6U/7BX]>[IA&[F$&J9"X!BYO=PS#W<?3FR][K(ML%+WRHBR:
MB)1$HB41*(E$2B)1$HB\UD4G"2K=PDFN@NGFBLBMABJDLDKC?!1)5/.V6"B:
MF&66&>&>-\<\;WQRM>U[VHBQ'#76ODQ */IP2&X 8N11,1H)A& F(B.EFZRS
MAN4!#<6-F8DB@X<N%T7P]%NY26765P5QS5SRR(O0_K^!RML>92F$Q&2LY2T$
ML).T/QL,8;2-B =+O@3,\@19.4B[0*]<N7@EN0P<(CG3A=PSP1654SR(K8?U
M="Y-.-<;%+#%5I5J?"6X0=XB^>-6PK";AFX"18*CVRR;%_BZ%M4$$;/4%[,L
ML/W6G[*E[Y7)^]9%:*1:QDE(K1H!:0&1J08P=L&'6,E0Z/S_ &1)(ITW6OAJ
M/SO^TQ=+JM4_G?\ 0E;YWHBIV4(A8T2& CHC&& *.OD"D?"L@ IJ)!$VRZSE
ML1##D&B;,8^;N7#AP@[9(H.$EUUE4U,5%<\LB*HC\4BT3P*IQ:- (TF=-D)*
M;3CX8<&P,R,MDGD4/E<!S9MB0-DLDDLB!5W99\\R23NY74OAC\B*_P!$2B)1
M$HB41*(E$2B)1%C*\*AKIX=(.8E&7#^4-F+.2OEP(I9Y(F8RWZ1K4ZY4:9+%
MFP_'_HL4'^;A)I;_ ";X)VHB]DXG%4GT@)I1F/IDI8W;M9203##L'TE:M&JC
M)JVD#O%M9<RW;,E56C=$BHY31:J*-T\<4L\L+D5&C 8*V;1EDWA<309PM?JH
M<T1C@=)M$W-TU$;N(RA@SQ2 K_M*JI?NB\&JG[:BF'ZOTYY6N1991$HB41*(
ME$2B+7/B&1?S!?Q3[WRLFSY].ZQ:YX#KZJF=RXLP2Q7?$HXR1S7;-<%G;%RV
M2S=/7";1FVQ46/X89+NW2R+9LC:]U%W"J:*6.:F>.-VI_6Z=TUW<!Y'U5I%[
M,0./'0\+*X,8?LK9Y/&(O/ @\:8IJV04R=-FDE66;VP6O9'.ZN&%L5;V3R^6
M=_E4:@.YP/W^*:[N \CZJZJRXJ@Z:,ER4;1>/[.+L6BK%RFZ>6:88J.KM&^9
M^RKBS9//!1Q='#.R.&>.2GZ<<K7O.I_6Z=TUW<!Y'U5*WGJ[QD\)-#\0=#AR
MCU$@_;I9KLF*HZ^5B"3QTE(LD&RC"^&=GN"ZF&36^&7[]D_TW^34_K=.Z:[N
M \CZJX)28ZNDFN@[ K(K)X*HK)#7BB2J2F-LTU$U,#M\,T\\+VRPSQO?'+&]
MLL;WM>UZ;/GT[IKNX#KZKT\0R+^8+^*?>^4V?/IW37/ =?5/$,B_F"_BGWOE
M-GSZ=TUSP'7U3Q#(OY@OXI][Y39\^G=-<\!U]4\0R+^8+^*?>^4V?/IW37/
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441*(E$2B)1$HB41*(E$2B)1%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g609070g64a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g64a10.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MQ"YVUTBM1&;(6T/+](+*/Z.T,!!(BY(W@C8GEC!A+1 @1%K36>FB)HB:(O\
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MW.&TNUO8?0V</&^6Y7BRO-V_>;6WN4-A:7ZVO-[M>(&]6ML+2#Y3: L]G P
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M%K#>8/\ >U[M8[.PCL;M:6HL"; 061@CU+3VYXE:PWCGNEQ-M:VUO%8VXAO
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MH8HXFA!B+0EH026 )7R6-C;7BTALK"RM+:UC<0V=E!%:1Q,"2T,(,18 DL,
M"3@%I>,<]X>S/(+Q\6/H9WJ!68<@G>![3;\*Q8GUR+<.[:(W(EJ!,MWZXM_:
MBJ%)D[;;6_.J\VFJC>KR;]PCB7#(;.*_W2UNOTIBALQ:\HB,4 A,0, B,<)
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M36H7 (S;H ;*&SK]J2P#A?2TNX*BW*R,.!TC?JL6X_K->G@\VR>/R[K91R5
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M-LGC\NZ=3F/[<$_!G_KT\'FV3Q^7=2GKE=)HB:(FB)HB:(FB*J?+;_#6%O\
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M/RZ= 9D=<WF5%@'B_P H<=)$(;&_VA6<+&W,+,/'F/.5!-9.+\)?PFB@<)&
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MB5G&V(E#9\B;68N\>C*_NJ&ZEEF#TS;TY@'";T># *N8S.I3D#$D ,'& QQ
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M]Z-][(^=33 N5>DKH\I0D$ =H=@7_-=@M%RFB*J?+;_#6%O\UG&?_5E>UO\
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MVNW-]K=O>[7MM;VN7-]J*-ZO.KWVIVWU0 2 3R@D Q,2P)Q+#$MFPQ/14,2
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M_)&7R()SGP[)"/8E1;U^'<O4R;5J38N7+=-%ZWO4PD=11&BF-#5?41@BN,X
M]#)B Q35_=F$@&D1 E3]X5,N72&;@L<H.;+EN[%N% ,>*>#W;MV-2<7H%R;%
MI+ 85R&PD=11&BF-#5:E)Y4XSAQ7&;+SK@&+"QV4AA,@2Y+8 L148T0)20T
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MR3W9OI\&F0Q6+PVASQ3V%$Y![IW]?RQ6K6></T?DD:>+Q,]HLV N,"VL3;L
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MJG4A8[.K[P)^-TYXI["B<D,MS5.I"QV=7W@3\;ISQ3V%$Y(9;FJ=2%CLZOO
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M$31$T1-$31%5/EM_AK"W^:SC/_JRO:W_ &>_C\3^P..?VZW6EPSZ]\^S;_\
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MF.8R.A4,8.9'JXD Q9@<@V [NL)ACZ*)=QU1@BPYYZQV^CL)1.)@G<!%PQ!
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MZ]ZJZC"8WHCF1VJJYP>&?&H<.H%1L ':H=F&L"HNTM[,$)4 "E*^1D9351A
MAE*5/%IJ^D9=R6F"TP?*C*L51<S:S0(V"2*8-LPF-Z*\QD?PF7?L%MD7C5@Z
M$>O,<?!A.DA<,B&.-&N,=%\"&8 [XGY1MG5I5OY!NK"J8*Y%Q^F.S626@XJ8
M[,JX-+.-X[+M57*S"8WHG,9'\,FG)><MQBP@7*23M>&FH.>E2BL^X>47\LCG
M;9(T]Y!R41*Q#29E "3@%[SCEK*9"V6@RHY*) R2^+L.5'6FT\(GF$QO1.8R
M.W3X]AH%LS#@W#K6MXY3F' , FJXB@RQ6-%Z]$4J!"8*G8Z/8DE"@D&PSVK$
M<7=QPSFU/HZJBY"H'2[=5NQ1+A0),4PF-Z*.9'456J3^*_'TD+@A9''R[;$C
MENVFQA\ Q%%1>J-K&E6'Z%:3;%OL/:<N_P ./0K506;ZP.KM0AA&N-48$C"$
M0PF-Z)S&1VF\YK?V#%: T!7$ 8Q09N#WUP$9"9[D V/"E9+XOV5:RON8T^%>
M!YU<:0&R2IW@9Y;)"2@>:!'3QTJ-.L^L5&$QO1 2.A_#51>.XA\<Q,L-+'8
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M<O;>H"?+*I]7WWW_ /ZMO;<BJKCL^<QDR<O]\OY1R;/7B/( -"QJRLPNF=6
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MCJ*(G6!J[7B=T6?$:82.HHBQ$?UV(<*,\6E?CLAL:&#&3]A9'VC)80NR#,L
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M,0@08@,CA0:O2TNILP39V6Z1P^#LQP^!$S/<JW)$4^OZE/@7S[+@H_:;C]B
M909N/G S*5@325@+A*JO(..VU8BVWI9BBV F'N+,DHMUE*PD<Y=EC[I*04R[
MZU&2YPKW!++BW#N@Y=:<_J*Z6CRQ2LU\C^1XN/DB9$R<QMP)XGS@H2[3@)I4
M5XI%@4KB&-R0F/4F]*@M$2/8"J94,1WSU8/_ )]3C+OA-^&6<THF+R6Z-L3(
M<Y+7HITJR#W3,#DVWHP'C4^XAOXY&86LIQ8/F!NO&' G4'Y(M!BC/9%6+;J<
MJ!>@#;8TL5=PV6F99R^###+(-/%=-,"ARB]@S"X Y!DBS0/$^.@Y<9,M[V98
MXH,3P\(A!E6JO]ZU)B2[%Z/?M[_SHNVZJ=_Y[:+E2QHB:(FB*G+8D.+!RE::
MPS1DK&$(_P >L:PA>24=463$:LBFY1R<1856^:R!C[(2 /FWQ[< D5#"8^,P
MD($F_+7+N] PM(AD^?GJMH"XN9L89!S,YH"NHWX.8W#&LCHX1*CK4@%MZ&9
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&T1-$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g609070g64b20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g64b20.jpg
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M  ,! 0$! 0         ! @,$!08'"0@*_\0 51$  0(#!08# P8*!0D'!0$
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MR894-\7HXA&9=UCC#%O(3+$,3$S 8 #$&5C6AT!]4]7VHO4SJJY)*RZAB6B
M)^(B2SZ*2C6#LFA23E1)8BP%[-A(@,_'G7KH\V#;-01$<:<I)#"#-TOT;![8
M>S]OV>-H0V^39Y8EV>9.DVF9+@M$CY7'%+L\N9+@CF"*9-FP1RH(9,4V]-@C
ME F9!'##P6?;6SK19A:1:9<J 0RXHX)L4,,V7O8C#+ABAABB>**,& " QO&(
MH 3%"0-5I=$)3 ),<A<WCQB)RV-$%Q1^.'Q[D68$$6VWV5FC]@[32<-UM?/K
MMC&^F,*)[:*IYW2WTWV^@LUIL]LD2K59)\JTV:? )DF?)CAF2ID$644$<),,
M0X8' @@L00O1E39<^7!-DQPS)4R$103((A%#%"<B",#]AP.*CG.=<B<(O1KR
M<O\ Y[V-_P#*HO\ [WY_-O\ [23_ $%_!O\ \6;4_P#AROS/\)OYOV9^V3?X
M!7K=S^0:_&TX1.$5EUA63RTC>L>'2>*1XHZ="Q@=M)795)<^9-/,,1HH2U"A
MS;U3?9;/I'Q%RV:A@[7'K18DR1V3V4^I]E/96=[6V\;-LVU=D;-M<V;9++8I
M6U)UKAF;1MUNG;BRV2R2K#8K=/B,4;Q6BTS94JPV*4-[;+5(@BA,6X(+Y$(B
MA!) %Y\3$6 # G$\689D@*8E.G"QA\:A!]NW1./)^V7? (P#%3%X84'-19<T
M[>[%%8JVA3S5H*#+OW+(-+2A5%HX:.MQ^&^RZK?VK5^#+VFL^R]@[1E2Y=OG
M^T4J.?L[95@LFVIUMBLTJR6RW3IYM<>R96PIPDV2Q1VB;(L6V+7:X),V3--F
MW9F1R]&5&(83F8\880(B6 ).-VZ< ["(EB"S*,.Z.MYB]'#W==REN\+.7[0>
MDH,6QAPL,'X+/ML*_P!J2;=N(\Y?+Q51-IN*UW))+[L4]U]?*G>P/MG9Y]FL
M\[V:VM*G6N;:)-G@CLL0WD=ELWRRT&]^)#*EV,&V&='%#)BL@BM4$R*1"9@R
M9<P$ P1 DD &$AVQ/DP)?*Z#$[8J"R*-GXB7< ).(?@C31)BNZ%DV^[5ZW2)
M,&I1ANL@IC&Z>'0]ZT=I8VQC.R*Z>V<8^UYN>!M/9>T=C6V;L[:MCM&S[=(@
MD1SK):I9E3Y4%JL\JUV>*.7%[T.]LT^3.@=B8)D);%9(,):($'# ACB'&'@7
M6$YT%$X1.$7G_>'_ *39'_[H?_N,;S_H[_R!?_"C^#'_ 'OMO_\ L#VI7\C?
M\J#_ +\?;3_T^SG_ .*[$53\_P!BK\!3A$X1;@0KHIM6=5]5-B"BT7:#;ED^
MT9AH\D.LM-3[2$E.1D@6,RAE73ZMQ#$8K&3Y=T.<SGM2L"%KOAT=?;J-FZ_P
M&TOPC;#V9M7;FR9\BVS)WL]8A;-HS9,W8\0:.QV:V29%GL4S:TK;%HF3X;99
M;/!.@V9\AAM4^"5.M<H"..']=V+^!?VIV[[/^RWM#9;7LN39O;#:9V;L>1:;
M/[20Q/+VC;=FVBU6S:<GV>G^SMDDV:+9MNM<RSS-M_TG'8;-'/L]@GQ12Y<<
M=,](%Z(%EFD+B!&V >X.-R81,:W%2 I'I $EL23FX-P,1+A@<AT?N(]ERZ6!
M$03 ZW4&%4MQV<,5E.=NS^W_ +,Q2(9FT;?*V%:1:;98Y^S]L3[+(M=EM-AM
M\6S;3!.BL]HM-D,J"UB" 6J3:IMEBAG2(A.&]A"\^V?@B]N9=JCE;&V3/]JK
M#%8=G;3LFV/9RS6^U;/M]BVKLJ';5BF6:"V6.P[0$^9L\S)L5AM%AD6Z"*S6
MJ$V8B1'$HLGTQ=0:KB0M4J@G2JT4V;:GM4PCC?1CZY'-9@VWPMKC*+Q)2)[I
M2;*S%1REH 7;&%-]![E!PIW3[:>RD,%DF1;?V8(;<(S92;3 #,W=L.SXP83[
MTN*&WB*Q79H@B-JACLX!FP1P#RX?P9^W\<>T)</LEMN*/91E"WB&QQD2-]LX
M;7ED1#W)T,6RHH-I&.1%-AAL$<NUQ&&1,@F145SZ=?#)PB<(L/(?_(!S_P"#
MD_\ [)?G'._S4W_=Q_\ M*]#9/YUV9^\+%_,REX_\^+7]"$X1.$6P?3'TV3O
MJMM<;4=>E(8$-/A[TLX,3R4,(N!8#V2C5MG.%7&5B9HD\(/QPP9'XR+-R$B[
M?)[MA>[)N_>,_$]H-O6/V<V;,VG;9=JG2H(X)4,JQV>.T3HXXQ%%E"TN5+A@
M@CF3)\^9*DRX8#>F"**"&+UMB['M6W;?+V?9([-*F1PQ1F9:I\,B5!!"88<R
M\<R.*..""7*DP3)L<40:"Z(XH=AJ^\FO>MFPFIY?%Y+6&[ZU74 =]BWYJ4,Y
M1 8':$ALJ-0JTITKF'*1A"%$GM239T[0C$CE$P$BVP=\1BB&I\8FMXEM]O-D
M6"U[2LMHL^T+FSH;;!\K@E6>*SVRV;/D6"T6O9UD'RH6@VJ7!M*R0PQ6B19[
M+-F138)=HBW$PP^M9?8[:ELLUAM$F=8K]N-DC^313)\,^RV6VS;9)LUNM)^3
MF0+-'%8+3%$),Z=:)<$,N*.0-[ #$Y)Y/3JC9FW#2NZ\+WK%%(U$YC'['I\)
M*#<0ED:FM>C+2 /0B)^/QJ6)D5823P7?QHQ&!<G&IC3>78C1$.]72[-G]M_9
MZ.5#%;K;*V/:1:+399]@VG-L\JU6:T62W3-G3H9QDSI]F,L6N7NX+1*M$RSS
M#,E79I,V 'KSO9/;<,PPV2R3-IR#)L]HDVRP2YTRSVB3:K)!;9,4H394F>(S
M9H]Y%)F28)T%R9>E@2XB(%CHJZL=E)JGKT_V=MFNEMT)GOB-N\HA-TH8A8RV
MZB^/]@\;HP!X/FB[H<H[;(Q<H(.JK:#2XQP[[A]K/9L"R$[:V>/EP$5E&_A>
M:#:S80PSA)ML,=E$,8AB-HES90%^5,$/5_\ IS;I-I V5;?_ +0M:#N8FE-9
MX;87BRB LL<%I)@,0$B9+FDB"9!%%J_SZ%>*G")PB<(O]>CG\SU_OA.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$6JW75_<DZQ/_I:Z@?_ ,3RWGT'LE_I5[,_\0;&_P#D;,O1V/\ G;9?
M[QL7\S*7^91S_="_?TX1.$6WSGK:NYSOT[,,'G[>%]. ZM&D9K1O(Y<G7<E(
M5?,GTU#2&5Q/V_D2Y/OG[S1H2)#V[!;9BR9:M<MED,+9^;A]EME0C;4>Y@-J
MVW';XI]N,BS&VR(+?9H;+-DV>T;G>0R8((;T$$<48OQ17KP++S!LFR#Y=%<A
M,VWQ6@S+09<K?RX;1*$F*7+F7+P@AA!,,,1B%Z*)W!9; !/*EVA&@0P& I^F
M1**4G8RB1Y9,YNT9S)TW>63J3U/"&<S:C,/)3'[4DT=E$D'MV<L)-T@SY ZR
M>"&>R?C3?8"P3IT<V;M+:DPF1%(D7XK)%%9H3!8=WNID5EBF7;/.V?(GR),9
MBL\N(S8#*BAF1/T8_9VSS(XHX[5:XCNS+EWC))E BSW;D1DF)I<=FES)<LDR
MX28P8(A$5!V7E")='ZMG=.0>HJV@<#DR<HTBXZ+F[78O(*I.ZLCM/3EWH4Q8
MF7TS=2F)1@8X(IS=8V,R<W(*^S=@)%W'5.W'[&V:=;[)M.U[2MUKMEG-G,^.
M?*V?%#:Q9-H3]IV2$R_D5RS0V>TVB8(#91*CW5P7Q-@AG#FBV)*F6B3:IUJG
MSYTO=[R*9!9HH9PDVF9:I,-W<-)$N;,B$.YN17!"+U^$1J8R?RGDZE+^9ZO*
M/IMI%+:+V4;NV&L'%H:#[0)6:$B<>)/'95Q8;F01)<,PA,>>A-863!M-3:;]
MZ3:$F#[(E'K2/8.R6>"RW=J[3BM&SI=AE[*M4<-@,=@@L,VT3H(89<-BADVD
M38[7/AF_*H)L6Z,$$$4$<&\BXI?L_)EB4UKM1F6:&SP62;$+.8K/#9XYDR$"
M$2!!,$<4V,1[V&,W###"83#>.CUW6](;WM"3VG*& 804D?L5JD%CJ+U &""1
MB/"8E& (K4F^*%%60.- A E%T5)DBKW5GZX3(/7Z[ARK]7LK9LG9%@L^S[/'
M-F2Y&]B,V>88ILV;/G3+1/FS-W!+EB*;/FS)AAERX)<%Z[+@A@$,(]>R66"Q
MV>79I<444,N^3'&08XXYD<4V9'%=$,(,<R.*(B&&&&%[L,,,( %4\]!=E.$7
MHUY.7_SWL;_Y5%_][\_FW_VDG^@OX-_^+-J?_#E?F?X3?S?LS]LF_P  KUNY
M_(-?C:<(G"*VJJM7\EJLF<)PV.RES)0VP#9X9>28:0#C7.5,%4@9.+'@!(:L
M9;[:,2+I!WJY5&ZKCM%=&;\@BZ^Q]D?:X>R<>U)D.Q-F[6F[4L)V<9]MG[5L
MMIL5EFF(6R"P6K9.T-GVFRQVZ68;/:9LN<)L5E$RS0QPR+1:8)NX([EYH88K
MP;WKS@<6,,4)#Y''$89$O*PW4.9CD=[/ (=$A23P:[&G7B.\C<.#FN]?S6N!
M;I9)\>=-![L4"GAMQE04W9ZDBFK-T1T721W;*^O8?PDVW9FS1LW9^Q-CV2";
M9IUFM\Z"+:<R9;P?9[;?LU9)L<-HVA.DV:=9+!M^W3#%9)4@6JUB1-M,,R"6
M945$P@$"&$.""1><^Y'+?&(@$"9$7 #EB7R4HBW4LXW,N&\V#L<Q(VVRQDC<
M.,>$W;M@E4:52I,=62TLC:JC5R-9LW[S+.1!2"3[TB[$BBBGHQW];9/X49AM
MLR5MVQ2/Z'M\HV;:<NQV2?:YTVSP^QLOV.@D"1'M?9<<4J;99$FT3S(VG8+3
M!:+TRSVF""&&SQ6&:7%YKI!$30DDC=[L,#$,,C^,#2(9*I;HFX:Q+$+2B/,'
M P(J)AP,6S=(8:KZ,XA"X]$$5=VF"AS+/5UJ"];39[FBZC1)?1LJ3?J);NE?
MCO;C;UB]I/:6V;6V;9YMEL$5CV+8+))G2]S,AD;&V'LW8T$<4GY7;S($X6#?
M0R(K=;8Y,,R&5':[1% 9T>9D0CC)A#!H0 <,(81#DY;+)RV3G-59SY)83A$X
M1>?]X?\ I-D?_NA_^XQO/^CO_(%_\*/X,?\ >^V__P"P/:E?R-_RH/\ OQ]M
M/_3[.?\ XKL15/S_ &*OP%.$3A%MO5'5]+J9CH03!X+ FID>ZCJ1V5/-)8[(
M3*-1B8D9P/BY\5F4Z1UNV<%B:[,D8 "0L@=!4&K!(FV5R_>/_@]N^P%@]HK7
M:9^T]I[5F6:;!:XK-899L,N5L^V6W9\K9LVVV6?\A-KBB@L\F"9)L]JGVBRR
M[3%'-,F.'=2I7ZS[+?A=VM[';.L-DV)L/84JVV>9LZ"W;4G#:LZ?MC9NS-KV
MC;=GV9;K(=IP[.ERYEKM,<FTVRP62QV^;8X)<B&TRXS/G3\]OUP3Y)<4F*AD
M'$!(VN+TBD?;=IW#2/A@E*R&C105%X_D3HH_20CDD(&W#\B]<D7<FV];4<:L
M-]AO.J/P:[*BAGF?M':<^TVR&>;=:HS8H)EKM-I]HK'[2S[3%+E62"1*BBME
MBE6:"5)EP29=C&[$!F@3EWHOPV;>ACLL-EV-L2QV+9L=FAV58)7])S)6S['8
MO8S:'L19;%!.M&T)MJGPR]G;2GVV9/M$^9:)NTCO8I@D1&SJVZQZX8@/B";>
MTHFX)RF# -!%5MX]&EW;!HNWZ; W3KZ^\D;BU8YD(^-B8M&'LC5(PBR1^=6;
MM2-AXX_5T7YX.VOP:V^=M"*/8EO@D6+:=J,_;D=KMD,$V9#'[86CVM,J"QP;
M$M8M,NS3[=;9=CAD[2V/.$4R 6RT6R4(H%]9[-?ALV1(V1#+]I]DS+3M/8E@
M%D]EI>S]G1S;/*F0?@YLGX/=_.VC,]J-G&PSK;9=F;-G[0BM&Q?:.SF&5-.S
MK'LZT1B8?,_G[(O\V)PB<(L/(?\ R <_^#D__LE^<<[_ #4W_=Q_^TKT-D_G
M79G[PL7\S*7C_P ^+7]"$X1.$5MT/<)[I_M^!7+%QH@P?KXWJ=%C#VCU0.\<
MZM7+3"3_ $'O&#W9#[#K?;.&[QNI]O77_:>;SXSYFV=ER=M;,MFRK1,FRI-M
ME;F9,DF 38(;T,;P&.&.!WA ]Z&(,^"[^R]H3=E;0LNT9$$N9-LDT38()MXR
MXHA"86CN10Q-CPB!YK<&N?*97+5\(J:*1J$UGN6JY2NQ+N:$F<M<F[!KBJY#
M9\CAM83!@E+&\?1CK=U;\Q8E2L7$QZ6%1*<<:J'D5P?K;WYBW>P.R]H6O:5I
MGVO:&[VA\NFPV6"*S0RK%;MHR-GR+5M"RQFS13C/,.S++'+EVB9/L\N89\6Y
MBAFW(?H+'[9;1L5FL$B39K$9EB-DEQ6F.&T13;78[#-MLZSV*T0">)(D@[0M
M$$<<F7*GQRQ)&]$4J]%V7OE-+544"- ]<UG'XQ$&I0+!8LQQ-'3&)Q5WTJE^
MD@='FY$I+7QHIJ)@9EW)M2Q<@\*OYPJL1>N5!*V0NN8/8#9P$Z*;;]H3[1:H
MI<VV6B9\D$5IM$'M'*]I8YT4N79H)4O>6R5#9S*EP0RX+(!+@A$P;TZB]L[<
M3*AEV.Q2I-GACEV61#\IBAD2#L.9L&"2(YD^.9,W=EF13MY,CBCCM),41W9W
M8O\ JSRFU>:5V6S=L!=E[.AD1EL7I!M$H8Y=@PW:3H=@W1<L1<S-W><7WCKP
M\%K2&'YEDW5=PLE=69/2%,(60):O&GB[2]@+<;=+&R;;#*V?:[39K1M:*TVN
M&&=-W'M;;/:D2X;+#LBT"?!)FV^UR;+N=H[+C!CEFUQVN7+,$?JV'VTL@LDS
M^DK)%,MMGD3Y.S1(LYBE2]][,V;V<BCBM,6TY!DQ39=CL\VT;RP[0A-V,6>"
MSQQWQXM\_5E^<IPB<(G"+_7HY_,]?[X3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%PN6S=XW7:.T$731T
MBJW<M7*6B[=PW6TV360715UV36163VV3524UVT4TVVTWUSKG.,T$@@@D$$$$
M%B",001B"#D4!(+@L1B",P:J(_DWKO\ P%"_W6!^!YR;^?\ /3?I(^ZWO)GS
MD?\ >B[I^3>N_P# 4+_=8'X'C?S_ )Z;])'W3>3/G(_[T7=/R;UW_@*%_NL#
M\#QOY_STWZ2/NF\F?.1_WHNZHNZ9=3=++1!,W6\/=I2#$Z.&W"4:%8S&*^K"
M 'Y_.YHJU:A'SLKH,;B1,?9B&26'CX[*PNN-TF>CUPBW\_YZ;])'W5$<P_ZR
M/^]%B2<L_AE6*'4YTE+"7);:MY2EEC)%(N_$YZ9ITYD XAM#X78 UP2!L(*\
M(CAQV%V%$CX=X^0;Z.$R3D6MJV/!3PH8W\_YZ;])'W3>3/G(_P"^>?/DNMBW
M1;>Z)-3SSI5BK\IBK9I;-;#HP5A[J;SB/P^7P>&M4"X&8Q2!PF)O9>ZG#0V#
M286A,,QZ/,%5K2UKHR3! R;?S_GIOTD7WDWD?SD?]Z)N/%_LT4GI&SZUMQ.B
M=B%*0R)+]0/2W&^I>'-=&8(]LW0VU@F;&B+Y;6-"=?M0?>VJL3&G<)I8EG:(
MMMJ("8 ;:D&_G_/3?I(^Z&.8'_K(\"1^-%Y<>./1;2?DWKO_  %"_P!U@?@>
M-_/^>F_21]U-Y,^<C_O1=T_)O7?^ H7^ZP/P/&_G_/3?I(^Z;R9\Y'_>B[I^
M3>N_\!0O]U@?@>-_/^>F_21]TWDSYR/^]%W7,C7\";YSLA"(BAMMCS;91C09
M+.V,9\^,9SHRUSG'G_M\V?[//SAG 6@"&>!/AA+PB<-Z(20Q($=X M@XQ99B
MBBB_&B,397B2W5US]B89_A&,?(!7A.<'R2R?JUG^AE_=66%!T"=B89_A&,?(
M!7A./DED_5K/]#+^ZC"@Z!.Q,,_PC&/D KPG'R2R?JUG^AE_=1A0= M1IIU&
MT=7\OFT<D%9N7[>*V *J(9V,KIY-Y))K-Q1Z_4C+@[2,QZ.N]F &+TX[C\@U
MDSXDFW*EG!V.)M&I(4,UD+Y)9/U:S_0R_NJW0V0R?(9.WU_%,DVONE)>N\C]
M15HZL6;OH<K*H(/<UA(85!9IES%DY5'D,6L?A.8>''&F3EE]HJJL^69ZKJZ(
MBB!-' I9\DLGZM9_H9?W5+H?$ 5PR6M8'K>CA]B0(,>G*NW+2N'SO>^';6:;
M:HPR-8O(A2@LU &1>F@TAGA!XI'Y7+GD<FP&G'K,,"0T8KF4I "(/7R2R?JU
MG^AE_=5NP\&.3!JU]'6]53E(/9H62.U*^C ,Y#;!G=;R@)[,%$,,3,*D3P6B
M[0>>RV>5V$F X"3$1]MLBX2#2,>@]22?).44WR2R?JUG^AE_=4NB@QY!6CV)
MAG^$8Q\@%>$X^263]6L_T,O[J,*#H$[$PS_",8^0"O"<?)+)^K6?Z&7]U&%!
MT"=B89_A&,?(!7A./DED_5K/]#+^ZC"@Z!<6T"@N^V=MX7$]]L^;S[;1P/MM
MGS8\V//G+/.<^;&,8Q_;_NQYN=N5,F2((94F9')E0O=ERHXI<$-XF(W8("(0
M\1,188DDG$E<$=CLDV(QS;+9YD99XXY$J.(L&#Q10DE@ !C@,%^?R?P/_!,1
M_=L-X+G)\JM/ZQ/^FF?>6/D%A_4K)_TTG[B?D_@?^"8C^[8;P7'RJT_K$_Z:
M9]Y/D%A_4K)_TTG[BQ)Z-U=& 9F2'8K#1P2/"2)PP06C0G*3$4)9K/R#Q7";
M#??*;9HW66WQIKMOG73/V==L^;&7RJT_K$_Z:9]Y/Z/L)_\ )63_ *:3]Q:@
MQ?JDZ<R*D7"RRK7L5F!T(#(DP[2HR\G!QH_):;)7\%@#R8"8G[&(S9Q5X8P2
MV%"<ND\F12H!)QL2,19&0/E5I_6)_P!-,^\K_1]AQ:Q60MQ^3R*L_P")S6 M
M?JCK:(T]([OKOI^%S*#U_H<>6(YL.-G*1>BF88:/(-F$9&2.ISA222"1[$,(
M!W))C%JU%ZCB[V>6="F3-)=T^56G]8G_ $TS[R#9]@/_ )*R?]-)/_\ "PC_
M *KX6'4G)HOT[0-M7D; =3$Z R9F<&$3I>O.C.]8I2W4=(9%%MZY8LHT0'MY
M&YG-6A0\KFO;X*)4'GG]?EG:3;1\JM/ZQ/\ IIGWD_HZP8-8[)P'Y-)S/_(?
M->AWY/X'_@F(_NV&\%Q\JM/ZQ/\ IIGWE/D%A_4K)_TTG[B?D_@?^"8C^[8;
MP7'RJT_K$_Z:9]Y/D%A_4K)_TTG[B?D_@?\ @F(_NV&\%Q\JM/ZQ/^FF?>3Y
M!8?U*R?]-)^XF:^@6<9QF$1#.,X\V<9C0;.,XS_OQG'J7]N,\?*K3^L3_IIG
MWD%@L(+BQ60$8@BSR7!K^(NO^32N/^'\)_=4%X#D^46CY^=]+']Y<VXD?,RO
MHX.R?DTKC_A_"?W5!> X^46CY^=]+']Y-Q(^9E?1P=D_)I7'_#^$_NJ"\!Q\
MHM'S\[Z6/[R;B1\S*^C@[*J+17JZMW=8BOR70HJ9M2R6E? 6N\?!L6J.&<1F
M%F3$L[=Z!GV^F -:5U.#8UGJUS[</,!$<V=#-3&2K%\HM'S\[Z6/[R;B1C_4
MRL _^;@\*<U04>ZK^CB3Q9M+AE>2/8:^80HX/:;=,TX4.OXK8\==2F!S%  T
M@SHLG%I4)'E/9A1VT;8T?"WXU\BS?H8;[OE%H^?G?2Q_>0V>2/\ 4ROHX.'D
MNH>N1LRML?5D?Z4*[.KV!6TBL&DE24C#1 ]-T0 Z"N-]Y@$D%7HAJ]"JOY:7
M;.46LNFMH#AT1)&UZEW:N=4FSY1:/GYWTL?WE=Q(;_-2N8W<'/ECEKFLW2MP
MU_9Y. ##]%5I&TK$?7B!C<FB[H5.(/(I#24I9"5^QDC>P"%O)3&)K&UC$HB\
MHR $-7&L-E#1)N\8=GSAU\HM'S\[Z6/[R&SR!_JI1R_U<''R\*YK<3\FE<?\
M/X3^ZH+P''RBT?/SOI8_O*;B1\S*^C@[)^32N/\ A_"?W5!> X^46CY^=]+'
M]Y-Q(^9E?1P=D_)I7'_#^$_NJ"\!Q\HM'S\[Z6/[R;B1\S*^C@[)^32N/^'\
M)_=4%X#CY1:/GYWTL?WDW$CYF5]'!V4VYPKE3A$X1.$3A$X1.$3A$X10"5VK
M7$(((!I5-8Z&.NV>A%I'7!)!62/!ZBR[;1^RCK;9<V\8[.6SAOAVV8*M_3H+
M(^D](GOKCN6?9]MM4!FV>RSILJ&(P13H8(A(AC AB,$4Z)I4,=V*&*[%&(F(
M+,77-+L\^="8Y<J9' #=,8A.[$0 -TQEH!$Q!8Q.Q!;%2T068'1C$P+547'D
M6^CIHLJU=LE%$%//]C?=J^0;.T,YQCS^C<()*8Q_;G3'GQSK3)<<F9'*F ".
M"(PQ 10Q $9B] 8H2U02%QQP101101 "*$L0"(@_C"2#X@D+H.I0&9N%6JZC
M_"R&^=%,)A33A/&V/]_V5FX]5%3']O\ ^I-3?7/_ %9YEC0]%AQ4=5P=L0/O
M27[OR#Z7PQH>A1Q4=0G;$#[TE^[\@^E\,:'H4<5'4)VQ ^])?N_(/I?#&AZ%
M'%1U"=L0/O27[OR#Z7PQH>A1Q4=0G;$#[TE^[\@^E\,:'H4<5'4)VQ ^])?N
M_(/I?#&AZ%'%1U"=L0/O27[OR#Z7PQH>A1Q4=0G;$#[TE^[\@^E\,:'H4<5'
M4)VQ ^])?N_(/I?#&AZ%'%1U"=L0/O27[OR#Z7PQH>A1Q4=0G;$#[TE^[\@^
ME\,:'H4<5'4)VQ ^])?N_(/I?#&AZ%'%1U"=L0/O27[OR#Z7PQH>A1Q4=0G;
M$#[TE^[\@^E\,:'H4<5'4)VQ ^])?N_(/I?#&AZ%'%1U"=L0/O27[OR#Z7PQ
MH>A1Q4=0G;$#[TE^[\@^E\,:'H4<5'4)VQ ^])?N_(/I?#&AZ%'%1U"=L0/O
M27[OR#Z7PQH>A1Q4=0G;$#[TE^[\@^E\,:'H4<5'4+[B8@<YQCTI+^W/F_M
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M>G"B<(G")PB<(G")PB<(M?>J%M,75-'M*^IH3?$V;FH22BT /N8L@%T.AIH
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M>8'&V@\@T>.0Y#9!-SJQ*H-EE%1[S9LLDXPU=Z(KY0535QIZ/?7;)%E.$5-
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M<<>!QPSQP8L%WKEZO+;$UC75EP=A&HCLKT0V;UL2J*2@ ^D+Z4+UN+ILOK3
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M3LG9%OWL7_E/TGB_%70=DN"IT[)V1;][%_Y3])XOQ5T'9+@J=.R=D6_>Q?\
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M]%BEBR4>5K.*3>;2M5["Y,U!:QNM&@%[8;R.2M>!IQ:<.8.E* "4K$P@S(3
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M@;N&H%0J>B;-P0->PB;66QC:-J('2H+5X8<"U?CZW$2F/259,H#0&*_E!A6
M@RY6%\R,R[CTA[91NR6=_OKP='( 2'R%@/*I/Q)%2KF J;,'0V/!V D]E \@
M@^B) @(^,C@WE\,RMLOT[.R,.ZT(HTE* G_E4$3SP(^&LE&JT"3,],-4=/J7
MGRFMG#QTQ(5PXE""[75KKH@2:L=4O3-%'"Q'RY=R?M586CTM%NI& 1_23NDJ
M@+2'HQO/I[E4>'MM2;^(RV]D^GY[H3:$@1D8W)LJZ?4V['9;CRK7V^U>LLC#
M8Q!'"^Y 6YX@]'^M69TWT=*Z6828,16K=K$9E,)).=J[@@8V.AM:/5X_5T;
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MAG6THIRMIT C$UL 5:U2Q^< H-C!.P%(F4+#961+"H4>FIPSI"6TB(*FB3,
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MJV %=-(P8FY\'#GK$Q8\C8RV9O?:;-SN:/C8?%H"Q>Y3>'W"(]-O$X7&Q>C
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M3><M?1.T)_WH?Y8]^L\;OGIZIO.6OHG:$_[T/\L>_6>-WST]4WG+7T3M"?\
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MC\NR'[*'&ZVC@1)L2!OJ\![Q\BA(5&AE,NRVP^'*CEG*;QCC9ZAMNUTW6U7
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M")PB<(G")PB<(G"*F@/]X&TO\HJ,_P!7]07/3G?F?9_[QVM_+;'7:C_(K/\
MM5L_@V%7+SS%U56Y7_RB\_\ YMO_ /,<YH/Q1Y_65PQ_C'R^H*@^H>OY-:53
MFH-$BJP4N9/UXLN0;2 U%G6D>#6-$STO:M3\>W3-#G1&)##8YLH/6;K*KNDV
M^735-;=PE8@X('%OK4A+$&BTI9=&=G/2+,5)#39>!1:UEMH>'1L&:8?-*./7
M];=G2^$J$D?0%=@QF%/:)B&\*<D5P?LZO5(SE7LTV9MU\73Y/@'RA<OUPYKD
MOCA@;N);,W80.A!+X9OGBN_772A>,!HJZZ_;3=?>76/T6UW6HTP[L6:2U=+J
M?&1:\P,^L?<K+%7#UJF9Q)ZC;MCZ*Z3Q\TB*"+D<P2!#L+T @$5%>.+_ &#R
M4,0,0.&$9.3>ZX89<CAP?R7//^FPK-'4 NFCX>0K>0[@(%.B@<R34'2'0GHM
M20%>&BZ^GS60UM%)+'JHK1LMIL?B#5BG<%:T,4(J>JQ ZKM+IP(' '/C@&#\
MAB[\.:"(8@EPY#CB/>()RXG!FP,6#D%7Q0<;M!M:5I2RQT6R#]Y5/33 96Y%
M,7HV,RVZX1'9W(;8GT.0>-FF7T6*-+&@<.'F-$==E%X \!+X36CNR".H7<N.
M 'B1G];4HLQ,P K$? %F!Z/YY K;3FEE.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A%B3X '*@9B,R8.,D,<D QZ%/ 33%L3#F@Y-LHS(BBHUZFLS(#
MB#199J]9.T56SILJH@NDHDIMKD@)&(+&H7G["NF^UX!7\#%8BU?2TC55%UY5
M,/CZ<K(Q3V4N0EQ4E=1:#REE'7"L7D:8,!4;NN#&6#;T,@AJC55Q&V[E(ZUX
M[I '$@9/DY))%#ECXYX+DO DXD ER<W8,'XMF_B.:SM(]*!^NB/2?)CPZ"+3
M*F:ML.M9K)Q_V'LG<1DTLW=P&):2W>.!2<U;1G*Q#4V?)M(]VCD2Y:9[ F1&
M1/&B%$)]W+ %_L'QS4,0-]B6)#>7%N'P%7EIT=;T^B_5E60:#AC1"U;%L)/,
MT.2\U6Q?:(693-:@H;((I,V$0E[0A'8^ZBWY+K.A2K/=T8C<0UW=#2HMR/!R
M80<0SXG'D0&8TX$#P5$0!A+Y 89AP2X(<>(X.7JK%O2L^H*RG5?0W-=5@=KG
M#)0)=DB:3?2(3NPXV->Q(@PA8?=6OSV(E7,R+,3!.PXZQ(N2[T:,#QH,;&8)
MD#3003P%"7#D#Z@3BPQ\% 80#B7S 8L'=^.)&0)PQZ7CT[ #PAI<A4J/( P\
MRZ@+.E,,CI-JX8NQ4;V=#8^[(>HN4TMVS6>3 !*[089QIKEVPG+8@MKHY>+Z
M:ZAXYXDL]/LQ=2+AEA" 6KCU+,'6Q'*LIPB<(G")PB\I"G1Q>&]DV<F/-M%J
M[L^=VH\F90Q9TH+(2.J;YET$S+(8!JI^$4B]>3&&0S-C,&<] D-C!ULPAXET
M^?C9"\&5[QF$N>9..>!(&1R+.7'@N010L,W &#-B 6+NY#MAPQ( XY28],]_
M'KW8W6-BU<"VM>&Q3UC FUAE7,=M! %:;^0@R<:9/H-HA3!;6''I%*IF/24-
M#K"NER V+.V@N'CYV278B788%\\#X4\^)=6]" SG$'%L0X;$OC3#(#BZG?Y%
M[#@%?]) DC'14Z=0"S;*.3^(BEWQ"'CBEM5;?(@*/T?J %B3V!1N864+K38P
MYB6K=A%#>TS,@18L&];LJQ AXL^&8+@L_P!7FI>!,?!P,26.!A)KB6=G\,6"
MH?3I5ZG3(\[8$H@E2O;HG=;7+44V$YLAVVK1H'MB#0:+Q%W!1[&M]]XY!::U
M@*$981!VU+R8_&II-I,[DQ"2.MPI6-%FP<N#CD"&#4 \R5;T(.98$$88EBY!
M+AR7=^! 977=73?<LY4T#QYI$WPL]1S_ *:RLFD4S(('8L$[5P@VUN(4Q1B;
MW4@=?#ALA>/HMH29.4I7'8!IJ?7'/RIF,4PD\!E=Q/ 8@X?5PYJ"*$8N<[V3
MXEWA+MUXA\BS[(].8 \'&VX3+#WX,3,;^M:5PV.DVKAB[%1IR80$K/\ +%RF
MDHV;SR4AI+:#+&=-=W#*<MWCC1-VY<):6$9\R2LQ'+E"!]OFSMZ+8CFEE.$3
MA$X1.$7FO*:"O.R;3L-Q+H'7(*N7KTK *\TBLVU;,6E-619, +]0YR5Q9&#,
M7AFW;QB0*1ZOSJQ]09%-%!4?$,52)2<S>5X().(88@$$8!\3Q+D8+D>$ ,2^
M!+CB!@ > 'V<@HZ?Z:>H$A?@Z]V$3K<<C7IR,NF=;L[&*N(U93>-&K.'C"45
M2?P1-&F56\3LPC-CH'3)P=-K?29X)NAK2.,Y\>EV)W88-@#@?"G-^+E410W2
M'.+XD8C 9XXXX"@X8K*33IEL76C>FFGW9'.KD<#N"OYD6B")0V&K:67)0MLP
MN/S8/YF8\L]BM?GY>X@(A_N-%+(AI2S,$60(:U);#:82T(\>I!8^1XJ"(/$?
M AVQ (<9\0'9\6967TX5=U 4]%IZR?A0"CF0(L5HJ#D%R2NS-H\>BU6 8_HZ
M=321Q)I('D5F<Z&.=AD4;X:#8!%4F[T(P&[F'$(C@"(/WH,_/R92(PDC'Q+
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E);C]LXUWE_!O_"\*)VSC7>7\&_\ "\(G;.-=Y?P;_P +PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g609070g67a67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g609070g67a67.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X=>?:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<V-V$V-SPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S8W838W+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R,S(X-C0Q)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" R."U*=6PM,C R,R P-SHR,SHS,28C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" R-RU*=6PM,C R,R R,3HU,SHS,28C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" R
M-RXP+C$F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @0F%R($-H87)T)B-X
M03LF(WA!.^* HB Q."!#35E+(&)L86-K(&]B:F5C=',@8VAA;F=E9"!T;R!G
M<F%Y<V-A;&4N)B-X03LF(WA!.^* HB S,3 @8FQA8VL@=&5X="!C:&%R86-T
M97)S(&-H86YG960@=&\@;W9E<G!R:6YT+B8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @
M(" @(" @("!!<FEA;"U";VQD350F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C
M;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!
M.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G-C=A-C<N86DF(WA!.U5S97)N
M86UE.B @(" @(" @(" @(" @1&5L=&$F(WA!.TQO8V%L(%1I;64Z(" @(" @
M(" @(" @(#(X+4IU;"TR,#(S(#(P.C$W.C0R)B-X03M%4U0@5&EM93H@(" @
M(" @(" @(" @(#(X+4IU;"TR,#(S(#$P.C0W.C0R)B-X03M38W)I<'0@5F5R
M<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @
M(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F
M(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@
M4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R
M('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L
M+4)O;&1-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!
M.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO
M;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^
M"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C,M,#<M,CA4,C Z,3<Z
M-3(K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D
M:69Y1&%T93XR,#(S+3 W+3(X5#(P.C$W.C4R*S U.C,P/"]X;7 Z36]D:69Y
M1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C,M,#<M,CA4,C Z
M,3<Z-3$K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R
M96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM
M<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @
M(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'
M26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @
M(" @/'AM<$=);6<Z:&5I9VAT/C$P,#PO>&UP1TEM9SIH96EG:'0^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O
M<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!
M05%3:UI*4F=!0D%G14-704I904%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!
M-%%K;$Y!*S!!04%!04%"04-704%!04%%028C>$$[05%*64%!04%!44%"+RLT
M041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*
M0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU4
M1D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&
M4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%:045!07=%4B8C
M>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W
M24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W
M449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))
M>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%
M;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&
M4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M
M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S53
M5FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!
M44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C
M>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE
M2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*
M4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E
M6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N
M6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$W>#5Y
M+TQ,5'9.3V],9EA'<#9H6B8C>$$[4W)#3&9H851"67EO16]"2TUR:78W-V9X
M1S-C-'%M,VQ,>7!B95=B1S5S<E<W=6)U0V4V:W4P*W1U2DAI.55,5TY7;T-5
M0E5K8W%N9B8C>$$[<FEQ9#1Q-T9867$W1EA9<3=&6%EQ-T954&4V:%E736%Y
M6'1Z1F%X=3-"2&UD67=7;U1X0EEI<&]#8U9B<W11<TPV27I75GI&9%)+>"8C
M>$$[4G!)6%=247<V<5-P27%+.4U65CA69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5E-N>D9"<6-T<T9S.5)J,"8C>$$[,DQH2TQM
M9#%"64M9>49D0U-/2E$O1E=U5&I+24)S8CE'=5EL66\W9%="9C11+TUU9E1B
M6#9L*UI+0T)926M3-%<Q:&Q%<FA)>C9J4R8C>$$[33=&=5)2,C)B8TAW>4Q9
M=G5F26XU<UA%57-&<BM9+W!E<69I<%E1=7DQ-6,K1&,K4R]A5VTO=SEU,D)7
M6"M4=DY.-35G5%9(=61*;B8C>$$[,&]71CE,6E%#-$1H<#!I<%-C2S92:TLY
M9&AV.#A66D1I<3)A5DE9;FQE=D-.4WI50EDP559.1E5%;C5$1E=/-DHK62]K
M;EA,*U!4.28C>$$[2S%72S9V6E9,>'=+<VES>7%I>45J:W$Y16M5+U1I<DI-
M5F1I<G-69&ER<U9D:7)Z=C@T2E!*13ER<#)N96).3W5.471N:V4U=#!T-28C
M>$$[1$AX9$5-6C5&6&I*<7-X,GI-,'5J;&UU:4YN6#8W=$=';7)I0E!&,TE4
M.'1V368U96%E.3-P*V@R575J,G))3'$V;'5P5D50-V]*1B8C>$$[>5IM:V%J
M3E564&,Y9#AN<61"4$9(:4I$6&\K,6-E;VYW>$)"<3DS;VQJ<2MK,S=/=&IE
M=UAB4F8S9V=L4U%R=5(X6$5M;31/641T128C>$$[6&ER1W)N.'@O2F1R<4QA
M9&1A:TE,=$HO<7)*3$9-:2MT>59/061K0TAE4F4O8UEQ>5A&6%EQ-T950F1E
M64Y"=$QH<F$V,4LQ=#=H2R8C>$$[1F]:6F\P8V-G5T966F=D,4)/2V\U2%(P
M5C!936I!37)+86=G-V=G:D97.%9D:7)S5F1I<G-65WE&>$=X4F549T5Q=E-P
M<'--5EE*-28C>$$[8SAX9FUV9%A';&Y7+TQ6=%I7='<W<'%9:FY$4W=,>%!P
M=79X<W!(269%2VLP27 S;W%Z,T9867%G3EDP3%1D6&<Y0R]J36MF1U)+0B8C
M>$$[;5@T6E5+4#EK:G%P>75E1TUI0V5C95,P>%-4.&MF>31K='!R85146&5/
M95-'95EM-75#>E,R-D9%9FQZ<412:E=N6$Q&5%!Y-2M7;B8C>$$[:W9Y-7%J
M87!O,FYI,798:4YU,&=K:V%S6DE9:6I-4CEP83$V,7(T-'$X=#AI*U))4$]D
M:#5N=#<K-78Y22MP*V%,*V1)-V5:1%5Y>"8C>$$[0F%684]H5#0V9T1B-SA+
M=EAV2UAL4S(X<S).>EI7=#-C,V-%.3%*9' Y8F-34$8V;U=S871116]#<$DU
M5D\O6$%Q=C5P,59T2CAV,R8C>$$[,F]R17,U=&\K6&]V<W)!:T%G+V9L,FYX
M94I-4C<R:E9:=D-X>6Y6.$EE3S90-2LP4T168E-A>CAP-F)A,V%Z5FEU;VQ#
M>5)V2V=G6B8C>$$[;%E+0T-9=FA/+U1.=DQS:4E"4$58;CAF=$)+56=/1&UE
M+SA!63DR>E)05'5X5DIT8S@T*U=T0W593%A68C5,935U5DQW46-89#)66"8C
M>$$[5D,S1TY73D]4<4U64FUI-C%P5W0V6D)Q;6Q82S-D:&-G=$)C2EAI=T)+
M;6Q11#%'2V\S1EA9<3AH+U!J+V5N4G8Y4V8Y8V5B,W-B;"8C>$$[3#1F<&58
M.6\K8U X-SE$1"]):S)M>#-U;W!Q8T185FA065-W6$U#16=S:W)O<D1B9F]C
M:C=1-FM99$]*15@V:"ML>&5W4#<X+W="528C>$$[+V5'6B]L:G%(-5ER<D0S
M6&Q(5#5)6C<V='1C5&5R27EF1WAU=T=J:UDW:C%Q<6%6;V%:>4]0=$U3>4-"
M:5%:4%E#5#%V3FUY94XV:B8C>$$[*UIN;$<T935H=2]+<TYW2E@O,&HQ1$=W
M9&QK16=:<7@W;FUG8C4U=5(R3U-0<2MX-398=$)!16IG4'I4<E4O>CDX;&%4
M3EHR;7!2,R8C>$$[85@Y,V%R96DS9VE-=U=.=S=F8G%L4T)'83!'879.:31*
M;5!C-W94-69%>&ED5GA"-D9P=6]7=7!A9&$V:F%0-FQR97=X,T9U-' X528C
M>$$[8W%H,$\Q97%N2VTU15EQ.&XX*UA8-5,S+VU+6F9-;6U81C-Q5G%0<3AJ
M<GE#;%!4:U1J.$UI8F-B:'4S6$TO1C)D:VY%4T956%8U*R8C>$$[,3A/2UIH
M2S=(:WIZ>5AQ;6HV:#5D=%1O-GI,<#EO<3)K075#5$IX9U5)3U1&;EIT=35.
M5&U.;G=3>%,T6F,S33 R<&IM:'AX-4HU;"8C>$$[3&M)3%<U=%1H,&DY;3!U
M2EHY4VEH9#=30GA66DI656Q54'A2+V%)<#EO67%K96<V<C4K;#$T,F5T-E)B
M=V%565IM5%5,851L*RMI=28C>$$[0VE":V1U45=72&DV-V5.85EQ>6Y&6%EQ
M9TYF9# P2%5N4FER<F%Z37)+845%4G-145)L=4583U!V1%9N3EDU931V;3,O
M179M4"]Q-B8C>$$[,VXO4U),+WI6;E<O;#AF.#!F25!N+S5Z3B]0;#AY*VYB
M66LR.%)/-4M,52]2;DA3-79O:V53<&=3>%!Z.2M:+VQF>4MT9S)V3D]O,28C
M>$$[1G!&="]1:4UU.$E5='E.4E0W67 S3TMP<#57.#%A5C5M,#$Y43 S,4)&
M1E!,87I2>DHV8VE444YW9$A1.4-$:7%C67$X*R]*<3!E=R8C>$$[,'989$Y*
M=%!4<W1:=31O5G,W;#=H46A93E=26&YU9E)K67-3,%DT52]L<E5L5C9$:7)(
M4'I'+S51;E8O*TU0+T%"<TUY.40O04@P9B8C>$$[931085@K3'HO<79N:E,O
M*T]N868X6F\O*TIJ3W%Y9E-F8SA,<"\W>5 Y669E*W%S-' Y261I<GI$.'A0
M3U=L858U;W0T<G9Y+V$V;B8C>$$[9#)58517;#=-4C9K4EIX24]"2T]6;SA3
M='-E;WIA851S-%IO8UA&5'!/,$\Q>G X;D)W,W1F4#EI8R]L9C5K<W19<TPR
M1WDP<4A38B8C>$$[83!L1$-#,TDT33@U6C-A9U9"571U8W Q=6LX16IE-V-N
M<S-T1#AY0V$T83@W6G1M0S=*,DMV269Z-"\S<#!B+T%&2B\Q>#5V97AU528C
M>$$[=F@K;#5F,FHU=R]Z=C!-1CAQ9T<U=D%254<R24E0.$%X;&IZ03ES4#A4
M2#EC9F-813="+W9J+U8O4T=9*U)R2WIT4$U6:6QR0VM#="8C>$$[2W!94G%&
M0DM20TYA,#A%4E9(<T)N;C)G:U1N:&9F.$%R975J>F5Z-3)B82M5<GHO04AR
M;B]W0TUJ+SA!16IN8E$U0C@Q>2]79F58;R8C>$$[35 U;5(K6'10,&Y4-V@W
M5D-B84@V=#9S8E!)459513%5-T1L3E-V=FYM9F%N84]E3W%Y4FE!4D=8-#9V
M96%%,6=H+U9(,U!5=DM'<28C>$$[,T]Q84],;3161F-/,%E736-60W%"4V=Q
M8WE/>CE23$YJ-'!C-V,P1S V>D]3*V-0>D@O-51F5B\K37<O-&=U9&)O4#=M
M4'5E0S=7+R8C>$$[>&UF=B]1.58O2FXO04I1=&8K66U8*T=A5'18*RLK065M
M-T0O04U82'9,3W,Q<G0R22]M<F-4,B]K;3EL9VMA2U98:#1Y27A6:%=6428C
M>$$[845B-6YD;7A">D%(>BLU,6YB17I(5'E)3DAB-W<X:#AL-G9Q,'9M,U-)
M-6(R95-.-W%)36I3=59)-4199VY.-W$X55)I:U%">659-R8C>$$[4#%'434T
M07EK4F9E6#!:;DM09$]X5DPO041(+T%-;SEQ;B]-2E X03AM,GDS0B]E4CDT
M8612+V1Y+W%N-VYY-6Y:=FTW-G9T9CDU;R8C>$$[9CE29C%:>$5U8C9B2&MQ
M645V3B]Z4S@V-GAO1V\R5G99<D$P8S!*:UE44FE3:D)I=3%4='1M,C=0,&--
M<U-:9$,V4'1B=$A*<#52128C>$$[2S-(5E4O2S-Z<G)8;4LX=C1T43E%2D%I
M4THV569#<D]X0DHS3F5M1'1(4G=X04=05E!:2&%'5%5'46Y7,6-N;VUA<#-B
M=WIY;"M74"8C>$$[*TMK.'IY-G!Q9#5P-&)Z0F1445%71C=&3D=&5EI%2$Y6
M83113V974$U':"M%0VTR1EAR2&Q,>7!B95=B1S5S<E<W=6)U0V4V:W4P*R8C
M>$$[='5*2&DY54Q73E=O0U5"56MC<6YF<F=61"]M3B]W06]4<2\O04)H+S0R
M1UIE:"]V;RLY=V4P=CA8;B]69E!';"]W1$A4=% K33!F+R8C>$$[04)-6C%7
M5#94-VYH9% X03-K9C9W*SDW6$HK95!K3E!.2CAT97)C3F9R8W)A4U-,1BLU
M4U8U4%)(3GE2>$A087!(8U4V:D]+9E-'9B8C>$$[-'$X1R]/8B]!2E1-+W=$
M34Y&+WAT;E1D;&8S4'A,>&YB,RM-9C5O+U-R+VPW-3(P3'EB-5@Q=E=T8F52
M3$YB:3%H06E1>4]Z>4(K228C>$$[049006YC-6@Y<S@T+T8R2',W.44O94AQ
M6&MZ>GIO9FTK>6YU.4LY6E5T-4)(2DAC4BMK+WA)2D5C0W!Q:G$Q5E!F3DLY
M1WE$1EAK4"8C>$$[-3AF-S V3B]Q5"]R:GIE.6IC<&9$.4QY+W1(>F@O;F9O
M64PU52\S<74O.$%M2% O04-D:GI!.7-0.%1(.6-F8UA%-T(O=FHO049F,"8C
M>$$[:&TO;$0O;$IB1"]J2B]X<6,X.3=/+W8T*SDV-E!.-T1N84YR-5-V4#DV
M-2\K36HO05!%:FYB435".#%Y+U=F95=55#92<&0Y1EE46"8C>$$[;'!&8U-W
M5S!(;WE327)-;%DT,E!%:V)62VI024\R<VMO-GI+068T>3DS;W8W;4@Y569C
M.64O3'(O;$A2+W=!6G!0-%IT3WAV-VHT;"8C>$$[>EDX;50U=%=4-7<O368X
M03549E8O=T1J35 X06E#-3%U9R]U62LU-$QT8B]!0FUF=B]1:3=B42]*3W$K
M5G1*4&U85S=V4T1:>C-$=R8C>$$[3&)3*VQ(24IM569(5E=5;CEY841/6C=A
M,7502'%/1U8S=VIO6'!E>$17;4AV4#-V5V9Y-B]W05!7=6EJ4SE$=C4W*WIT
M>3 P36QW4R8C>$$[-5=/9&DV<7)K1&MO<6506#4U<CA'<G@U4U)%.&YB9W%0
M-75F.&],9F8V.$@O2C5C,TA:;CDK4&HY>G$K,G8X049P9D0W=SA8.&Q32B8C
M>$$[2#5T,&E34F=Q2F12<S=(;T%'<5-C,RMT24='6E X,'9+9&TO-'A$*W,Y
M0CAV-D)R,FTV;F)8=#4K6E1A:D9$8TI*4&%4065N3$)36"8C>$$[,4DR0FQ.
M1U!Q2GA954$T+UI06$])+U!99C4X9FTY+UEE<T%G9T5B9S=G-6MP4R]Z2"]Y
M:C)Q9CAW:R\O04-B8DQC2#DU2#-H<#%(.28C>$$[,TPK<69U9DQM9&TK8G9Q
M*S$O,VUH+S%&+U9N15,U=G!S95-P9U,X6B]06"]!23=/;2\X04U-,R]!0V-/
M9$(R4#E%=F4X<#=29EA$,R8C>$$[1E4O26XO:F\V="]X:&DO-&MC2&)0,'@Y
M-TPR9"MQ9G5(-EAS5V%"-FPU;BM5=#$U9G-,9GIF8T-D-U9'.'A8=W9*3'=*
M0D8V-$E$928C>$$[;35K8T]+3'5F:#-R.$EP=7$Y2'1B>3!U-'I,87IX,T59
M66]8:5I854UV5595;F-9<6M0-6IF.$%+139V+W=!668K3FAM6&]F-S90=B8C
M>$$[8TAT3"]&-2\Q6'HQ<$-H=%=S;%!1>GA!+W=$0FI/;WIM<V-J-48T8E-I
M.'-F-G<K.6YS=C5W*UEH-6Y44W8P37)O-&I,86])5TU)2B8C>$$[:FQK1E=R
M*WE94798<5)N;$$W57IC2$9C4&0Q-F5F;2MH.%IE>6%F3SEX65<P.&Q/8W-3
M3SE/;%=513!Z;TU-:DM!2C9G3FIW,S@U=B8C>$$[*U5Z4"]-3D8O=T%B6C%8
M6E@Y>CA3.%HR.2]J2"MA4#!P9#5D.#5A:C55.'-A<F975FHK:VUA5T506G%H
M:V1X6&HX2VIW-3%0>7I2*R8C>$$[,"MP;FIN:D530GAC6% T3V0W4&UO5#DT
M96UF;#<U,C%86#=R,#=U,&IS,4M3:W=H0VIG>%-E;4LW;EEJ9D]B,$]V>5IC
M=D)+<7$Y=B8C>$$[9SE&1U9S*WID33-K4#4X9C<P-DXO<50O04LT.#-V63-+
M6'<O4SAV-U(X-&8U,S9'0RM64#DV<G8O;4A0+THR4$U$,G<O=T%42#EC9B8C
M>$$[8UA%-T(O=FHO5B]31V(K55 K56QS4#A!:DHO>'%C.#DW3R]V-"LY-C90
M3C=$;F%.<C53=E Y-C4O=T1J22\X07A)-3(P3U%F3F-V,28C>$$[;C-L;6-8
M*SAT<B]Z1%%F.&U6>G@S='HO04)Z3"]73#-E:2]U668Q4CEZ,5 X=78K561(
M+T%";6LO:&TS-T<O=5!I6$YJ>5I0;3%:4"8C>$$[;D0X>"]W1&Q..5@O04]-
M=R]W0TE,;E<V1"LU:C=N9W4Q=CA!1UHK+SE#*T148E153D%S26)P4SAA:#-!
M1$UV>&5P2V].5DDV8W1V9B8C>$$[4$]V875::G)34B]-1#!F62]W1&DX9FHY
M-S!R.'%9;S1497=X2T9J:FIH4D9(44MV24%::3EH;3544'4O4S=E0UDO;34O
M=T%O3&9F-B8C>$$[.$@O2C5C-TAS>BLO2'@K-3%V8E@K3%,K2#-H-&(U92\T
M-U9P+W(O=T]B<G18+T9C;CE36#-02V1N9C1X1#-P<' O;'%Z<V19=716:28C
M>$$[;&M-.31R0U=.:5!4*TM1=E5!05508CEE94Y4>D=54DAU939F4FM(.7I(
M+W%J.5=D,4AK1S5"95DO=T1L2'15+S5H2B\K5&):9F<O=B8C>$$[22LX3D]O
M+W4U9C%4.7HU8WIS,WID.5@R=BLX,% K;W8V<S1I6$XY3FIY5DU#6&I0-38O
M.&1N5&8K65IV*U1H>F]/>"]O;#<S;%!A3"8C>$$[-C1E-'%N-44O=T1(4C%B
M+T%)=WAF.%-/1'1N-EDK.6PW3R]64#-$.4PR3$Y!.5,X;CAL*U9F>3<X,C9"
M<65K<F%35#9B<$=S6%-O4"8C>$$[575O;%<U-#A:2DEQ,U9Y44-88C=*559*
M25%6,U9E:"M84$LK:6583&$T=&1(='IB5S$Q8U!D>5$X,V123$M&1&Q!-6)G
M<#0Q-')T5R8C>$$[=FII<4(O36(O;$-D6"\T=R]W1$=W>DPP4#DY2#-U1#)L
M+VDX+W=#<2ME.4<O=T-/>%DO.'A%6"]!0DU:,"MP+W4U9C%4.7IW*VPO=B8C
M>$$[668Q:#DW3#@X36912'1U:B]W1$A)<V8K665,+T%)9TTW=E1F,V-F-F\K
M-75$>$@X-78X06Q->B]!37<P6"]',F1:,E8O8R]%=D=D=B8C>$$[9C1X+VUJ
M.4M6*U=0*T]B4"]W05IL+S1I8S54,C(O>5@K9"MH>F5W4&]L-W=Z+SA!3&8X
M03530B\K660O*TI,;DTY:2\S,RMA9C!04B8C>$$[4C5V5',V='-E42]N>"]V
M5&\S*W!0*W503C<R3GEL.% P=DPK,&9/2"MD*VAG=FQ4+V5Q-R]W0UEC+SA!
M2C)0340R=R]X368Q>#EX8R8C>$$[5'-(*RM0.$%6+U-'8BM54"M5;'-0*TUN
M+T=P>GHS<S<K+VHW,W)O.#-S3V1O,G9L2S@O,W)N+S1Y4#A!.%-/9'1$:TAZ
M6$PY6CDU6B8C>$$[;D8O=DQA+SAW,$@O04-:6%!(93-0.&-Y+W="679D-DPK
M-6@O5D@S4%4O>38O=T-59$@O1V%4*T=B9G-B*S0K2F,R4$IK*V)6:RMC4"8C
M>$$[>D@O-51F5B\K37<O-&=U9&)O4#=M4'5E0S=7+WAM9G8O46ID22\T-#EL
M+W%0+WEE:WIZ:C)U+W@S+TYI.4@R4"]I.&9J.3<P4#AR=B8C>$$[-S=59CE7
M3#EB6FHY:&,U+T0Y3'0T23<X,U X06Q"8C<O6&<O-5!,;EDY;68S-"M0,T]T
M-V$O>&%8=RLX4$1F3#,O2&%T4#A!6"]G8R8C>$$[,UAA=BM+-5 V:W9U954W
M3R]W05EH-S)6-31Q.3 Y,6<O=5DO.55F<7IV-#AG,TE,>D@O>6HR<68X=VLO
M+TIT<W9W9C-K9F5';E5F,R8C>$$[8W8V<"LU.'5:,F(U=3ES=G9-,S5V5S$W
M9'<V9C56=#=V5$QA:',W:S-#3$IC4D%X06A536]O-%)M23551&1.<69&>$UU
M8C9B2&LY2"8C>$$[>4M8:E U-B\X9&Y49BM96G8K5&AZ;T]X+V]L-S-L4&%,
M-C1E-'-F.&HV9F\R;U='<C)U<V%H3'!L;S,Q6B]R8T)#=4=I:TUG04Q*228C
M>$$[0G-H,W!L2&(R;VAI:D1I3E=3;C)D-7HK2#98;S,U8C9D-4XP<3AU:&]0
M;4,U,5IR.4EK94\T;#ED961S<D0Q02]!9D=Y16-T.396<"8C>$$[535Z<TY:
M:6Y,:$(Y6'AE<'1"9FQ18F91-UAZ5$YQ=#=A,CAD,35G=DI),BMU4E-X07-!
M>%)7*TAJ=7)(9V1X=G-->55V4TQ7.'1,=28C>$$[37DR<SAD>$='2T8T;58Q
M1$PQ1E9*,T=+<$0K63,O2T4V=CA!.%EF*TYH;5AO9C<V4'9C2'1,+T8U+S%8
M>C-O,R](67-F*UEI3"]I628C>$$[>G Y5"]D>2]Q;C=N:#E,+T%(<U V=RLY
M;"ME1U!O1#(S4B\K3U)9+SAW.%@O14)N9#9B*S=J+U9(,TYW94DO;DXO>6U:
M+S5H;W8X028C>$$[:F)/<S=++W5F:5AJ3S-V.%DO>E(K;$LO3$@O2$YN+S1Z
M3"]X135Y;G1T+VMV.#<Y1&TY9V923#-H;B\U8B\X04M14"]!37<W+W=$128C
M>$$[;'IM97AF-S<O3E V2&]O.#-P,F17,E!)9GHT+S-P,&(O56XO049X-79E
M>'55=F@K;#5F,FHU=R]Z=C!-1CAQ9C<Q6&8O34]F*U1S928C>$$[64AT:"]I
M62]R:C=I-&Y94#DX9C9V-E%Z9GEH+WEK=&@O=T%:4"M.5&YN=EHS.2](,W98
M4C5V66,W4G1F2U8U+W984"]!35I(+W=#2B8C>$$[2$\R:'E$-7)L*W,K.'-Z
M:2]W0C5B6"]M1V<O-4UR;FIV8FXK3UIF-GAE-S!8.7I$*W%0=65P+VPQ+WEJ
M;R\T>E-F=WIB.6IF,TAX3"8C>$$[;7@U36YZ87-N>F@K62\X07EM*W(O=T1'
M668X045&>G)D0B]C>#EZ=UAA,RM->CDO-D5B<$@O2$AS=CA!568X03504UHU
M>#=89C0W+R8C>$$[04IS6&\K>"\X6&HX9G9E:"]L9"]F86HO04MS6#8R>D@W
M0S5Z*T@V6&)W4C,U=68X;TQF9C8X2"]!0V583W@W32]V>#AF=61B,C$O:28C
M>$$[,'9H.31E1RM8=CA!:G17;BMV.$%W3V)R=%@O1F-N.5-8,U!+9&YF-'A$
M,W-R>GA6-W W<D(O8W@O=T-Q4#%:,SAE46)K1C5J+W=#528C>$$[93%4+T%*
M:$HO=T1K,C)8-% W>5!V1%1Q4#=U6#E5+V,K6$TW3C@S6FQQ5B\K64LK8C5'
M=#E6-&58,&QO,71Y9C%/259W=U5J<#AF2"8C>$$[=C!Z>&I.<6$T:&-U2WHQ
M4&4K:U<Y<CAQ4WE3*UAB1U-6,FMK6D-79&E34V52-FLU,&5G:U1H:51Z<'1(
M2C5F*V5V.$%X,F1.+W=#628C>$$[6G8X06LT8S9Z<V8V2F4Y-5@R:2MU2'5,
M1'1#<S=E*S!F5F)+-5AN8EA1:FAN4W!(2DI%;59H56(W9S5O=F)/4FI$15)Z
M16HK:%!S+R8C>$$[+T@O;2]P6F@K53)H86)O;717,6QP,&)2,CE:-4],3SAH
M-4]H3$AK-5DU>5!:=5=5.5-$3&Y2*S4V85!.4B],=GEB;U!M=V5C<E!78B8C
M>$$[5EI,3S X>C,P,$)G;FMJ8WEU;U8K86])+W-Q5DMN:S(O=T%G5#%J63E9
M.'5E5CE%.'57,7AA-E!B;3)T<G$T93=K:#5U-FE754M(2R8C>$$[0GDS0E1X
M<GA8871F2$%Q0B]-8B]!2E%N5B\X06I$+WAS37DY1"]F4CDW9SEP9C1V4"MQ
M*V4Y1R\T-T9J+W=!>$58+T5X;E0V;BLW;"8C>$$[+U90,U!$-E@K.6@O5T@S
M<W9Z=W@Y064R-E X03AC:7@O=T-994PO:4%Z=3E.+V1X+W%J-VTT4$5F>FTO
M-51-+SAW,%@O1S)D6C)6+R8C>$$[8R]%=D=D=F8T>"]M:CE+5BM74"M/8E O
M04U:;"]W0TEN3U4Y='8X04IF-3,V2$XW02MI6'9$4"]!370O*U5G9B]M2&8O
M:5,U>E!9=B8C>$$[.3DO;6XY1#!596(P-T]R8DAK4#4X9C<P-DXO<50O<FIZ
M93EJ8W!F1#E,>2]T2'IH+VYF;UE,-54O=T(V<G8X035H>B]!36Y9.'=08B8C
M>$$[1"]%>"]82#-&>$]W9C<T+S%F,&AM+VQ$+VQ*8D0O:DHO=T%A;E!097IV
M-RM0=F5U:GIE=S4R:F$K57)Z+V5U9B]J22\O16IN8E$U0B8C>$$[.#%Y+U=F
M95=:>&8W>3)V+T%$1%%F.&U6>G@S='HO2$UV.5EV9#9,*S5H+U9(,U!5+W=!
M=78K561(+T=A5"M'8F9S8BLT*TIC,E!*:R8C>$$[*V)6:RMC4'I(+S549E8O
M*TUW+S1G=61B;U W;5!U94,W5R]X;69V+T%%23-34#A!:FHR6"MO+R]!0V5K
M>GIJ,G4O>#,O3FDY2#)0+R8C>$$[04EV2#0O93E$+TLW*RLQ2"]6:2]7,EDO
M65A/9G<O4S=E0T\O3GHO;$)B-R]!1C10*U1Y-3)06FXY*U!J.7IR93)V.$%&
M<&9$-W<X3B8C>$$[.'9F.&1Q,"\Q+S1(3C$R<B]I=50K<$PW;FQ/>G8X66@W
M,E8U-'$Y,#DQ9R]U62\Y569Q>G8T.&<S24QZ2"]Y:C)Q9CAW:R\O04-B8B8C
M>$$[3#A(.35(,VAP,4@Y,TPK<69U9DQM9&TK8G91<B]W1#-U=68K37(O.%-/
M948V:BLX;#=Z.3<V43E:.&XO05!+3E=(+T=-+SA!16IN6"8C>$$[.6YF,T5F
M8S)J:SAX+U!8+T%)-T]M+SA!34TS+T%#8T]D8C)0.45V93AR-U)F6$0S1FEV
M;%@O95,K+S1Y468X045:8S!(='(O04AE4"8C>$$[*W-F=50W4"]!368K8BML
M;E!K2"]!2E-E,B\Q6E K5%IZ:BMY4#A92'@K-39A4$YM6&Q(>6)O,VMR5#E2
M5S-V6C598GDU;#%'.'5R*R8C>$$[4TIM5C-58WDP:7!&.$E#.5AQ9F9/=F)%
M+W1,,GIV2796=$HT-VE)17(V:U1Q-CAH,4962D92:7%29FU.+W=!;U1Q+R]!
M0F@O-#)'6B8C>$$[96@O=F\K.7=E,'8X6&XO5F9096IF.&1I>"\U:4EV.$%I
M67IP.50O9'DO<6XW;F@Y3"]E=R]R1#<R6#4T62MG4&)D2"]!3T]262\X028C
M>$$[35!&+WA!6C-E;2]U-"\Q4CEZ8TAI4#5Z9CAP;68K66%,+VIB3W,W2R]U
M9FE8:D\S=CA9+WI2*VQ++TQ(+TA.;B]W0TUY+SA!151N2R8C>$$[93(S*U,O
M>G8P3V(R0CE%=F5'9B]!2F(O05!+45 O>D1V+WA*8S5N<U@K*R]Z5"MH-DM0
M3C9D;E9T:GE(."M0.39D1R\Q2B\Q>#5V928C>$$[>'55=F@K;#5F,FHU=R]Z
M=C!-1CAQ9C<Q6&8X07I$;B]!2D]X-6=E,D@K2FHK=5!U3&ED9R]W0CAF-G8V
M47IF>6@O>6MT:"]X:R\T,28C>$$[3V5E.6YF,SAF93ED2&TY:'IT1S$X<%AN
M*SEC+R]'4B\K2DA/,FAY1#5R;"MS*SAS>FDO,VQT9BM9840O04I-<FYJ=F)N
M*T]:9C9X928C>$$[-S!8.7I$*W%0=65P+VPQ+WEJ;R\T>E-F=WIB.6IF,TAX
M3&UX-4UN>F%S;GIH*UDO+TMB-G8O>&U(+T5&>G)D0B]C>#EZ=UAA,RM->B8C
M>$$[.2\V16)P2"]!0G@W3"]59B]K.4IN;DAT9"]J=BMB1C90<V8O04)E4'@K
M.39(*U8S.3EQ4"MR1BMT<W@K=W5C+V@K;#(X160K8FXO2R8C>$$[0S,S*W9"
M+WEE6$]X-TTO=G@X9G5D8C(Q+VDP=F@Y-&5'*UAV*T\Q868V+SA$;38W5B]X
M6$HO56PY>GEN6C,K35$Y-TLX.%9E-F4V=R8C>$$[9C--9BMQ4#%:,SAE46)K
M1C5J+S52-U90*UE39B]K,C)8-% W>5!V1%1Q4#=U6#E5+V,K6$TW3C@S96A8
M+W=$=F1C+SA:6"\T:V,X3"8C>$$[,4@Y-4PS;C<S,&@V>C50+T%/56%S4#A!
M:D=F*TI(3W8W3R]U22LU=$A*-6HK978O04(R9$XO-6AM+S5/2$]T-T@K:5AV
M958Y;W9R:"8C>$$[-VEX6'ER+W9*9F8X6DE0*TEY-6]08E@K-W@O,6HY>69:
M+SA!:B]Z9C!S-3AG+SA!2U0R,RMR2B]Y8D]C9C)2+VI!*U S4%12-793.28C
M>$$[63!I=S%J4S=N5$PK37DR9#)H:FU137E%<69";$E92#-'9&4R251Y>C55
M,$QY>EIZ,E=I5S5T8E-E9#=P;T]B=6]K:T-H=4A-='A"-"8C>$$[,31J8714
M,WA63DHT24HT;6AN:E=72CEN:F-";$DY=V1S24I"<TE-45)295 O=T-)=E!-
M3W)A:F$R+S5E851Q6G-P,U,S1G!D,FM5,R8C>$$[<$EZ<6LP:5!Z6D]F<#%5
M9&0V9&-S3V%:+VE0>F%X9W@O=T$P9DI',C-M9GI59%@P0WAV+T%#;'!D9TPU
M;V]T6%=3-'17;&AK678V9R8C>$$[:FI%9UDP6#!M6%II969Y<FEF;'-F.#)0
M>41:5#%65E9&0W%!<7%+2V\R04$V041,44M3>$0X>61,,5-843)V3D-/;#(R
M<E)Y25AU.28C>$$[5VEJ84%X54LX1V1L66ER371-=&IL:TYG4T=U5TM%:EI!
M4'=9;BMI4'IA:6QA5D(U56HP4# U+U)U,6I:6DI#-GE,6GEU4VAI*S!9:28C
M>$$[,T=G4&)+.&\X5#8O5EAF=6U/3TUE44%:4"M714]V;E1B<6)Z0F,V4F98
M=VXT=UA/:D)05%=%=WAN9WA65BM,;5-F:U)L8V--26UW028C>$$[4&=Z6G)L
M:7-7+TUA82]S.4%/;S9B<$9L<D8O0DQ'9W0W.6\T,$5C<FA'26MK24,P2D(Y
M.&Y$2DM026M-2C0T>2MO07-2.'8V+W=#8R8C>$$[3#(O=#0O.$%L6'1G;6YT
M24ER=E5R839S-55A36]816E+:'%!>#1%2U-D:E@S=UI38V=Q9G%(;G5I3TM%
M9'=!4&=N=C5:-G9Q3W51,R8C>$$[."MS-DYP,FTS5FY/<5=W<UI)3&HT5VI$
M16PT;FMO47A)<G18=WEG64U93FE)*U1.;E=7<&54*UID8SAX85HU=G5T3C O
M=T%L-E!Q=28C>$$[;DHV2G173GIA5S$Q2UI7:%9G56QR>"M/96<K2&5N=4UT
M.&5F.#0O3G O3#0O=T-B2#5*9G%(;D@X>&),5')+930X9S9865A%.&LX8B8C
M>$$[,C$S95=I56IJ.45W;4UL,$1%:5)W5C(K>C(W-#!S34I'>D5%;GEB4D5$
M65!:24QE,W0P.4]#2DEK<EAG:6A252MW>5590TEO0VMQ;28C>$$[4U9G;C5N
M6'(V3' X1C5O*VIA5G%E<C-6>'=A,C%"-$QD<$EW:DTW23AH6&TT64MT4#AR
M3$)M;4)12BMB56--0V)-4CAK:6@X>65E-"8C>$$[3#%93E$O3'5X<TY04TLU
M0798=F)-4G9.1W-J47%O8FIX5U9O>#1K5G(P>6Y*:FIK3GE(16909&Y'06E+
M07!L;C5C6"MT-FIO,7AE828C>$$[,6\Q=&\Q-3EA;&AI:71':F1:24EQ0EA,
M4G1)2S@K4VM6,DEW4GA2:CE)05I-:3%3,RMS869C4FDS:75P3T1'1T-D43!B
M4T%644U$,B8C>$$[-55Y,DUI1%E.35I216A21G9)3DXX,BME8G$P16QJ*UAM
M:S,Q.'%U,&XQ3SAS,D9U-#)J:FQO4V5414AE;R]$2E-Y>DEO:VME.6=-128C
M>$$[06)%4CAM46%,<F9M0S8X-7)P5W!E5V1-<W1'67E,.6)%='4X-&-7.&-I
M25EG+TQL>EIW9F@W93%C>&9Y,E X06UX*U%B2'!)04%O3B8C>$$[9T]G>35,
M5&]K:4UJ<4A2=U9:5T91461I0T1I1%-K5SAE+U1V;FU,54IR2G9Y-C!Q.&Q7
M85=/3DE,;3!J:T554E@Y*SAB.#)O-GE+428C>$$[;S961E1V;#-J>B]N2#5T
M4#5F2"]!1%DO24DV2'I4-6U'=C9.6F%T-58P=E1B83A3139R2DYC,G!L:&51
M4T-4:6Y.4U%(16%J6G583"8C>$$[-5II2%0T>B]!06HU0G1P-FQ&1D9&1TDT
M:U=/3F1L4E%!0CAG37-J14%53U-72"]M6%!R=&YP.7)E-DIO3FAR9'HV=VEU
M5C%";S0Q:28C>$$[:$ML=5EK8VHY;V-A94Q$3$DU2E(U16AH4$9'6$U!<U-G
M.'HK95AS-WDU:"],=E0W4WIJ<S4W:3-V5&0R8W-%,'-65$9V1U5!4F=',R8C
M>$$[<CE/47DO=E!R.5AV,U=/3TUE44%::BM897!Y-G9P.7AD-FIP=&AP*W%7
M.7I,1C9&:DI$8V-983!I8WE232\R,7(T9DQ+-#194DYI228C>$$[0CEZ3DUR
M-WE4-6%V.6)B5W)U,$TR;TY&1D-885-4:GAG8WE29G5W,T-Q<W@S<&QI<#5I
M<G-6669E86(U2CAH;E903G!T;F=M=E=23"8C>$$[*V1895)N86%D;B\S62]&
M87E416LQ07A69T5N;40O;D@O6%!-8BMC-VA*,#%B5&)U,V$U=EA&>D1(1F-1
M=7-C3%-+<D-*=4I58C!)<"8C>$$[.7)#<DQ2*V9(-65E;F%4;35U0EI8<U14
M>%AV;T]99W%Z1T%C=4Y857,T,DA'=FI3:'=+:V9M1#@S+WE-.#(V4610,64Y
M:W5D36%33R8C>$$[66=W6%5A*W!&2V=&94-Q,W=T26A)3WA"-S<P5EI&-5HX
M,"]L=#5P<S1V2C)K;'!)3%-Z:F1,0C1P;WA(0EIY4GAQ0DEW;U1%+W Y1R8C
M>$$[3TMP-S5..&DK5W9*,6A.66%"8DYB5S%X3#8X>79,2DU7:S1+;DQL2WIN
M;V<V67%N*TMO1%A.1# S5SE.:S S56]J3&%3<VIS;UIK628C>$$[3D4T:U)L
M6E-'56AL0G%$:7)':&0K5%!Y-6ES=$9T-$IO23E596%A1TY#,&],45)X2DEX
M85)T:E1H.$LK-4%O1%)6:DAL9GHQ*U,O;"8C>$$[1T1563E)85A4-&QK0UAA
M4TI0>$1X>5)Q441*5E9!93E5:S%#+T97=$)H5D]*+WHV+TQM,&523E%U<#=,
M:&-F5E9-,79)43<P0DI5>"8C>$$[:50T4EAQ869H9U9J=7$O;4(K470O<3A7
M=%AL,TTQ.&]3*SE227(Q1G)A=$1+:G5Q2T9*4G)A3VQF;#-W<7I79E1V268U
M;#960F5U<"8C>$$[,4=Y=%IB;4-#6E1.059E:E<X-$905&%J3%5F3$%R34U6
M9&ER>F8X04Y05R]Y>%<K=&1*.#9X5'E#,G1Z<6-5:4Q+,&-C851X<'I0;R8C
M>$$[;FYY-7%"<W K1W99;D951G)V-7%F:WHU;3 R4%1T6G5:2F)7-5EH26UG
M=59.6&I:2SAO,3(U4GEN=E=H=W%J9DMV-7(O;%!&9%<S;"8C>$$[<E%R,E%0
M8WIY3D)#66)K:C$W>6-3<T,X:2]T>5A6971"-UE&83 S+T%*>4@O2W956%-+
M,3%'9#=H,35#,D9P8W1*5V=*54MS8F-M,R8C>$$[<%)A,5!3=4MP4'!F-6UF
M:U(U4G4W+U4W2S9M=$QN6&92;79*:F(S<VYR36EL:U!X;W=$56U*8GAR6'=X
M5D<V6'(S-4UA:BM954@V4"8C>$$[36MV;64W=7!'4G=L,&MF<C(P8W%U9FHT
M>&EG3#E"*S$W-%9E<5E&9&ER>F96.5HO3$1Y="MA5%A&-T908F5B3E9S23-L
M=30Q;65'4R8C>$$[,VMM5S-25U)#>3AG,%!8:'-.-C1Q>#-69DXS+T%$:CDU
M:S$K,S%F56UL9E8T5FIL:&QA1S=1<7%3245F.3)/1E169F5N5VU&5U<R;B8C
M>$$[-35F;'9D-FA$65<R;WE36$YW94U3+U8U=T-X35E#,5I",3E593)"56YU
M9GHP+TM,5S=3,S!U+W5:=RMP3D@V9&A,8E1#475**TU96B8C>$$[:T1)<F5P
M1T0Y=F)&5DLP+TUN.&QP3D1K.&I*8U10<'-56#9*=4Q34TLU67(V:D=!4D=5
M9W1Y2G)2;&)A;E5B67%Y,SAT.4(X:C9F;R8C>$$[<#%$>69B;414=%90<718
M,5)Y84YM42]"3'5P1&-Q-V9W>%9L=4MU>%8R2W):9E,Y32MR>#E0.$%A-55P
M.4YC5E52*VHK3S-O.&%J<"8C>$$[>'!7;W Y3F-684@V33E*865J-E@W2#)/
M4#=85'0O3BM/2W1$.48Q,CE#=F(W1F5O+VI41E932#9P>2]C*VYY<"MX>')X
M<C=D<31Q<B8C>$$[67$W1EA9<7-L.4-Q97)W<E@T3U9/=$\Q9F)&5D8O,&)2
M*V9O,"\S6GDT9C505W8K>"]$1E=P9C!85#DY-D90.'9H-&YX.2M8-#1Q<"8C
M>$$[,B\V12MQ=R]6=G$S,50P;"MR*VXV9G K:G@K2&AX*TAH>#95,G!I<4UJ
M.4QI9E0T.&545C0P<'DU2&PP-SAQ,3DX5EA9<3=&5D=8-B8C>$$[;C9V-S,P
M+U8T1VY0:GDT5C,V-S!R:7%W9F\S86YO.69H<'@V*S)+<59R*V<O<D9X.58K
M<F974%58-C$V6' X+U8Y3D](<6-D*UAP*R8C>$$[;E-U+TAJ,G!I<E@K-$@V
M+T0O=DPK:T]$+U8O-W8Q=E0U2C9N1#ER:GDY4&Q4=GAR,GA65V(Y1U58;#9.
M3G5&94@X;W!4+UDO:&EQ-28C>$$[4'%(<6IH-EAR5E!';DAL5VAR4VTO5$96
M9D9867%O4V95=G)#*W V6#%J:CA03&IZ-#$W5C-P:7$Q9C!B56-F4G(R<'@X
M4B]::7%N828C>$$[+V]8,4IV<6XQ8C%F5D@Q:C!V5#5E<GA3;E!J*S-W-&1D
M-E4Y<U98:CE&.'A4,$]D0E-N0W1+;6XT,7A6=&8P8E4X9E)R*S%4:"]0,R8C
M>$$[+W=";BM/2W$X9G X9C-D3T\Y3TY+5G)V,#DX5F8O+UH\+WAM<$=);6<Z
M:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \
M>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D0R,T)#-#A&-#$R1$5%,3$X.40S
M.3A$,3$T04$W.#8W/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP
M34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D0R,T)#-#A&-#$R1$5%,3$X.40S.3A$
M,3$T04$W.#8W/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X
M-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I
M=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N
M8V5)1#YX;7 N:6ED.D0Q,T)#-#A&-#$R1$5%,3$X.40S.3A$,3$T04$W.#8W
M/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE
M;G1)1#YX;7 N9&ED.D0Q,T)#-#A&-#$R1$5%,3$X.40S.3A$,3$T04$W.#8W
M/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q
M-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO
M;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z-S$T8V5B8C8M8SED-RTV-31A+3@P,C(M9# Y.# P,3,W8S)A/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(S+3 W+3(X5# W.C(S.C$S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B R-RXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1#(S
M0D,T.$8T,3)$144Q,3@Y1#,Y.$0Q,31!03<X-C<\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#<M,CA4
M,C Z,3<Z-3(K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL
M;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U
M<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@
M(" @(" @(" \:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^061O8F4@26QL
M=7-T<F%T;W(\+VEL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T
M1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS
M:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS
M.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @
M(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z
M2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS
M<&%R96YC>3X*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY0
M86=E<SX*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C0Y+C8P-C(X
M,SPO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^-S N,34W-#<Q/"]S
M=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0:6-A<SPO<W1$:6TZ
M=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @
M(#QX;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L+4)O;&1-5#PO
M<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T
M1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO
M;E-T<FEN9SY697)S:6]N(#4N,#8\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT
M.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE
M3F%M93YA<FEA;&)D7S N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @
M(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E
M3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-
M86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0
M;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.
M86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP
M1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT
M<SX*(" @(" @(" @(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/E=H:71E/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P
M,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0FQA8VL\+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D--64L@4F5D/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--
M64L@665L;&]W/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+($=R965N/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@0WEA;CPO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0TU92R!";'5E/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--
M64L@36%G96YT83PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ-2!-/3$P,"!9
M/3DP($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$T
M+CDY.3DY.#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDP+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C$P+C P,# P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3DP(%D]
M.#4@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P
M,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/CDP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.#4N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TX,"!9/3DU($L]
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XX,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDU+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T]-3 @63TQ,# @2STP/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],S4@63TX-2!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M,S4N,# P,# T/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXX-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,]-2!-/3 @63TY,"!+/3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C4N,# P,# Q/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/CDP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STR,"!-/3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXQ.2XY.3DY.3@\+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STU,"!-/3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STW-2!-/3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXW-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STX-2!-/3$P(%D],3 P($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C@U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P,CPO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P,CPO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,].3 @33TS,"!9/3DU($L],S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/CDP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C,P+C P,# P,CPO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^.34N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,S N,# P,# R/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STW-2!-/3 @63TW-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C<U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXW
M-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].# @
M33TQ,"!9/30U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^.# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P,# R/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXT-2XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-S @33TQ
M-2!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XQ-"XY.3DY.3@\+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3@U($T]-3 @63TP
M($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.#4N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ,# @33TY-2!9/34@2STP
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^.34N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXU+C P,# P,3PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ,# @33TQ,# @63TR-2!+/3(U
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,C4N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,C4N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3$P,"!9/3 @2STP
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW-2XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3$P,"!9/3 @2STP/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STS-2!-/3$P,"!9/3,U($L],3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,U+C P,# P-#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C,U+C P,# P-#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P
M+C P,# P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],3 @33TQ,# @63TU,"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P+C P,# P,CPO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C4P+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STP($T].34@63TR,"!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M.34N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXQ.2XY.3DY.3@\+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],C4@33TR-2!9/30P($L],#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,C4N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,C4N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXS.2XY.3DY.38\+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,]-# @33TT-2!9/34P($L]-3PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,SDN.3DY.3DV/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-#4N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXU,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXU+C P,# P,3PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,]-3 @33TU,"!9/38P($L],C4\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^-C N,# P,# T/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,C4N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STU-2!-/38P(%D]-C4@2STT,#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^-34N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-C N,# P,# T
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXV-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXS.2XY.3DY.38\+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3(U($T]-# @63TV-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C(U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C,Y+CDY.3DY-CPO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^-C4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/3,P($T]-3 @63TW-2!+/3$P/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXS,"XP,# P,#(\+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C<U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P,CPO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],S4@33TV,"!9/3@P($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C,U+C P,# P-#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C8P+C P,# P-#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^.# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,C4N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STT,"!-/38U(%D].3 @2STS-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,SDN.3DY.3DV/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-C4N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXY,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXS-2XP,# P,#0\+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/30P($T]-S @63TQ,# @2STU,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,SDN.3DY.3DV/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-S N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-3 N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STU,"!-/3<P(%D].# @2STW,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-S N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXX,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXW,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP
M1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D=R87ES/"]X;7!'.F=R
M;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C$\
M+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO
M<F%N=',^"B @(" @(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/3 @33TP(%D],"!+/3$P,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STP($T],"!9/3 @2STY,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXX.2XY.3DT,#4\+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP
M(%D],"!+/3@P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C<Y+CDY.#<Y-3PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]
M-S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M-CDN.3DY-S R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STV,#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXU.2XY.3DQ
M,#0\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/34P/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C4P+C P,# P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,],"!-/3 @63TP($L]-# \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,SDN.3DY-# Q/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T],"!9/3 @2STS,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXR.2XY.3@X,#(\+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @
M33TP(%D],"!+/3(P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C$Y+CDY.3<P,3PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP
M($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^.2XY.3DQ,#,\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/34\+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-"XY.3@X
M,#,\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(" @(" @(" @(#PO>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE
M/D)R:6=H=',\+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \
M>&UP1SIG<F]U<%1Y<&4^,3PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3$P,"!9/3$P,"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STP($T]-S4@63TQ,# @2STP/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C<U+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P
M,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STP($T],3 @63TY-2!+/3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N
M,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXY-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,].#4@33TQ,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C@U+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P
M,# P,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STQ,# @33TY,"!9/3 @2STP/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.3 N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STV,"!-/3DP(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C8P+C P,# P-#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDP+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,"XP,#,P.3D\+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,S Y.3PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X
M;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O
M=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0
M<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z
M>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@ Y@)= P$1  (1 0,1 ?_$ !\  0 #  (# 0$!
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@'"[&G\;JN"2VQYBY<,XK"01"2'W31HN_<MQ0M#9R\509-M
M=W#I31+3;G5%'7913GCWNO'//.=C*)7&3N9P$HE[##R.F44Z@X5AX\9=,-OW
M[:,.V6GC:HRPBM*B*TTJ(FE5H=-:&?2VR\CFMHIN\>.97)8&(F,>]=.FW[QW
M"PKM7CYMAR[1IX]:1AE51AA%::7!$(7R#Q!X$:ZKVKV<Z]0>9WPVJ\^#C#N%
ML <O DW! J9A[$L8>HAH9.YAI$80 E^LYF92*0&;'F<3 GW 2*R HT1%N>XM
M;8V>V)CX>6S]PY<1<5",QSEAQ$NHEE8=M\^AV6FGCEIIEE>R0[U%95<Y$1%I
M14K\Y=Y>392]"51<ZLC%Q,7 0,Q;E<0\BH*(@6V8QW#0T6TPRZB66&VV>PQ;
MA4>(F:K32LUJRIQ6G_% HF:U0.GUC/@,)/;1J7R\T$KR3/[MBC>-1*[@-"J&
M1$T"1*,E%/E"9RV*:[12:P:O[,CJ9=="80&/.A!)-'Y8^^5E4KII6F*47171
M5=G?3<4-_%4ZU28A#F%7,K.M'24]FHIU><E(Y6\Q1"@I?*$K$4Y,.B;P+HW=
MC0V]82A$T,:<[2$/QH-('10<(6'%7(9JIYJZ=GKZU/2O_%SZG(ZOBK4Z=:1J
M%/;1TM_:8PBTH9-X *K&AI)V">$FE?OZY=DSCE_"XV\7W!EWT/+C.$GK19LX
ME++6*.7VA&&EV::4T8U6B;?KT'+BOBM=*H\\#BY//Y;%#92=R:OW\>E-469'
M9##R<2=ULT,F)X$+19H1AT72^_'5KI(^<;M&BH^:,B''O6@F3K @S5WE\J;^
MC''0NC<[Q'FW?&?JR$S)(!6U3S&T8RL$5+,YX5WD]7 )#\4G$Z@3US"%)17C
MIO-8SH:@)A)I+ +]P,(>]^$;:<L%!Q D*HQ7;31OX*B*FTN@P6# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MDS8H-$VC=N*YRIH6GD3[OK+"\%HP!@# & , 8 P!@# & , 8 P!@# & , 8
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MM*B+AL(J?RAW2;^TA7'_ .P>_P"PS[?VJ+QODA./_98_$,7?S@+F/UBV<_\
MDO?P1_*'=)O[2%<?_L'O^PQ[5%XWR0G'_LL?B#^<!<Q^L6SG_P E[^"=VU)?
MU-7PV-NZ?L./6 VC:[%L=6C[A9?08N33<JL$G7PR"'.NSI-FZW2][QMQSP@I
M[O/'N?C^<GMEK0V8;AG<_E,7*FXQEZW#,Q;#+"OF7*L,O6F*--51A7C"-5IB
MTA]I92WEC[<NXU]9&T$OG[J7-N'<<W+WC3QF&>1++QIPR]5IABBO67+Q6:5J
MC"Z#N#.@/K1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M@# & 1([Z>3+LMZ(I=ZOWS[RZ_6'8[AZ ]*ABB_34[>1Q2F_1VC#-DEA",,
MTE^ I\T>RGUCK/U9,\T_RH/C"Q_B<X]/+R1K(5^)[QN$K.=%FY:M-NCO5:Q*
MVA513"HA96O:\>21Y$0*9Z8"U!VDU0--)R*<F@\B'GS4:GC&1&QL]BATJ3C$
MW%DG(R5""X_;5MKJN;[YRUK7'=]>]I/=V3U!ZZV\9TD-B5PC(C*<GA$L2?[2
M69#%DR-<Q^4Q>(#4^ LA')Z0\<#G,V9NH!KIQ!3>\PE#P['2;X^4<N@JJ:%]
M5]>3<0DI@H, 8!P0I8U8CG^[ U.X(P*"W._"C(I*(^U?CG?P2B._&[=V^3<,
MW/P"ZJ6_&VB:OP2RB?/_  *;<<]BZD\W?NV'SB5S%\Z>,HT[>NH&)>.VV5T-
M,-L.E9:978K*JATK^T=GH5\\AXJ?26&B'+2L/7#^:0+E\Z;32P\=/'[+;#2;
M66F45-P]4O95+.FSMDYG]7N6;_E3E\T7E436;/>5>->%>7:"C_9)SRIQKKPI
MRMIOSOQKKQM[O'''N?I_(4[_ .C37Z.B_P $_+_2NRWRED'TQ+O[R>6$FU2.
M3#E..2ZNG!^2.T%':80_&53!]\W:IM&V[G1@[V>E':#%LDV0V5X763:H)HI\
MZHI:ZZ_F]D\V<.VWS^5S%RY=IG/'KV"B7;MAG1G-MMNF664JJ)5I40_:'M'9
MZ+?.X:%GTFB8A\UF.G$/-(%\^>MT5<UVZ=OVFVVJ(JYK+*K1%P.Q<ZX[D8 P
M!@# & , Z'GO7.N[-LII9<UX-&WC.D+6H!*+KOFND1Y@]U&(*6L-SPS38:%T
M9&:3KJ-!^2K4VW21#(N6O#+99?ATF*UPIOHN_A7[R/=0>'=5%/5>:JAC/K8F
MP*5SBG91,R4[(058S*XS0T5KV#UG515.&P&%Q[:O1L/JV%QB0(:1_B33H(T,
M,IQ)9#]T1=1P"K5:T3UTZ=W'SX4PIW#U*ZL0GIY4B%/0&1S*4@&YMV;T*3AV
M%=FMEW T0(]Q3:/ XZ+V67:!&A V1X&:DI-*GL@F!]V_D,A*O5P5:\A)O!08
M P!@# .F[\MUS1562FU4ZWF%HL(:Q<&Y" A!ZJ(T5&Q@8U<$)#*GAFZ+)JB"
M,@<:%M'!0RJ^F#9YHR14W9,WJFFR? JB56E43OU^Q%7ZB'JWB;5DR3$(&J3[
M'18^2Z;6'W4=1F65Z/!O@\'KS:K=R$ =FE)(O#2%I*,+=B90L!CTG-"H(S7Y
MTL,Y%7RS9DL]?6I7-78J*E49JFZM:;],%QH2(ZS]IX=VE"/Y'!8Y*!(06 @#
MXB^D6@A)-"3S>-)S-U"4.190FD2)1:)&(/("AH8J\BQ!A/8_\@FBBR19(<**
ME/+Z^NW=0D]@H, 8 P!@# & 8E/$K\\W8GZWC?9..Y([<[JTLEX@^Z?%D+N4
M?KNO"X6ANJ9>0:S)9A$EGT/\Y?6CTPPOUJCGPEY^KVV/ $P]"T97N+UQ7;\;
M91TADW.Y&D3<C & , 8 P!@# & , 8 P#.OV]'71 ?$6BJH!/MA)J7L6Q^G2
MTH3XOB[655IR8W<A;AG&H'7U=47)@RP ",C$BFLR&R:Y(P%T; W8F2<QD :B
MB$L%Z>]715$:V)6E-VJ+MIH6GG-%&"P8 P!@# *@/&V\G0?TUPGV=G&9]R<-
M8$1Q<F72Y::D9:.J&$XYR7J^=&2[-ZR*88!L8\('R)UK]9+)]NSF1^W^ZS9Q
MXG)^K(8E[R2-1UF^$;1]>1Q9QF&3948 P!@# *_+0\0*'P3MF/Z=QR $Y]:#
MF%AI.[X2L*J8*CH7F4=M200&(A!]A3".%I86.IU,82,;1YF]^YQL<CQ/XN59
MZR7:-BM,,[96FCO5Y4TTJ=-#/%5'-&41/61UIM>N8:?GG86'EIGN:B4YCH89
MUN7C06=RL<2@3P^PDH[B6%96):-&3QJY=B*LL:4B=BXT4*2-"JLIL6N"84Q6
MNSS47"NDLRK>7J3Z!Q*8N1:8!_(00XB7C>ID9(%HL;6;Z?+45?F RBPI\5C)
M7AV"+J,%5&VI,>[32WWUTXVY%IS; & , 8 P!@$2.^GDR[+>B*7>K]\^\NOU
MAV.X>@/2H8HOTU.WD<4IOT=HPS9)80C# +5.DLYF4 ZV747@\I/1(JZO&G!K
MDC'2CP0]7'JP*Y72K)5RR6154:J.6C5?=#;;E/95NBISKSLGISQ%Y[)E/YW9
MVR]W,;(9M,)/&/9_%PKV)EL6^@W[R&;ET8];<-O'#;#;3IIZX<O&F%565;=,
M-*E645)#\B%IIF1WB*RTTRO\K6;2K*JBT_(YSA5*88(>7*N^/9"+64 K]267
ML9:GHY)Y3I) 5@+$N&@F(,$G)M92,-SNTK<_!D2,>C[/5D*<*$3<D%-&2:W'
M+I1O%/+K6WAS"11DY9O3G<*\@XZ EZP$7.)TX5Y$S-\T[A&$F#:I+G><X<QL
M:]5[$L,N82!B'CUIA4=LM[TLM/6F&F^SM)FM,LYJMMHJJTN&*^Y2J(TN+241
ME54Y-5G=>^+4@4?GS"UKC!-) F_43$&IJ6X*C]F!5\*6;O\ 5D6=--7.JS!3
ME31NY<)Z<[>\U64][[[G@6BMO>;9V<QLF?WA6BC'L$TY1J)A)Y-%AGR/X9S$
MLMN5>O'3Q7:L/F416W;#2TJK+-:%'C;YVVTPKYM59IBC;=%JB+A546F.XAHH
MZ7R60S#K77$BE1LI(CQ'[KOCYDT^<$23SXK.I,R;?&7CI15=;XNS;-VJ/O\
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M<0C?& ;D.@'DMZU^BN._PU,C5O3UB6PX<C.<A-K<-J;NXXK2[F-$P,^!,MC
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MDS)D^:Z+O.'F.B11*'/*F3&# +.O"Y^E:Q?1[I[2",VIR4.ZZTW%QGK.#.;
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M&MJ4<1)/UW:0IOS8(U /(:?TMK^<(_Q-<M;]XUX+7(I^KCM[GYUWSV2XGO&
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M7'VT>?3D16;J))C%R ]!=W$QRKJ&VWL_DSC1UJM"UW@F8;5NCH".CW$Q(O\
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MPM?HZL_ZZC/426;T9)W<U:OAR$Z R=E ^\>>$G(6CYM@<X8!D_\ '#\WD/\
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MNR4\6X;T,&2TY*VI&S'C]I.OHX]3D<IL., UDU]\P81]4(UZE99+_9SN>D/
MTKZ"X.^8]XSX+/(AR_.Y+A@'SM%_Y];^]4_?VR6=G0G>3D//D\[8\\-KG*?E
ME2PGIT+_ "IV:_5A+?;?16:0>R$_FV3WA^1\D:;>9%VM"T/]'\T_>2R9W)GG
M>)-!@%XGA=?1#8'I(4]F(_F^>2CW&6BXSM]52X[.![6WX?\ "A9IFTIS1@#
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MULX)FG1E Y'#OG=%OK&#]9M<[21_'4GX4E_2W)<Q[]GPF>5#6KDPAWPP!@%
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MN2"\B^&*JA5>_P!_'E.. >B74N,2FK9H I@$+DE-"1@> OFI>5\(-$ A.6G
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MQUK"XTN.!55=.S#R)A0Z"1\(CJ"G'!0!1O:+ATF:FI"9RO>Q'S:5VP#L895
M.<0.S2(YDR:FX/(P-%T\&>"1@\&\19P 2LP)M"#^0/3(KG+O4PHE$PHJJE/.
MOG+0<%HP!@# & 1Y[3=7:@[D4M(Z!O0(]/UQ*B<4+%F TDL'([.X=*@\N%?%
MB;?79=LDN_"H,2B:?''! *[)"UN>&[Y;!5%5%JFE"+MC>$[TXLMU:I0Q#S@X
M];UY"^P\A.BBS%5V,LH97A^K]G<>'G@QV/- Y"*R^:<O0I *59Z2"7&)4.X8
M2-,03%BJ-*FW93R:>7D38AZ=WX/W2!V5L)[M 2R0JRQ ,/(XIJ48+1[E(,\K
M!VLNCR\#.CKO@[I4<29&!1PX8CNK1:3_ ".%$.I?)')(,Y=W[-BIL[YW5*O#
MXZLSSKH#ZL3J <S.H(;I+T:X$R0@J1*U>TE;"6@VK*OC6^FCP"UA,5F9>&0+
M7GETI'(@F/ :*.6+/738$:5%SMNW!,>_W]IXE,^'MUSH2U!EK5NPF8MY'PY,
M;%88[F!!_7L2(GX-6=;2B4@(XLGPJWD4FA-0P($44=$7@E%(0X=B! L@7+NW
MHIG+2F[IP3'%5TZ=O>)PX*# & , K7BGA+=(H>I4^PRM2"Z%,RGLO+(BR(2)
M^X9KO.V(1>-6R./I)\(;%PNT?W8B(FP543^Y5H#!;#5M7(U)?D7*TJUJNFFQ
M-E:;VWUQ. -O!7Z--XO"8MM%I6Y2@)LX0"%G)6/;%E $DC\ BYV$//@HFD*^
M0"86L(2FZ-,13&PU"0IU(N9Q]TIV0F"H9S6ZN.^OK]F]4E?1/22B.M\NLZ:U
M(,D,:,W.ZF)2T^&\@<(M9M(9E:]C6\M+3.C%%DXWEX W:<NC<:D[=RW-#H%L
M B*[QZ/B<8^2116E6E5K2B)O(B4IZ]_21O7\(#J$\AKV)/N;>>O3I.9*S&>+
MV>5UL*=Q.Q:U"T]/JTE\D;M4/E*!3&M8X#C<A9(,V1T@Z8;S!20<3TF:E)(5
MSEW=RF]1:I3O%H:"*+9%%NW3T10;I)HHI)Z\:II(I:<)IIZ:\?BUTTTUUUUU
MX_%QKQQQQ@M/UP#I7LI!9]:'72_*SJJ7;5_:%B4M:<%K>>:%C('>$SV6P8Z
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MU=QV/R75,TDHLF6TU,#WG&I)-571]KQPYU4WU4XVY%%6JJNZJJ2;P4& , 8
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MXU ]HZH)>Z&*R+C9 XIJGR"#UR3MUV6X55:II\L5ZR!2&;B''&_O#\?C$J?
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M./R'PE.M$F@INO7\FN-((>4M=5ZX:2:(ID]=KBH6!==93\ X5@2S?3AK!:Z
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([R:F"@P#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
